Abstract Id: DrugDDI.d505
Sentence Id: DrugDDI.d505.s0
No formal drug /drug interaction studies with Plenaxis@ were performed.

DrugDDI.d505.s0.e0 8 11
drug
drug



Abstract Id: DrugDDI.d505
Sentence Id: DrugDDI.d505.s1
Cytochrome P-450 is not known to be involved in the metabolism of Plenaxis@.

DrugDDI.d505.s1.e0 0 14
drug
Cytochrome P-450



Abstract Id: DrugDDI.d505
Sentence Id: DrugDDI.d505.s2
Plenaxis@ is highly bound to plasma proteins (96 to 99%).

DrugDDI.d505.s2.e0 24 37
drug
plasma proteins



Abstract Id: DrugDDI.d505
Sentence Id: DrugDDI.d505.s3
Laboratory Tests Response to Plenaxis@ should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.

DrugDDI.d505.s3.e0 67 83
drug
total testosterone



Abstract Id: DrugDDI.d505
Sentence Id: DrugDDI.d505.s4
Serum transaminase levels should be obtained before starting treatment with Plenaxis@ and periodically during treatment.

DrugDDI.d505.s4.e0 5 16
drug
transaminase



Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s0
Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control.

DrugDDI.d103.s0.e0 7 11
drug
drugs
DrugDDI.d103.s0.new.DISO.e1 25 37
DISO
hyperglycemia



Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s1
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products, estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel-blocking drugs , and isoniazid .

DrugDDI.d103.s1.e0 5 9
drug
drugs
DrugDDI.d103.s1.e1 20 28
drug
thiazides
DrugDDI.d103.s1.e2 37 45
drug
diuretics
DrugDDI.d103.s1.e3 47 61
drug
corticosteroids
DrugDDI.d103.s1.e4 63 76
drug
phenothiazines
DrugDDI.d103.s1.e5 78 84
drug
thyroid
DrugDDI.d103.s1.e6 94 102
drug
estrogens
DrugDDI.d103.s1.e7 104 121
drug
oral contraceptives
DrugDDI.d103.s1.e8 123 131
drug
phenytoin
DrugDDI.d103.s1.e9 133 145
drug
nicotinic acid
DrugDDI.d103.s1.e10 147 162
drug
sympathomimetics
DrugDDI.d103.s1.e11 164 191
drug
calcium channel-blocking drugs
DrugDDI.d103.s1.e12 196 204
drug
isoniazid

interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e1 false
interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e2 false
interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e3 false
interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e4 false
interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e5 false
interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e6 false
interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e7 false
interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e8 false
interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e9 false
interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e10 false
interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e11 false
interaction DrugDDI.d103.s1.e0 DrugDDI.d103.s1.e12 false
interaction DrugDDI.d103.s1.e1 DrugDDI.d103.s1.e2 false
interaction DrugDDI.d103.s1.e1 DrugDDI.d103.s1.e3 false
interaction DrugDDI.d103.s1.e1 DrugDDI.d103.s1.e4 false
interaction DrugDDI.d103.s1.e1 DrugDDI.d103.s1.e5 false
interaction DrugDDI.d103.s1.e1 DrugDDI.d103.s1.e6 false
interaction DrugDDI.d103.s1.e1 DrugDDI.d103.s1.e7 false
interaction DrugDDI.d103.s1.e1 DrugDDI.d103.s1.e8 false
interaction DrugDDI.d103.s1.e1 DrugDDI.d103.s1.e9 false
interaction DrugDDI.d103.s1.e1 DrugDDI.d103.s1.e10 false
interaction DrugDDI.d103.s1.e1 DrugDDI.d103.s1.e11 false
interaction DrugDDI.d103.s1.e1 DrugDDI.d103.s1.e12 false
interaction DrugDDI.d103.s1.e2 DrugDDI.d103.s1.e3 false
interaction DrugDDI.d103.s1.e2 DrugDDI.d103.s1.e4 false
interaction DrugDDI.d103.s1.e2 DrugDDI.d103.s1.e5 false
interaction DrugDDI.d103.s1.e2 DrugDDI.d103.s1.e6 false
interaction DrugDDI.d103.s1.e2 DrugDDI.d103.s1.e7 false
interaction DrugDDI.d103.s1.e2 DrugDDI.d103.s1.e8 false
interaction DrugDDI.d103.s1.e2 DrugDDI.d103.s1.e9 false
interaction DrugDDI.d103.s1.e2 DrugDDI.d103.s1.e10 false
interaction DrugDDI.d103.s1.e2 DrugDDI.d103.s1.e11 false
interaction DrugDDI.d103.s1.e2 DrugDDI.d103.s1.e12 false
interaction DrugDDI.d103.s1.e3 DrugDDI.d103.s1.e4 false
interaction DrugDDI.d103.s1.e3 DrugDDI.d103.s1.e5 false
interaction DrugDDI.d103.s1.e3 DrugDDI.d103.s1.e6 false
interaction DrugDDI.d103.s1.e3 DrugDDI.d103.s1.e7 false
interaction DrugDDI.d103.s1.e3 DrugDDI.d103.s1.e8 false
interaction DrugDDI.d103.s1.e3 DrugDDI.d103.s1.e9 false
interaction DrugDDI.d103.s1.e3 DrugDDI.d103.s1.e10 false
interaction DrugDDI.d103.s1.e3 DrugDDI.d103.s1.e11 false
interaction DrugDDI.d103.s1.e3 DrugDDI.d103.s1.e12 false
interaction DrugDDI.d103.s1.e4 DrugDDI.d103.s1.e5 false
interaction DrugDDI.d103.s1.e4 DrugDDI.d103.s1.e6 false
interaction DrugDDI.d103.s1.e4 DrugDDI.d103.s1.e7 false
interaction DrugDDI.d103.s1.e4 DrugDDI.d103.s1.e8 false
interaction DrugDDI.d103.s1.e4 DrugDDI.d103.s1.e9 false
interaction DrugDDI.d103.s1.e4 DrugDDI.d103.s1.e10 false
interaction DrugDDI.d103.s1.e4 DrugDDI.d103.s1.e11 false
interaction DrugDDI.d103.s1.e4 DrugDDI.d103.s1.e12 false
interaction DrugDDI.d103.s1.e5 DrugDDI.d103.s1.e6 false
interaction DrugDDI.d103.s1.e5 DrugDDI.d103.s1.e7 false
interaction DrugDDI.d103.s1.e5 DrugDDI.d103.s1.e8 false
interaction DrugDDI.d103.s1.e5 DrugDDI.d103.s1.e9 false
interaction DrugDDI.d103.s1.e5 DrugDDI.d103.s1.e10 false
interaction DrugDDI.d103.s1.e5 DrugDDI.d103.s1.e11 false
interaction DrugDDI.d103.s1.e5 DrugDDI.d103.s1.e12 false
interaction DrugDDI.d103.s1.e6 DrugDDI.d103.s1.e7 false
interaction DrugDDI.d103.s1.e6 DrugDDI.d103.s1.e8 false
interaction DrugDDI.d103.s1.e6 DrugDDI.d103.s1.e9 false
interaction DrugDDI.d103.s1.e6 DrugDDI.d103.s1.e10 false
interaction DrugDDI.d103.s1.e6 DrugDDI.d103.s1.e11 false
interaction DrugDDI.d103.s1.e6 DrugDDI.d103.s1.e12 false
interaction DrugDDI.d103.s1.e7 DrugDDI.d103.s1.e8 false
interaction DrugDDI.d103.s1.e7 DrugDDI.d103.s1.e9 false
interaction DrugDDI.d103.s1.e7 DrugDDI.d103.s1.e10 false
interaction DrugDDI.d103.s1.e7 DrugDDI.d103.s1.e11 false
interaction DrugDDI.d103.s1.e7 DrugDDI.d103.s1.e12 false
interaction DrugDDI.d103.s1.e8 DrugDDI.d103.s1.e9 false
interaction DrugDDI.d103.s1.e8 DrugDDI.d103.s1.e10 false
interaction DrugDDI.d103.s1.e8 DrugDDI.d103.s1.e11 false
interaction DrugDDI.d103.s1.e8 DrugDDI.d103.s1.e12 false
interaction DrugDDI.d103.s1.e9 DrugDDI.d103.s1.e10 false
interaction DrugDDI.d103.s1.e9 DrugDDI.d103.s1.e11 false
interaction DrugDDI.d103.s1.e9 DrugDDI.d103.s1.e12 false
interaction DrugDDI.d103.s1.e10 DrugDDI.d103.s1.e11 false
interaction DrugDDI.d103.s1.e10 DrugDDI.d103.s1.e12 false
interaction DrugDDI.d103.s1.e11 DrugDDI.d103.s1.e12 false

Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s2
When such drugs are administered to a patient receiving Acarbose , the patient should be closely observed for loss of blood glucose control.

DrugDDI.d103.s2.e0 8 12
drug
drugs
DrugDDI.d103.s2.e1 47 54
drug
Acarbose

interaction DrugDDI.d103.s2.e0 DrugDDI.d103.s2.e1 true

Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s3
When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin , patients should be observed closely for any evidence of hypoglycemia.

DrugDDI.d103.s3.e0 8 12
drug
drugs
DrugDDI.d103.s3.e1 46 53
drug
Acarbose
DrugDDI.d103.s3.e2 71 83
drug
sulfonylureas
DrugDDI.d103.s3.e3 86 92
drug
insulin
DrugDDI.d103.s3.new.DISO.e4 141 152
DISO
hypoglycemia

interaction DrugDDI.d103.s3.e0 DrugDDI.d103.s3.e1 false
interaction DrugDDI.d103.s3.e0 DrugDDI.d103.s3.e2 false
interaction DrugDDI.d103.s3.e0 DrugDDI.d103.s3.e3 false
interaction DrugDDI.d103.s3.e1 DrugDDI.d103.s3.e2 true
interaction DrugDDI.d103.s3.e1 DrugDDI.d103.s3.e3 false
interaction DrugDDI.d103.s3.e2 DrugDDI.d103.s3.e3 false

Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s4
Intestinal adsorbents (e. g., charcoal ) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly.

DrugDDI.d103.s4.e0 10 19
drug
adsorbents
DrugDDI.d103.s4.e1 26 33
drug
charcoal
DrugDDI.d103.s4.e2 38 64
drug
digestive enzyme preparations
DrugDDI.d103.s4.e3 110 116
drug
amylase
DrugDDI.d103.s4.e4 118 127
drug
pancreatin
DrugDDI.d103.s4.e5 149 156
drug
Acarbose

interaction DrugDDI.d103.s4.e0 DrugDDI.d103.s4.e1 false
interaction DrugDDI.d103.s4.e0 DrugDDI.d103.s4.e2 false
interaction DrugDDI.d103.s4.e0 DrugDDI.d103.s4.e3 false
interaction DrugDDI.d103.s4.e0 DrugDDI.d103.s4.e4 false
interaction DrugDDI.d103.s4.e0 DrugDDI.d103.s4.e5 true
interaction DrugDDI.d103.s4.e1 DrugDDI.d103.s4.e2 false
interaction DrugDDI.d103.s4.e1 DrugDDI.d103.s4.e3 false
interaction DrugDDI.d103.s4.e1 DrugDDI.d103.s4.e4 false
interaction DrugDDI.d103.s4.e1 DrugDDI.d103.s4.e5 false
interaction DrugDDI.d103.s4.e2 DrugDDI.d103.s4.e3 false
interaction DrugDDI.d103.s4.e2 DrugDDI.d103.s4.e4 false
interaction DrugDDI.d103.s4.e2 DrugDDI.d103.s4.e5 true
interaction DrugDDI.d103.s4.e3 DrugDDI.d103.s4.e4 false
interaction DrugDDI.d103.s4.e3 DrugDDI.d103.s4.e5 false
interaction DrugDDI.d103.s4.e4 DrugDDI.d103.s4.e5 true

Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s5
Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.

DrugDDI.d103.s5.e0 0 7
drug
Acarbose
DrugDDI.d103.s5.e1 46 52
drug
digoxin

interaction DrugDDI.d103.s5.e0 DrugDDI.d103.s5.e1 true

Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s6
Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , nifedipine , propranolol , or ranitidine .

DrugDDI.d103.s6.e0 39 46
drug
Acarbose
DrugDDI.d103.s6.e1 105 111
drug
digoxin
DrugDDI.d103.s6.e2 113 122
drug
nifedipine
DrugDDI.d103.s6.e3 124 134
drug
propranolol
DrugDDI.d103.s6.e4 138 147
drug
ranitidine

interaction DrugDDI.d103.s6.e0 DrugDDI.d103.s6.e1 false
interaction DrugDDI.d103.s6.e0 DrugDDI.d103.s6.e2 false
interaction DrugDDI.d103.s6.e0 DrugDDI.d103.s6.e3 false
interaction DrugDDI.d103.s6.e0 DrugDDI.d103.s6.e4 false
interaction DrugDDI.d103.s6.e1 DrugDDI.d103.s6.e2 false
interaction DrugDDI.d103.s6.e1 DrugDDI.d103.s6.e3 false
interaction DrugDDI.d103.s6.e1 DrugDDI.d103.s6.e4 false
interaction DrugDDI.d103.s6.e2 DrugDDI.d103.s6.e3 false
interaction DrugDDI.d103.s6.e2 DrugDDI.d103.s6.e4 false
interaction DrugDDI.d103.s6.e3 DrugDDI.d103.s6.e4 false

Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s7
Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.

DrugDDI.d103.s7.e0 0 7
drug
Acarbose
DrugDDI.d103.s7.e1 58 69
drug
sulfonylurea

interaction DrugDDI.d103.s7.e0 DrugDDI.d103.s7.e1 false

Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s8
Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).

DrugDDI.d103.s8.e0 0 7
drug
Acarbose
DrugDDI.d103.s8.e1 17 23
drug
digoxin
DrugDDI.d103.s8.e2 68 74
drug
digoxin
DrugDDI.d103.s8.e3 123 125
drug
max
DrugDDI.d103.s8.e4 205 211
drug
digoxin

interaction DrugDDI.d103.s8.e0 DrugDDI.d103.s8.e1 true
interaction DrugDDI.d103.s8.e0 DrugDDI.d103.s8.e2 false
interaction DrugDDI.d103.s8.e0 DrugDDI.d103.s8.e3 false
interaction DrugDDI.d103.s8.e0 DrugDDI.d103.s8.e4 false
interaction DrugDDI.d103.s8.e1 DrugDDI.d103.s8.e2 false
interaction DrugDDI.d103.s8.e1 DrugDDI.d103.s8.e3 false
interaction DrugDDI.d103.s8.e1 DrugDDI.d103.s8.e4 false
interaction DrugDDI.d103.s8.e2 DrugDDI.d103.s8.e3 false
interaction DrugDDI.d103.s8.e2 DrugDDI.d103.s8.e4 false
interaction DrugDDI.d103.s8.e3 DrugDDI.d103.s8.e4 false

Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s9
The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.

DrugDDI.d103.s9.e0 11 19
drug
metformin
DrugDDI.d103.s9.e1 39 46
drug
Acarbose

interaction DrugDDI.d103.s9.e0 DrugDDI.d103.s9.e1 false

Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s10
However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin .

DrugDDI.d103.s10.e0 28 36
drug
metformin
DrugDDI.d103.s10.e1 75 82
drug
Acarbose
DrugDDI.d103.s10.e2 117 125
drug
metformin

interaction DrugDDI.d103.s10.e0 DrugDDI.d103.s10.e1 true
interaction DrugDDI.d103.s10.e0 DrugDDI.d103.s10.e2 false
interaction DrugDDI.d103.s10.e1 DrugDDI.d103.s10.e2 false

Abstract Id: DrugDDI.d103
Sentence Id: DrugDDI.d103.s11
There is little if any clinically significant interaction between Acarbose and metformin .

DrugDDI.d103.s11.e0 57 64
drug
Acarbose
DrugDDI.d103.s11.e1 68 76
drug
metformin

interaction DrugDDI.d103.s11.e0 DrugDDI.d103.s11.e1 true

Abstract Id: DrugDDI.d518
Sentence Id: DrugDDI.d518.s0
Catecholamine-depleting drugs , such as reserpine , may have an additive effect when given with beta-blocking agent s.

DrugDDI.d518.s0.e0 23 27
drug
drugs
DrugDDI.d518.s0.e1 35 43
drug
reserpine
DrugDDI.d518.s0.e2 81 98
drug
beta-blocking agent

interaction DrugDDI.d518.s0.e0 DrugDDI.d518.s0.e1 false
interaction DrugDDI.d518.s0.e0 DrugDDI.d518.s0.e2 true
interaction DrugDDI.d518.s0.e1 DrugDDI.d518.s0.e2 false

Abstract Id: DrugDDI.d518
Sentence Id: DrugDDI.d518.s1
Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.

DrugDDI.d518.s1.e0 19 28
drug
acebutolol
DrugDDI.d518.s1.new.DISO.e1 230 240
DISO
tachycardia



Abstract Id: DrugDDI.d518
Sentence Id: DrugDDI.d518.s2
Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonist s and alpha-adrenergic stimulants , including those contained in proprietary cold remedies and vasoconstrictive nasal drops.

DrugDDI.d518.s2.e0 68 92
drug
beta-adrenergic antagonist
DrugDDI.d518.s2.e1 113 122
drug
stimulants

interaction DrugDDI.d518.s2.e0 DrugDDI.d518.s2.e1 true

Abstract Id: DrugDDI.d518
Sentence Id: DrugDDI.d518.s3
Patients receiving beta-blockers should be warned of this potential hazard.

DrugDDI.d518.s3.e0 17 29
drug
beta-blockers



Abstract Id: DrugDDI.d518
Sentence Id: DrugDDI.d518.s4
Blunting of the antihypertensive effect of beta-adrenoceptor blocking agent s by nonsteroidal anti-inflammatory drugs has been reported.

DrugDDI.d518.s4.e0 13 28
drug
antihypertensive
DrugDDI.d518.s4.e1 37 66
drug
beta-adrenoceptor blocking agent
DrugDDI.d518.s4.e2 70 103
drug
nonsteroidal anti-inflammatory drugs

interaction DrugDDI.d518.s4.e0 DrugDDI.d518.s4.e1 false
interaction DrugDDI.d518.s4.e0 DrugDDI.d518.s4.e2 false
interaction DrugDDI.d518.s4.e1 DrugDDI.d518.s4.e2 true

Abstract Id: DrugDDI.d518
Sentence Id: DrugDDI.d518.s5
No significant interactions with digoxin , hydrochlorothiazide , hydralazine , sulfinpyrazone , oral contraceptives , tolbutamide , or warfarin have been observed.

DrugDDI.d518.s5.e0 29 35
drug
digoxin
DrugDDI.d518.s5.e1 37 55
drug
hydrochlorothiazide
DrugDDI.d518.s5.e2 57 67
drug
hydralazine
DrugDDI.d518.s5.e3 69 82
drug
sulfinpyrazone
DrugDDI.d518.s5.e4 84 101
drug
oral contraceptives
DrugDDI.d518.s5.e5 103 113
drug
tolbutamide
DrugDDI.d518.s5.e6 117 124
drug
warfarin

interaction DrugDDI.d518.s5.e0 DrugDDI.d518.s5.e1 false
interaction DrugDDI.d518.s5.e0 DrugDDI.d518.s5.e2 false
interaction DrugDDI.d518.s5.e0 DrugDDI.d518.s5.e3 false
interaction DrugDDI.d518.s5.e0 DrugDDI.d518.s5.e4 false
interaction DrugDDI.d518.s5.e0 DrugDDI.d518.s5.e5 false
interaction DrugDDI.d518.s5.e0 DrugDDI.d518.s5.e6 false
interaction DrugDDI.d518.s5.e1 DrugDDI.d518.s5.e2 false
interaction DrugDDI.d518.s5.e1 DrugDDI.d518.s5.e3 false
interaction DrugDDI.d518.s5.e1 DrugDDI.d518.s5.e4 false
interaction DrugDDI.d518.s5.e1 DrugDDI.d518.s5.e5 false
interaction DrugDDI.d518.s5.e1 DrugDDI.d518.s5.e6 false
interaction DrugDDI.d518.s5.e2 DrugDDI.d518.s5.e3 false
interaction DrugDDI.d518.s5.e2 DrugDDI.d518.s5.e4 false
interaction DrugDDI.d518.s5.e2 DrugDDI.d518.s5.e5 false
interaction DrugDDI.d518.s5.e2 DrugDDI.d518.s5.e6 false
interaction DrugDDI.d518.s5.e3 DrugDDI.d518.s5.e4 false
interaction DrugDDI.d518.s5.e3 DrugDDI.d518.s5.e5 false
interaction DrugDDI.d518.s5.e3 DrugDDI.d518.s5.e6 false
interaction DrugDDI.d518.s5.e4 DrugDDI.d518.s5.e5 false
interaction DrugDDI.d518.s5.e4 DrugDDI.d518.s5.e6 false
interaction DrugDDI.d518.s5.e5 DrugDDI.d518.s5.e6 false

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s0
DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin .

DrugDDI.d452.s0.e0 0 5
drug
DIAMOX
DrugDDI.d452.s0.e1 14 22
drug
phenytoin
DrugDDI.d452.s0.e2 59 67
drug
phenytoin

interaction DrugDDI.d452.s0.e0 DrugDDI.d452.s0.e1 true
interaction DrugDDI.d452.s0.e0 DrugDDI.d452.s0.e2 true
interaction DrugDDI.d452.s0.e1 DrugDDI.d452.s0.e2 false

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s1
This may increase or enhance the occurrence of osteomalacia in some patients receiving chronic phenytoin therapy.

DrugDDI.d452.s1.new.DISO.e1 39 50
DISO
osteomalacia
DrugDDI.d452.s1.e0 81 89
drug
phenytoin



Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s3
By decreasing the gastrointestinal absorption of primidone , DIAMOX may decrease serum concentrations of primidone and its metabolites , with a consequent possible decrease in anticonvulsant effect.

DrugDDI.d452.s3.e0 43 51
drug
primidone
DrugDDI.d452.s3.e1 53 58
drug
DIAMOX
DrugDDI.d452.s3.e2 91 99
drug
primidone
DrugDDI.d452.s3.e3 106 116
drug
metabolites
DrugDDI.d452.s3.e4 151 164
drug
anticonvulsant

interaction DrugDDI.d452.s3.e0 DrugDDI.d452.s3.e1 false
interaction DrugDDI.d452.s3.e0 DrugDDI.d452.s3.e2 false
interaction DrugDDI.d452.s3.e0 DrugDDI.d452.s3.e3 false
interaction DrugDDI.d452.s3.e0 DrugDDI.d452.s3.e4 false
interaction DrugDDI.d452.s3.e1 DrugDDI.d452.s3.e2 true
interaction DrugDDI.d452.s3.e1 DrugDDI.d452.s3.e3 false
interaction DrugDDI.d452.s3.e1 DrugDDI.d452.s3.e4 false
interaction DrugDDI.d452.s3.e2 DrugDDI.d452.s3.e3 false
interaction DrugDDI.d452.s3.e2 DrugDDI.d452.s3.e4 false
interaction DrugDDI.d452.s3.e3 DrugDDI.d452.s3.e4 false

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s4
Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone .

DrugDDI.d452.s4.e0 63 68
drug
DIAMOX
DrugDDI.d452.s4.e1 88 96
drug
primidone

interaction DrugDDI.d452.s4.e0 DrugDDI.d452.s4.e1 true

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s5
Because of possible additive effects with other carbonic anhydrase inhibitors , concomitant use is not advisable.

DrugDDI.d452.s5.e0 41 67
drug
carbonic anhydrase inhibitors



Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s6
Acetazolamide may increase the effects of other folic acid antagonists .

DrugDDI.d452.s6.e0 0 12
drug
Acetazolamide
DrugDDI.d452.s6.e1 41 60
drug
folic acid antagonists

interaction DrugDDI.d452.s6.e0 DrugDDI.d452.s6.e1 true

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s7
Acetazolamide may increase or decrease blood glucose levels.

DrugDDI.d452.s7.e0 0 12
drug
Acetazolamide



Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s8
Consideration should be taken in patients being treated with antidiabetic agents .

DrugDDI.d452.s8.e0 52 69
drug
antidiabetic agents



Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s9
Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.

DrugDDI.d452.s9.e0 0 12
drug
Acetazolamide
DrugDDI.d452.s9.e1 40 50
drug
amphetamine

interaction DrugDDI.d452.s9.e0 DrugDDI.d452.s9.e1 true

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s10
Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.

DrugDDI.d452.s10.e0 0 12
drug
Acetazolamide
DrugDDI.d452.s10.e1 38 46
drug
quinidine

interaction DrugDDI.d452.s10.e0 DrugDDI.d452.s10.e1 true

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s11
Acetazolamide may prevent the urinary antiseptic effect of methenamine .

DrugDDI.d452.s11.e0 0 12
drug
Acetazolamide
DrugDDI.d452.s11.e1 16 22
drug
prevent
DrugDDI.d452.s11.e2 33 42
drug
antiseptic
DrugDDI.d452.s11.e3 51 61
drug
methenamine

interaction DrugDDI.d452.s11.e0 DrugDDI.d452.s11.e1 false
interaction DrugDDI.d452.s11.e0 DrugDDI.d452.s11.e2 false
interaction DrugDDI.d452.s11.e0 DrugDDI.d452.s11.e3 true
interaction DrugDDI.d452.s11.e1 DrugDDI.d452.s11.e2 false
interaction DrugDDI.d452.s11.e1 DrugDDI.d452.s11.e3 false
interaction DrugDDI.d452.s11.e2 DrugDDI.d452.s11.e3 false

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s12
Acetazolamide increases lithium excretion and the lithium may be decreased.

DrugDDI.d452.s12.e0 0 12
drug
Acetazolamide
DrugDDI.d452.s12.e1 22 28
drug
lithium
DrugDDI.d452.s12.e2 44 50
drug
lithium

interaction DrugDDI.d452.s12.e0 DrugDDI.d452.s12.e1 true
interaction DrugDDI.d452.s12.e0 DrugDDI.d452.s12.e2 false
interaction DrugDDI.d452.s12.e1 DrugDDI.d452.s12.e2 false

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s13
Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.

DrugDDI.d452.s13.e0 0 12
drug
Acetazolamide
DrugDDI.d452.s13.e1 16 32
drug
sodium bicarbonate

interaction DrugDDI.d452.s13.e0 DrugDDI.d452.s13.e1 true

Abstract Id: DrugDDI.d452
Sentence Id: DrugDDI.d452.s14
Acetazolamide may elevate cyclosporine levels.

DrugDDI.d452.s14.e0 0 12
drug
Acetazolamide
DrugDDI.d452.s14.e1 23 34
drug
cyclosporine

interaction DrugDDI.d452.s14.e0 DrugDDI.d452.s14.e1 true

Abstract Id: DrugDDI.d60
Sentence Id: DrugDDI.d60.s0
As DIFFERIN Gel has the potential to produce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol , astringents , spices or lime ) should be approached with caution.

DrugDDI.d60.s0.e0 2 9
drug
DIFFERIN
DrugDDI.d60.s0.e1 242 248
drug
alcohol
DrugDDI.d60.s0.e2 250 260
drug
astringents
DrugDDI.d60.s0.e3 270 273
drug
lime

interaction DrugDDI.d60.s0.e0 DrugDDI.d60.s0.e1 false
interaction DrugDDI.d60.s0.e0 DrugDDI.d60.s0.e2 false
interaction DrugDDI.d60.s0.e0 DrugDDI.d60.s0.e3 false
interaction DrugDDI.d60.s0.e1 DrugDDI.d60.s0.e2 false
interaction DrugDDI.d60.s0.e1 DrugDDI.d60.s0.e3 false
interaction DrugDDI.d60.s0.e2 DrugDDI.d60.s0.e3 false

Abstract Id: DrugDDI.d60
Sentence Id: DrugDDI.d60.s1
Particular caution should be exercised in using preparations containing sulfur , resorcinol , or salicylic acid in combination with DIFFERIN Gel.

DrugDDI.d60.s1.e0 63 68
drug
sulfur
DrugDDI.d60.s1.e1 70 79
drug
resorcinol
DrugDDI.d60.s1.e2 83 95
drug
salicylic acid
DrugDDI.d60.s1.e3 113 120
drug
DIFFERIN

interaction DrugDDI.d60.s1.e0 DrugDDI.d60.s1.e1 false
interaction DrugDDI.d60.s1.e0 DrugDDI.d60.s1.e2 false
interaction DrugDDI.d60.s1.e0 DrugDDI.d60.s1.e3 true
interaction DrugDDI.d60.s1.e1 DrugDDI.d60.s1.e2 false
interaction DrugDDI.d60.s1.e1 DrugDDI.d60.s1.e3 true
interaction DrugDDI.d60.s1.e2 DrugDDI.d60.s1.e3 false

Abstract Id: DrugDDI.d60
Sentence Id: DrugDDI.d60.s2
If these preparations have been used it is advisable not to start therapy with DIFFERIN Gel until the effects of such preparations in the skin have subsided.

DrugDDI.d60.s2.e0 65 72
drug
DIFFERIN



Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s0
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin , amikacin ), amphotericin B , cyclosporine , non-steroidal anti-inflammatory drugs (e.g., ibuprofen ), tacrolimus , vancomycin .

DrugDDI.d409.s0.e0 15 24
drug
medication
DrugDDI.d409.s0.e1 118 132
drug
aminoglycosides
DrugDDI.d409.s0.e2 139 148
drug
gentamicin
DrugDDI.d409.s0.e3 150 157
drug
amikacin
DrugDDI.d409.s0.e4 160 172
drug
amphotericin B
DrugDDI.d409.s0.e5 174 185
drug
cyclosporine
DrugDDI.d409.s0.e6 187 221
drug
non-steroidal anti-inflammatory drugs
DrugDDI.d409.s0.e7 228 236
drug
ibuprofen
DrugDDI.d409.s0.e8 239 248
drug
tacrolimus
DrugDDI.d409.s0.e9 250 259
drug
vancomycin

interaction DrugDDI.d409.s0.e0 DrugDDI.d409.s0.e1 false
interaction DrugDDI.d409.s0.e0 DrugDDI.d409.s0.e2 false
interaction DrugDDI.d409.s0.e0 DrugDDI.d409.s0.e3 false
interaction DrugDDI.d409.s0.e0 DrugDDI.d409.s0.e4 false
interaction DrugDDI.d409.s0.e0 DrugDDI.d409.s0.e5 false
interaction DrugDDI.d409.s0.e0 DrugDDI.d409.s0.e6 false
interaction DrugDDI.d409.s0.e0 DrugDDI.d409.s0.e7 false
interaction DrugDDI.d409.s0.e0 DrugDDI.d409.s0.e8 false
interaction DrugDDI.d409.s0.e0 DrugDDI.d409.s0.e9 false
interaction DrugDDI.d409.s0.e1 DrugDDI.d409.s0.e2 false
interaction DrugDDI.d409.s0.e1 DrugDDI.d409.s0.e3 false
interaction DrugDDI.d409.s0.e1 DrugDDI.d409.s0.e4 false
interaction DrugDDI.d409.s0.e1 DrugDDI.d409.s0.e5 false
interaction DrugDDI.d409.s0.e1 DrugDDI.d409.s0.e6 false
interaction DrugDDI.d409.s0.e1 DrugDDI.d409.s0.e7 false
interaction DrugDDI.d409.s0.e1 DrugDDI.d409.s0.e8 false
interaction DrugDDI.d409.s0.e1 DrugDDI.d409.s0.e9 false
interaction DrugDDI.d409.s0.e2 DrugDDI.d409.s0.e3 false
interaction DrugDDI.d409.s0.e2 DrugDDI.d409.s0.e4 false
interaction DrugDDI.d409.s0.e2 DrugDDI.d409.s0.e5 false
interaction DrugDDI.d409.s0.e2 DrugDDI.d409.s0.e6 false
interaction DrugDDI.d409.s0.e2 DrugDDI.d409.s0.e7 false
interaction DrugDDI.d409.s0.e2 DrugDDI.d409.s0.e8 false
interaction DrugDDI.d409.s0.e2 DrugDDI.d409.s0.e9 false
interaction DrugDDI.d409.s0.e3 DrugDDI.d409.s0.e4 false
interaction DrugDDI.d409.s0.e3 DrugDDI.d409.s0.e5 false
interaction DrugDDI.d409.s0.e3 DrugDDI.d409.s0.e6 false
interaction DrugDDI.d409.s0.e3 DrugDDI.d409.s0.e7 false
interaction DrugDDI.d409.s0.e3 DrugDDI.d409.s0.e8 false
interaction DrugDDI.d409.s0.e3 DrugDDI.d409.s0.e9 false
interaction DrugDDI.d409.s0.e4 DrugDDI.d409.s0.e5 false
interaction DrugDDI.d409.s0.e4 DrugDDI.d409.s0.e6 false
interaction DrugDDI.d409.s0.e4 DrugDDI.d409.s0.e7 false
interaction DrugDDI.d409.s0.e4 DrugDDI.d409.s0.e8 false
interaction DrugDDI.d409.s0.e4 DrugDDI.d409.s0.e9 false
interaction DrugDDI.d409.s0.e5 DrugDDI.d409.s0.e6 false
interaction DrugDDI.d409.s0.e5 DrugDDI.d409.s0.e7 false
interaction DrugDDI.d409.s0.e5 DrugDDI.d409.s0.e8 false
interaction DrugDDI.d409.s0.e5 DrugDDI.d409.s0.e9 false
interaction DrugDDI.d409.s0.e6 DrugDDI.d409.s0.e7 false
interaction DrugDDI.d409.s0.e6 DrugDDI.d409.s0.e8 false
interaction DrugDDI.d409.s0.e6 DrugDDI.d409.s0.e9 false
interaction DrugDDI.d409.s0.e7 DrugDDI.d409.s0.e8 false
interaction DrugDDI.d409.s0.e7 DrugDDI.d409.s0.e9 false
interaction DrugDDI.d409.s0.e8 DrugDDI.d409.s0.e9 false

Abstract Id: DrugDDI.d409
Sentence Id: DrugDDI.d409.s1
Do not start or stop any medicine without doctor or pharmacist approval.

DrugDDI.d409.s1.e0 19 26
drug
medicine



Abstract Id: DrugDDI.d167
Sentence Id: DrugDDI.d167.s0
Drug /Laboratory Interactions : No formal drug interaction studies have been performed with Campath .

DrugDDI.d167.s0.e0 0 3
drug
Drug
DrugDDI.d167.s0.e1 79 85
drug
Campath

interaction DrugDDI.d167.s0.e0 DrugDDI.d167.s0.e1 false

Abstract Id: DrugDDI.d167
Sentence Id: DrugDDI.d167.s1
An immune response to Campath may interfere with subsequent diagnostic serum tests that utilize antibodies .

DrugDDI.d167.s1.e0 18 24
drug
Campath
DrugDDI.d167.s1.e1 82 91
drug
antibodies

interaction DrugDDI.d167.s1.e0 DrugDDI.d167.s1.e1 true

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s0
Because alosetron is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of alosetron .

DrugDDI.d450.s0.e0 7 15
drug
alosetron
DrugDDI.d450.s0.e1 133 141
drug
alosetron

interaction DrugDDI.d450.s0.e0 DrugDDI.d450.s0.e1 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s1
Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4 , CYP2C9 , and CYP2C19 .

DrugDDI.d450.s1.e0 0 10
drug
Fluvoxamine
DrugDDI.d450.s1.e1 36 41
drug
CYP1A2
DrugDDI.d450.s1.e2 57 62
drug
CYP3A4
DrugDDI.d450.s1.e3 64 69
drug
CYP2C9
DrugDDI.d450.s1.e4 74 80
drug
CYP2C19

interaction DrugDDI.d450.s1.e0 DrugDDI.d450.s1.e1 true
interaction DrugDDI.d450.s1.e0 DrugDDI.d450.s1.e2 true
interaction DrugDDI.d450.s1.e0 DrugDDI.d450.s1.e3 true
interaction DrugDDI.d450.s1.e0 DrugDDI.d450.s1.e4 true
interaction DrugDDI.d450.s1.e1 DrugDDI.d450.s1.e2 false
interaction DrugDDI.d450.s1.e1 DrugDDI.d450.s1.e3 false
interaction DrugDDI.d450.s1.e1 DrugDDI.d450.s1.e4 false
interaction DrugDDI.d450.s1.e2 DrugDDI.d450.s1.e3 false
interaction DrugDDI.d450.s1.e2 DrugDDI.d450.s1.e4 false
interaction DrugDDI.d450.s1.e3 DrugDDI.d450.s1.e4 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s2
In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of alosetron 1 mg on the last day.

DrugDDI.d450.s2.e0 55 65
drug
fluvoxamine
DrugDDI.d450.s2.e1 134 145
drug
alosetron 1 mg

interaction DrugDDI.d450.s2.e0 DrugDDI.d450.s2.e1 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s3
Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.

DrugDDI.d450.s3.e0 0 10
drug
Fluvoxamine
DrugDDI.d450.s3.e1 24 32
drug
alosetron

interaction DrugDDI.d450.s3.e0 DrugDDI.d450.s3.e1 true

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s4
Concomitant administration of alosetron and fluvoxamine is contraindicated.

DrugDDI.d450.s4.e0 27 35
drug
alosetron
DrugDDI.d450.s4.e1 39 49
drug
fluvoxamine

interaction DrugDDI.d450.s4.e0 DrugDDI.d450.s4.e1 true

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s5
Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotic s and cimetidine , has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.

DrugDDI.d450.s5.e0 27 35
drug
alosetron
DrugDDI.d450.s5.e1 47 52
drug
CYP1A2
DrugDDI.d450.s5.e2 73 91
drug
quinolone antibiotic
DrugDDI.d450.s5.e3 96 105
drug
cimetidine

interaction DrugDDI.d450.s5.e0 DrugDDI.d450.s5.e1 true
interaction DrugDDI.d450.s5.e0 DrugDDI.d450.s5.e2 false
interaction DrugDDI.d450.s5.e0 DrugDDI.d450.s5.e3 true
interaction DrugDDI.d450.s5.e1 DrugDDI.d450.s5.e2 false
interaction DrugDDI.d450.s5.e1 DrugDDI.d450.s5.e3 false
interaction DrugDDI.d450.s5.e2 DrugDDI.d450.s5.e3 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s6
Ketoconazole is a known strong inhibitor of CYP3A4 .

DrugDDI.d450.s6.e0 0 11
drug
Ketoconazole
DrugDDI.d450.s6.e1 37 42
drug
CYP3A4

interaction DrugDDI.d450.s6.e0 DrugDDI.d450.s6.e1 true

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s7
In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day.

DrugDDI.d450.s7.e0 55 71
drug
ketoconazole 200 mg
DrugDDI.d450.s7.e1 113 124
drug
alosetron 1 mg

interaction DrugDDI.d450.s7.e0 DrugDDI.d450.s7.e1 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s8
Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.

DrugDDI.d450.s8.e0 0 11
drug
Ketoconazole
DrugDDI.d450.s8.e1 25 33
drug
alosetron

interaction DrugDDI.d450.s8.e0 DrugDDI.d450.s8.e1 true

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s9
Caution should be used when alosetron and ketoconazole are administered concomitantly.

DrugDDI.d450.s9.e0 23 31
drug
alosetron
DrugDDI.d450.s9.e1 35 46
drug
ketoconazole

interaction DrugDDI.d450.s9.e0 DrugDDI.d450.s9.e1 true

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s10
Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin , telithromycin , protease inhibitors , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.

DrugDDI.d450.s10.e0 18 26
drug
alosetron
DrugDDI.d450.s10.e1 36 41
drug
CYP3A4
DrugDDI.d450.s10.e2 59 72
drug
clarithromycin
DrugDDI.d450.s10.e3 74 86
drug
telithromycin
DrugDDI.d450.s10.e4 88 105
drug
protease inhibitors
DrugDDI.d450.s10.e5 107 118
drug
voriconazole
DrugDDI.d450.s10.e6 123 134
drug
itraconazole

interaction DrugDDI.d450.s10.e0 DrugDDI.d450.s10.e1 false
interaction DrugDDI.d450.s10.e0 DrugDDI.d450.s10.e2 false
interaction DrugDDI.d450.s10.e0 DrugDDI.d450.s10.e3 false
interaction DrugDDI.d450.s10.e0 DrugDDI.d450.s10.e4 false
interaction DrugDDI.d450.s10.e0 DrugDDI.d450.s10.e5 false
interaction DrugDDI.d450.s10.e0 DrugDDI.d450.s10.e6 false
interaction DrugDDI.d450.s10.e1 DrugDDI.d450.s10.e2 false
interaction DrugDDI.d450.s10.e1 DrugDDI.d450.s10.e3 false
interaction DrugDDI.d450.s10.e1 DrugDDI.d450.s10.e4 false
interaction DrugDDI.d450.s10.e1 DrugDDI.d450.s10.e5 false
interaction DrugDDI.d450.s10.e1 DrugDDI.d450.s10.e6 false
interaction DrugDDI.d450.s10.e2 DrugDDI.d450.s10.e3 false
interaction DrugDDI.d450.s10.e2 DrugDDI.d450.s10.e4 false
interaction DrugDDI.d450.s10.e2 DrugDDI.d450.s10.e5 false
interaction DrugDDI.d450.s10.e2 DrugDDI.d450.s10.e6 false
interaction DrugDDI.d450.s10.e3 DrugDDI.d450.s10.e4 false
interaction DrugDDI.d450.s10.e3 DrugDDI.d450.s10.e5 false
interaction DrugDDI.d450.s10.e3 DrugDDI.d450.s10.e6 false
interaction DrugDDI.d450.s10.e4 DrugDDI.d450.s10.e5 false
interaction DrugDDI.d450.s10.e4 DrugDDI.d450.s10.e6 false
interaction DrugDDI.d450.s10.e5 DrugDDI.d450.s10.e6 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s11
The effect of induction or inhibition of other pathways on exposure to alosetron and its metabolites is not known.

DrugDDI.d450.s11.e0 59 67
drug
alosetron
DrugDDI.d450.s11.e1 74 84
drug
metabolites

interaction DrugDDI.d450.s11.e0 DrugDDI.d450.s11.e1 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s12
In vitro human liver microsome studies and an in vivo metabolic probe study demonstrated that alosetron did not inhibit CYP enzyme s 2D6, 3A4, 2C9, or 2C19.

DrugDDI.d450.s12.e0 79 87
drug
alosetron
DrugDDI.d450.s12.e1 101 109
drug
CYP enzyme

interaction DrugDDI.d450.s12.e0 DrugDDI.d450.s12.e1 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s13
In vitro, at total drug concentrations 27-fold higher than peak plasma concentrations observed with the 1-mg dosage, alosetron inhibited CYP enzyme s 1A2 (60%) and 2E1 (50%).

DrugDDI.d450.s13.e0 100 108
drug
alosetron
DrugDDI.d450.s13.e1 118 126
drug
CYP enzyme

interaction DrugDDI.d450.s13.e0 DrugDDI.d450.s13.e1 true

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s14
In an in vivo metabolic probe study, alosetron did not inhibit CYP2E1 but did produce 30% inhibition of both CYP1A2 and N-acetyltransferase .

DrugDDI.d450.s14.e0 30 38
drug
alosetron
DrugDDI.d450.s14.e1 52 57
drug
CYP2E1
DrugDDI.d450.s14.e2 90 95
drug
CYP1A2
DrugDDI.d450.s14.e3 99 117
drug
N-acetyltransferase

interaction DrugDDI.d450.s14.e0 DrugDDI.d450.s14.e1 false
interaction DrugDDI.d450.s14.e0 DrugDDI.d450.s14.e2 true
interaction DrugDDI.d450.s14.e0 DrugDDI.d450.s14.e3 false
interaction DrugDDI.d450.s14.e1 DrugDDI.d450.s14.e2 false
interaction DrugDDI.d450.s14.e1 DrugDDI.d450.s14.e3 false
interaction DrugDDI.d450.s14.e2 DrugDDI.d450.s14.e3 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s15
Although not studied with alosetron , inhibition of N- acetyltransferase may have clinically relevant consequences for drugs such as isoniazid , procainamide , and hydralazine .

DrugDDI.d450.s15.e0 22 30
drug
alosetron
DrugDDI.d450.s15.e1 46 62
drug
acetyltransferase
DrugDDI.d450.s15.e2 103 107
drug
drugs
DrugDDI.d450.s15.e3 114 122
drug
isoniazid
DrugDDI.d450.s15.e4 124 135
drug
procainamide
DrugDDI.d450.s15.e5 140 150
drug
hydralazine

interaction DrugDDI.d450.s15.e0 DrugDDI.d450.s15.e1 false
interaction DrugDDI.d450.s15.e0 DrugDDI.d450.s15.e2 false
interaction DrugDDI.d450.s15.e0 DrugDDI.d450.s15.e3 false
interaction DrugDDI.d450.s15.e0 DrugDDI.d450.s15.e4 false
interaction DrugDDI.d450.s15.e0 DrugDDI.d450.s15.e5 false
interaction DrugDDI.d450.s15.e1 DrugDDI.d450.s15.e2 true
interaction DrugDDI.d450.s15.e1 DrugDDI.d450.s15.e3 true
interaction DrugDDI.d450.s15.e1 DrugDDI.d450.s15.e4 true
interaction DrugDDI.d450.s15.e1 DrugDDI.d450.s15.e5 true
interaction DrugDDI.d450.s15.e2 DrugDDI.d450.s15.e3 false
interaction DrugDDI.d450.s15.e2 DrugDDI.d450.s15.e4 false
interaction DrugDDI.d450.s15.e2 DrugDDI.d450.s15.e5 false
interaction DrugDDI.d450.s15.e3 DrugDDI.d450.s15.e4 false
interaction DrugDDI.d450.s15.e3 DrugDDI.d450.s15.e5 false
interaction DrugDDI.d450.s15.e4 DrugDDI.d450.s15.e5 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s16
The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed.

DrugDDI.d450.s16.e0 11 16
drug
CYP1A2
DrugDDI.d450.s16.e1 66 77
drug
theophylline

interaction DrugDDI.d450.s16.e0 DrugDDI.d450.s16.e1 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s17
Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agent s ethinyl estradiol and levonorgestrel ( CYP3A4 substrates).

DrugDDI.d450.s17.e0 22 30
drug
alosetron
DrugDDI.d450.s17.e1 90 111
drug
oral contraceptive agent
DrugDDI.d450.s17.e2 132 145
drug
levonorgestrel
DrugDDI.d450.s17.e3 147 152
drug
CYP3A4

interaction DrugDDI.d450.s17.e0 DrugDDI.d450.s17.e1 false
interaction DrugDDI.d450.s17.e0 DrugDDI.d450.s17.e2 false
interaction DrugDDI.d450.s17.e0 DrugDDI.d450.s17.e3 false
interaction DrugDDI.d450.s17.e1 DrugDDI.d450.s17.e2 false
interaction DrugDDI.d450.s17.e1 DrugDDI.d450.s17.e3 false
interaction DrugDDI.d450.s17.e2 DrugDDI.d450.s17.e3 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s18
A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride .

DrugDDI.d450.s18.e0 45 53
drug
alosetron
DrugDDI.d450.s18.e1 75 83
drug
cisapride

interaction DrugDDI.d450.s18.e0 DrugDDI.d450.s18.e1 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s19
No significant effects on cisapride metabolism or QT interval were noted.

DrugDDI.d450.s19.e0 22 30
drug
cisapride



Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s20
The effect of alosetron on monoamine oxidases and on intestinal first pass secondary to high intraluminal concentrations have not been examined.

DrugDDI.d450.s20.e0 11 19
drug
alosetron
DrugDDI.d450.s20.e1 22 38
drug
monoamine oxidases

interaction DrugDDI.d450.s20.e0 DrugDDI.d450.s20.e1 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s21
Based on the above data from in vitro and in vivo studies, it is unlikely that alosetron will inhibit the hepatic metabolic clearance of drugs metabolized by the major CYP enzyme 3A4, as well as the CYP enzyme s 2D6, 2C9, 2C19, 2E1, or 1A2.

DrugDDI.d450.s21.e0 63 71
drug
alosetron
DrugDDI.d450.s21.e1 113 117
drug
drugs
DrugDDI.d450.s21.e2 139 141
drug
CYP
DrugDDI.d450.s21.e3 163 171
drug
CYP enzyme

interaction DrugDDI.d450.s21.e0 DrugDDI.d450.s21.e1 false
interaction DrugDDI.d450.s21.e0 DrugDDI.d450.s21.e2 false
interaction DrugDDI.d450.s21.e0 DrugDDI.d450.s21.e3 false
interaction DrugDDI.d450.s21.e1 DrugDDI.d450.s21.e2 false
interaction DrugDDI.d450.s21.e1 DrugDDI.d450.s21.e3 false
interaction DrugDDI.d450.s21.e2 DrugDDI.d450.s21.e3 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s22
Alosetron does not appear to induce the major cytochrome P450 ( CYP ) drug metabolizing enzyme 3A.

DrugDDI.d450.s22.e0 0 8
drug
Alosetron
DrugDDI.d450.s22.e1 38 51
drug
cytochrome P450
DrugDDI.d450.s22.e2 53 55
drug
CYP
DrugDDI.d450.s22.e3 57 60
drug
drug

interaction DrugDDI.d450.s22.e0 DrugDDI.d450.s22.e1 false
interaction DrugDDI.d450.s22.e0 DrugDDI.d450.s22.e2 false
interaction DrugDDI.d450.s22.e0 DrugDDI.d450.s22.e3 false
interaction DrugDDI.d450.s22.e1 DrugDDI.d450.s22.e2 false
interaction DrugDDI.d450.s22.e1 DrugDDI.d450.s22.e3 false
interaction DrugDDI.d450.s22.e2 DrugDDI.d450.s22.e3 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s23
Alosetron also does not appear to induce CYP enzyme s 2E1 or 2C19.

DrugDDI.d450.s23.e0 0 8
drug
Alosetron
DrugDDI.d450.s23.e1 34 42
drug
CYP enzyme

interaction DrugDDI.d450.s23.e0 DrugDDI.d450.s23.e1 false

Abstract Id: DrugDDI.d450
Sentence Id: DrugDDI.d450.s24
It is not known whether alosetron might induce other enzymes.

DrugDDI.d450.s24.e0 19 27
drug
alosetron



Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s0
The interaction of Activase with other cardioactive or cerebroactive drugs has not been studied.

DrugDDI.d503.s0.e0 16 23
drug
Activase
DrugDDI.d503.s0.e1 60 64
drug
drugs

interaction DrugDDI.d503.s0.e0 DrugDDI.d503.s0.e1 false

Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s1
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.

DrugDDI.d503.s1.e0 34 40
drug
heparin
DrugDDI.d503.s1.e1 64 68
drug
drugs
DrugDDI.d503.s1.e2 101 119
drug
acetylsalicylic acid
DrugDDI.d503.s1.e3 121 132
drug
dipyridamole
DrugDDI.d503.s1.e4 136 144
drug
Abciximab
DrugDDI.d503.s1.e5 210 217
drug
Activase

interaction DrugDDI.d503.s1.e0 DrugDDI.d503.s1.e1 false
interaction DrugDDI.d503.s1.e0 DrugDDI.d503.s1.e2 false
interaction DrugDDI.d503.s1.e0 DrugDDI.d503.s1.e3 false
interaction DrugDDI.d503.s1.e0 DrugDDI.d503.s1.e4 false
interaction DrugDDI.d503.s1.e0 DrugDDI.d503.s1.e5 false
interaction DrugDDI.d503.s1.e1 DrugDDI.d503.s1.e2 false
interaction DrugDDI.d503.s1.e1 DrugDDI.d503.s1.e3 false
interaction DrugDDI.d503.s1.e1 DrugDDI.d503.s1.e4 false
interaction DrugDDI.d503.s1.e1 DrugDDI.d503.s1.e5 false
interaction DrugDDI.d503.s1.e2 DrugDDI.d503.s1.e3 false
interaction DrugDDI.d503.s1.e2 DrugDDI.d503.s1.e4 false
interaction DrugDDI.d503.s1.e2 DrugDDI.d503.s1.e5 true
interaction DrugDDI.d503.s1.e3 DrugDDI.d503.s1.e4 false
interaction DrugDDI.d503.s1.e3 DrugDDI.d503.s1.e5 true
interaction DrugDDI.d503.s1.e4 DrugDDI.d503.s1.e5 true

Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s2
Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.

DrugDDI.d503.s2.e0 20 26
drug
Aspirin
DrugDDI.d503.s2.e1 30 36
drug
heparin
DrugDDI.d503.s2.e2 97 104
drug
Activase
DrugDDI.d503.s2.new.DISO.e3 122 165
DISO
acute myocardial infarction or pulmonary embolism

interaction DrugDDI.d503.s2.e0 DrugDDI.d503.s2.e1 false
interaction DrugDDI.d503.s2.e0 DrugDDI.d503.s2.e2 false
interaction DrugDDI.d503.s2.e1 DrugDDI.d503.s2.e2 false

Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s3
Because heparin , aspirin , or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.

DrugDDI.d503.s3.e0 7 13
drug
heparin
DrugDDI.d503.s3.e1 15 21
drug
aspirin
DrugDDI.d503.s3.e2 25 32
drug
Activase

interaction DrugDDI.d503.s3.e0 DrugDDI.d503.s3.e1 false
interaction DrugDDI.d503.s3.e0 DrugDDI.d503.s3.e2 false
interaction DrugDDI.d503.s3.e1 DrugDDI.d503.s3.e2 false

Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s4
The concomitant use of heparin or aspirin during the first 24 hours following symptom onset were prohibit ed in The NINDS t-PA Stroke Trial.

DrugDDI.d503.s4.e0 19 25
drug
heparin
DrugDDI.d503.s4.e1 28 34
drug
aspirin
DrugDDI.d503.s4.e2 81 88
drug
prohibit

interaction DrugDDI.d503.s4.e0 DrugDDI.d503.s4.e1 true
interaction DrugDDI.d503.s4.e0 DrugDDI.d503.s4.e2 false
interaction DrugDDI.d503.s4.e1 DrugDDI.d503.s4.e2 false

Abstract Id: DrugDDI.d503
Sentence Id: DrugDDI.d503.s5
The safety of such concomitant use with Activase for the management of acute ischemic stroke is unknown.

DrugDDI.d503.s5.e0 33 40
drug
Activase
DrugDDI.d503.s5.new.DISO.e1 59 77
DISO
acute ischemic stroke



Abstract Id: DrugDDI.d0
Sentence Id: DrugDDI.d0.s0
Special consideration should be given to the administration of ETHYOL@ in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.

DrugDDI.d0.s0.e0 80 95
drug
antihypertensive
DrugDDI.d0.s0.e1 114 118
drug
drugs

interaction DrugDDI.d0.s0.e0 DrugDDI.d0.s0.e1 false

Abstract Id: DrugDDI.d153
Sentence Id: DrugDDI.d153.s0
Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides , procaine , or thiazolesulfone.

DrugDDI.d153.s0.e0 88 99
drug
sulfonamides
DrugDDI.d153.s0.e1 101 108
drug
procaine

interaction DrugDDI.d153.s0.e0 DrugDDI.d153.s0.e1 false

Abstract Id: DrugDDI.d153
Sentence Id: DrugDDI.d153.s2
Probenecid depresses tubular secretion of certain weak acids such as PAH.

DrugDDI.d153.s2.e0 0 9
drug
Probenecid



Abstract Id: DrugDDI.d153
Sentence Id: DrugDDI.d153.s3
Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.

DrugDDI.d153.s3.e0 27 36
drug
probenecid



Abstract Id: DrugDDI.d342
Sentence Id: DrugDDI.d342.s0
Aminosalicylic acid may decrease the amount of digoxin ( Lanoxin , Lanoxicaps ) that gets absorbed into your body.

DrugDDI.d342.s0.e0 0 17
drug
Aminosalicylic acid
DrugDDI.d342.s0.e1 40 46
drug
digoxin
DrugDDI.d342.s0.e2 48 54
drug
Lanoxin
DrugDDI.d342.s0.e3 56 65
drug
Lanoxicaps
DrugDDI.d342.s0.e4 71 74
drug
gets

interaction DrugDDI.d342.s0.e0 DrugDDI.d342.s0.e1 true
interaction DrugDDI.d342.s0.e0 DrugDDI.d342.s0.e2 false
interaction DrugDDI.d342.s0.e0 DrugDDI.d342.s0.e3 true
interaction DrugDDI.d342.s0.e0 DrugDDI.d342.s0.e4 false
interaction DrugDDI.d342.s0.e1 DrugDDI.d342.s0.e2 false
interaction DrugDDI.d342.s0.e1 DrugDDI.d342.s0.e3 false
interaction DrugDDI.d342.s0.e1 DrugDDI.d342.s0.e4 false
interaction DrugDDI.d342.s0.e2 DrugDDI.d342.s0.e3 false
interaction DrugDDI.d342.s0.e2 DrugDDI.d342.s0.e4 false
interaction DrugDDI.d342.s0.e3 DrugDDI.d342.s0.e4 false

Abstract Id: DrugDDI.d342
Sentence Id: DrugDDI.d342.s1
In the case that you are taking digoxin while taking aminosalicylic acid , higher doses of digoxin may be needed.

DrugDDI.d342.s1.e0 25 31
drug
digoxin
DrugDDI.d342.s1.e1 43 60
drug
aminosalicylic acid
DrugDDI.d342.s1.e2 75 81
drug
digoxin

interaction DrugDDI.d342.s1.e0 DrugDDI.d342.s1.e1 true
interaction DrugDDI.d342.s1.e0 DrugDDI.d342.s1.e2 false
interaction DrugDDI.d342.s1.e1 DrugDDI.d342.s1.e2 false

Abstract Id: DrugDDI.d342
Sentence Id: DrugDDI.d342.s2
Aminosalicylic acid may also decrease the absorption of vitamin B12 , which can lead to a deficiency.

DrugDDI.d342.s2.e0 0 17
drug
Aminosalicylic acid
DrugDDI.d342.s2.e1 48 57
drug
vitamin B12
DrugDDI.d342.s2.new.DISO.e2 73 83
DISO
a deficiency

interaction DrugDDI.d342.s2.e0 DrugDDI.d342.s2.e1 true

Abstract Id: DrugDDI.d342
Sentence Id: DrugDDI.d342.s3
Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid .

DrugDDI.d342.s3.e0 57 74
drug
aminosalicylic acid



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s0
Amiodarone is metabolized to desethylamiodarone by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 ( CYP3A4 ) and CYP2C8 .

DrugDDI.d63.s0.e0 0 9
drug
Amiodarone
DrugDDI.d63.s0.e1 25 42
drug
desethylamiodarone
DrugDDI.d63.s0.e2 48 61
drug
cytochrome P450
DrugDDI.d63.s0.e3 94 111
drug
cytochromes P450 3A4
DrugDDI.d63.s0.e4 113 118
drug
CYP3A4
DrugDDI.d63.s0.e5 123 128
drug
CYP2C8

interaction DrugDDI.d63.s0.e0 DrugDDI.d63.s0.e1 false
interaction DrugDDI.d63.s0.e0 DrugDDI.d63.s0.e2 true
interaction DrugDDI.d63.s0.e0 DrugDDI.d63.s0.e3 false
interaction DrugDDI.d63.s0.e0 DrugDDI.d63.s0.e4 true
interaction DrugDDI.d63.s0.e0 DrugDDI.d63.s0.e5 false
interaction DrugDDI.d63.s0.e1 DrugDDI.d63.s0.e2 false
interaction DrugDDI.d63.s0.e1 DrugDDI.d63.s0.e3 false
interaction DrugDDI.d63.s0.e1 DrugDDI.d63.s0.e4 false
interaction DrugDDI.d63.s0.e1 DrugDDI.d63.s0.e5 false
interaction DrugDDI.d63.s0.e2 DrugDDI.d63.s0.e3 false
interaction DrugDDI.d63.s0.e2 DrugDDI.d63.s0.e4 false
interaction DrugDDI.d63.s0.e2 DrugDDI.d63.s0.e5 false
interaction DrugDDI.d63.s0.e3 DrugDDI.d63.s0.e4 false
interaction DrugDDI.d63.s0.e3 DrugDDI.d63.s0.e5 false
interaction DrugDDI.d63.s0.e4 DrugDDI.d63.s0.e5 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s1
The CYP3A4 isoenzyme is present in both the liver and intestines.

DrugDDI.d63.s1.e0 3 17
drug
CYP3A4 isoenzyme
DrugDDI.d63.s1.e1 36 40
drug
liver

interaction DrugDDI.d63.s1.e0 DrugDDI.d63.s1.e1 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s2
Amiodarone is also known to be an inhibitor of CYP3A4 .

DrugDDI.d63.s2.e0 0 9
drug
Amiodarone
DrugDDI.d63.s2.e1 38 43
drug
CYP3A4

interaction DrugDDI.d63.s2.e0 DrugDDI.d63.s2.e1 true

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s3
Therefore, amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP3A4 .

DrugDDI.d63.s3.e0 10 19
drug
amiodarone
DrugDDI.d63.s3.e1 54 58
drug
drugs
DrugDDI.d63.s3.e2 113 118
drug
CYP3A4

interaction DrugDDI.d63.s3.e0 DrugDDI.d63.s3.e1 true
interaction DrugDDI.d63.s3.e0 DrugDDI.d63.s3.e2 false
interaction DrugDDI.d63.s3.e1 DrugDDI.d63.s3.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s4
While only a limited number of in vivo drug-drug interactions with amiodarone have been reported, chiefly with the oral formulation, the potential for other interactions should be anticipated.

DrugDDI.d63.s4.e0 56 65
drug
amiodarone



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s5
This is especially important for drugs associated with serious toxicity, such as other antiarrhythmics .

DrugDDI.d63.s5.e0 28 32
drug
drugs
DrugDDI.d63.s5.e1 74 88
drug
antiarrhythmics

interaction DrugDDI.d63.s5.e0 DrugDDI.d63.s5.e1 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s6
If such drugs are needed, their dose should be reassessed and, where appropriate, plasma concentration measured.

DrugDDI.d63.s6.e0 6 10
drug
drugs



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s7
In view of the long and variable half-life of amiodarone , potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of amiodarone .

DrugDDI.d63.s7.e0 37 46
drug
amiodarone
DrugDDI.d63.s7.e1 104 113
drug
medication
DrugDDI.d63.s7.e2 125 129
drug
drugs
DrugDDI.d63.s7.e3 164 173
drug
amiodarone

interaction DrugDDI.d63.s7.e0 DrugDDI.d63.s7.e1 false
interaction DrugDDI.d63.s7.e0 DrugDDI.d63.s7.e2 false
interaction DrugDDI.d63.s7.e0 DrugDDI.d63.s7.e3 false
interaction DrugDDI.d63.s7.e1 DrugDDI.d63.s7.e2 false
interaction DrugDDI.d63.s7.e1 DrugDDI.d63.s7.e3 false
interaction DrugDDI.d63.s7.e2 DrugDDI.d63.s7.e3 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s8
Since amiodarone is a substrate for CYP3A4 and CYP2C8 , drugs /substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone .

DrugDDI.d63.s8.e0 5 14
drug
amiodarone
DrugDDI.d63.s8.e1 30 35
drug
CYP3A4
DrugDDI.d63.s8.e2 39 44
drug
CYP2C8
DrugDDI.d63.s8.e3 46 50
drug
drugs
DrugDDI.d63.s8.e4 78 87
drug
isoenzymes
DrugDDI.d63.s8.e5 143 152
drug
amiodarone

interaction DrugDDI.d63.s8.e0 DrugDDI.d63.s8.e1 false
interaction DrugDDI.d63.s8.e0 DrugDDI.d63.s8.e2 false
interaction DrugDDI.d63.s8.e0 DrugDDI.d63.s8.e3 false
interaction DrugDDI.d63.s8.e0 DrugDDI.d63.s8.e4 false
interaction DrugDDI.d63.s8.e0 DrugDDI.d63.s8.e5 false
interaction DrugDDI.d63.s8.e1 DrugDDI.d63.s8.e2 false
interaction DrugDDI.d63.s8.e1 DrugDDI.d63.s8.e3 false
interaction DrugDDI.d63.s8.e1 DrugDDI.d63.s8.e4 false
interaction DrugDDI.d63.s8.e1 DrugDDI.d63.s8.e5 false
interaction DrugDDI.d63.s8.e2 DrugDDI.d63.s8.e3 false
interaction DrugDDI.d63.s8.e2 DrugDDI.d63.s8.e4 false
interaction DrugDDI.d63.s8.e2 DrugDDI.d63.s8.e5 false
interaction DrugDDI.d63.s8.e3 DrugDDI.d63.s8.e4 false
interaction DrugDDI.d63.s8.e3 DrugDDI.d63.s8.e5 true
interaction DrugDDI.d63.s8.e4 DrugDDI.d63.s8.e5 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s9
Reported examples include the following: Protease Inhibitors : Protease inhibitors are known to inhibit CYP3A4 to varying degrees.

DrugDDI.d63.s9.e0 36 53
drug
Protease Inhibitors
DrugDDI.d63.s9.e1 55 72
drug
Protease inhibitors
DrugDDI.d63.s9.e2 90 95
drug
CYP3A4

interaction DrugDDI.d63.s9.e0 DrugDDI.d63.s9.e1 false
interaction DrugDDI.d63.s9.e0 DrugDDI.d63.s9.e2 false
interaction DrugDDI.d63.s9.e1 DrugDDI.d63.s9.e2 true

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s10
A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.

DrugDDI.d63.s10.e0 29 43
drug
amiodarone 200 mg
DrugDDI.d63.s10.e1 47 55
drug
indinavir
DrugDDI.d63.s10.e2 96 105
drug
amiodarone

interaction DrugDDI.d63.s10.e0 DrugDDI.d63.s10.e1 true
interaction DrugDDI.d63.s10.e0 DrugDDI.d63.s10.e2 false
interaction DrugDDI.d63.s10.e1 DrugDDI.d63.s10.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s13
Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.

DrugDDI.d63.s13.e0 13 22
drug
amiodarone
DrugDDI.d63.s13.e1 53 62
drug
amiodarone
DrugDDI.d63.s13.e2 98 114
drug
protease inhibitor

interaction DrugDDI.d63.s13.e0 DrugDDI.d63.s13.e1 false
interaction DrugDDI.d63.s13.e0 DrugDDI.d63.s13.e2 true
interaction DrugDDI.d63.s13.e1 DrugDDI.d63.s13.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s14
Histamine H2 antagonists : Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.

DrugDDI.d63.s14.e0 0 21
drug
Histamine H2 antagonists
DrugDDI.d63.s14.e1 23 32
drug
Cimetidine
DrugDDI.d63.s14.e2 41 46
drug
CYP3A4

interaction DrugDDI.d63.s14.e0 DrugDDI.d63.s14.e1 false
interaction DrugDDI.d63.s14.e0 DrugDDI.d63.s14.e2 false
interaction DrugDDI.d63.s14.e1 DrugDDI.d63.s14.e2 true

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s15
Other substances: Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone .

DrugDDI.d63.s15.e0 64 73
drug
amiodarone
DrugDDI.d63.s15.e1 129 138
drug
amiodarone

interaction DrugDDI.d63.s15.e0 DrugDDI.d63.s15.e1 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s16
Grapefruit juice should not be taken during treatment with oral amiodarone .

DrugDDI.d63.s16.e0 54 63
drug
amiodarone



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s17
This information should be considered when changing from intravenous amiodarone to oral amiodarone .

DrugDDI.d63.s17.e0 60 69
drug
amiodarone
DrugDDI.d63.s17.e1 76 85
drug
amiodarone

interaction DrugDDI.d63.s17.e0 DrugDDI.d63.s17.e1 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s18
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2 , CYP2C9 , CYP2D6 , and CYP3A4 .

DrugDDI.d63.s18.e0 0 9
drug
Amiodarone
DrugDDI.d63.s18.e1 51 56
drug
CYP1A2
DrugDDI.d63.s18.e2 58 63
drug
CYP2C9
DrugDDI.d63.s18.e3 65 70
drug
CYP2D6
DrugDDI.d63.s18.e4 75 80
drug
CYP3A4

interaction DrugDDI.d63.s18.e0 DrugDDI.d63.s18.e1 true
interaction DrugDDI.d63.s18.e0 DrugDDI.d63.s18.e2 false
interaction DrugDDI.d63.s18.e0 DrugDDI.d63.s18.e3 true
interaction DrugDDI.d63.s18.e0 DrugDDI.d63.s18.e4 false
interaction DrugDDI.d63.s18.e1 DrugDDI.d63.s18.e2 false
interaction DrugDDI.d63.s18.e1 DrugDDI.d63.s18.e3 false
interaction DrugDDI.d63.s18.e1 DrugDDI.d63.s18.e4 false
interaction DrugDDI.d63.s18.e2 DrugDDI.d63.s18.e3 false
interaction DrugDDI.d63.s18.e2 DrugDDI.d63.s18.e4 false
interaction DrugDDI.d63.s18.e3 DrugDDI.d63.s18.e4 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s19
This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes.

DrugDDI.d63.s19.e0 60 64
drug
drugs



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s20
Reported examples of this interaction include the following: Immunosuppressive s: Cyclosporine ( CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine .

DrugDDI.d63.s20.e0 53 69
drug
Immunosuppressive
DrugDDI.d63.s20.e1 72 83
drug
Cyclosporine
DrugDDI.d63.s20.e2 85 90
drug
CYP3A4
DrugDDI.d63.s20.e3 134 143
drug
amiodarone
DrugDDI.d63.s20.e4 210 221
drug
cyclosporine
DrugDDI.d63.s20.e5 276 287
drug
cyclosporine

interaction DrugDDI.d63.s20.e0 DrugDDI.d63.s20.e1 false
interaction DrugDDI.d63.s20.e0 DrugDDI.d63.s20.e2 false
interaction DrugDDI.d63.s20.e0 DrugDDI.d63.s20.e3 false
interaction DrugDDI.d63.s20.e0 DrugDDI.d63.s20.e4 false
interaction DrugDDI.d63.s20.e0 DrugDDI.d63.s20.e5 false
interaction DrugDDI.d63.s20.e1 DrugDDI.d63.s20.e2 false
interaction DrugDDI.d63.s20.e1 DrugDDI.d63.s20.e3 true
interaction DrugDDI.d63.s20.e1 DrugDDI.d63.s20.e4 false
interaction DrugDDI.d63.s20.e1 DrugDDI.d63.s20.e5 false
interaction DrugDDI.d63.s20.e2 DrugDDI.d63.s20.e3 true
interaction DrugDDI.d63.s20.e2 DrugDDI.d63.s20.e4 false
interaction DrugDDI.d63.s20.e2 DrugDDI.d63.s20.e5 false
interaction DrugDDI.d63.s20.e3 DrugDDI.d63.s20.e4 false
interaction DrugDDI.d63.s20.e3 DrugDDI.d63.s20.e5 false
interaction DrugDDI.d63.s20.e4 DrugDDI.d63.s20.e5 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s21
HMG-CoA Reductase Inhibitors : Simvastatin ( CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.

DrugDDI.d63.s21.e0 0 25
drug
HMG-CoA Reductase Inhibitors
DrugDDI.d63.s21.e1 27 37
drug
Simvastatin
DrugDDI.d63.s21.e2 39 44
drug
CYP3A4
DrugDDI.d63.s21.e3 72 81
drug
amiodarone
DrugDDI.d63.s21.new.DISO.e4 112 119
DISO
myopathy
DrugDDI.d63.s21.new.DISO.e5 121 134
DISO
rhabdomyolysis

interaction DrugDDI.d63.s21.e0 DrugDDI.d63.s21.e1 false
interaction DrugDDI.d63.s21.e0 DrugDDI.d63.s21.e2 false
interaction DrugDDI.d63.s21.e0 DrugDDI.d63.s21.e3 false
interaction DrugDDI.d63.s21.e1 DrugDDI.d63.s21.e2 false
interaction DrugDDI.d63.s21.e1 DrugDDI.d63.s21.e3 true
interaction DrugDDI.d63.s21.e2 DrugDDI.d63.s21.e3 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s22
Cardiovasculars: Cardiac glycosides : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.

DrugDDI.d63.s22.e0 16 32
drug
Cardiac glycosides
DrugDDI.d63.s22.e1 53 59
drug
digoxin
DrugDDI.d63.s22.e2 88 97
drug
amiodarone
DrugDDI.d63.s22.e3 133 139
drug
digoxin

interaction DrugDDI.d63.s22.e0 DrugDDI.d63.s22.e1 false
interaction DrugDDI.d63.s22.e0 DrugDDI.d63.s22.e2 false
interaction DrugDDI.d63.s22.e0 DrugDDI.d63.s22.e3 false
interaction DrugDDI.d63.s22.e1 DrugDDI.d63.s22.e2 true
interaction DrugDDI.d63.s22.e1 DrugDDI.d63.s22.e3 false
interaction DrugDDI.d63.s22.e2 DrugDDI.d63.s22.e3 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s23
Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day.

DrugDDI.d63.s23.e0 0 9
drug
Amiodarone
DrugDDI.d63.s23.e1 32 38
drug
digoxin
DrugDDI.d63.s23.e2 56 62
drug
digoxin

interaction DrugDDI.d63.s23.e0 DrugDDI.d63.s23.e1 true
interaction DrugDDI.d63.s23.e0 DrugDDI.d63.s23.e2 false
interaction DrugDDI.d63.s23.e1 DrugDDI.d63.s23.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s24
On administration of oral amiodarone , the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.

DrugDDI.d63.s24.e0 22 31
drug
amiodarone



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s25
If digitalis treatment is continued, serum levels should be closely monitored and patients observed for clinical evidence of toxicity.

DrugDDI.d63.s25.e0 2 10
drug
digitalis



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s26
These precautions probably should apply to digitoxin administration as well.

DrugDDI.d63.s26.e0 37 45
drug
digitoxin



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s27
Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone .

DrugDDI.d63.s27.e0 0 14
drug
Antiarrhythmics
DrugDDI.d63.s27.e1 21 39
drug
antiarrhythmic drugs
DrugDDI.d63.s27.e2 47 55
drug
quinidine
DrugDDI.d63.s27.e3 57 68
drug
procainamide
DrugDDI.d63.s27.e4 70 81
drug
disopyramide
DrugDDI.d63.s27.e5 86 94
drug
phenytoin
DrugDDI.d63.s27.e6 124 133
drug
amiodarone

interaction DrugDDI.d63.s27.e0 DrugDDI.d63.s27.e1 false
interaction DrugDDI.d63.s27.e0 DrugDDI.d63.s27.e2 false
interaction DrugDDI.d63.s27.e0 DrugDDI.d63.s27.e3 false
interaction DrugDDI.d63.s27.e0 DrugDDI.d63.s27.e4 false
interaction DrugDDI.d63.s27.e0 DrugDDI.d63.s27.e5 false
interaction DrugDDI.d63.s27.e0 DrugDDI.d63.s27.e6 false
interaction DrugDDI.d63.s27.e1 DrugDDI.d63.s27.e2 false
interaction DrugDDI.d63.s27.e1 DrugDDI.d63.s27.e3 false
interaction DrugDDI.d63.s27.e1 DrugDDI.d63.s27.e4 false
interaction DrugDDI.d63.s27.e1 DrugDDI.d63.s27.e5 false
interaction DrugDDI.d63.s27.e1 DrugDDI.d63.s27.e6 false
interaction DrugDDI.d63.s27.e2 DrugDDI.d63.s27.e3 false
interaction DrugDDI.d63.s27.e2 DrugDDI.d63.s27.e4 false
interaction DrugDDI.d63.s27.e2 DrugDDI.d63.s27.e5 false
interaction DrugDDI.d63.s27.e2 DrugDDI.d63.s27.e6 false
interaction DrugDDI.d63.s27.e3 DrugDDI.d63.s27.e4 false
interaction DrugDDI.d63.s27.e3 DrugDDI.d63.s27.e5 false
interaction DrugDDI.d63.s27.e3 DrugDDI.d63.s27.e6 false
interaction DrugDDI.d63.s27.e4 DrugDDI.d63.s27.e5 false
interaction DrugDDI.d63.s27.e4 DrugDDI.d63.s27.e6 false
interaction DrugDDI.d63.s27.e5 DrugDDI.d63.s27.e6 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s28
There have been case reports of increased steady-state levels of quinidine , procainamide , and phenytoin during concomitant therapy with amiodarone .

DrugDDI.d63.s28.e0 55 63
drug
quinidine
DrugDDI.d63.s28.e1 65 76
drug
procainamide
DrugDDI.d63.s28.e2 81 89
drug
phenytoin
DrugDDI.d63.s28.e3 118 127
drug
amiodarone

interaction DrugDDI.d63.s28.e0 DrugDDI.d63.s28.e1 false
interaction DrugDDI.d63.s28.e0 DrugDDI.d63.s28.e2 false
interaction DrugDDI.d63.s28.e0 DrugDDI.d63.s28.e3 true
interaction DrugDDI.d63.s28.e1 DrugDDI.d63.s28.e2 false
interaction DrugDDI.d63.s28.e1 DrugDDI.d63.s28.e3 false
interaction DrugDDI.d63.s28.e2 DrugDDI.d63.s28.e3 true

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s29
Phenytoin decreases serum amiodarone levels.

DrugDDI.d63.s29.e0 0 8
drug
Phenytoin



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s30
Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days.

DrugDDI.d63.s30.e0 0 9
drug
Amiodarone
DrugDDI.d63.s30.e1 32 40
drug
quinidine
DrugDDI.d63.s30.e2 50 58
drug
quinidine

interaction DrugDDI.d63.s30.e0 DrugDDI.d63.s30.e1 true
interaction DrugDDI.d63.s30.e0 DrugDDI.d63.s30.e2 false
interaction DrugDDI.d63.s30.e1 DrugDDI.d63.s30.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s31
Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.

DrugDDI.d63.s31.e0 0 9
drug
Amiodarone
DrugDDI.d63.s31.e1 32 43
drug
procainamide
DrugDDI.d63.s31.e2 95 106
drug
procainamide
DrugDDI.d63.s31.e3 118 129
drug
procainamide

interaction DrugDDI.d63.s31.e0 DrugDDI.d63.s31.e1 true
interaction DrugDDI.d63.s31.e0 DrugDDI.d63.s31.e2 false
interaction DrugDDI.d63.s31.e0 DrugDDI.d63.s31.e3 false
interaction DrugDDI.d63.s31.e1 DrugDDI.d63.s31.e2 false
interaction DrugDDI.d63.s31.e1 DrugDDI.d63.s31.e3 false
interaction DrugDDI.d63.s31.e2 DrugDDI.d63.s31.e3 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s32
Quinidine and procainamide doses should be reduced by one-third when either is administered with amiodarone .

DrugDDI.d63.s32.e0 0 8
drug
Quinidine
DrugDDI.d63.s32.e1 83 92
drug
amiodarone

interaction DrugDDI.d63.s32.e0 DrugDDI.d63.s32.e1 true

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s33
Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone ; .

DrugDDI.d63.s33.e0 14 23
drug
flecainide
DrugDDI.d63.s33.e1 69 78
drug
amiodarone

interaction DrugDDI.d63.s33.e0 DrugDDI.d63.s33.e1 true

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s34
because of this, the dosage of flecainide should be adjusted when these drugs are administered concomitantly.

DrugDDI.d63.s34.e0 25 34
drug
flecainide
DrugDDI.d63.s34.e1 60 64
drug
drugs

interaction DrugDDI.d63.s34.e0 DrugDDI.d63.s34.e1 true

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s35
In general, any added antiarrhythmic drug should be initiated at a lower than usual dose with careful monitoring.

DrugDDI.d63.s35.e0 18 35
drug
antiarrhythmic drug



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s36
Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone .

DrugDDI.d63.s36.e0 13 22
drug
amiodarone
DrugDDI.d63.s36.e1 32 45
drug
antiarrhythmic
DrugDDI.d63.s36.new.DISO.e3 100 121
DISO
ventricular arrhythmias
DrugDDI.d63.s36.e2 190 199
drug
amiodarone

interaction DrugDDI.d63.s36.e0 DrugDDI.d63.s36.e1 true
interaction DrugDDI.d63.s36.e0 DrugDDI.d63.s36.e2 false
interaction DrugDDI.d63.s36.e1 DrugDDI.d63.s36.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s37
During transfer to oral amiodarone , the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral amiodarone .

DrugDDI.d63.s37.e0 20 29
drug
amiodarone
DrugDDI.d63.s37.e1 131 140
drug
amiodarone

interaction DrugDDI.d63.s37.e0 DrugDDI.d63.s37.e1 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s38
The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted.

DrugDDI.d63.s38.e0 27 45
drug
antiarrhythmic agent
DrugDDI.d63.s38.e1 79 88
drug
amiodarone

interaction DrugDDI.d63.s38.e0 DrugDDI.d63.s38.e1 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s39
If the treatment is continued, these patients should be particularly carefully monitored for adverse effects, especially conduction disturbances and exacerbation of tachyarrhythmias, as amiodarone is continued.

DrugDDI.d63.s39.new.DISO.e1 144 159
DISO
tachyarrhythmias
DrugDDI.d63.s39.e0 163 172
drug
amiodarone



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s40
In amiodarone -treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.

DrugDDI.d63.s40.e0 2 11
drug
amiodarone
DrugDDI.d63.s40.e1 48 61
drug
antiarrhythmic

interaction DrugDDI.d63.s40.e0 DrugDDI.d63.s40.e1 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s41
Antihypertensives : Amiodarone should be used with caution in patients receiving @- receptor blocking agents (e.g., propranolol , a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil , a CYP3A4 substrate, and diltiazem , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block; .

DrugDDI.d63.s41.e0 0 16
drug
Antihypertensives
DrugDDI.d63.s41.e1 18 27
drug
Amiodarone
DrugDDI.d63.s41.e2 72 79
drug
receptor
DrugDDI.d63.s41.e3 100 110
drug
propranolol
DrugDDI.d63.s41.e4 113 118
drug
CYP3A4
DrugDDI.d63.s41.e5 131 144
drug
calcium channel
DrugDDI.d63.s41.e6 162 170
drug
verapamil
DrugDDI.d63.s41.e7 173 178
drug
CYP3A4
DrugDDI.d63.s41.e8 192 200
drug
diltiazem
DrugDDI.d63.s41.e9 203 208
drug
CYP3A4
DrugDDI.d63.s41.new.DISO.e10 280 286
DISO
AV block

interaction DrugDDI.d63.s41.e0 DrugDDI.d63.s41.e1 false
interaction DrugDDI.d63.s41.e0 DrugDDI.d63.s41.e2 false
interaction DrugDDI.d63.s41.e0 DrugDDI.d63.s41.e3 false
interaction DrugDDI.d63.s41.e0 DrugDDI.d63.s41.e4 false
interaction DrugDDI.d63.s41.e0 DrugDDI.d63.s41.e5 false
interaction DrugDDI.d63.s41.e0 DrugDDI.d63.s41.e6 false
interaction DrugDDI.d63.s41.e0 DrugDDI.d63.s41.e7 false
interaction DrugDDI.d63.s41.e0 DrugDDI.d63.s41.e8 false
interaction DrugDDI.d63.s41.e0 DrugDDI.d63.s41.e9 false
interaction DrugDDI.d63.s41.e1 DrugDDI.d63.s41.e2 true
interaction DrugDDI.d63.s41.e1 DrugDDI.d63.s41.e3 false
interaction DrugDDI.d63.s41.e1 DrugDDI.d63.s41.e4 false
interaction DrugDDI.d63.s41.e1 DrugDDI.d63.s41.e5 true
interaction DrugDDI.d63.s41.e1 DrugDDI.d63.s41.e6 false
interaction DrugDDI.d63.s41.e1 DrugDDI.d63.s41.e7 false
interaction DrugDDI.d63.s41.e1 DrugDDI.d63.s41.e8 true
interaction DrugDDI.d63.s41.e1 DrugDDI.d63.s41.e9 false
interaction DrugDDI.d63.s41.e2 DrugDDI.d63.s41.e3 false
interaction DrugDDI.d63.s41.e2 DrugDDI.d63.s41.e4 false
interaction DrugDDI.d63.s41.e2 DrugDDI.d63.s41.e5 false
interaction DrugDDI.d63.s41.e2 DrugDDI.d63.s41.e6 false
interaction DrugDDI.d63.s41.e2 DrugDDI.d63.s41.e7 false
interaction DrugDDI.d63.s41.e2 DrugDDI.d63.s41.e8 false
interaction DrugDDI.d63.s41.e2 DrugDDI.d63.s41.e9 false
interaction DrugDDI.d63.s41.e3 DrugDDI.d63.s41.e4 false
interaction DrugDDI.d63.s41.e3 DrugDDI.d63.s41.e5 false
interaction DrugDDI.d63.s41.e3 DrugDDI.d63.s41.e6 false
interaction DrugDDI.d63.s41.e3 DrugDDI.d63.s41.e7 false
interaction DrugDDI.d63.s41.e3 DrugDDI.d63.s41.e8 false
interaction DrugDDI.d63.s41.e3 DrugDDI.d63.s41.e9 false
interaction DrugDDI.d63.s41.e4 DrugDDI.d63.s41.e5 false
interaction DrugDDI.d63.s41.e4 DrugDDI.d63.s41.e6 false
interaction DrugDDI.d63.s41.e4 DrugDDI.d63.s41.e7 false
interaction DrugDDI.d63.s41.e4 DrugDDI.d63.s41.e8 false
interaction DrugDDI.d63.s41.e4 DrugDDI.d63.s41.e9 false
interaction DrugDDI.d63.s41.e5 DrugDDI.d63.s41.e6 false
interaction DrugDDI.d63.s41.e5 DrugDDI.d63.s41.e7 false
interaction DrugDDI.d63.s41.e5 DrugDDI.d63.s41.e8 false
interaction DrugDDI.d63.s41.e5 DrugDDI.d63.s41.e9 false
interaction DrugDDI.d63.s41.e6 DrugDDI.d63.s41.e7 false
interaction DrugDDI.d63.s41.e6 DrugDDI.d63.s41.e8 false
interaction DrugDDI.d63.s41.e6 DrugDDI.d63.s41.e9 false
interaction DrugDDI.d63.s41.e7 DrugDDI.d63.s41.e8 false
interaction DrugDDI.d63.s41.e7 DrugDDI.d63.s41.e9 false
interaction DrugDDI.d63.s41.e8 DrugDDI.d63.s41.e9 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s42
if necessary, amiodarone can continue to be used after insertion of a pacemaker in patients with severe bradycardia or sinus arrest.

DrugDDI.d63.s42.e0 12 21
drug
amiodarone
DrugDDI.d63.s42.new.DISO.e1 87 97
DISO
bradycardia



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s43
Anticoagulants : Potentiation of warfarin -type ( CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.

DrugDDI.d63.s43.e0 0 13
drug
Anticoagulants
DrugDDI.d63.s43.e1 29 36
drug
warfarin
DrugDDI.d63.s43.e2 43 48
drug
CYP2C9
DrugDDI.d63.s43.e3 52 57
drug
CYP3A4
DrugDDI.d63.s43.e4 68 80
drug
anticoagulant
DrugDDI.d63.s43.e5 126 135
drug
amiodarone

interaction DrugDDI.d63.s43.e0 DrugDDI.d63.s43.e1 false
interaction DrugDDI.d63.s43.e0 DrugDDI.d63.s43.e2 false
interaction DrugDDI.d63.s43.e0 DrugDDI.d63.s43.e3 false
interaction DrugDDI.d63.s43.e0 DrugDDI.d63.s43.e4 false
interaction DrugDDI.d63.s43.e0 DrugDDI.d63.s43.e5 false
interaction DrugDDI.d63.s43.e1 DrugDDI.d63.s43.e2 false
interaction DrugDDI.d63.s43.e1 DrugDDI.d63.s43.e3 false
interaction DrugDDI.d63.s43.e1 DrugDDI.d63.s43.e4 false
interaction DrugDDI.d63.s43.e1 DrugDDI.d63.s43.e5 true
interaction DrugDDI.d63.s43.e2 DrugDDI.d63.s43.e3 false
interaction DrugDDI.d63.s43.e2 DrugDDI.d63.s43.e4 false
interaction DrugDDI.d63.s43.e2 DrugDDI.d63.s43.e5 false
interaction DrugDDI.d63.s43.e3 DrugDDI.d63.s43.e4 false
interaction DrugDDI.d63.s43.e3 DrugDDI.d63.s43.e5 false
interaction DrugDDI.d63.s43.e4 DrugDDI.d63.s43.e5 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s44
Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.

DrugDDI.d63.s44.e0 35 42
drug
warfarin
DrugDDI.d63.s44.e1 47 56
drug
amiodarone
DrugDDI.d63.s44.e2 116 128
drug
anticoagulant

interaction DrugDDI.d63.s44.e0 DrugDDI.d63.s44.e1 true
interaction DrugDDI.d63.s44.e0 DrugDDI.d63.s44.e2 false
interaction DrugDDI.d63.s44.e1 DrugDDI.d63.s44.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s45
Some drugs /substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).

DrugDDI.d63.s45.e0 4 8
drug
drugs
DrugDDI.d63.s45.e1 55 64
drug
amiodarone
DrugDDI.d63.s45.e2 92 97
drug
CYP3A4

interaction DrugDDI.d63.s45.e0 DrugDDI.d63.s45.e1 true
interaction DrugDDI.d63.s45.e0 DrugDDI.d63.s45.e2 false
interaction DrugDDI.d63.s45.e1 DrugDDI.d63.s45.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s46
This may lead to low amiodarone serum levels and potential decrease in efficacy.

DrugDDI.d63.s46.e0 16 25
drug
amiodarone



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s47
Reported examples of this interaction include the following: Antibiotics : Rifampin is a potent inducer of CYP3A4 .

DrugDDI.d63.s47.e0 53 63
drug
Antibiotics
DrugDDI.d63.s47.e1 65 72
drug
Rifampin
DrugDDI.d63.s47.e2 91 96
drug
CYP3A4

interaction DrugDDI.d63.s47.e0 DrugDDI.d63.s47.e1 false
interaction DrugDDI.d63.s47.e0 DrugDDI.d63.s47.e2 false
interaction DrugDDI.d63.s47.e1 DrugDDI.d63.s47.e2 true

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s48
Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone .

DrugDDI.d63.s48.e0 16 23
drug
rifampin
DrugDDI.d63.s48.e1 45 54
drug
amiodarone
DrugDDI.d63.s48.e2 109 118
drug
amiodarone
DrugDDI.d63.s48.e3 122 139
drug
desethylamiodarone

interaction DrugDDI.d63.s48.e0 DrugDDI.d63.s48.e1 true
interaction DrugDDI.d63.s48.e0 DrugDDI.d63.s48.e2 false
interaction DrugDDI.d63.s48.e0 DrugDDI.d63.s48.e3 false
interaction DrugDDI.d63.s48.e1 DrugDDI.d63.s48.e2 false
interaction DrugDDI.d63.s48.e1 DrugDDI.d63.s48.e3 false
interaction DrugDDI.d63.s48.e2 DrugDDI.d63.s48.e3 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s49
Other substances, including herbal preparations : St. John@s Wort ( Hypericum perforatum ) induces CYP3A4 .

DrugDDI.d63.s49.e0 25 42
drug
herbal preparations
DrugDDI.d63.s49.e1 58 76
drug
Hypericum perforatum
DrugDDI.d63.s49.e2 85 90
drug
CYP3A4

interaction DrugDDI.d63.s49.e0 DrugDDI.d63.s49.e1 false
interaction DrugDDI.d63.s49.e0 DrugDDI.d63.s49.e2 false
interaction DrugDDI.d63.s49.e1 DrugDDI.d63.s49.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s50
Since amiodarone is a substrate for CYP3A4 , there is the potential that the use of St. John@s Wort in patients receiving amiodarone could result in reduced amiodarone levels.

DrugDDI.d63.s50.e0 5 14
drug
amiodarone
DrugDDI.d63.s50.e1 30 35
drug
CYP3A4
DrugDDI.d63.s50.e2 100 109
drug
amiodarone
DrugDDI.d63.s50.e3 130 139
drug
amiodarone

interaction DrugDDI.d63.s50.e0 DrugDDI.d63.s50.e1 false
interaction DrugDDI.d63.s50.e0 DrugDDI.d63.s50.e2 false
interaction DrugDDI.d63.s50.e0 DrugDDI.d63.s50.e3 false
interaction DrugDDI.d63.s50.e1 DrugDDI.d63.s50.e2 false
interaction DrugDDI.d63.s50.e1 DrugDDI.d63.s50.e3 false
interaction DrugDDI.d63.s50.e2 DrugDDI.d63.s50.e3 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s51
Other reported interactions with amiodarone : Fentanyl ( CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.

DrugDDI.d63.s51.e0 29 38
drug
amiodarone
DrugDDI.d63.s51.e1 40 47
drug
Fentanyl
DrugDDI.d63.s51.e2 49 54
drug
CYP3A4
DrugDDI.d63.s51.e3 82 91
drug
amiodarone

interaction DrugDDI.d63.s51.e0 DrugDDI.d63.s51.e1 false
interaction DrugDDI.d63.s51.e0 DrugDDI.d63.s51.e2 false
interaction DrugDDI.d63.s51.e0 DrugDDI.d63.s51.e3 false
interaction DrugDDI.d63.s51.e1 DrugDDI.d63.s51.e2 false
interaction DrugDDI.d63.s51.e1 DrugDDI.d63.s51.e3 true
interaction DrugDDI.d63.s51.e2 DrugDDI.d63.s51.e3 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s52
Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine ( CYP3A4 substrate) given for local anesthesia .

DrugDDI.d63.s52.new.DISO.e4 0 15
DISO
Sinus bradycardia
DrugDDI.d63.s52.e0 39 48
drug
amiodarone
DrugDDI.d63.s52.e1 66 74
drug
lidocaine
DrugDDI.d63.s52.e2 76 81
drug
CYP3A4
DrugDDI.d63.s52.e3 100 114
drug
local anesthesia

interaction DrugDDI.d63.s52.e0 DrugDDI.d63.s52.e1 true
interaction DrugDDI.d63.s52.e0 DrugDDI.d63.s52.e2 false
interaction DrugDDI.d63.s52.e0 DrugDDI.d63.s52.e3 false
interaction DrugDDI.d63.s52.e1 DrugDDI.d63.s52.e2 false
interaction DrugDDI.d63.s52.e1 DrugDDI.d63.s52.e3 false
interaction DrugDDI.d63.s52.e2 DrugDDI.d63.s52.e3 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s53
Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone .

DrugDDI.d63.s53.e0 31 39
drug
lidocaine
DrugDDI.d63.s53.e1 112 121
drug
amiodarone

interaction DrugDDI.d63.s53.e0 DrugDDI.d63.s53.e1 true

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s54
Dextromethorphan is a substrate for both CYP2D6 and CYP3A4 .

DrugDDI.d63.s54.e0 0 15
drug
Dextromethorphan
DrugDDI.d63.s54.e1 35 40
drug
CYP2D6
DrugDDI.d63.s54.e2 44 49
drug
CYP3A4

interaction DrugDDI.d63.s54.e0 DrugDDI.d63.s54.e1 true
interaction DrugDDI.d63.s54.e0 DrugDDI.d63.s54.e2 false
interaction DrugDDI.d63.s54.e1 DrugDDI.d63.s54.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s55
Amiodarone inhibits CYP2D6 .

DrugDDI.d63.s55.e0 0 9
drug
Amiodarone
DrugDDI.d63.s55.e1 18 23
drug
CYP2D6

interaction DrugDDI.d63.s55.e0 DrugDDI.d63.s55.e1 true

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s56
Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1 /2.

DrugDDI.d63.s56.e0 0 13
drug
Cholestyramine
DrugDDI.d63.s56.e1 49 58
drug
amiodarone
DrugDDI.d63.s56.e2 88 89
drug
t1

interaction DrugDDI.d63.s56.e0 DrugDDI.d63.s56.e1 true
interaction DrugDDI.d63.s56.e0 DrugDDI.d63.s56.e2 false
interaction DrugDDI.d63.s56.e1 DrugDDI.d63.s56.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s57
Disopyramide increases QT prolongation which could cause arrhythmia.

DrugDDI.d63.s57.e0 0 11
drug
Disopyramide
DrugDDI.d63.s57.new.DISO.e1 50 59
DISO
arrhythmia



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s58
Fluoroquinolones , macrolide antibiotics , and azoles are known to cause QTc prolongation.

DrugDDI.d63.s58.e0 0 15
drug
Fluoroquinolones
DrugDDI.d63.s58.e1 17 36
drug
macrolide antibiotics

interaction DrugDDI.d63.s58.e0 DrugDDI.d63.s58.e1 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s59
There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones , macrolide antibiotics , or azoles were administered concomitantly.

DrugDDI.d63.s59.e0 71 80
drug
amiodarone
DrugDDI.d63.s59.e1 85 100
drug
fluoroquinolones
DrugDDI.d63.s59.e2 102 121
drug
macrolide antibiotics

interaction DrugDDI.d63.s59.e0 DrugDDI.d63.s59.e1 true
interaction DrugDDI.d63.s59.e0 DrugDDI.d63.s59.e2 false
interaction DrugDDI.d63.s59.e1 DrugDDI.d63.s59.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s60
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol , diltiazem , and verapamil .

DrugDDI.d63.s60.e0 98 108
drug
propranolol
DrugDDI.d63.s60.e1 110 118
drug
diltiazem
DrugDDI.d63.s60.e2 123 131
drug
verapamil

interaction DrugDDI.d63.s60.e0 DrugDDI.d63.s60.e1 false
interaction DrugDDI.d63.s60.e0 DrugDDI.d63.s60.e2 false
interaction DrugDDI.d63.s60.e1 DrugDDI.d63.s60.e2 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s61
Volatile Anesthetic Agents :.

DrugDDI.d63.s61.e0 8 23
drug
Anesthetic Agents



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s62
In addition to the interactions noted above, chronic ( 2 weeks) oral Cordarone administration impairs metabolism of phenytoin , dextromethorphan , and methotrexate .

DrugDDI.d63.s62.e0 57 65
drug
Cordarone
DrugDDI.d63.s62.e1 99 107
drug
phenytoin
DrugDDI.d63.s62.e2 109 124
drug
dextromethorphan
DrugDDI.d63.s62.e3 129 140
drug
methotrexate

interaction DrugDDI.d63.s62.e0 DrugDDI.d63.s62.e1 true
interaction DrugDDI.d63.s62.e0 DrugDDI.d63.s62.e2 false
interaction DrugDDI.d63.s62.e0 DrugDDI.d63.s62.e3 true
interaction DrugDDI.d63.s62.e1 DrugDDI.d63.s62.e2 false
interaction DrugDDI.d63.s62.e1 DrugDDI.d63.s62.e3 false
interaction DrugDDI.d63.s62.e2 DrugDDI.d63.s62.e3 false

Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s63
Electrolyte Disturbances Patients with hypokalemia or hypomagnesemia should have the condition corrected whenever possible before being treated with Cordarone I.V. , as these disorders can exaggerate the degree of QTc prolongation and increase the potential for TdP.

DrugDDI.d63.s63.new.DISO.e1 35 45
DISO
hypokalemia
DrugDDI.d63.s63.new.DISO.e2 48 61
DISO
hypomagnesemia
DrugDDI.d63.s63.e0 131 143
drug
Cordarone I.V.



Abstract Id: DrugDDI.d63
Sentence Id: DrugDDI.d63.s64
Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics .

DrugDDI.d63.s64.e0 140 148
drug
diuretics



Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s0
In vitro data indicate that NORVASC has no effect on the human plasma protein binding of digoxin , phenytoin , warfarin , and indomethacin .

DrugDDI.d539.s0.e0 23 29
drug
NORVASC
DrugDDI.d539.s0.e1 46 56
drug
human plasma
DrugDDI.d539.s0.e2 73 79
drug
digoxin
DrugDDI.d539.s0.e3 81 89
drug
phenytoin
DrugDDI.d539.s0.e4 91 98
drug
warfarin
DrugDDI.d539.s0.e5 103 114
drug
indomethacin

interaction DrugDDI.d539.s0.e0 DrugDDI.d539.s0.e1 false
interaction DrugDDI.d539.s0.e0 DrugDDI.d539.s0.e2 false
interaction DrugDDI.d539.s0.e0 DrugDDI.d539.s0.e3 false
interaction DrugDDI.d539.s0.e0 DrugDDI.d539.s0.e4 false
interaction DrugDDI.d539.s0.e0 DrugDDI.d539.s0.e5 false
interaction DrugDDI.d539.s0.e1 DrugDDI.d539.s0.e2 false
interaction DrugDDI.d539.s0.e1 DrugDDI.d539.s0.e3 false
interaction DrugDDI.d539.s0.e1 DrugDDI.d539.s0.e4 false
interaction DrugDDI.d539.s0.e1 DrugDDI.d539.s0.e5 false
interaction DrugDDI.d539.s0.e2 DrugDDI.d539.s0.e3 false
interaction DrugDDI.d539.s0.e2 DrugDDI.d539.s0.e4 false
interaction DrugDDI.d539.s0.e2 DrugDDI.d539.s0.e5 false
interaction DrugDDI.d539.s0.e3 DrugDDI.d539.s0.e4 false
interaction DrugDDI.d539.s0.e3 DrugDDI.d539.s0.e5 false
interaction DrugDDI.d539.s0.e4 DrugDDI.d539.s0.e5 false

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s1
Effect of other agents on NORVASC .

DrugDDI.d539.s1.e0 21 27
drug
NORVASC



Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s2
CIMETIDINE : Co-administration of NORVASC with cimetidine did not alter the pharmacokinetics of NORVASC .

DrugDDI.d539.s2.e0 0 9
drug
CIMETIDINE
DrugDDI.d539.s2.e1 30 36
drug
NORVASC
DrugDDI.d539.s2.e2 41 50
drug
cimetidine
DrugDDI.d539.s2.e3 83 89
drug
NORVASC

interaction DrugDDI.d539.s2.e0 DrugDDI.d539.s2.e1 false
interaction DrugDDI.d539.s2.e0 DrugDDI.d539.s2.e2 false
interaction DrugDDI.d539.s2.e0 DrugDDI.d539.s2.e3 false
interaction DrugDDI.d539.s2.e1 DrugDDI.d539.s2.e2 false
interaction DrugDDI.d539.s2.e1 DrugDDI.d539.s2.e3 false
interaction DrugDDI.d539.s2.e2 DrugDDI.d539.s2.e3 false

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s3
GRAPEFRUIT JUICE: Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine .

DrugDDI.d539.s3.e0 78 91
drug
amlodipine 10 mg
DrugDDI.d539.s3.e1 158 167
drug
amlodipine

interaction DrugDDI.d539.s3.e0 DrugDDI.d539.s3.e1 false

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s4
MAALOX ( antacid ): Co-administration of the antacid Maalox with a single dose of NORVASC had no significant effect on the pharmacokinetics of NORVASC .

DrugDDI.d539.s4.e0 0 5
drug
MAALOX
DrugDDI.d539.s4.e1 7 13
drug
antacid
DrugDDI.d539.s4.e2 45 50
drug
Maalox
DrugDDI.d539.s4.e3 68 74
drug
NORVASC
DrugDDI.d539.s4.e4 120 126
drug
NORVASC

interaction DrugDDI.d539.s4.e0 DrugDDI.d539.s4.e1 false
interaction DrugDDI.d539.s4.e0 DrugDDI.d539.s4.e2 false
interaction DrugDDI.d539.s4.e0 DrugDDI.d539.s4.e3 false
interaction DrugDDI.d539.s4.e0 DrugDDI.d539.s4.e4 false
interaction DrugDDI.d539.s4.e1 DrugDDI.d539.s4.e2 false
interaction DrugDDI.d539.s4.e1 DrugDDI.d539.s4.e3 false
interaction DrugDDI.d539.s4.e1 DrugDDI.d539.s4.e4 false
interaction DrugDDI.d539.s4.e2 DrugDDI.d539.s4.e3 false
interaction DrugDDI.d539.s4.e2 DrugDDI.d539.s4.e4 false
interaction DrugDDI.d539.s4.e3 DrugDDI.d539.s4.e4 false

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s5
SILDENAFIL : A single 100 mg dose of sildenafil (Viagra@) in subjects with essential hypertension had no effect on the pharmacokinetic parameters of NORVASC .

DrugDDI.d539.s5.e0 0 9
drug
SILDENAFIL
DrugDDI.d539.s5.e1 29 38
drug
sildenafil
DrugDDI.d539.s5.new.DISO.e3 62 82
DISO
essential hypertension
DrugDDI.d539.s5.e2 126 132
drug
NORVASC

interaction DrugDDI.d539.s5.e0 DrugDDI.d539.s5.e1 false
interaction DrugDDI.d539.s5.e0 DrugDDI.d539.s5.e2 false
interaction DrugDDI.d539.s5.e1 DrugDDI.d539.s5.e2 false

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s6
When NORVASC and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.

DrugDDI.d539.s6.e0 4 10
drug
NORVASC
DrugDDI.d539.s6.e1 14 23
drug
sildenafil

interaction DrugDDI.d539.s6.e0 DrugDDI.d539.s6.e1 true

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s7
Effect of NORVASC on other agents.

DrugDDI.d539.s7.e0 8 14
drug
NORVASC



Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s8
ATORVASTATIN : Co-administration of multiple 10 mg doses of NORVASC with 80 mg of atorvastatin resulted in no significant change in the steady state pharmacokinetic parameters of atorvastatin .

DrugDDI.d539.s8.e0 0 11
drug
ATORVASTATIN
DrugDDI.d539.s8.e1 51 57
drug
NORVASC
DrugDDI.d539.s8.e2 68 79
drug
atorvastatin
DrugDDI.d539.s8.e3 152 163
drug
atorvastatin

interaction DrugDDI.d539.s8.e0 DrugDDI.d539.s8.e1 false
interaction DrugDDI.d539.s8.e0 DrugDDI.d539.s8.e2 false
interaction DrugDDI.d539.s8.e0 DrugDDI.d539.s8.e3 false
interaction DrugDDI.d539.s8.e1 DrugDDI.d539.s8.e2 true
interaction DrugDDI.d539.s8.e1 DrugDDI.d539.s8.e3 false
interaction DrugDDI.d539.s8.e2 DrugDDI.d539.s8.e3 false

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s9
DIGOXIN : Co-administration of NORVASC with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.

DrugDDI.d539.s9.e0 0 6
drug
DIGOXIN
DrugDDI.d539.s9.e1 27 33
drug
NORVASC
DrugDDI.d539.s9.e2 38 44
drug
digoxin
DrugDDI.d539.s9.e3 77 83
drug
digoxin

interaction DrugDDI.d539.s9.e0 DrugDDI.d539.s9.e1 false
interaction DrugDDI.d539.s9.e0 DrugDDI.d539.s9.e2 false
interaction DrugDDI.d539.s9.e0 DrugDDI.d539.s9.e3 false
interaction DrugDDI.d539.s9.e1 DrugDDI.d539.s9.e2 false
interaction DrugDDI.d539.s9.e1 DrugDDI.d539.s9.e3 false
interaction DrugDDI.d539.s9.e2 DrugDDI.d539.s9.e3 false

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s10
ETHANOL ( alcohol ): Single and multiple 10 mg doses of NORVASC had no significant effect on the pharmacokinetics of ethanol .

DrugDDI.d539.s10.e0 0 6
drug
ETHANOL
DrugDDI.d539.s10.e1 8 14
drug
alcohol
DrugDDI.d539.s10.e2 45 51
drug
NORVASC
DrugDDI.d539.s10.e3 97 103
drug
ethanol

interaction DrugDDI.d539.s10.e0 DrugDDI.d539.s10.e1 false
interaction DrugDDI.d539.s10.e0 DrugDDI.d539.s10.e2 false
interaction DrugDDI.d539.s10.e0 DrugDDI.d539.s10.e3 false
interaction DrugDDI.d539.s10.e1 DrugDDI.d539.s10.e2 false
interaction DrugDDI.d539.s10.e1 DrugDDI.d539.s10.e3 false
interaction DrugDDI.d539.s10.e2 DrugDDI.d539.s10.e3 false

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s11
WARFARIN : Co-administration of NORVASC with warfarin did not change the warfarin prothrombin response time.

DrugDDI.d539.s11.e0 0 7
drug
WARFARIN
DrugDDI.d539.s11.e1 28 34
drug
NORVASC
DrugDDI.d539.s11.e2 39 46
drug
warfarin
DrugDDI.d539.s11.e3 70 80
drug
prothrombin

interaction DrugDDI.d539.s11.e0 DrugDDI.d539.s11.e1 false
interaction DrugDDI.d539.s11.e0 DrugDDI.d539.s11.e2 false
interaction DrugDDI.d539.s11.e0 DrugDDI.d539.s11.e3 false
interaction DrugDDI.d539.s11.e1 DrugDDI.d539.s11.e2 false
interaction DrugDDI.d539.s11.e1 DrugDDI.d539.s11.e3 false
interaction DrugDDI.d539.s11.e2 DrugDDI.d539.s11.e3 false

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s12
In clinical trials, NORVASC has been safely administered with thiazide diuretics , beta-blockers , angiotensin-converting enzyme inhibitors , long-acting nitrates , sublingual nitroglycerin , digoxin , warfarin , non-steroidal anti-inflammatory drugs , antibiotics , and oral hypoglycemic drugs .

DrugDDI.d539.s12.e0 17 23
drug
NORVASC
DrugDDI.d539.s12.e1 53 69
drug
thiazide diuretics
DrugDDI.d539.s12.e2 71 83
drug
beta-blockers
DrugDDI.d539.s12.e3 85 122
drug
angiotensin-converting enzyme inhibitors
DrugDDI.d539.s12.e4 135 142
drug
nitrates
DrugDDI.d539.s12.e5 154 166
drug
nitroglycerin
DrugDDI.d539.s12.e6 168 174
drug
digoxin
DrugDDI.d539.s12.e7 176 183
drug
warfarin
DrugDDI.d539.s12.e8 185 219
drug
non-steroidal anti-inflammatory drugs
DrugDDI.d539.s12.e9 221 231
drug
antibiotics
DrugDDI.d539.s12.e10 236 256
drug
oral hypoglycemic drugs

interaction DrugDDI.d539.s12.e0 DrugDDI.d539.s12.e1 false
interaction DrugDDI.d539.s12.e0 DrugDDI.d539.s12.e2 false
interaction DrugDDI.d539.s12.e0 DrugDDI.d539.s12.e3 false
interaction DrugDDI.d539.s12.e0 DrugDDI.d539.s12.e4 false
interaction DrugDDI.d539.s12.e0 DrugDDI.d539.s12.e5 false
interaction DrugDDI.d539.s12.e0 DrugDDI.d539.s12.e6 false
interaction DrugDDI.d539.s12.e0 DrugDDI.d539.s12.e7 false
interaction DrugDDI.d539.s12.e0 DrugDDI.d539.s12.e8 false
interaction DrugDDI.d539.s12.e0 DrugDDI.d539.s12.e9 false
interaction DrugDDI.d539.s12.e0 DrugDDI.d539.s12.e10 false
interaction DrugDDI.d539.s12.e1 DrugDDI.d539.s12.e2 false
interaction DrugDDI.d539.s12.e1 DrugDDI.d539.s12.e3 false
interaction DrugDDI.d539.s12.e1 DrugDDI.d539.s12.e4 false
interaction DrugDDI.d539.s12.e1 DrugDDI.d539.s12.e5 false
interaction DrugDDI.d539.s12.e1 DrugDDI.d539.s12.e6 false
interaction DrugDDI.d539.s12.e1 DrugDDI.d539.s12.e7 false
interaction DrugDDI.d539.s12.e1 DrugDDI.d539.s12.e8 false
interaction DrugDDI.d539.s12.e1 DrugDDI.d539.s12.e9 false
interaction DrugDDI.d539.s12.e1 DrugDDI.d539.s12.e10 false
interaction DrugDDI.d539.s12.e2 DrugDDI.d539.s12.e3 false
interaction DrugDDI.d539.s12.e2 DrugDDI.d539.s12.e4 false
interaction DrugDDI.d539.s12.e2 DrugDDI.d539.s12.e5 false
interaction DrugDDI.d539.s12.e2 DrugDDI.d539.s12.e6 false
interaction DrugDDI.d539.s12.e2 DrugDDI.d539.s12.e7 false
interaction DrugDDI.d539.s12.e2 DrugDDI.d539.s12.e8 false
interaction DrugDDI.d539.s12.e2 DrugDDI.d539.s12.e9 false
interaction DrugDDI.d539.s12.e2 DrugDDI.d539.s12.e10 false
interaction DrugDDI.d539.s12.e3 DrugDDI.d539.s12.e4 false
interaction DrugDDI.d539.s12.e3 DrugDDI.d539.s12.e5 false
interaction DrugDDI.d539.s12.e3 DrugDDI.d539.s12.e6 false
interaction DrugDDI.d539.s12.e3 DrugDDI.d539.s12.e7 false
interaction DrugDDI.d539.s12.e3 DrugDDI.d539.s12.e8 false
interaction DrugDDI.d539.s12.e3 DrugDDI.d539.s12.e9 false
interaction DrugDDI.d539.s12.e3 DrugDDI.d539.s12.e10 false
interaction DrugDDI.d539.s12.e4 DrugDDI.d539.s12.e5 false
interaction DrugDDI.d539.s12.e4 DrugDDI.d539.s12.e6 false
interaction DrugDDI.d539.s12.e4 DrugDDI.d539.s12.e7 false
interaction DrugDDI.d539.s12.e4 DrugDDI.d539.s12.e8 false
interaction DrugDDI.d539.s12.e4 DrugDDI.d539.s12.e9 false
interaction DrugDDI.d539.s12.e4 DrugDDI.d539.s12.e10 false
interaction DrugDDI.d539.s12.e5 DrugDDI.d539.s12.e6 false
interaction DrugDDI.d539.s12.e5 DrugDDI.d539.s12.e7 false
interaction DrugDDI.d539.s12.e5 DrugDDI.d539.s12.e8 false
interaction DrugDDI.d539.s12.e5 DrugDDI.d539.s12.e9 false
interaction DrugDDI.d539.s12.e5 DrugDDI.d539.s12.e10 false
interaction DrugDDI.d539.s12.e6 DrugDDI.d539.s12.e7 false
interaction DrugDDI.d539.s12.e6 DrugDDI.d539.s12.e8 false
interaction DrugDDI.d539.s12.e6 DrugDDI.d539.s12.e9 false
interaction DrugDDI.d539.s12.e6 DrugDDI.d539.s12.e10 false
interaction DrugDDI.d539.s12.e7 DrugDDI.d539.s12.e8 false
interaction DrugDDI.d539.s12.e7 DrugDDI.d539.s12.e9 false
interaction DrugDDI.d539.s12.e7 DrugDDI.d539.s12.e10 false
interaction DrugDDI.d539.s12.e8 DrugDDI.d539.s12.e9 false
interaction DrugDDI.d539.s12.e8 DrugDDI.d539.s12.e10 false
interaction DrugDDI.d539.s12.e9 DrugDDI.d539.s12.e10 false

Abstract Id: DrugDDI.d539
Sentence Id: DrugDDI.d539.s13
Drug /Laboratory Test Interactions: None known.

DrugDDI.d539.s13.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s0
Probenecid decreases the renal tubular secretion of amoxicillin .

DrugDDI.d117.s0.e0 0 9
drug
Probenecid
DrugDDI.d117.s0.e1 45 55
drug
amoxicillin

interaction DrugDDI.d117.s0.e0 DrugDDI.d117.s0.e1 true

Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s1
Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin .

DrugDDI.d117.s1.e0 15 25
drug
amoxicillin
DrugDDI.d117.s1.e1 29 38
drug
probenecid
DrugDDI.d117.s1.e2 84 94
drug
amoxicillin

interaction DrugDDI.d117.s1.e0 DrugDDI.d117.s1.e1 true
interaction DrugDDI.d117.s1.e0 DrugDDI.d117.s1.e2 false
interaction DrugDDI.d117.s1.e1 DrugDDI.d117.s1.e2 false

Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s2
Chloramphenicol , macrolides , sulfonamides , and tetracy-clines may interfere with the bactericidal effects of penicillin .

DrugDDI.d117.s2.e0 0 14
drug
Chloramphenicol
DrugDDI.d117.s2.e1 16 25
drug
macrolides
DrugDDI.d117.s2.e2 27 38
drug
sulfonamides
DrugDDI.d117.s2.e3 97 106
drug
penicillin

interaction DrugDDI.d117.s2.e0 DrugDDI.d117.s2.e1 false
interaction DrugDDI.d117.s2.e0 DrugDDI.d117.s2.e2 false
interaction DrugDDI.d117.s2.e0 DrugDDI.d117.s2.e3 true
interaction DrugDDI.d117.s2.e1 DrugDDI.d117.s2.e2 false
interaction DrugDDI.d117.s2.e1 DrugDDI.d117.s2.e3 true
interaction DrugDDI.d117.s2.e2 DrugDDI.d117.s2.e3 true

Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s5
Drug /Laboratory Test Interactions: High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST@, Benedict@s Solution, or Fehling@s Solution.

DrugDDI.d117.s5.e0 0 3
drug
Drug
DrugDDI.d117.s5.e1 57 66
drug
ampicillin
DrugDDI.d117.s5.e2 128 134
drug
glucose

interaction DrugDDI.d117.s5.e0 DrugDDI.d117.s5.e1 false
interaction DrugDDI.d117.s5.e0 DrugDDI.d117.s5.e2 false
interaction DrugDDI.d117.s5.e1 DrugDDI.d117.s5.e2 false

Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s6
Since this effect may also occur with amoxicillin , it is recommended that glucose tests based on enzymatic glucose oxi-dase reactions (such as CLINISTIX@) be used.

DrugDDI.d117.s6.e0 31 41
drug
amoxicillin
DrugDDI.d117.s6.e1 81 104
drug
enzymatic glucose oxi-dase

interaction DrugDDI.d117.s6.e0 DrugDDI.d117.s6.e1 false

Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s7
Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol , estriol-glucuronide, conjugated estrone , and estradiol has been noted.

DrugDDI.d117.s7.e0 25 34
drug
ampicillin
DrugDDI.d117.s7.e1 107 113
drug
estriol
DrugDDI.d117.s7.e2 145 151
drug
estrone
DrugDDI.d117.s7.e3 156 164
drug
estradiol

interaction DrugDDI.d117.s7.e0 DrugDDI.d117.s7.e1 false
interaction DrugDDI.d117.s7.e0 DrugDDI.d117.s7.e2 false
interaction DrugDDI.d117.s7.e0 DrugDDI.d117.s7.e3 false
interaction DrugDDI.d117.s7.e1 DrugDDI.d117.s7.e2 false
interaction DrugDDI.d117.s7.e1 DrugDDI.d117.s7.e3 false
interaction DrugDDI.d117.s7.e2 DrugDDI.d117.s7.e3 false

Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s8
This effect may also occur with amoxicillin .

DrugDDI.d117.s8.e0 26 36
drug
amoxicillin



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s10
Studies to detect mutagenic potential of amoxicillin alone have not been conducted; .

DrugDDI.d117.s10.e0 35 45
drug
amoxicillin



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s11
however, the following information is available from tests on a 4:1 mixture of amoxicillin and potassium clavulanate ( AUGMENTIN ).

DrugDDI.d117.s11.e0 66 76
drug
amoxicillin
DrugDDI.d117.s11.e1 80 99
drug
potassium clavulanate
DrugDDI.d117.s11.e2 101 109
drug
AUGMENTIN

interaction DrugDDI.d117.s11.e0 DrugDDI.d117.s11.e1 false
interaction DrugDDI.d117.s11.e0 DrugDDI.d117.s11.e2 false
interaction DrugDDI.d117.s11.e1 DrugDDI.d117.s11.e2 false

Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s12
AUGMENTIN was non-mutagenic in the Ame s bacterial mutation assay, and the yeast gene conversion assay.

DrugDDI.d117.s12.e0 0 8
drug
AUGMENTIN
DrugDDI.d117.s12.e1 30 32
drug
Ame

interaction DrugDDI.d117.s12.e0 DrugDDI.d117.s12.e1 false

Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s13
AUGMENTIN was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival.

DrugDDI.d117.s13.e0 0 8
drug
AUGMENTIN
DrugDDI.d117.s13.new.DISO.e1 31 43
DISO
mouse lymphoma



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s14
AUGMENTIN was negative in the mouse micronucleus test, and in the dominant lethal assay in mice.

DrugDDI.d117.s14.e0 0 8
drug
AUGMENTIN



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s15
Potassium clavulanate alone was tested in the Ame s bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays.

DrugDDI.d117.s15.e0 0 19
drug
Potassium clavulanate
DrugDDI.d117.s15.e1 39 41
drug
Ame

interaction DrugDDI.d117.s15.e0 DrugDDI.d117.s15.e1 false

Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s18
Reproduction studies have been performed in mice and rats at doses up to 10 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to amoxicillin .

DrugDDI.d117.s18.e0 144 154
drug
amoxicillin



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s20
Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

DrugDDI.d117.s20.e0 74 77
drug
drug



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s21
Labor and Delivery: Oral ampicillin -class antibiotics are poorly absorbed during labor.

DrugDDI.d117.s21.e0 17 30
drug
Oral ampicillin



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s22
Studies in guinea pigs showed that intravenous administration of ampicillin slightly decreased the uterine tone and frequency of contractions but moderately increased the height and duration of contractions.

DrugDDI.d117.s22.e0 56 65
drug
ampicillin



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s23
However, it is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.

DrugDDI.d117.s23.e0 32 42
drug
amoxicillin



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s24
Nursing Mothers: Penicillins have been shown to be excreted in human milk.

DrugDDI.d117.s24.e0 15 25
drug
Penicillins



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s25
Amoxicillin use by nursing mothers may lead to sensitization of infants.

DrugDDI.d117.s25.e0 0 10
drug
Amoxicillin



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s26
Caution should be exercised when amoxicillin is administered to a nursing woman.

DrugDDI.d117.s26.e0 28 38
drug
amoxicillin



Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s27
Pediatric Use: Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed.

DrugDDI.d117.s27.e0 0 8
drug
Pediatric
DrugDDI.d117.s27.e1 98 108
drug
amoxicillin

interaction DrugDDI.d117.s27.e0 DrugDDI.d117.s27.e1 false

Abstract Id: DrugDDI.d117
Sentence Id: DrugDDI.d117.s28
Dosing of AMOXIL should be modified in pediatric patients 12 weeks or younger (@3 months).

DrugDDI.d117.s28.e0 8 13
drug
AMOXIL
DrugDDI.d117.s28.e1 32 40
drug
pediatric

interaction DrugDDI.d117.s28.e0 DrugDDI.d117.s28.e1 false

Abstract Id: DrugDDI.d28
Sentence Id: DrugDDI.d28.s1
Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret@ when the two agents were administered together.

DrugDDI.d28.s1.e0 113 124
drug
methotrexate



Abstract Id: DrugDDI.d28
Sentence Id: DrugDDI.d28.s2
In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret@ and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).

DrugDDI.d28.s2.e0 85 94
drug
etanercept
DrugDDI.d28.s2.new.DISO.e2 119 128
DISO
infections
DrugDDI.d28.s2.e1 175 184
drug
etanercept

interaction DrugDDI.d28.s2.e0 DrugDDI.d28.s2.e1 false

Abstract Id: DrugDDI.d28
Sentence Id: DrugDDI.d28.s3
Two percent of patients treated concurrently with Kineret@ and etanercept developed neutropenia ( ANC 1 x 109/L ).

DrugDDI.d28.s3.e0 54 63
drug
etanercept
DrugDDI.d28.s3.new.DISO.e2 73 83
DISO
neutropenia
DrugDDI.d28.s3.e1 85 94
drug
ANC  1 x 109/L

interaction DrugDDI.d28.s3.e0 DrugDDI.d28.s3.e1 false

Abstract Id: DrugDDI.d552
Sentence Id: DrugDDI.d552.s0
No clinically relevant drug-drug interactions have been observed with drugs likely to be co-administered with anidulafungin .

DrugDDI.d552.s0.e0 61 65
drug
drugs
DrugDDI.d552.s0.e1 95 107
drug
anidulafungin

interaction DrugDDI.d552.s0.e0 DrugDDI.d552.s0.e1 false

Abstract Id: DrugDDI.d290
Sentence Id: DrugDDI.d290.s0
Caution should be observed when anileridine is coadministered with other opioids , sedatives , phenothiazines , or anesthetics , as these agents may increase respiratory and circulatory depression.

DrugDDI.d290.s0.e0 27 37
drug
anileridine
DrugDDI.d290.s0.e1 63 69
drug
opioids
DrugDDI.d290.s0.e2 71 79
drug
sedatives
DrugDDI.d290.s0.e3 81 94
drug
phenothiazines
DrugDDI.d290.s0.e4 98 108
drug
anesthetics
DrugDDI.d290.s0.new.DISO.e5 159 168
DISO
depression

interaction DrugDDI.d290.s0.e0 DrugDDI.d290.s0.e1 false
interaction DrugDDI.d290.s0.e0 DrugDDI.d290.s0.e2 true
interaction DrugDDI.d290.s0.e0 DrugDDI.d290.s0.e3 false
interaction DrugDDI.d290.s0.e0 DrugDDI.d290.s0.e4 true
interaction DrugDDI.d290.s0.e1 DrugDDI.d290.s0.e2 false
interaction DrugDDI.d290.s0.e1 DrugDDI.d290.s0.e3 false
interaction DrugDDI.d290.s0.e1 DrugDDI.d290.s0.e4 false
interaction DrugDDI.d290.s0.e2 DrugDDI.d290.s0.e3 false
interaction DrugDDI.d290.s0.e2 DrugDDI.d290.s0.e4 false
interaction DrugDDI.d290.s0.e3 DrugDDI.d290.s0.e4 false

Abstract Id: DrugDDI.d224
Sentence Id: DrugDDI.d224.s0
Ketoconazole / Itraconazole , Macrolides , Including Erythromycin .

DrugDDI.d224.s0.e0 0 11
drug
Ketoconazole
DrugDDI.d224.s0.e1 13 24
drug
Itraconazole
DrugDDI.d224.s0.e2 26 35
drug
Macrolides
DrugDDI.d224.s0.e3 46 57
drug
Erythromycin

interaction DrugDDI.d224.s0.e0 DrugDDI.d224.s0.e1 false
interaction DrugDDI.d224.s0.e0 DrugDDI.d224.s0.e2 false
interaction DrugDDI.d224.s0.e0 DrugDDI.d224.s0.e3 false
interaction DrugDDI.d224.s0.e1 DrugDDI.d224.s0.e2 false
interaction DrugDDI.d224.s0.e1 DrugDDI.d224.s0.e3 false
interaction DrugDDI.d224.s0.e2 DrugDDI.d224.s0.e3 false

Abstract Id: DrugDDI.d582
Sentence Id: DrugDDI.d582.s0
Atovaquone is highly bound to plasma protein (99.9%).

DrugDDI.d582.s0.e0 0 9
drug
Atovaquone
DrugDDI.d582.s0.e1 25 37
drug
plasma protein

interaction DrugDDI.d582.s0.e0 DrugDDI.d582.s0.e1 true

Abstract Id: DrugDDI.d582
Sentence Id: DrugDDI.d582.s1
Therefore, caution should be used when administering MEPRON concurrently with other highly plasma protein- bound drugs with narrow therapeutic indices, as competition for binding sites may occur.

DrugDDI.d582.s1.e0 46 51
drug
MEPRON



Abstract Id: DrugDDI.d582
Sentence Id: DrugDDI.d582.s2
The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone .

DrugDDI.d582.s2.e0 11 23
drug
plasma protein
DrugDDI.d582.s2.e1 33 42
drug
atovaquone
DrugDDI.d582.s2.e2 45 55
drug
human plasma
DrugDDI.d582.s2.e3 111 119
drug
phenytoin
DrugDDI.d582.s2.e4 148 156
drug
phenytoin
DrugDDI.d582.s2.e5 180 189
drug
atovaquone

interaction DrugDDI.d582.s2.e0 DrugDDI.d582.s2.e1 false
interaction DrugDDI.d582.s2.e0 DrugDDI.d582.s2.e2 false
interaction DrugDDI.d582.s2.e0 DrugDDI.d582.s2.e3 false
interaction DrugDDI.d582.s2.e0 DrugDDI.d582.s2.e4 false
interaction DrugDDI.d582.s2.e0 DrugDDI.d582.s2.e5 false
interaction DrugDDI.d582.s2.e1 DrugDDI.d582.s2.e2 false
interaction DrugDDI.d582.s2.e1 DrugDDI.d582.s2.e3 false
interaction DrugDDI.d582.s2.e1 DrugDDI.d582.s2.e4 false
interaction DrugDDI.d582.s2.e1 DrugDDI.d582.s2.e5 false
interaction DrugDDI.d582.s2.e2 DrugDDI.d582.s2.e3 false
interaction DrugDDI.d582.s2.e2 DrugDDI.d582.s2.e4 false
interaction DrugDDI.d582.s2.e2 DrugDDI.d582.s2.e5 false
interaction DrugDDI.d582.s2.e3 DrugDDI.d582.s2.e4 false
interaction DrugDDI.d582.s2.e3 DrugDDI.d582.s2.e5 false
interaction DrugDDI.d582.s2.e4 DrugDDI.d582.s2.e5 false

Abstract Id: DrugDDI.d582
Sentence Id: DrugDDI.d582.s3
Rifampin : Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.

DrugDDI.d582.s3.e0 0 7
drug
Rifampin
DrugDDI.d582.s3.e1 27 34
drug
rifampin
DrugDDI.d582.s3.e2 38 43
drug
MEPRON
DrugDDI.d582.s3.e3 110 119
drug
atovaquone

interaction DrugDDI.d582.s3.e0 DrugDDI.d582.s3.e1 false
interaction DrugDDI.d582.s3.e0 DrugDDI.d582.s3.e2 false
interaction DrugDDI.d582.s3.e0 DrugDDI.d582.s3.e3 false
interaction DrugDDI.d582.s3.e1 DrugDDI.d582.s3.e2 true
interaction DrugDDI.d582.s3.e1 DrugDDI.d582.s3.e3 false
interaction DrugDDI.d582.s3.e2 DrugDDI.d582.s3.e3 false

Abstract Id: DrugDDI.d582
Sentence Id: DrugDDI.d582.s4
Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON .

DrugDDI.d582.s4.e0 14 21
drug
rifampin
DrugDDI.d582.s4.e1 73 78
drug
MEPRON

interaction DrugDDI.d582.s4.e0 DrugDDI.d582.s4.e1 true

Abstract Id: DrugDDI.d582
Sentence Id: DrugDDI.d582.s5
Rifabutin , another rifamycin , is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin .

DrugDDI.d582.s5.e0 0 8
drug
Rifabutin
DrugDDI.d582.s5.e1 17 25
drug
rifamycin
DrugDDI.d582.s5.e2 50 57
drug
rifampin
DrugDDI.d582.s5.e3 107 114
drug
rifampin

interaction DrugDDI.d582.s5.e0 DrugDDI.d582.s5.e1 false
interaction DrugDDI.d582.s5.e0 DrugDDI.d582.s5.e2 false
interaction DrugDDI.d582.s5.e0 DrugDDI.d582.s5.e3 false
interaction DrugDDI.d582.s5.e1 DrugDDI.d582.s5.e2 false
interaction DrugDDI.d582.s5.e1 DrugDDI.d582.s5.e3 false
interaction DrugDDI.d582.s5.e2 DrugDDI.d582.s5.e3 false

Abstract Id: DrugDDI.d582
Sentence Id: DrugDDI.d582.s6
No interaction trials have been conducted with MEPRON and rifabutin .

DrugDDI.d582.s6.e0 40 45
drug
MEPRON
DrugDDI.d582.s6.e1 49 57
drug
rifabutin

interaction DrugDDI.d582.s6.e0 DrugDDI.d582.s6.e1 false

Abstract Id: DrugDDI.d582
Sentence Id: DrugDDI.d582.s7
Drug / Laboratory Test Interactions: It is not known if MEPRON interferes with clinical laboratory test or assay results.

DrugDDI.d582.s7.e0 0 3
drug
Drug
DrugDDI.d582.s7.e1 46 51
drug
MEPRON

interaction DrugDDI.d582.s7.e0 DrugDDI.d582.s7.e1 false

Abstract Id: DrugDDI.d39
Sentence Id: DrugDDI.d39.s0
When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine .

DrugDDI.d39.s0.e0 4 11
drug
atropine
DrugDDI.d39.s0.e1 15 25
drug
pralidoxime
DrugDDI.d39.s0.new.DISO.e5 86 96
DISO
tachycardia
DrugDDI.d39.s0.e2 165 172
drug
atropine
DrugDDI.d39.s0.e3 191 201
drug
pralidoxime
DrugDDI.d39.s0.e4 226 233
drug
atropine

interaction DrugDDI.d39.s0.e0 DrugDDI.d39.s0.e1 true
interaction DrugDDI.d39.s0.e0 DrugDDI.d39.s0.e2 false
interaction DrugDDI.d39.s0.e0 DrugDDI.d39.s0.e3 false
interaction DrugDDI.d39.s0.e0 DrugDDI.d39.s0.e4 false
interaction DrugDDI.d39.s0.e1 DrugDDI.d39.s0.e2 false
interaction DrugDDI.d39.s0.e1 DrugDDI.d39.s0.e3 false
interaction DrugDDI.d39.s0.e1 DrugDDI.d39.s0.e4 false
interaction DrugDDI.d39.s0.e2 DrugDDI.d39.s0.e3 false
interaction DrugDDI.d39.s0.e2 DrugDDI.d39.s0.e4 false
interaction DrugDDI.d39.s0.e3 DrugDDI.d39.s0.e4 false

Abstract Id: DrugDDI.d39
Sentence Id: DrugDDI.d39.s1
The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime .

DrugDDI.d39.s1.e0 123 130
drug
atropine
DrugDDI.d39.s1.e1 134 144
drug
pralidoxime

interaction DrugDDI.d39.s1.e0 DrugDDI.d39.s1.e1 false

Abstract Id: DrugDDI.d39
Sentence Id: DrugDDI.d39.s2
Since barbiturates are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions.

DrugDDI.d39.s2.e0 5 16
drug
barbiturates
DrugDDI.d39.s2.e1 36 54
drug
anticholinesterases

interaction DrugDDI.d39.s2.e0 DrugDDI.d39.s2.e1 true

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s0
Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 span class= c94 @?

DrugDDI.d554.s0.e0 19 28
drug
nelfinavir
DrugDDI.d554.s0.e1 60 71
drug
azithromycin

interaction DrugDDI.d554.s0.e0 DrugDDI.d554.s0.e1 true

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s1
600 mg tablets) results in increased azithromycin serum concentrations.

DrugDDI.d554.s1.e0 31 42
drug
azithromycin



Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s2
Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir , close monitoring for known side effects of azithromycin , such as liver enzyme abnormalities and hearing impairment, is warranted.

DrugDDI.d554.s2.e0 25 36
drug
azithromycin
DrugDDI.d554.s2.e1 86 95
drug
nelfinavir
DrugDDI.d554.s2.e2 133 144
drug
azithromycin
DrugDDI.d554.s2.new.DISO.e3 179 195
DISO
hearing impairment

interaction DrugDDI.d554.s2.e0 DrugDDI.d554.s2.e1 true
interaction DrugDDI.d554.s2.e0 DrugDDI.d554.s2.e2 false
interaction DrugDDI.d554.s2.e1 DrugDDI.d554.s2.e2 false

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s3
Azithromycin did not affect the prothrombin time response to a single dose of warfarin .

DrugDDI.d554.s3.e0 0 11
drug
Azithromycin
DrugDDI.d554.s3.e1 65 72
drug
warfarin

interaction DrugDDI.d554.s3.e0 DrugDDI.d554.s3.e1 false

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s4
However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.

DrugDDI.d554.s4.e0 96 107
drug
azithromycin
DrugDDI.d554.s4.e1 111 118
drug
warfarin

interaction DrugDDI.d554.s4.e0 DrugDDI.d554.s4.e1 true

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s5
Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.

DrugDDI.d554.s5.e0 15 24
drug
macrolides
DrugDDI.d554.s5.e1 28 35
drug
warfarin

interaction DrugDDI.d554.s5.e0 DrugDDI.d554.s5.e1 true

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s6
Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered.

DrugDDI.d554.s6.e0 39 50
drug
azithromycin
DrugDDI.d554.s6.e1 59 63
drug
drugs

interaction DrugDDI.d554.s6.e0 DrugDDI.d554.s6.e1 false

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s7
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline (intravenous and oral), triazolam , trimethoprim / sulfamethoxazole or zidovudine .

DrugDDI.d554.s7.e0 27 38
drug
azithromycin
DrugDDI.d554.s7.e1 78 89
drug
atorvastatin
DrugDDI.d554.s7.e2 91 103
drug
carbamazepine
DrugDDI.d554.s7.e3 105 114
drug
cetirizine
DrugDDI.d554.s7.e4 116 125
drug
didanosine
DrugDDI.d554.s7.e5 127 135
drug
efavirenz
DrugDDI.d554.s7.e6 137 147
drug
fluconazole
DrugDDI.d554.s7.e7 149 157
drug
indinavir
DrugDDI.d554.s7.e8 159 167
drug
midazolam
DrugDDI.d554.s7.e9 169 177
drug
rifabutin
DrugDDI.d554.s7.e10 179 188
drug
sildenafil
DrugDDI.d554.s7.e11 190 201
drug
theophylline
DrugDDI.d554.s7.e12 223 231
drug
triazolam
DrugDDI.d554.s7.e13 233 244
drug
trimethoprim
DrugDDI.d554.s7.e14 246 261
drug
sulfamethoxazole
DrugDDI.d554.s7.e15 264 273
drug
zidovudine

interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e1 true
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e2 false
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e3 true
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e4 false
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e5 true
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e6 false
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e7 true
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e8 false
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e9 true
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e10 false
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e11 true
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e13 true
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e0 DrugDDI.d554.s7.e15 true
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e2 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e3 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e4 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e5 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e6 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e7 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e8 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e9 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e10 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e11 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e1 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e3 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e4 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e5 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e6 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e7 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e8 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e9 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e10 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e11 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e2 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e4 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e5 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e6 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e7 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e8 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e9 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e10 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e11 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e3 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e4 DrugDDI.d554.s7.e5 false
interaction DrugDDI.d554.s7.e4 DrugDDI.d554.s7.e6 false
interaction DrugDDI.d554.s7.e4 DrugDDI.d554.s7.e7 false
interaction DrugDDI.d554.s7.e4 DrugDDI.d554.s7.e8 false
interaction DrugDDI.d554.s7.e4 DrugDDI.d554.s7.e9 false
interaction DrugDDI.d554.s7.e4 DrugDDI.d554.s7.e10 false
interaction DrugDDI.d554.s7.e4 DrugDDI.d554.s7.e11 false
interaction DrugDDI.d554.s7.e4 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e4 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e4 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e4 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e5 DrugDDI.d554.s7.e6 false
interaction DrugDDI.d554.s7.e5 DrugDDI.d554.s7.e7 false
interaction DrugDDI.d554.s7.e5 DrugDDI.d554.s7.e8 false
interaction DrugDDI.d554.s7.e5 DrugDDI.d554.s7.e9 false
interaction DrugDDI.d554.s7.e5 DrugDDI.d554.s7.e10 false
interaction DrugDDI.d554.s7.e5 DrugDDI.d554.s7.e11 false
interaction DrugDDI.d554.s7.e5 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e5 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e5 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e5 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e6 DrugDDI.d554.s7.e7 false
interaction DrugDDI.d554.s7.e6 DrugDDI.d554.s7.e8 false
interaction DrugDDI.d554.s7.e6 DrugDDI.d554.s7.e9 false
interaction DrugDDI.d554.s7.e6 DrugDDI.d554.s7.e10 false
interaction DrugDDI.d554.s7.e6 DrugDDI.d554.s7.e11 false
interaction DrugDDI.d554.s7.e6 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e6 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e6 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e6 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e7 DrugDDI.d554.s7.e8 false
interaction DrugDDI.d554.s7.e7 DrugDDI.d554.s7.e9 false
interaction DrugDDI.d554.s7.e7 DrugDDI.d554.s7.e10 false
interaction DrugDDI.d554.s7.e7 DrugDDI.d554.s7.e11 false
interaction DrugDDI.d554.s7.e7 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e7 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e7 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e7 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e8 DrugDDI.d554.s7.e9 false
interaction DrugDDI.d554.s7.e8 DrugDDI.d554.s7.e10 false
interaction DrugDDI.d554.s7.e8 DrugDDI.d554.s7.e11 false
interaction DrugDDI.d554.s7.e8 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e8 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e8 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e8 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e9 DrugDDI.d554.s7.e10 false
interaction DrugDDI.d554.s7.e9 DrugDDI.d554.s7.e11 false
interaction DrugDDI.d554.s7.e9 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e9 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e9 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e9 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e10 DrugDDI.d554.s7.e11 false
interaction DrugDDI.d554.s7.e10 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e10 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e10 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e10 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e11 DrugDDI.d554.s7.e12 false
interaction DrugDDI.d554.s7.e11 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e11 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e11 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e12 DrugDDI.d554.s7.e13 false
interaction DrugDDI.d554.s7.e12 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e12 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e13 DrugDDI.d554.s7.e14 false
interaction DrugDDI.d554.s7.e13 DrugDDI.d554.s7.e15 false
interaction DrugDDI.d554.s7.e14 DrugDDI.d554.s7.e15 false

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s8
Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin .

DrugDDI.d554.s8.e0 21 29
drug
efavirenz
DrugDDI.d554.s8.e1 32 42
drug
fluconazole
DrugDDI.d554.s8.e2 82 93
drug
azithromycin

interaction DrugDDI.d554.s8.e0 DrugDDI.d554.s8.e1 false
interaction DrugDDI.d554.s8.e0 DrugDDI.d554.s8.e2 false
interaction DrugDDI.d554.s8.e1 DrugDDI.d554.s8.e2 false

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s9
No dosage adjustment of either drug is recommended when azithromycin is co administered with any of the above agents.

DrugDDI.d554.s9.e0 26 29
drug
drug
DrugDDI.d554.s9.e1 47 58
drug
azithromycin

interaction DrugDDI.d554.s9.e0 DrugDDI.d554.s9.e1 false

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s10
Interactions with the drugs listed below have not been reported in clinical trials with azithromycin ; .

DrugDDI.d554.s10.e0 19 23
drug
drugs
DrugDDI.d554.s10.e1 74 85
drug
azithromycin

interaction DrugDDI.d554.s10.e0 DrugDDI.d554.s10.e1 false

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s12
Nonetheless, they have been observed with macrolide products.

DrugDDI.d554.s12.e0 36 44
drug
macrolide



Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s13
Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin @elevated digoxin concentrations.

DrugDDI.d554.s13.e0 57 68
drug
azithromycin
DrugDDI.d554.s13.e1 77 81
drug
drugs
DrugDDI.d554.s13.e2 140 146
drug
Digoxin

interaction DrugDDI.d554.s13.e0 DrugDDI.d554.s13.e1 false
interaction DrugDDI.d554.s13.e0 DrugDDI.d554.s13.e2 false
interaction DrugDDI.d554.s13.e1 DrugDDI.d554.s13.e2 false

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s14
Ergotamine or dihydro ergot amine@acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.

DrugDDI.d554.s14.e0 0 9
drug
Ergotamine
DrugDDI.d554.s14.e1 19 23
drug
ergot
DrugDDI.d554.s14.new.DISO.e2 69 87
DISO
peripheral vasospasm

interaction DrugDDI.d554.s14.e0 DrugDDI.d554.s14.e1 false

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s15
Cyclosporine , hexobarbital and phenytoin concentrations.

DrugDDI.d554.s15.e0 0 11
drug
Cyclosporine
DrugDDI.d554.s15.e1 13 24
drug
hexobarbital
DrugDDI.d554.s15.e2 28 36
drug
phenytoin

interaction DrugDDI.d554.s15.e0 DrugDDI.d554.s15.e1 false
interaction DrugDDI.d554.s15.e0 DrugDDI.d554.s15.e2 false
interaction DrugDDI.d554.s15.e1 DrugDDI.d554.s15.e2 false

Abstract Id: DrugDDI.d554
Sentence Id: DrugDDI.d554.s17
Repeat Treatment Studies evaluating the use of repeated courses of Zmax have not been conducted.

DrugDDI.d554.s17.e0 57 60
drug
Zmax



Abstract Id: DrugDDI.d535
Sentence Id: DrugDDI.d535.s0
Azlocillin should not be administered concomitantly with amikacin , ciprofloxacin , gentamicin , netilmicin , or tobramycin .

DrugDDI.d535.s0.e0 0 9
drug
Azlocillin
DrugDDI.d535.s0.e1 50 57
drug
amikacin
DrugDDI.d535.s0.e2 59 71
drug
ciprofloxacin
DrugDDI.d535.s0.e3 73 82
drug
gentamicin
DrugDDI.d535.s0.e4 84 93
drug
netilmicin
DrugDDI.d535.s0.e5 97 106
drug
tobramycin

interaction DrugDDI.d535.s0.e0 DrugDDI.d535.s0.e1 true
interaction DrugDDI.d535.s0.e0 DrugDDI.d535.s0.e2 false
interaction DrugDDI.d535.s0.e0 DrugDDI.d535.s0.e3 true
interaction DrugDDI.d535.s0.e0 DrugDDI.d535.s0.e4 false
interaction DrugDDI.d535.s0.e0 DrugDDI.d535.s0.e5 true
interaction DrugDDI.d535.s0.e1 DrugDDI.d535.s0.e2 false
interaction DrugDDI.d535.s0.e1 DrugDDI.d535.s0.e3 false
interaction DrugDDI.d535.s0.e1 DrugDDI.d535.s0.e4 false
interaction DrugDDI.d535.s0.e1 DrugDDI.d535.s0.e5 false
interaction DrugDDI.d535.s0.e2 DrugDDI.d535.s0.e3 false
interaction DrugDDI.d535.s0.e2 DrugDDI.d535.s0.e4 false
interaction DrugDDI.d535.s0.e2 DrugDDI.d535.s0.e5 false
interaction DrugDDI.d535.s0.e3 DrugDDI.d535.s0.e4 false
interaction DrugDDI.d535.s0.e3 DrugDDI.d535.s0.e5 false
interaction DrugDDI.d535.s0.e4 DrugDDI.d535.s0.e5 false

Abstract Id: DrugDDI.d517
Sentence Id: DrugDDI.d517.s0
Injection : There is inadequate systematic experience with the use of baclofen injection in combination with other medications to predict specific drug-drug interactions.

DrugDDI.d517.s0.e0 59 66
drug
baclofen
DrugDDI.d517.s0.e1 93 108
drug
other medications

interaction DrugDDI.d517.s0.e0 DrugDDI.d517.s0.e1 false

Abstract Id: DrugDDI.d517
Sentence Id: DrugDDI.d517.s1
Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.

DrugDDI.d517.s1.e0 40 47
drug
baclofen
DrugDDI.d517.s1.e1 68 75
drug
morphine

interaction DrugDDI.d517.s1.e0 DrugDDI.d517.s1.e1 true

Abstract Id: DrugDDI.d517
Sentence Id: DrugDDI.d517.s2
SIDE EFFECTS (KEMSTRO) : The most common adverse reaction during treatment with baclofen is transient drowsiness (10-63%).

DrugDDI.d517.s2.new.DISO.e1 12 18
DISO
KEMSTRO
DrugDDI.d517.s2.e0 68 75
drug
baclofen



Abstract Id: DrugDDI.d517
Sentence Id: DrugDDI.d517.s3
In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen tablets compared to 36% of those in the placebo group.

DrugDDI.d517.s3.e0 85 99
drug
baclofen tablets



Abstract Id: DrugDDI.d517
Sentence Id: DrugDDI.d517.s15
The following laboratory tests have been found to be abnormal in a few patients receiving baclofen : increased SGOT, elevated alkaline phosphatase , and elevation of blood sugar.

DrugDDI.d517.s15.e0 75 82
drug
baclofen
DrugDDI.d517.s15.e1 106 124
drug
alkaline phosphatase

interaction DrugDDI.d517.s15.e0 DrugDDI.d517.s15.e1 false

Abstract Id: DrugDDI.d517
Sentence Id: DrugDDI.d517.s16
The adverse experience profile seen with KEMSTROTM was similar to that seen with baclofen tablets .

DrugDDI.d517.s16.e0 68 82
drug
baclofen tablets



Abstract Id: DrugDDI.d500
Sentence Id: DrugDDI.d500.s0
Bentiromide may interact with acetaminophen (e.g., Tylenol ), chloramphenicol (e.g., Chloromycetin ), local anesthetics (e.g., benzocaine and lidocaine ), para-aminobenzoic acid ( PABA )-containing preparations (e.g., sunscreens and some multivitamins ), procainamide (e.g., Pronestyl ), sulfonamides ( sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).

DrugDDI.d500.s0.e0 0 10
drug
Bentiromide
DrugDDI.d500.s0.e1 26 38
drug
acetaminophen
DrugDDI.d500.s0.e2 45 51
drug
Tylenol
DrugDDI.d500.s0.e3 54 68
drug
chloramphenicol
DrugDDI.d500.s0.e4 75 87
drug
Chloromycetin
DrugDDI.d500.s0.e5 90 105
drug
local anesthetics
DrugDDI.d500.s0.e6 112 121
drug
benzocaine
DrugDDI.d500.s0.e7 125 133
drug
lidocaine
DrugDDI.d500.s0.e8 136 156
drug
para-aminobenzoic acid
DrugDDI.d500.s0.e9 158 161
drug
PABA
DrugDDI.d500.s0.e10 192 201
drug
sunscreens
DrugDDI.d500.s0.e11 209 221
drug
multivitamins
DrugDDI.d500.s0.e12 224 235
drug
procainamide
DrugDDI.d500.s0.e13 242 250
drug
Pronestyl
DrugDDI.d500.s0.e14 253 264
drug
sulfonamides
DrugDDI.d500.s0.e15 266 270
drug
sulfa
DrugDDI.d500.s0.e16 282 298
drug
thiazide diuretics
DrugDDI.d500.s0.e17 310 318
drug
medicines
DrugDDI.d500.s0.e18 394 403
drug
pancreatic

interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e1 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e2 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e3 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e4 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e5 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e6 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e7 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e8 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e9 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e10 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e11 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e12 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e13 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e14 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e15 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e16 true
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e0 DrugDDI.d500.s0.e18 true
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e2 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e3 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e4 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e5 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e6 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e7 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e8 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e9 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e10 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e11 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e12 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e1 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e3 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e4 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e5 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e6 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e7 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e8 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e9 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e10 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e11 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e12 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e2 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e4 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e5 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e6 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e7 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e8 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e9 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e10 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e11 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e12 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e3 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e5 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e6 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e7 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e8 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e9 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e10 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e11 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e12 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e4 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e6 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e7 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e8 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e9 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e10 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e11 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e12 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e5 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e7 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e8 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e9 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e10 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e11 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e12 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e6 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e7 DrugDDI.d500.s0.e8 false
interaction DrugDDI.d500.s0.e7 DrugDDI.d500.s0.e9 false
interaction DrugDDI.d500.s0.e7 DrugDDI.d500.s0.e10 false
interaction DrugDDI.d500.s0.e7 DrugDDI.d500.s0.e11 false
interaction DrugDDI.d500.s0.e7 DrugDDI.d500.s0.e12 false
interaction DrugDDI.d500.s0.e7 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e7 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e7 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e7 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e7 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e7 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e8 DrugDDI.d500.s0.e9 false
interaction DrugDDI.d500.s0.e8 DrugDDI.d500.s0.e10 false
interaction DrugDDI.d500.s0.e8 DrugDDI.d500.s0.e11 false
interaction DrugDDI.d500.s0.e8 DrugDDI.d500.s0.e12 false
interaction DrugDDI.d500.s0.e8 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e8 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e8 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e8 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e8 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e8 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e9 DrugDDI.d500.s0.e10 false
interaction DrugDDI.d500.s0.e9 DrugDDI.d500.s0.e11 false
interaction DrugDDI.d500.s0.e9 DrugDDI.d500.s0.e12 false
interaction DrugDDI.d500.s0.e9 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e9 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e9 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e9 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e9 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e9 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e10 DrugDDI.d500.s0.e11 false
interaction DrugDDI.d500.s0.e10 DrugDDI.d500.s0.e12 false
interaction DrugDDI.d500.s0.e10 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e10 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e10 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e10 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e10 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e10 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e11 DrugDDI.d500.s0.e12 false
interaction DrugDDI.d500.s0.e11 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e11 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e11 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e11 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e11 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e11 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e12 DrugDDI.d500.s0.e13 false
interaction DrugDDI.d500.s0.e12 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e12 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e12 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e12 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e12 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e13 DrugDDI.d500.s0.e14 false
interaction DrugDDI.d500.s0.e13 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e13 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e13 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e13 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e14 DrugDDI.d500.s0.e15 false
interaction DrugDDI.d500.s0.e14 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e14 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e14 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e15 DrugDDI.d500.s0.e16 false
interaction DrugDDI.d500.s0.e15 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e15 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e16 DrugDDI.d500.s0.e17 false
interaction DrugDDI.d500.s0.e16 DrugDDI.d500.s0.e18 false
interaction DrugDDI.d500.s0.e17 DrugDDI.d500.s0.e18 false

Abstract Id: DrugDDI.d194
Sentence Id: DrugDDI.d194.s0
Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors .

DrugDDI.d194.s0.new.DISO.e2 0 17
DISO
Hypertensive crises
DrugDDI.d194.s0.e0 34 54
drug
sympathomimetic amines
DrugDDI.d194.s0.e1 106 131
drug
monoamine oxidase inhibitors

interaction DrugDDI.d194.s0.e0 DrugDDI.d194.s0.e1 true

Abstract Id: DrugDDI.d194
Sentence Id: DrugDDI.d194.s1
DIDREX should not be used concomitantly with other CNS stimulants .

DrugDDI.d194.s1.e0 0 5
drug
DIDREX
DrugDDI.d194.s1.e1 43 55
drug
CNS stimulants

interaction DrugDDI.d194.s1.e0 DrugDDI.d194.s1.e1 true

Abstract Id: DrugDDI.d194
Sentence Id: DrugDDI.d194.s2
Amphetamines may decrease the hypotensive effect of antihypertensives .

DrugDDI.d194.s2.e0 0 11
drug
Amphetamines
DrugDDI.d194.s2.e1 45 61
drug
antihypertensives

interaction DrugDDI.d194.s2.e0 DrugDDI.d194.s2.e1 true

Abstract Id: DrugDDI.d194
Sentence Id: DrugDDI.d194.s3
Amphetamines may enhance the effects of tricyclic antidepressants .

DrugDDI.d194.s3.e0 0 11
drug
Amphetamines
DrugDDI.d194.s3.e1 34 57
drug
tricyclic antidepressants

interaction DrugDDI.d194.s3.e0 DrugDDI.d194.s3.e1 true

Abstract Id: DrugDDI.d194
Sentence Id: DrugDDI.d194.s4
Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines .

DrugDDI.d194.s4.e0 7 24
drug
alkalinizing agents
DrugDDI.d194.s4.e1 66 77
drug
amphetamines

interaction DrugDDI.d194.s4.e0 DrugDDI.d194.s4.e1 true

Abstract Id: DrugDDI.d194
Sentence Id: DrugDDI.d194.s5
Urinary acidifying agents decrease blood levels and increase excretion of amphetamines .

DrugDDI.d194.s5.e0 7 22
drug
acidifying agents
DrugDDI.d194.s5.e1 64 75
drug
amphetamines

interaction DrugDDI.d194.s5.e0 DrugDDI.d194.s5.e1 true

Abstract Id: DrugDDI.d236
Sentence Id: DrugDDI.d236.s0
Benzthiazide may interact with alcohol , blood thinner s, decongestant drugs (allergy, cold, and sinus medicines ), diabetic drugs , lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications .

DrugDDI.d236.s0.e0 0 11
drug
Benzthiazide
DrugDDI.d236.s0.e1 27 33
drug
alcohol
DrugDDI.d236.s0.e2 35 46
drug
blood thinner
DrugDDI.d236.s0.e3 49 65
drug
decongestant drugs
DrugDDI.d236.s0.e4 88 96
drug
medicines
DrugDDI.d236.s0.e5 107 111
drug
drugs
DrugDDI.d236.s0.e6 113 119
drug
lithium
DrugDDI.d236.s0.e7 121 134
drug
norepinephrine
DrugDDI.d236.s0.e8 136 141
drug
NSAIDs
DrugDDI.d236.s0.e9 146 150
drug
Aleve
DrugDDI.d236.s0.e10 153 161
drug
Ibuprofen
DrugDDI.d236.s0.e11 183 193
drug
medications

interaction DrugDDI.d236.s0.e0 DrugDDI.d236.s0.e1 true
interaction DrugDDI.d236.s0.e0 DrugDDI.d236.s0.e2 true
interaction DrugDDI.d236.s0.e0 DrugDDI.d236.s0.e3 true
interaction DrugDDI.d236.s0.e0 DrugDDI.d236.s0.e4 true
interaction DrugDDI.d236.s0.e0 DrugDDI.d236.s0.e5 true
interaction DrugDDI.d236.s0.e0 DrugDDI.d236.s0.e6 true
interaction DrugDDI.d236.s0.e0 DrugDDI.d236.s0.e7 true
interaction DrugDDI.d236.s0.e0 DrugDDI.d236.s0.e8 true
interaction DrugDDI.d236.s0.e0 DrugDDI.d236.s0.e9 true
interaction DrugDDI.d236.s0.e0 DrugDDI.d236.s0.e10 true
interaction DrugDDI.d236.s0.e0 DrugDDI.d236.s0.e11 true
interaction DrugDDI.d236.s0.e1 DrugDDI.d236.s0.e2 false
interaction DrugDDI.d236.s0.e1 DrugDDI.d236.s0.e3 false
interaction DrugDDI.d236.s0.e1 DrugDDI.d236.s0.e4 false
interaction DrugDDI.d236.s0.e1 DrugDDI.d236.s0.e5 false
interaction DrugDDI.d236.s0.e1 DrugDDI.d236.s0.e6 false
interaction DrugDDI.d236.s0.e1 DrugDDI.d236.s0.e7 false
interaction DrugDDI.d236.s0.e1 DrugDDI.d236.s0.e8 false
interaction DrugDDI.d236.s0.e1 DrugDDI.d236.s0.e9 false
interaction DrugDDI.d236.s0.e1 DrugDDI.d236.s0.e10 false
interaction DrugDDI.d236.s0.e1 DrugDDI.d236.s0.e11 false
interaction DrugDDI.d236.s0.e2 DrugDDI.d236.s0.e3 false
interaction DrugDDI.d236.s0.e2 DrugDDI.d236.s0.e4 false
interaction DrugDDI.d236.s0.e2 DrugDDI.d236.s0.e5 false
interaction DrugDDI.d236.s0.e2 DrugDDI.d236.s0.e6 false
interaction DrugDDI.d236.s0.e2 DrugDDI.d236.s0.e7 false
interaction DrugDDI.d236.s0.e2 DrugDDI.d236.s0.e8 false
interaction DrugDDI.d236.s0.e2 DrugDDI.d236.s0.e9 false
interaction DrugDDI.d236.s0.e2 DrugDDI.d236.s0.e10 false
interaction DrugDDI.d236.s0.e2 DrugDDI.d236.s0.e11 false
interaction DrugDDI.d236.s0.e3 DrugDDI.d236.s0.e4 false
interaction DrugDDI.d236.s0.e3 DrugDDI.d236.s0.e5 false
interaction DrugDDI.d236.s0.e3 DrugDDI.d236.s0.e6 false
interaction DrugDDI.d236.s0.e3 DrugDDI.d236.s0.e7 false
interaction DrugDDI.d236.s0.e3 DrugDDI.d236.s0.e8 false
interaction DrugDDI.d236.s0.e3 DrugDDI.d236.s0.e9 false
interaction DrugDDI.d236.s0.e3 DrugDDI.d236.s0.e10 false
interaction DrugDDI.d236.s0.e3 DrugDDI.d236.s0.e11 false
interaction DrugDDI.d236.s0.e4 DrugDDI.d236.s0.e5 false
interaction DrugDDI.d236.s0.e4 DrugDDI.d236.s0.e6 false
interaction DrugDDI.d236.s0.e4 DrugDDI.d236.s0.e7 false
interaction DrugDDI.d236.s0.e4 DrugDDI.d236.s0.e8 false
interaction DrugDDI.d236.s0.e4 DrugDDI.d236.s0.e9 false
interaction DrugDDI.d236.s0.e4 DrugDDI.d236.s0.e10 false
interaction DrugDDI.d236.s0.e4 DrugDDI.d236.s0.e11 false
interaction DrugDDI.d236.s0.e5 DrugDDI.d236.s0.e6 false
interaction DrugDDI.d236.s0.e5 DrugDDI.d236.s0.e7 false
interaction DrugDDI.d236.s0.e5 DrugDDI.d236.s0.e8 false
interaction DrugDDI.d236.s0.e5 DrugDDI.d236.s0.e9 false
interaction DrugDDI.d236.s0.e5 DrugDDI.d236.s0.e10 false
interaction DrugDDI.d236.s0.e5 DrugDDI.d236.s0.e11 false
interaction DrugDDI.d236.s0.e6 DrugDDI.d236.s0.e7 false
interaction DrugDDI.d236.s0.e6 DrugDDI.d236.s0.e8 false
interaction DrugDDI.d236.s0.e6 DrugDDI.d236.s0.e9 false
interaction DrugDDI.d236.s0.e6 DrugDDI.d236.s0.e10 false
interaction DrugDDI.d236.s0.e6 DrugDDI.d236.s0.e11 false
interaction DrugDDI.d236.s0.e7 DrugDDI.d236.s0.e8 false
interaction DrugDDI.d236.s0.e7 DrugDDI.d236.s0.e9 false
interaction DrugDDI.d236.s0.e7 DrugDDI.d236.s0.e10 false
interaction DrugDDI.d236.s0.e7 DrugDDI.d236.s0.e11 false
interaction DrugDDI.d236.s0.e8 DrugDDI.d236.s0.e9 false
interaction DrugDDI.d236.s0.e8 DrugDDI.d236.s0.e10 false
interaction DrugDDI.d236.s0.e8 DrugDDI.d236.s0.e11 false
interaction DrugDDI.d236.s0.e9 DrugDDI.d236.s0.e10 false
interaction DrugDDI.d236.s0.e9 DrugDDI.d236.s0.e11 false
interaction DrugDDI.d236.s0.e10 DrugDDI.d236.s0.e11 false

Abstract Id: DrugDDI.d285
Sentence Id: DrugDDI.d285.s0
No formal drug interaction studies with anti-neoplastic agents have been conducted.

DrugDDI.d285.s0.e0 34 54
drug
anti-neoplastic agents



Abstract Id: DrugDDI.d285
Sentence Id: DrugDDI.d285.s1
In Study 1, patients with colorectal cancer were given irinotecan /5-FU/leucovorin (bolus-IFL) with or without AVASTIN .

DrugDDI.d285.s1.new.DISO.e2 21 36
DISO
colorectal cancer
DrugDDI.d285.s1.e0 46 55
drug
irinotecan
DrugDDI.d285.s1.e1 96 102
drug
AVASTIN

interaction DrugDDI.d285.s1.e0 DrugDDI.d285.s1.e1 false

Abstract Id: DrugDDI.d285
Sentence Id: DrugDDI.d285.s2
Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN .

DrugDDI.d285.s2.e0 0 9
drug
Irinotecan
DrugDDI.d285.s2.e1 88 94
drug
AVASTIN

interaction DrugDDI.d285.s2.e0 DrugDDI.d285.s2.e1 false

Abstract Id: DrugDDI.d285
Sentence Id: DrugDDI.d285.s3
The concentrations of SN38, the active metabolite of irinotecan , were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone.

DrugDDI.d285.s3.e0 27 42
drug
active metabolite
DrugDDI.d285.s3.e1 45 54
drug
irinotecan
DrugDDI.d285.s3.e2 123 129
drug
AVASTIN

interaction DrugDDI.d285.s3.e0 DrugDDI.d285.s3.e1 false
interaction DrugDDI.d285.s3.e0 DrugDDI.d285.s3.e2 false
interaction DrugDDI.d285.s3.e1 DrugDDI.d285.s3.e2 true

Abstract Id: DrugDDI.d285
Sentence Id: DrugDDI.d285.s4
In Study 1, patients receiving bolus-IFL plus AVASTIN had a higher incidence of Grade 3-4 diarrhea and neutropenia.

DrugDDI.d285.s4.e0 39 45
drug
AVASTIN
DrugDDI.d285.s4.new.DISO.e1 86 96
DISO
neutropenia



Abstract Id: DrugDDI.d285
Sentence Id: DrugDDI.d285.s5
Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.

DrugDDI.d285.s5.e0 115 124
drug
irinotecan
DrugDDI.d285.s5.e1 128 134
drug
AVASTIN

interaction DrugDDI.d285.s5.e0 DrugDDI.d285.s5.e1 true

Abstract Id: DrugDDI.d498
Sentence Id: DrugDDI.d498.s0
In vitro studies have shown CASODEX can displace coumarin anticoagulant s, such as warfarin , from their protein -binding sites.

DrugDDI.d498.s0.e0 23 29
drug
CASODEX
DrugDDI.d498.s0.e1 41 61
drug
coumarin anticoagulant
DrugDDI.d498.s0.e2 70 77
drug
warfarin
DrugDDI.d498.s0.e3 88 94
drug
protein

interaction DrugDDI.d498.s0.e0 DrugDDI.d498.s0.e1 false
interaction DrugDDI.d498.s0.e0 DrugDDI.d498.s0.e2 false
interaction DrugDDI.d498.s0.e0 DrugDDI.d498.s0.e3 false
interaction DrugDDI.d498.s0.e1 DrugDDI.d498.s0.e2 false
interaction DrugDDI.d498.s0.e1 DrugDDI.d498.s0.e3 false
interaction DrugDDI.d498.s0.e2 DrugDDI.d498.s0.e3 false

Abstract Id: DrugDDI.d498
Sentence Id: DrugDDI.d498.s1
It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulant s, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.

DrugDDI.d498.s1.e0 21 27
drug
CASODEX
DrugDDI.d498.s1.e1 63 83
drug
coumarin anticoagulant
DrugDDI.d498.s1.e2 144 156
drug
anticoagulant

interaction DrugDDI.d498.s1.e0 DrugDDI.d498.s1.e1 false
interaction DrugDDI.d498.s1.e0 DrugDDI.d498.s1.e2 false
interaction DrugDDI.d498.s1.e1 DrugDDI.d498.s1.e2 false

Abstract Id: DrugDDI.d222
Sentence Id: DrugDDI.d222.s0
No formal drug interaction studies have been conducted with VELCADE .

DrugDDI.d222.s0.e0 51 57
drug
VELCADE



Abstract Id: DrugDDI.d222
Sentence Id: DrugDDI.d222.s1
In vitro studies with human liver microsomes indicate that bortezomib is primarily a substrate for cytochrome P450 3A4 , 2C19, and 1A2.

DrugDDI.d222.s1.e0 50 59
drug
bortezomib
DrugDDI.d222.s1.e1 84 100
drug
cytochrome P450 3A4

interaction DrugDDI.d222.s1.e0 DrugDDI.d222.s1.e1 false

Abstract Id: DrugDDI.d222
Sentence Id: DrugDDI.d222.s2
Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy .

DrugDDI.d222.s2.e0 36 42
drug
VELCADE
DrugDDI.d222.s2.e1 46 50
drug
drugs
DrugDDI.d222.s2.e2 80 96
drug
cytochrome P450 3A4

interaction DrugDDI.d222.s2.e0 DrugDDI.d222.s2.e1 false
interaction DrugDDI.d222.s2.e0 DrugDDI.d222.s2.e2 false
interaction DrugDDI.d222.s2.e1 DrugDDI.d222.s2.e2 false

Abstract Id: DrugDDI.d222
Sentence Id: DrugDDI.d222.s3
During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics .

DrugDDI.d222.s3.new.DISO.e1 21 32
DISO
hypoglycemia
DrugDDI.d222.s3.new.DISO.e2 36 48
DISO
hyperglycemia
DrugDDI.d222.s3.e0 88 104
drug
oral hypoglycemics



Abstract Id: DrugDDI.d222
Sentence Id: DrugDDI.d222.s4
Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.

DrugDDI.d222.s4.e0 14 31
drug
antidiabetic agents
DrugDDI.d222.s4.e1 41 47
drug
VELCADE
DrugDDI.d222.s4.e2 136 147
drug
antidiabetic

interaction DrugDDI.d222.s4.e0 DrugDDI.d222.s4.e1 false
interaction DrugDDI.d222.s4.e0 DrugDDI.d222.s4.e2 false
interaction DrugDDI.d222.s4.e1 DrugDDI.d222.s4.e2 false

Abstract Id: DrugDDI.d134
Sentence Id: DrugDDI.d134.s0
Co-administration of BOTOX@ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare -like compounds) should only be performed with caution as the effect of the toxin may be potentiated.

DrugDDI.d134.s0.e0 28 42
drug
aminoglycosides
DrugDDI.d134.s0.e1 102 107
drug
curare
DrugDDI.d134.s0.e2 171 175
drug
toxin

interaction DrugDDI.d134.s0.e0 DrugDDI.d134.s0.e1 false
interaction DrugDDI.d134.s0.e0 DrugDDI.d134.s0.e2 false
interaction DrugDDI.d134.s0.e1 DrugDDI.d134.s0.e2 false

Abstract Id: DrugDDI.d134
Sentence Id: DrugDDI.d134.s1
The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown.

DrugDDI.d134.s1.e0 33 51
drug
botulinum neurotoxin



Abstract Id: DrugDDI.d134
Sentence Id: DrugDDI.d134.s2
Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin .

DrugDDI.d134.s2.new.DISO.e2 9 29
DISO
neuromuscular weakness
DrugDDI.d134.s2.e0 71 84
drug
botulinum toxin
DrugDDI.d134.s2.e1 142 155
drug
botulinum toxin

interaction DrugDDI.d134.s2.e0 DrugDDI.d134.s2.e1 false

Abstract Id: DrugDDI.d398
Sentence Id: DrugDDI.d398.s0
Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection .

DrugDDI.d398.s0.new.DISO.e2 0 16
DISO
Digitalis toxicity
DrugDDI.d398.s0.e0 53 66
drug
norepinephrine
DrugDDI.d398.s0.e1 75 100
drug
Bretylium Tosylate Injection

interaction DrugDDI.d398.s0.e0 DrugDDI.d398.s0.e1 true

Abstract Id: DrugDDI.d398
Sentence Id: DrugDDI.d398.s1
The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate .

DrugDDI.d398.s1.e0 3 16
drug
pressor effects
DrugDDI.d398.s1.e1 39 46
drug
dopamine
DrugDDI.d398.s1.e2 49 62
drug
norepinephrine
DrugDDI.d398.s1.e3 76 92
drug
Bretylium Tosylate

interaction DrugDDI.d398.s1.e0 DrugDDI.d398.s1.e1 false
interaction DrugDDI.d398.s1.e0 DrugDDI.d398.s1.e2 false
interaction DrugDDI.d398.s1.e0 DrugDDI.d398.s1.e3 false
interaction DrugDDI.d398.s1.e1 DrugDDI.d398.s1.e2 false
interaction DrugDDI.d398.s1.e1 DrugDDI.d398.s1.e3 true
interaction DrugDDI.d398.s1.e2 DrugDDI.d398.s1.e3 true

Abstract Id: DrugDDI.d398
Sentence Id: DrugDDI.d398.s3
Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate , these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.

DrugDDI.d398.s3.e0 70 78
drug
lidocaine
DrugDDI.d398.s3.e1 82 98
drug
Bretylium Tosylate
DrugDDI.d398.s3.e2 105 109
drug
drugs

interaction DrugDDI.d398.s3.e0 DrugDDI.d398.s3.e1 false
interaction DrugDDI.d398.s3.e0 DrugDDI.d398.s3.e2 false
interaction DrugDDI.d398.s3.e1 DrugDDI.d398.s3.e2 false

Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s0
Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide .

DrugDDI.d316.s0.e0 31 42
drug
ketoconazole
DrugDDI.d316.s0.e1 61 66
drug
CYP3A4
DrugDDI.d316.s0.e2 80 84
drug
liver
DrugDDI.d316.s0.e3 159 172
drug
oral budesonide

interaction DrugDDI.d316.s0.e0 DrugDDI.d316.s0.e1 false
interaction DrugDDI.d316.s0.e0 DrugDDI.d316.s0.e2 false
interaction DrugDDI.d316.s0.e0 DrugDDI.d316.s0.e3 true
interaction DrugDDI.d316.s0.e1 DrugDDI.d316.s0.e2 false
interaction DrugDDI.d316.s0.e1 DrugDDI.d316.s0.e3 false
interaction DrugDDI.d316.s0.e2 DrugDDI.d316.s0.e3 false

Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s1
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole , intraconazole, ritonavir , indinavir , saquinavir , erythromycin , etc.) is indicated, reduction of the budesonide dose should be considered.

DrugDDI.d316.s1.e0 27 32
drug
CYP3A4
DrugDDI.d316.s1.e1 48 59
drug
ketoconazole
DrugDDI.d316.s1.e2 75 83
drug
ritonavir
DrugDDI.d316.s1.e3 85 93
drug
indinavir
DrugDDI.d316.s1.e4 95 104
drug
saquinavir
DrugDDI.d316.s1.e5 106 117
drug
erythromycin
DrugDDI.d316.s1.e6 150 159
drug
budesonide

interaction DrugDDI.d316.s1.e0 DrugDDI.d316.s1.e1 false
interaction DrugDDI.d316.s1.e0 DrugDDI.d316.s1.e2 false
interaction DrugDDI.d316.s1.e0 DrugDDI.d316.s1.e3 false
interaction DrugDDI.d316.s1.e0 DrugDDI.d316.s1.e4 false
interaction DrugDDI.d316.s1.e0 DrugDDI.d316.s1.e5 false
interaction DrugDDI.d316.s1.e0 DrugDDI.d316.s1.e6 false
interaction DrugDDI.d316.s1.e1 DrugDDI.d316.s1.e2 false
interaction DrugDDI.d316.s1.e1 DrugDDI.d316.s1.e3 false
interaction DrugDDI.d316.s1.e1 DrugDDI.d316.s1.e4 false
interaction DrugDDI.d316.s1.e1 DrugDDI.d316.s1.e5 false
interaction DrugDDI.d316.s1.e1 DrugDDI.d316.s1.e6 true
interaction DrugDDI.d316.s1.e2 DrugDDI.d316.s1.e3 false
interaction DrugDDI.d316.s1.e2 DrugDDI.d316.s1.e4 false
interaction DrugDDI.d316.s1.e2 DrugDDI.d316.s1.e5 false
interaction DrugDDI.d316.s1.e2 DrugDDI.d316.s1.e6 false
interaction DrugDDI.d316.s1.e3 DrugDDI.d316.s1.e4 false
interaction DrugDDI.d316.s1.e3 DrugDDI.d316.s1.e5 false
interaction DrugDDI.d316.s1.e3 DrugDDI.d316.s1.e6 true
interaction DrugDDI.d316.s1.e4 DrugDDI.d316.s1.e5 false
interaction DrugDDI.d316.s1.e4 DrugDDI.d316.s1.e6 false
interaction DrugDDI.d316.s1.e5 DrugDDI.d316.s1.e6 true

Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s2
After extensive intake of grapefruit juice (which inhibits CYP3A4 activity predominantly in the intestinal mucosa), the systemic exposure for oral budesonide increased about two times.

DrugDDI.d316.s2.e0 51 56
drug
CYP3A4
DrugDDI.d316.s2.e1 123 136
drug
oral budesonide

interaction DrugDDI.d316.s2.e0 DrugDDI.d316.s2.e1 false

Abstract Id: DrugDDI.d316
Sentence Id: DrugDDI.d316.s3
As with other drugs primarily being metabolized through CYP3A4 , ingestion of grapefruit or grapefruit juice should be avoided in connection with budesonide administration.

DrugDDI.d316.s3.e0 11 15
drug
drugs
DrugDDI.d316.s3.e1 48 53
drug
CYP3A4
DrugDDI.d316.s3.e2 66 75
drug
grapefruit
DrugDDI.d316.s3.e3 124 133
drug
budesonide

interaction DrugDDI.d316.s3.e0 DrugDDI.d316.s3.e1 false
interaction DrugDDI.d316.s3.e0 DrugDDI.d316.s3.e2 false
interaction DrugDDI.d316.s3.e0 DrugDDI.d316.s3.e3 false
interaction DrugDDI.d316.s3.e1 DrugDDI.d316.s3.e2 false
interaction DrugDDI.d316.s3.e1 DrugDDI.d316.s3.e3 false
interaction DrugDDI.d316.s3.e2 DrugDDI.d316.s3.e3 true

Abstract Id: DrugDDI.d570
Sentence Id: DrugDDI.d570.s0
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.

DrugDDI.d570.s0.e0 19 33
drug
local anesthetic
DrugDDI.d570.s0.e1 53 63
drug
epinephrine
DrugDDI.d570.s0.e2 66 79
drug
norepinephrine
DrugDDI.d570.s0.e3 99 124
drug
monoamine oxidase inhibitors
DrugDDI.d570.s0.e4 127 150
drug
tricyclic antidepressants

interaction DrugDDI.d570.s0.e0 DrugDDI.d570.s0.e1 true
interaction DrugDDI.d570.s0.e0 DrugDDI.d570.s0.e2 false
interaction DrugDDI.d570.s0.e0 DrugDDI.d570.s0.e3 true
interaction DrugDDI.d570.s0.e0 DrugDDI.d570.s0.e4 true
interaction DrugDDI.d570.s0.e1 DrugDDI.d570.s0.e2 false
interaction DrugDDI.d570.s0.e1 DrugDDI.d570.s0.e3 true
interaction DrugDDI.d570.s0.e1 DrugDDI.d570.s0.e4 true
interaction DrugDDI.d570.s0.e2 DrugDDI.d570.s0.e3 true
interaction DrugDDI.d570.s0.e2 DrugDDI.d570.s0.e4 true
interaction DrugDDI.d570.s0.e3 DrugDDI.d570.s0.e4 false

Abstract Id: DrugDDI.d570
Sentence Id: DrugDDI.d570.s3
Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.

DrugDDI.d570.s3.e0 26 41
drug
vasopressor drugs
DrugDDI.d570.s3.e1 57 69
drug
oxytocic drugs

interaction DrugDDI.d570.s3.e0 DrugDDI.d570.s3.e1 true

Abstract Id: DrugDDI.d570
Sentence Id: DrugDDI.d570.s4
Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine .

DrugDDI.d570.s4.e0 0 13
drug
Phenothiazines
DrugDDI.d570.s4.e1 17 30
drug
butyrophenones
DrugDDI.d570.s4.e2 52 64
drug
pressor effect
DrugDDI.d570.s4.e3 67 77
drug
epinephrine

interaction DrugDDI.d570.s4.e0 DrugDDI.d570.s4.e1 false
interaction DrugDDI.d570.s4.e0 DrugDDI.d570.s4.e2 false
interaction DrugDDI.d570.s4.e0 DrugDDI.d570.s4.e3 true
interaction DrugDDI.d570.s4.e1 DrugDDI.d570.s4.e2 false
interaction DrugDDI.d570.s4.e1 DrugDDI.d570.s4.e3 true
interaction DrugDDI.d570.s4.e2 DrugDDI.d570.s4.e3 false

Abstract Id: DrugDDI.d223
Sentence Id: DrugDDI.d223.s0
The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.

DrugDDI.d223.s0.e0 15 24
drug
butalbital
DrugDDI.d223.s0.e1 40 55
drug
monoamine oxidase

interaction DrugDDI.d223.s0.e0 DrugDDI.d223.s0.e1 false

Abstract Id: DrugDDI.d223
Sentence Id: DrugDDI.d223.s1
Butalbital , acetaminophen and caffeine may enhance the effects of: other narcotic analgesic s, alcohol , general anesthetics , tranquilizers such as chlordiazepoxide , sedative-hypnotics , or other CNS depressants , causing increased CNS depression.

DrugDDI.d223.s1.e0 0 9
drug
Butalbital
DrugDDI.d223.s1.e1 27 34
drug
caffeine
DrugDDI.d223.s1.e2 58 79
drug
other narcotic analgesic
DrugDDI.d223.s1.e3 82 88
drug
alcohol
DrugDDI.d223.s1.e4 90 107
drug
general anesthetics
DrugDDI.d223.s1.e5 109 121
drug
tranquilizers
DrugDDI.d223.s1.e6 128 143
drug
chlordiazepoxide
DrugDDI.d223.s1.e7 145 162
drug
sedative-hypnotics
DrugDDI.d223.s1.e8 171 184
drug
CNS depressants

interaction DrugDDI.d223.s1.e0 DrugDDI.d223.s1.e1 false
interaction DrugDDI.d223.s1.e0 DrugDDI.d223.s1.e2 false
interaction DrugDDI.d223.s1.e0 DrugDDI.d223.s1.e3 false
interaction DrugDDI.d223.s1.e0 DrugDDI.d223.s1.e4 false
interaction DrugDDI.d223.s1.e0 DrugDDI.d223.s1.e5 false
interaction DrugDDI.d223.s1.e0 DrugDDI.d223.s1.e6 false
interaction DrugDDI.d223.s1.e0 DrugDDI.d223.s1.e7 false
interaction DrugDDI.d223.s1.e0 DrugDDI.d223.s1.e8 false
interaction DrugDDI.d223.s1.e1 DrugDDI.d223.s1.e2 false
interaction DrugDDI.d223.s1.e1 DrugDDI.d223.s1.e3 false
interaction DrugDDI.d223.s1.e1 DrugDDI.d223.s1.e4 false
interaction DrugDDI.d223.s1.e1 DrugDDI.d223.s1.e5 false
interaction DrugDDI.d223.s1.e1 DrugDDI.d223.s1.e6 false
interaction DrugDDI.d223.s1.e1 DrugDDI.d223.s1.e7 false
interaction DrugDDI.d223.s1.e1 DrugDDI.d223.s1.e8 false
interaction DrugDDI.d223.s1.e2 DrugDDI.d223.s1.e3 false
interaction DrugDDI.d223.s1.e2 DrugDDI.d223.s1.e4 false
interaction DrugDDI.d223.s1.e2 DrugDDI.d223.s1.e5 false
interaction DrugDDI.d223.s1.e2 DrugDDI.d223.s1.e6 false
interaction DrugDDI.d223.s1.e2 DrugDDI.d223.s1.e7 false
interaction DrugDDI.d223.s1.e2 DrugDDI.d223.s1.e8 false
interaction DrugDDI.d223.s1.e3 DrugDDI.d223.s1.e4 false
interaction DrugDDI.d223.s1.e3 DrugDDI.d223.s1.e5 false
interaction DrugDDI.d223.s1.e3 DrugDDI.d223.s1.e6 false
interaction DrugDDI.d223.s1.e3 DrugDDI.d223.s1.e7 false
interaction DrugDDI.d223.s1.e3 DrugDDI.d223.s1.e8 false
interaction DrugDDI.d223.s1.e4 DrugDDI.d223.s1.e5 false
interaction DrugDDI.d223.s1.e4 DrugDDI.d223.s1.e6 false
interaction DrugDDI.d223.s1.e4 DrugDDI.d223.s1.e7 false
interaction DrugDDI.d223.s1.e4 DrugDDI.d223.s1.e8 false
interaction DrugDDI.d223.s1.e5 DrugDDI.d223.s1.e6 false
interaction DrugDDI.d223.s1.e5 DrugDDI.d223.s1.e7 false
interaction DrugDDI.d223.s1.e5 DrugDDI.d223.s1.e8 false
interaction DrugDDI.d223.s1.e6 DrugDDI.d223.s1.e7 false
interaction DrugDDI.d223.s1.e6 DrugDDI.d223.s1.e8 false
interaction DrugDDI.d223.s1.e7 DrugDDI.d223.s1.e8 false

Abstract Id: DrugDDI.d223
Sentence Id: DrugDDI.d223.s2
Drug /Laboratory Test Interactions Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid .

DrugDDI.d223.s2.e0 0 3
drug
Drug
DrugDDI.d223.s2.e1 31 43
drug
Acetaminophen
DrugDDI.d223.s2.e2 82 113
drug
urinary 5-hydroxyindoleacetic acid

interaction DrugDDI.d223.s2.e0 DrugDDI.d223.s2.e1 false
interaction DrugDDI.d223.s2.e0 DrugDDI.d223.s2.e2 false
interaction DrugDDI.d223.s2.e1 DrugDDI.d223.s2.e2 false

Abstract Id: DrugDDI.d38
Sentence Id: DrugDDI.d38.s0
Interactions may occur with the following: adrenocorticoids ( cortisone -like medicine ), anticoagulants ( blood thinner s), carbamazepine , corticotropin ( barbiturates may decrease the effects of these medicines ), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium , valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( barbiturates may decrease the effectiveness of these oral contraceptives , and you may need to change to a different type of birth control ).

DrugDDI.d38.s0.e0 54 62
drug
cortisone
DrugDDI.d38.s0.e1 68 75
drug
medicine
DrugDDI.d38.s0.e2 78 91
drug
anticoagulants
DrugDDI.d38.s0.e3 93 104
drug
blood thinner
DrugDDI.d38.s0.e4 108 120
drug
carbamazepine
DrugDDI.d38.s0.e5 122 134
drug
corticotropin
DrugDDI.d38.s0.e6 136 147
drug
barbiturates
DrugDDI.d38.s0.e7 176 184
drug
medicines
DrugDDI.d38.s0.e8 234 242
drug
medicines
DrugDDI.d38.s0.e9 247 258
drug
barbiturates
DrugDDI.d38.s0.e10 279 291
drug
CNS depressant
DrugDDI.d38.s0.e11 301 316
drug
divalproex sodium
DrugDDI.d38.s0.e12 318 329
drug
valproic acid
DrugDDI.d38.s0.e13 341 349
drug
medicines
DrugDDI.d38.s0.e14 354 365
drug
barbiturates
DrugDDI.d38.s0.e15 392 399
drug
medicine
DrugDDI.d38.s0.e16 422 439
drug
oral contraceptives
DrugDDI.d38.s0.e17 450 458
drug
estrogens
DrugDDI.d38.s0.e18 460 471
drug
barbiturates
DrugDDI.d38.s0.e19 506 523
drug
oral contraceptives
DrugDDI.d38.s0.e20 564 575
drug
birth control

interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e1 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e2 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e3 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e4 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e5 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e6 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e7 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e8 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e9 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e10 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e11 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e0 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e2 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e3 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e4 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e5 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e6 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e7 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e8 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e9 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e10 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e11 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e1 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e3 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e4 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e5 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e6 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e7 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e8 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e9 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e10 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e11 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e2 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e4 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e5 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e6 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e7 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e8 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e9 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e10 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e11 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e3 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e5 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e6 true
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e7 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e8 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e9 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e10 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e11 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e4 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e6 true
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e7 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e8 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e9 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e10 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e11 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e5 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e7 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e8 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e9 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e10 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e11 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e6 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e8 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e9 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e10 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e11 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e7 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e9 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e10 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e11 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e8 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e9 DrugDDI.d38.s0.e10 true
interaction DrugDDI.d38.s0.e9 DrugDDI.d38.s0.e11 false
interaction DrugDDI.d38.s0.e9 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e9 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e9 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e9 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e9 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e9 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e9 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e9 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e9 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e10 DrugDDI.d38.s0.e11 false
interaction DrugDDI.d38.s0.e10 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e10 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e10 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e10 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e10 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e10 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e10 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e10 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e10 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e11 DrugDDI.d38.s0.e12 false
interaction DrugDDI.d38.s0.e11 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e11 DrugDDI.d38.s0.e14 true
interaction DrugDDI.d38.s0.e11 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e11 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e11 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e11 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e11 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e11 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e12 DrugDDI.d38.s0.e13 false
interaction DrugDDI.d38.s0.e12 DrugDDI.d38.s0.e14 true
interaction DrugDDI.d38.s0.e12 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e12 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e12 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e12 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e12 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e12 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e13 DrugDDI.d38.s0.e14 false
interaction DrugDDI.d38.s0.e13 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e13 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e13 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e13 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e13 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e13 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e14 DrugDDI.d38.s0.e15 false
interaction DrugDDI.d38.s0.e14 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e14 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e14 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e14 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e14 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e15 DrugDDI.d38.s0.e16 false
interaction DrugDDI.d38.s0.e15 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e15 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e15 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e15 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e16 DrugDDI.d38.s0.e17 false
interaction DrugDDI.d38.s0.e16 DrugDDI.d38.s0.e18 true
interaction DrugDDI.d38.s0.e16 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e16 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e17 DrugDDI.d38.s0.e18 false
interaction DrugDDI.d38.s0.e17 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e17 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e18 DrugDDI.d38.s0.e19 false
interaction DrugDDI.d38.s0.e18 DrugDDI.d38.s0.e20 false
interaction DrugDDI.d38.s0.e19 DrugDDI.d38.s0.e20 false

Abstract Id: DrugDDI.d218
Sentence Id: DrugDDI.d218.s0
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines , butyrophenones , thioxanthines, or metoclopramide .

DrugDDI.d218.s0.e0 0 7
drug
DOSTINEX
DrugDDI.d218.s0.e1 68 81
drug
phenothiazines
DrugDDI.d218.s0.e2 83 96
drug
butyrophenones
DrugDDI.d218.s0.e3 114 127
drug
metoclopramide

interaction DrugDDI.d218.s0.e0 DrugDDI.d218.s0.e1 false
interaction DrugDDI.d218.s0.e0 DrugDDI.d218.s0.e2 false
interaction DrugDDI.d218.s0.e0 DrugDDI.d218.s0.e3 false
interaction DrugDDI.d218.s0.e1 DrugDDI.d218.s0.e2 false
interaction DrugDDI.d218.s0.e1 DrugDDI.d218.s0.e3 false
interaction DrugDDI.d218.s0.e2 DrugDDI.d218.s0.e3 false

Abstract Id: DrugDDI.d349
Sentence Id: DrugDDI.d349.s0
No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide , nifedipine , digoxin , warfarin , hydrochlorothiazide , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).

DrugDDI.d349.s0.e0 56 75
drug
candesartan cilexetil
DrugDDI.d349.s0.e1 90 94
drug
drugs
DrugDDI.d349.s0.e2 101 109
drug
glyburide
DrugDDI.d349.s0.e3 111 120
drug
nifedipine
DrugDDI.d349.s0.e4 122 128
drug
digoxin
DrugDDI.d349.s0.e5 130 137
drug
warfarin
DrugDDI.d349.s0.e6 139 157
drug
hydrochlorothiazide
DrugDDI.d349.s0.e7 162 179
drug
oral contraceptives
DrugDDI.d349.s0.e8 211 219
drug
enalapril
DrugDDI.d349.s0.new.DISO.e9 234 245
DISO
heart failure

interaction DrugDDI.d349.s0.e0 DrugDDI.d349.s0.e1 false
interaction DrugDDI.d349.s0.e0 DrugDDI.d349.s0.e2 false
interaction DrugDDI.d349.s0.e0 DrugDDI.d349.s0.e3 false
interaction DrugDDI.d349.s0.e0 DrugDDI.d349.s0.e4 false
interaction DrugDDI.d349.s0.e0 DrugDDI.d349.s0.e5 false
interaction DrugDDI.d349.s0.e0 DrugDDI.d349.s0.e6 false
interaction DrugDDI.d349.s0.e0 DrugDDI.d349.s0.e7 false
interaction DrugDDI.d349.s0.e0 DrugDDI.d349.s0.e8 false
interaction DrugDDI.d349.s0.e1 DrugDDI.d349.s0.e2 false
interaction DrugDDI.d349.s0.e1 DrugDDI.d349.s0.e3 false
interaction DrugDDI.d349.s0.e1 DrugDDI.d349.s0.e4 false
interaction DrugDDI.d349.s0.e1 DrugDDI.d349.s0.e5 false
interaction DrugDDI.d349.s0.e1 DrugDDI.d349.s0.e6 false
interaction DrugDDI.d349.s0.e1 DrugDDI.d349.s0.e7 false
interaction DrugDDI.d349.s0.e1 DrugDDI.d349.s0.e8 false
interaction DrugDDI.d349.s0.e2 DrugDDI.d349.s0.e3 false
interaction DrugDDI.d349.s0.e2 DrugDDI.d349.s0.e4 false
interaction DrugDDI.d349.s0.e2 DrugDDI.d349.s0.e5 false
interaction DrugDDI.d349.s0.e2 DrugDDI.d349.s0.e6 false
interaction DrugDDI.d349.s0.e2 DrugDDI.d349.s0.e7 false
interaction DrugDDI.d349.s0.e2 DrugDDI.d349.s0.e8 false
interaction DrugDDI.d349.s0.e3 DrugDDI.d349.s0.e4 false
interaction DrugDDI.d349.s0.e3 DrugDDI.d349.s0.e5 false
interaction DrugDDI.d349.s0.e3 DrugDDI.d349.s0.e6 false
interaction DrugDDI.d349.s0.e3 DrugDDI.d349.s0.e7 false
interaction DrugDDI.d349.s0.e3 DrugDDI.d349.s0.e8 false
interaction DrugDDI.d349.s0.e4 DrugDDI.d349.s0.e5 false
interaction DrugDDI.d349.s0.e4 DrugDDI.d349.s0.e6 false
interaction DrugDDI.d349.s0.e4 DrugDDI.d349.s0.e7 false
interaction DrugDDI.d349.s0.e4 DrugDDI.d349.s0.e8 false
interaction DrugDDI.d349.s0.e5 DrugDDI.d349.s0.e6 false
interaction DrugDDI.d349.s0.e5 DrugDDI.d349.s0.e7 false
interaction DrugDDI.d349.s0.e5 DrugDDI.d349.s0.e8 false
interaction DrugDDI.d349.s0.e6 DrugDDI.d349.s0.e7 false
interaction DrugDDI.d349.s0.e6 DrugDDI.d349.s0.e8 false
interaction DrugDDI.d349.s0.e7 DrugDDI.d349.s0.e8 false

Abstract Id: DrugDDI.d349
Sentence Id: DrugDDI.d349.s1
Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.

DrugDDI.d349.s1.e0 7 17
drug
candesartan
DrugDDI.d349.s1.e1 52 65
drug
cytochrome P450
DrugDDI.d349.s1.e2 116 119
drug
P450
DrugDDI.d349.s1.e3 144 148
drug
drugs

interaction DrugDDI.d349.s1.e0 DrugDDI.d349.s1.e1 false
interaction DrugDDI.d349.s1.e0 DrugDDI.d349.s1.e2 false
interaction DrugDDI.d349.s1.e0 DrugDDI.d349.s1.e3 false
interaction DrugDDI.d349.s1.e1 DrugDDI.d349.s1.e2 false
interaction DrugDDI.d349.s1.e1 DrugDDI.d349.s1.e3 false
interaction DrugDDI.d349.s1.e2 DrugDDI.d349.s1.e3 false

Abstract Id: DrugDDI.d349
Sentence Id: DrugDDI.d349.s2
Lithium@ Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors , and with some angiotensin II receptor antagonists .

DrugDDI.d349.s2.e0 34 40
drug
lithium
DrugDDI.d349.s2.e1 115 121
drug
lithium
DrugDDI.d349.s2.e2 126 138
drug
ACE inhibitors
DrugDDI.d349.s2.e3 151 182
drug
angiotensin II receptor antagonists

interaction DrugDDI.d349.s2.e0 DrugDDI.d349.s2.e1 false
interaction DrugDDI.d349.s2.e0 DrugDDI.d349.s2.e2 false
interaction DrugDDI.d349.s2.e0 DrugDDI.d349.s2.e3 false
interaction DrugDDI.d349.s2.e1 DrugDDI.d349.s2.e2 true
interaction DrugDDI.d349.s2.e1 DrugDDI.d349.s2.e3 true
interaction DrugDDI.d349.s2.e2 DrugDDI.d349.s2.e3 false

Abstract Id: DrugDDI.d349
Sentence Id: DrugDDI.d349.s3
An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND , so careful monitoring of serum lithium levels is recommended during concomitant use.

DrugDDI.d349.s3.e0 17 23
drug
lithium
DrugDDI.d349.s3.e1 85 91
drug
lithium
DrugDDI.d349.s3.e2 96 102
drug
ATACAND

interaction DrugDDI.d349.s3.e0 DrugDDI.d349.s3.e1 false
interaction DrugDDI.d349.s3.e0 DrugDDI.d349.s3.e2 false
interaction DrugDDI.d349.s3.e1 DrugDDI.d349.s3.e2 true

Abstract Id: DrugDDI.d303
Sentence Id: DrugDDI.d303.s0
Geocillin ( carbenicillin indanyl sodium ) blood levels may be increased and prolonged by concurrent administration of probenecid .

DrugDDI.d303.s0.e0 0 8
drug
Geocillin
DrugDDI.d303.s0.e1 10 35
drug
carbenicillin indanyl sodium
DrugDDI.d303.s0.e2 102 111
drug
probenecid

interaction DrugDDI.d303.s0.e0 DrugDDI.d303.s0.e1 false
interaction DrugDDI.d303.s0.e0 DrugDDI.d303.s0.e2 true
interaction DrugDDI.d303.s0.e1 DrugDDI.d303.s0.e2 true

Abstract Id: DrugDDI.d156
Sentence Id: DrugDDI.d156.s0
Iodine or iodine excess may decrease the effect of Carbimazole , and an iodine deficiency can increase the effect of Carbimazole .

DrugDDI.d156.s0.e0 0 5
drug
Iodine
DrugDDI.d156.s0.e1 8 13
drug
iodine
DrugDDI.d156.s0.e2 42 52
drug
Carbimazole
DrugDDI.d156.s0.new.DISO.e4 59 74
DISO
iodine deficiency
DrugDDI.d156.s0.e3 97 107
drug
Carbimazole

interaction DrugDDI.d156.s0.e0 DrugDDI.d156.s0.e1 false
interaction DrugDDI.d156.s0.e0 DrugDDI.d156.s0.e2 true
interaction DrugDDI.d156.s0.e0 DrugDDI.d156.s0.e3 false
interaction DrugDDI.d156.s0.e1 DrugDDI.d156.s0.e2 true
interaction DrugDDI.d156.s0.e1 DrugDDI.d156.s0.e3 false
interaction DrugDDI.d156.s0.e2 DrugDDI.d156.s0.e3 false

Abstract Id: DrugDDI.d156
Sentence Id: DrugDDI.d156.s1
Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents .

DrugDDI.d156.s1.e0 20 26
drug
digoxin
DrugDDI.d156.s1.e1 30 38
drug
digitoxin
DrugDDI.d156.s1.e2 66 82
drug
antithyroid agents

interaction DrugDDI.d156.s1.e0 DrugDDI.d156.s1.e1 false
interaction DrugDDI.d156.s1.e0 DrugDDI.d156.s1.e2 true
interaction DrugDDI.d156.s1.e1 DrugDDI.d156.s1.e2 true

Abstract Id: DrugDDI.d156
Sentence Id: DrugDDI.d156.s3
Antithyroid agents may decrease thyroid al uptake of sodium iodide I131 , a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole .

DrugDDI.d156.s3.e0 0 16
drug
Antithyroid agents
DrugDDI.d156.s3.e1 28 34
drug
thyroid
DrugDDI.d156.s3.e2 45 60
drug
sodium iodide I131
DrugDDI.d156.s3.e3 118 128
drug
Carbimazole

interaction DrugDDI.d156.s3.e0 DrugDDI.d156.s3.e1 false
interaction DrugDDI.d156.s3.e0 DrugDDI.d156.s3.e2 true
interaction DrugDDI.d156.s3.e0 DrugDDI.d156.s3.e3 false
interaction DrugDDI.d156.s3.e1 DrugDDI.d156.s3.e2 false
interaction DrugDDI.d156.s3.e1 DrugDDI.d156.s3.e3 false
interaction DrugDDI.d156.s3.e2 DrugDDI.d156.s3.e3 false

Abstract Id: DrugDDI.d156
Sentence Id: DrugDDI.d156.s4
Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status.

DrugDDI.d156.s4.e0 18 35
drug
oral anticoagulants
DrugDDI.d156.s4.e1 58 64
drug
thyroid

interaction DrugDDI.d156.s4.e0 DrugDDI.d156.s4.e1 false

Abstract Id: DrugDDI.d156
Sentence Id: DrugDDI.d156.s5
An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended .

DrugDDI.d156.s5.e0 46 58
drug
anticoagulant



Abstract Id: DrugDDI.d506
Sentence Id: DrugDDI.d506.s0
The renal effects of nephrotoxic compounds may be potentiated by Carboplatin .

DrugDDI.d506.s0.e0 55 65
drug
Carboplatin



Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s0
Inhibitors of CYP2D6 ; .

DrugDDI.d348.s0.e0 12 17
drug
CYP2D6



Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s1
poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine , fluoxetine , paroxetine , and propafenone ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .

DrugDDI.d348.s1.e0 18 28
drug
debrisoquin
DrugDDI.d348.s1.e1 44 53
drug
carvedilol
DrugDDI.d348.s1.e2 76 81
drug
CYP2D6
DrugDDI.d348.s1.e3 89 97
drug
quinidine
DrugDDI.d348.s1.e4 99 108
drug
fluoxetine
DrugDDI.d348.s1.e5 110 119
drug
paroxetine
DrugDDI.d348.s1.e6 124 134
drug
propafenone
DrugDDI.d348.s1.e7 163 167
drug
drugs
DrugDDI.d348.s1.e8 213 222
drug
enantiomer
DrugDDI.d348.s1.e9 225 234
drug
carvedilol

interaction DrugDDI.d348.s1.e0 DrugDDI.d348.s1.e1 false
interaction DrugDDI.d348.s1.e0 DrugDDI.d348.s1.e2 false
interaction DrugDDI.d348.s1.e0 DrugDDI.d348.s1.e3 false
interaction DrugDDI.d348.s1.e0 DrugDDI.d348.s1.e4 false
interaction DrugDDI.d348.s1.e0 DrugDDI.d348.s1.e5 false
interaction DrugDDI.d348.s1.e0 DrugDDI.d348.s1.e6 false
interaction DrugDDI.d348.s1.e0 DrugDDI.d348.s1.e7 false
interaction DrugDDI.d348.s1.e0 DrugDDI.d348.s1.e8 false
interaction DrugDDI.d348.s1.e0 DrugDDI.d348.s1.e9 false
interaction DrugDDI.d348.s1.e1 DrugDDI.d348.s1.e2 false
interaction DrugDDI.d348.s1.e1 DrugDDI.d348.s1.e3 false
interaction DrugDDI.d348.s1.e1 DrugDDI.d348.s1.e4 false
interaction DrugDDI.d348.s1.e1 DrugDDI.d348.s1.e5 false
interaction DrugDDI.d348.s1.e1 DrugDDI.d348.s1.e6 false
interaction DrugDDI.d348.s1.e1 DrugDDI.d348.s1.e7 false
interaction DrugDDI.d348.s1.e1 DrugDDI.d348.s1.e8 false
interaction DrugDDI.d348.s1.e1 DrugDDI.d348.s1.e9 false
interaction DrugDDI.d348.s1.e2 DrugDDI.d348.s1.e3 false
interaction DrugDDI.d348.s1.e2 DrugDDI.d348.s1.e4 false
interaction DrugDDI.d348.s1.e2 DrugDDI.d348.s1.e5 false
interaction DrugDDI.d348.s1.e2 DrugDDI.d348.s1.e6 false
interaction DrugDDI.d348.s1.e2 DrugDDI.d348.s1.e7 false
interaction DrugDDI.d348.s1.e2 DrugDDI.d348.s1.e8 false
interaction DrugDDI.d348.s1.e2 DrugDDI.d348.s1.e9 false
interaction DrugDDI.d348.s1.e3 DrugDDI.d348.s1.e4 false
interaction DrugDDI.d348.s1.e3 DrugDDI.d348.s1.e5 false
interaction DrugDDI.d348.s1.e3 DrugDDI.d348.s1.e6 false
interaction DrugDDI.d348.s1.e3 DrugDDI.d348.s1.e7 false
interaction DrugDDI.d348.s1.e3 DrugDDI.d348.s1.e8 false
interaction DrugDDI.d348.s1.e3 DrugDDI.d348.s1.e9 true
interaction DrugDDI.d348.s1.e4 DrugDDI.d348.s1.e5 false
interaction DrugDDI.d348.s1.e4 DrugDDI.d348.s1.e6 false
interaction DrugDDI.d348.s1.e4 DrugDDI.d348.s1.e7 false
interaction DrugDDI.d348.s1.e4 DrugDDI.d348.s1.e8 false
interaction DrugDDI.d348.s1.e4 DrugDDI.d348.s1.e9 true
interaction DrugDDI.d348.s1.e5 DrugDDI.d348.s1.e6 false
interaction DrugDDI.d348.s1.e5 DrugDDI.d348.s1.e7 false
interaction DrugDDI.d348.s1.e5 DrugDDI.d348.s1.e8 false
interaction DrugDDI.d348.s1.e5 DrugDDI.d348.s1.e9 true
interaction DrugDDI.d348.s1.e6 DrugDDI.d348.s1.e7 false
interaction DrugDDI.d348.s1.e6 DrugDDI.d348.s1.e8 false
interaction DrugDDI.d348.s1.e6 DrugDDI.d348.s1.e9 true
interaction DrugDDI.d348.s1.e7 DrugDDI.d348.s1.e8 false
interaction DrugDDI.d348.s1.e7 DrugDDI.d348.s1.e9 true
interaction DrugDDI.d348.s1.e8 DrugDDI.d348.s1.e9 false

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s2
Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the a-blocking R(+) enantiomer .

DrugDDI.d348.s2.e0 209 218
drug
enantiomer



Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s3
Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors ) should be observed closely for signs of hypotension and/or severe bradycardia.

DrugDDI.d348.s3.e0 82 85
drug
drug
DrugDDI.d348.s3.e1 120 128
drug
reserpine
DrugDDI.d348.s3.e2 132 157
drug
monoamine oxidase inhibitors
DrugDDI.d348.s3.new.DISO.e3 215 225
DISO
bradycardia

interaction DrugDDI.d348.s3.e0 DrugDDI.d348.s3.e1 false
interaction DrugDDI.d348.s3.e0 DrugDDI.d348.s3.e2 false
interaction DrugDDI.d348.s3.e1 DrugDDI.d348.s3.e2 false

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s4
Clonidine : Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.

DrugDDI.d348.s4.e0 0 8
drug
Clonidine
DrugDDI.d348.s4.e1 37 45
drug
clonidine

interaction DrugDDI.d348.s4.e0 DrugDDI.d348.s4.e1 false

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s5
When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.

DrugDDI.d348.s5.e0 61 69
drug
clonidine



Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s6
Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage.

DrugDDI.d348.s6.e0 0 8
drug
Clonidine



Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s7
Cyclosporine : Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.

DrugDDI.d348.s7.e0 0 11
drug
Cyclosporine
DrugDDI.d348.s7.e1 40 51
drug
cyclosporine
DrugDDI.d348.s7.e2 99 108
drug
carvedilol

interaction DrugDDI.d348.s7.e0 DrugDDI.d348.s7.e1 false
interaction DrugDDI.d348.s7.e0 DrugDDI.d348.s7.e2 false
interaction DrugDDI.d348.s7.e1 DrugDDI.d348.s7.e2 true

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s8
In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed.

DrugDDI.d348.s8.e0 30 41
drug
cyclosporine
DrugDDI.d348.s8.e1 73 84
drug
cyclosporine

interaction DrugDDI.d348.s8.e0 DrugDDI.d348.s8.e1 false

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s9
On the average for the group, the dose of cyclosporine was reduced about 20% in these patients.

DrugDDI.d348.s9.e0 33 44
drug
cyclosporine



Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s10
Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.

DrugDDI.d348.s10.e0 82 93
drug
cyclosporine
DrugDDI.d348.s10.e1 143 152
drug
carvedilol
DrugDDI.d348.s10.e2 176 187
drug
cyclosporine

interaction DrugDDI.d348.s10.e0 DrugDDI.d348.s10.e1 true
interaction DrugDDI.d348.s10.e0 DrugDDI.d348.s10.e2 false
interaction DrugDDI.d348.s10.e1 DrugDDI.d348.s10.e2 false

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s11
Digoxin : Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.

DrugDDI.d348.s11.e0 0 6
drug
Digoxin
DrugDDI.d348.s11.e1 8 14
drug
Digoxin
DrugDDI.d348.s11.e2 55 61
drug
digoxin
DrugDDI.d348.s11.e3 65 74
drug
carvedilol

interaction DrugDDI.d348.s11.e0 DrugDDI.d348.s11.e1 false
interaction DrugDDI.d348.s11.e0 DrugDDI.d348.s11.e2 false
interaction DrugDDI.d348.s11.e0 DrugDDI.d348.s11.e3 false
interaction DrugDDI.d348.s11.e1 DrugDDI.d348.s11.e2 false
interaction DrugDDI.d348.s11.e1 DrugDDI.d348.s11.e3 false
interaction DrugDDI.d348.s11.e2 DrugDDI.d348.s11.e3 true

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s12
Both digoxin and COREG slow AV conduction.

DrugDDI.d348.s12.e0 4 10
drug
digoxin
DrugDDI.d348.s12.e1 14 18
drug
COREG

interaction DrugDDI.d348.s12.e0 DrugDDI.d348.s12.e1 false

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s13
Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG .

DrugDDI.d348.s13.e0 31 37
drug
digoxin
DrugDDI.d348.s13.e1 91 95
drug
COREG

interaction DrugDDI.d348.s13.e0 DrugDDI.d348.s13.e1 true

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s14
Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.

DrugDDI.d348.s14.e0 41 48
drug
Rifampin
DrugDDI.d348.s14.e1 78 87
drug
carvedilol

interaction DrugDDI.d348.s14.e0 DrugDDI.d348.s14.e1 true

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s15
Cimetidine increased AUC by about 30% but caused no change in Cmax.

DrugDDI.d348.s15.e0 0 9
drug
Cimetidine



Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s16
Calcium Channel Blockers : Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem .

DrugDDI.d348.s16.e0 0 21
drug
Calcium Channel Blockers
DrugDDI.d348.s16.e1 112 116
drug
COREG
DrugDDI.d348.s16.e2 138 146
drug
diltiazem

interaction DrugDDI.d348.s16.e0 DrugDDI.d348.s16.e1 false
interaction DrugDDI.d348.s16.e0 DrugDDI.d348.s16.e2 false
interaction DrugDDI.d348.s16.e1 DrugDDI.d348.s16.e2 true

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s17
As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.

DrugDDI.d348.s17.e0 44 48
drug
COREG
DrugDDI.d348.s17.e1 77 98
drug
calcium channel blockers
DrugDDI.d348.s17.e2 104 112
drug
verapamil
DrugDDI.d348.s17.e3 115 123
drug
diltiazem

interaction DrugDDI.d348.s17.e0 DrugDDI.d348.s17.e1 true
interaction DrugDDI.d348.s17.e0 DrugDDI.d348.s17.e2 false
interaction DrugDDI.d348.s17.e0 DrugDDI.d348.s17.e3 false
interaction DrugDDI.d348.s17.e1 DrugDDI.d348.s17.e2 false
interaction DrugDDI.d348.s17.e1 DrugDDI.d348.s17.e3 false
interaction DrugDDI.d348.s17.e2 DrugDDI.d348.s17.e3 false

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s18
Insulin or Oral Hypoglycemics : Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics .

DrugDDI.d348.s18.e0 0 6
drug
Insulin
DrugDDI.d348.s18.e1 9 25
drug
Oral Hypoglycemics
DrugDDI.d348.s18.e2 98 104
drug
insulin
DrugDDI.d348.s18.e3 108 124
drug
oral hypoglycemics

interaction DrugDDI.d348.s18.e0 DrugDDI.d348.s18.e1 false
interaction DrugDDI.d348.s18.e0 DrugDDI.d348.s18.e2 false
interaction DrugDDI.d348.s18.e0 DrugDDI.d348.s18.e3 false
interaction DrugDDI.d348.s18.e1 DrugDDI.d348.s18.e2 false
interaction DrugDDI.d348.s18.e1 DrugDDI.d348.s18.e3 false
interaction DrugDDI.d348.s18.e2 DrugDDI.d348.s18.e3 false

Abstract Id: DrugDDI.d348
Sentence Id: DrugDDI.d348.s19
Therefore, in patients taking insulin or oral hypoglycemics , regular monitoring of blood glucose is recommended.

DrugDDI.d348.s19.e0 26 32
drug
insulin
DrugDDI.d348.s19.e1 35 51
drug
oral hypoglycemics

interaction DrugDDI.d348.s19.e0 DrugDDI.d348.s19.e1 false

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s0
Studies in vitro show that caspofungin acetate is not an inhibitor of any enzyme in the cytochrome P450 ( CYP ) system.

DrugDDI.d59.s0.e0 22 39
drug
caspofungin acetate
DrugDDI.d59.s0.e1 72 85
drug
cytochrome P450
DrugDDI.d59.s0.e2 87 89
drug
CYP

interaction DrugDDI.d59.s0.e0 DrugDDI.d59.s0.e1 false
interaction DrugDDI.d59.s0.e0 DrugDDI.d59.s0.e2 false
interaction DrugDDI.d59.s0.e1 DrugDDI.d59.s0.e2 false

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s1
In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other drugs .

DrugDDI.d59.s1.e0 18 28
drug
caspofungin
DrugDDI.d59.s1.e1 44 49
drug
CYP3A4
DrugDDI.d59.s1.e2 67 71
drug
drugs

interaction DrugDDI.d59.s1.e0 DrugDDI.d59.s1.e1 false
interaction DrugDDI.d59.s1.e0 DrugDDI.d59.s1.e2 false
interaction DrugDDI.d59.s1.e1 DrugDDI.d59.s1.e2 false

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s2
Caspofungin is not a substrate for P- glycoprotein and is a poor substrate for cytochrome P450 enzymes.

DrugDDI.d59.s2.e0 0 10
drug
Caspofungin
DrugDDI.d59.s2.e1 31 42
drug
glycoprotein
DrugDDI.d59.s2.e2 65 78
drug
cytochrome P450

interaction DrugDDI.d59.s2.e0 DrugDDI.d59.s2.e1 false
interaction DrugDDI.d59.s2.e0 DrugDDI.d59.s2.e2 false
interaction DrugDDI.d59.s2.e1 DrugDDI.d59.s2.e2 false

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s3
Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole , amphotericin B , mycophenolate , nelfinavir , or tacrolimus .

DrugDDI.d59.s3.e0 63 70
drug
CANCIDAS
DrugDDI.d59.s3.e1 86 97
drug
itraconazole
DrugDDI.d59.s3.e2 99 111
drug
amphotericin B
DrugDDI.d59.s3.e3 113 125
drug
mycophenolate
DrugDDI.d59.s3.e4 127 136
drug
nelfinavir
DrugDDI.d59.s3.e5 140 149
drug
tacrolimus

interaction DrugDDI.d59.s3.e0 DrugDDI.d59.s3.e1 false
interaction DrugDDI.d59.s3.e0 DrugDDI.d59.s3.e2 false
interaction DrugDDI.d59.s3.e0 DrugDDI.d59.s3.e3 false
interaction DrugDDI.d59.s3.e0 DrugDDI.d59.s3.e4 false
interaction DrugDDI.d59.s3.e0 DrugDDI.d59.s3.e5 false
interaction DrugDDI.d59.s3.e1 DrugDDI.d59.s3.e2 false
interaction DrugDDI.d59.s3.e1 DrugDDI.d59.s3.e3 false
interaction DrugDDI.d59.s3.e1 DrugDDI.d59.s3.e4 false
interaction DrugDDI.d59.s3.e1 DrugDDI.d59.s3.e5 false
interaction DrugDDI.d59.s3.e2 DrugDDI.d59.s3.e3 false
interaction DrugDDI.d59.s3.e2 DrugDDI.d59.s3.e4 false
interaction DrugDDI.d59.s3.e2 DrugDDI.d59.s3.e5 false
interaction DrugDDI.d59.s3.e3 DrugDDI.d59.s3.e4 false
interaction DrugDDI.d59.s3.e3 DrugDDI.d59.s3.e5 false
interaction DrugDDI.d59.s3.e4 DrugDDI.d59.s3.e5 false

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s4
CANCIDAS has no effect on the pharmacokinetics of itraconazole , amphotericin B , or the active metabolite of mycophenolate .

DrugDDI.d59.s4.e0 0 7
drug
CANCIDAS
DrugDDI.d59.s4.e1 42 53
drug
itraconazole
DrugDDI.d59.s4.e2 55 67
drug
amphotericin B
DrugDDI.d59.s4.e3 74 89
drug
active metabolite
DrugDDI.d59.s4.e4 92 104
drug
mycophenolate

interaction DrugDDI.d59.s4.e0 DrugDDI.d59.s4.e1 false
interaction DrugDDI.d59.s4.e0 DrugDDI.d59.s4.e2 false
interaction DrugDDI.d59.s4.e0 DrugDDI.d59.s4.e3 false
interaction DrugDDI.d59.s4.e0 DrugDDI.d59.s4.e4 false
interaction DrugDDI.d59.s4.e1 DrugDDI.d59.s4.e2 false
interaction DrugDDI.d59.s4.e1 DrugDDI.d59.s4.e3 false
interaction DrugDDI.d59.s4.e1 DrugDDI.d59.s4.e4 false
interaction DrugDDI.d59.s4.e2 DrugDDI.d59.s4.e3 false
interaction DrugDDI.d59.s4.e2 DrugDDI.d59.s4.e4 false
interaction DrugDDI.d59.s4.e3 DrugDDI.d59.s4.e4 false

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s5
CANCIDAS reduced the blood AUC0-12 of tacrolimus ( FK-506 , Prograf span class= c4 @3) by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.

DrugDDI.d59.s5.e0 0 7
drug
CANCIDAS
DrugDDI.d59.s5.e1 32 41
drug
tacrolimus
DrugDDI.d59.s5.e2 43 48
drug
FK-506
DrugDDI.d59.s5.e3 67 68
drug
c4
DrugDDI.d59.s5.e4 186 195
drug
tacrolimus
DrugDDI.d59.s5.e5 255 262
drug
CANCIDAS
DrugDDI.d59.s5.e6 317 326
drug
tacrolimus

interaction DrugDDI.d59.s5.e0 DrugDDI.d59.s5.e1 true
interaction DrugDDI.d59.s5.e0 DrugDDI.d59.s5.e2 true
interaction DrugDDI.d59.s5.e0 DrugDDI.d59.s5.e3 true
interaction DrugDDI.d59.s5.e0 DrugDDI.d59.s5.e4 false
interaction DrugDDI.d59.s5.e0 DrugDDI.d59.s5.e5 false
interaction DrugDDI.d59.s5.e0 DrugDDI.d59.s5.e6 false
interaction DrugDDI.d59.s5.e1 DrugDDI.d59.s5.e2 false
interaction DrugDDI.d59.s5.e1 DrugDDI.d59.s5.e3 false
interaction DrugDDI.d59.s5.e1 DrugDDI.d59.s5.e4 false
interaction DrugDDI.d59.s5.e1 DrugDDI.d59.s5.e5 false
interaction DrugDDI.d59.s5.e1 DrugDDI.d59.s5.e6 false
interaction DrugDDI.d59.s5.e2 DrugDDI.d59.s5.e3 false
interaction DrugDDI.d59.s5.e2 DrugDDI.d59.s5.e4 false
interaction DrugDDI.d59.s5.e2 DrugDDI.d59.s5.e5 false
interaction DrugDDI.d59.s5.e2 DrugDDI.d59.s5.e6 false
interaction DrugDDI.d59.s5.e3 DrugDDI.d59.s5.e4 false
interaction DrugDDI.d59.s5.e3 DrugDDI.d59.s5.e5 false
interaction DrugDDI.d59.s5.e3 DrugDDI.d59.s5.e6 false
interaction DrugDDI.d59.s5.e4 DrugDDI.d59.s5.e5 false
interaction DrugDDI.d59.s5.e4 DrugDDI.d59.s5.e6 false
interaction DrugDDI.d59.s5.e5 DrugDDI.d59.s5.e6 false

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s6
For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.

DrugDDI.d59.s6.e0 54 63
drug
tacrolimus
DrugDDI.d59.s6.e1 97 106
drug
tacrolimus

interaction DrugDDI.d59.s6.e0 DrugDDI.d59.s6.e1 false

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s7
In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.

DrugDDI.d59.s7.e0 21 32
drug
cyclosporine
DrugDDI.d59.s7.e1 81 91
drug
caspofungin

interaction DrugDDI.d59.s7.e0 DrugDDI.d59.s7.e1 true

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s8
CANCIDAS did not increase the plasma levels of cyclosporine .

DrugDDI.d59.s8.e0 0 7
drug
CANCIDAS
DrugDDI.d59.s8.e1 39 50
drug
cyclosporine

interaction DrugDDI.d59.s8.e0 DrugDDI.d59.s8.e1 false

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s9
There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.

DrugDDI.d59.s9.e0 29 33
drug
liver
DrugDDI.d59.s9.e1 40 42
drug
AST
DrugDDI.d59.s9.e2 47 54
drug
CANCIDAS
DrugDDI.d59.s9.e3 58 69
drug
cyclosporine

interaction DrugDDI.d59.s9.e0 DrugDDI.d59.s9.e1 false
interaction DrugDDI.d59.s9.e0 DrugDDI.d59.s9.e2 false
interaction DrugDDI.d59.s9.e0 DrugDDI.d59.s9.e3 false
interaction DrugDDI.d59.s9.e1 DrugDDI.d59.s9.e2 false
interaction DrugDDI.d59.s9.e1 DrugDDI.d59.s9.e3 false
interaction DrugDDI.d59.s9.e2 DrugDDI.d59.s9.e3 true

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s10
A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.

DrugDDI.d59.s10.e0 30 37
drug
rifampin
DrugDDI.d59.s10.e1 79 89
drug
caspofungin

interaction DrugDDI.d59.s10.e0 DrugDDI.d59.s10.e1 true

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s11
Patients on rifampin should receive 70 mg of CANCIDAS daily.

DrugDDI.d59.s11.e0 10 17
drug
rifampin
DrugDDI.d59.s11.e1 37 44
drug
CANCIDAS

interaction DrugDDI.d59.s11.e0 DrugDDI.d59.s11.e1 false

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s12
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.

DrugDDI.d59.s12.e0 127 135
drug
efavirenz
DrugDDI.d59.s12.e1 137 146
drug
nevirapine
DrugDDI.d59.s12.e2 148 156
drug
phenytoin
DrugDDI.d59.s12.e3 158 170
drug
dexamethasone
DrugDDI.d59.s12.e4 174 186
drug
carbamazepine
DrugDDI.d59.s12.e5 192 199
drug
CANCIDAS
DrugDDI.d59.s12.e6 243 253
drug
caspofungin

interaction DrugDDI.d59.s12.e0 DrugDDI.d59.s12.e1 false
interaction DrugDDI.d59.s12.e0 DrugDDI.d59.s12.e2 false
interaction DrugDDI.d59.s12.e0 DrugDDI.d59.s12.e3 false
interaction DrugDDI.d59.s12.e0 DrugDDI.d59.s12.e4 false
interaction DrugDDI.d59.s12.e0 DrugDDI.d59.s12.e5 true
interaction DrugDDI.d59.s12.e0 DrugDDI.d59.s12.e6 false
interaction DrugDDI.d59.s12.e1 DrugDDI.d59.s12.e2 false
interaction DrugDDI.d59.s12.e1 DrugDDI.d59.s12.e3 false
interaction DrugDDI.d59.s12.e1 DrugDDI.d59.s12.e4 false
interaction DrugDDI.d59.s12.e1 DrugDDI.d59.s12.e5 true
interaction DrugDDI.d59.s12.e1 DrugDDI.d59.s12.e6 false
interaction DrugDDI.d59.s12.e2 DrugDDI.d59.s12.e3 false
interaction DrugDDI.d59.s12.e2 DrugDDI.d59.s12.e4 false
interaction DrugDDI.d59.s12.e2 DrugDDI.d59.s12.e5 true
interaction DrugDDI.d59.s12.e2 DrugDDI.d59.s12.e6 false
interaction DrugDDI.d59.s12.e3 DrugDDI.d59.s12.e4 false
interaction DrugDDI.d59.s12.e3 DrugDDI.d59.s12.e5 true
interaction DrugDDI.d59.s12.e3 DrugDDI.d59.s12.e6 false
interaction DrugDDI.d59.s12.e4 DrugDDI.d59.s12.e5 true
interaction DrugDDI.d59.s12.e4 DrugDDI.d59.s12.e6 false
interaction DrugDDI.d59.s12.e5 DrugDDI.d59.s12.e6 false

Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s13
It is not known which drug clearance mechanism involved in caspofungin disposition may be inducible.

DrugDDI.d59.s13.e0 49 59
drug
caspofungin



Abstract Id: DrugDDI.d59
Sentence Id: DrugDDI.d59.s14
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of 70 mg of CANCIDAS should be considered .

DrugDDI.d59.s14.e0 4 11
drug
CANCIDAS
DrugDDI.d59.s14.e1 63 71
drug
efavirenz
DrugDDI.d59.s14.e2 73 82
drug
nevirapine
DrugDDI.d59.s14.e3 84 92
drug
phenytoin
DrugDDI.d59.s14.e4 94 106
drug
dexamethasone
DrugDDI.d59.s14.e5 110 122
drug
carbamazepine
DrugDDI.d59.s14.e6 147 154
drug
CANCIDAS

interaction DrugDDI.d59.s14.e0 DrugDDI.d59.s14.e1 true
interaction DrugDDI.d59.s14.e0 DrugDDI.d59.s14.e2 true
interaction DrugDDI.d59.s14.e0 DrugDDI.d59.s14.e3 true
interaction DrugDDI.d59.s14.e0 DrugDDI.d59.s14.e4 true
interaction DrugDDI.d59.s14.e0 DrugDDI.d59.s14.e5 true
interaction DrugDDI.d59.s14.e0 DrugDDI.d59.s14.e6 false
interaction DrugDDI.d59.s14.e1 DrugDDI.d59.s14.e2 false
interaction DrugDDI.d59.s14.e1 DrugDDI.d59.s14.e3 false
interaction DrugDDI.d59.s14.e1 DrugDDI.d59.s14.e4 false
interaction DrugDDI.d59.s14.e1 DrugDDI.d59.s14.e5 false
interaction DrugDDI.d59.s14.e1 DrugDDI.d59.s14.e6 false
interaction DrugDDI.d59.s14.e2 DrugDDI.d59.s14.e3 false
interaction DrugDDI.d59.s14.e2 DrugDDI.d59.s14.e4 false
interaction DrugDDI.d59.s14.e2 DrugDDI.d59.s14.e5 false
interaction DrugDDI.d59.s14.e2 DrugDDI.d59.s14.e6 false
interaction DrugDDI.d59.s14.e3 DrugDDI.d59.s14.e4 false
interaction DrugDDI.d59.s14.e3 DrugDDI.d59.s14.e5 false
interaction DrugDDI.d59.s14.e3 DrugDDI.d59.s14.e6 false
interaction DrugDDI.d59.s14.e4 DrugDDI.d59.s14.e5 false
interaction DrugDDI.d59.s14.e4 DrugDDI.d59.s14.e6 false
interaction DrugDDI.d59.s14.e5 DrugDDI.d59.s14.e6 false

Abstract Id: DrugDDI.d67
Sentence Id: DrugDDI.d67.s0
Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.

DrugDDI.d67.s0.e0 0 9
drug
Probenecid
DrugDDI.d67.s0.e1 44 57
drug
cephalosporins
DrugDDI.d67.s0.e2 115 127
drug
cephalosporin

interaction DrugDDI.d67.s0.e0 DrugDDI.d67.s0.e1 true
interaction DrugDDI.d67.s0.e0 DrugDDI.d67.s0.e2 false
interaction DrugDDI.d67.s0.e1 DrugDDI.d67.s0.e2 false

Abstract Id: DrugDDI.d67
Sentence Id: DrugDDI.d67.s1
Drug /Laboratory Test Interactions : A false positive reaction for glucose in the urine may occur with Benedicts solution, Fehlings solution or with CLINITEST@ tablets, but not with enzyme-based tests such as CLINISTIX@.

DrugDDI.d67.s1.e0 0 3
drug
Drug
DrugDDI.d67.s1.e1 57 63
drug
glucose

interaction DrugDDI.d67.s1.e0 DrugDDI.d67.s1.e1 false

Abstract Id: DrugDDI.d67
Sentence Id: DrugDDI.d67.s2
Positive direct and indirect antiglobulin (Coombs) tests have occurred; .

DrugDDI.d67.s2.e0 25 36
drug
antiglobulin



Abstract Id: DrugDDI.d67
Sentence Id: DrugDDI.d67.s3
these may also occur in neonates whose mothers received cephalosporins before delivery.

DrugDDI.d67.s3.e0 47 60
drug
cephalosporins



Abstract Id: DrugDDI.d152
Sentence Id: DrugDDI.d152.s0
Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol , the estrogenic component in most oral contraceptives .

DrugDDI.d152.s0.e0 0 17
drug
Oral Contraceptives
DrugDDI.d152.s0.e1 33 49
drug
cefditoren pivoxil
DrugDDI.d152.s0.e2 84 99
drug
ethinyl estradiol
DrugDDI.d152.s0.e3 104 113
drug
estrogenic
DrugDDI.d152.s0.e4 129 146
drug
oral contraceptives

interaction DrugDDI.d152.s0.e0 DrugDDI.d152.s0.e1 false
interaction DrugDDI.d152.s0.e0 DrugDDI.d152.s0.e2 false
interaction DrugDDI.d152.s0.e0 DrugDDI.d152.s0.e3 false
interaction DrugDDI.d152.s0.e0 DrugDDI.d152.s0.e4 false
interaction DrugDDI.d152.s0.e1 DrugDDI.d152.s0.e2 false
interaction DrugDDI.d152.s0.e1 DrugDDI.d152.s0.e3 false
interaction DrugDDI.d152.s0.e1 DrugDDI.d152.s0.e4 false
interaction DrugDDI.d152.s0.e2 DrugDDI.d152.s0.e3 false
interaction DrugDDI.d152.s0.e2 DrugDDI.d152.s0.e4 false
interaction DrugDDI.d152.s0.e3 DrugDDI.d152.s0.e4 false

Abstract Id: DrugDDI.d152
Sentence Id: DrugDDI.d152.s1
Antacids Co-administration of a single dose of an antacid which contained both magnesium (800 mg) and aluminum (900 mg) hydroxides reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 14% decrease in mean Cmax and an 11% decrease in mean AUC.

DrugDDI.d152.s1.e0 0 7
drug
Antacids
DrugDDI.d152.s1.e1 42 48
drug
antacid
DrugDDI.d152.s1.e2 67 75
drug
magnesium
DrugDDI.d152.s1.e3 155 171
drug
cefditoren pivoxil

interaction DrugDDI.d152.s1.e0 DrugDDI.d152.s1.e1 false
interaction DrugDDI.d152.s1.e0 DrugDDI.d152.s1.e2 false
interaction DrugDDI.d152.s1.e0 DrugDDI.d152.s1.e3 false
interaction DrugDDI.d152.s1.e1 DrugDDI.d152.s1.e2 false
interaction DrugDDI.d152.s1.e1 DrugDDI.d152.s1.e3 true
interaction DrugDDI.d152.s1.e2 DrugDDI.d152.s1.e3 false

Abstract Id: DrugDDI.d152
Sentence Id: DrugDDI.d152.s2
Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids .

DrugDDI.d152.s2.e0 64 80
drug
cefditoren pivoxil
DrugDDI.d152.s2.e1 105 112
drug
antacids

interaction DrugDDI.d152.s2.e0 DrugDDI.d152.s2.e1 true

Abstract Id: DrugDDI.d152
Sentence Id: DrugDDI.d152.s3
H2-Receptor Antagonists Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.

DrugDDI.d152.s3.e0 0 21
drug
H2-Receptor Antagonists
DrugDDI.d152.s3.e1 79 88
drug
famotidine
DrugDDI.d152.s3.e2 139 155
drug
cefditoren pivoxil

interaction DrugDDI.d152.s3.e0 DrugDDI.d152.s3.e1 false
interaction DrugDDI.d152.s3.e0 DrugDDI.d152.s3.e2 false
interaction DrugDDI.d152.s3.e1 DrugDDI.d152.s3.e2 true

Abstract Id: DrugDDI.d152
Sentence Id: DrugDDI.d152.s4
Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with H2 receptor antagonists.

DrugDDI.d152.s4.e0 64 80
drug
cefditoren pivoxil
DrugDDI.d152.s4.e1 105 114
drug
H2 receptor

interaction DrugDDI.d152.s4.e0 DrugDDI.d152.s4.e1 true

Abstract Id: DrugDDI.d152
Sentence Id: DrugDDI.d152.s5
Probenecid : As with other b-lactam antibiotics , co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.

DrugDDI.d152.s5.e0 0 9
drug
Probenecid
DrugDDI.d152.s5.e1 22 40
drug
b-lactam antibiotics
DrugDDI.d152.s5.e2 61 70
drug
probenecid
DrugDDI.d152.s5.e3 75 91
drug
cefditoren pivoxil
DrugDDI.d152.s5.e4 133 142
drug
cefditoren

interaction DrugDDI.d152.s5.e0 DrugDDI.d152.s5.e1 false
interaction DrugDDI.d152.s5.e0 DrugDDI.d152.s5.e2 false
interaction DrugDDI.d152.s5.e0 DrugDDI.d152.s5.e3 false
interaction DrugDDI.d152.s5.e0 DrugDDI.d152.s5.e4 false
interaction DrugDDI.d152.s5.e1 DrugDDI.d152.s5.e2 false
interaction DrugDDI.d152.s5.e1 DrugDDI.d152.s5.e3 false
interaction DrugDDI.d152.s5.e1 DrugDDI.d152.s5.e4 false
interaction DrugDDI.d152.s5.e2 DrugDDI.d152.s5.e3 true
interaction DrugDDI.d152.s5.e2 DrugDDI.d152.s5.e4 false
interaction DrugDDI.d152.s5.e3 DrugDDI.d152.s5.e4 false

Abstract Id: DrugDDI.d152
Sentence Id: DrugDDI.d152.s6
Drug /Laboratory Test Interactions Cephalosporins are known to occasionally induce a positive direct Coombs test.

DrugDDI.d152.s6.e0 0 3
drug
Drug
DrugDDI.d152.s6.e1 31 44
drug
Cephalosporins

interaction DrugDDI.d152.s6.e0 DrugDDI.d152.s6.e1 false

Abstract Id: DrugDDI.d152
Sentence Id: DrugDDI.d152.s7
A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedicts or Fehlings solution or with CLINITEST tablets), but not with enzyme-based tests for glycosuria (e.g., CLINISTIX, TES-TAPE).

DrugDDI.d152.s7.e0 26 32
drug
glucose



Abstract Id: DrugDDI.d152
Sentence Id: DrugDDI.d152.s8
As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood/plasma glucose levels in patients receiving cefditoren pivoxil .

DrugDDI.d152.s8.e0 81 94
drug
glucose oxidase
DrugDDI.d152.s8.e1 97 106
drug
hexokinase
DrugDDI.d152.s8.e2 174 190
drug
cefditoren pivoxil

interaction DrugDDI.d152.s8.e0 DrugDDI.d152.s8.e1 false
interaction DrugDDI.d152.s8.e0 DrugDDI.d152.s8.e2 false
interaction DrugDDI.d152.s8.e1 DrugDDI.d152.s8.e2 false

Abstract Id: DrugDDI.d373
Sentence Id: DrugDDI.d373.s0
Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics .

DrugDDI.d373.s0.e0 74 87
drug
cephalosporins
DrugDDI.d373.s0.e1 91 115
drug
aminoglycoside antibiotics

interaction DrugDDI.d373.s0.e0 DrugDDI.d373.s0.e1 true

Abstract Id: DrugDDI.d373
Sentence Id: DrugDDI.d373.s1
Drug /Laboratory Test Interactions : As with cephalothin , high concentrations of cefoxitin ( 100 micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the Jaff@ reaction, and produce false increases of modest degree in the levels of creatinine reported.

DrugDDI.d373.s1.e0 0 3
drug
Drug
DrugDDI.d373.s1.e1 38 48
drug
cephalothin
DrugDDI.d373.s1.e2 70 78
drug
cefoxitin
DrugDDI.d373.s1.e3 225 234
drug
creatinine

interaction DrugDDI.d373.s1.e0 DrugDDI.d373.s1.e1 false
interaction DrugDDI.d373.s1.e0 DrugDDI.d373.s1.e2 false
interaction DrugDDI.d373.s1.e0 DrugDDI.d373.s1.e3 false
interaction DrugDDI.d373.s1.e1 DrugDDI.d373.s1.e2 false
interaction DrugDDI.d373.s1.e1 DrugDDI.d373.s1.e3 false
interaction DrugDDI.d373.s1.e2 DrugDDI.d373.s1.e3 false

Abstract Id: DrugDDI.d373
Sentence Id: DrugDDI.d373.s2
Serum samples from patients treated with cefoxitin should not be analyzed for creatinine if withdrawn within 2 hours of drug administration.

DrugDDI.d373.s2.e0 35 43
drug
cefoxitin
DrugDDI.d373.s2.e1 66 75
drug
creatinine

interaction DrugDDI.d373.s2.e0 DrugDDI.d373.s2.e1 false

Abstract Id: DrugDDI.d373
Sentence Id: DrugDDI.d373.s3
High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy- corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported.

DrugDDI.d373.s3.e0 20 28
drug
cefoxitin
DrugDDI.d373.s3.e1 86 100
drug
corticosteroids

interaction DrugDDI.d373.s3.e0 DrugDDI.d373.s3.e1 true

Abstract Id: DrugDDI.d373
Sentence Id: DrugDDI.d373.s4
A false-positive reaction for glucose in the urine may occur.

DrugDDI.d373.s4.e0 26 32
drug
glucose



Abstract Id: DrugDDI.d373
Sentence Id: DrugDDI.d373.s7
@ Registered trademark of Ame s Company, Division of Miles Laboratories, Inc.

DrugDDI.d373.s7.e0 22 24
drug
Ame



Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s0
Immunosuppressive Drugs, Fibric Acid Derivatives , Niacin ( Nicotinic Acid , Erythromycin , Azole Antifungals : Skeletal Muscle.

DrugDDI.d169.s0.e0 0 16
drug
Immunosuppressive
DrugDDI.d169.s0.e1 33 43
drug
Derivatives
DrugDDI.d169.s0.e2 45 50
drug
Niacin
DrugDDI.d169.s0.e3 52 64
drug
Nicotinic Acid
DrugDDI.d169.s0.e4 66 77
drug
Erythromycin
DrugDDI.d169.s0.e5 79 94
drug
Azole Antifungals

interaction DrugDDI.d169.s0.e0 DrugDDI.d169.s0.e1 false
interaction DrugDDI.d169.s0.e0 DrugDDI.d169.s0.e2 false
interaction DrugDDI.d169.s0.e0 DrugDDI.d169.s0.e3 false
interaction DrugDDI.d169.s0.e0 DrugDDI.d169.s0.e4 false
interaction DrugDDI.d169.s0.e0 DrugDDI.d169.s0.e5 false
interaction DrugDDI.d169.s0.e1 DrugDDI.d169.s0.e2 false
interaction DrugDDI.d169.s0.e1 DrugDDI.d169.s0.e3 false
interaction DrugDDI.d169.s0.e1 DrugDDI.d169.s0.e4 false
interaction DrugDDI.d169.s0.e1 DrugDDI.d169.s0.e5 false
interaction DrugDDI.d169.s0.e2 DrugDDI.d169.s0.e3 false
interaction DrugDDI.d169.s0.e2 DrugDDI.d169.s0.e4 false
interaction DrugDDI.d169.s0.e2 DrugDDI.d169.s0.e5 false
interaction DrugDDI.d169.s0.e3 DrugDDI.d169.s0.e4 false
interaction DrugDDI.d169.s0.e3 DrugDDI.d169.s0.e5 false
interaction DrugDDI.d169.s0.e4 DrugDDI.d169.s0.e5 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s1
ANTACID ( Magnesium-Aluminum Hydroxide ): Cerivastatin plasma concentrations were not affected by co-administration of antacid .

DrugDDI.d169.s1.e0 0 6
drug
ANTACID
DrugDDI.d169.s1.e1 8 34
drug
Magnesium-Aluminum Hydroxide
DrugDDI.d169.s1.e2 37 48
drug
Cerivastatin
DrugDDI.d169.s1.e3 105 111
drug
antacid

interaction DrugDDI.d169.s1.e0 DrugDDI.d169.s1.e1 false
interaction DrugDDI.d169.s1.e0 DrugDDI.d169.s1.e2 false
interaction DrugDDI.d169.s1.e0 DrugDDI.d169.s1.e3 false
interaction DrugDDI.d169.s1.e1 DrugDDI.d169.s1.e2 false
interaction DrugDDI.d169.s1.e1 DrugDDI.d169.s1.e3 false
interaction DrugDDI.d169.s1.e2 DrugDDI.d169.s1.e3 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s2
CIMETlDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine .

DrugDDI.d169.s2.e0 11 22
drug
Cerivastatin
DrugDDI.d169.s2.e1 79 88
drug
cimetidine

interaction DrugDDI.d169.s2.e0 DrugDDI.d169.s2.e1 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s3
CHOLESTYRAMINE : The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.

DrugDDI.d169.s3.e0 0 13
drug
CHOLESTYRAMINE
DrugDDI.d169.s3.e1 32 57
drug
bile-acidsequestering agent
DrugDDI.d169.s3.e2 95 112
drug
cerivastatin sodium

interaction DrugDDI.d169.s3.e0 DrugDDI.d169.s3.e1 false
interaction DrugDDI.d169.s3.e0 DrugDDI.d169.s3.e2 false
interaction DrugDDI.d169.s3.e1 DrugDDI.d169.s3.e2 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s4
In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.

DrugDDI.d169.s4.e0 48 65
drug
cerivastatin sodium
DrugDDI.d169.s4.e1 72 85
drug
cholestyramine
DrugDDI.d169.s4.e2 157 174
drug
cerivastatin sodium

interaction DrugDDI.d169.s4.e0 DrugDDI.d169.s4.e1 true
interaction DrugDDI.d169.s4.e0 DrugDDI.d169.s4.e2 false
interaction DrugDDI.d169.s4.e1 DrugDDI.d169.s4.e2 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s5
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.

DrugDDI.d169.s5.e0 44 57
drug
cholestyramine
DrugDDI.d169.s5.e1 91 108
drug
cerivastatin sodium
DrugDDI.d169.s5.e2 175 186
drug
cerivastatin
DrugDDI.d169.s5.e3 251 268
drug
cerivastatin sodium

interaction DrugDDI.d169.s5.e0 DrugDDI.d169.s5.e1 true
interaction DrugDDI.d169.s5.e0 DrugDDI.d169.s5.e2 false
interaction DrugDDI.d169.s5.e0 DrugDDI.d169.s5.e3 false
interaction DrugDDI.d169.s5.e1 DrugDDI.d169.s5.e2 false
interaction DrugDDI.d169.s5.e1 DrugDDI.d169.s5.e3 false
interaction DrugDDI.d169.s5.e2 DrugDDI.d169.s5.e3 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s6
Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium .

DrugDDI.d169.s6.e0 48 65
drug
cerivastatin sodium
DrugDDI.d169.s6.e1 83 96
drug
cholestyramine
DrugDDI.d169.s6.e2 179 196
drug
cerivastatin sodium

interaction DrugDDI.d169.s6.e0 DrugDDI.d169.s6.e1 false
interaction DrugDDI.d169.s6.e0 DrugDDI.d169.s6.e2 false
interaction DrugDDI.d169.s6.e1 DrugDDI.d169.s6.e2 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s7
DIGOXIN : Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium .

DrugDDI.d169.s7.e0 0 6
drug
DIGOXIN
DrugDDI.d169.s7.e1 30 36
drug
digoxin
DrugDDI.d169.s7.e2 101 118
drug
cerivastatin sodium

interaction DrugDDI.d169.s7.e0 DrugDDI.d169.s7.e1 false
interaction DrugDDI.d169.s7.e0 DrugDDI.d169.s7.e2 false
interaction DrugDDI.d169.s7.e1 DrugDDI.d169.s7.e2 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s8
Cerivastatin plasma concentrations were also not affected by co-administration of digoxin .

DrugDDI.d169.s8.e0 0 11
drug
Cerivastatin
DrugDDI.d169.s8.e1 72 78
drug
digoxin

interaction DrugDDI.d169.s8.e0 DrugDDI.d169.s8.e1 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s9
WARFARIN : Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.

DrugDDI.d169.s9.e0 0 7
drug
WARFARIN
DrugDDI.d169.s9.e1 28 35
drug
warfarin
DrugDDI.d169.s9.e2 39 50
drug
cerivastatin
DrugDDI.d169.s9.e3 121 129
drug
factor VII
DrugDDI.d169.s9.e4 163 170
drug
warfarin

interaction DrugDDI.d169.s9.e0 DrugDDI.d169.s9.e1 false
interaction DrugDDI.d169.s9.e0 DrugDDI.d169.s9.e2 false
interaction DrugDDI.d169.s9.e0 DrugDDI.d169.s9.e3 false
interaction DrugDDI.d169.s9.e0 DrugDDI.d169.s9.e4 false
interaction DrugDDI.d169.s9.e1 DrugDDI.d169.s9.e2 false
interaction DrugDDI.d169.s9.e1 DrugDDI.d169.s9.e3 false
interaction DrugDDI.d169.s9.e1 DrugDDI.d169.s9.e4 false
interaction DrugDDI.d169.s9.e2 DrugDDI.d169.s9.e3 false
interaction DrugDDI.d169.s9.e2 DrugDDI.d169.s9.e4 false
interaction DrugDDI.d169.s9.e3 DrugDDI.d169.s9.e4 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s10
The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium .

DrugDDI.d169.s10.e0 40 47
drug
warfarin
DrugDDI.d169.s10.e1 87 104
drug
cerivastatin sodium

interaction DrugDDI.d169.s10.e0 DrugDDI.d169.s10.e1 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s11
Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium .

DrugDDI.d169.s11.e0 19 26
drug
warfarin
DrugDDI.d169.s11.e1 30 41
drug
cerivastatin
DrugDDI.d169.s11.e2 74 91
drug
cerivastatin sodium

interaction DrugDDI.d169.s11.e0 DrugDDI.d169.s11.e1 false
interaction DrugDDI.d169.s11.e0 DrugDDI.d169.s11.e2 false
interaction DrugDDI.d169.s11.e1 DrugDDI.d169.s11.e2 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s12
ERYTHROMYCIN : In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin , a known inhibitor of cytochrome P450 3A4 .

DrugDDI.d169.s12.e0 0 11
drug
ERYTHROMYCIN
DrugDDI.d169.s12.e1 56 67
drug
cerivastatin
DrugDDI.d169.s12.e2 155 166
drug
erythromycin
DrugDDI.d169.s12.e3 185 201
drug
cytochrome P450 3A4

interaction DrugDDI.d169.s12.e0 DrugDDI.d169.s12.e1 false
interaction DrugDDI.d169.s12.e0 DrugDDI.d169.s12.e2 false
interaction DrugDDI.d169.s12.e0 DrugDDI.d169.s12.e3 false
interaction DrugDDI.d169.s12.e1 DrugDDI.d169.s12.e2 true
interaction DrugDDI.d169.s12.e1 DrugDDI.d169.s12.e3 false
interaction DrugDDI.d169.s12.e2 DrugDDI.d169.s12.e3 false

Abstract Id: DrugDDI.d169
Sentence Id: DrugDDI.d169.s13
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers , diuretics , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions.

DrugDDI.d169.s13.e0 93 110
drug
cerivastatin sodium
DrugDDI.d169.s13.e1 135 162
drug
angiotensin- converting enzyme
DrugDDI.d169.s13.e2 192 214
drug
calcium-channel blockers
DrugDDI.d169.s13.e3 216 224
drug
diuretics
DrugDDI.d169.s13.e4 229 262
drug
nonsteroidal anti-inflammatory drugs
DrugDDI.d169.s13.e5 264 269
drug
NSAIDs

interaction DrugDDI.d169.s13.e0 DrugDDI.d169.s13.e1 false
interaction DrugDDI.d169.s13.e0 DrugDDI.d169.s13.e2 false
interaction DrugDDI.d169.s13.e0 DrugDDI.d169.s13.e3 false
interaction DrugDDI.d169.s13.e0 DrugDDI.d169.s13.e4 false
interaction DrugDDI.d169.s13.e0 DrugDDI.d169.s13.e5 false
interaction DrugDDI.d169.s13.e1 DrugDDI.d169.s13.e2 false
interaction DrugDDI.d169.s13.e1 DrugDDI.d169.s13.e3 false
interaction DrugDDI.d169.s13.e1 DrugDDI.d169.s13.e4 false
interaction DrugDDI.d169.s13.e1 DrugDDI.d169.s13.e5 false
interaction DrugDDI.d169.s13.e2 DrugDDI.d169.s13.e3 false
interaction DrugDDI.d169.s13.e2 DrugDDI.d169.s13.e4 false
interaction DrugDDI.d169.s13.e2 DrugDDI.d169.s13.e5 false
interaction DrugDDI.d169.s13.e3 DrugDDI.d169.s13.e4 false
interaction DrugDDI.d169.s13.e3 DrugDDI.d169.s13.e5 false
interaction DrugDDI.d169.s13.e4 DrugDDI.d169.s13.e5 false

Abstract Id: DrugDDI.d125
Sentence Id: DrugDDI.d125.s0
Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide .

DrugDDI.d125.s0.e0 174 191
drug
oral anticoagulants
DrugDDI.d125.s0.e1 195 210
drug
chlordiazepoxide

interaction DrugDDI.d125.s0.e0 DrugDDI.d125.s0.e1 true

Abstract Id: DrugDDI.d125
Sentence Id: DrugDDI.d125.s1
The concomitant use of alcohol or other central nervous system depressants may have an additive effect.

DrugDDI.d125.s1.e0 19 25
drug
alcohol
DrugDDI.d125.s1.e1 33 63
drug
central nervous system depressants

interaction DrugDDI.d125.s1.e0 DrugDDI.d125.s1.e1 true

Abstract Id: DrugDDI.d261
Sentence Id: DrugDDI.d261.s0
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors , tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.

DrugDDI.d261.s0.e0 19 33
drug
local anesthetic
DrugDDI.d261.s0.e1 53 63
drug
epinephrine
DrugDDI.d261.s0.e2 66 79
drug
norepinephrine
DrugDDI.d261.s0.e3 99 124
drug
monoamine oxidase inhibitors
DrugDDI.d261.s0.e4 126 149
drug
tricyclic antidepressants
DrugDDI.d261.s0.e5 152 165
drug
phenothiazines

interaction DrugDDI.d261.s0.e0 DrugDDI.d261.s0.e1 false
interaction DrugDDI.d261.s0.e0 DrugDDI.d261.s0.e2 false
interaction DrugDDI.d261.s0.e0 DrugDDI.d261.s0.e3 true
interaction DrugDDI.d261.s0.e0 DrugDDI.d261.s0.e4 true
interaction DrugDDI.d261.s0.e0 DrugDDI.d261.s0.e5 true
interaction DrugDDI.d261.s0.e1 DrugDDI.d261.s0.e2 false
interaction DrugDDI.d261.s0.e1 DrugDDI.d261.s0.e3 true
interaction DrugDDI.d261.s0.e1 DrugDDI.d261.s0.e4 true
interaction DrugDDI.d261.s0.e1 DrugDDI.d261.s0.e5 true
interaction DrugDDI.d261.s0.e2 DrugDDI.d261.s0.e3 false
interaction DrugDDI.d261.s0.e2 DrugDDI.d261.s0.e4 false
interaction DrugDDI.d261.s0.e2 DrugDDI.d261.s0.e5 false
interaction DrugDDI.d261.s0.e3 DrugDDI.d261.s0.e4 false
interaction DrugDDI.d261.s0.e3 DrugDDI.d261.s0.e5 false
interaction DrugDDI.d261.s0.e4 DrugDDI.d261.s0.e5 false

Abstract Id: DrugDDI.d261
Sentence Id: DrugDDI.d261.s3
Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.

DrugDDI.d261.s3.e0 26 41
drug
vasopressor drugs
DrugDDI.d261.s3.e1 109 121
drug
oxytocic drugs

interaction DrugDDI.d261.s3.e0 DrugDDI.d261.s3.e1 true

Abstract Id: DrugDDI.d261
Sentence Id: DrugDDI.d261.s4
The para-aminobenzoic acid metabolite of chloroprocaine inhibits the action of sulfonamides .

DrugDDI.d261.s4.e0 3 23
drug
para-aminobenzoic acid
DrugDDI.d261.s4.e1 36 49
drug
chloroprocaine
DrugDDI.d261.s4.e2 69 80
drug
sulfonamides

interaction DrugDDI.d261.s4.e0 DrugDDI.d261.s4.e1 false
interaction DrugDDI.d261.s4.e0 DrugDDI.d261.s4.e2 false
interaction DrugDDI.d261.s4.e1 DrugDDI.d261.s4.e2 true

Abstract Id: DrugDDI.d261
Sentence Id: DrugDDI.d261.s5
Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.

DrugDDI.d261.s5.e0 10 23
drug
chloroprocaine
DrugDDI.d261.s5.e1 61 71
drug
sulfonamide

interaction DrugDDI.d261.s5.e0 DrugDDI.d261.s5.e1 true

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s0
When given concurrently the following drugs may interact with thiazide diuretics .

DrugDDI.d354.s0.e0 33 37
drug
drugs
DrugDDI.d354.s0.e1 53 69
drug
thiazide diuretics

interaction DrugDDI.d354.s0.e0 DrugDDI.d354.s0.e1 true

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s1
- Alcohol , barbiturates , or narcotics : Potentiation of otthostatic hypotension may occur .

DrugDDI.d354.s1.e0 1 7
drug
Alcohol
DrugDDI.d354.s1.e1 9 20
drug
barbiturates
DrugDDI.d354.s1.e2 24 32
drug
narcotics

interaction DrugDDI.d354.s1.e0 DrugDDI.d354.s1.e1 false
interaction DrugDDI.d354.s1.e0 DrugDDI.d354.s1.e2 false
interaction DrugDDI.d354.s1.e1 DrugDDI.d354.s1.e2 false

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s3
- Antidiabetic drugs : (Oral agents and insulin ) Dosage adjustment of the antidiabetic drug may be required .

DrugDDI.d354.s3.e0 1 17
drug
Antidiabetic drugs
DrugDDI.d354.s3.e1 33 39
drug
insulin
DrugDDI.d354.s3.e2 62 77
drug
antidiabetic drug

interaction DrugDDI.d354.s3.e0 DrugDDI.d354.s3.e1 false
interaction DrugDDI.d354.s3.e0 DrugDDI.d354.s3.e2 false
interaction DrugDDI.d354.s3.e1 DrugDDI.d354.s3.e2 false

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s5
- Other antihypertensive drugs : Additive effect or potentiation .

DrugDDI.d354.s5.e0 6 26
drug
antihypertensive drugs



Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s7
- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract .

DrugDDI.d354.s7.e0 1 14
drug
Cholestyramine
DrugDDI.d354.s7.e1 18 27
drug
colestipol
DrugDDI.d354.s7.e2 52 61
drug
colestipol
DrugDDI.d354.s7.e3 93 109
drug
thiazide diuretics
DrugDDI.d354.s7.e4 121 128
drug
diuretic

interaction DrugDDI.d354.s7.e0 DrugDDI.d354.s7.e1 false
interaction DrugDDI.d354.s7.e0 DrugDDI.d354.s7.e2 false
interaction DrugDDI.d354.s7.e0 DrugDDI.d354.s7.e3 false
interaction DrugDDI.d354.s7.e0 DrugDDI.d354.s7.e4 false
interaction DrugDDI.d354.s7.e1 DrugDDI.d354.s7.e2 false
interaction DrugDDI.d354.s7.e1 DrugDDI.d354.s7.e3 false
interaction DrugDDI.d354.s7.e1 DrugDDI.d354.s7.e4 false
interaction DrugDDI.d354.s7.e2 DrugDDI.d354.s7.e3 true
interaction DrugDDI.d354.s7.e2 DrugDDI.d354.s7.e4 true
interaction DrugDDI.d354.s7.e3 DrugDDI.d354.s7.e4 false

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s9
- Corticosteroids , ACTH : Intensified electrolyte depletion, particularly hypokalemia .

DrugDDI.d354.s9.e0 1 15
drug
Corticosteroids
DrugDDI.d354.s9.e1 17 20
drug
ACTH

interaction DrugDDI.d354.s9.e0 DrugDDI.d354.s9.e1 false

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s11
- Pressor amines (e.g., norepinephrine ): Possible decreased response to pressor amines but not sufficient to preclude their use .

DrugDDI.d354.s11.e0 1 13
drug
Pressor amines
DrugDDI.d354.s11.e1 20 33
drug
norepinephrine
DrugDDI.d354.s11.e2 63 75
drug
pressor amines

interaction DrugDDI.d354.s11.e0 DrugDDI.d354.s11.e1 false
interaction DrugDDI.d354.s11.e0 DrugDDI.d354.s11.e2 false
interaction DrugDDI.d354.s11.e1 DrugDDI.d354.s11.e2 false

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s13
- Skeletal muscle relaxants , nondepolarizing (e.g., tubocurarine ): Possible increased responsiveness to the muscle relaxant .

DrugDDI.d354.s13.e0 1 23
drug
Skeletal muscle relaxants
DrugDDI.d354.s13.e1 46 57
drug
tubocurarine
DrugDDI.d354.s13.e2 96 109
drug
muscle relaxant

interaction DrugDDI.d354.s13.e0 DrugDDI.d354.s13.e1 false
interaction DrugDDI.d354.s13.e0 DrugDDI.d354.s13.e2 false
interaction DrugDDI.d354.s13.e1 DrugDDI.d354.s13.e2 false

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s15
- Lithium : Generally should not be given with diuretics .

DrugDDI.d354.s15.e0 1 7
drug
Lithium
DrugDDI.d354.s15.e1 38 46
drug
diuretics

interaction DrugDDI.d354.s15.e0 DrugDDI.d354.s15.e1 false

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s16
Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.

DrugDDI.d354.s16.e0 0 7
drug
Diuretic
DrugDDI.d354.s16.e1 39 45
drug
lithium
DrugDDI.d354.s16.new.DISO.e2 63 77
DISO
lithium toxicity

interaction DrugDDI.d354.s16.e0 DrugDDI.d354.s16.e1 true

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s17
Refer to the package insert for lithium preparation s before use of such preparations with chlorothiazide .

DrugDDI.d354.s17.e0 26 43
drug
lithium preparation
DrugDDI.d354.s17.e1 76 89
drug
chlorothiazide

interaction DrugDDI.d354.s17.e0 DrugDDI.d354.s17.e1 false

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s19
- Non-steroidal Anti-inflammatory Drugs : In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic , natriuretic, and antihypertensive effects of loop, potassium -sparing and thiazide diuretics .

DrugDDI.d354.s19.e0 1 35
drug
Non-steroidal Anti-inflammatory Drugs
DrugDDI.d354.s19.e1 72 106
drug
non-steroidal anti-inflammatory agent
DrugDDI.d354.s19.e2 119 126
drug
diuretic
DrugDDI.d354.s19.e3 143 158
drug
antihypertensive
DrugDDI.d354.s19.e4 173 181
drug
potassium
DrugDDI.d354.s19.e5 193 209
drug
thiazide diuretics

interaction DrugDDI.d354.s19.e0 DrugDDI.d354.s19.e1 false
interaction DrugDDI.d354.s19.e0 DrugDDI.d354.s19.e2 false
interaction DrugDDI.d354.s19.e0 DrugDDI.d354.s19.e3 false
interaction DrugDDI.d354.s19.e0 DrugDDI.d354.s19.e4 false
interaction DrugDDI.d354.s19.e0 DrugDDI.d354.s19.e5 false
interaction DrugDDI.d354.s19.e1 DrugDDI.d354.s19.e2 false
interaction DrugDDI.d354.s19.e1 DrugDDI.d354.s19.e3 false
interaction DrugDDI.d354.s19.e1 DrugDDI.d354.s19.e4 true
interaction DrugDDI.d354.s19.e1 DrugDDI.d354.s19.e5 true
interaction DrugDDI.d354.s19.e2 DrugDDI.d354.s19.e3 false
interaction DrugDDI.d354.s19.e2 DrugDDI.d354.s19.e4 false
interaction DrugDDI.d354.s19.e2 DrugDDI.d354.s19.e5 false
interaction DrugDDI.d354.s19.e3 DrugDDI.d354.s19.e4 false
interaction DrugDDI.d354.s19.e3 DrugDDI.d354.s19.e5 false
interaction DrugDDI.d354.s19.e4 DrugDDI.d354.s19.e5 false

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s20
Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained .

DrugDDI.d354.s20.e0 14 27
drug
chlorothiazide
DrugDDI.d354.s20.e1 31 66
drug
non-steroidal anti-inflammatory agents
DrugDDI.d354.s20.e2 155 162
drug
diuretic

interaction DrugDDI.d354.s20.e0 DrugDDI.d354.s20.e1 true
interaction DrugDDI.d354.s20.e0 DrugDDI.d354.s20.e2 false
interaction DrugDDI.d354.s20.e1 DrugDDI.d354.s20.e2 false

Abstract Id: DrugDDI.d354
Sentence Id: DrugDDI.d354.s22
- Drug /Laboratory Test Interactions: Thiazides should be discontinued before carrying out tests for parathyroid function.

DrugDDI.d354.s22.e0 1 4
drug
Drug
DrugDDI.d354.s22.e1 33 41
drug
Thiazides
DrugDDI.d354.s22.e2 87 97
drug
parathyroid

interaction DrugDDI.d354.s22.e0 DrugDDI.d354.s22.e1 false
interaction DrugDDI.d354.s22.e0 DrugDDI.d354.s22.e2 false
interaction DrugDDI.d354.s22.e1 DrugDDI.d354.s22.e2 false

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s0
Interactions for vitamin D analogues ( Vitamin D2 , Vitamin D3 , Calcitriol , and Calcidiol ): Cholestyramine : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins; .

DrugDDI.d113.s0.e0 33 41
drug
Vitamin D2
DrugDDI.d113.s0.e1 43 51
drug
Vitamin D3
DrugDDI.d113.s0.e2 53 62
drug
Calcitriol
DrugDDI.d113.s0.e3 67 75
drug
Calcidiol
DrugDDI.d113.s0.e4 78 91
drug
Cholestyramine
DrugDDI.d113.s0.e5 93 106
drug
Cholestyramine

interaction DrugDDI.d113.s0.e0 DrugDDI.d113.s0.e1 false
interaction DrugDDI.d113.s0.e0 DrugDDI.d113.s0.e2 false
interaction DrugDDI.d113.s0.e0 DrugDDI.d113.s0.e3 false
interaction DrugDDI.d113.s0.e0 DrugDDI.d113.s0.e4 false
interaction DrugDDI.d113.s0.e0 DrugDDI.d113.s0.e5 false
interaction DrugDDI.d113.s0.e1 DrugDDI.d113.s0.e2 false
interaction DrugDDI.d113.s0.e1 DrugDDI.d113.s0.e3 false
interaction DrugDDI.d113.s0.e1 DrugDDI.d113.s0.e4 false
interaction DrugDDI.d113.s0.e1 DrugDDI.d113.s0.e5 false
interaction DrugDDI.d113.s0.e2 DrugDDI.d113.s0.e3 false
interaction DrugDDI.d113.s0.e2 DrugDDI.d113.s0.e4 false
interaction DrugDDI.d113.s0.e2 DrugDDI.d113.s0.e5 false
interaction DrugDDI.d113.s0.e3 DrugDDI.d113.s0.e4 false
interaction DrugDDI.d113.s0.e3 DrugDDI.d113.s0.e5 false
interaction DrugDDI.d113.s0.e4 DrugDDI.d113.s0.e5 false

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s1
as such it may impair intestinal absorption of any of vitamin D .

DrugDDI.d113.s1.e0 44 51
drug
vitamin D



Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s2
Phenytoin / Phenobarbital : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D , but may reduce endogenous plasma levels of calcitriol /ergocalcitriol by accelerating metabolism.

DrugDDI.d113.s2.e0 0 8
drug
Phenytoin
DrugDDI.d113.s2.e1 10 22
drug
Phenobarbital
DrugDDI.d113.s2.e2 45 53
drug
phenytoin
DrugDDI.d113.s2.e3 56 68
drug
phenobarbital
DrugDDI.d113.s2.e4 104 111
drug
vitamin D
DrugDDI.d113.s2.e5 149 158
drug
calcitriol

interaction DrugDDI.d113.s2.e0 DrugDDI.d113.s2.e1 false
interaction DrugDDI.d113.s2.e0 DrugDDI.d113.s2.e2 false
interaction DrugDDI.d113.s2.e0 DrugDDI.d113.s2.e3 false
interaction DrugDDI.d113.s2.e0 DrugDDI.d113.s2.e4 false
interaction DrugDDI.d113.s2.e0 DrugDDI.d113.s2.e5 false
interaction DrugDDI.d113.s2.e1 DrugDDI.d113.s2.e2 false
interaction DrugDDI.d113.s2.e1 DrugDDI.d113.s2.e3 false
interaction DrugDDI.d113.s2.e1 DrugDDI.d113.s2.e4 false
interaction DrugDDI.d113.s2.e1 DrugDDI.d113.s2.e5 false
interaction DrugDDI.d113.s2.e2 DrugDDI.d113.s2.e3 false
interaction DrugDDI.d113.s2.e2 DrugDDI.d113.s2.e4 false
interaction DrugDDI.d113.s2.e2 DrugDDI.d113.s2.e5 true
interaction DrugDDI.d113.s2.e3 DrugDDI.d113.s2.e4 false
interaction DrugDDI.d113.s2.e3 DrugDDI.d113.s2.e5 true
interaction DrugDDI.d113.s2.e4 DrugDDI.d113.s2.e5 false

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s3
Since blood level of calcitriol /ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.

DrugDDI.d113.s3.e0 17 26
drug
calcitriol
DrugDDI.d113.s3.e1 69 77
drug
Rocaltrol
DrugDDI.d113.s3.e2 99 103
drug
drugs

interaction DrugDDI.d113.s3.e0 DrugDDI.d113.s3.e1 true
interaction DrugDDI.d113.s3.e0 DrugDDI.d113.s3.e2 false
interaction DrugDDI.d113.s3.e1 DrugDDI.d113.s3.e2 false

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s4
Thiazides : Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.

DrugDDI.d113.s4.e0 0 8
drug
Thiazides
DrugDDI.d113.s4.e1 10 18
drug
Thiazides
DrugDDI.d113.s4.new.DISO.e3 35 47
DISO
hypercalcemia
DrugDDI.d113.s4.e2 64 70
drug
calcium

interaction DrugDDI.d113.s4.e0 DrugDDI.d113.s4.e1 false
interaction DrugDDI.d113.s4.e0 DrugDDI.d113.s4.e2 false
interaction DrugDDI.d113.s4.e1 DrugDDI.d113.s4.e2 false

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s5
Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.

DrugDDI.d113.s5.e0 54 62
drug
thiazides
DrugDDI.d113.s5.e1 67 74
drug
vitamin D
DrugDDI.d113.s5.new.DISO.e2 81 93
DISO
hypercalcemia

interaction DrugDDI.d113.s5.e0 DrugDDI.d113.s5.e1 true

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s7
Digitalis : Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis , as hypercalcemia in such patients may precipitate cardiac arrhythmias.

DrugDDI.d113.s7.e0 0 8
drug
Digitalis
DrugDDI.d113.s7.e1 10 17
drug
Vitamin D
DrugDDI.d113.s7.e2 81 89
drug
digitalis
DrugDDI.d113.s7.new.DISO.e3 93 105
DISO
hypercalcemia
DrugDDI.d113.s7.new.DISO.e4 134 151
DISO
cardiac arrhythmias

interaction DrugDDI.d113.s7.e0 DrugDDI.d113.s7.e1 false
interaction DrugDDI.d113.s7.e0 DrugDDI.d113.s7.e2 false
interaction DrugDDI.d113.s7.e1 DrugDDI.d113.s7.e2 true

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s8
Ketoconazole : Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D .

DrugDDI.d113.s8.e0 0 11
drug
Ketoconazole
DrugDDI.d113.s8.e1 13 24
drug
Ketoconazole
DrugDDI.d113.s8.e2 69 76
drug
vitamin D

interaction DrugDDI.d113.s8.e0 DrugDDI.d113.s8.e1 false
interaction DrugDDI.d113.s8.e0 DrugDDI.d113.s8.e2 false
interaction DrugDDI.d113.s8.e1 DrugDDI.d113.s8.e2 true

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s9
Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.

DrugDDI.d113.s9.e0 114 125
drug
ketoconazole



Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s10
However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.

DrugDDI.d113.s10.e0 38 49
drug
ketoconazole
DrugDDI.d113.s10.e1 54 61
drug
vitamin D

interaction DrugDDI.d113.s10.e0 DrugDDI.d113.s10.e1 false

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s11
Corticosteroids : A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids , which inhibit calcium absorption.

DrugDDI.d113.s11.e0 0 14
drug
Corticosteroids
DrugDDI.d113.s11.e1 94 100
drug
calcium
DrugDDI.d113.s11.e2 115 129
drug
corticosteroids
DrugDDI.d113.s11.e3 143 149
drug
calcium

interaction DrugDDI.d113.s11.e0 DrugDDI.d113.s11.e1 false
interaction DrugDDI.d113.s11.e0 DrugDDI.d113.s11.e2 false
interaction DrugDDI.d113.s11.e0 DrugDDI.d113.s11.e3 false
interaction DrugDDI.d113.s11.e1 DrugDDI.d113.s11.e2 false
interaction DrugDDI.d113.s11.e1 DrugDDI.d113.s11.e3 false
interaction DrugDDI.d113.s11.e2 DrugDDI.d113.s11.e3 false

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s12
Phosphate-Binding Agents : Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.

DrugDDI.d113.s12.e0 0 22
drug
Phosphate-Binding Agents
DrugDDI.d113.s12.e1 29 36
drug
vitamin D
DrugDDI.d113.s12.e2 114 136
drug
phosphate-binding agents

interaction DrugDDI.d113.s12.e0 DrugDDI.d113.s12.e1 false
interaction DrugDDI.d113.s12.e0 DrugDDI.d113.s12.e2 false
interaction DrugDDI.d113.s12.e1 DrugDDI.d113.s12.e2 true

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s13
Vitamin D : The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.

DrugDDI.d113.s13.e0 0 7
drug
Vitamin D
DrugDDI.d113.s13.new.DISO.e1 113 125
DISO
hypercalcemia



Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s14
Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.

DrugDDI.d113.s14.e0 0 6
drug
Calcium
DrugDDI.d113.s14.e1 49 78
drug
calcium-containing preparations

interaction DrugDDI.d113.s14.e0 DrugDDI.d113.s14.e1 false

Abstract Id: DrugDDI.d113
Sentence Id: DrugDDI.d113.s15
Magnesium : Magnesium-containing preparations (eg, antacids ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.

DrugDDI.d113.s15.e0 0 8
drug
Magnesium
DrugDDI.d113.s15.e1 10 41
drug
Magnesium-containing preparations
DrugDDI.d113.s15.e2 46 53
drug
antacids
DrugDDI.d113.s15.new.DISO.e4 63 77
DISO
hypermagnesemia
DrugDDI.d113.s15.e3 123 130
drug
vitamin D

interaction DrugDDI.d113.s15.e0 DrugDDI.d113.s15.e1 false
interaction DrugDDI.d113.s15.e0 DrugDDI.d113.s15.e2 false
interaction DrugDDI.d113.s15.e0 DrugDDI.d113.s15.e3 false
interaction DrugDDI.d113.s15.e1 DrugDDI.d113.s15.e2 false
interaction DrugDDI.d113.s15.e1 DrugDDI.d113.s15.e3 true
interaction DrugDDI.d113.s15.e2 DrugDDI.d113.s15.e3 false

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s0
Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones .

DrugDDI.d462.s0.e0 22 33
drug
theophylline
DrugDDI.d462.s0.e1 74 83
drug
quinolones

interaction DrugDDI.d462.s0.e0 DrugDDI.d462.s0.e1 true

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s1
There have been reports of theophylline -related side-effects in patients on concomitant theophylline -quinolone therapy.

DrugDDI.d462.s1.e0 22 33
drug
theophylline
DrugDDI.d462.s1.e1 77 88
drug
theophylline

interaction DrugDDI.d462.s1.e0 DrugDDI.d462.s1.e1 false

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s2
Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.

DrugDDI.d462.s2.e0 22 33
drug
theophylline



Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s3
Quinolones have also been shown to interfere with the metabolism of caffeine .

DrugDDI.d462.s3.e0 0 9
drug
Quinolones
DrugDDI.d462.s3.e1 57 64
drug
caffeine

interaction DrugDDI.d462.s3.e0 DrugDDI.d462.s3.e1 true

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s4
This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life.

DrugDDI.d462.s4.e0 31 38
drug
caffeine



Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s5
Although this interaction has not been reported with cinoxacin , caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.

DrugDDI.d462.s5.e0 45 53
drug
cinoxacin
DrugDDI.d462.s5.e1 83 91
drug
cinoxacin
DrugDDI.d462.s5.e2 116 134
drug
caffeine-containing

interaction DrugDDI.d462.s5.e0 DrugDDI.d462.s5.e1 false
interaction DrugDDI.d462.s5.e0 DrugDDI.d462.s5.e2 false
interaction DrugDDI.d462.s5.e1 DrugDDI.d462.s5.e2 true

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s6
Antacids or sucralfate substantially interfere with the absorption of some quinolones , resulting in low urine levels.

DrugDDI.d462.s6.e0 0 7
drug
Antacids
DrugDDI.d462.s6.e1 10 19
drug
sucralfate
DrugDDI.d462.s6.e2 65 74
drug
quinolones

interaction DrugDDI.d462.s6.e0 DrugDDI.d462.s6.e1 false
interaction DrugDDI.d462.s6.e0 DrugDDI.d462.s6.e2 true
interaction DrugDDI.d462.s6.e1 DrugDDI.d462.s6.e2 true

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s7
Also, concomitant administration of quinolones with products containing iron , multivitamins containing zinc , or Videx ( didanosine ) chewable/ buffer ed tablets or the pediatric powder for oral solution may result in low urine levels.

DrugDDI.d462.s7.e0 32 41
drug
quinolones
DrugDDI.d462.s7.e1 64 67
drug
iron
DrugDDI.d462.s7.e2 69 81
drug
multivitamins
DrugDDI.d462.s7.e3 92 95
drug
zinc
DrugDDI.d462.s7.e4 99 103
drug
Videx
DrugDDI.d462.s7.e5 105 114
drug
didanosine
DrugDDI.d462.s7.e6 125 130
drug
buffer
DrugDDI.d462.s7.e7 145 153
drug
pediatric

interaction DrugDDI.d462.s7.e0 DrugDDI.d462.s7.e1 true
interaction DrugDDI.d462.s7.e0 DrugDDI.d462.s7.e2 false
interaction DrugDDI.d462.s7.e0 DrugDDI.d462.s7.e3 true
interaction DrugDDI.d462.s7.e0 DrugDDI.d462.s7.e4 false
interaction DrugDDI.d462.s7.e0 DrugDDI.d462.s7.e5 true
interaction DrugDDI.d462.s7.e0 DrugDDI.d462.s7.e6 false
interaction DrugDDI.d462.s7.e0 DrugDDI.d462.s7.e7 false
interaction DrugDDI.d462.s7.e1 DrugDDI.d462.s7.e2 false
interaction DrugDDI.d462.s7.e1 DrugDDI.d462.s7.e3 false
interaction DrugDDI.d462.s7.e1 DrugDDI.d462.s7.e4 false
interaction DrugDDI.d462.s7.e1 DrugDDI.d462.s7.e5 false
interaction DrugDDI.d462.s7.e1 DrugDDI.d462.s7.e6 false
interaction DrugDDI.d462.s7.e1 DrugDDI.d462.s7.e7 false
interaction DrugDDI.d462.s7.e2 DrugDDI.d462.s7.e3 false
interaction DrugDDI.d462.s7.e2 DrugDDI.d462.s7.e4 false
interaction DrugDDI.d462.s7.e2 DrugDDI.d462.s7.e5 false
interaction DrugDDI.d462.s7.e2 DrugDDI.d462.s7.e6 false
interaction DrugDDI.d462.s7.e2 DrugDDI.d462.s7.e7 false
interaction DrugDDI.d462.s7.e3 DrugDDI.d462.s7.e4 false
interaction DrugDDI.d462.s7.e3 DrugDDI.d462.s7.e5 false
interaction DrugDDI.d462.s7.e3 DrugDDI.d462.s7.e6 false
interaction DrugDDI.d462.s7.e3 DrugDDI.d462.s7.e7 false
interaction DrugDDI.d462.s7.e4 DrugDDI.d462.s7.e5 false
interaction DrugDDI.d462.s7.e4 DrugDDI.d462.s7.e6 false
interaction DrugDDI.d462.s7.e4 DrugDDI.d462.s7.e7 false
interaction DrugDDI.d462.s7.e5 DrugDDI.d462.s7.e6 false
interaction DrugDDI.d462.s7.e5 DrugDDI.d462.s7.e7 false
interaction DrugDDI.d462.s7.e6 DrugDDI.d462.s7.e7 false

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s8
Quinolones , including cinoxacin , may enhance the effects of oral anticoagulants , such as warfarin or its derivatives .

DrugDDI.d462.s8.e0 0 9
drug
Quinolones
DrugDDI.d462.s8.e1 20 28
drug
cinoxacin
DrugDDI.d462.s8.e2 52 69
drug
oral anticoagulants
DrugDDI.d462.s8.e3 77 84
drug
warfarin
DrugDDI.d462.s8.e4 90 100
drug
derivatives

interaction DrugDDI.d462.s8.e0 DrugDDI.d462.s8.e1 false
interaction DrugDDI.d462.s8.e0 DrugDDI.d462.s8.e2 false
interaction DrugDDI.d462.s8.e0 DrugDDI.d462.s8.e3 true
interaction DrugDDI.d462.s8.e0 DrugDDI.d462.s8.e4 true
interaction DrugDDI.d462.s8.e1 DrugDDI.d462.s8.e2 false
interaction DrugDDI.d462.s8.e1 DrugDDI.d462.s8.e3 true
interaction DrugDDI.d462.s8.e1 DrugDDI.d462.s8.e4 true
interaction DrugDDI.d462.s8.e2 DrugDDI.d462.s8.e3 false
interaction DrugDDI.d462.s8.e2 DrugDDI.d462.s8.e4 false
interaction DrugDDI.d462.s8.e3 DrugDDI.d462.s8.e4 false

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s10
Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.

DrugDDI.d462.s10.e0 47 73
drug
quinolone class antimicrobial
DrugDDI.d462.s10.e1 80 112
drug
nonsteroidal anti-inflammatory drug

interaction DrugDDI.d462.s10.e0 DrugDDI.d462.s10.e1 true

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s11
Animal studies also suggest an increased potential for seizures when these 2 drugs are given concomitantly.

DrugDDI.d462.s11.e0 65 69
drug
drugs



Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s12
Fenbufen is not approved in the United States at this time.

DrugDDI.d462.s12.e0 0 7
drug
Fenbufen



Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s13
Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.

DrugDDI.d462.s13.e0 95 103
drug
cinoxacin
DrugDDI.d462.s13.e1 114 148
drug
nonsteroidal anti-inflammatory agents

interaction DrugDDI.d462.s13.e0 DrugDDI.d462.s13.e1 true

Abstract Id: DrugDDI.d462
Sentence Id: DrugDDI.d462.s14
Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine .

DrugDDI.d462.s14.e0 8 19
drug
cyclosporine
DrugDDI.d462.s14.e1 70 79
drug
quinolones
DrugDDI.d462.s14.e2 83 94
drug
cyclosporine

interaction DrugDDI.d462.s14.e0 DrugDDI.d462.s14.e1 false
interaction DrugDDI.d462.s14.e0 DrugDDI.d462.s14.e2 false
interaction DrugDDI.d462.s14.e1 DrugDDI.d462.s14.e2 true

Abstract Id: DrugDDI.d12
Sentence Id: DrugDDI.d12.s0
Plasma levels of anticonvulsant agent s may become subtherapeutic during cisplatin therapy.

DrugDDI.d12.s0.e0 14 32
drug
anticonvulsant agent
DrugDDI.d12.s0.e1 63 71
drug
cisplatin

interaction DrugDDI.d12.s0.e0 DrugDDI.d12.s0.e1 true

Abstract Id: DrugDDI.d12
Sentence Id: DrugDDI.d12.s1
In a randomized trial in advanced ovarian cancer, response duration was adversely affected when pyridoxine was used in combination with altretamine ( hexamethylmelamine ) and cisplatin .1 .

DrugDDI.d12.s1.new.DISO.e4 20 40
DISO
advanced ovarian cancer
DrugDDI.d12.s1.e0 82 91
drug
pyridoxine
DrugDDI.d12.s1.e1 116 126
drug
altretamine
DrugDDI.d12.s1.e2 128 145
drug
hexamethylmelamine
DrugDDI.d12.s1.e3 150 158
drug
cisplatin

interaction DrugDDI.d12.s1.e0 DrugDDI.d12.s1.e1 true
interaction DrugDDI.d12.s1.e0 DrugDDI.d12.s1.e2 true
interaction DrugDDI.d12.s1.e0 DrugDDI.d12.s1.e3 true
interaction DrugDDI.d12.s1.e1 DrugDDI.d12.s1.e2 false
interaction DrugDDI.d12.s1.e1 DrugDDI.d12.s1.e3 false
interaction DrugDDI.d12.s1.e2 DrugDDI.d12.s1.e3 false

Abstract Id: DrugDDI.d430
Sentence Id: DrugDDI.d430.s0
Central nervous system depressant (CNS) drugs including alcohol , antidepressants , antihistamines , antipsychotics , blood pressure medications ( reserpine , methyldopa , beta-blockers ), motion sickness medications , muscle relaxants , narcotics , sedatives , sleeping pills and tranquilizers .

DrugDDI.d430.s0.e0 0 29
drug
Central nervous system depressant
DrugDDI.d430.s0.e1 35 39
drug
drugs
DrugDDI.d430.s0.e2 49 55
drug
alcohol
DrugDDI.d430.s0.e3 57 71
drug
antidepressants
DrugDDI.d430.s0.e4 73 86
drug
antihistamines
DrugDDI.d430.s0.e5 88 101
drug
antipsychotics
DrugDDI.d430.s0.e6 116 126
drug
medications
DrugDDI.d430.s0.e7 128 136
drug
reserpine
DrugDDI.d430.s0.e8 138 147
drug
methyldopa
DrugDDI.d430.s0.e9 149 161
drug
beta-blockers
DrugDDI.d430.s0.e10 178 188
drug
medications
DrugDDI.d430.s0.e11 190 204
drug
muscle relaxants
DrugDDI.d430.s0.e12 206 214
drug
narcotics
DrugDDI.d430.s0.e13 216 224
drug
sedatives
DrugDDI.d430.s0.e14 242 254
drug
tranquilizers

interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e1 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e2 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e3 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e4 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e5 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e6 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e7 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e8 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e9 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e10 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e11 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e0 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e2 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e3 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e4 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e5 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e6 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e7 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e8 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e9 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e10 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e11 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e1 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e3 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e4 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e5 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e6 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e7 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e8 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e9 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e10 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e11 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e2 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e3 DrugDDI.d430.s0.e4 false
interaction DrugDDI.d430.s0.e3 DrugDDI.d430.s0.e5 false
interaction DrugDDI.d430.s0.e3 DrugDDI.d430.s0.e6 false
interaction DrugDDI.d430.s0.e3 DrugDDI.d430.s0.e7 false
interaction DrugDDI.d430.s0.e3 DrugDDI.d430.s0.e8 false
interaction DrugDDI.d430.s0.e3 DrugDDI.d430.s0.e9 false
interaction DrugDDI.d430.s0.e3 DrugDDI.d430.s0.e10 false
interaction DrugDDI.d430.s0.e3 DrugDDI.d430.s0.e11 false
interaction DrugDDI.d430.s0.e3 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e3 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e3 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e4 DrugDDI.d430.s0.e5 false
interaction DrugDDI.d430.s0.e4 DrugDDI.d430.s0.e6 false
interaction DrugDDI.d430.s0.e4 DrugDDI.d430.s0.e7 false
interaction DrugDDI.d430.s0.e4 DrugDDI.d430.s0.e8 false
interaction DrugDDI.d430.s0.e4 DrugDDI.d430.s0.e9 false
interaction DrugDDI.d430.s0.e4 DrugDDI.d430.s0.e10 false
interaction DrugDDI.d430.s0.e4 DrugDDI.d430.s0.e11 false
interaction DrugDDI.d430.s0.e4 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e4 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e4 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e5 DrugDDI.d430.s0.e6 false
interaction DrugDDI.d430.s0.e5 DrugDDI.d430.s0.e7 false
interaction DrugDDI.d430.s0.e5 DrugDDI.d430.s0.e8 false
interaction DrugDDI.d430.s0.e5 DrugDDI.d430.s0.e9 false
interaction DrugDDI.d430.s0.e5 DrugDDI.d430.s0.e10 false
interaction DrugDDI.d430.s0.e5 DrugDDI.d430.s0.e11 false
interaction DrugDDI.d430.s0.e5 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e5 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e5 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e6 DrugDDI.d430.s0.e7 false
interaction DrugDDI.d430.s0.e6 DrugDDI.d430.s0.e8 false
interaction DrugDDI.d430.s0.e6 DrugDDI.d430.s0.e9 false
interaction DrugDDI.d430.s0.e6 DrugDDI.d430.s0.e10 false
interaction DrugDDI.d430.s0.e6 DrugDDI.d430.s0.e11 false
interaction DrugDDI.d430.s0.e6 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e6 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e6 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e7 DrugDDI.d430.s0.e8 false
interaction DrugDDI.d430.s0.e7 DrugDDI.d430.s0.e9 false
interaction DrugDDI.d430.s0.e7 DrugDDI.d430.s0.e10 false
interaction DrugDDI.d430.s0.e7 DrugDDI.d430.s0.e11 false
interaction DrugDDI.d430.s0.e7 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e7 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e7 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e8 DrugDDI.d430.s0.e9 false
interaction DrugDDI.d430.s0.e8 DrugDDI.d430.s0.e10 false
interaction DrugDDI.d430.s0.e8 DrugDDI.d430.s0.e11 false
interaction DrugDDI.d430.s0.e8 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e8 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e8 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e9 DrugDDI.d430.s0.e10 false
interaction DrugDDI.d430.s0.e9 DrugDDI.d430.s0.e11 false
interaction DrugDDI.d430.s0.e9 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e9 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e9 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e10 DrugDDI.d430.s0.e11 false
interaction DrugDDI.d430.s0.e10 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e10 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e10 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e11 DrugDDI.d430.s0.e12 false
interaction DrugDDI.d430.s0.e11 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e11 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e12 DrugDDI.d430.s0.e13 false
interaction DrugDDI.d430.s0.e12 DrugDDI.d430.s0.e14 false
interaction DrugDDI.d430.s0.e13 DrugDDI.d430.s0.e14 false

Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s0
Amantadine , tricyclic antidepressants , and MAOIs may increase anticholinergic effect of clidinium .

DrugDDI.d425.s0.e0 0 9
drug
Amantadine
DrugDDI.d425.s0.e1 11 34
drug
tricyclic antidepressants
DrugDDI.d425.s0.e2 55 69
drug
anticholinergic
DrugDDI.d425.s0.e3 78 86
drug
clidinium

interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e1 false
interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e2 false
interaction DrugDDI.d425.s0.e0 DrugDDI.d425.s0.e3 true
interaction DrugDDI.d425.s0.e1 DrugDDI.d425.s0.e2 false
interaction DrugDDI.d425.s0.e1 DrugDDI.d425.s0.e3 true
interaction DrugDDI.d425.s0.e2 DrugDDI.d425.s0.e3 false

Abstract Id: DrugDDI.d425
Sentence Id: DrugDDI.d425.s1
Clidinium may decrease the effect of phenothiazines , levodopa , and ketoconazole .

DrugDDI.d425.s1.e0 0 8
drug
Clidinium
DrugDDI.d425.s1.e1 31 44
drug
phenothiazines
DrugDDI.d425.s1.e2 46 53
drug
levodopa
DrugDDI.d425.s1.e3 58 69
drug
ketoconazole

interaction DrugDDI.d425.s1.e0 DrugDDI.d425.s1.e1 true
interaction DrugDDI.d425.s1.e0 DrugDDI.d425.s1.e2 true
interaction DrugDDI.d425.s1.e0 DrugDDI.d425.s1.e3 true
interaction DrugDDI.d425.s1.e1 DrugDDI.d425.s1.e2 false
interaction DrugDDI.d425.s1.e1 DrugDDI.d425.s1.e3 false
interaction DrugDDI.d425.s1.e2 DrugDDI.d425.s1.e3 false

Abstract Id: DrugDDI.d40
Sentence Id: DrugDDI.d40.s0
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents .

DrugDDI.d40.s0.e0 0 10
drug
Clindamycin
DrugDDI.d40.s0.e1 90 116
drug
neuromuscular blocking agents

interaction DrugDDI.d40.s0.e0 DrugDDI.d40.s0.e1 true

Abstract Id: DrugDDI.d40
Sentence Id: DrugDDI.d40.s2
Antagonism has been demonstrated between clindamycin and erythromycin in vitro.

DrugDDI.d40.s2.e0 36 46
drug
clindamycin
DrugDDI.d40.s2.e1 50 61
drug
erythromycin

interaction DrugDDI.d40.s2.e0 DrugDDI.d40.s2.e1 true

Abstract Id: DrugDDI.d40
Sentence Id: DrugDDI.d40.s3
Because of possible clinical significance, these two drugs should not be administered concurrently.

DrugDDI.d40.s3.e0 46 50
drug
drugs



Abstract Id: DrugDDI.d119
Sentence Id: DrugDDI.d119.s0
Alcohol (increases bioavailability by 50%), cimetidine , and valproates.

DrugDDI.d119.s0.e0 0 6
drug
Alcohol
DrugDDI.d119.s0.e1 39 48
drug
cimetidine

interaction DrugDDI.d119.s0.e0 DrugDDI.d119.s0.e1 false

Abstract Id: DrugDDI.d118
Sentence Id: DrugDDI.d118.s0
Although no clinical drug-drug interaction studies have been conducted to date, on the basis of the in vitro studies, cytochrome p450 inhibitors and inducers are unlikely to affect the metabolism of clofarabine .

DrugDDI.d118.s0.e0 99 112
drug
cytochrome p450
DrugDDI.d118.s0.e1 168 178
drug
clofarabine

interaction DrugDDI.d118.s0.e0 DrugDDI.d118.s0.e1 false

Abstract Id: DrugDDI.d118
Sentence Id: DrugDDI.d118.s1
The effect of clofarabine on the metabolism of cytochrome p450 substrates has not been studied.

DrugDDI.d118.s1.e0 11 21
drug
clofarabine
DrugDDI.d118.s1.e1 39 52
drug
cytochrome p450

interaction DrugDDI.d118.s1.e0 DrugDDI.d118.s1.e1 false

Abstract Id: DrugDDI.d118
Sentence Id: DrugDDI.d118.s2
Drug /Laboratory Tests Interactions : There are no known clinically significant interactions of CLOLAR@ with other medications or laboratory tests.

DrugDDI.d118.s2.e0 0 3
drug
Drug
DrugDDI.d118.s2.e1 99 109
drug
medications

interaction DrugDDI.d118.s2.e0 DrugDDI.d118.s2.e1 false

Abstract Id: DrugDDI.d118
Sentence Id: DrugDDI.d118.s3
No formal drug /laboratory test interaction studies have been conducted with CLOLAR@ .

DrugDDI.d118.s3.e0 8 11
drug
drug



Abstract Id: DrugDDI.d558
Sentence Id: DrugDDI.d558.s0
Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.

DrugDDI.d558.s0.e0 31 37
drug
dapsone
DrugDDI.d558.s0.e1 78 85
drug
Lamprene

interaction DrugDDI.d558.s0.e0 DrugDDI.d558.s0.e1 true

Abstract Id: DrugDDI.d558
Sentence Id: DrugDDI.d558.s1
If leprosy -associated inflammatory reactions develop in patients being treated with dapsone and clofazimine , it is still advisable to continue treatment with both drugs .

DrugDDI.d558.s1.e0 2 8
drug
leprosy
DrugDDI.d558.s1.e1 74 80
drug
dapsone
DrugDDI.d558.s1.e2 84 94
drug
clofazimine
DrugDDI.d558.s1.e3 141 145
drug
drugs

interaction DrugDDI.d558.s1.e0 DrugDDI.d558.s1.e1 false
interaction DrugDDI.d558.s1.e0 DrugDDI.d558.s1.e2 false
interaction DrugDDI.d558.s1.e0 DrugDDI.d558.s1.e3 false
interaction DrugDDI.d558.s1.e1 DrugDDI.d558.s1.e2 false
interaction DrugDDI.d558.s1.e1 DrugDDI.d558.s1.e3 false
interaction DrugDDI.d558.s1.e2 DrugDDI.d558.s1.e3 false

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s0
Tablet : If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants , the effect of clonidine may be reduced, thus necessitating an increase in dosage.

DrugDDI.d467.s0.e0 26 47
drug
clonidine hydrochloride
DrugDDI.d467.s0.e1 60 83
drug
tricyclic antidepressants
DrugDDI.d467.s0.e2 96 104
drug
clonidine

interaction DrugDDI.d467.s0.e0 DrugDDI.d467.s0.e1 true
interaction DrugDDI.d467.s0.e0 DrugDDI.d467.s0.e2 false
interaction DrugDDI.d467.s0.e1 DrugDDI.d467.s0.e2 false

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s1
Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol , barbiturates or other sedatives .

DrugDDI.d467.s1.e0 0 21
drug
Clonidine hydrochloride
DrugDDI.d467.s1.e1 58 64
drug
alcohol
DrugDDI.d467.s1.e2 66 77
drug
barbiturates
DrugDDI.d467.s1.e3 85 93
drug
sedatives

interaction DrugDDI.d467.s1.e0 DrugDDI.d467.s1.e1 true
interaction DrugDDI.d467.s1.e0 DrugDDI.d467.s1.e2 true
interaction DrugDDI.d467.s1.e0 DrugDDI.d467.s1.e3 true
interaction DrugDDI.d467.s1.e1 DrugDDI.d467.s1.e2 false
interaction DrugDDI.d467.s1.e1 DrugDDI.d467.s1.e3 false
interaction DrugDDI.d467.s1.e2 DrugDDI.d467.s1.e3 false

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s2
Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol , barbiturates or other sedating drugs .

DrugDDI.d467.s2.e0 0 12
drug
Amitriptyline
DrugDDI.d467.s2.e1 30 38
drug
clonidine
DrugDDI.d467.s2.new.DISO.e6 65 78
DISO
corneal lesions
DrugDDI.d467.s2.e2 102 110
drug
Clonidine
DrugDDI.d467.s2.e3 149 155
drug
alcohol
DrugDDI.d467.s2.e4 157 168
drug
barbiturates
DrugDDI.d467.s2.e5 184 188
drug
drugs

interaction DrugDDI.d467.s2.e0 DrugDDI.d467.s2.e1 true
interaction DrugDDI.d467.s2.e0 DrugDDI.d467.s2.e2 false
interaction DrugDDI.d467.s2.e0 DrugDDI.d467.s2.e3 false
interaction DrugDDI.d467.s2.e0 DrugDDI.d467.s2.e4 false
interaction DrugDDI.d467.s2.e0 DrugDDI.d467.s2.e5 false
interaction DrugDDI.d467.s2.e1 DrugDDI.d467.s2.e2 false
interaction DrugDDI.d467.s2.e1 DrugDDI.d467.s2.e3 false
interaction DrugDDI.d467.s2.e1 DrugDDI.d467.s2.e4 false
interaction DrugDDI.d467.s2.e1 DrugDDI.d467.s2.e5 false
interaction DrugDDI.d467.s2.e2 DrugDDI.d467.s2.e3 true
interaction DrugDDI.d467.s2.e2 DrugDDI.d467.s2.e4 true
interaction DrugDDI.d467.s2.e2 DrugDDI.d467.s2.e5 true
interaction DrugDDI.d467.s2.e3 DrugDDI.d467.s2.e4 false
interaction DrugDDI.d467.s2.e3 DrugDDI.d467.s2.e5 false
interaction DrugDDI.d467.s2.e4 DrugDDI.d467.s2.e5 false

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s3
Narcotic analgesics may potentiate the hypotensive effects of clonidine .

DrugDDI.d467.s3.e0 0 17
drug
Narcotic analgesics
DrugDDI.d467.s3.e1 54 62
drug
clonidine

interaction DrugDDI.d467.s3.e0 DrugDDI.d467.s3.e1 true

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s4
Tricyclic antidepressants may antagonize the hypotensive effects of clonidine .

DrugDDI.d467.s4.e0 0 23
drug
Tricyclic antidepressants
DrugDDI.d467.s4.e1 60 68
drug
clonidine

interaction DrugDDI.d467.s4.e0 DrugDDI.d467.s4.e1 true

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s5
The effects of tricyclic antidepressants on clonidine s analgesic actions are not known.

DrugDDI.d467.s5.e0 12 35
drug
tricyclic antidepressants
DrugDDI.d467.s5.e1 38 46
drug
clonidine
DrugDDI.d467.s5.e2 48 56
drug
analgesic

interaction DrugDDI.d467.s5.e0 DrugDDI.d467.s5.e1 false
interaction DrugDDI.d467.s5.e0 DrugDDI.d467.s5.e2 false
interaction DrugDDI.d467.s5.e1 DrugDDI.d467.s5.e2 false

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s6
Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.

DrugDDI.d467.s6.e0 0 11
drug
Beta blockers
DrugDDI.d467.s6.e1 56 64
drug
clonidine

interaction DrugDDI.d467.s6.e0 DrugDDI.d467.s6.e1 false

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s7
Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis , calcium channel blockers , and beta-blockers .) .

DrugDDI.d467.s7.new.DISO.e4 60 66
DISO
AV block
DrugDDI.d467.s7.e0 105 113
drug
clonidine
DrugDDI.d467.s7.e1 179 187
drug
digitalis
DrugDDI.d467.s7.e2 189 210
drug
calcium channel blockers
DrugDDI.d467.s7.e3 215 227
drug
beta-blockers

interaction DrugDDI.d467.s7.e0 DrugDDI.d467.s7.e1 true
interaction DrugDDI.d467.s7.e0 DrugDDI.d467.s7.e2 true
interaction DrugDDI.d467.s7.e0 DrugDDI.d467.s7.e3 true
interaction DrugDDI.d467.s7.e1 DrugDDI.d467.s7.e2 false
interaction DrugDDI.d467.s7.e1 DrugDDI.d467.s7.e3 false
interaction DrugDDI.d467.s7.e2 DrugDDI.d467.s7.e3 false

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s8
There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine .

DrugDDI.d467.s8.new.DISO.e2 36 48
DISO
acute delirium
DrugDDI.d467.s8.e0 83 94
drug
fluphenazine
DrugDDI.d467.s8.e1 102 110
drug
clonidine

interaction DrugDDI.d467.s8.e0 DrugDDI.d467.s8.e1 true

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s9
Symptoms resolved when clonidine was withdrawn and recurred when the patient was rechallenged with clonidine .

DrugDDI.d467.s9.e0 20 28
drug
clonidine
DrugDDI.d467.s9.e1 85 93
drug
clonidine

interaction DrugDDI.d467.s9.e0 DrugDDI.d467.s9.e1 false

Abstract Id: DrugDDI.d467
Sentence Id: DrugDDI.d467.s10
Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics , including both sensory and motor blockade.

DrugDDI.d467.s10.e0 8 16
drug
clonidine
DrugDDI.d467.s10.e1 70 85
drug
local anesthetics

interaction DrugDDI.d467.s10.e0 DrugDDI.d467.s10.e1 true

Abstract Id: DrugDDI.d474
Sentence Id: DrugDDI.d474.s0
Colchicine is inhibited by acidifying agents .

DrugDDI.d474.s0.e0 0 9
drug
Colchicine
DrugDDI.d474.s0.e1 23 38
drug
acidifying agents

interaction DrugDDI.d474.s0.e0 DrugDDI.d474.s0.e1 true

Abstract Id: DrugDDI.d474
Sentence Id: DrugDDI.d474.s1
The action of colchicine is potentiated by alkalinizing agents .

DrugDDI.d474.s1.e0 11 20
drug
colchicine
DrugDDI.d474.s1.e1 36 53
drug
alkalinizing agents

interaction DrugDDI.d474.s1.e0 DrugDDI.d474.s1.e1 true

Abstract Id: DrugDDI.d474
Sentence Id: DrugDDI.d474.s2
Colchicine may increase sensitivity to the CNS depressants .

DrugDDI.d474.s2.e0 0 9
drug
Colchicine
DrugDDI.d474.s2.e1 37 50
drug
CNS depressants

interaction DrugDDI.d474.s2.e0 DrugDDI.d474.s2.e1 true

Abstract Id: DrugDDI.d474
Sentence Id: DrugDDI.d474.s3
Response to sympathomimetic agents may be enhanced by colchicine .

DrugDDI.d474.s3.e0 10 30
drug
sympathomimetic agents
DrugDDI.d474.s3.e1 46 55
drug
colchicine

interaction DrugDDI.d474.s3.e0 DrugDDI.d474.s3.e1 true

Abstract Id: DrugDDI.d469
Sentence Id: DrugDDI.d469.s0
Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.

DrugDDI.d469.s0.e0 0 12
drug
Corticotropin



Abstract Id: DrugDDI.d191
Sentence Id: DrugDDI.d191.s1
Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.

DrugDDI.d191.s1.e0 0 4
drug
Drugs
DrugDDI.d191.s1.e1 35 47
drug
phenobarbital
DrugDDI.d191.s1.e2 49 57
drug
phenytoin
DrugDDI.d191.s1.e3 61 68
drug
rifampin
DrugDDI.d191.s1.e4 94 108
drug
corticosteroids
DrugDDI.d191.s1.e5 133 146
drug
corticosteroid

interaction DrugDDI.d191.s1.e0 DrugDDI.d191.s1.e1 false
interaction DrugDDI.d191.s1.e0 DrugDDI.d191.s1.e2 false
interaction DrugDDI.d191.s1.e0 DrugDDI.d191.s1.e3 false
interaction DrugDDI.d191.s1.e0 DrugDDI.d191.s1.e4 true
interaction DrugDDI.d191.s1.e0 DrugDDI.d191.s1.e5 false
interaction DrugDDI.d191.s1.e1 DrugDDI.d191.s1.e2 false
interaction DrugDDI.d191.s1.e1 DrugDDI.d191.s1.e3 false
interaction DrugDDI.d191.s1.e1 DrugDDI.d191.s1.e4 true
interaction DrugDDI.d191.s1.e1 DrugDDI.d191.s1.e5 false
interaction DrugDDI.d191.s1.e2 DrugDDI.d191.s1.e3 false
interaction DrugDDI.d191.s1.e2 DrugDDI.d191.s1.e4 true
interaction DrugDDI.d191.s1.e2 DrugDDI.d191.s1.e5 false
interaction DrugDDI.d191.s1.e3 DrugDDI.d191.s1.e4 true
interaction DrugDDI.d191.s1.e3 DrugDDI.d191.s1.e5 false
interaction DrugDDI.d191.s1.e4 DrugDDI.d191.s1.e5 false

Abstract Id: DrugDDI.d191
Sentence Id: DrugDDI.d191.s2
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.

DrugDDI.d191.s2.e0 0 4
drug
Drugs
DrugDDI.d191.s2.e1 11 24
drug
troleandomycin
DrugDDI.d191.s2.e2 28 39
drug
ketoconazole
DrugDDI.d191.s2.e3 65 79
drug
corticosteroids

interaction DrugDDI.d191.s2.e0 DrugDDI.d191.s2.e1 false
interaction DrugDDI.d191.s2.e0 DrugDDI.d191.s2.e2 false
interaction DrugDDI.d191.s2.e0 DrugDDI.d191.s2.e3 true
interaction DrugDDI.d191.s2.e1 DrugDDI.d191.s2.e2 false
interaction DrugDDI.d191.s2.e1 DrugDDI.d191.s2.e3 true
interaction DrugDDI.d191.s2.e2 DrugDDI.d191.s2.e3 true

Abstract Id: DrugDDI.d191
Sentence Id: DrugDDI.d191.s3
Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity.

DrugDDI.d191.s3.e0 19 32
drug
corticosteroid



Abstract Id: DrugDDI.d191
Sentence Id: DrugDDI.d191.s4
Corticosteroids may increase the clearance of chronic high dose aspirin .

DrugDDI.d191.s4.e0 0 14
drug
Corticosteroids
DrugDDI.d191.s4.e1 55 61
drug
aspirin

interaction DrugDDI.d191.s4.e0 DrugDDI.d191.s4.e1 true

Abstract Id: DrugDDI.d191
Sentence Id: DrugDDI.d191.s5
This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.

DrugDDI.d191.s5.e0 86 99
drug
corticosteroid



Abstract Id: DrugDDI.d191
Sentence Id: DrugDDI.d191.s6
Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.

DrugDDI.d191.s6.e0 0 6
drug
Aspirin
DrugDDI.d191.s6.e1 46 61
drug
cortico-steroids

interaction DrugDDI.d191.s6.e0 DrugDDI.d191.s6.e1 true

Abstract Id: DrugDDI.d191
Sentence Id: DrugDDI.d191.s7
The effect of corticosteroids on oral anticoagulants is variable.

DrugDDI.d191.s7.e0 11 25
drug
corticosteroids
DrugDDI.d191.s7.e1 28 45
drug
oral anticoagulants

interaction DrugDDI.d191.s7.e0 DrugDDI.d191.s7.e1 true

Abstract Id: DrugDDI.d191
Sentence Id: DrugDDI.d191.s8
There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids .

DrugDDI.d191.s8.e0 52 65
drug
anticoagulants
DrugDDI.d191.s8.e1 91 105
drug
corticosteroids

interaction DrugDDI.d191.s8.e0 DrugDDI.d191.s8.e1 true

Abstract Id: DrugDDI.d25
Sentence Id: DrugDDI.d25.s0
Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.

DrugDDI.d25.s0.e0 31 44
drug
Cromolyn sodium
DrugDDI.d25.s0.e1 48 60
drug
isoproterenol

interaction DrugDDI.d25.s0.e0 DrugDDI.d25.s0.e1 false

Abstract Id: DrugDDI.d25
Sentence Id: DrugDDI.d25.s1
Cromolyn sodium alone in doses up to 540 mg/kg/day (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) did not cause significant increases in resorptions or major malformations.

DrugDDI.d25.s1.e0 0 13
drug
Cromolyn sodium



Abstract Id: DrugDDI.d25
Sentence Id: DrugDDI.d25.s2
Isoproterenol alone at a dose of 2.7 mg/kg/day (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) increased both resorptions and malformations.

DrugDDI.d25.s2.e0 0 12
drug
Isoproterenol



Abstract Id: DrugDDI.d25
Sentence Id: DrugDDI.d25.s3
The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.

DrugDDI.d25.s3.e0 27 40
drug
cromolyn sodium
DrugDDI.d25.s3.e1 141 153
drug
isoproterenol

interaction DrugDDI.d25.s3.e0 DrugDDI.d25.s3.e1 true

Abstract Id: DrugDDI.d230
Sentence Id: DrugDDI.d230.s0
May interact with wthionamide ( Trecator-SC ) and isoniazid ( Nydrazid ).

DrugDDI.d230.s0.e0 27 37
drug
Trecator-SC
DrugDDI.d230.s0.e1 42 50
drug
isoniazid
DrugDDI.d230.s0.e2 52 59
drug
Nydrazid

interaction DrugDDI.d230.s0.e0 DrugDDI.d230.s0.e1 false
interaction DrugDDI.d230.s0.e0 DrugDDI.d230.s0.e2 false
interaction DrugDDI.d230.s0.e1 DrugDDI.d230.s0.e2 false

Abstract Id: DrugDDI.d168
Sentence Id: DrugDDI.d168.s0
Warfarin Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug , and the INR was not significantly altered.

DrugDDI.d168.s0.e0 0 7
drug
Warfarin
DrugDDI.d168.s0.e1 35 44
drug
daptomycin
DrugDDI.d168.s0.e2 80 87
drug
warfarin
DrugDDI.d168.s0.e3 159 162
drug
drug

interaction DrugDDI.d168.s0.e0 DrugDDI.d168.s0.e1 false
interaction DrugDDI.d168.s0.e0 DrugDDI.d168.s0.e2 false
interaction DrugDDI.d168.s0.e0 DrugDDI.d168.s0.e3 false
interaction DrugDDI.d168.s0.e1 DrugDDI.d168.s0.e2 false
interaction DrugDDI.d168.s0.e1 DrugDDI.d168.s0.e3 false
interaction DrugDDI.d168.s0.e2 DrugDDI.d168.s0.e3 false

Abstract Id: DrugDDI.d168
Sentence Id: DrugDDI.d168.s1
As experience with the concomitant administration of daptomycin and warfarin is limited to volunteer studies, anticoagulant activity in patients receiving daptomycin and warfarin should be monitored for the first several days after initiating therapy with Fentanyl .

DrugDDI.d168.s1.e0 46 55
drug
daptomycin
DrugDDI.d168.s1.e1 59 66
drug
warfarin
DrugDDI.d168.s1.e2 135 144
drug
daptomycin
DrugDDI.d168.s1.e3 148 155
drug
warfarin
DrugDDI.d168.s1.e4 221 228
drug
Fentanyl

interaction DrugDDI.d168.s1.e0 DrugDDI.d168.s1.e1 false
interaction DrugDDI.d168.s1.e0 DrugDDI.d168.s1.e2 false
interaction DrugDDI.d168.s1.e0 DrugDDI.d168.s1.e3 false
interaction DrugDDI.d168.s1.e0 DrugDDI.d168.s1.e4 false
interaction DrugDDI.d168.s1.e1 DrugDDI.d168.s1.e2 false
interaction DrugDDI.d168.s1.e1 DrugDDI.d168.s1.e3 false
interaction DrugDDI.d168.s1.e1 DrugDDI.d168.s1.e4 false
interaction DrugDDI.d168.s1.e2 DrugDDI.d168.s1.e3 false
interaction DrugDDI.d168.s1.e2 DrugDDI.d168.s1.e4 false
interaction DrugDDI.d168.s1.e3 DrugDDI.d168.s1.e4 false

Abstract Id: DrugDDI.d168
Sentence Id: DrugDDI.d168.s2
HMG-CoA Reductase Inhibitors Inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.

DrugDDI.d168.s2.e0 0 25
drug
HMG-CoA Reductase Inhibitors
DrugDDI.d168.s2.e1 38 53
drug
HMG-CoA reductase
DrugDDI.d168.s2.new.DISO.e2 62 69
DISO
myopathy

interaction DrugDDI.d168.s2.e0 DrugDDI.d168.s2.e1 false

Abstract Id: DrugDDI.d168
Sentence Id: DrugDDI.d168.s3
There were no reports of skeletal myopathy in a placebo-controlled Phase : I trial in which 10 healthy subjects on stable simvastatin therapy were treated concurrently with daptomycin (4 mg/kg once every 24 hours) for 14 days.

DrugDDI.d168.s3.new.DISO.e2 28 35
DISO
myopathy
DrugDDI.d168.s3.e0 101 111
drug
simvastatin
DrugDDI.d168.s3.e1 146 155
drug
daptomycin

interaction DrugDDI.d168.s3.e0 DrugDDI.d168.s3.e1 false

Abstract Id: DrugDDI.d168
Sentence Id: DrugDDI.d168.s4
Experience with co-administration of HMG-CoA reduc-tase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl .

DrugDDI.d168.s4.e0 33 39
drug
HMG-CoA
DrugDDI.d168.s4.e1 63 70
drug
Fentanyl
DrugDDI.d168.s4.e2 155 180
drug
HMG-CoA reductase inhibitors
DrugDDI.d168.s4.e3 200 207
drug
Fentanyl

interaction DrugDDI.d168.s4.e0 DrugDDI.d168.s4.e1 false
interaction DrugDDI.d168.s4.e0 DrugDDI.d168.s4.e2 false
interaction DrugDDI.d168.s4.e0 DrugDDI.d168.s4.e3 false
interaction DrugDDI.d168.s4.e1 DrugDDI.d168.s4.e2 false
interaction DrugDDI.d168.s4.e1 DrugDDI.d168.s4.e3 false
interaction DrugDDI.d168.s4.e2 DrugDDI.d168.s4.e3 false

Abstract Id: DrugDDI.d51
Sentence Id: DrugDDI.d51.s0
Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.

DrugDDI.d51.s0.e0 5 14
drug
Cerubidine
DrugDDI.d51.s0.e1 49 59
drug
doxorubicin
DrugDDI.d51.s0.new.DISO.e2 78 91
DISO
cardiotoxicity

interaction DrugDDI.d51.s0.e0 DrugDDI.d51.s0.e1 true

Abstract Id: DrugDDI.d51
Sentence Id: DrugDDI.d51.s1
Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine .

DrugDDI.d51.s1.e0 0 9
drug
Cerubidine
DrugDDI.d51.s1.e1 98 108
drug
doxorubicin
DrugDDI.d51.s1.e2 111 120
drug
Cerubidine

interaction DrugDDI.d51.s1.e0 DrugDDI.d51.s1.e1 true
interaction DrugDDI.d51.s1.e0 DrugDDI.d51.s1.e2 false
interaction DrugDDI.d51.s1.e1 DrugDDI.d51.s1.e2 false

Abstract Id: DrugDDI.d51
Sentence Id: DrugDDI.d51.s2
Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.

DrugDDI.d51.s2.e0 0 15
drug
Cyclophosphamide
DrugDDI.d51.s2.e1 36 45
drug
Cerubidine

interaction DrugDDI.d51.s2.e0 DrugDDI.d51.s2.e1 true

Abstract Id: DrugDDI.d51
Sentence Id: DrugDDI.d51.s3
Dosage reduction of Cerubidine may be required when used concurrently with other myelosuppressive agents.

DrugDDI.d51.s3.e0 17 26
drug
Cerubidine



Abstract Id: DrugDDI.d51
Sentence Id: DrugDDI.d51.s4
Hepatotoxic medications , such as high-dose methotrexate , may impair liver function and increase the risk of toxicity.

DrugDDI.d51.s4.e0 11 21
drug
medications
DrugDDI.d51.s4.e1 38 49
drug
methotrexate

interaction DrugDDI.d51.s4.e0 DrugDDI.d51.s4.e1 false

Abstract Id: DrugDDI.d157
Sentence Id: DrugDDI.d157.s0
Drug interaction studies with decitabine have not been conducted.

DrugDDI.d157.s0.e0 26 35
drug
decitabine



Abstract Id: DrugDDI.d157
Sentence Id: DrugDDI.d157.s1
In vitro studies in human liver microsomes suggest that decitabine is unlikely to inhibit or induce cytochrome P450 enzymes.

DrugDDI.d157.s1.e0 47 56
drug
decitabine
DrugDDI.d157.s1.e1 84 97
drug
cytochrome P450

interaction DrugDDI.d157.s1.e0 DrugDDI.d157.s1.e1 false

Abstract Id: DrugDDI.d157
Sentence Id: DrugDDI.d157.s2
In vitro metabolism studies have suggested that decitabine is not a substrate for the human liver cytochrome P450 enzyme s.

DrugDDI.d157.s2.e0 41 50
drug
decitabine
DrugDDI.d157.s2.e1 82 101
drug
cytochrome P450 enzyme

interaction DrugDDI.d157.s2.e0 DrugDDI.d157.s2.e1 false

Abstract Id: DrugDDI.d157
Sentence Id: DrugDDI.d157.s3
As plasma protein binding of decitabine is negligible ( 1%), interactions due to displacement of more highly protein bound drugs from plasma proteins are not expected.

DrugDDI.d157.s3.e0 2 14
drug
plasma protein
DrugDDI.d157.s3.e1 24 33
drug
decitabine
DrugDDI.d157.s3.e2 113 126
drug
plasma proteins

interaction DrugDDI.d157.s3.e0 DrugDDI.d157.s3.e1 false
interaction DrugDDI.d157.s3.e0 DrugDDI.d157.s3.e2 false
interaction DrugDDI.d157.s3.e1 DrugDDI.d157.s3.e2 false

Abstract Id: DrugDDI.d492
Sentence Id: DrugDDI.d492.s0
Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

DrugDDI.d492.s0.e0 10 22
drug
tetracyclines
DrugDDI.d492.s0.e1 142 154
drug
anticoagulant

interaction DrugDDI.d492.s0.e0 DrugDDI.d492.s0.e1 true

Abstract Id: DrugDDI.d492
Sentence Id: DrugDDI.d492.s1
Since bacteriostat ic drugs, such as the tetracycline class of antibiotics , may interfere with the bactericidal action of penicillins , it is not advisable to administer these drugs concomitantly.

DrugDDI.d492.s1.e0 5 16
drug
bacteriostat
DrugDDI.d492.s1.e1 34 45
drug
tetracycline
DrugDDI.d492.s1.e2 53 63
drug
antibiotics
DrugDDI.d492.s1.e3 104 114
drug
penicillins
DrugDDI.d492.s1.e4 149 153
drug
drugs

interaction DrugDDI.d492.s1.e0 DrugDDI.d492.s1.e1 false
interaction DrugDDI.d492.s1.e0 DrugDDI.d492.s1.e2 false
interaction DrugDDI.d492.s1.e0 DrugDDI.d492.s1.e3 true
interaction DrugDDI.d492.s1.e0 DrugDDI.d492.s1.e4 false
interaction DrugDDI.d492.s1.e1 DrugDDI.d492.s1.e2 false
interaction DrugDDI.d492.s1.e1 DrugDDI.d492.s1.e3 false
interaction DrugDDI.d492.s1.e1 DrugDDI.d492.s1.e4 false
interaction DrugDDI.d492.s1.e2 DrugDDI.d492.s1.e3 true
interaction DrugDDI.d492.s1.e2 DrugDDI.d492.s1.e4 false
interaction DrugDDI.d492.s1.e3 DrugDDI.d492.s1.e4 false

Abstract Id: DrugDDI.d492
Sentence Id: DrugDDI.d492.s2
Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effect ive.

DrugDDI.d492.s2.e0 15 27
drug
tetracyclines
DrugDDI.d492.s2.e1 32 49
drug
oral contraceptives
DrugDDI.d492.s2.e2 59 86
drug
oral contraceptives less effect

interaction DrugDDI.d492.s2.e0 DrugDDI.d492.s2.e1 true
interaction DrugDDI.d492.s2.e0 DrugDDI.d492.s2.e2 false
interaction DrugDDI.d492.s2.e1 DrugDDI.d492.s2.e2 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s1
Drugs Metabolized by P450 2D6 : The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 ( debrisoquin hydroxylase ) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); .

DrugDDI.d392.s1.e0 0 4
drug
Drugs
DrugDDI.d392.s1.e1 18 24
drug
P450 2D6
DrugDDI.d392.s1.e2 53 56
drug
drug
DrugDDI.d392.s1.e3 94 115
drug
debrisoquin hydroxylase

interaction DrugDDI.d392.s1.e0 DrugDDI.d392.s1.e1 false
interaction DrugDDI.d392.s1.e0 DrugDDI.d392.s1.e2 false
interaction DrugDDI.d392.s1.e0 DrugDDI.d392.s1.e3 false
interaction DrugDDI.d392.s1.e1 DrugDDI.d392.s1.e2 false
interaction DrugDDI.d392.s1.e1 DrugDDI.d392.s1.e3 false
interaction DrugDDI.d392.s1.e2 DrugDDI.d392.s1.e3 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s2
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.

DrugDDI.d392.s2.e0 41 54
drug
P450 2D6 isozyme



Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s3
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.

DrugDDI.d392.s3.e0 60 83
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s4
Depending on the traction of drug metabolized by P450 2D6 , the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).

DrugDDI.d392.s4.e0 24 27
drug
drug
DrugDDI.d392.s4.e1 41 47
drug
P450 2D6

interaction DrugDDI.d392.s4.e0 DrugDDI.d392.s4.e1 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s5
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o.

DrugDDI.d392.s5.e0 18 22
drug
drugs
DrugDDI.d392.s5.e1 47 53
drug
isozyme

interaction DrugDDI.d392.s5.e0 DrugDDI.d392.s5.e1 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s7
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.

DrugDDI.d392.s7.e0 91 95
drug
drugs



Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s8
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme ( quinidine ; .

DrugDDI.d392.s8.e0 3 7
drug
drugs
DrugDDI.d392.s8.e1 19 35
drug
cytochrome P450 2D6
DrugDDI.d392.s8.e2 80 88
drug
quinidine

interaction DrugDDI.d392.s8.e0 DrugDDI.d392.s8.e1 false
interaction DrugDDI.d392.s8.e0 DrugDDI.d392.s8.e2 false
interaction DrugDDI.d392.s8.e1 DrugDDI.d392.s8.e2 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s9
cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type 1C antiarrhythrnics propatenone and flecainide ).

DrugDDI.d392.s9.e0 0 9
drug
cimetidine
DrugDDI.d392.s9.e1 38 44
drug
P450 2D6
DrugDDI.d392.s9.e2 55 69
drug
antidepressants
DrugDDI.d392.s9.e3 71 84
drug
phenothiazines
DrugDDI.d392.s9.e4 128 137
drug
flecainide

interaction DrugDDI.d392.s9.e0 DrugDDI.d392.s9.e1 false
interaction DrugDDI.d392.s9.e0 DrugDDI.d392.s9.e2 false
interaction DrugDDI.d392.s9.e0 DrugDDI.d392.s9.e3 false
interaction DrugDDI.d392.s9.e0 DrugDDI.d392.s9.e4 false
interaction DrugDDI.d392.s9.e1 DrugDDI.d392.s9.e2 false
interaction DrugDDI.d392.s9.e1 DrugDDI.d392.s9.e3 false
interaction DrugDDI.d392.s9.e1 DrugDDI.d392.s9.e4 false
interaction DrugDDI.d392.s9.e2 DrugDDI.d392.s9.e3 false
interaction DrugDDI.d392.s9.e2 DrugDDI.d392.s9.e4 false
interaction DrugDDI.d392.s9.e3 DrugDDI.d392.s9.e4 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s10
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine , seriraline, and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition.

DrugDDI.d392.s10.e0 20 46
drug
serotonin reuptake inhibitors
DrugDDI.d392.s10.e1 60 69
drug
fluoxetine
DrugDDI.d392.s10.e2 85 94
drug
paroxetine
DrugDDI.d392.s10.e3 103 109
drug
P450 2D6

interaction DrugDDI.d392.s10.e0 DrugDDI.d392.s10.e1 false
interaction DrugDDI.d392.s10.e0 DrugDDI.d392.s10.e2 false
interaction DrugDDI.d392.s10.e0 DrugDDI.d392.s10.e3 false
interaction DrugDDI.d392.s10.e1 DrugDDI.d392.s10.e2 false
interaction DrugDDI.d392.s10.e1 DrugDDI.d392.s10.e3 false
interaction DrugDDI.d392.s10.e2 DrugDDI.d392.s10.e3 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s12
Nevertheless, caution is indicated in the co-administration of T .A. with any of the SSRIs and also in switching from one class to the other.

DrugDDI.d392.s12.e0 55 55
drug
T



Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s13
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine , given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).

DrugDDI.d392.s13.e0 103 112
drug
fluoxetine
DrugDDI.d392.s13.e1 149 164
drug
active metabolite

interaction DrugDDI.d392.s13.e0 DrugDDI.d392.s13.e1 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s14
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug .

DrugDDI.d392.s14.e0 16 39
drug
tricyclic antidepressants
DrugDDI.d392.s14.e1 44 48
drug
drugs
DrugDDI.d392.s14.e2 63 79
drug
cytochrome P450 2D6
DrugDDI.d392.s14.e3 133 155
drug
tricyclic antidepressant
DrugDDI.d392.s14.e4 166 169
drug
drug

interaction DrugDDI.d392.s14.e0 DrugDDI.d392.s14.e1 true
interaction DrugDDI.d392.s14.e0 DrugDDI.d392.s14.e2 false
interaction DrugDDI.d392.s14.e0 DrugDDI.d392.s14.e3 false
interaction DrugDDI.d392.s14.e0 DrugDDI.d392.s14.e4 false
interaction DrugDDI.d392.s14.e1 DrugDDI.d392.s14.e2 false
interaction DrugDDI.d392.s14.e1 DrugDDI.d392.s14.e3 false
interaction DrugDDI.d392.s14.e1 DrugDDI.d392.s14.e4 false
interaction DrugDDI.d392.s14.e2 DrugDDI.d392.s14.e3 false
interaction DrugDDI.d392.s14.e2 DrugDDI.d392.s14.e4 false
interaction DrugDDI.d392.s14.e3 DrugDDI.d392.s14.e4 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s15
Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.

DrugDDI.d392.s15.e0 35 39
drug
drugs
DrugDDI.d392.s15.e1 83 105
drug
tricyclic antidepressant

interaction DrugDDI.d392.s15.e0 DrugDDI.d392.s15.e1 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s16
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6 .

DrugDDI.d392.s16.e0 86 89
drug
drug
DrugDDI.d392.s16.e1 112 118
drug
P450 2D6

interaction DrugDDI.d392.s16.e0 DrugDDI.d392.s16.e1 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s18
Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs .

DrugDDI.d392.s18.e0 63 66
drug
drug
DrugDDI.d392.s18.e1 91 105
drug
anticholinergic
DrugDDI.d392.s18.e2 108 127
drug
sympathomimetic drugs

interaction DrugDDI.d392.s18.e0 DrugDDI.d392.s18.e1 true
interaction DrugDDI.d392.s18.e0 DrugDDI.d392.s18.e2 true
interaction DrugDDI.d392.s18.e1 DrugDDI.d392.s18.e2 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s20
Clinical experience in the concurrent administration of ECT and antidepressant drugs is limited.

DrugDDI.d392.s20.new.DISO.e1 49 51
DISO
ECT
DrugDDI.d392.s20.e0 55 73
drug
antidepressant drugs



Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s23
If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative / hypnotics , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam ) are additive.

DrugDDI.d392.s23.e0 2 25
drug
desipramine hydrochloride
DrugDDI.d392.s23.e1 49 66
drug
psychotropic agents
DrugDDI.d392.s23.e2 73 85
drug
tranquilizers
DrugDDI.d392.s23.e3 88 95
drug
sedative
DrugDDI.d392.s23.e4 97 105
drug
hypnotics
DrugDDI.d392.s23.e5 184 191
drug
sedative
DrugDDI.d392.s23.e6 201 211
drug
desipramine
DrugDDI.d392.s23.e7 215 229
drug
benzodiazepines
DrugDDI.d392.s23.e8 236 251
drug
chlordiazepoxide
DrugDDI.d392.s23.e9 254 261
drug
diazepam

interaction DrugDDI.d392.s23.e0 DrugDDI.d392.s23.e1 true
interaction DrugDDI.d392.s23.e0 DrugDDI.d392.s23.e2 true
interaction DrugDDI.d392.s23.e0 DrugDDI.d392.s23.e3 true
interaction DrugDDI.d392.s23.e0 DrugDDI.d392.s23.e4 true
interaction DrugDDI.d392.s23.e0 DrugDDI.d392.s23.e5 false
interaction DrugDDI.d392.s23.e0 DrugDDI.d392.s23.e6 false
interaction DrugDDI.d392.s23.e0 DrugDDI.d392.s23.e7 false
interaction DrugDDI.d392.s23.e0 DrugDDI.d392.s23.e8 false
interaction DrugDDI.d392.s23.e0 DrugDDI.d392.s23.e9 false
interaction DrugDDI.d392.s23.e1 DrugDDI.d392.s23.e2 false
interaction DrugDDI.d392.s23.e1 DrugDDI.d392.s23.e3 false
interaction DrugDDI.d392.s23.e1 DrugDDI.d392.s23.e4 false
interaction DrugDDI.d392.s23.e1 DrugDDI.d392.s23.e5 false
interaction DrugDDI.d392.s23.e1 DrugDDI.d392.s23.e6 false
interaction DrugDDI.d392.s23.e1 DrugDDI.d392.s23.e7 false
interaction DrugDDI.d392.s23.e1 DrugDDI.d392.s23.e8 false
interaction DrugDDI.d392.s23.e1 DrugDDI.d392.s23.e9 false
interaction DrugDDI.d392.s23.e2 DrugDDI.d392.s23.e3 false
interaction DrugDDI.d392.s23.e2 DrugDDI.d392.s23.e4 false
interaction DrugDDI.d392.s23.e2 DrugDDI.d392.s23.e5 false
interaction DrugDDI.d392.s23.e2 DrugDDI.d392.s23.e6 false
interaction DrugDDI.d392.s23.e2 DrugDDI.d392.s23.e7 false
interaction DrugDDI.d392.s23.e2 DrugDDI.d392.s23.e8 false
interaction DrugDDI.d392.s23.e2 DrugDDI.d392.s23.e9 false
interaction DrugDDI.d392.s23.e3 DrugDDI.d392.s23.e4 false
interaction DrugDDI.d392.s23.e3 DrugDDI.d392.s23.e5 false
interaction DrugDDI.d392.s23.e3 DrugDDI.d392.s23.e6 false
interaction DrugDDI.d392.s23.e3 DrugDDI.d392.s23.e7 false
interaction DrugDDI.d392.s23.e3 DrugDDI.d392.s23.e8 false
interaction DrugDDI.d392.s23.e3 DrugDDI.d392.s23.e9 false
interaction DrugDDI.d392.s23.e4 DrugDDI.d392.s23.e5 false
interaction DrugDDI.d392.s23.e4 DrugDDI.d392.s23.e6 false
interaction DrugDDI.d392.s23.e4 DrugDDI.d392.s23.e7 false
interaction DrugDDI.d392.s23.e4 DrugDDI.d392.s23.e8 false
interaction DrugDDI.d392.s23.e4 DrugDDI.d392.s23.e9 false
interaction DrugDDI.d392.s23.e5 DrugDDI.d392.s23.e6 false
interaction DrugDDI.d392.s23.e5 DrugDDI.d392.s23.e7 false
interaction DrugDDI.d392.s23.e5 DrugDDI.d392.s23.e8 false
interaction DrugDDI.d392.s23.e5 DrugDDI.d392.s23.e9 false
interaction DrugDDI.d392.s23.e6 DrugDDI.d392.s23.e7 false
interaction DrugDDI.d392.s23.e6 DrugDDI.d392.s23.e8 false
interaction DrugDDI.d392.s23.e6 DrugDDI.d392.s23.e9 false
interaction DrugDDI.d392.s23.e7 DrugDDI.d392.s23.e8 false
interaction DrugDDI.d392.s23.e7 DrugDDI.d392.s23.e9 false
interaction DrugDDI.d392.s23.e8 DrugDDI.d392.s23.e9 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s24
Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine .

DrugDDI.d392.s24.e0 7 14
drug
sedative
DrugDDI.d392.s24.e1 18 32
drug
anticholinergic
DrugDDI.d392.s24.e2 45 62
drug
major tranquilizers
DrugDDI.d392.s24.e3 87 97
drug
desipramine

interaction DrugDDI.d392.s24.e0 DrugDDI.d392.s24.e1 false
interaction DrugDDI.d392.s24.e0 DrugDDI.d392.s24.e2 false
interaction DrugDDI.d392.s24.e0 DrugDDI.d392.s24.e3 false
interaction DrugDDI.d392.s24.e1 DrugDDI.d392.s24.e2 false
interaction DrugDDI.d392.s24.e1 DrugDDI.d392.s24.e3 false
interaction DrugDDI.d392.s24.e2 DrugDDI.d392.s24.e3 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s26
Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants .

DrugDDI.d392.s26.e0 26 35
drug
cimetidine
DrugDDI.d392.s26.e1 39 62
drug
tricyclic antidepressants
DrugDDI.d392.s26.e2 125 148
drug
tricyclic antidepressants

interaction DrugDDI.d392.s26.e0 DrugDDI.d392.s26.e1 true
interaction DrugDDI.d392.s26.e0 DrugDDI.d392.s26.e2 false
interaction DrugDDI.d392.s26.e1 DrugDDI.d392.s26.e2 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s27
Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.

DrugDDI.d392.s27.e0 39 62
drug
tricyclic antidepressants
DrugDDI.d392.s27.e1 100 109
drug
cimetidine
DrugDDI.d392.s27.e2 162 184
drug
tricyclic antidepressant

interaction DrugDDI.d392.s27.e0 DrugDDI.d392.s27.e1 true
interaction DrugDDI.d392.s27.e0 DrugDDI.d392.s27.e2 false
interaction DrugDDI.d392.s27.e1 DrugDDI.d392.s27.e2 false

Abstract Id: DrugDDI.d392
Sentence Id: DrugDDI.d392.s28
There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.

DrugDDI.d392.s28.e0 73 96
drug
tricyclic antidepressants
DrugDDI.d392.s28.e1 101 110
drug
fluoxetine

interaction DrugDDI.d392.s28.e0 DrugDDI.d392.s28.e1 true

Abstract Id: DrugDDI.d298
Sentence Id: DrugDDI.d298.s0
General : In vitro studies in human liver microsomes demonstrated no evidence of cytochrome P450-mediated drug interactions that are likely to be of clinical relevance.

DrugDDI.d298.s0.e0 68 77
drug
cytochrome



Abstract Id: DrugDDI.d298
Sentence Id: DrugDDI.d298.s1
Anesthetics / Sedatives / Hypnotics / Opioids Co-administration of PRECEDEX with anesthetics , sedatives , hypnotics , and opioids is likely to lead to an enhancement of effects.

DrugDDI.d298.s1.e0 0 10
drug
Anesthetics
DrugDDI.d298.s1.e1 12 20
drug
Sedatives
DrugDDI.d298.s1.e2 22 30
drug
Hypnotics
DrugDDI.d298.s1.e3 32 38
drug
Opioids
DrugDDI.d298.s1.e4 58 65
drug
PRECEDEX
DrugDDI.d298.s1.e5 70 80
drug
anesthetics
DrugDDI.d298.s1.e6 82 90
drug
sedatives
DrugDDI.d298.s1.e7 92 100
drug
hypnotics
DrugDDI.d298.s1.e8 105 111
drug
opioids

interaction DrugDDI.d298.s1.e0 DrugDDI.d298.s1.e1 false
interaction DrugDDI.d298.s1.e0 DrugDDI.d298.s1.e2 false
interaction DrugDDI.d298.s1.e0 DrugDDI.d298.s1.e3 false
interaction DrugDDI.d298.s1.e0 DrugDDI.d298.s1.e4 false
interaction DrugDDI.d298.s1.e0 DrugDDI.d298.s1.e5 false
interaction DrugDDI.d298.s1.e0 DrugDDI.d298.s1.e6 false
interaction DrugDDI.d298.s1.e0 DrugDDI.d298.s1.e7 false
interaction DrugDDI.d298.s1.e0 DrugDDI.d298.s1.e8 false
interaction DrugDDI.d298.s1.e1 DrugDDI.d298.s1.e2 false
interaction DrugDDI.d298.s1.e1 DrugDDI.d298.s1.e3 false
interaction DrugDDI.d298.s1.e1 DrugDDI.d298.s1.e4 false
interaction DrugDDI.d298.s1.e1 DrugDDI.d298.s1.e5 false
interaction DrugDDI.d298.s1.e1 DrugDDI.d298.s1.e6 false
interaction DrugDDI.d298.s1.e1 DrugDDI.d298.s1.e7 false
interaction DrugDDI.d298.s1.e1 DrugDDI.d298.s1.e8 false
interaction DrugDDI.d298.s1.e2 DrugDDI.d298.s1.e3 false
interaction DrugDDI.d298.s1.e2 DrugDDI.d298.s1.e4 false
interaction DrugDDI.d298.s1.e2 DrugDDI.d298.s1.e5 false
interaction DrugDDI.d298.s1.e2 DrugDDI.d298.s1.e6 false
interaction DrugDDI.d298.s1.e2 DrugDDI.d298.s1.e7 false
interaction DrugDDI.d298.s1.e2 DrugDDI.d298.s1.e8 false
interaction DrugDDI.d298.s1.e3 DrugDDI.d298.s1.e4 false
interaction DrugDDI.d298.s1.e3 DrugDDI.d298.s1.e5 false
interaction DrugDDI.d298.s1.e3 DrugDDI.d298.s1.e6 false
interaction DrugDDI.d298.s1.e3 DrugDDI.d298.s1.e7 false
interaction DrugDDI.d298.s1.e3 DrugDDI.d298.s1.e8 false
interaction DrugDDI.d298.s1.e4 DrugDDI.d298.s1.e5 true
interaction DrugDDI.d298.s1.e4 DrugDDI.d298.s1.e6 true
interaction DrugDDI.d298.s1.e4 DrugDDI.d298.s1.e7 true
interaction DrugDDI.d298.s1.e4 DrugDDI.d298.s1.e8 true
interaction DrugDDI.d298.s1.e5 DrugDDI.d298.s1.e6 false
interaction DrugDDI.d298.s1.e5 DrugDDI.d298.s1.e7 false
interaction DrugDDI.d298.s1.e5 DrugDDI.d298.s1.e8 false
interaction DrugDDI.d298.s1.e6 DrugDDI.d298.s1.e7 false
interaction DrugDDI.d298.s1.e6 DrugDDI.d298.s1.e8 false
interaction DrugDDI.d298.s1.e7 DrugDDI.d298.s1.e8 false

Abstract Id: DrugDDI.d298
Sentence Id: DrugDDI.d298.s2
Specific studies have confirmed these effects with sevoflurane , isoflurane , propofol , alfentanil , and midazolam .

DrugDDI.d298.s2.e0 44 54
drug
sevoflurane
DrugDDI.d298.s2.e1 56 65
drug
isoflurane
DrugDDI.d298.s2.e2 67 74
drug
propofol
DrugDDI.d298.s2.e3 76 85
drug
alfentanil
DrugDDI.d298.s2.e4 90 98
drug
midazolam

interaction DrugDDI.d298.s2.e0 DrugDDI.d298.s2.e1 false
interaction DrugDDI.d298.s2.e0 DrugDDI.d298.s2.e2 false
interaction DrugDDI.d298.s2.e0 DrugDDI.d298.s2.e3 false
interaction DrugDDI.d298.s2.e0 DrugDDI.d298.s2.e4 false
interaction DrugDDI.d298.s2.e1 DrugDDI.d298.s2.e2 false
interaction DrugDDI.d298.s2.e1 DrugDDI.d298.s2.e3 false
interaction DrugDDI.d298.s2.e1 DrugDDI.d298.s2.e4 false
interaction DrugDDI.d298.s2.e2 DrugDDI.d298.s2.e3 false
interaction DrugDDI.d298.s2.e2 DrugDDI.d298.s2.e4 false
interaction DrugDDI.d298.s2.e3 DrugDDI.d298.s2.e4 false

Abstract Id: DrugDDI.d298
Sentence Id: DrugDDI.d298.s3
No pharmacokinetic interactions between dexmedetomidine and isoflurane , propofol , alfentanil , and midazolam have been demonstrated.

DrugDDI.d298.s3.e0 36 50
drug
dexmedetomidine
DrugDDI.d298.s3.e1 54 63
drug
isoflurane
DrugDDI.d298.s3.e2 65 72
drug
propofol
DrugDDI.d298.s3.e3 74 83
drug
alfentanil
DrugDDI.d298.s3.e4 88 96
drug
midazolam

interaction DrugDDI.d298.s3.e0 DrugDDI.d298.s3.e1 false
interaction DrugDDI.d298.s3.e0 DrugDDI.d298.s3.e2 false
interaction DrugDDI.d298.s3.e0 DrugDDI.d298.s3.e3 false
interaction DrugDDI.d298.s3.e0 DrugDDI.d298.s3.e4 false
interaction DrugDDI.d298.s3.e1 DrugDDI.d298.s3.e2 false
interaction DrugDDI.d298.s3.e1 DrugDDI.d298.s3.e3 false
interaction DrugDDI.d298.s3.e1 DrugDDI.d298.s3.e4 false
interaction DrugDDI.d298.s3.e2 DrugDDI.d298.s3.e3 false
interaction DrugDDI.d298.s3.e2 DrugDDI.d298.s3.e4 false
interaction DrugDDI.d298.s3.e3 DrugDDI.d298.s3.e4 false

Abstract Id: DrugDDI.d298
Sentence Id: DrugDDI.d298.s4
However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX , a reduction in dosage of PRECEDEX on the concomitant anesthetic , sedative, hypnotic or opioid may be required.

DrugDDI.d298.s4.e0 72 79
drug
PRECEDEX
DrugDDI.d298.s4.e1 101 108
drug
PRECEDEX
DrugDDI.d298.s4.e2 125 134
drug
anesthetic
DrugDDI.d298.s4.e3 145 152
drug
hypnotic
DrugDDI.d298.s4.e4 155 160
drug
opioid

interaction DrugDDI.d298.s4.e0 DrugDDI.d298.s4.e1 false
interaction DrugDDI.d298.s4.e0 DrugDDI.d298.s4.e2 true
interaction DrugDDI.d298.s4.e0 DrugDDI.d298.s4.e3 true
interaction DrugDDI.d298.s4.e0 DrugDDI.d298.s4.e4 true
interaction DrugDDI.d298.s4.e1 DrugDDI.d298.s4.e2 false
interaction DrugDDI.d298.s4.e1 DrugDDI.d298.s4.e3 false
interaction DrugDDI.d298.s4.e1 DrugDDI.d298.s4.e4 false
interaction DrugDDI.d298.s4.e2 DrugDDI.d298.s4.e3 false
interaction DrugDDI.d298.s4.e2 DrugDDI.d298.s4.e4 false
interaction DrugDDI.d298.s4.e3 DrugDDI.d298.s4.e4 false

Abstract Id: DrugDDI.d298
Sentence Id: DrugDDI.d298.s5
Neuromuscular Blockers : In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.

DrugDDI.d298.s5.e0 0 20
drug
Neuromuscular Blockers
DrugDDI.d298.s5.e1 70 77
drug
PRECEDEX
DrugDDI.d298.s5.e2 217 226
drug
rocuronium

interaction DrugDDI.d298.s5.e0 DrugDDI.d298.s5.e1 false
interaction DrugDDI.d298.s5.e0 DrugDDI.d298.s5.e2 false
interaction DrugDDI.d298.s5.e1 DrugDDI.d298.s5.e2 false

Abstract Id: DrugDDI.d15
Sentence Id: DrugDDI.d15.s0
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol ), corticosteroids (increased effect of corticosteroids ).

DrugDDI.d15.s0.e0 11 24
drug
anticoagulants
DrugDDI.d15.s0.e1 61 72
drug
barbiturates
DrugDDI.d15.s0.e2 74 81
drug
rifampin
DrugDDI.d15.s0.e3 107 122
drug
microsomal enzyme
DrugDDI.d15.s0.e4 156 173
drug
diethylstilbestrol
DrugDDI.d15.s0.e5 176 190
drug
corticosteroids
DrugDDI.d15.s0.e6 209 223
drug
corticosteroids

interaction DrugDDI.d15.s0.e0 DrugDDI.d15.s0.e1 false
interaction DrugDDI.d15.s0.e0 DrugDDI.d15.s0.e2 false
interaction DrugDDI.d15.s0.e0 DrugDDI.d15.s0.e3 false
interaction DrugDDI.d15.s0.e0 DrugDDI.d15.s0.e4 false
interaction DrugDDI.d15.s0.e0 DrugDDI.d15.s0.e5 false
interaction DrugDDI.d15.s0.e0 DrugDDI.d15.s0.e6 false
interaction DrugDDI.d15.s0.e1 DrugDDI.d15.s0.e2 false
interaction DrugDDI.d15.s0.e1 DrugDDI.d15.s0.e3 false
interaction DrugDDI.d15.s0.e1 DrugDDI.d15.s0.e4 false
interaction DrugDDI.d15.s0.e1 DrugDDI.d15.s0.e5 false
interaction DrugDDI.d15.s0.e1 DrugDDI.d15.s0.e6 false
interaction DrugDDI.d15.s0.e2 DrugDDI.d15.s0.e3 false
interaction DrugDDI.d15.s0.e2 DrugDDI.d15.s0.e4 false
interaction DrugDDI.d15.s0.e2 DrugDDI.d15.s0.e5 false
interaction DrugDDI.d15.s0.e2 DrugDDI.d15.s0.e6 false
interaction DrugDDI.d15.s0.e3 DrugDDI.d15.s0.e4 false
interaction DrugDDI.d15.s0.e3 DrugDDI.d15.s0.e5 false
interaction DrugDDI.d15.s0.e3 DrugDDI.d15.s0.e6 false
interaction DrugDDI.d15.s0.e4 DrugDDI.d15.s0.e5 false
interaction DrugDDI.d15.s0.e4 DrugDDI.d15.s0.e6 false
interaction DrugDDI.d15.s0.e5 DrugDDI.d15.s0.e6 false

Abstract Id: DrugDDI.d62
Sentence Id: DrugDDI.d62.s0
Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.

DrugDDI.d62.s0.e0 16 32
drug
thiazide diuretics
DrugDDI.d62.s0.new.DISO.e2 35 49
DISO
hypoparathyroid
DrugDDI.d62.s0.e1 92 109
drug
dihydrotachysterol
DrugDDI.d62.s0.new.DISO.e3 118 130
DISO
hypercalcemia

interaction DrugDDI.d62.s0.e0 DrugDDI.d62.s0.e1 false

Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s0
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants ( hypnotics , sedatives , tranquilizers , etc).

DrugDDI.d337.s0.e0 0 27
drug
Diphenhydramine hydrochloride
DrugDDI.d337.s0.e1 50 56
drug
alcohol
DrugDDI.d337.s0.e2 65 78
drug
CNS depressants
DrugDDI.d337.s0.e3 80 88
drug
hypnotics
DrugDDI.d337.s0.e4 90 98
drug
sedatives
DrugDDI.d337.s0.e5 100 112
drug
tranquilizers

interaction DrugDDI.d337.s0.e0 DrugDDI.d337.s0.e1 false
interaction DrugDDI.d337.s0.e0 DrugDDI.d337.s0.e2 false
interaction DrugDDI.d337.s0.e0 DrugDDI.d337.s0.e3 false
interaction DrugDDI.d337.s0.e0 DrugDDI.d337.s0.e4 false
interaction DrugDDI.d337.s0.e0 DrugDDI.d337.s0.e5 false
interaction DrugDDI.d337.s0.e1 DrugDDI.d337.s0.e2 false
interaction DrugDDI.d337.s0.e1 DrugDDI.d337.s0.e3 false
interaction DrugDDI.d337.s0.e1 DrugDDI.d337.s0.e4 false
interaction DrugDDI.d337.s0.e1 DrugDDI.d337.s0.e5 false
interaction DrugDDI.d337.s0.e2 DrugDDI.d337.s0.e3 false
interaction DrugDDI.d337.s0.e2 DrugDDI.d337.s0.e4 false
interaction DrugDDI.d337.s0.e2 DrugDDI.d337.s0.e5 false
interaction DrugDDI.d337.s0.e3 DrugDDI.d337.s0.e4 false
interaction DrugDDI.d337.s0.e3 DrugDDI.d337.s0.e5 false
interaction DrugDDI.d337.s0.e4 DrugDDI.d337.s0.e5 false

Abstract Id: DrugDDI.d337
Sentence Id: DrugDDI.d337.s1
MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines .

DrugDDI.d337.s1.e0 0 12
drug
MAO inhibitors
DrugDDI.d337.s1.e1 35 49
drug
anticholinergic
DrugDDI.d337.s1.e2 67 80
drug
antihistamines

interaction DrugDDI.d337.s1.e0 DrugDDI.d337.s1.e1 false
interaction DrugDDI.d337.s1.e0 DrugDDI.d337.s1.e2 false
interaction DrugDDI.d337.s1.e1 DrugDDI.d337.s1.e2 false

Abstract Id: DrugDDI.d189
Sentence Id: DrugDDI.d189.s0
CNS depression@producing medications - concurrent use may potentiate the effects of either these medications or diphenidol ; .

DrugDDI.d189.s0.e0 84 94
drug
medications
DrugDDI.d189.s0.e1 97 106
drug
diphenidol

interaction DrugDDI.d189.s0.e0 DrugDDI.d189.s0.e1 false

Abstract Id: DrugDDI.d189
Sentence Id: DrugDDI.d189.s1
anticholinergics or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with diphenidol ; .

DrugDDI.d189.s1.e0 0 15
drug
anticholinergics
DrugDDI.d189.s1.e1 18 33
drug
other medications
DrugDDI.d189.s1.e2 38 52
drug
anticholinergic
DrugDDI.d189.s1.e3 109 119
drug
medications
DrugDDI.d189.s1.e4 143 152
drug
diphenidol

interaction DrugDDI.d189.s1.e0 DrugDDI.d189.s1.e1 false
interaction DrugDDI.d189.s1.e0 DrugDDI.d189.s1.e2 false
interaction DrugDDI.d189.s1.e0 DrugDDI.d189.s1.e3 false
interaction DrugDDI.d189.s1.e0 DrugDDI.d189.s1.e4 false
interaction DrugDDI.d189.s1.e1 DrugDDI.d189.s1.e2 false
interaction DrugDDI.d189.s1.e1 DrugDDI.d189.s1.e3 false
interaction DrugDDI.d189.s1.e1 DrugDDI.d189.s1.e4 false
interaction DrugDDI.d189.s1.e2 DrugDDI.d189.s1.e3 false
interaction DrugDDI.d189.s1.e2 DrugDDI.d189.s1.e4 false
interaction DrugDDI.d189.s1.e3 DrugDDI.d189.s1.e4 true

Abstract Id: DrugDDI.d189
Sentence Id: DrugDDI.d189.s2
apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.

DrugDDI.d189.s2.e0 0 10
drug
apomorphine
DrugDDI.d189.s2.e1 28 37
drug
diphenidol
DrugDDI.d189.s2.e2 52 57
drug
emetic
DrugDDI.d189.s2.e3 68 78
drug
apomorphine

interaction DrugDDI.d189.s2.e0 DrugDDI.d189.s2.e1 false
interaction DrugDDI.d189.s2.e0 DrugDDI.d189.s2.e2 false
interaction DrugDDI.d189.s2.e0 DrugDDI.d189.s2.e3 false
interaction DrugDDI.d189.s2.e1 DrugDDI.d189.s2.e2 false
interaction DrugDDI.d189.s2.e1 DrugDDI.d189.s2.e3 true
interaction DrugDDI.d189.s2.e2 DrugDDI.d189.s2.e3 false

Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s0
Known drug interactions include barbiturates , tranquilizers , and alcohol .

DrugDDI.d448.s0.e0 28 39
drug
barbiturates
DrugDDI.d448.s0.e1 41 53
drug
tranquilizers
DrugDDI.d448.s0.e2 58 64
drug
alcohol

interaction DrugDDI.d448.s0.e0 DrugDDI.d448.s0.e1 false
interaction DrugDDI.d448.s0.e0 DrugDDI.d448.s0.e2 false
interaction DrugDDI.d448.s0.e1 DrugDDI.d448.s0.e2 false

Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s1
Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.

DrugDDI.d448.s1.e0 0 15
drug
Diphenoxylate HCl
DrugDDI.d448.s1.e1 19 33
drug
atropine sulfate
DrugDDI.d448.s1.e2 49 61
drug
MAO inhibitors
DrugDDI.d448.s1.e3 84 109
drug
diphenoxylate hydrochloride
DrugDDI.d448.s1.e4 137 152
drug
microsomal enzyme

interaction DrugDDI.d448.s1.e0 DrugDDI.d448.s1.e1 false
interaction DrugDDI.d448.s1.e0 DrugDDI.d448.s1.e2 true
interaction DrugDDI.d448.s1.e0 DrugDDI.d448.s1.e3 false
interaction DrugDDI.d448.s1.e0 DrugDDI.d448.s1.e4 false
interaction DrugDDI.d448.s1.e1 DrugDDI.d448.s1.e2 true
interaction DrugDDI.d448.s1.e1 DrugDDI.d448.s1.e3 false
interaction DrugDDI.d448.s1.e1 DrugDDI.d448.s1.e4 false
interaction DrugDDI.d448.s1.e2 DrugDDI.d448.s1.e3 false
interaction DrugDDI.d448.s1.e2 DrugDDI.d448.s1.e4 false
interaction DrugDDI.d448.s1.e3 DrugDDI.d448.s1.e4 false

Abstract Id: DrugDDI.d448
Sentence Id: DrugDDI.d448.s2
Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.

DrugDDI.d448.s2.e0 10 22
drug
diphenoxylate
DrugDDI.d448.s2.e1 72 76
drug
drugs
DrugDDI.d448.s2.e2 121 134
drug
microsomal drug

interaction DrugDDI.d448.s2.e0 DrugDDI.d448.s2.e1 true
interaction DrugDDI.d448.s2.e0 DrugDDI.d448.s2.e2 false
interaction DrugDDI.d448.s2.e1 DrugDDI.d448.s2.e2 false

Abstract Id: DrugDDI.d383
Sentence Id: DrugDDI.d383.s0
Disulfiram appears to decrease the rate at which certain drugs are metabolized and therefore may increase the blood levels and the possibility of clinical toxicity of drugs given concomitantly.

DrugDDI.d383.s0.e0 0 9
drug
Disulfiram
DrugDDI.d383.s0.e1 48 52
drug
drugs
DrugDDI.d383.s0.e2 141 145
drug
drugs

interaction DrugDDI.d383.s0.e0 DrugDDI.d383.s0.e1 false
interaction DrugDDI.d383.s0.e0 DrugDDI.d383.s0.e2 false
interaction DrugDDI.d383.s0.e1 DrugDDI.d383.s0.e2 false

Abstract Id: DrugDDI.d383
Sentence Id: DrugDDI.d383.s1
DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENER S.

DrugDDI.d383.s1.e0 0 9
drug
DISULFIRAM
DrugDDI.d383.s1.e1 57 65
drug
PHENYTOIN
DrugDDI.d383.s1.e2 72 79
drug
CONGENER

interaction DrugDDI.d383.s1.e0 DrugDDI.d383.s1.e1 false
interaction DrugDDI.d383.s1.e0 DrugDDI.d383.s1.e2 false
interaction DrugDDI.d383.s1.e1 DrugDDI.d383.s1.e2 false

Abstract Id: DrugDDI.d383
Sentence Id: DrugDDI.d383.s2
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.

DrugDDI.d383.s2.e0 43 47
drug
DRUGS
DrugDDI.d383.s2.e1 99 108
drug
DISULFIRAM
DrugDDI.d383.s2.e2 121 129
drug
PHENYTOIN

interaction DrugDDI.d383.s2.e0 DrugDDI.d383.s2.e1 false
interaction DrugDDI.d383.s2.e0 DrugDDI.d383.s2.e2 false
interaction DrugDDI.d383.s2.e1 DrugDDI.d383.s2.e2 false

Abstract Id: DrugDDI.d383
Sentence Id: DrugDDI.d383.s4
SERUM LEVELS OF PHENYTOIN SHOULD BE DETERMINED ON DIFFERENT DAYS FOR EVIDENCE OF AN INCREASE OR FOR A CONTINUING RISE IN LEVELS.

DrugDDI.d383.s4.e0 13 21
drug
PHENYTOIN



Abstract Id: DrugDDI.d383
Sentence Id: DrugDDI.d383.s6
It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram . since disulfiram may prolong prothrombin time.

DrugDDI.d383.s6.e0 35 52
drug
oral anticoagulants
DrugDDI.d383.s6.e1 76 85
drug
disulfiram
DrugDDI.d383.s6.e2 92 101
drug
disulfiram

interaction DrugDDI.d383.s6.e0 DrugDDI.d383.s6.e1 false
interaction DrugDDI.d383.s6.e0 DrugDDI.d383.s6.e2 false
interaction DrugDDI.d383.s6.e1 DrugDDI.d383.s6.e2 false

Abstract Id: DrugDDI.d383
Sentence Id: DrugDDI.d383.s7
Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status; .

DrugDDI.d383.s7.e0 14 22
drug
isoniazid
DrugDDI.d383.s7.e1 27 36
drug
disulfiram

interaction DrugDDI.d383.s7.e0 DrugDDI.d383.s7.e1 false

Abstract Id: DrugDDI.d383
Sentence Id: DrugDDI.d383.s8
the disulfiram should be discontinued if such signs appear.

DrugDDI.d383.s8.e0 3 12
drug
disulfiram



Abstract Id: DrugDDI.d383
Sentence Id: DrugDDI.d383.s9
In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.

DrugDDI.d383.s9.e0 30 39
drug
disulfiram
DrugDDI.d383.s9.e1 43 49
drug
nitrite
DrugDDI.d383.s9.new.DISO.e4 91 96
DISO
tumors
DrugDDI.d383.s9.e2 123 132
drug
disulfiram
DrugDDI.d383.s9.e3 145 152
drug
nitrites

interaction DrugDDI.d383.s9.e0 DrugDDI.d383.s9.e1 false
interaction DrugDDI.d383.s9.e0 DrugDDI.d383.s9.e2 false
interaction DrugDDI.d383.s9.e0 DrugDDI.d383.s9.e3 false
interaction DrugDDI.d383.s9.e1 DrugDDI.d383.s9.e2 false
interaction DrugDDI.d383.s9.e1 DrugDDI.d383.s9.e3 false
interaction DrugDDI.d383.s9.e2 DrugDDI.d383.s9.e3 false

Abstract Id: DrugDDI.d383
Sentence Id: DrugDDI.d383.s10
Disulfiram alone in the rat@s diet did not lead to such tumors.

DrugDDI.d383.s10.e0 0 9
drug
Disulfiram
DrugDDI.d383.s10.new.DISO.e1 45 50
DISO
tumors



Abstract Id: DrugDDI.d106
Sentence Id: DrugDDI.d106.s0
There have been no formal clinical studies to evaluate the drug interactions of TAXOTERE with other medications .

DrugDDI.d106.s0.e0 67 74
drug
TAXOTERE
DrugDDI.d106.s0.e1 79 94
drug
other medications

interaction DrugDDI.d106.s0.e0 DrugDDI.d106.s0.e1 false

Abstract Id: DrugDDI.d106
Sentence Id: DrugDDI.d106.s1
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4 , such as cyclosporine , terfenadine , ketoconazole , erythromycin , and troleandomycin .

DrugDDI.d106.s1.e0 42 50
drug
docetaxel
DrugDDI.d106.s1.e1 142 158
drug
cytochrome P450 3A4
DrugDDI.d106.s1.e2 166 177
drug
cyclosporine
DrugDDI.d106.s1.e3 179 189
drug
terfenadine
DrugDDI.d106.s1.e4 191 202
drug
ketoconazole
DrugDDI.d106.s1.e5 204 215
drug
erythromycin
DrugDDI.d106.s1.e6 220 233
drug
troleandomycin

interaction DrugDDI.d106.s1.e0 DrugDDI.d106.s1.e1 true
interaction DrugDDI.d106.s1.e0 DrugDDI.d106.s1.e2 true
interaction DrugDDI.d106.s1.e0 DrugDDI.d106.s1.e3 true
interaction DrugDDI.d106.s1.e0 DrugDDI.d106.s1.e4 true
interaction DrugDDI.d106.s1.e0 DrugDDI.d106.s1.e5 true
interaction DrugDDI.d106.s1.e0 DrugDDI.d106.s1.e6 true
interaction DrugDDI.d106.s1.e1 DrugDDI.d106.s1.e2 false
interaction DrugDDI.d106.s1.e1 DrugDDI.d106.s1.e3 false
interaction DrugDDI.d106.s1.e1 DrugDDI.d106.s1.e4 false
interaction DrugDDI.d106.s1.e1 DrugDDI.d106.s1.e5 false
interaction DrugDDI.d106.s1.e1 DrugDDI.d106.s1.e6 false
interaction DrugDDI.d106.s1.e2 DrugDDI.d106.s1.e3 false
interaction DrugDDI.d106.s1.e2 DrugDDI.d106.s1.e4 false
interaction DrugDDI.d106.s1.e2 DrugDDI.d106.s1.e5 false
interaction DrugDDI.d106.s1.e2 DrugDDI.d106.s1.e6 false
interaction DrugDDI.d106.s1.e3 DrugDDI.d106.s1.e4 false
interaction DrugDDI.d106.s1.e3 DrugDDI.d106.s1.e5 false
interaction DrugDDI.d106.s1.e3 DrugDDI.d106.s1.e6 false
interaction DrugDDI.d106.s1.e4 DrugDDI.d106.s1.e5 false
interaction DrugDDI.d106.s1.e4 DrugDDI.d106.s1.e6 false
interaction DrugDDI.d106.s1.e5 DrugDDI.d106.s1.e6 false

Abstract Id: DrugDDI.d106
Sentence Id: DrugDDI.d106.s2
Caution should be exercised with these drugs when treating patients receiving TAXOTERE as there is a potential for a significant interaction.

DrugDDI.d106.s2.e0 33 37
drug
drugs
DrugDDI.d106.s2.e1 67 74
drug
TAXOTERE

interaction DrugDDI.d106.s2.e0 DrugDDI.d106.s2.e1 true

Abstract Id: DrugDDI.d212
Sentence Id: DrugDDI.d212.s0
Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics , bronchodilators , enzyme supplements, vitamins , oral or inhaled corticosteroids , and analgesics .

DrugDDI.d212.s0.e0 31 39
drug
Pulmozyme
DrugDDI.d212.s0.new.DISO.e6 94 107
DISO
cystic fibrosis
DrugDDI.d212.s0.e1 154 164
drug
antibiotics
DrugDDI.d212.s0.e2 166 180
drug
bronchodilators
DrugDDI.d212.s0.e3 200 207
drug
vitamins
DrugDDI.d212.s0.e4 222 236
drug
corticosteroids
DrugDDI.d212.s0.e5 241 250
drug
analgesics

interaction DrugDDI.d212.s0.e0 DrugDDI.d212.s0.e1 false
interaction DrugDDI.d212.s0.e0 DrugDDI.d212.s0.e2 false
interaction DrugDDI.d212.s0.e0 DrugDDI.d212.s0.e3 false
interaction DrugDDI.d212.s0.e0 DrugDDI.d212.s0.e4 false
interaction DrugDDI.d212.s0.e0 DrugDDI.d212.s0.e5 false
interaction DrugDDI.d212.s0.e1 DrugDDI.d212.s0.e2 false
interaction DrugDDI.d212.s0.e1 DrugDDI.d212.s0.e3 false
interaction DrugDDI.d212.s0.e1 DrugDDI.d212.s0.e4 false
interaction DrugDDI.d212.s0.e1 DrugDDI.d212.s0.e5 false
interaction DrugDDI.d212.s0.e2 DrugDDI.d212.s0.e3 false
interaction DrugDDI.d212.s0.e2 DrugDDI.d212.s0.e4 false
interaction DrugDDI.d212.s0.e2 DrugDDI.d212.s0.e5 false
interaction DrugDDI.d212.s0.e3 DrugDDI.d212.s0.e4 false
interaction DrugDDI.d212.s0.e3 DrugDDI.d212.s0.e5 false
interaction DrugDDI.d212.s0.e4 DrugDDI.d212.s0.e5 false

Abstract Id: DrugDDI.d43
Sentence Id: DrugDDI.d43.s0
Prior administration of succinylcholine has no clinically important effect on the neuromuscular blocking action of NUROMAX .

DrugDDI.d43.s0.e0 21 35
drug
succinylcholine
DrugDDI.d43.s0.e1 100 106
drug
NUROMAX

interaction DrugDDI.d43.s0.e0 DrugDDI.d43.s0.e1 false

Abstract Id: DrugDDI.d43
Sentence Id: DrugDDI.d43.s1
The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.

DrugDDI.d43.s1.e0 8 14
drug
NUROMAX
DrugDDI.d43.s1.e1 21 35
drug
succinylcholine
DrugDDI.d43.s1.e2 69 83
drug
succinylcholine

interaction DrugDDI.d43.s1.e0 DrugDDI.d43.s1.e1 false
interaction DrugDDI.d43.s1.e0 DrugDDI.d43.s1.e2 false
interaction DrugDDI.d43.s1.e1 DrugDDI.d43.s1.e2 false

Abstract Id: DrugDDI.d43
Sentence Id: DrugDDI.d43.s2
There are no clinical data on concomitant use of NUROMAX and other nondepolarizing neuromuscular blocking agents .

DrugDDI.d43.s2.e0 40 46
drug
NUROMAX
DrugDDI.d43.s2.e1 70 96
drug
neuromuscular blocking agents

interaction DrugDDI.d43.s2.e0 DrugDDI.d43.s2.e1 false

Abstract Id: DrugDDI.d43
Sentence Id: DrugDDI.d43.s3
Isoflurane , enflurane , and halothane decrease the ED50 of NUROMAX by 30% to 45%.

DrugDDI.d43.s3.e0 0 9
drug
Isoflurane
DrugDDI.d43.s3.e1 11 19
drug
enflurane
DrugDDI.d43.s3.e2 24 32
drug
halothane
DrugDDI.d43.s3.e3 50 56
drug
NUROMAX

interaction DrugDDI.d43.s3.e0 DrugDDI.d43.s3.e1 false
interaction DrugDDI.d43.s3.e0 DrugDDI.d43.s3.e2 false
interaction DrugDDI.d43.s3.e0 DrugDDI.d43.s3.e3 true
interaction DrugDDI.d43.s3.e1 DrugDDI.d43.s3.e2 false
interaction DrugDDI.d43.s3.e1 DrugDDI.d43.s3.e3 true
interaction DrugDDI.d43.s3.e2 DrugDDI.d43.s3.e3 true

Abstract Id: DrugDDI.d43
Sentence Id: DrugDDI.d43.s5
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agent s such as NUROMAX include certain antibiotics (e. g., aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate), magnesium salt s, lithium , local anesthetics , procainamide , and quinidine .

DrugDDI.d43.s5.e0 5 9
drug
drugs
DrugDDI.d43.s5.e1 57 76
drug
nondepolarizing agent
DrugDDI.d43.s5.e2 84 90
drug
NUROMAX
DrugDDI.d43.s5.e3 105 115
drug
antibiotics
DrugDDI.d43.s5.e4 122 136
drug
aminoglycosides
DrugDDI.d43.s5.e5 138 150
drug
tetracyclines
DrugDDI.d43.s5.e6 152 161
drug
bacitracin
DrugDDI.d43.s5.e7 163 172
drug
polymyxins
DrugDDI.d43.s5.e8 174 183
drug
lincomycin
DrugDDI.d43.s5.e9 185 195
drug
clindamycin
DrugDDI.d43.s5.e10 197 204
drug
colistin
DrugDDI.d43.s5.e11 209 214
drug
sodium
DrugDDI.d43.s5.e12 231 243
drug
magnesium salt
DrugDDI.d43.s5.e13 246 252
drug
lithium
DrugDDI.d43.s5.e14 254 269
drug
local anesthetics
DrugDDI.d43.s5.e15 271 282
drug
procainamide
DrugDDI.d43.s5.e16 287 295
drug
quinidine

interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e1 true
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e2 true
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e3 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e4 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e5 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e6 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e7 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e8 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e9 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e10 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e11 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e12 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e0 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e2 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e3 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e4 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e5 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e6 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e7 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e8 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e9 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e10 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e11 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e12 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e1 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e3 false
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e4 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e5 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e6 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e7 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e8 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e9 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e10 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e11 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e12 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e13 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e14 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e15 true
interaction DrugDDI.d43.s5.e2 DrugDDI.d43.s5.e16 true
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e4 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e5 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e6 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e7 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e8 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e9 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e10 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e11 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e12 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e3 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e5 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e6 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e7 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e8 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e9 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e10 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e11 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e12 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e4 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e5 DrugDDI.d43.s5.e6 false
interaction DrugDDI.d43.s5.e5 DrugDDI.d43.s5.e7 false
interaction DrugDDI.d43.s5.e5 DrugDDI.d43.s5.e8 false
interaction DrugDDI.d43.s5.e5 DrugDDI.d43.s5.e9 false
interaction DrugDDI.d43.s5.e5 DrugDDI.d43.s5.e10 false
interaction DrugDDI.d43.s5.e5 DrugDDI.d43.s5.e11 false
interaction DrugDDI.d43.s5.e5 DrugDDI.d43.s5.e12 false
interaction DrugDDI.d43.s5.e5 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e5 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e5 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e5 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e6 DrugDDI.d43.s5.e7 false
interaction DrugDDI.d43.s5.e6 DrugDDI.d43.s5.e8 false
interaction DrugDDI.d43.s5.e6 DrugDDI.d43.s5.e9 false
interaction DrugDDI.d43.s5.e6 DrugDDI.d43.s5.e10 false
interaction DrugDDI.d43.s5.e6 DrugDDI.d43.s5.e11 false
interaction DrugDDI.d43.s5.e6 DrugDDI.d43.s5.e12 false
interaction DrugDDI.d43.s5.e6 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e6 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e6 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e6 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e7 DrugDDI.d43.s5.e8 false
interaction DrugDDI.d43.s5.e7 DrugDDI.d43.s5.e9 false
interaction DrugDDI.d43.s5.e7 DrugDDI.d43.s5.e10 false
interaction DrugDDI.d43.s5.e7 DrugDDI.d43.s5.e11 false
interaction DrugDDI.d43.s5.e7 DrugDDI.d43.s5.e12 false
interaction DrugDDI.d43.s5.e7 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e7 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e7 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e7 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e8 DrugDDI.d43.s5.e9 false
interaction DrugDDI.d43.s5.e8 DrugDDI.d43.s5.e10 false
interaction DrugDDI.d43.s5.e8 DrugDDI.d43.s5.e11 false
interaction DrugDDI.d43.s5.e8 DrugDDI.d43.s5.e12 false
interaction DrugDDI.d43.s5.e8 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e8 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e8 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e8 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e9 DrugDDI.d43.s5.e10 false
interaction DrugDDI.d43.s5.e9 DrugDDI.d43.s5.e11 false
interaction DrugDDI.d43.s5.e9 DrugDDI.d43.s5.e12 false
interaction DrugDDI.d43.s5.e9 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e9 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e9 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e9 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e10 DrugDDI.d43.s5.e11 false
interaction DrugDDI.d43.s5.e10 DrugDDI.d43.s5.e12 false
interaction DrugDDI.d43.s5.e10 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e10 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e10 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e10 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e11 DrugDDI.d43.s5.e12 false
interaction DrugDDI.d43.s5.e11 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e11 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e11 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e11 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e12 DrugDDI.d43.s5.e13 false
interaction DrugDDI.d43.s5.e12 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e12 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e12 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e13 DrugDDI.d43.s5.e14 false
interaction DrugDDI.d43.s5.e13 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e13 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e14 DrugDDI.d43.s5.e15 false
interaction DrugDDI.d43.s5.e14 DrugDDI.d43.s5.e16 false
interaction DrugDDI.d43.s5.e15 DrugDDI.d43.s5.e16 false

Abstract Id: DrugDDI.d43
Sentence Id: DrugDDI.d43.s6
As with some other nondepolarizing neuromuscular blocking agents , the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine .

DrugDDI.d43.s6.e0 30 56
drug
neuromuscular blocking agents
DrugDDI.d43.s6.e1 101 107
drug
NUROMAX
DrugDDI.d43.s6.e2 171 179
drug
phenytoin
DrugDDI.d43.s6.e3 182 194
drug
carbamazepine

interaction DrugDDI.d43.s6.e0 DrugDDI.d43.s6.e1 false
interaction DrugDDI.d43.s6.e0 DrugDDI.d43.s6.e2 true
interaction DrugDDI.d43.s6.e0 DrugDDI.d43.s6.e3 true
interaction DrugDDI.d43.s6.e1 DrugDDI.d43.s6.e2 true
interaction DrugDDI.d43.s6.e1 DrugDDI.d43.s6.e3 true
interaction DrugDDI.d43.s6.e2 DrugDDI.d43.s6.e3 false

Abstract Id: DrugDDI.d55
Sentence Id: DrugDDI.d55.s0
Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .

DrugDDI.d55.s0.e0 16 23
drug
doxapram
DrugDDI.d55.s0.e1 49 63
drug
sympathomimetic
DrugDDI.d55.s0.e2 66 81
drug
monoamine oxidase
DrugDDI.d55.s0.e3 110 130
drug
additive pressor effect

interaction DrugDDI.d55.s0.e0 DrugDDI.d55.s0.e1 true
interaction DrugDDI.d55.s0.e0 DrugDDI.d55.s0.e2 true
interaction DrugDDI.d55.s0.e0 DrugDDI.d55.s0.e3 false
interaction DrugDDI.d55.s0.e1 DrugDDI.d55.s0.e2 false
interaction DrugDDI.d55.s0.e1 DrugDDI.d55.s0.e3 false
interaction DrugDDI.d55.s0.e2 DrugDDI.d55.s0.e3 false

Abstract Id: DrugDDI.d55
Sentence Id: DrugDDI.d55.s1
In patients who have received muscle relaxants , doxapram may temporarily mask the residual effects of muscle relaxant drugs .

DrugDDI.d55.s1.e0 25 39
drug
muscle relaxants
DrugDDI.d55.s1.e1 41 48
drug
doxapram
DrugDDI.d55.s1.e2 101 105
drug
drugs

interaction DrugDDI.d55.s1.e0 DrugDDI.d55.s1.e1 true
interaction DrugDDI.d55.s1.e0 DrugDDI.d55.s1.e2 false
interaction DrugDDI.d55.s1.e1 DrugDDI.d55.s1.e2 false

Abstract Id: DrugDDI.d55
Sentence Id: DrugDDI.d55.s2
In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for arrhythmias, including ventricular tachycardia and ventricular fibrillation.

DrugDDI.d55.s2.e0 127 134
drug
doxapram
DrugDDI.d55.s2.new.DISO.e1 216 226
DISO
arrhythmias
DrugDDI.d55.s2.new.DISO.e2 237 258
DISO
ventricular tachycardia
DrugDDI.d55.s2.new.DISO.e3 262 284
DISO
ventricular fibrillation



Abstract Id: DrugDDI.d93
Sentence Id: DrugDDI.d93.s0
Drug interaction studies with Xigris have not been performed in patients with severe sepsis.

DrugDDI.d93.s0.e0 26 31
drug
Xigris
DrugDDI.d93.s0.new.DISO.e1 72 77
DISO
sepsis



Abstract Id: DrugDDI.d93
Sentence Id: DrugDDI.d93.s1
However, since there is an increased risk of bleeding with Xigris , caution should be employed when Xigris is used with other drugs that affect hemostasis.

DrugDDI.d93.s1.e0 49 54
drug
Xigris
DrugDDI.d93.s1.e1 83 88
drug
Xigris
DrugDDI.d93.s1.e2 104 108
drug
drugs

interaction DrugDDI.d93.s1.e0 DrugDDI.d93.s1.e1 false
interaction DrugDDI.d93.s1.e0 DrugDDI.d93.s1.e2 false
interaction DrugDDI.d93.s1.e1 DrugDDI.d93.s1.e2 true

Abstract Id: DrugDDI.d93
Sentence Id: DrugDDI.d93.s2
Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin ( unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.

DrugDDI.d93.s2.e0 78 84
drug
heparin
DrugDDI.d93.s2.e1 86 106
drug
unfractionated heparin
DrugDDI.d93.s2.e2 129 140
drug
prophylactic
DrugDDI.d93.s2.e3 148 173
drug
low molecular weight heparins

interaction DrugDDI.d93.s2.e0 DrugDDI.d93.s2.e1 false
interaction DrugDDI.d93.s2.e0 DrugDDI.d93.s2.e2 false
interaction DrugDDI.d93.s2.e0 DrugDDI.d93.s2.e3 false
interaction DrugDDI.d93.s2.e1 DrugDDI.d93.s2.e2 false
interaction DrugDDI.d93.s2.e1 DrugDDI.d93.s2.e3 false
interaction DrugDDI.d93.s2.e2 DrugDDI.d93.s2.e3 false

Abstract Id: DrugDDI.d93
Sentence Id: DrugDDI.d93.s3
Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial.

DrugDDI.d93.s3.e0 35 41
drug
heparin
DrugDDI.d93.s3.e1 102 107
drug
Xigris

interaction DrugDDI.d93.s3.e0 DrugDDI.d93.s3.e1 false

Abstract Id: DrugDDI.d93
Sentence Id: DrugDDI.d93.s4
Drug /Laboratory Test Interaction Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII , IX, and XI assays).

DrugDDI.d93.s4.e0 0 3
drug
Drug
DrugDDI.d93.s4.e1 37 42
drug
Xigris
DrugDDI.d93.s4.e2 65 70
drug
Xigris
DrugDDI.d93.s4.e3 156 165
drug
factor VIII

interaction DrugDDI.d93.s4.e0 DrugDDI.d93.s4.e1 false
interaction DrugDDI.d93.s4.e0 DrugDDI.d93.s4.e2 false
interaction DrugDDI.d93.s4.e0 DrugDDI.d93.s4.e3 false
interaction DrugDDI.d93.s4.e1 DrugDDI.d93.s4.e2 false
interaction DrugDDI.d93.s4.e1 DrugDDI.d93.s4.e3 false
interaction DrugDDI.d93.s4.e2 DrugDDI.d93.s4.e3 false

Abstract Id: DrugDDI.d93
Sentence Id: DrugDDI.d93.s6
Xigris present in plasma samples does not interfere with one-stage factor assays based on the PT (such as factor II , V, VII, and X assays).

DrugDDI.d93.s6.e0 0 5
drug
Xigris
DrugDDI.d93.s6.e1 88 95
drug
factor II

interaction DrugDDI.d93.s6.e0 DrugDDI.d93.s6.e1 false

Abstract Id: DrugDDI.d522
Sentence Id: DrugDDI.d522.s1
Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc . 7 .

DrugDDI.d522.s1.e0 33 54
drug
edetate calcium disodium
DrugDDI.d522.s1.e1 66 87
drug
Edetate calcium disodium
DrugDDI.d522.s1.e2 113 116
drug
zinc
DrugDDI.d522.s1.e3 150 153
drug
zinc

interaction DrugDDI.d522.s1.e0 DrugDDI.d522.s1.e1 false
interaction DrugDDI.d522.s1.e0 DrugDDI.d522.s1.e2 false
interaction DrugDDI.d522.s1.e0 DrugDDI.d522.s1.e3 false
interaction DrugDDI.d522.s1.e1 DrugDDI.d522.s1.e2 true
interaction DrugDDI.d522.s1.e1 DrugDDI.d522.s1.e3 false
interaction DrugDDI.d522.s1.e2 DrugDDI.d522.s1.e3 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s0
Efavirenz has been shown in vivo to induce CYP3A4 .

DrugDDI.d496.s0.e0 0 8
drug
Efavirenz
DrugDDI.d496.s0.e1 35 40
drug
CYP3A4

interaction DrugDDI.d496.s0.e0 DrugDDI.d496.s0.e1 true

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s1
Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with SUSTIVA ( efavirenz ).

DrugDDI.d496.s1.e0 33 38
drug
CYP3A4
DrugDDI.d496.s1.e1 97 103
drug
SUSTIVA
DrugDDI.d496.s1.e2 105 113
drug
efavirenz

interaction DrugDDI.d496.s1.e0 DrugDDI.d496.s1.e1 false
interaction DrugDDI.d496.s1.e0 DrugDDI.d496.s1.e2 false
interaction DrugDDI.d496.s1.e1 DrugDDI.d496.s1.e2 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s2
In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations.

DrugDDI.d496.s2.e0 34 42
drug
efavirenz
DrugDDI.d496.s2.e1 66 73
drug
isozymes
DrugDDI.d496.s2.e2 94 102
drug
efavirenz

interaction DrugDDI.d496.s2.e0 DrugDDI.d496.s2.e1 true
interaction DrugDDI.d496.s2.e0 DrugDDI.d496.s2.e2 false
interaction DrugDDI.d496.s2.e1 DrugDDI.d496.s2.e2 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s3
Coadministration of efavirenz with drugs primarily metabolized by these isozymes may result in altered plasma concentrations of the coadministered drug .

DrugDDI.d496.s3.e0 18 26
drug
efavirenz
DrugDDI.d496.s3.e1 31 35
drug
drugs
DrugDDI.d496.s3.e2 63 70
drug
isozymes
DrugDDI.d496.s3.e3 128 131
drug
drug

interaction DrugDDI.d496.s3.e0 DrugDDI.d496.s3.e1 true
interaction DrugDDI.d496.s3.e0 DrugDDI.d496.s3.e2 false
interaction DrugDDI.d496.s3.e0 DrugDDI.d496.s3.e3 false
interaction DrugDDI.d496.s3.e1 DrugDDI.d496.s3.e2 false
interaction DrugDDI.d496.s3.e1 DrugDDI.d496.s3.e3 false
interaction DrugDDI.d496.s3.e2 DrugDDI.d496.s3.e3 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s4
Therefore, appropriate dose adjustments may be necessary for these drugs .

DrugDDI.d496.s4.e0 58 62
drug
drugs



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s5
Drugs which induce CYP3A4 activity (eg, phenobarbital , rifampin , rifabutin ) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.

DrugDDI.d496.s5.e0 0 4
drug
Drugs
DrugDDI.d496.s5.e1 16 21
drug
CYP3A4
DrugDDI.d496.s5.e2 34 46
drug
phenobarbital
DrugDDI.d496.s5.e3 48 55
drug
rifampin
DrugDDI.d496.s5.e4 57 65
drug
rifabutin
DrugDDI.d496.s5.e5 106 114
drug
efavirenz

interaction DrugDDI.d496.s5.e0 DrugDDI.d496.s5.e1 false
interaction DrugDDI.d496.s5.e0 DrugDDI.d496.s5.e2 false
interaction DrugDDI.d496.s5.e0 DrugDDI.d496.s5.e3 false
interaction DrugDDI.d496.s5.e0 DrugDDI.d496.s5.e4 false
interaction DrugDDI.d496.s5.e0 DrugDDI.d496.s5.e5 true
interaction DrugDDI.d496.s5.e1 DrugDDI.d496.s5.e2 false
interaction DrugDDI.d496.s5.e1 DrugDDI.d496.s5.e3 false
interaction DrugDDI.d496.s5.e1 DrugDDI.d496.s5.e4 false
interaction DrugDDI.d496.s5.e1 DrugDDI.d496.s5.e5 false
interaction DrugDDI.d496.s5.e2 DrugDDI.d496.s5.e3 false
interaction DrugDDI.d496.s5.e2 DrugDDI.d496.s5.e4 false
interaction DrugDDI.d496.s5.e2 DrugDDI.d496.s5.e5 true
interaction DrugDDI.d496.s5.e3 DrugDDI.d496.s5.e4 false
interaction DrugDDI.d496.s5.e3 DrugDDI.d496.s5.e5 true
interaction DrugDDI.d496.s5.e4 DrugDDI.d496.s5.e5 true

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s6
Drug interactions with SUSTIVA are summarized in Table 5.

DrugDDI.d496.s6.e0 20 26
drug
SUSTIVA



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s7
Table 5a: Drugs That Should Not Be Coadministered With SUSTIVA .

DrugDDI.d496.s7.e0 8 12
drug
Drugs
DrugDDI.d496.s7.e1 46 52
drug
SUSTIVA

interaction DrugDDI.d496.s7.e0 DrugDDI.d496.s7.e1 true

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s8
Drug Class .

DrugDDI.d496.s8.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s9
Drugs Within Class Not To Be Coadministered With SUSTIVA .

DrugDDI.d496.s9.e0 0 4
drug
Drugs
DrugDDI.d496.s9.e1 41 47
drug
SUSTIVA

interaction DrugDDI.d496.s9.e0 DrugDDI.d496.s9.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s10
Antihistamines Benzodiazepines GI Motility Agents Anti-Migraine Antifungal .

DrugDDI.d496.s10.e0 0 13
drug
Antihistamines



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s11
astemizole midazolam, triazolam cisapride ergot derivatives voriconazole .

DrugDDI.d496.s11.e0 0 9
drug
astemizole
DrugDDI.d496.s11.e1 20 28
drug
triazolam
DrugDDI.d496.s11.e2 54 65
drug
voriconazole

interaction DrugDDI.d496.s11.e0 DrugDDI.d496.s11.e1 false
interaction DrugDDI.d496.s11.e0 DrugDDI.d496.s11.e2 false
interaction DrugDDI.d496.s11.e1 DrugDDI.d496.s11.e2 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s14
Drug Name .

DrugDDI.d496.s14.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s17
Atazanavir .

DrugDDI.d496.s17.e0 0 9
drug
Atazanavir



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s19
When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).

DrugDDI.d496.s19.e0 22 28
drug
SUSTIVA
DrugDDI.d496.s19.e1 75 84
drug
atazanavir
DrugDDI.d496.s19.e2 96 109
drug
ritonavir 100 mg
DrugDDI.d496.s19.e3 113 119
drug
SUSTIVA

interaction DrugDDI.d496.s19.e0 DrugDDI.d496.s19.e1 false
interaction DrugDDI.d496.s19.e0 DrugDDI.d496.s19.e2 false
interaction DrugDDI.d496.s19.e0 DrugDDI.d496.s19.e3 false
interaction DrugDDI.d496.s19.e1 DrugDDI.d496.s19.e2 false
interaction DrugDDI.d496.s19.e1 DrugDDI.d496.s19.e3 false
interaction DrugDDI.d496.s19.e2 DrugDDI.d496.s19.e3 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s20
Dosing recommendations for SUSTIVA and atazanavir in treatment-experienced patients have not been established.

DrugDDI.d496.s20.e0 24 30
drug
SUSTIVA
DrugDDI.d496.s20.e1 34 43
drug
atazanavir

interaction DrugDDI.d496.s20.e0 DrugDDI.d496.s20.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s22
Drug Name .

DrugDDI.d496.s22.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s25
Clarithromycin .

DrugDDI.d496.s25.e0 0 13
drug
Clarithromycin



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s26
@@ clarithromycin concentration .

DrugDDI.d496.s26.e0 2 15
drug
clarithromycin



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s27
Plasma concentrations decreased by SUSTIVA ; .

DrugDDI.d496.s27.e0 31 37
drug
SUSTIVA



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s29
In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin .

DrugDDI.d496.s29.e0 53 59
drug
SUSTIVA
DrugDDI.d496.s29.e1 63 76
drug
clarithromycin

interaction DrugDDI.d496.s29.e0 DrugDDI.d496.s29.e1 true

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s30
No dose adjustment of SUSTIVA is recommended when given with clarithromycin .

DrugDDI.d496.s30.e0 18 24
drug
SUSTIVA
DrugDDI.d496.s30.e1 51 64
drug
clarithromycin

interaction DrugDDI.d496.s30.e0 DrugDDI.d496.s30.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s31
Alternatives to clarithromycin , such as azithromycin , should be considered.

DrugDDI.d496.s31.e0 14 27
drug
clarithromycin
DrugDDI.d496.s31.e1 35 46
drug
azithromycin

interaction DrugDDI.d496.s31.e0 DrugDDI.d496.s31.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s32
Other macrolide antibiotics , such as erythromycin , have not been studied in combination with SUSTIVA .

DrugDDI.d496.s32.e0 5 24
drug
macrolide antibiotics
DrugDDI.d496.s32.e1 32 43
drug
erythromycin
DrugDDI.d496.s32.e2 80 86
drug
SUSTIVA

interaction DrugDDI.d496.s32.e0 DrugDDI.d496.s32.e1 false
interaction DrugDDI.d496.s32.e0 DrugDDI.d496.s32.e2 false
interaction DrugDDI.d496.s32.e1 DrugDDI.d496.s32.e2 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s35
Indinavir .

DrugDDI.d496.s35.e0 0 8
drug
Indinavir



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s36
@@ indinavir concentration .

DrugDDI.d496.s36.e0 2 10
drug
indinavir



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s37
The optimal dose of indinavir , when given in combination with SUSTIVA , is not known.

DrugDDI.d496.s37.e0 16 24
drug
indinavir
DrugDDI.d496.s37.e1 52 58
drug
SUSTIVA

interaction DrugDDI.d496.s37.e0 DrugDDI.d496.s37.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s38
Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA .

DrugDDI.d496.s38.e0 13 21
drug
indinavir
DrugDDI.d496.s38.e1 77 85
drug
indinavir
DrugDDI.d496.s38.e2 101 107
drug
SUSTIVA

interaction DrugDDI.d496.s38.e0 DrugDDI.d496.s38.e1 false
interaction DrugDDI.d496.s38.e0 DrugDDI.d496.s38.e2 false
interaction DrugDDI.d496.s38.e1 DrugDDI.d496.s38.e2 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s39
When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.

DrugDDI.d496.s39.e0 4 12
drug
indinavir
DrugDDI.d496.s39.e1 61 67
drug
SUSTIVA
DrugDDI.d496.s39.e2 88 96
drug
indinavir
DrugDDI.d496.s39.e3 174 182
drug
indinavir

interaction DrugDDI.d496.s39.e0 DrugDDI.d496.s39.e1 true
interaction DrugDDI.d496.s39.e0 DrugDDI.d496.s39.e2 false
interaction DrugDDI.d496.s39.e0 DrugDDI.d496.s39.e3 false
interaction DrugDDI.d496.s39.e1 DrugDDI.d496.s39.e2 false
interaction DrugDDI.d496.s39.e1 DrugDDI.d496.s39.e3 false
interaction DrugDDI.d496.s39.e2 DrugDDI.d496.s39.e3 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s40
Lopinavir / ritonavir .

DrugDDI.d496.s40.e0 0 8
drug
Lopinavir
DrugDDI.d496.s40.e1 10 18
drug
ritonavir

interaction DrugDDI.d496.s40.e0 DrugDDI.d496.s40.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s41
@@ lopinavir concentration .

DrugDDI.d496.s41.e0 2 10
drug
lopinavir



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s42
A dose increase of lopinavir / ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA .

DrugDDI.d496.s42.e0 15 23
drug
lopinavir
DrugDDI.d496.s42.e1 25 33
drug
ritonavir
DrugDDI.d496.s42.e2 124 130
drug
SUSTIVA

interaction DrugDDI.d496.s42.e0 DrugDDI.d496.s42.e1 false
interaction DrugDDI.d496.s42.e0 DrugDDI.d496.s42.e2 false
interaction DrugDDI.d496.s42.e1 DrugDDI.d496.s42.e2 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s43
Methadone .

DrugDDI.d496.s43.e0 0 8
drug
Methadone



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s44
@@ methadone concentration .

DrugDDI.d496.s44.e0 2 10
drug
methadone



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s45
Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of methadone and signs of opiate withdrawal.

DrugDDI.d496.s45.e0 104 112
drug
methadone
DrugDDI.d496.s45.e1 123 128
drug
opiate

interaction DrugDDI.d496.s45.e0 DrugDDI.d496.s45.e1 true

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s48
Ethinyl estradiol .

DrugDDI.d496.s48.e0 0 15
drug
Ethinyl estradiol



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s49
@@ ethinyl estradiol concentration .

DrugDDI.d496.s49.e0 2 17
drug
ethinyl estradiol



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s50
Plasma concentrations increased by SUSTIVA ( efavirenz ); .

DrugDDI.d496.s50.e0 31 37
drug
SUSTIVA
DrugDDI.d496.s50.e1 39 47
drug
efavirenz

interaction DrugDDI.d496.s50.e0 DrugDDI.d496.s50.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s52
Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives .

DrugDDI.d496.s52.e0 32 40
drug
efavirenz
DrugDDI.d496.s52.e1 45 62
drug
oral contraceptives
DrugDDI.d496.s52.e2 153 170
drug
oral contraceptives

interaction DrugDDI.d496.s52.e0 DrugDDI.d496.s52.e1 false
interaction DrugDDI.d496.s52.e0 DrugDDI.d496.s52.e2 false
interaction DrugDDI.d496.s52.e1 DrugDDI.d496.s52.e2 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s53
Rifabutin .

DrugDDI.d496.s53.e0 0 8
drug
Rifabutin



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s54
@@ rifabutin concentration .

DrugDDI.d496.s54.e0 2 10
drug
rifabutin



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s55
Increase daily dose of rifabutin by 50%.

DrugDDI.d496.s55.e0 19 27
drug
rifabutin



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s56
Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.

DrugDDI.d496.s56.e0 19 27
drug
rifabutin
DrugDDI.d496.s56.e1 47 55
drug
rifabutin

interaction DrugDDI.d496.s56.e0 DrugDDI.d496.s56.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s57
Rifampin .

DrugDDI.d496.s57.e0 0 7
drug
Rifampin



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s58
@@ efavirenz concentration .

DrugDDI.d496.s58.e0 2 10
drug
efavirenz



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s59
Clinical significance of reduced efavirenz concentrations unknown.

DrugDDI.d496.s59.e0 29 37
drug
efavirenz



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s60
Ritonavir .

DrugDDI.d496.s60.e0 0 8
drug
Ritonavir



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s61
@@ ritonavir concentration .

DrugDDI.d496.s61.e0 2 10
drug
ritonavir



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s63
Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir .

DrugDDI.d496.s63.e0 12 23
drug
liver enzymes
DrugDDI.d496.s63.e1 41 47
drug
SUSTIVA
DrugDDI.d496.s63.e2 71 79
drug
ritonavir

interaction DrugDDI.d496.s63.e0 DrugDDI.d496.s63.e1 false
interaction DrugDDI.d496.s63.e0 DrugDDI.d496.s63.e2 false
interaction DrugDDI.d496.s63.e1 DrugDDI.d496.s63.e2 true

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s64
@@ efavirenz concentration .

DrugDDI.d496.s64.e0 2 10
drug
efavirenz



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s65
Saquinavir .

DrugDDI.d496.s65.e0 0 9
drug
Saquinavir



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s66
@@ saquinavir concentration .

DrugDDI.d496.s66.e0 2 11
drug
saquinavir



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s67
Should not be used as sole protease inhibitor in combination with SUSTIVA .

DrugDDI.d496.s67.e0 21 37
drug
protease inhibitor
DrugDDI.d496.s67.e1 55 61
drug
SUSTIVA

interaction DrugDDI.d496.s67.e0 DrugDDI.d496.s67.e1 true

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s68
Sertraline .

DrugDDI.d496.s68.e0 0 9
drug
Sertraline



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s69
@@ sertraline concentration .

DrugDDI.d496.s69.e0 2 11
drug
sertraline



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s71
Other Potentially Clinically Significant Drug or Herbal Product Interactions With SUSTIVAb .

DrugDDI.d496.s71.e0 37 40
drug
Drug



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s72
Anticoagulants : Warfarin .

DrugDDI.d496.s72.e0 0 13
drug
Anticoagulants
DrugDDI.d496.s72.e1 15 22
drug
Warfarin

interaction DrugDDI.d496.s72.e0 DrugDDI.d496.s72.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s73
Plasma concentrations and effects potentially increased or decreased by SUSTIVA .

DrugDDI.d496.s73.e0 63 69
drug
SUSTIVA



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s74
Anticonvulsants : Phenytoin Phenobarbital Carbamazepine .

DrugDDI.d496.s74.e0 0 14
drug
Anticonvulsants
DrugDDI.d496.s74.e1 25 37
drug
Phenobarbital

interaction DrugDDI.d496.s74.e0 DrugDDI.d496.s74.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s75
Potential for reduction in anticonvulsant and/or efavirenz plasma levels; .

DrugDDI.d496.s75.e0 23 36
drug
anticonvulsant
DrugDDI.d496.s75.e1 43 51
drug
efavirenz

interaction DrugDDI.d496.s75.e0 DrugDDI.d496.s75.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s76
periodic monitoring of anticonvulsant plasma levels should be conducted.

DrugDDI.d496.s76.e0 20 33
drug
anticonvulsant



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s77
Antifungals : Itraconazole Ketoconazole .

DrugDDI.d496.s77.e0 0 10
drug
Antifungals
DrugDDI.d496.s77.e1 12 23
drug
Itraconazole

interaction DrugDDI.d496.s77.e0 DrugDDI.d496.s77.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s78
Drug interaction studies with SUSTIVA and these imidazole and triazole antifungals have not been conducted.

DrugDDI.d496.s78.e0 26 32
drug
SUSTIVA
DrugDDI.d496.s78.e1 41 49
drug
imidazole
DrugDDI.d496.s78.e2 53 71
drug
triazole antifungals

interaction DrugDDI.d496.s78.e0 DrugDDI.d496.s78.e1 false
interaction DrugDDI.d496.s78.e0 DrugDDI.d496.s78.e2 false
interaction DrugDDI.d496.s78.e1 DrugDDI.d496.s78.e2 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s79
SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole .

DrugDDI.d496.s79.e0 0 6
drug
SUSTIVA
DrugDDI.d496.s79.e1 54 65
drug
itraconazole
DrugDDI.d496.s79.e2 69 80
drug
ketoconazole

interaction DrugDDI.d496.s79.e0 DrugDDI.d496.s79.e1 true
interaction DrugDDI.d496.s79.e0 DrugDDI.d496.s79.e2 true
interaction DrugDDI.d496.s79.e1 DrugDDI.d496.s79.e2 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s80
Anti-HIV protease inhibitors : Saquinavir / ritonavir combination .

DrugDDI.d496.s80.e0 0 25
drug
Anti-HIV protease inhibitors
DrugDDI.d496.s80.e1 27 36
drug
Saquinavir
DrugDDI.d496.s80.e2 38 46
drug
ritonavir

interaction DrugDDI.d496.s80.e0 DrugDDI.d496.s80.e1 false
interaction DrugDDI.d496.s80.e0 DrugDDI.d496.s80.e2 false
interaction DrugDDI.d496.s80.e1 DrugDDI.d496.s80.e2 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s82
Amprenavir .

DrugDDI.d496.s82.e0 0 9
drug
Amprenavir



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s83
SUSTIVAhas the potential to decrease serum concentrations of amprenavir .

DrugDDI.d496.s83.e0 53 62
drug
amprenavir



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s84
Non-nucleoside reverse transcriptase inhibitors .

DrugDDI.d496.s84.e0 0 43
drug
Non-nucleoside reverse transcriptase inhibitors



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s86
St. John@s wort ( Hypericum perforatum ) .

DrugDDI.d496.s86.e0 14 32
drug
Hypericum perforatum



Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s87
Expected to substantially decrease plasma levels of efavirenz ;has not been studied in combination with SUSTIVA .

DrugDDI.d496.s87.e0 45 53
drug
efavirenz
DrugDDI.d496.s87.e1 89 95
drug
SUSTIVA

interaction DrugDDI.d496.s87.e0 DrugDDI.d496.s87.e1 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s90
Other Drugs : Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA ( efavirenz ) is given with the following: aluminum/ magnesium hydroxide antacids, azithromycin , cetirizine , famotidine , fluconazole , lamivudine , lorazepam , nelfinavir , paroxetine , and zidovudine .

DrugDDI.d496.s90.e0 5 9
drug
Drugs
DrugDDI.d496.s90.e1 88 94
drug
SUSTIVA
DrugDDI.d496.s90.e2 96 104
drug
efavirenz
DrugDDI.d496.s90.e3 139 156
drug
magnesium hydroxide
DrugDDI.d496.s90.e4 166 177
drug
azithromycin
DrugDDI.d496.s90.e5 179 188
drug
cetirizine
DrugDDI.d496.s90.e6 190 199
drug
famotidine
DrugDDI.d496.s90.e7 201 211
drug
fluconazole
DrugDDI.d496.s90.e8 213 222
drug
lamivudine
DrugDDI.d496.s90.e9 224 232
drug
lorazepam
DrugDDI.d496.s90.e10 234 243
drug
nelfinavir
DrugDDI.d496.s90.e11 245 254
drug
paroxetine
DrugDDI.d496.s90.e12 259 268
drug
zidovudine

interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e1 false
interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e2 false
interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e3 false
interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e4 false
interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e5 false
interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e6 false
interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e7 false
interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e8 false
interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e9 false
interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e10 false
interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e11 false
interaction DrugDDI.d496.s90.e0 DrugDDI.d496.s90.e12 false
interaction DrugDDI.d496.s90.e1 DrugDDI.d496.s90.e2 false
interaction DrugDDI.d496.s90.e1 DrugDDI.d496.s90.e3 false
interaction DrugDDI.d496.s90.e1 DrugDDI.d496.s90.e4 false
interaction DrugDDI.d496.s90.e1 DrugDDI.d496.s90.e5 false
interaction DrugDDI.d496.s90.e1 DrugDDI.d496.s90.e6 false
interaction DrugDDI.d496.s90.e1 DrugDDI.d496.s90.e7 false
interaction DrugDDI.d496.s90.e1 DrugDDI.d496.s90.e8 false
interaction DrugDDI.d496.s90.e1 DrugDDI.d496.s90.e9 false
interaction DrugDDI.d496.s90.e1 DrugDDI.d496.s90.e10 false
interaction DrugDDI.d496.s90.e1 DrugDDI.d496.s90.e11 false
interaction DrugDDI.d496.s90.e1 DrugDDI.d496.s90.e12 false
interaction DrugDDI.d496.s90.e2 DrugDDI.d496.s90.e3 false
interaction DrugDDI.d496.s90.e2 DrugDDI.d496.s90.e4 false
interaction DrugDDI.d496.s90.e2 DrugDDI.d496.s90.e5 false
interaction DrugDDI.d496.s90.e2 DrugDDI.d496.s90.e6 false
interaction DrugDDI.d496.s90.e2 DrugDDI.d496.s90.e7 false
interaction DrugDDI.d496.s90.e2 DrugDDI.d496.s90.e8 false
interaction DrugDDI.d496.s90.e2 DrugDDI.d496.s90.e9 false
interaction DrugDDI.d496.s90.e2 DrugDDI.d496.s90.e10 false
interaction DrugDDI.d496.s90.e2 DrugDDI.d496.s90.e11 false
interaction DrugDDI.d496.s90.e2 DrugDDI.d496.s90.e12 false
interaction DrugDDI.d496.s90.e3 DrugDDI.d496.s90.e4 false
interaction DrugDDI.d496.s90.e3 DrugDDI.d496.s90.e5 false
interaction DrugDDI.d496.s90.e3 DrugDDI.d496.s90.e6 false
interaction DrugDDI.d496.s90.e3 DrugDDI.d496.s90.e7 false
interaction DrugDDI.d496.s90.e3 DrugDDI.d496.s90.e8 false
interaction DrugDDI.d496.s90.e3 DrugDDI.d496.s90.e9 false
interaction DrugDDI.d496.s90.e3 DrugDDI.d496.s90.e10 false
interaction DrugDDI.d496.s90.e3 DrugDDI.d496.s90.e11 false
interaction DrugDDI.d496.s90.e3 DrugDDI.d496.s90.e12 false
interaction DrugDDI.d496.s90.e4 DrugDDI.d496.s90.e5 false
interaction DrugDDI.d496.s90.e4 DrugDDI.d496.s90.e6 false
interaction DrugDDI.d496.s90.e4 DrugDDI.d496.s90.e7 false
interaction DrugDDI.d496.s90.e4 DrugDDI.d496.s90.e8 false
interaction DrugDDI.d496.s90.e4 DrugDDI.d496.s90.e9 false
interaction DrugDDI.d496.s90.e4 DrugDDI.d496.s90.e10 false
interaction DrugDDI.d496.s90.e4 DrugDDI.d496.s90.e11 false
interaction DrugDDI.d496.s90.e4 DrugDDI.d496.s90.e12 false
interaction DrugDDI.d496.s90.e5 DrugDDI.d496.s90.e6 false
interaction DrugDDI.d496.s90.e5 DrugDDI.d496.s90.e7 false
interaction DrugDDI.d496.s90.e5 DrugDDI.d496.s90.e8 false
interaction DrugDDI.d496.s90.e5 DrugDDI.d496.s90.e9 false
interaction DrugDDI.d496.s90.e5 DrugDDI.d496.s90.e10 false
interaction DrugDDI.d496.s90.e5 DrugDDI.d496.s90.e11 false
interaction DrugDDI.d496.s90.e5 DrugDDI.d496.s90.e12 false
interaction DrugDDI.d496.s90.e6 DrugDDI.d496.s90.e7 false
interaction DrugDDI.d496.s90.e6 DrugDDI.d496.s90.e8 false
interaction DrugDDI.d496.s90.e6 DrugDDI.d496.s90.e9 false
interaction DrugDDI.d496.s90.e6 DrugDDI.d496.s90.e10 false
interaction DrugDDI.d496.s90.e6 DrugDDI.d496.s90.e11 false
interaction DrugDDI.d496.s90.e6 DrugDDI.d496.s90.e12 false
interaction DrugDDI.d496.s90.e7 DrugDDI.d496.s90.e8 false
interaction DrugDDI.d496.s90.e7 DrugDDI.d496.s90.e9 false
interaction DrugDDI.d496.s90.e7 DrugDDI.d496.s90.e10 false
interaction DrugDDI.d496.s90.e7 DrugDDI.d496.s90.e11 false
interaction DrugDDI.d496.s90.e7 DrugDDI.d496.s90.e12 false
interaction DrugDDI.d496.s90.e8 DrugDDI.d496.s90.e9 false
interaction DrugDDI.d496.s90.e8 DrugDDI.d496.s90.e10 false
interaction DrugDDI.d496.s90.e8 DrugDDI.d496.s90.e11 false
interaction DrugDDI.d496.s90.e8 DrugDDI.d496.s90.e12 false
interaction DrugDDI.d496.s90.e9 DrugDDI.d496.s90.e10 false
interaction DrugDDI.d496.s90.e9 DrugDDI.d496.s90.e11 false
interaction DrugDDI.d496.s90.e9 DrugDDI.d496.s90.e12 false
interaction DrugDDI.d496.s90.e10 DrugDDI.d496.s90.e11 false
interaction DrugDDI.d496.s90.e10 DrugDDI.d496.s90.e12 false
interaction DrugDDI.d496.s90.e11 DrugDDI.d496.s90.e12 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s91
Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine .

DrugDDI.d496.s91.e0 54 60
drug
SUSTIVA
DrugDDI.d496.s91.e1 78 87
drug
lamivudine
DrugDDI.d496.s91.e2 91 100
drug
zidovudine

interaction DrugDDI.d496.s91.e0 DrugDDI.d496.s91.e1 false
interaction DrugDDI.d496.s91.e0 DrugDDI.d496.s91.e2 false
interaction DrugDDI.d496.s91.e1 DrugDDI.d496.s91.e2 false

Abstract Id: DrugDDI.d496
Sentence Id: DrugDDI.d496.s92
Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.

DrugDDI.d496.s92.e0 100 108
drug
efavirenz
DrugDDI.d496.s92.e1 129 135
drug
compete

interaction DrugDDI.d496.s92.e0 DrugDDI.d496.s92.e1 false

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s0
Inhibitors of CYP3A4 -Eplerenone metabolism is predominantly mediated via CYP3A4 .

DrugDDI.d578.s0.e0 12 17
drug
CYP3A4
DrugDDI.d578.s0.e1 65 70
drug
CYP3A4

interaction DrugDDI.d578.s0.e0 DrugDDI.d578.s0.e1 false

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s1
A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone .

DrugDDI.d578.s1.e0 63 68
drug
INSPRA
DrugDDI.d578.s1.e1 78 94
drug
ketoconazole 200 mg
DrugDDI.d578.s1.e2 120 125
drug
CYP3A4
DrugDDI.d578.s1.e3 165 174
drug
eplerenone
DrugDDI.d578.s1.e4 202 211
drug
eplerenone

interaction DrugDDI.d578.s1.e0 DrugDDI.d578.s1.e1 true
interaction DrugDDI.d578.s1.e0 DrugDDI.d578.s1.e2 false
interaction DrugDDI.d578.s1.e0 DrugDDI.d578.s1.e3 false
interaction DrugDDI.d578.s1.e0 DrugDDI.d578.s1.e4 false
interaction DrugDDI.d578.s1.e1 DrugDDI.d578.s1.e2 false
interaction DrugDDI.d578.s1.e1 DrugDDI.d578.s1.e3 false
interaction DrugDDI.d578.s1.e1 DrugDDI.d578.s1.e4 false
interaction DrugDDI.d578.s1.e2 DrugDDI.d578.s1.e3 false
interaction DrugDDI.d578.s1.e2 DrugDDI.d578.s1.e4 false
interaction DrugDDI.d578.s1.e3 DrugDDI.d578.s1.e4 false

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s2
INSPRA should not be used with drugs described as strong inhibitors of CYP3A4 in their labeling.

DrugDDI.d578.s2.e0 0 5
drug
INSPRA
DrugDDI.d578.s2.e1 25 29
drug
drugs
DrugDDI.d578.s2.e2 59 64
drug
CYP3A4

interaction DrugDDI.d578.s2.e0 DrugDDI.d578.s2.e1 true
interaction DrugDDI.d578.s2.e0 DrugDDI.d578.s2.e2 false
interaction DrugDDI.d578.s2.e1 DrugDDI.d578.s2.e2 false

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s3
Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.

DrugDDI.d578.s3.e0 16 25
drug
eplerenone
DrugDDI.d578.s3.e1 35 40
drug
CYP3A4
DrugDDI.d578.s3.e2 57 73
drug
erythromycin 500 mg
DrugDDI.d578.s3.e3 78 91
drug
verapamil 240 mg
DrugDDI.d578.s3.e4 95 104
drug
saquinavir
DrugDDI.d578.s3.e5 115 130
drug
fluconazole 200 mg
DrugDDI.d578.s3.e6 161 170
drug
eplerenone

interaction DrugDDI.d578.s3.e0 DrugDDI.d578.s3.e1 true
interaction DrugDDI.d578.s3.e0 DrugDDI.d578.s3.e2 true
interaction DrugDDI.d578.s3.e0 DrugDDI.d578.s3.e3 true
interaction DrugDDI.d578.s3.e0 DrugDDI.d578.s3.e4 true
interaction DrugDDI.d578.s3.e0 DrugDDI.d578.s3.e5 true
interaction DrugDDI.d578.s3.e0 DrugDDI.d578.s3.e6 false
interaction DrugDDI.d578.s3.e1 DrugDDI.d578.s3.e2 false
interaction DrugDDI.d578.s3.e1 DrugDDI.d578.s3.e3 false
interaction DrugDDI.d578.s3.e1 DrugDDI.d578.s3.e4 false
interaction DrugDDI.d578.s3.e1 DrugDDI.d578.s3.e5 false
interaction DrugDDI.d578.s3.e1 DrugDDI.d578.s3.e6 false
interaction DrugDDI.d578.s3.e2 DrugDDI.d578.s3.e3 false
interaction DrugDDI.d578.s3.e2 DrugDDI.d578.s3.e4 false
interaction DrugDDI.d578.s3.e2 DrugDDI.d578.s3.e5 false
interaction DrugDDI.d578.s3.e2 DrugDDI.d578.s3.e6 false
interaction DrugDDI.d578.s3.e3 DrugDDI.d578.s3.e4 false
interaction DrugDDI.d578.s3.e3 DrugDDI.d578.s3.e5 false
interaction DrugDDI.d578.s3.e3 DrugDDI.d578.s3.e6 false
interaction DrugDDI.d578.s3.e4 DrugDDI.d578.s3.e5 false
interaction DrugDDI.d578.s3.e4 DrugDDI.d578.s3.e6 false
interaction DrugDDI.d578.s3.e5 DrugDDI.d578.s3.e6 false

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s4
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).

DrugDDI.d578.s4.e0 0 12
drug
ACE Inhibitors
DrugDDI.d578.s4.e1 16 47
drug
Angiotensin II Receptor Antagonists
DrugDDI.d578.s4.new.DISO.e5 49 95
DISO
Congestive Heart Failure Post-Myocardial Infarction
DrugDDI.d578.s4.e2 134 139
drug
INSPRA
DrugDDI.d578.s4.e3 160 172
drug
ACE inhibitors
DrugDDI.d578.s4.e4 175 206
drug
angiotensin II receptor antagonists

interaction DrugDDI.d578.s4.e0 DrugDDI.d578.s4.e1 false
interaction DrugDDI.d578.s4.e0 DrugDDI.d578.s4.e2 false
interaction DrugDDI.d578.s4.e0 DrugDDI.d578.s4.e3 false
interaction DrugDDI.d578.s4.e0 DrugDDI.d578.s4.e4 false
interaction DrugDDI.d578.s4.e1 DrugDDI.d578.s4.e2 false
interaction DrugDDI.d578.s4.e1 DrugDDI.d578.s4.e3 false
interaction DrugDDI.d578.s4.e1 DrugDDI.d578.s4.e4 false
interaction DrugDDI.d578.s4.e2 DrugDDI.d578.s4.e3 false
interaction DrugDDI.d578.s4.e2 DrugDDI.d578.s4.e4 false
interaction DrugDDI.d578.s4.e3 DrugDDI.d578.s4.e4 false

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s6
ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).

DrugDDI.d578.s6.e0 0 12
drug
ACE Inhibitors
DrugDDI.d578.s6.e1 16 47
drug
Angiotensin II Receptor Antagonists
DrugDDI.d578.s6.e2 120 125
drug
INSPRA
DrugDDI.d578.s6.e3 137 149
drug
ACE inhibitors
DrugDDI.d578.s6.e4 153 184
drug
angiotensin II receptor antagonists

interaction DrugDDI.d578.s6.e0 DrugDDI.d578.s6.e1 false
interaction DrugDDI.d578.s6.e0 DrugDDI.d578.s6.e2 false
interaction DrugDDI.d578.s6.e0 DrugDDI.d578.s6.e3 false
interaction DrugDDI.d578.s6.e0 DrugDDI.d578.s6.e4 true
interaction DrugDDI.d578.s6.e1 DrugDDI.d578.s6.e2 false
interaction DrugDDI.d578.s6.e1 DrugDDI.d578.s6.e3 false
interaction DrugDDI.d578.s6.e1 DrugDDI.d578.s6.e4 false
interaction DrugDDI.d578.s6.e2 DrugDDI.d578.s6.e3 true
interaction DrugDDI.d578.s6.e2 DrugDDI.d578.s6.e4 false
interaction DrugDDI.d578.s6.e3 DrugDDI.d578.s6.e4 false

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s7
In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium 5.5 mEq/L) from 17% on enalapril alone to 38%.

DrugDDI.d578.s7.new.DISO.e3 23 38
DISO
microalbuminuria
DrugDDI.d578.s7.e0 39 44
drug
INSPRA
DrugDDI.d578.s7.e1 77 89
drug
enalapril 10 mg
DrugDDI.d578.s7.new.DISO.e4 113 124
DISO
hyperkalemia
DrugDDI.d578.s7.e2 158 166
drug
enalapril

interaction DrugDDI.d578.s7.e0 DrugDDI.d578.s7.e1 true
interaction DrugDDI.d578.s7.e0 DrugDDI.d578.s7.e2 false
interaction DrugDDI.d578.s7.e1 DrugDDI.d578.s7.e2 false

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s8
Lithium -A drug interaction study of eplerenone with lithium has not been conducted.

DrugDDI.d578.s8.e0 0 6
drug
Lithium
DrugDDI.d578.s8.e1 31 40
drug
eplerenone
DrugDDI.d578.s8.e2 45 51
drug
lithium

interaction DrugDDI.d578.s8.e0 DrugDDI.d578.s8.e1 false
interaction DrugDDI.d578.s8.e0 DrugDDI.d578.s8.e2 false
interaction DrugDDI.d578.s8.e1 DrugDDI.d578.s8.e2 false

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s9
Lithium toxicity has been reported in patients receiving lithium concomitantly with diuretics and ACE inhibitors .

DrugDDI.d578.s9.e0 49 55
drug
lithium
DrugDDI.d578.s9.e1 73 81
drug
diuretics
DrugDDI.d578.s9.e2 85 97
drug
ACE inhibitors

interaction DrugDDI.d578.s9.e0 DrugDDI.d578.s9.e1 true
interaction DrugDDI.d578.s9.e0 DrugDDI.d578.s9.e2 true
interaction DrugDDI.d578.s9.e1 DrugDDI.d578.s9.e2 false

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s10
Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium .

DrugDDI.d578.s10.e0 47 52
drug
INSPRA
DrugDDI.d578.s10.e1 84 90
drug
lithium

interaction DrugDDI.d578.s10.e0 DrugDDI.d578.s10.e1 true

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s11
Nonsteroidal Anti-Inflammatory Drugs ( NSAIDs )-A drug interaction study of eplerenone with an NSAID has not been conducted.

DrugDDI.d578.s11.e0 0 33
drug
Nonsteroidal Anti-Inflammatory Drugs
DrugDDI.d578.s11.e1 35 40
drug
NSAIDs
DrugDDI.d578.s11.e2 66 75
drug
eplerenone
DrugDDI.d578.s11.e3 82 86
drug
NSAID

interaction DrugDDI.d578.s11.e0 DrugDDI.d578.s11.e1 false
interaction DrugDDI.d578.s11.e0 DrugDDI.d578.s11.e2 false
interaction DrugDDI.d578.s11.e0 DrugDDI.d578.s11.e3 false
interaction DrugDDI.d578.s11.e1 DrugDDI.d578.s11.e2 false
interaction DrugDDI.d578.s11.e1 DrugDDI.d578.s11.e3 false
interaction DrugDDI.d578.s11.e2 DrugDDI.d578.s11.e3 false

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s12
The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.

DrugDDI.d578.s12.e0 24 57
drug
potassium-sparing antihypertensives
DrugDDI.d578.s12.e1 62 67
drug
NSAIDs
DrugDDI.d578.s12.new.DISO.e2 144 155
DISO
hyperkalemia

interaction DrugDDI.d578.s12.e0 DrugDDI.d578.s12.e1 true

Abstract Id: DrugDDI.d578
Sentence Id: DrugDDI.d578.s13
Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.

DrugDDI.d578.s13.e0 14 19
drug
INSPRA
DrugDDI.d578.s13.e1 23 28
drug
NSAIDs

interaction DrugDDI.d578.s13.e0 DrugDDI.d578.s13.e1 true

Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s0
Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.

DrugDDI.d145.s0.e0 40 51
drug
ketoconazole
DrugDDI.d145.s0.e1 61 69
drug
erlotinib

interaction DrugDDI.d145.s0.e0 DrugDDI.d145.s0.e1 true

Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s1
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , troleandomycin ( TAO ), and voriconazole .

DrugDDI.d145.s1.e0 44 50
drug
TARCEVA
DrugDDI.d145.s1.e1 55 66
drug
ketoconazole
DrugDDI.d145.s1.e2 81 86
drug
CYP3A4
DrugDDI.d145.s1.e3 120 129
drug
atazanavir
DrugDDI.d145.s1.e4 131 144
drug
clarithromycin
DrugDDI.d145.s1.e5 146 154
drug
indinavir
DrugDDI.d145.s1.e6 156 167
drug
itraconazole
DrugDDI.d145.s1.e7 169 178
drug
nefazodone
DrugDDI.d145.s1.e8 180 189
drug
nelfinavir
DrugDDI.d145.s1.e9 191 199
drug
ritonavir
DrugDDI.d145.s1.e10 201 210
drug
saquinavir
DrugDDI.d145.s1.e11 212 224
drug
telithromycin
DrugDDI.d145.s1.e12 226 239
drug
troleandomycin
DrugDDI.d145.s1.e13 241 243
drug
TAO
DrugDDI.d145.s1.e14 249 260
drug
voriconazole

interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e1 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e2 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e3 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e4 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e5 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e6 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e7 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e8 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e9 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e10 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e11 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e12 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e13 true
interaction DrugDDI.d145.s1.e0 DrugDDI.d145.s1.e14 true
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e2 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e3 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e4 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e5 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e6 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e7 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e8 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e9 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e10 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e11 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e12 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e1 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e3 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e4 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e5 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e6 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e7 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e8 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e9 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e10 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e11 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e12 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e2 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e3 DrugDDI.d145.s1.e4 false
interaction DrugDDI.d145.s1.e3 DrugDDI.d145.s1.e5 false
interaction DrugDDI.d145.s1.e3 DrugDDI.d145.s1.e6 false
interaction DrugDDI.d145.s1.e3 DrugDDI.d145.s1.e7 false
interaction DrugDDI.d145.s1.e3 DrugDDI.d145.s1.e8 false
interaction DrugDDI.d145.s1.e3 DrugDDI.d145.s1.e9 false
interaction DrugDDI.d145.s1.e3 DrugDDI.d145.s1.e10 false
interaction DrugDDI.d145.s1.e3 DrugDDI.d145.s1.e11 false
interaction DrugDDI.d145.s1.e3 DrugDDI.d145.s1.e12 false
interaction DrugDDI.d145.s1.e3 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e3 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e4 DrugDDI.d145.s1.e5 false
interaction DrugDDI.d145.s1.e4 DrugDDI.d145.s1.e6 false
interaction DrugDDI.d145.s1.e4 DrugDDI.d145.s1.e7 false
interaction DrugDDI.d145.s1.e4 DrugDDI.d145.s1.e8 false
interaction DrugDDI.d145.s1.e4 DrugDDI.d145.s1.e9 false
interaction DrugDDI.d145.s1.e4 DrugDDI.d145.s1.e10 false
interaction DrugDDI.d145.s1.e4 DrugDDI.d145.s1.e11 false
interaction DrugDDI.d145.s1.e4 DrugDDI.d145.s1.e12 false
interaction DrugDDI.d145.s1.e4 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e4 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e5 DrugDDI.d145.s1.e6 false
interaction DrugDDI.d145.s1.e5 DrugDDI.d145.s1.e7 false
interaction DrugDDI.d145.s1.e5 DrugDDI.d145.s1.e8 false
interaction DrugDDI.d145.s1.e5 DrugDDI.d145.s1.e9 false
interaction DrugDDI.d145.s1.e5 DrugDDI.d145.s1.e10 false
interaction DrugDDI.d145.s1.e5 DrugDDI.d145.s1.e11 false
interaction DrugDDI.d145.s1.e5 DrugDDI.d145.s1.e12 false
interaction DrugDDI.d145.s1.e5 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e5 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e6 DrugDDI.d145.s1.e7 false
interaction DrugDDI.d145.s1.e6 DrugDDI.d145.s1.e8 false
interaction DrugDDI.d145.s1.e6 DrugDDI.d145.s1.e9 false
interaction DrugDDI.d145.s1.e6 DrugDDI.d145.s1.e10 false
interaction DrugDDI.d145.s1.e6 DrugDDI.d145.s1.e11 false
interaction DrugDDI.d145.s1.e6 DrugDDI.d145.s1.e12 false
interaction DrugDDI.d145.s1.e6 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e6 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e7 DrugDDI.d145.s1.e8 false
interaction DrugDDI.d145.s1.e7 DrugDDI.d145.s1.e9 false
interaction DrugDDI.d145.s1.e7 DrugDDI.d145.s1.e10 false
interaction DrugDDI.d145.s1.e7 DrugDDI.d145.s1.e11 false
interaction DrugDDI.d145.s1.e7 DrugDDI.d145.s1.e12 false
interaction DrugDDI.d145.s1.e7 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e7 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e8 DrugDDI.d145.s1.e9 false
interaction DrugDDI.d145.s1.e8 DrugDDI.d145.s1.e10 false
interaction DrugDDI.d145.s1.e8 DrugDDI.d145.s1.e11 false
interaction DrugDDI.d145.s1.e8 DrugDDI.d145.s1.e12 false
interaction DrugDDI.d145.s1.e8 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e8 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e9 DrugDDI.d145.s1.e10 false
interaction DrugDDI.d145.s1.e9 DrugDDI.d145.s1.e11 false
interaction DrugDDI.d145.s1.e9 DrugDDI.d145.s1.e12 false
interaction DrugDDI.d145.s1.e9 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e9 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e10 DrugDDI.d145.s1.e11 false
interaction DrugDDI.d145.s1.e10 DrugDDI.d145.s1.e12 false
interaction DrugDDI.d145.s1.e10 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e10 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e11 DrugDDI.d145.s1.e12 false
interaction DrugDDI.d145.s1.e11 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e11 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e12 DrugDDI.d145.s1.e13 false
interaction DrugDDI.d145.s1.e12 DrugDDI.d145.s1.e14 false
interaction DrugDDI.d145.s1.e13 DrugDDI.d145.s1.e14 false

Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s2
Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.

DrugDDI.d145.s2.e0 33 42
drug
rifampicin
DrugDDI.d145.s2.e1 52 60
drug
erlotinib

interaction DrugDDI.d145.s2.e0 DrugDDI.d145.s2.e1 true

Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s3
Alternate treatments lacking CYP3A4 inducing activity should be considered.

DrugDDI.d145.s3.e0 26 31
drug
CYP3A4



Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s4
If an alternative treatment is unavailable, a TARCEVA dose greater than 150 mg should be considered for NSCLC patients, and greater than 100 mg considered for pancreatic cancer patients.

DrugDDI.d145.s4.e0 39 45
drug
TARCEVA
DrugDDI.d145.s4.new.DISO.e1 87 91
DISO
NSCLC
DrugDDI.d145.s4.new.DISO.e2 133 148
DISO
pancreatic cancer



Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s5
If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.

DrugDDI.d145.s5.e0 5 11
drug
TARCEVA
DrugDDI.d145.s5.e1 80 89
drug
rifampicin

interaction DrugDDI.d145.s5.e0 DrugDDI.d145.s5.e1 true

Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s6
Other CYP3A4 inducers include, but are not limited to, rifabutin , rifapentine , phenytoin , carbamazepine , phenobarbital and St. Johns Wort .

DrugDDI.d145.s6.e0 5 10
drug
CYP3A4
DrugDDI.d145.s6.e1 46 54
drug
rifabutin
DrugDDI.d145.s6.e2 56 66
drug
rifapentine
DrugDDI.d145.s6.e3 68 76
drug
phenytoin
DrugDDI.d145.s6.e4 78 90
drug
carbamazepine
DrugDDI.d145.s6.e5 92 104
drug
phenobarbital
DrugDDI.d145.s6.e6 108 119
drug
St. Johns Wort

interaction DrugDDI.d145.s6.e0 DrugDDI.d145.s6.e1 false
interaction DrugDDI.d145.s6.e0 DrugDDI.d145.s6.e2 false
interaction DrugDDI.d145.s6.e0 DrugDDI.d145.s6.e3 false
interaction DrugDDI.d145.s6.e0 DrugDDI.d145.s6.e4 false
interaction DrugDDI.d145.s6.e0 DrugDDI.d145.s6.e5 false
interaction DrugDDI.d145.s6.e0 DrugDDI.d145.s6.e6 false
interaction DrugDDI.d145.s6.e1 DrugDDI.d145.s6.e2 false
interaction DrugDDI.d145.s6.e1 DrugDDI.d145.s6.e3 false
interaction DrugDDI.d145.s6.e1 DrugDDI.d145.s6.e4 false
interaction DrugDDI.d145.s6.e1 DrugDDI.d145.s6.e5 false
interaction DrugDDI.d145.s6.e1 DrugDDI.d145.s6.e6 false
interaction DrugDDI.d145.s6.e2 DrugDDI.d145.s6.e3 false
interaction DrugDDI.d145.s6.e2 DrugDDI.d145.s6.e4 false
interaction DrugDDI.d145.s6.e2 DrugDDI.d145.s6.e5 false
interaction DrugDDI.d145.s6.e2 DrugDDI.d145.s6.e6 false
interaction DrugDDI.d145.s6.e3 DrugDDI.d145.s6.e4 false
interaction DrugDDI.d145.s6.e3 DrugDDI.d145.s6.e5 false
interaction DrugDDI.d145.s6.e3 DrugDDI.d145.s6.e6 false
interaction DrugDDI.d145.s6.e4 DrugDDI.d145.s6.e5 false
interaction DrugDDI.d145.s6.e4 DrugDDI.d145.s6.e6 false
interaction DrugDDI.d145.s6.e5 DrugDDI.d145.s6.e6 false

Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s7
Hepatotoxicity Asymptomatic increases in liver transaminases have been observed in TARCEVA treated patients; .

DrugDDI.d145.s7.e0 42 54
drug
transaminases
DrugDDI.d145.s7.e1 73 79
drug
TARCEVA

interaction DrugDDI.d145.s7.e0 DrugDDI.d145.s7.e1 false

Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s8
therefore, periodic liver function testing ( transaminases , bilirubin , and alkaline phosphatase ) should be considered.

DrugDDI.d145.s8.e0 39 51
drug
transaminases
DrugDDI.d145.s8.e1 53 61
drug
bilirubin
DrugDDI.d145.s8.e2 66 84
drug
alkaline phosphatase

interaction DrugDDI.d145.s8.e0 DrugDDI.d145.s8.e1 false
interaction DrugDDI.d145.s8.e0 DrugDDI.d145.s8.e2 false
interaction DrugDDI.d145.s8.e1 DrugDDI.d145.s8.e2 false

Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s9
Dose reduction or interruption of TARCEVA should be considered if changes in liver function are severe.

DrugDDI.d145.s9.e0 29 35
drug
TARCEVA



Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s10
Patients with Hepatic Impairment : In vitro and in vivo evidence suggest that erlotinib is cleared primarily by the liver .

DrugDDI.d145.s10.new.DISO.e2 12 28
DISO
Hepatic Impairment
DrugDDI.d145.s10.e0 65 73
drug
erlotinib
DrugDDI.d145.s10.e1 97 101
drug
liver

interaction DrugDDI.d145.s10.e0 DrugDDI.d145.s10.e1 false

Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s11
Therefore, erlotinib exposure may be increased in patients with hepatic dysfunction.

DrugDDI.d145.s11.e0 10 18
drug
erlotinib
DrugDDI.d145.s11.new.DISO.e1 55 72
DISO
hepatic dysfunction



Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s12
Elevated International Normalized Ratio and Potential Bleeding International Normalized Ratio (INR) elevations and infrequent reports of bleeding events including gastrointestinal and non-gastrointestinal bleedings have been reported in clinical studies, some associated with concomitant warfarin administration.

DrugDDI.d145.s12.e0 255 262
drug
warfarin



Abstract Id: DrugDDI.d145
Sentence Id: DrugDDI.d145.s13
Patients taking warfarin or other coumarin-derivative anticoagulants should be monitored regularly for changes in prothrombin time or INR .

DrugDDI.d145.s13.e0 14 21
drug
warfarin
DrugDDI.d145.s13.e1 29 61
drug
coumarin-derivative anticoagulants

interaction DrugDDI.d145.s13.e0 DrugDDI.d145.s13.e1 true

Abstract Id: DrugDDI.d124
Sentence Id: DrugDDI.d124.s0
When ertapenem is co-administered with probenecid ( 500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem .

DrugDDI.d124.s0.e0 4 12
drug
ertapenem
DrugDDI.d124.s0.e1 34 43
drug
probenecid
DrugDDI.d124.s0.e2 45 47
drug
500
DrugDDI.d124.s0.e3 67 76
drug
probenecid
DrugDDI.d124.s0.e4 139 147
drug
ertapenem

interaction DrugDDI.d124.s0.e0 DrugDDI.d124.s0.e1 true
interaction DrugDDI.d124.s0.e0 DrugDDI.d124.s0.e2 false
interaction DrugDDI.d124.s0.e0 DrugDDI.d124.s0.e3 false
interaction DrugDDI.d124.s0.e0 DrugDDI.d124.s0.e4 false
interaction DrugDDI.d124.s0.e1 DrugDDI.d124.s0.e2 false
interaction DrugDDI.d124.s0.e1 DrugDDI.d124.s0.e3 false
interaction DrugDDI.d124.s0.e1 DrugDDI.d124.s0.e4 false
interaction DrugDDI.d124.s0.e2 DrugDDI.d124.s0.e3 false
interaction DrugDDI.d124.s0.e2 DrugDDI.d124.s0.e4 false
interaction DrugDDI.d124.s0.e3 DrugDDI.d124.s0.e4 false

Abstract Id: DrugDDI.d124
Sentence Id: DrugDDI.d124.s1
Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.

DrugDDI.d124.s1.e0 12 20
drug
ertapenem
DrugDDI.d124.s1.e1 36 45
drug
probenecid

interaction DrugDDI.d124.s1.e0 DrugDDI.d124.s1.e1 true

Abstract Id: DrugDDI.d124
Sentence Id: DrugDDI.d124.s3
Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.

DrugDDI.d124.s3.e0 58 67
drug
probenecid
DrugDDI.d124.s3.e1 90 98
drug
ertapenem

interaction DrugDDI.d124.s3.e0 DrugDDI.d124.s3.e1 true

Abstract Id: DrugDDI.d124
Sentence Id: DrugDDI.d124.s4
In vitro studies indicate that ertapenem does not inhibit P- glycoprotein -mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P- glycoprotein -mediated transport.

DrugDDI.d124.s4.e0 26 34
drug
ertapenem
DrugDDI.d124.s4.e1 51 62
drug
glycoprotein
DrugDDI.d124.s4.e2 83 89
drug
digoxin
DrugDDI.d124.s4.e3 92 102
drug
vinblastine
DrugDDI.d124.s4.e4 110 118
drug
ertapenem
DrugDDI.d124.s4.e5 139 150
drug
glycoprotein

interaction DrugDDI.d124.s4.e0 DrugDDI.d124.s4.e1 false
interaction DrugDDI.d124.s4.e0 DrugDDI.d124.s4.e2 false
interaction DrugDDI.d124.s4.e0 DrugDDI.d124.s4.e3 false
interaction DrugDDI.d124.s4.e0 DrugDDI.d124.s4.e4 false
interaction DrugDDI.d124.s4.e0 DrugDDI.d124.s4.e5 false
interaction DrugDDI.d124.s4.e1 DrugDDI.d124.s4.e2 false
interaction DrugDDI.d124.s4.e1 DrugDDI.d124.s4.e3 false
interaction DrugDDI.d124.s4.e1 DrugDDI.d124.s4.e4 false
interaction DrugDDI.d124.s4.e1 DrugDDI.d124.s4.e5 false
interaction DrugDDI.d124.s4.e2 DrugDDI.d124.s4.e3 false
interaction DrugDDI.d124.s4.e2 DrugDDI.d124.s4.e4 false
interaction DrugDDI.d124.s4.e2 DrugDDI.d124.s4.e5 false
interaction DrugDDI.d124.s4.e3 DrugDDI.d124.s4.e4 false
interaction DrugDDI.d124.s4.e3 DrugDDI.d124.s4.e5 false
interaction DrugDDI.d124.s4.e4 DrugDDI.d124.s4.e5 false

Abstract Id: DrugDDI.d124
Sentence Id: DrugDDI.d124.s5
In vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the following six cytochrome p450 ( CYP ) isoforms : 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.

DrugDDI.d124.s5.e0 48 56
drug
ertapenem
DrugDDI.d124.s5.e1 111 124
drug
cytochrome p450
DrugDDI.d124.s5.e2 126 128
drug
CYP
DrugDDI.d124.s5.e3 130 137
drug
isoforms

interaction DrugDDI.d124.s5.e0 DrugDDI.d124.s5.e1 false
interaction DrugDDI.d124.s5.e0 DrugDDI.d124.s5.e2 false
interaction DrugDDI.d124.s5.e0 DrugDDI.d124.s5.e3 false
interaction DrugDDI.d124.s5.e1 DrugDDI.d124.s5.e2 false
interaction DrugDDI.d124.s5.e1 DrugDDI.d124.s5.e3 false
interaction DrugDDI.d124.s5.e2 DrugDDI.d124.s5.e3 false

Abstract Id: DrugDDI.d124
Sentence Id: DrugDDI.d124.s6
Drug interactions caused by inhibition of P- glycoprotein -mediated drug clearance or CYP -mediated drug clearance with the listed isoforms are unlikely.

DrugDDI.d124.s6.e0 38 49
drug
glycoprotein
DrugDDI.d124.s6.e1 74 76
drug
CYP
DrugDDI.d124.s6.e2 112 119
drug
isoforms

interaction DrugDDI.d124.s6.e0 DrugDDI.d124.s6.e1 false
interaction DrugDDI.d124.s6.e0 DrugDDI.d124.s6.e2 false
interaction DrugDDI.d124.s6.e1 DrugDDI.d124.s6.e2 false

Abstract Id: DrugDDI.d124
Sentence Id: DrugDDI.d124.s7
Other than with probenecid , no specific clinical drug interaction studies have been conducted .

DrugDDI.d124.s7.e0 13 22
drug
probenecid



Abstract Id: DrugDDI.d388
Sentence Id: DrugDDI.d388.s1
Drug and Laboratory Test Interactions 1.

DrugDDI.d388.s1.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d388
Sentence Id: DrugDDI.d388.s4
increased factors II , VII antigen , VIII antigen , VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin ; .

DrugDDI.d388.s4.e0 9 17
drug
factors II
DrugDDI.d388.s4.e1 22 28
drug
antigen
DrugDDI.d388.s4.e2 34 40
drug
antigen
DrugDDI.d388.s4.e3 42 54
drug
VIII coagulant
DrugDDI.d388.s4.e4 105 124
drug
beta-thromboglobulin

interaction DrugDDI.d388.s4.e0 DrugDDI.d388.s4.e1 false
interaction DrugDDI.d388.s4.e0 DrugDDI.d388.s4.e2 false
interaction DrugDDI.d388.s4.e0 DrugDDI.d388.s4.e3 false
interaction DrugDDI.d388.s4.e0 DrugDDI.d388.s4.e4 false
interaction DrugDDI.d388.s4.e1 DrugDDI.d388.s4.e2 false
interaction DrugDDI.d388.s4.e1 DrugDDI.d388.s4.e3 false
interaction DrugDDI.d388.s4.e1 DrugDDI.d388.s4.e4 false
interaction DrugDDI.d388.s4.e2 DrugDDI.d388.s4.e3 false
interaction DrugDDI.d388.s4.e2 DrugDDI.d388.s4.e4 false
interaction DrugDDI.d388.s4.e3 DrugDDI.d388.s4.e4 false

Abstract Id: DrugDDI.d388
Sentence Id: DrugDDI.d388.s5
decreased levels of anti-factor Xa and antithrombin III , decreased antithrombin III activity; .

DrugDDI.d388.s5.e0 17 29
drug
anti-factor Xa
DrugDDI.d388.s5.e1 33 47
drug
antithrombin III
DrugDDI.d388.s5.e2 58 72
drug
antithrombin III

interaction DrugDDI.d388.s5.e0 DrugDDI.d388.s5.e1 false
interaction DrugDDI.d388.s5.e0 DrugDDI.d388.s5.e2 false
interaction DrugDDI.d388.s5.e1 DrugDDI.d388.s5.e2 false

Abstract Id: DrugDDI.d388
Sentence Id: DrugDDI.d388.s6
increased levels of fibrinogen and fibrinogen activity; .

DrugDDI.d388.s6.e0 17 26
drug
fibrinogen



Abstract Id: DrugDDI.d388
Sentence Id: DrugDDI.d388.s9
Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone levels, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay.

DrugDDI.d388.s9.e0 104 122
drug
protein-bound iodine



Abstract Id: DrugDDI.d388
Sentence Id: DrugDDI.d388.s11
Free T4 and T3 concentrations are unaltered.

DrugDDI.d388.s11.e0 9 10
drug
T3



Abstract Id: DrugDDI.d388
Sentence Id: DrugDDI.d388.s12
Patients on thyroid replacement therapy may require higher doses of thyroid hormone .

DrugDDI.d388.s12.e0 10 16
drug
thyroid
DrugDDI.d388.s12.e1 58 71
drug
thyroid hormone

interaction DrugDDI.d388.s12.e0 DrugDDI.d388.s12.e1 false

Abstract Id: DrugDDI.d388
Sentence Id: DrugDDI.d388.s14
Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin ( CBG ), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.

DrugDDI.d388.s14.e0 5 19
drug
binding proteins
DrugDDI.d388.s14.e1 46 74
drug
corticosteroid binding globulin
DrugDDI.d388.s14.e2 76 78
drug
CBG
DrugDDI.d388.s14.e3 81 106
drug
sex hormone-binding globulin
DrugDDI.d388.s14.e4 148 162
drug
corticosteroids

interaction DrugDDI.d388.s14.e0 DrugDDI.d388.s14.e1 false
interaction DrugDDI.d388.s14.e0 DrugDDI.d388.s14.e2 false
interaction DrugDDI.d388.s14.e0 DrugDDI.d388.s14.e3 false
interaction DrugDDI.d388.s14.e0 DrugDDI.d388.s14.e4 false
interaction DrugDDI.d388.s14.e1 DrugDDI.d388.s14.e2 false
interaction DrugDDI.d388.s14.e1 DrugDDI.d388.s14.e3 false
interaction DrugDDI.d388.s14.e1 DrugDDI.d388.s14.e4 false
interaction DrugDDI.d388.s14.e2 DrugDDI.d388.s14.e3 false
interaction DrugDDI.d388.s14.e2 DrugDDI.d388.s14.e4 false
interaction DrugDDI.d388.s14.e3 DrugDDI.d388.s14.e4 false

Abstract Id: DrugDDI.d388
Sentence Id: DrugDDI.d388.s16
Other plasma proteins may be increased ( angiotensinogen /renin substrate , alpha-1-antitrypsin , ceruloplasmin ).

DrugDDI.d388.s16.e0 5 18
drug
plasma proteins
DrugDDI.d388.s16.e1 34 48
drug
angiotensinogen
DrugDDI.d388.s16.e2 49 63
drug
/renin substrate
DrugDDI.d388.s16.e3 65 83
drug
alpha-1-antitrypsin
DrugDDI.d388.s16.e4 85 97
drug
ceruloplasmin

interaction DrugDDI.d388.s16.e0 DrugDDI.d388.s16.e1 false
interaction DrugDDI.d388.s16.e0 DrugDDI.d388.s16.e2 false
interaction DrugDDI.d388.s16.e0 DrugDDI.d388.s16.e3 false
interaction DrugDDI.d388.s16.e0 DrugDDI.d388.s16.e4 false
interaction DrugDDI.d388.s16.e1 DrugDDI.d388.s16.e2 false
interaction DrugDDI.d388.s16.e1 DrugDDI.d388.s16.e3 false
interaction DrugDDI.d388.s16.e1 DrugDDI.d388.s16.e4 false
interaction DrugDDI.d388.s16.e2 DrugDDI.d388.s16.e3 false
interaction DrugDDI.d388.s16.e2 DrugDDI.d388.s16.e4 false
interaction DrugDDI.d388.s16.e3 DrugDDI.d388.s16.e4 false

Abstract Id: DrugDDI.d388
Sentence Id: DrugDDI.d388.s18
Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels.

DrugDDI.d388.s18.e0 25 35
drug
cholesterol
DrugDDI.d388.s18.e1 69 82
drug
LDL cholesterol

interaction DrugDDI.d388.s18.e0 DrugDDI.d388.s18.e1 false

Abstract Id: DrugDDI.d217
Sentence Id: DrugDDI.d217.s1
However, it was observed that the pharmacokinetics of ENBREL@ was unaltered by concomitant methotrexate in rheumatoid arthritis patients.

DrugDDI.d217.s1.e0 78 89
drug
methotrexate
DrugDDI.d217.s1.new.DISO.e1 92 110
DISO
rheumatoid arthritis



Abstract Id: DrugDDI.d217
Sentence Id: DrugDDI.d217.s2
In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL@ and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL@ alone (0%).

DrugDDI.d217.s2.e0 84 91
drug
anakinra
DrugDDI.d217.s2.new.DISO.e1 116 125
DISO
infections



Abstract Id: DrugDDI.d217
Sentence Id: DrugDDI.d217.s3
Two percent of patients treated concurrently with ENBREL@ and anakinra developed neutropenia ( ANC 1 x 109/L ).

DrugDDI.d217.s3.e0 53 60
drug
anakinra
DrugDDI.d217.s3.new.DISO.e2 70 80
DISO
neutropenia
DrugDDI.d217.s3.e1 82 91
drug
ANC   1 x 109/L

interaction DrugDDI.d217.s3.e0 DrugDDI.d217.s3.e1 false

Abstract Id: DrugDDI.d217
Sentence Id: DrugDDI.d217.s4
Patients in a clinical study who were on established therapy with sulfasalazine , to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.

DrugDDI.d217.s4.e0 55 67
drug
sulfasalazine
DrugDDI.d217.s4.e1 76 81
drug
ENBREL
DrugDDI.d217.s4.e2 181 186
drug
ENBREL
DrugDDI.d217.s4.e3 191 203
drug
sulfasalazine

interaction DrugDDI.d217.s4.e0 DrugDDI.d217.s4.e1 true
interaction DrugDDI.d217.s4.e0 DrugDDI.d217.s4.e2 false
interaction DrugDDI.d217.s4.e0 DrugDDI.d217.s4.e3 false
interaction DrugDDI.d217.s4.e1 DrugDDI.d217.s4.e2 false
interaction DrugDDI.d217.s4.e1 DrugDDI.d217.s4.e3 false
interaction DrugDDI.d217.s4.e2 DrugDDI.d217.s4.e3 false

Abstract Id: DrugDDI.d174
Sentence Id: DrugDDI.d174.s0
Dicumarol and warfarin may decrease hypoprothrombinemic effect.

DrugDDI.d174.s0.e0 0 8
drug
Dicumarol
DrugDDI.d174.s0.e1 12 19
drug
warfarin

interaction DrugDDI.d174.s0.e0 DrugDDI.d174.s0.e1 true

Abstract Id: DrugDDI.d174
Sentence Id: DrugDDI.d174.s1
Other depressasnts such as alcohol , barbiturates , and MAOIs may enhance CNS depression when administered with ethchlorvynol .

DrugDDI.d174.s1.e0 23 29
drug
alcohol
DrugDDI.d174.s1.e1 31 42
drug
barbiturates
DrugDDI.d174.s1.e2 95 107
drug
ethchlorvynol

interaction DrugDDI.d174.s1.e0 DrugDDI.d174.s1.e1 false
interaction DrugDDI.d174.s1.e0 DrugDDI.d174.s1.e2 true
interaction DrugDDI.d174.s1.e1 DrugDDI.d174.s1.e2 true

Abstract Id: DrugDDI.d9
Sentence Id: DrugDDI.d9.s0
Certain endocrine and liver function tests may be affected by estrogen -containing oral contraceptives .

DrugDDI.d9.s0.e0 52 59
drug
estrogen
DrugDDI.d9.s0.e1 71 88
drug
oral contraceptives

interaction DrugDDI.d9.s0.e0 DrugDDI.d9.s0.e1 false

Abstract Id: DrugDDI.d9
Sentence Id: DrugDDI.d9.s1
The following similar changes may be expected with larger doses of estrogen : Increased sulfobromophthalein retention; .

DrugDDI.d9.s1.e0 56 63
drug
estrogen



Abstract Id: DrugDDI.d9
Sentence Id: DrugDDI.d9.s2
increased prothrombin and factors VII , VIII, IX, and X; .

DrugDDI.d9.s2.e0 9 19
drug
prothrombin
DrugDDI.d9.s2.e1 23 32
drug
factors VII

interaction DrugDDI.d9.s2.e0 DrugDDI.d9.s2.e1 false

Abstract Id: DrugDDI.d9
Sentence Id: DrugDDI.d9.s3
decreased antithrombin 3; .

DrugDDI.d9.s3.e0 9 20
drug
antithrombin



Abstract Id: DrugDDI.d9
Sentence Id: DrugDDI.d9.s4
increased norepinephrine -induced platel et aggregation; .

DrugDDI.d9.s4.e0 9 22
drug
norepinephrine



Abstract Id: DrugDDI.d9
Sentence Id: DrugDDI.d9.s5
increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone , as measured by PBI, T4 by column, or T4 by radioimmunoassay.

DrugDDI.d9.s5.e0 70 83
drug
thyroid hormone
DrugDDI.d9.s5.e1 101 102
drug
T4
DrugDDI.d9.s5.e2 114 115
drug
T4

interaction DrugDDI.d9.s5.e0 DrugDDI.d9.s5.e1 false
interaction DrugDDI.d9.s5.e0 DrugDDI.d9.s5.e2 false
interaction DrugDDI.d9.s5.e1 DrugDDI.d9.s5.e2 false

Abstract Id: DrugDDI.d9
Sentence Id: DrugDDI.d9.s11
increased serum triglyceride and phospholipid concentration.

DrugDDI.d9.s11.e0 29 40
drug
phospholipid



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s0
Ethinyl estradiol : Substrate of CYP3A4 (major), 3A5-7 (minor); .

DrugDDI.d132.s0.e0 0 15
drug
Ethinyl estradiol
DrugDDI.d132.s0.e1 28 33
drug
CYP3A4

interaction DrugDDI.d132.s0.e0 DrugDDI.d132.s0.e1 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s1
Inhibits CYP1A2 (weak), 2B6 (weak), 2C19 (weak), 3A4 (weak).

DrugDDI.d132.s1.e0 8 13
drug
CYP1A2



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s2
Acetaminophen : May increase plasma concentration of synthetic estrogens , possibly by inhibiting conjugation.

DrugDDI.d132.s2.e0 0 12
drug
Acetaminophen
DrugDDI.d132.s2.e1 46 63
drug
synthetic estrogens

interaction DrugDDI.d132.s2.e0 DrugDDI.d132.s2.e1 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s3
Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen .

DrugDDI.d132.s3.e0 19 32
drug
contraceptives
DrugDDI.d132.s3.e1 72 84
drug
acetaminophen

interaction DrugDDI.d132.s3.e0 DrugDDI.d132.s3.e1 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s4
Acitretin : Interferes with the contraceptive effect of microdosed progestin -containing minipill preparations.

DrugDDI.d132.s4.e0 0 8
drug
Acitretin
DrugDDI.d132.s4.e1 27 39
drug
contraceptive
DrugDDI.d132.s4.e2 58 66
drug
progestin

interaction DrugDDI.d132.s4.e0 DrugDDI.d132.s4.e1 false
interaction DrugDDI.d132.s4.e0 DrugDDI.d132.s4.e2 true
interaction DrugDDI.d132.s4.e1 DrugDDI.d132.s4.e2 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s5
The effect on other progestational contraceptives (eg, implants, injectables) is unknown.

DrugDDI.d132.s5.e0 30 43
drug
contraceptives



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s6
Aminoglutethimide : May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.

DrugDDI.d132.s6.e0 0 16
drug
Aminoglutethimide
DrugDDI.d132.s6.e1 29 31
drug
CYP
DrugDDI.d132.s6.e2 44 53
drug
progestins
DrugDDI.d132.s6.e3 81 93
drug
contraceptive

interaction DrugDDI.d132.s6.e0 DrugDDI.d132.s6.e1 false
interaction DrugDDI.d132.s6.e0 DrugDDI.d132.s6.e2 false
interaction DrugDDI.d132.s6.e0 DrugDDI.d132.s6.e3 false
interaction DrugDDI.d132.s6.e1 DrugDDI.d132.s6.e2 false
interaction DrugDDI.d132.s6.e1 DrugDDI.d132.s6.e3 false
interaction DrugDDI.d132.s6.e2 DrugDDI.d132.s6.e3 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s7
Use of a nonhormonal contraceptive product is recommended.

DrugDDI.d132.s7.e0 17 29
drug
contraceptive



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s8
Antibiotics ( ampicillin , tetracycline ): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.

DrugDDI.d132.s8.e0 0 10
drug
Antibiotics
DrugDDI.d132.s8.e1 12 21
drug
ampicillin
DrugDDI.d132.s8.e2 23 34
drug
tetracycline
DrugDDI.d132.s8.e3 153 163
drug
antibiotics

interaction DrugDDI.d132.s8.e0 DrugDDI.d132.s8.e1 false
interaction DrugDDI.d132.s8.e0 DrugDDI.d132.s8.e2 false
interaction DrugDDI.d132.s8.e0 DrugDDI.d132.s8.e3 false
interaction DrugDDI.d132.s8.e1 DrugDDI.d132.s8.e2 false
interaction DrugDDI.d132.s8.e1 DrugDDI.d132.s8.e3 false
interaction DrugDDI.d132.s8.e2 DrugDDI.d132.s8.e3 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s9
Use of a nonhormonal contraceptive product is recommended.

DrugDDI.d132.s9.e0 17 29
drug
contraceptive



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s10
Anticoagulants : Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.

DrugDDI.d132.s10.e0 0 13
drug
Anticoagulants
DrugDDI.d132.s10.e1 34 47
drug
contraceptives
DrugDDI.d132.s10.e2 81 88
drug
coumarin

interaction DrugDDI.d132.s10.e0 DrugDDI.d132.s10.e1 false
interaction DrugDDI.d132.s10.e0 DrugDDI.d132.s10.e2 false
interaction DrugDDI.d132.s10.e1 DrugDDI.d132.s10.e2 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s11
Combination hormonal contraceptives may also increase risk of thromboembolic disorders.

DrugDDI.d132.s11.e0 19 32
drug
contraceptives
DrugDDI.d132.s11.new.DISO.e1 54 76
DISO
thromboembolic disorders



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s12
Anticonvulsants ( carbamazepine , felbamate , phenobarbital , phenytoin , topiramate ): Increase the metabolism of ethinyl estradiol and/or some progestins , leading to possible decrease in contraceptive effectiveness.

DrugDDI.d132.s12.e0 0 14
drug
Anticonvulsants
DrugDDI.d132.s12.e1 16 28
drug
carbamazepine
DrugDDI.d132.s12.e2 30 38
drug
felbamate
DrugDDI.d132.s12.e3 40 52
drug
phenobarbital
DrugDDI.d132.s12.e4 54 62
drug
phenytoin
DrugDDI.d132.s12.e5 64 73
drug
topiramate
DrugDDI.d132.s12.e6 99 114
drug
ethinyl estradiol
DrugDDI.d132.s12.e7 125 134
drug
progestins
DrugDDI.d132.s12.e8 163 175
drug
contraceptive

interaction DrugDDI.d132.s12.e0 DrugDDI.d132.s12.e1 false
interaction DrugDDI.d132.s12.e0 DrugDDI.d132.s12.e2 false
interaction DrugDDI.d132.s12.e0 DrugDDI.d132.s12.e3 false
interaction DrugDDI.d132.s12.e0 DrugDDI.d132.s12.e4 false
interaction DrugDDI.d132.s12.e0 DrugDDI.d132.s12.e5 false
interaction DrugDDI.d132.s12.e0 DrugDDI.d132.s12.e6 false
interaction DrugDDI.d132.s12.e0 DrugDDI.d132.s12.e7 false
interaction DrugDDI.d132.s12.e0 DrugDDI.d132.s12.e8 false
interaction DrugDDI.d132.s12.e1 DrugDDI.d132.s12.e2 false
interaction DrugDDI.d132.s12.e1 DrugDDI.d132.s12.e3 false
interaction DrugDDI.d132.s12.e1 DrugDDI.d132.s12.e4 false
interaction DrugDDI.d132.s12.e1 DrugDDI.d132.s12.e5 false
interaction DrugDDI.d132.s12.e1 DrugDDI.d132.s12.e6 false
interaction DrugDDI.d132.s12.e1 DrugDDI.d132.s12.e7 false
interaction DrugDDI.d132.s12.e1 DrugDDI.d132.s12.e8 false
interaction DrugDDI.d132.s12.e2 DrugDDI.d132.s12.e3 false
interaction DrugDDI.d132.s12.e2 DrugDDI.d132.s12.e4 false
interaction DrugDDI.d132.s12.e2 DrugDDI.d132.s12.e5 false
interaction DrugDDI.d132.s12.e2 DrugDDI.d132.s12.e6 false
interaction DrugDDI.d132.s12.e2 DrugDDI.d132.s12.e7 false
interaction DrugDDI.d132.s12.e2 DrugDDI.d132.s12.e8 false
interaction DrugDDI.d132.s12.e3 DrugDDI.d132.s12.e4 false
interaction DrugDDI.d132.s12.e3 DrugDDI.d132.s12.e5 false
interaction DrugDDI.d132.s12.e3 DrugDDI.d132.s12.e6 false
interaction DrugDDI.d132.s12.e3 DrugDDI.d132.s12.e7 false
interaction DrugDDI.d132.s12.e3 DrugDDI.d132.s12.e8 false
interaction DrugDDI.d132.s12.e4 DrugDDI.d132.s12.e5 false
interaction DrugDDI.d132.s12.e4 DrugDDI.d132.s12.e6 false
interaction DrugDDI.d132.s12.e4 DrugDDI.d132.s12.e7 false
interaction DrugDDI.d132.s12.e4 DrugDDI.d132.s12.e8 false
interaction DrugDDI.d132.s12.e5 DrugDDI.d132.s12.e6 false
interaction DrugDDI.d132.s12.e5 DrugDDI.d132.s12.e7 false
interaction DrugDDI.d132.s12.e5 DrugDDI.d132.s12.e8 false
interaction DrugDDI.d132.s12.e6 DrugDDI.d132.s12.e7 false
interaction DrugDDI.d132.s12.e6 DrugDDI.d132.s12.e8 false
interaction DrugDDI.d132.s12.e7 DrugDDI.d132.s12.e8 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s13
Use of a nonhormonal contraceptive product is recommended.

DrugDDI.d132.s13.e0 17 29
drug
contraceptive



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s14
Ascorbic acid : Doses of ascorbic acid ( vitamin C ) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation; .

DrugDDI.d132.s14.e0 0 11
drug
Ascorbic acid
DrugDDI.d132.s14.e1 20 31
drug
ascorbic acid
DrugDDI.d132.s14.e2 33 40
drug
vitamin C
DrugDDI.d132.s14.e3 95 112
drug
synthetic estrogens

interaction DrugDDI.d132.s14.e0 DrugDDI.d132.s14.e1 false
interaction DrugDDI.d132.s14.e0 DrugDDI.d132.s14.e2 false
interaction DrugDDI.d132.s14.e0 DrugDDI.d132.s14.e3 false
interaction DrugDDI.d132.s14.e1 DrugDDI.d132.s14.e2 false
interaction DrugDDI.d132.s14.e1 DrugDDI.d132.s14.e3 true
interaction DrugDDI.d132.s14.e2 DrugDDI.d132.s14.e3 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s16
Atorvastatin : Atorvastatin increases the AUC for norethindrone and ethinyl estradiol .

DrugDDI.d132.s16.e0 0 11
drug
Atorvastatin
DrugDDI.d132.s16.e1 13 24
drug
Atorvastatin
DrugDDI.d132.s16.e2 43 55
drug
norethindrone
DrugDDI.d132.s16.e3 59 74
drug
ethinyl estradiol

interaction DrugDDI.d132.s16.e0 DrugDDI.d132.s16.e1 false
interaction DrugDDI.d132.s16.e0 DrugDDI.d132.s16.e2 false
interaction DrugDDI.d132.s16.e0 DrugDDI.d132.s16.e3 false
interaction DrugDDI.d132.s16.e1 DrugDDI.d132.s16.e2 true
interaction DrugDDI.d132.s16.e1 DrugDDI.d132.s16.e3 true
interaction DrugDDI.d132.s16.e2 DrugDDI.d132.s16.e3 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s17
Benzodiazepines : Combination hormonal contraceptives may decrease the clearance of some benzodiazepines ( alprazolam , chlordiazepoxide , diazepam ) and increase the clearance of others ( lorazepam , oxazepam , temazepam ).

DrugDDI.d132.s17.e0 0 14
drug
Benzodiazepines
DrugDDI.d132.s17.e1 35 48
drug
contraceptives
DrugDDI.d132.s17.e2 78 92
drug
benzodiazepines
DrugDDI.d132.s17.e3 94 103
drug
alprazolam
DrugDDI.d132.s17.e4 105 120
drug
chlordiazepoxide
DrugDDI.d132.s17.e5 122 129
drug
diazepam
DrugDDI.d132.s17.e6 163 171
drug
lorazepam
DrugDDI.d132.s17.e7 173 180
drug
oxazepam
DrugDDI.d132.s17.e8 182 190
drug
temazepam

interaction DrugDDI.d132.s17.e0 DrugDDI.d132.s17.e1 false
interaction DrugDDI.d132.s17.e0 DrugDDI.d132.s17.e2 false
interaction DrugDDI.d132.s17.e0 DrugDDI.d132.s17.e3 false
interaction DrugDDI.d132.s17.e0 DrugDDI.d132.s17.e4 false
interaction DrugDDI.d132.s17.e0 DrugDDI.d132.s17.e5 false
interaction DrugDDI.d132.s17.e0 DrugDDI.d132.s17.e6 false
interaction DrugDDI.d132.s17.e0 DrugDDI.d132.s17.e7 false
interaction DrugDDI.d132.s17.e0 DrugDDI.d132.s17.e8 false
interaction DrugDDI.d132.s17.e1 DrugDDI.d132.s17.e2 true
interaction DrugDDI.d132.s17.e1 DrugDDI.d132.s17.e3 true
interaction DrugDDI.d132.s17.e1 DrugDDI.d132.s17.e4 true
interaction DrugDDI.d132.s17.e1 DrugDDI.d132.s17.e5 true
interaction DrugDDI.d132.s17.e1 DrugDDI.d132.s17.e6 true
interaction DrugDDI.d132.s17.e1 DrugDDI.d132.s17.e7 true
interaction DrugDDI.d132.s17.e1 DrugDDI.d132.s17.e8 true
interaction DrugDDI.d132.s17.e2 DrugDDI.d132.s17.e3 false
interaction DrugDDI.d132.s17.e2 DrugDDI.d132.s17.e4 false
interaction DrugDDI.d132.s17.e2 DrugDDI.d132.s17.e5 false
interaction DrugDDI.d132.s17.e2 DrugDDI.d132.s17.e6 false
interaction DrugDDI.d132.s17.e2 DrugDDI.d132.s17.e7 false
interaction DrugDDI.d132.s17.e2 DrugDDI.d132.s17.e8 false
interaction DrugDDI.d132.s17.e3 DrugDDI.d132.s17.e4 false
interaction DrugDDI.d132.s17.e3 DrugDDI.d132.s17.e5 false
interaction DrugDDI.d132.s17.e3 DrugDDI.d132.s17.e6 false
interaction DrugDDI.d132.s17.e3 DrugDDI.d132.s17.e7 false
interaction DrugDDI.d132.s17.e3 DrugDDI.d132.s17.e8 false
interaction DrugDDI.d132.s17.e4 DrugDDI.d132.s17.e5 false
interaction DrugDDI.d132.s17.e4 DrugDDI.d132.s17.e6 false
interaction DrugDDI.d132.s17.e4 DrugDDI.d132.s17.e7 false
interaction DrugDDI.d132.s17.e4 DrugDDI.d132.s17.e8 false
interaction DrugDDI.d132.s17.e5 DrugDDI.d132.s17.e6 false
interaction DrugDDI.d132.s17.e5 DrugDDI.d132.s17.e7 false
interaction DrugDDI.d132.s17.e5 DrugDDI.d132.s17.e8 false
interaction DrugDDI.d132.s17.e6 DrugDDI.d132.s17.e7 false
interaction DrugDDI.d132.s17.e6 DrugDDI.d132.s17.e8 false
interaction DrugDDI.d132.s17.e7 DrugDDI.d132.s17.e8 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s18
Clofibric acid : Combination hormonal contraceptives may increase the clearance of clofibric acid .

DrugDDI.d132.s18.e0 0 12
drug
Clofibric acid
DrugDDI.d132.s18.e1 33 46
drug
contraceptives
DrugDDI.d132.s18.e2 72 84
drug
clofibric acid

interaction DrugDDI.d132.s18.e0 DrugDDI.d132.s18.e1 false
interaction DrugDDI.d132.s18.e0 DrugDDI.d132.s18.e2 false
interaction DrugDDI.d132.s18.e1 DrugDDI.d132.s18.e2 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s19
Cyclosporine : Combination hormonal contraceptives may inhibit the metabolism of cyclosporine , leading to increased plasma concentrations; .

DrugDDI.d132.s19.e0 0 11
drug
Cyclosporine
DrugDDI.d132.s19.e1 32 45
drug
contraceptives
DrugDDI.d132.s19.e2 71 82
drug
cyclosporine

interaction DrugDDI.d132.s19.e0 DrugDDI.d132.s19.e1 false
interaction DrugDDI.d132.s19.e0 DrugDDI.d132.s19.e2 false
interaction DrugDDI.d132.s19.e1 DrugDDI.d132.s19.e2 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s20
monitor cyclosporine levels.

DrugDDI.d132.s20.e0 7 18
drug
cyclosporine



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s21
CYP3A4 inducers: CYP3A4 inducers may decrease the levels/effects of ethinyl estradiol .

DrugDDI.d132.s21.e0 0 5
drug
CYP3A4
DrugDDI.d132.s21.e1 15 20
drug
CYP3A4
DrugDDI.d132.s21.e2 59 74
drug
ethinyl estradiol

interaction DrugDDI.d132.s21.e0 DrugDDI.d132.s21.e1 false
interaction DrugDDI.d132.s21.e0 DrugDDI.d132.s21.e2 false
interaction DrugDDI.d132.s21.e1 DrugDDI.d132.s21.e2 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s22
Example inducers include aminoglutethimide , carbamazepine , nafcillin , nevirapine , phenobarbital , phenytoin , and rifamycins .

DrugDDI.d132.s22.e0 22 38
drug
aminoglutethimide
DrugDDI.d132.s22.e1 40 52
drug
carbamazepine
DrugDDI.d132.s22.e2 54 62
drug
nafcillin
DrugDDI.d132.s22.e3 64 73
drug
nevirapine
DrugDDI.d132.s22.e4 75 87
drug
phenobarbital
DrugDDI.d132.s22.e5 89 97
drug
phenytoin
DrugDDI.d132.s22.e6 102 111
drug
rifamycins

interaction DrugDDI.d132.s22.e0 DrugDDI.d132.s22.e1 false
interaction DrugDDI.d132.s22.e0 DrugDDI.d132.s22.e2 false
interaction DrugDDI.d132.s22.e0 DrugDDI.d132.s22.e3 false
interaction DrugDDI.d132.s22.e0 DrugDDI.d132.s22.e4 false
interaction DrugDDI.d132.s22.e0 DrugDDI.d132.s22.e5 false
interaction DrugDDI.d132.s22.e0 DrugDDI.d132.s22.e6 false
interaction DrugDDI.d132.s22.e1 DrugDDI.d132.s22.e2 false
interaction DrugDDI.d132.s22.e1 DrugDDI.d132.s22.e3 false
interaction DrugDDI.d132.s22.e1 DrugDDI.d132.s22.e4 false
interaction DrugDDI.d132.s22.e1 DrugDDI.d132.s22.e5 false
interaction DrugDDI.d132.s22.e1 DrugDDI.d132.s22.e6 false
interaction DrugDDI.d132.s22.e2 DrugDDI.d132.s22.e3 false
interaction DrugDDI.d132.s22.e2 DrugDDI.d132.s22.e4 false
interaction DrugDDI.d132.s22.e2 DrugDDI.d132.s22.e5 false
interaction DrugDDI.d132.s22.e2 DrugDDI.d132.s22.e6 false
interaction DrugDDI.d132.s22.e3 DrugDDI.d132.s22.e4 false
interaction DrugDDI.d132.s22.e3 DrugDDI.d132.s22.e5 false
interaction DrugDDI.d132.s22.e3 DrugDDI.d132.s22.e6 false
interaction DrugDDI.d132.s22.e4 DrugDDI.d132.s22.e5 false
interaction DrugDDI.d132.s22.e4 DrugDDI.d132.s22.e6 false
interaction DrugDDI.d132.s22.e5 DrugDDI.d132.s22.e6 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s23
Griseofulvin : Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes; .

DrugDDI.d132.s23.e0 0 11
drug
Griseofulvin
DrugDDI.d132.s23.e1 13 24
drug
Griseofulvin
DrugDDI.d132.s23.e2 68 81
drug
contraceptives

interaction DrugDDI.d132.s23.e0 DrugDDI.d132.s23.e1 false
interaction DrugDDI.d132.s23.e0 DrugDDI.d132.s23.e2 false
interaction DrugDDI.d132.s23.e1 DrugDDI.d132.s23.e2 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s25
Use of barrier form of contraception is suggested while on griseofulvin therapy.

DrugDDI.d132.s25.e0 49 60
drug
griseofulvin



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s26
Morphine : Combination hormonal contraceptives may increase the clearance of morphine .

DrugDDI.d132.s26.e0 0 7
drug
Morphine
DrugDDI.d132.s26.e1 28 41
drug
contraceptives
DrugDDI.d132.s26.e2 67 74
drug
morphine

interaction DrugDDI.d132.s26.e0 DrugDDI.d132.s26.e1 false
interaction DrugDDI.d132.s26.e0 DrugDDI.d132.s26.e2 false
interaction DrugDDI.d132.s26.e1 DrugDDI.d132.s26.e2 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s27
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives ; .

DrugDDI.d132.s27.e0 0 43
drug
Non-nucleoside reverse transcriptase inhibitors
DrugDDI.d132.s27.e1 53 62
drug
Nevirapine
DrugDDI.d132.s27.e2 107 120
drug
contraceptives

interaction DrugDDI.d132.s27.e0 DrugDDI.d132.s27.e1 false
interaction DrugDDI.d132.s27.e0 DrugDDI.d132.s27.e2 false
interaction DrugDDI.d132.s27.e1 DrugDDI.d132.s27.e2 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s28
use of a nonhormonal contraceptive product is recommended.

DrugDDI.d132.s28.e0 17 29
drug
contraceptive



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s29
No data for delavirdine ; .

DrugDDI.d132.s29.e0 9 19
drug
delavirdine



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s30
incomplete data for efavirenz .

DrugDDI.d132.s30.e0 17 25
drug
efavirenz



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s31
Prednisolone : Ethinyl estradiol may inhibit the metabolism of prednisolone , leading to increased plasma concentrations.

DrugDDI.d132.s31.e0 0 11
drug
Prednisolone
DrugDDI.d132.s31.e1 13 28
drug
Ethinyl estradiol
DrugDDI.d132.s31.e2 54 65
drug
prednisolone

interaction DrugDDI.d132.s31.e0 DrugDDI.d132.s31.e1 false
interaction DrugDDI.d132.s31.e0 DrugDDI.d132.s31.e2 false
interaction DrugDDI.d132.s31.e1 DrugDDI.d132.s31.e2 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s32
Protease inhibitors : Amprenavir , lopinavir , nelfinavir , and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives ; .

DrugDDI.d132.s32.e0 0 17
drug
Protease inhibitors
DrugDDI.d132.s32.e1 19 28
drug
Amprenavir
DrugDDI.d132.s32.e2 30 38
drug
lopinavir
DrugDDI.d132.s32.e3 40 49
drug
nelfinavir
DrugDDI.d132.s32.e4 54 62
drug
ritonavir
DrugDDI.d132.s32.e5 119 132
drug
contraceptives

interaction DrugDDI.d132.s32.e0 DrugDDI.d132.s32.e1 false
interaction DrugDDI.d132.s32.e0 DrugDDI.d132.s32.e2 false
interaction DrugDDI.d132.s32.e0 DrugDDI.d132.s32.e3 false
interaction DrugDDI.d132.s32.e0 DrugDDI.d132.s32.e4 false
interaction DrugDDI.d132.s32.e0 DrugDDI.d132.s32.e5 false
interaction DrugDDI.d132.s32.e1 DrugDDI.d132.s32.e2 false
interaction DrugDDI.d132.s32.e1 DrugDDI.d132.s32.e3 false
interaction DrugDDI.d132.s32.e1 DrugDDI.d132.s32.e4 false
interaction DrugDDI.d132.s32.e1 DrugDDI.d132.s32.e5 true
interaction DrugDDI.d132.s32.e2 DrugDDI.d132.s32.e3 false
interaction DrugDDI.d132.s32.e2 DrugDDI.d132.s32.e4 false
interaction DrugDDI.d132.s32.e2 DrugDDI.d132.s32.e5 true
interaction DrugDDI.d132.s32.e3 DrugDDI.d132.s32.e4 false
interaction DrugDDI.d132.s32.e3 DrugDDI.d132.s32.e5 true
interaction DrugDDI.d132.s32.e4 DrugDDI.d132.s32.e5 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s33
use of a nonhormonal contraceptive product is recommended.

DrugDDI.d132.s33.e0 17 29
drug
contraceptive



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s34
Indinavir has been shown to increase plasma levels of combination hormonal contraceptives .

DrugDDI.d132.s34.e0 0 8
drug
Indinavir
DrugDDI.d132.s34.e1 64 77
drug
contraceptives

interaction DrugDDI.d132.s34.e0 DrugDDI.d132.s34.e1 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s35
No data for saquinavir .

DrugDDI.d132.s35.e0 9 18
drug
saquinavir



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s36
Rifampin : Rifampin increases the metabolism of ethinyl estradiol and some progestins ( norethindrone ) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.

DrugDDI.d132.s36.e0 0 7
drug
Rifampin
DrugDDI.d132.s36.e1 9 16
drug
Rifampin
DrugDDI.d132.s36.e2 41 56
drug
ethinyl estradiol
DrugDDI.d132.s36.e3 64 73
drug
progestins
DrugDDI.d132.s36.e4 75 87
drug
norethindrone
DrugDDI.d132.s36.e5 109 121
drug
contraceptive

interaction DrugDDI.d132.s36.e0 DrugDDI.d132.s36.e1 false
interaction DrugDDI.d132.s36.e0 DrugDDI.d132.s36.e2 false
interaction DrugDDI.d132.s36.e0 DrugDDI.d132.s36.e3 false
interaction DrugDDI.d132.s36.e0 DrugDDI.d132.s36.e4 false
interaction DrugDDI.d132.s36.e0 DrugDDI.d132.s36.e5 false
interaction DrugDDI.d132.s36.e1 DrugDDI.d132.s36.e2 true
interaction DrugDDI.d132.s36.e1 DrugDDI.d132.s36.e3 true
interaction DrugDDI.d132.s36.e1 DrugDDI.d132.s36.e4 true
interaction DrugDDI.d132.s36.e1 DrugDDI.d132.s36.e5 false
interaction DrugDDI.d132.s36.e2 DrugDDI.d132.s36.e3 false
interaction DrugDDI.d132.s36.e2 DrugDDI.d132.s36.e4 false
interaction DrugDDI.d132.s36.e2 DrugDDI.d132.s36.e5 false
interaction DrugDDI.d132.s36.e3 DrugDDI.d132.s36.e4 false
interaction DrugDDI.d132.s36.e3 DrugDDI.d132.s36.e5 false
interaction DrugDDI.d132.s36.e4 DrugDDI.d132.s36.e5 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s37
Use of a nonhormonal contraceptive product is recommended.

DrugDDI.d132.s37.e0 17 29
drug
contraceptive



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s38
Salicylic acid : Combination hormonal contraceptives may increase the clearance of salicylic acid .

DrugDDI.d132.s38.e0 0 12
drug
Salicylic acid
DrugDDI.d132.s38.e1 33 46
drug
contraceptives
DrugDDI.d132.s38.e2 72 84
drug
salicylic acid

interaction DrugDDI.d132.s38.e0 DrugDDI.d132.s38.e1 false
interaction DrugDDI.d132.s38.e0 DrugDDI.d132.s38.e2 false
interaction DrugDDI.d132.s38.e1 DrugDDI.d132.s38.e2 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s39
Selegiline : Combination hormonal contraceptives may increase the serum concentration of selegiline .

DrugDDI.d132.s39.e0 0 9
drug
Selegiline
DrugDDI.d132.s39.e1 30 43
drug
contraceptives
DrugDDI.d132.s39.e2 78 87
drug
selegiline

interaction DrugDDI.d132.s39.e0 DrugDDI.d132.s39.e1 false
interaction DrugDDI.d132.s39.e0 DrugDDI.d132.s39.e2 false
interaction DrugDDI.d132.s39.e1 DrugDDI.d132.s39.e2 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s40
Theophylline : Ethinyl estradiol may inhibit the metabolism of theophylline , leading to increased plasma concentrations.

DrugDDI.d132.s40.e0 0 11
drug
Theophylline
DrugDDI.d132.s40.e1 13 28
drug
Ethinyl estradiol
DrugDDI.d132.s40.e2 54 65
drug
theophylline

interaction DrugDDI.d132.s40.e0 DrugDDI.d132.s40.e1 false
interaction DrugDDI.d132.s40.e0 DrugDDI.d132.s40.e2 false
interaction DrugDDI.d132.s40.e1 DrugDDI.d132.s40.e2 true

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s41
Tricyclic antidepressants ( amitriptyline , imipramine , nortriptyline ): Metabolism may be inhibited by combination hormonal contraceptives , increasing plasma levels of antidepressant ; .

DrugDDI.d132.s41.e0 0 23
drug
Tricyclic antidepressants
DrugDDI.d132.s41.e1 25 37
drug
amitriptyline
DrugDDI.d132.s41.e2 39 48
drug
imipramine
DrugDDI.d132.s41.e3 50 62
drug
nortriptyline
DrugDDI.d132.s41.e4 110 123
drug
contraceptives
DrugDDI.d132.s41.e5 149 162
drug
antidepressant

interaction DrugDDI.d132.s41.e0 DrugDDI.d132.s41.e1 false
interaction DrugDDI.d132.s41.e0 DrugDDI.d132.s41.e2 false
interaction DrugDDI.d132.s41.e0 DrugDDI.d132.s41.e3 false
interaction DrugDDI.d132.s41.e0 DrugDDI.d132.s41.e4 false
interaction DrugDDI.d132.s41.e0 DrugDDI.d132.s41.e5 false
interaction DrugDDI.d132.s41.e1 DrugDDI.d132.s41.e2 false
interaction DrugDDI.d132.s41.e1 DrugDDI.d132.s41.e3 false
interaction DrugDDI.d132.s41.e1 DrugDDI.d132.s41.e4 false
interaction DrugDDI.d132.s41.e1 DrugDDI.d132.s41.e5 false
interaction DrugDDI.d132.s41.e2 DrugDDI.d132.s41.e3 false
interaction DrugDDI.d132.s41.e2 DrugDDI.d132.s41.e4 false
interaction DrugDDI.d132.s41.e2 DrugDDI.d132.s41.e5 false
interaction DrugDDI.d132.s41.e3 DrugDDI.d132.s41.e4 false
interaction DrugDDI.d132.s41.e3 DrugDDI.d132.s41.e5 false
interaction DrugDDI.d132.s41.e4 DrugDDI.d132.s41.e5 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s43
ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine .

DrugDDI.d132.s43.e0 0 6
drug
ETHANOL
DrugDDI.d132.s43.new.DISO.e4 18 21
DISO
HERB
DrugDDI.d132.s43.e1 52 59
drug
caffeine
DrugDDI.d132.s43.e2 94 107
drug
contraceptives
DrugDDI.d132.s43.e3 131 138
drug
caffeine

interaction DrugDDI.d132.s43.e0 DrugDDI.d132.s43.e1 false
interaction DrugDDI.d132.s43.e0 DrugDDI.d132.s43.e2 false
interaction DrugDDI.d132.s43.e0 DrugDDI.d132.s43.e3 false
interaction DrugDDI.d132.s43.e1 DrugDDI.d132.s43.e2 true
interaction DrugDDI.d132.s43.e1 DrugDDI.d132.s43.e3 false
interaction DrugDDI.d132.s43.e2 DrugDDI.d132.s43.e3 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s44
Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well; .

DrugDDI.d132.s44.e0 24 39
drug
ethinyl estradiol



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s46
Herb/Nutraceutical: St Johns wort may decrease the effectiveness of combination hormonal contraceptives by inducing hepatic enzymes.

DrugDDI.d132.s46.e0 78 91
drug
contraceptives



Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s47
Avoid dong quai and black cohosh (have estrogen activity).

DrugDDI.d132.s47.e0 5 12
drug
dong quai
DrugDDI.d132.s47.e1 16 26
drug
black cohosh
DrugDDI.d132.s47.e2 32 39
drug
estrogen

interaction DrugDDI.d132.s47.e0 DrugDDI.d132.s47.e1 false
interaction DrugDDI.d132.s47.e0 DrugDDI.d132.s47.e2 false
interaction DrugDDI.d132.s47.e1 DrugDDI.d132.s47.e2 false

Abstract Id: DrugDDI.d132
Sentence Id: DrugDDI.d132.s48
Avoid saw palmetto , red clover , ginseng .

DrugDDI.d132.s48.e0 5 15
drug
saw palmetto
DrugDDI.d132.s48.e1 17 25
drug
red clover
DrugDDI.d132.s48.e2 27 33
drug
ginseng

interaction DrugDDI.d132.s48.e0 DrugDDI.d132.s48.e1 false
interaction DrugDDI.d132.s48.e0 DrugDDI.d132.s48.e2 false
interaction DrugDDI.d132.s48.e1 DrugDDI.d132.s48.e2 false

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s0
CYP3A4 Inhibitors@Felodipine is metabolized by CYP3A4 .

DrugDDI.d411.s0.e0 0 5
drug
CYP3A4
DrugDDI.d411.s0.e1 42 47
drug
CYP3A4

interaction DrugDDI.d411.s0.e0 DrugDDI.d411.s0.e1 true

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s1
Co-administration of CYP3A4 inhibitors (eg, ketoconazole , itraconazole , erythromycin , grapefruit juice, cimetidine ) with felodipine may lead to several- fold increases in the plasma levels of felodipine , either due to an increase in bioavailability or due to a decrease in metabolism.

DrugDDI.d411.s1.e0 19 24
drug
CYP3A4
DrugDDI.d411.s1.e1 39 50
drug
ketoconazole
DrugDDI.d411.s1.e2 52 63
drug
itraconazole
DrugDDI.d411.s1.e3 65 76
drug
erythromycin
DrugDDI.d411.s1.e4 94 103
drug
cimetidine
DrugDDI.d411.s1.e5 109 118
drug
felodipine
DrugDDI.d411.s1.e6 168 177
drug
felodipine

interaction DrugDDI.d411.s1.e0 DrugDDI.d411.s1.e1 false
interaction DrugDDI.d411.s1.e0 DrugDDI.d411.s1.e2 false
interaction DrugDDI.d411.s1.e0 DrugDDI.d411.s1.e3 false
interaction DrugDDI.d411.s1.e0 DrugDDI.d411.s1.e4 false
interaction DrugDDI.d411.s1.e0 DrugDDI.d411.s1.e5 true
interaction DrugDDI.d411.s1.e0 DrugDDI.d411.s1.e6 false
interaction DrugDDI.d411.s1.e1 DrugDDI.d411.s1.e2 false
interaction DrugDDI.d411.s1.e1 DrugDDI.d411.s1.e3 false
interaction DrugDDI.d411.s1.e1 DrugDDI.d411.s1.e4 false
interaction DrugDDI.d411.s1.e1 DrugDDI.d411.s1.e5 true
interaction DrugDDI.d411.s1.e1 DrugDDI.d411.s1.e6 false
interaction DrugDDI.d411.s1.e2 DrugDDI.d411.s1.e3 false
interaction DrugDDI.d411.s1.e2 DrugDDI.d411.s1.e4 false
interaction DrugDDI.d411.s1.e2 DrugDDI.d411.s1.e5 true
interaction DrugDDI.d411.s1.e2 DrugDDI.d411.s1.e6 false
interaction DrugDDI.d411.s1.e3 DrugDDI.d411.s1.e4 false
interaction DrugDDI.d411.s1.e3 DrugDDI.d411.s1.e5 true
interaction DrugDDI.d411.s1.e3 DrugDDI.d411.s1.e6 false
interaction DrugDDI.d411.s1.e4 DrugDDI.d411.s1.e5 true
interaction DrugDDI.d411.s1.e4 DrugDDI.d411.s1.e6 false
interaction DrugDDI.d411.s1.e5 DrugDDI.d411.s1.e6 false

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s3
These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor).

DrugDDI.d411.s3.e0 51 62
drug
itraconazole
DrugDDI.d411.s3.e1 71 76
drug
CYP3A4

interaction DrugDDI.d411.s3.e0 DrugDDI.d411.s3.e1 false

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s4
Caution should be used when CYP3A4 inhibitors are co-administered with felodipine .

DrugDDI.d411.s4.e0 23 28
drug
CYP3A4
DrugDDI.d411.s4.e1 61 70
drug
felodipine

interaction DrugDDI.d411.s4.e0 DrugDDI.d411.s4.e1 true

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s5
A conservative approach to dosing felodipine should be taken.

DrugDDI.d411.s5.e0 29 38
drug
felodipine



Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s6
The following specific interactions have been reported: Itraconazole@Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine .

DrugDDI.d411.s6.e0 116 125
drug
felodipine
DrugDDI.d411.s6.e1 130 141
drug
itraconazole
DrugDDI.d411.s6.e2 257 266
drug
felodipine

interaction DrugDDI.d411.s6.e0 DrugDDI.d411.s6.e1 true
interaction DrugDDI.d411.s6.e0 DrugDDI.d411.s6.e2 false
interaction DrugDDI.d411.s6.e1 DrugDDI.d411.s6.e2 false

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s7
Erythromycin@Co-administration of felodipine ( PLENDIL ) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine .

DrugDDI.d411.s7.e0 32 41
drug
felodipine
DrugDDI.d411.s7.e1 43 49
drug
PLENDIL
DrugDDI.d411.s7.e2 55 66
drug
erythromycin
DrugDDI.d411.s7.e3 164 173
drug
felodipine

interaction DrugDDI.d411.s7.e0 DrugDDI.d411.s7.e1 false
interaction DrugDDI.d411.s7.e0 DrugDDI.d411.s7.e2 true
interaction DrugDDI.d411.s7.e0 DrugDDI.d411.s7.e3 false
interaction DrugDDI.d411.s7.e1 DrugDDI.d411.s7.e2 true
interaction DrugDDI.d411.s7.e1 DrugDDI.d411.s7.e3 false
interaction DrugDDI.d411.s7.e2 DrugDDI.d411.s7.e3 false

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s8
Grapefruit juice@Co-administration of felodipine with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of felodipine .

DrugDDI.d411.s8.e0 0 9
drug
Grapefruit
DrugDDI.d411.s8.e1 35 44
drug
felodipine
DrugDDI.d411.s8.e2 145 154
drug
felodipine

interaction DrugDDI.d411.s8.e0 DrugDDI.d411.s8.e1 false
interaction DrugDDI.d411.s8.e0 DrugDDI.d411.s8.e2 false
interaction DrugDDI.d411.s8.e1 DrugDDI.d411.s8.e2 false

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s9
Cimetidine@Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine .

DrugDDI.d411.s9.e0 30 39
drug
felodipine
DrugDDI.d411.s9.e1 44 53
drug
cimetidine
DrugDDI.d411.s9.e2 144 153
drug
felodipine

interaction DrugDDI.d411.s9.e0 DrugDDI.d411.s9.e1 true
interaction DrugDDI.d411.s9.e0 DrugDDI.d411.s9.e2 false
interaction DrugDDI.d411.s9.e1 DrugDDI.d411.s9.e2 false

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s10
Beta-Blocking Agents@ : A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine .

DrugDDI.d411.s10.e0 44 53
drug
felodipine
DrugDDI.d411.s10.e1 71 80
drug
metoprolol
DrugDDI.d411.s10.e2 136 145
drug
felodipine

interaction DrugDDI.d411.s10.e0 DrugDDI.d411.s10.e1 false
interaction DrugDDI.d411.s10.e0 DrugDDI.d411.s10.e2 false
interaction DrugDDI.d411.s10.e1 DrugDDI.d411.s10.e2 false

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s11
The AUC and Cmax of metoprolol , however, were increased approximately 31 and 38%, respectively.

DrugDDI.d411.s11.e0 15 24
drug
metoprolol



Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s12
In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.

DrugDDI.d411.s12.e0 35 46
drug
beta blockers
DrugDDI.d411.s12.e1 56 65
drug
metoprolol
DrugDDI.d411.s12.e2 98 107
drug
felodipine

interaction DrugDDI.d411.s12.e0 DrugDDI.d411.s12.e1 false
interaction DrugDDI.d411.s12.e0 DrugDDI.d411.s12.e2 false
interaction DrugDDI.d411.s12.e1 DrugDDI.d411.s12.e2 false

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s13
Digoxin@ : When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered.

DrugDDI.d411.s13.e0 35 41
drug
PLENDIL
DrugDDI.d411.s13.e1 63 69
drug
digoxin
DrugDDI.d411.s13.new.DISO.e2 84 95
DISO
heart failure

interaction DrugDDI.d411.s13.e0 DrugDDI.d411.s13.e1 false

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s14
Anticonvulsants@ : In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin , carbamazepine , or phenobarbital ) than in healthy volunteers.

DrugDDI.d411.s14.e0 70 79
drug
felodipine
DrugDDI.d411.s14.e1 156 164
drug
phenytoin
DrugDDI.d411.s14.e2 166 178
drug
carbamazepine
DrugDDI.d411.s14.e3 182 194
drug
phenobarbital

interaction DrugDDI.d411.s14.e0 DrugDDI.d411.s14.e1 true
interaction DrugDDI.d411.s14.e0 DrugDDI.d411.s14.e2 true
interaction DrugDDI.d411.s14.e0 DrugDDI.d411.s14.e3 true
interaction DrugDDI.d411.s14.e1 DrugDDI.d411.s14.e2 false
interaction DrugDDI.d411.s14.e1 DrugDDI.d411.s14.e3 false
interaction DrugDDI.d411.s14.e2 DrugDDI.d411.s14.e3 false

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s15
In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately 6% of that observed in healthy volunteers.

DrugDDI.d411.s15.e0 34 43
drug
felodipine



Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s16
Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.

DrugDDI.d411.s16.e0 66 81
drug
antihypertensive



Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s17
Tacrolimus@ Felodipine may increase the blood concentration of tacrolimus .

DrugDDI.d411.s17.e0 11 20
drug
Felodipine
DrugDDI.d411.s17.e1 55 64
drug
tacrolimus

interaction DrugDDI.d411.s17.e0 DrugDDI.d411.s17.e1 true

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s18
When given concomitantly with felodipine , the tacrolimus blood concentration should be followed and the tacrolimus dose may need to be adjusted.

DrugDDI.d411.s18.e0 26 35
drug
felodipine
DrugDDI.d411.s18.e1 40 49
drug
tacrolimus

interaction DrugDDI.d411.s18.e0 DrugDDI.d411.s18.e1 true

Abstract Id: DrugDDI.d411
Sentence Id: DrugDDI.d411.s19
Other Concomitant Therapy@ : In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone .

DrugDDI.d411.s19.e0 90 99
drug
felodipine
DrugDDI.d411.s19.e1 125 136
drug
indomethacin
DrugDDI.d411.s19.e2 139 152
drug
spironolactone

interaction DrugDDI.d411.s19.e0 DrugDDI.d411.s19.e1 false
interaction DrugDDI.d411.s19.e0 DrugDDI.d411.s19.e2 false
interaction DrugDDI.d411.s19.e1 DrugDDI.d411.s19.e2 false

Abstract Id: DrugDDI.d210
Sentence Id: DrugDDI.d210.s0
Fenfluramine may increase slightly the effect of antihypertensive drugs , e.g., guanethidine , methyldopa , reserpine .

DrugDDI.d210.s0.e0 0 11
drug
Fenfluramine
DrugDDI.d210.s0.e1 42 62
drug
antihypertensive drugs
DrugDDI.d210.s0.e2 69 80
drug
guanethidine
DrugDDI.d210.s0.e3 82 91
drug
methyldopa
DrugDDI.d210.s0.e4 93 101
drug
reserpine

interaction DrugDDI.d210.s0.e0 DrugDDI.d210.s0.e1 true
interaction DrugDDI.d210.s0.e0 DrugDDI.d210.s0.e2 true
interaction DrugDDI.d210.s0.e0 DrugDDI.d210.s0.e3 true
interaction DrugDDI.d210.s0.e0 DrugDDI.d210.s0.e4 true
interaction DrugDDI.d210.s0.e1 DrugDDI.d210.s0.e2 false
interaction DrugDDI.d210.s0.e1 DrugDDI.d210.s0.e3 false
interaction DrugDDI.d210.s0.e1 DrugDDI.d210.s0.e4 false
interaction DrugDDI.d210.s0.e2 DrugDDI.d210.s0.e3 false
interaction DrugDDI.d210.s0.e2 DrugDDI.d210.s0.e4 false
interaction DrugDDI.d210.s0.e3 DrugDDI.d210.s0.e4 false

Abstract Id: DrugDDI.d210
Sentence Id: DrugDDI.d210.s1
Other CNS depressant drugs should be used with caution in patients taking fenfluramine , since the effects may be additive.

DrugDDI.d210.s1.e0 5 22
drug
CNS depressant drugs
DrugDDI.d210.s1.e1 62 73
drug
fenfluramine

interaction DrugDDI.d210.s1.e0 DrugDDI.d210.s1.e1 true

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s0
Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANT S ARE GIVEN IN CONJUNCTION WITH TRICOR .

DrugDDI.d199.s0.e0 0 17
drug
Oral Anticoagulants
DrugDDI.d199.s0.e1 46 66
drug
COUMARIN ANTICOAGULANT
DrugDDI.d199.s0.e2 93 98
drug
TRICOR

interaction DrugDDI.d199.s0.e0 DrugDDI.d199.s0.e1 false
interaction DrugDDI.d199.s0.e0 DrugDDI.d199.s0.e2 false
interaction DrugDDI.d199.s0.e1 DrugDDI.d199.s0.e2 true

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s1
THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS.

DrugDDI.d199.s1.e0 14 27
drug
ANTICOAGULANTS
DrugDDI.d199.s1.e1 94 100
drug
PREVENT

interaction DrugDDI.d199.s1.e0 DrugDDI.d199.s1.e1 false

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s3
HMG-CoA reductase inhibitors The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.

DrugDDI.d199.s3.e0 0 25
drug
HMG-CoA reductase inhibitors
DrugDDI.d199.s3.e1 42 47
drug
TRICOR
DrugDDI.d199.s3.e2 51 76
drug
HMG-CoA reductase inhibitors
DrugDDI.d199.s3.e3 181 184
drug
drug

interaction DrugDDI.d199.s3.e0 DrugDDI.d199.s3.e1 false
interaction DrugDDI.d199.s3.e0 DrugDDI.d199.s3.e2 false
interaction DrugDDI.d199.s3.e0 DrugDDI.d199.s3.e3 false
interaction DrugDDI.d199.s3.e1 DrugDDI.d199.s3.e2 true
interaction DrugDDI.d199.s3.e1 DrugDDI.d199.s3.e3 false
interaction DrugDDI.d199.s3.e2 DrugDDI.d199.s3.e3 false

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s4
Resins : Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.

DrugDDI.d199.s4.e0 0 5
drug
Resins
DrugDDI.d199.s4.e1 12 31
drug
bile acid sequestrants
DrugDDI.d199.s4.e2 44 48
drug
drugs
DrugDDI.d199.s4.e3 85 90
drug
TRICOR
DrugDDI.d199.s4.e4 125 132
drug
bile acid

interaction DrugDDI.d199.s4.e0 DrugDDI.d199.s4.e1 false
interaction DrugDDI.d199.s4.e0 DrugDDI.d199.s4.e2 false
interaction DrugDDI.d199.s4.e0 DrugDDI.d199.s4.e3 false
interaction DrugDDI.d199.s4.e0 DrugDDI.d199.s4.e4 false
interaction DrugDDI.d199.s4.e1 DrugDDI.d199.s4.e2 false
interaction DrugDDI.d199.s4.e1 DrugDDI.d199.s4.e3 true
interaction DrugDDI.d199.s4.e1 DrugDDI.d199.s4.e4 false
interaction DrugDDI.d199.s4.e2 DrugDDI.d199.s4.e3 false
interaction DrugDDI.d199.s4.e2 DrugDDI.d199.s4.e4 false
interaction DrugDDI.d199.s4.e3 DrugDDI.d199.s4.e4 false

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s5
Cyclosporine : Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR , there is a risk that an interaction will lead to deterioration.

DrugDDI.d199.s5.e0 0 11
drug
Cyclosporine
DrugDDI.d199.s5.e1 20 31
drug
cyclosporine
DrugDDI.d199.s5.e2 93 97
drug
rises
DrugDDI.d199.s5.e3 170 181
drug
fibrate drugs
DrugDDI.d199.s5.e4 191 196
drug
TRICOR

interaction DrugDDI.d199.s5.e0 DrugDDI.d199.s5.e1 false
interaction DrugDDI.d199.s5.e0 DrugDDI.d199.s5.e2 false
interaction DrugDDI.d199.s5.e0 DrugDDI.d199.s5.e3 false
interaction DrugDDI.d199.s5.e0 DrugDDI.d199.s5.e4 true
interaction DrugDDI.d199.s5.e1 DrugDDI.d199.s5.e2 false
interaction DrugDDI.d199.s5.e1 DrugDDI.d199.s5.e3 true
interaction DrugDDI.d199.s5.e1 DrugDDI.d199.s5.e4 false
interaction DrugDDI.d199.s5.e2 DrugDDI.d199.s5.e3 false
interaction DrugDDI.d199.s5.e2 DrugDDI.d199.s5.e4 false
interaction DrugDDI.d199.s5.e3 DrugDDI.d199.s5.e4 false

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s6
The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed .

DrugDDI.d199.s6.e0 26 31
drug
TRICOR
DrugDDI.d199.s6.e1 36 53
drug
immunosuppressants

interaction DrugDDI.d199.s6.e0 DrugDDI.d199.s6.e1 true

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s8
@ Drug-drug interactions In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome ( CYP ) P450 isoforms CYP3A4, CYP2D6 , CYP2E1 , or CYP1A2 .

DrugDDI.d199.s8.e0 73 83
drug
fenofibrate
DrugDDI.d199.s8.e1 87 100
drug
fenofibric acid
DrugDDI.d199.s8.e2 119 128
drug
cytochrome
DrugDDI.d199.s8.e3 130 132
drug
CYP
DrugDDI.d199.s8.e4 134 137
drug
P450
DrugDDI.d199.s8.e5 153 158
drug
CYP2D6
DrugDDI.d199.s8.e6 160 165
drug
CYP2E1
DrugDDI.d199.s8.e7 169 174
drug
CYP1A2

interaction DrugDDI.d199.s8.e0 DrugDDI.d199.s8.e1 false
interaction DrugDDI.d199.s8.e0 DrugDDI.d199.s8.e2 false
interaction DrugDDI.d199.s8.e0 DrugDDI.d199.s8.e3 false
interaction DrugDDI.d199.s8.e0 DrugDDI.d199.s8.e4 false
interaction DrugDDI.d199.s8.e0 DrugDDI.d199.s8.e5 false
interaction DrugDDI.d199.s8.e0 DrugDDI.d199.s8.e6 false
interaction DrugDDI.d199.s8.e0 DrugDDI.d199.s8.e7 false
interaction DrugDDI.d199.s8.e1 DrugDDI.d199.s8.e2 false
interaction DrugDDI.d199.s8.e1 DrugDDI.d199.s8.e3 false
interaction DrugDDI.d199.s8.e1 DrugDDI.d199.s8.e4 false
interaction DrugDDI.d199.s8.e1 DrugDDI.d199.s8.e5 false
interaction DrugDDI.d199.s8.e1 DrugDDI.d199.s8.e6 false
interaction DrugDDI.d199.s8.e1 DrugDDI.d199.s8.e7 false
interaction DrugDDI.d199.s8.e2 DrugDDI.d199.s8.e3 false
interaction DrugDDI.d199.s8.e2 DrugDDI.d199.s8.e4 false
interaction DrugDDI.d199.s8.e2 DrugDDI.d199.s8.e5 false
interaction DrugDDI.d199.s8.e2 DrugDDI.d199.s8.e6 false
interaction DrugDDI.d199.s8.e2 DrugDDI.d199.s8.e7 false
interaction DrugDDI.d199.s8.e3 DrugDDI.d199.s8.e4 false
interaction DrugDDI.d199.s8.e3 DrugDDI.d199.s8.e5 false
interaction DrugDDI.d199.s8.e3 DrugDDI.d199.s8.e6 false
interaction DrugDDI.d199.s8.e3 DrugDDI.d199.s8.e7 false
interaction DrugDDI.d199.s8.e4 DrugDDI.d199.s8.e5 false
interaction DrugDDI.d199.s8.e4 DrugDDI.d199.s8.e6 false
interaction DrugDDI.d199.s8.e4 DrugDDI.d199.s8.e7 false
interaction DrugDDI.d199.s8.e5 DrugDDI.d199.s8.e6 false
interaction DrugDDI.d199.s8.e5 DrugDDI.d199.s8.e7 false
interaction DrugDDI.d199.s8.e6 DrugDDI.d199.s8.e7 false

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s9
They are weak inhibitors of CYP2C19 and CYP2A6 , and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.

DrugDDI.d199.s9.e0 23 29
drug
CYP2C19
DrugDDI.d199.s9.e1 33 38
drug
CYP2A6
DrugDDI.d199.s9.e2 71 76
drug
CYP2C9

interaction DrugDDI.d199.s9.e0 DrugDDI.d199.s9.e1 false
interaction DrugDDI.d199.s9.e0 DrugDDI.d199.s9.e2 false
interaction DrugDDI.d199.s9.e1 DrugDDI.d199.s9.e2 false

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s10
Potentiation of coumarin-type anticoagulants has been observed with prolongation of the prothrombin time/INR.

DrugDDI.d199.s10.e0 14 40
drug
coumarin-type anticoagulants



Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s11
Bile acid sequestrants have been shown to bind other drugs given concurrently.

DrugDDI.d199.s11.e0 0 19
drug
Bile acid sequestrants
DrugDDI.d199.s11.e1 44 48
drug
drugs

interaction DrugDDI.d199.s11.e0 DrugDDI.d199.s11.e1 true

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s12
Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .

DrugDDI.d199.s12.e0 10 20
drug
fenofibrate
DrugDDI.d199.s12.e1 68 75
drug
bile acid

interaction DrugDDI.d199.s12.e0 DrugDDI.d199.s12.e1 true

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s13
Concomitant administration of fenofibrate (equivalent to 145mg TRICOR ) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3@-hydroxy-iso- pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.

DrugDDI.d199.s13.e0 27 37
drug
fenofibrate
DrugDDI.d199.s13.e1 56 61
drug
TRICOR
DrugDDI.d199.s13.e2 67 77
drug
pravastatin
DrugDDI.d199.s13.e3 150 160
drug
pravastatin
DrugDDI.d199.s13.e4 279 289
drug
pravastatin

interaction DrugDDI.d199.s13.e0 DrugDDI.d199.s13.e1 false
interaction DrugDDI.d199.s13.e0 DrugDDI.d199.s13.e2 true
interaction DrugDDI.d199.s13.e0 DrugDDI.d199.s13.e3 false
interaction DrugDDI.d199.s13.e0 DrugDDI.d199.s13.e4 false
interaction DrugDDI.d199.s13.e1 DrugDDI.d199.s13.e2 true
interaction DrugDDI.d199.s13.e1 DrugDDI.d199.s13.e3 false
interaction DrugDDI.d199.s13.e1 DrugDDI.d199.s13.e4 false
interaction DrugDDI.d199.s13.e2 DrugDDI.d199.s13.e3 false
interaction DrugDDI.d199.s13.e2 DrugDDI.d199.s13.e4 false
interaction DrugDDI.d199.s13.e3 DrugDDI.d199.s13.e4 false

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s14
A single dose of pravastatin had no clinically important effect on the pharmacokinetics of fenofibric acid .

DrugDDI.d199.s14.e0 13 23
drug
pravastatin
DrugDDI.d199.s14.e1 77 90
drug
fenofibric acid

interaction DrugDDI.d199.s14.e0 DrugDDI.d199.s14.e1 false

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s15
Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR ) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.

DrugDDI.d199.s15.e0 27 37
drug
fenofibrate
DrugDDI.d199.s15.e1 56 61
drug
TRICOR
DrugDDI.d199.s15.e2 67 78
drug
atorvastatin
DrugDDI.d199.s15.e3 174 185
drug
atorvastatin

interaction DrugDDI.d199.s15.e0 DrugDDI.d199.s15.e1 false
interaction DrugDDI.d199.s15.e0 DrugDDI.d199.s15.e2 true
interaction DrugDDI.d199.s15.e0 DrugDDI.d199.s15.e3 false
interaction DrugDDI.d199.s15.e1 DrugDDI.d199.s15.e2 true
interaction DrugDDI.d199.s15.e1 DrugDDI.d199.s15.e3 false
interaction DrugDDI.d199.s15.e2 DrugDDI.d199.s15.e3 false

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s16
The atorvastatin Cmax values were not significantly affected by fenofibrate .

DrugDDI.d199.s16.e0 3 14
drug
atorvastatin
DrugDDI.d199.s16.e1 55 65
drug
fenofibrate

interaction DrugDDI.d199.s16.e0 DrugDDI.d199.s16.e1 false

Abstract Id: DrugDDI.d199
Sentence Id: DrugDDI.d199.s17
The pharmacokinetics of fenofibric acid were not significantly affected by atorvastatin .

DrugDDI.d199.s17.e0 21 34
drug
fenofibric acid
DrugDDI.d199.s17.e1 65 76
drug
atorvastatin

interaction DrugDDI.d199.s17.e0 DrugDDI.d199.s17.e1 false

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s0
Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.

DrugDDI.d95.s0.e0 19 30
drug
Erythromycin
DrugDDI.d95.s0.e1 34 45
drug
Ketoconazole

interaction DrugDDI.d95.s0.e0 DrugDDI.d95.s0.e1 true

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s1
However, co@ administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine .

DrugDDI.d95.s1.e0 27 51
drug
fexofenadine hydrochloride
DrugDDI.d95.s1.e1 62 73
drug
ketoconazole
DrugDDI.d95.s1.e2 76 87
drug
erythromycin
DrugDDI.d95.s1.e3 124 135
drug
fexofenadine

interaction DrugDDI.d95.s1.e0 DrugDDI.d95.s1.e1 true
interaction DrugDDI.d95.s1.e0 DrugDDI.d95.s1.e2 true
interaction DrugDDI.d95.s1.e0 DrugDDI.d95.s1.e3 false
interaction DrugDDI.d95.s1.e1 DrugDDI.d95.s1.e2 false
interaction DrugDDI.d95.s1.e1 DrugDDI.d95.s1.e3 false
interaction DrugDDI.d95.s1.e2 DrugDDI.d95.s1.e3 false

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s2
Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole .

DrugDDI.d95.s2.e0 0 11
drug
Fexofenadine
DrugDDI.d95.s2.e1 52 63
drug
erythromycin
DrugDDI.d95.s2.e2 66 77
drug
ketoconazole

interaction DrugDDI.d95.s2.e0 DrugDDI.d95.s2.e1 false
interaction DrugDDI.d95.s2.e0 DrugDDI.d95.s2.e2 false
interaction DrugDDI.d95.s2.e1 DrugDDI.d95.s2.e2 false

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s3
In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).

DrugDDI.d95.s3.e0 19 46
drug
fexofenadine hydrochloride 120
DrugDDI.d95.s3.e1 108 124
drug
erythromycin 500 mg
DrugDDI.d95.s3.e2 138 154
drug
ketoconazole 400 mg

interaction DrugDDI.d95.s3.e0 DrugDDI.d95.s3.e1 false
interaction DrugDDI.d95.s3.e0 DrugDDI.d95.s3.e2 false
interaction DrugDDI.d95.s3.e1 DrugDDI.d95.s3.e2 false

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s4
No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole .

DrugDDI.d95.s4.e0 81 105
drug
fexofenadine hydrochloride
DrugDDI.d95.s4.e1 136 147
drug
erythromycin
DrugDDI.d95.s4.e2 150 161
drug
ketoconazole

interaction DrugDDI.d95.s4.e0 DrugDDI.d95.s4.e1 false
interaction DrugDDI.d95.s4.e0 DrugDDI.d95.s4.e2 false
interaction DrugDDI.d95.s4.e1 DrugDDI.d95.s4.e2 false

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s5
The findings of these studies are summarized in the following table: Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24) .

DrugDDI.d95.s5.e0 79 90
drug
fexofenadine
DrugDDI.d95.s5.e1 140 167
drug
fexofenadine hydrochloride 120

interaction DrugDDI.d95.s5.e0 DrugDDI.d95.s5.e1 false

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s6
Concomitant Drug .

DrugDDI.d95.s6.e0 11 14
drug
Drug



Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s9
Erythromycin (500 mg every 8 hrs) .

DrugDDI.d95.s9.e0 0 11
drug
Erythromycin



Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s12
Ketoconazole (400 mg once daily) .

DrugDDI.d95.s12.e0 0 11
drug
Ketoconazole



Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s17
These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.

DrugDDI.d95.s17.e0 24 35
drug
ketoconazole
DrugDDI.d95.s17.e1 38 49
drug
erythromycin
DrugDDI.d95.s17.e2 75 86
drug
fexofenadine

interaction DrugDDI.d95.s17.e0 DrugDDI.d95.s17.e1 false
interaction DrugDDI.d95.s17.e0 DrugDDI.d95.s17.e2 true
interaction DrugDDI.d95.s17.e1 DrugDDI.d95.s17.e2 true

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s18
This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p- glycoprotein . in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.

DrugDDI.d95.s18.e0 42 53
drug
fexofenadine
DrugDDI.d95.s18.e1 97 108
drug
glycoprotein
DrugDDI.d95.s18.e2 176 187
drug
ketoconazole
DrugDDI.d95.s18.e3 197 208
drug
fexofenadine
DrugDDI.d95.s18.e4 240 251
drug
erythromycin

interaction DrugDDI.d95.s18.e0 DrugDDI.d95.s18.e1 false
interaction DrugDDI.d95.s18.e0 DrugDDI.d95.s18.e2 false
interaction DrugDDI.d95.s18.e0 DrugDDI.d95.s18.e3 false
interaction DrugDDI.d95.s18.e0 DrugDDI.d95.s18.e4 false
interaction DrugDDI.d95.s18.e1 DrugDDI.d95.s18.e2 false
interaction DrugDDI.d95.s18.e1 DrugDDI.d95.s18.e3 false
interaction DrugDDI.d95.s18.e1 DrugDDI.d95.s18.e4 false
interaction DrugDDI.d95.s18.e2 DrugDDI.d95.s18.e3 true
interaction DrugDDI.d95.s18.e2 DrugDDI.d95.s18.e4 false
interaction DrugDDI.d95.s18.e3 DrugDDI.d95.s18.e4 false

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s19
Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox@) decreased fexofenadine AUC by 41% and cmax by 43%.

DrugDDI.d95.s19.e0 20 27
drug
Antacids
DrugDDI.d95.s19.e1 51 75
drug
fexofenadine hydrochloride
DrugDDI.d95.s19.e2 121 146
drug
magnesium containing antacid
DrugDDI.d95.s19.e3 165 176
drug
fexofenadine

interaction DrugDDI.d95.s19.e0 DrugDDI.d95.s19.e1 false
interaction DrugDDI.d95.s19.e0 DrugDDI.d95.s19.e2 false
interaction DrugDDI.d95.s19.e0 DrugDDI.d95.s19.e3 false
interaction DrugDDI.d95.s19.e1 DrugDDI.d95.s19.e2 true
interaction DrugDDI.d95.s19.e1 DrugDDI.d95.s19.e3 false
interaction DrugDDI.d95.s19.e2 DrugDDI.d95.s19.e3 false

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s20
ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids .

DrugDDI.d95.s20.e0 0 6
drug
ALLEGRA
DrugDDI.d95.s20.e1 51 77
drug
magnesium containing antacids

interaction DrugDDI.d95.s20.e0 DrugDDI.d95.s20.e1 true

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s21
Interactions with Fruit Juices Fruit juices such as grapefruit , orange and apple may reduce the bioavailability and exposure of fexofenadine .

DrugDDI.d95.s21.e0 44 53
drug
grapefruit
DrugDDI.d95.s21.e1 109 120
drug
fexofenadine

interaction DrugDDI.d95.s21.e0 DrugDDI.d95.s21.e1 true

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s23
The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water .

DrugDDI.d95.s23.e0 49 73
drug
fexofenadine hydrochloride
DrugDDI.d95.s23.e1 99 108
drug
grapefruit
DrugDDI.d95.s23.e2 133 137
drug
water

interaction DrugDDI.d95.s23.e0 DrugDDI.d95.s23.e1 true
interaction DrugDDI.d95.s23.e0 DrugDDI.d95.s23.e2 false
interaction DrugDDI.d95.s23.e1 DrugDDI.d95.s23.e2 false

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s26
In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.

DrugDDI.d95.s26.e0 76 85
drug
grapefruit
DrugDDI.d95.s26.e1 164 175
drug
fexofenadine

interaction DrugDDI.d95.s26.e0 DrugDDI.d95.s26.e1 true

Abstract Id: DrugDDI.d95
Sentence Id: DrugDDI.d95.s27
Therefore, to maximize the effects of fexofenadine , it is recommended that ALLEGRA should be taken with water .

DrugDDI.d95.s27.e0 32 43
drug
fexofenadine
DrugDDI.d95.s27.e1 64 70
drug
ALLEGRA
DrugDDI.d95.s27.e2 88 92
drug
water

interaction DrugDDI.d95.s27.e0 DrugDDI.d95.s27.e1 false
interaction DrugDDI.d95.s27.e0 DrugDDI.d95.s27.e2 false
interaction DrugDDI.d95.s27.e1 DrugDDI.d95.s27.e2 false

Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s0
Androgens may increase sensitivity to oral anticoagulahts.

DrugDDI.d433.s0.e0 0 8
drug
Androgens



Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s1
Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.

DrugDDI.d433.s1.e0 11 23
drug
anticoagulant
DrugDDI.d433.s1.new.DISO.e1 83 101
DISO
hypoprothrombinemia



Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s2
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone .

DrugDDI.d433.s2.e0 26 40
drug
oxyphenbutazone
DrugDDI.d433.s2.e1 44 52
drug
androgens
DrugDDI.d433.s2.e2 85 99
drug
oxyphenbutazone

interaction DrugDDI.d433.s2.e0 DrugDDI.d433.s2.e1 true
interaction DrugDDI.d433.s2.e0 DrugDDI.d433.s2.e2 false
interaction DrugDDI.d433.s2.e1 DrugDDI.d433.s2.e2 false

Abstract Id: DrugDDI.d433
Sentence Id: DrugDDI.d433.s3
In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.

DrugDDI.d433.s3.e0 40 48
drug
androgens
DrugDDI.d433.s3.e1 85 91
drug
insulin

interaction DrugDDI.d433.s3.e0 DrugDDI.d433.s3.e1 true

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s0
Antacids : Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).

DrugDDI.d332.s0.e0 0 7
drug
Antacids
DrugDDI.d332.s0.e1 25 36
drug
flurbiprofen
DrugDDI.d332.s0.e2 78 94
drug
antacid suspension
DrugDDI.d332.s0.e3 114 125
drug
flurbiprofen

interaction DrugDDI.d332.s0.e0 DrugDDI.d332.s0.e1 false
interaction DrugDDI.d332.s0.e0 DrugDDI.d332.s0.e2 false
interaction DrugDDI.d332.s0.e0 DrugDDI.d332.s0.e3 false
interaction DrugDDI.d332.s0.e1 DrugDDI.d332.s0.e2 false
interaction DrugDDI.d332.s0.e1 DrugDDI.d332.s0.e3 false
interaction DrugDDI.d332.s0.e2 DrugDDI.d332.s0.e3 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s1
In geriatric subjects ( n=7 ) there was a reduction in the rate but not the extent of flurbiprofen absorption.

DrugDDI.d332.s1.e0 20 22
drug
n=7
DrugDDI.d332.s1.e1 68 79
drug
flurbiprofen

interaction DrugDDI.d332.s1.e0 DrugDDI.d332.s1.e1 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s2
Anticoagulants : Flurbiprofen like other nonsteroidal anti-inflammatory drugs , has been shown to affect bleeding parameters in patients receiving anti-coagulants , and serious clinical bleeding has been reported.

DrugDDI.d332.s2.e0 0 13
drug
Anticoagulants
DrugDDI.d332.s2.e1 15 26
drug
Flurbiprofen
DrugDDI.d332.s2.e2 36 69
drug
nonsteroidal anti-inflammatory drugs
DrugDDI.d332.s2.e3 128 142
drug
anti-coagulants

interaction DrugDDI.d332.s2.e0 DrugDDI.d332.s2.e1 false
interaction DrugDDI.d332.s2.e0 DrugDDI.d332.s2.e2 false
interaction DrugDDI.d332.s2.e0 DrugDDI.d332.s2.e3 false
interaction DrugDDI.d332.s2.e1 DrugDDI.d332.s2.e2 false
interaction DrugDDI.d332.s2.e1 DrugDDI.d332.s2.e3 true
interaction DrugDDI.d332.s2.e2 DrugDDI.d332.s2.e3 true

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s3
The physician should be cautious when administering flurbiprofen to patients taking anticoagulants .

DrugDDI.d332.s3.e0 45 56
drug
flurbiprofen
DrugDDI.d332.s3.e1 73 86
drug
anticoagulants

interaction DrugDDI.d332.s3.e0 DrugDDI.d332.s3.e1 true

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s4
Aspirin : Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.

DrugDDI.d332.s4.e0 0 6
drug
Aspirin
DrugDDI.d332.s4.e1 34 40
drug
aspirin
DrugDDI.d332.s4.e2 44 55
drug
flurbiprofen
DrugDDI.d332.s4.e3 79 90
drug
flurbiprofen

interaction DrugDDI.d332.s4.e0 DrugDDI.d332.s4.e1 false
interaction DrugDDI.d332.s4.e0 DrugDDI.d332.s4.e2 false
interaction DrugDDI.d332.s4.e0 DrugDDI.d332.s4.e3 false
interaction DrugDDI.d332.s4.e1 DrugDDI.d332.s4.e2 true
interaction DrugDDI.d332.s4.e1 DrugDDI.d332.s4.e3 false
interaction DrugDDI.d332.s4.e2 DrugDDI.d332.s4.e3 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s5
This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).

DrugDDI.d332.s5.e0 12 18
drug
aspirin
DrugDDI.d332.s5.e1 61 94
drug
nonsteroidal anti-inflammatory drugs
DrugDDI.d332.s5.new.DISO.e2 140 158
DISO
rheumatoid arthritis

interaction DrugDDI.d332.s5.e0 DrugDDI.d332.s5.e1 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s6
Concurrent use of flurbiprofen and aspirin is therefore not recommended.

DrugDDI.d332.s6.e0 15 26
drug
flurbiprofen
DrugDDI.d332.s6.e1 30 36
drug
aspirin

interaction DrugDDI.d332.s6.e0 DrugDDI.d332.s6.e1 true

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s7
Beta-adrenergic Blocking Agents : The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).

DrugDDI.d332.s7.e0 0 28
drug
Beta-adrenergic Blocking Agents
DrugDDI.d332.s7.e1 41 52
drug
flurbiprofen
DrugDDI.d332.s7.e2 78 88
drug
propranolol
DrugDDI.d332.s7.e3 92 99
drug
atenolol
DrugDDI.d332.s7.new.DISO.e4 125 149
DISO
uncomplicated hypertension

interaction DrugDDI.d332.s7.e0 DrugDDI.d332.s7.e1 false
interaction DrugDDI.d332.s7.e0 DrugDDI.d332.s7.e2 false
interaction DrugDDI.d332.s7.e0 DrugDDI.d332.s7.e3 false
interaction DrugDDI.d332.s7.e1 DrugDDI.d332.s7.e2 false
interaction DrugDDI.d332.s7.e1 DrugDDI.d332.s7.e3 false
interaction DrugDDI.d332.s7.e2 DrugDDI.d332.s7.e3 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s8
Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol .

DrugDDI.d332.s8.e0 0 11
drug
Flurbiprofen
DrugDDI.d332.s8.e1 69 79
drug
propranolol
DrugDDI.d332.s8.e2 86 93
drug
atenolol

interaction DrugDDI.d332.s8.e0 DrugDDI.d332.s8.e1 true
interaction DrugDDI.d332.s8.e0 DrugDDI.d332.s8.e2 false
interaction DrugDDI.d332.s8.e1 DrugDDI.d332.s8.e2 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s9
Flurbiprofen did not appear to affect the beta-blocker -mediated reduction in heart rate.

DrugDDI.d332.s9.e0 0 11
drug
Flurbiprofen
DrugDDI.d332.s9.e1 35 46
drug
beta-blocker

interaction DrugDDI.d332.s9.e0 DrugDDI.d332.s9.e1 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s10
Flurbiprofen did not affect the pharmacokinetic profile of either drug , and the mechanism under lying the interference with propranolol s hypotensive effect is unknown.

DrugDDI.d332.s10.e0 0 11
drug
Flurbiprofen
DrugDDI.d332.s10.e1 57 60
drug
drug
DrugDDI.d332.s10.e2 106 116
drug
propranolol

interaction DrugDDI.d332.s10.e0 DrugDDI.d332.s10.e1 false
interaction DrugDDI.d332.s10.e0 DrugDDI.d332.s10.e2 false
interaction DrugDDI.d332.s10.e1 DrugDDI.d332.s10.e2 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s11
Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.

DrugDDI.d332.s11.e0 18 29
drug
flurbiprofen
DrugDDI.d332.s11.e1 34 45
drug
beta-blocker

interaction DrugDDI.d332.s11.e0 DrugDDI.d332.s11.e1 true

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s12
Cimetidine , Ranitidine : In normal volunteers ( n=9 ), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine .

DrugDDI.d332.s12.e0 0 9
drug
Cimetidine
DrugDDI.d332.s12.e1 11 20
drug
Ranitidine
DrugDDI.d332.s12.e2 41 43
drug
n=9
DrugDDI.d332.s12.e3 62 71
drug
cimetidine
DrugDDI.d332.s12.e4 74 83
drug
ranitidine
DrugDDI.d332.s12.e5 96 107
drug
flurbiprofen
DrugDDI.d332.s12.e6 222 233
drug
flurbiprofen
DrugDDI.d332.s12.e7 246 255
drug
cimetidine

interaction DrugDDI.d332.s12.e0 DrugDDI.d332.s12.e1 false
interaction DrugDDI.d332.s12.e0 DrugDDI.d332.s12.e2 false
interaction DrugDDI.d332.s12.e0 DrugDDI.d332.s12.e3 false
interaction DrugDDI.d332.s12.e0 DrugDDI.d332.s12.e4 false
interaction DrugDDI.d332.s12.e0 DrugDDI.d332.s12.e5 false
interaction DrugDDI.d332.s12.e0 DrugDDI.d332.s12.e6 false
interaction DrugDDI.d332.s12.e0 DrugDDI.d332.s12.e7 false
interaction DrugDDI.d332.s12.e1 DrugDDI.d332.s12.e2 false
interaction DrugDDI.d332.s12.e1 DrugDDI.d332.s12.e3 false
interaction DrugDDI.d332.s12.e1 DrugDDI.d332.s12.e4 false
interaction DrugDDI.d332.s12.e1 DrugDDI.d332.s12.e5 false
interaction DrugDDI.d332.s12.e1 DrugDDI.d332.s12.e6 false
interaction DrugDDI.d332.s12.e1 DrugDDI.d332.s12.e7 false
interaction DrugDDI.d332.s12.e2 DrugDDI.d332.s12.e3 false
interaction DrugDDI.d332.s12.e2 DrugDDI.d332.s12.e4 false
interaction DrugDDI.d332.s12.e2 DrugDDI.d332.s12.e5 false
interaction DrugDDI.d332.s12.e2 DrugDDI.d332.s12.e6 false
interaction DrugDDI.d332.s12.e2 DrugDDI.d332.s12.e7 false
interaction DrugDDI.d332.s12.e3 DrugDDI.d332.s12.e4 false
interaction DrugDDI.d332.s12.e3 DrugDDI.d332.s12.e5 false
interaction DrugDDI.d332.s12.e3 DrugDDI.d332.s12.e6 true
interaction DrugDDI.d332.s12.e3 DrugDDI.d332.s12.e7 false
interaction DrugDDI.d332.s12.e4 DrugDDI.d332.s12.e5 false
interaction DrugDDI.d332.s12.e4 DrugDDI.d332.s12.e6 false
interaction DrugDDI.d332.s12.e4 DrugDDI.d332.s12.e7 false
interaction DrugDDI.d332.s12.e5 DrugDDI.d332.s12.e6 false
interaction DrugDDI.d332.s12.e5 DrugDDI.d332.s12.e7 false
interaction DrugDDI.d332.s12.e6 DrugDDI.d332.s12.e7 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s13
Digoxin : Studies of concomitant administration of flurbiprofen and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug .

DrugDDI.d332.s13.e0 0 6
drug
Digoxin
DrugDDI.d332.s13.e1 44 55
drug
flurbiprofen
DrugDDI.d332.s13.e2 59 65
drug
digoxin
DrugDDI.d332.s13.e3 136 139
drug
drug

interaction DrugDDI.d332.s13.e0 DrugDDI.d332.s13.e1 false
interaction DrugDDI.d332.s13.e0 DrugDDI.d332.s13.e2 false
interaction DrugDDI.d332.s13.e0 DrugDDI.d332.s13.e3 false
interaction DrugDDI.d332.s13.e1 DrugDDI.d332.s13.e2 false
interaction DrugDDI.d332.s13.e1 DrugDDI.d332.s13.e3 false
interaction DrugDDI.d332.s13.e2 DrugDDI.d332.s13.e3 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s14
Diuretics : Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs , can interfere with the effects of furosemide .

DrugDDI.d332.s14.e0 0 8
drug
Diuretics
DrugDDI.d332.s14.e1 48 59
drug
flurbiprofen
DrugDDI.d332.s14.e2 69 102
drug
nonsteroidal anti-inflammatory drugs
DrugDDI.d332.s14.e3 132 141
drug
furosemide

interaction DrugDDI.d332.s14.e0 DrugDDI.d332.s14.e1 false
interaction DrugDDI.d332.s14.e0 DrugDDI.d332.s14.e2 false
interaction DrugDDI.d332.s14.e0 DrugDDI.d332.s14.e3 false
interaction DrugDDI.d332.s14.e1 DrugDDI.d332.s14.e2 false
interaction DrugDDI.d332.s14.e1 DrugDDI.d332.s14.e3 true
interaction DrugDDI.d332.s14.e2 DrugDDI.d332.s14.e3 true

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s15
Although results have varied from study to study, effects have been shown on furosemide-stimulated diuresis , natriuresis, and kaliuresis.

DrugDDI.d332.s15.e0 64 92
drug
furosemide-stimulated diuresis



Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s16
Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics .

DrugDDI.d332.s16.e0 5 38
drug
nonsteroidal anti-inflammatory drugs
DrugDDI.d332.s16.e1 50 62
drug
prostaglandin
DrugDDI.d332.s16.e2 100 116
drug
thiazide diuretics
DrugDDI.d332.s16.e3 137 162
drug
potassium-sparing diuretics

interaction DrugDDI.d332.s16.e0 DrugDDI.d332.s16.e1 false
interaction DrugDDI.d332.s16.e0 DrugDDI.d332.s16.e2 true
interaction DrugDDI.d332.s16.e0 DrugDDI.d332.s16.e3 true
interaction DrugDDI.d332.s16.e1 DrugDDI.d332.s16.e2 false
interaction DrugDDI.d332.s16.e1 DrugDDI.d332.s16.e3 false
interaction DrugDDI.d332.s16.e2 DrugDDI.d332.s16.e3 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s17
Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.

DrugDDI.d332.s17.e0 17 28
drug
flurbiprofen
DrugDDI.d332.s17.e1 32 41
drug
furosemide
DrugDDI.d332.s17.e2 49 57
drug
diuretics

interaction DrugDDI.d332.s17.e0 DrugDDI.d332.s17.e1 true
interaction DrugDDI.d332.s17.e0 DrugDDI.d332.s17.e2 false
interaction DrugDDI.d332.s17.e1 DrugDDI.d332.s17.e2 true

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s18
Oral Hypoglycemic Agents : In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin ( n= 3 ) or glyburide with phenformin (n=6).

DrugDDI.d332.s18.e0 4 21
drug
Hypoglycemic Agents
DrugDDI.d332.s18.e1 34 45
drug
flurbiprofen
DrugDDI.d332.s18.e2 93 101
drug
glyburide
DrugDDI.d332.s18.e3 108 116
drug
metformin
DrugDDI.d332.s18.e4 122 135
drug
chlorpropamide
DrugDDI.d332.s18.e5 140 149
drug
phenformin
DrugDDI.d332.s18.e6 151 153
drug
n= 3
DrugDDI.d332.s18.e7 157 165
drug
glyburide
DrugDDI.d332.s18.e8 170 179
drug
phenformin

interaction DrugDDI.d332.s18.e0 DrugDDI.d332.s18.e1 false
interaction DrugDDI.d332.s18.e0 DrugDDI.d332.s18.e2 false
interaction DrugDDI.d332.s18.e0 DrugDDI.d332.s18.e3 false
interaction DrugDDI.d332.s18.e0 DrugDDI.d332.s18.e4 false
interaction DrugDDI.d332.s18.e0 DrugDDI.d332.s18.e5 false
interaction DrugDDI.d332.s18.e0 DrugDDI.d332.s18.e6 false
interaction DrugDDI.d332.s18.e0 DrugDDI.d332.s18.e7 false
interaction DrugDDI.d332.s18.e0 DrugDDI.d332.s18.e8 false
interaction DrugDDI.d332.s18.e1 DrugDDI.d332.s18.e2 false
interaction DrugDDI.d332.s18.e1 DrugDDI.d332.s18.e3 false
interaction DrugDDI.d332.s18.e1 DrugDDI.d332.s18.e4 false
interaction DrugDDI.d332.s18.e1 DrugDDI.d332.s18.e5 false
interaction DrugDDI.d332.s18.e1 DrugDDI.d332.s18.e6 false
interaction DrugDDI.d332.s18.e1 DrugDDI.d332.s18.e7 false
interaction DrugDDI.d332.s18.e1 DrugDDI.d332.s18.e8 false
interaction DrugDDI.d332.s18.e2 DrugDDI.d332.s18.e3 false
interaction DrugDDI.d332.s18.e2 DrugDDI.d332.s18.e4 false
interaction DrugDDI.d332.s18.e2 DrugDDI.d332.s18.e5 false
interaction DrugDDI.d332.s18.e2 DrugDDI.d332.s18.e6 false
interaction DrugDDI.d332.s18.e2 DrugDDI.d332.s18.e7 false
interaction DrugDDI.d332.s18.e2 DrugDDI.d332.s18.e8 false
interaction DrugDDI.d332.s18.e3 DrugDDI.d332.s18.e4 false
interaction DrugDDI.d332.s18.e3 DrugDDI.d332.s18.e5 false
interaction DrugDDI.d332.s18.e3 DrugDDI.d332.s18.e6 false
interaction DrugDDI.d332.s18.e3 DrugDDI.d332.s18.e7 false
interaction DrugDDI.d332.s18.e3 DrugDDI.d332.s18.e8 false
interaction DrugDDI.d332.s18.e4 DrugDDI.d332.s18.e5 false
interaction DrugDDI.d332.s18.e4 DrugDDI.d332.s18.e6 false
interaction DrugDDI.d332.s18.e4 DrugDDI.d332.s18.e7 false
interaction DrugDDI.d332.s18.e4 DrugDDI.d332.s18.e8 false
interaction DrugDDI.d332.s18.e5 DrugDDI.d332.s18.e6 false
interaction DrugDDI.d332.s18.e5 DrugDDI.d332.s18.e7 false
interaction DrugDDI.d332.s18.e5 DrugDDI.d332.s18.e8 false
interaction DrugDDI.d332.s18.e6 DrugDDI.d332.s18.e7 false
interaction DrugDDI.d332.s18.e6 DrugDDI.d332.s18.e8 false
interaction DrugDDI.d332.s18.e7 DrugDDI.d332.s18.e8 false

Abstract Id: DrugDDI.d332
Sentence Id: DrugDDI.d332.s19
Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents , there were no signs or symptoms of hypoglycemia.

DrugDDI.d332.s19.e0 91 102
drug
flurbiprofen
DrugDDI.d332.s19.e1 106 123
drug
hypoglycemic agents
DrugDDI.d332.s19.new.DISO.e2 153 164
DISO
hypoglycemia

interaction DrugDDI.d332.s19.e0 DrugDDI.d332.s19.e1 true

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s0
Diuretics : Patients on diuretics , especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium .

DrugDDI.d561.s0.e0 0 8
drug
Diuretics
DrugDDI.d561.s0.e1 20 28
drug
diuretics
DrugDDI.d561.s0.e2 166 181
drug
fosinopril sodium

interaction DrugDDI.d561.s0.e0 DrugDDI.d561.s0.e1 false
interaction DrugDDI.d561.s0.e0 DrugDDI.d561.s0.e2 false
interaction DrugDDI.d561.s0.e1 DrugDDI.d561.s0.e2 true

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s1
The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium .

DrugDDI.d561.s1.e0 72 79
drug
diuretic
DrugDDI.d561.s1.e1 134 149
drug
fosinopril sodium

interaction DrugDDI.d561.s1.e0 DrugDDI.d561.s1.e1 false

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s3
Potassium Supplement s and Potassium-Sparing Diuretics : Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics .

DrugDDI.d561.s3.e0 0 18
drug
Potassium Supplement
DrugDDI.d561.s3.e1 23 48
drug
Potassium-Sparing Diuretics
DrugDDI.d561.s3.e2 50 65
drug
Fosinopril sodium
DrugDDI.d561.s3.e3 78 86
drug
potassium
DrugDDI.d561.s3.e4 99 115
drug
thiazide diuretics

interaction DrugDDI.d561.s3.e0 DrugDDI.d561.s3.e1 false
interaction DrugDDI.d561.s3.e0 DrugDDI.d561.s3.e2 false
interaction DrugDDI.d561.s3.e0 DrugDDI.d561.s3.e3 false
interaction DrugDDI.d561.s3.e0 DrugDDI.d561.s3.e4 false
interaction DrugDDI.d561.s3.e1 DrugDDI.d561.s3.e2 false
interaction DrugDDI.d561.s3.e1 DrugDDI.d561.s3.e3 false
interaction DrugDDI.d561.s3.e1 DrugDDI.d561.s3.e4 false
interaction DrugDDI.d561.s3.e2 DrugDDI.d561.s3.e3 false
interaction DrugDDI.d561.s3.e2 DrugDDI.d561.s3.e4 true
interaction DrugDDI.d561.s3.e3 DrugDDI.d561.s3.e4 false

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s4
Potassium-sparing diuretics ( spironolactone , amiloride , triamterene , and others) or potassium supplement s can increase the risk of hyperkalemia.

DrugDDI.d561.s4.e0 0 25
drug
Potassium-sparing diuretics
DrugDDI.d561.s4.e1 27 40
drug
spironolactone
DrugDDI.d561.s4.e2 42 50
drug
amiloride
DrugDDI.d561.s4.e3 52 62
drug
triamterene
DrugDDI.d561.s4.e4 76 94
drug
potassium supplement
DrugDDI.d561.s4.new.DISO.e5 116 127
DISO
hyperkalemia

interaction DrugDDI.d561.s4.e0 DrugDDI.d561.s4.e1 false
interaction DrugDDI.d561.s4.e0 DrugDDI.d561.s4.e2 false
interaction DrugDDI.d561.s4.e0 DrugDDI.d561.s4.e3 false
interaction DrugDDI.d561.s4.e0 DrugDDI.d561.s4.e4 false
interaction DrugDDI.d561.s4.e1 DrugDDI.d561.s4.e2 false
interaction DrugDDI.d561.s4.e1 DrugDDI.d561.s4.e3 false
interaction DrugDDI.d561.s4.e1 DrugDDI.d561.s4.e4 false
interaction DrugDDI.d561.s4.e2 DrugDDI.d561.s4.e3 false
interaction DrugDDI.d561.s4.e2 DrugDDI.d561.s4.e4 false
interaction DrugDDI.d561.s4.e3 DrugDDI.d561.s4.e4 false

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s6
Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium .

DrugDDI.d561.s6.e0 0 6
drug
Lithium
DrugDDI.d561.s6.e1 98 110
drug
ACE inhibitors
DrugDDI.d561.s6.e2 128 134
drug
lithium

interaction DrugDDI.d561.s6.e0 DrugDDI.d561.s6.e1 false
interaction DrugDDI.d561.s6.e0 DrugDDI.d561.s6.e2 false
interaction DrugDDI.d561.s6.e1 DrugDDI.d561.s6.e2 true

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s7
These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.

DrugDDI.d561.s7.e0 5 9
drug
drugs



Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s8
If a diuretic is also used, the risk of lithium toxicity may be increased.

DrugDDI.d561.s8.e0 3 10
drug
diuretic



Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s9
Antacids : In a clinical pharmacology study, coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril .

DrugDDI.d561.s9.e0 0 7
drug
Antacids
DrugDDI.d561.s9.e1 58 64
drug
antacid
DrugDDI.d561.s9.e2 66 82
drug
aluminum hydroxide
DrugDDI.d561.s9.e3 84 101
drug
magnesium hydroxide
DrugDDI.d561.s9.e4 106 116
drug
simethicone
DrugDDI.d561.s9.e5 122 131
drug
fosinopril
DrugDDI.d561.s9.e6 171 182
drug
fosinoprilat
DrugDDI.d561.s9.e7 197 206
drug
fosinopril
DrugDDI.d561.s9.e8 239 246
drug
antacids
DrugDDI.d561.s9.e9 268 277
drug
fosinopril

interaction DrugDDI.d561.s9.e0 DrugDDI.d561.s9.e1 false
interaction DrugDDI.d561.s9.e0 DrugDDI.d561.s9.e2 false
interaction DrugDDI.d561.s9.e0 DrugDDI.d561.s9.e3 false
interaction DrugDDI.d561.s9.e0 DrugDDI.d561.s9.e4 false
interaction DrugDDI.d561.s9.e0 DrugDDI.d561.s9.e5 false
interaction DrugDDI.d561.s9.e0 DrugDDI.d561.s9.e6 false
interaction DrugDDI.d561.s9.e0 DrugDDI.d561.s9.e7 false
interaction DrugDDI.d561.s9.e0 DrugDDI.d561.s9.e8 false
interaction DrugDDI.d561.s9.e0 DrugDDI.d561.s9.e9 false
interaction DrugDDI.d561.s9.e1 DrugDDI.d561.s9.e2 false
interaction DrugDDI.d561.s9.e1 DrugDDI.d561.s9.e3 false
interaction DrugDDI.d561.s9.e1 DrugDDI.d561.s9.e4 false
interaction DrugDDI.d561.s9.e1 DrugDDI.d561.s9.e5 true
interaction DrugDDI.d561.s9.e1 DrugDDI.d561.s9.e6 false
interaction DrugDDI.d561.s9.e1 DrugDDI.d561.s9.e7 false
interaction DrugDDI.d561.s9.e1 DrugDDI.d561.s9.e8 false
interaction DrugDDI.d561.s9.e1 DrugDDI.d561.s9.e9 false
interaction DrugDDI.d561.s9.e2 DrugDDI.d561.s9.e3 false
interaction DrugDDI.d561.s9.e2 DrugDDI.d561.s9.e4 false
interaction DrugDDI.d561.s9.e2 DrugDDI.d561.s9.e5 false
interaction DrugDDI.d561.s9.e2 DrugDDI.d561.s9.e6 false
interaction DrugDDI.d561.s9.e2 DrugDDI.d561.s9.e7 false
interaction DrugDDI.d561.s9.e2 DrugDDI.d561.s9.e8 false
interaction DrugDDI.d561.s9.e2 DrugDDI.d561.s9.e9 false
interaction DrugDDI.d561.s9.e3 DrugDDI.d561.s9.e4 false
interaction DrugDDI.d561.s9.e3 DrugDDI.d561.s9.e5 true
interaction DrugDDI.d561.s9.e3 DrugDDI.d561.s9.e6 false
interaction DrugDDI.d561.s9.e3 DrugDDI.d561.s9.e7 false
interaction DrugDDI.d561.s9.e3 DrugDDI.d561.s9.e8 false
interaction DrugDDI.d561.s9.e3 DrugDDI.d561.s9.e9 false
interaction DrugDDI.d561.s9.e4 DrugDDI.d561.s9.e5 false
interaction DrugDDI.d561.s9.e4 DrugDDI.d561.s9.e6 false
interaction DrugDDI.d561.s9.e4 DrugDDI.d561.s9.e7 false
interaction DrugDDI.d561.s9.e4 DrugDDI.d561.s9.e8 false
interaction DrugDDI.d561.s9.e4 DrugDDI.d561.s9.e9 false
interaction DrugDDI.d561.s9.e5 DrugDDI.d561.s9.e6 false
interaction DrugDDI.d561.s9.e5 DrugDDI.d561.s9.e7 false
interaction DrugDDI.d561.s9.e5 DrugDDI.d561.s9.e8 false
interaction DrugDDI.d561.s9.e5 DrugDDI.d561.s9.e9 false
interaction DrugDDI.d561.s9.e6 DrugDDI.d561.s9.e7 false
interaction DrugDDI.d561.s9.e6 DrugDDI.d561.s9.e8 false
interaction DrugDDI.d561.s9.e6 DrugDDI.d561.s9.e9 false
interaction DrugDDI.d561.s9.e7 DrugDDI.d561.s9.e8 false
interaction DrugDDI.d561.s9.e7 DrugDDI.d561.s9.e9 false
interaction DrugDDI.d561.s9.e8 DrugDDI.d561.s9.e9 true

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s11
Other: Neither fosinopril sodium nor its metabolites have been found to interact with food.

DrugDDI.d561.s11.e0 13 28
drug
fosinopril sodium
DrugDDI.d561.s11.e1 35 45
drug
metabolites

interaction DrugDDI.d561.s11.e0 DrugDDI.d561.s11.e1 false

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s12
In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone , nifedipine , propanolol , hydrochlorothiazide , cimetidine , metoclopramide , propantheline , digoxin , and warfarin , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs .

DrugDDI.d561.s12.e0 67 80
drug
chlorthalidone
DrugDDI.d561.s12.e1 82 91
drug
nifedipine
DrugDDI.d561.s12.e2 93 102
drug
propanolol
DrugDDI.d561.s12.e3 104 122
drug
hydrochlorothiazide
DrugDDI.d561.s12.e4 124 133
drug
cimetidine
DrugDDI.d561.s12.e5 135 148
drug
metoclopramide
DrugDDI.d561.s12.e6 150 162
drug
propantheline
DrugDDI.d561.s12.e7 164 170
drug
digoxin
DrugDDI.d561.s12.e8 175 182
drug
warfarin
DrugDDI.d561.s12.e9 204 215
drug
fosinoprilat
DrugDDI.d561.s12.e10 249 258
drug
fosinopril
DrugDDI.d561.s12.e11 276 280
drug
drugs

interaction DrugDDI.d561.s12.e0 DrugDDI.d561.s12.e1 false
interaction DrugDDI.d561.s12.e0 DrugDDI.d561.s12.e2 false
interaction DrugDDI.d561.s12.e0 DrugDDI.d561.s12.e3 false
interaction DrugDDI.d561.s12.e0 DrugDDI.d561.s12.e4 false
interaction DrugDDI.d561.s12.e0 DrugDDI.d561.s12.e5 false
interaction DrugDDI.d561.s12.e0 DrugDDI.d561.s12.e6 false
interaction DrugDDI.d561.s12.e0 DrugDDI.d561.s12.e7 false
interaction DrugDDI.d561.s12.e0 DrugDDI.d561.s12.e8 false
interaction DrugDDI.d561.s12.e0 DrugDDI.d561.s12.e9 false
interaction DrugDDI.d561.s12.e0 DrugDDI.d561.s12.e10 false
interaction DrugDDI.d561.s12.e0 DrugDDI.d561.s12.e11 false
interaction DrugDDI.d561.s12.e1 DrugDDI.d561.s12.e2 false
interaction DrugDDI.d561.s12.e1 DrugDDI.d561.s12.e3 false
interaction DrugDDI.d561.s12.e1 DrugDDI.d561.s12.e4 false
interaction DrugDDI.d561.s12.e1 DrugDDI.d561.s12.e5 false
interaction DrugDDI.d561.s12.e1 DrugDDI.d561.s12.e6 false
interaction DrugDDI.d561.s12.e1 DrugDDI.d561.s12.e7 false
interaction DrugDDI.d561.s12.e1 DrugDDI.d561.s12.e8 false
interaction DrugDDI.d561.s12.e1 DrugDDI.d561.s12.e9 false
interaction DrugDDI.d561.s12.e1 DrugDDI.d561.s12.e10 false
interaction DrugDDI.d561.s12.e1 DrugDDI.d561.s12.e11 false
interaction DrugDDI.d561.s12.e2 DrugDDI.d561.s12.e3 false
interaction DrugDDI.d561.s12.e2 DrugDDI.d561.s12.e4 false
interaction DrugDDI.d561.s12.e2 DrugDDI.d561.s12.e5 false
interaction DrugDDI.d561.s12.e2 DrugDDI.d561.s12.e6 false
interaction DrugDDI.d561.s12.e2 DrugDDI.d561.s12.e7 false
interaction DrugDDI.d561.s12.e2 DrugDDI.d561.s12.e8 false
interaction DrugDDI.d561.s12.e2 DrugDDI.d561.s12.e9 false
interaction DrugDDI.d561.s12.e2 DrugDDI.d561.s12.e10 false
interaction DrugDDI.d561.s12.e2 DrugDDI.d561.s12.e11 false
interaction DrugDDI.d561.s12.e3 DrugDDI.d561.s12.e4 false
interaction DrugDDI.d561.s12.e3 DrugDDI.d561.s12.e5 false
interaction DrugDDI.d561.s12.e3 DrugDDI.d561.s12.e6 false
interaction DrugDDI.d561.s12.e3 DrugDDI.d561.s12.e7 false
interaction DrugDDI.d561.s12.e3 DrugDDI.d561.s12.e8 false
interaction DrugDDI.d561.s12.e3 DrugDDI.d561.s12.e9 false
interaction DrugDDI.d561.s12.e3 DrugDDI.d561.s12.e10 false
interaction DrugDDI.d561.s12.e3 DrugDDI.d561.s12.e11 false
interaction DrugDDI.d561.s12.e4 DrugDDI.d561.s12.e5 false
interaction DrugDDI.d561.s12.e4 DrugDDI.d561.s12.e6 false
interaction DrugDDI.d561.s12.e4 DrugDDI.d561.s12.e7 false
interaction DrugDDI.d561.s12.e4 DrugDDI.d561.s12.e8 false
interaction DrugDDI.d561.s12.e4 DrugDDI.d561.s12.e9 false
interaction DrugDDI.d561.s12.e4 DrugDDI.d561.s12.e10 false
interaction DrugDDI.d561.s12.e4 DrugDDI.d561.s12.e11 false
interaction DrugDDI.d561.s12.e5 DrugDDI.d561.s12.e6 false
interaction DrugDDI.d561.s12.e5 DrugDDI.d561.s12.e7 false
interaction DrugDDI.d561.s12.e5 DrugDDI.d561.s12.e8 false
interaction DrugDDI.d561.s12.e5 DrugDDI.d561.s12.e9 false
interaction DrugDDI.d561.s12.e5 DrugDDI.d561.s12.e10 false
interaction DrugDDI.d561.s12.e5 DrugDDI.d561.s12.e11 false
interaction DrugDDI.d561.s12.e6 DrugDDI.d561.s12.e7 false
interaction DrugDDI.d561.s12.e6 DrugDDI.d561.s12.e8 false
interaction DrugDDI.d561.s12.e6 DrugDDI.d561.s12.e9 false
interaction DrugDDI.d561.s12.e6 DrugDDI.d561.s12.e10 false
interaction DrugDDI.d561.s12.e6 DrugDDI.d561.s12.e11 false
interaction DrugDDI.d561.s12.e7 DrugDDI.d561.s12.e8 false
interaction DrugDDI.d561.s12.e7 DrugDDI.d561.s12.e9 false
interaction DrugDDI.d561.s12.e7 DrugDDI.d561.s12.e10 false
interaction DrugDDI.d561.s12.e7 DrugDDI.d561.s12.e11 false
interaction DrugDDI.d561.s12.e8 DrugDDI.d561.s12.e9 false
interaction DrugDDI.d561.s12.e8 DrugDDI.d561.s12.e10 false
interaction DrugDDI.d561.s12.e8 DrugDDI.d561.s12.e11 false
interaction DrugDDI.d561.s12.e9 DrugDDI.d561.s12.e10 false
interaction DrugDDI.d561.s12.e9 DrugDDI.d561.s12.e11 false
interaction DrugDDI.d561.s12.e10 DrugDDI.d561.s12.e11 false

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s13
In a study with concomitant administration of aspirin and fosinopril sodium , the bioavailability of unbound fosinoprilat was not altered.

DrugDDI.d561.s13.e0 39 45
drug
aspirin
DrugDDI.d561.s13.e1 49 64
drug
fosinopril sodium
DrugDDI.d561.s13.e2 93 104
drug
fosinoprilat

interaction DrugDDI.d561.s13.e0 DrugDDI.d561.s13.e1 false
interaction DrugDDI.d561.s13.e0 DrugDDI.d561.s13.e2 false
interaction DrugDDI.d561.s13.e1 DrugDDI.d561.s13.e2 false

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s14
In a pharmacokinetic interaction study with warfarin , bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of warfarin were not significantly changed.

DrugDDI.d561.s14.e0 38 45
drug
warfarin
DrugDDI.d561.s14.e1 153 160
drug
warfarin

interaction DrugDDI.d561.s14.e0 DrugDDI.d561.s14.e1 false

Abstract Id: DrugDDI.d561
Sentence Id: DrugDDI.d561.s15
Drug /Laboratory Test Interaction Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab@ RIA Kit for Digoxin .

DrugDDI.d561.s15.e0 0 3
drug
Drug
DrugDDI.d561.s15.e1 30 39
drug
Fosinopril
DrugDDI.d561.s15.e2 113 119
drug
Digoxin

interaction DrugDDI.d561.s15.e0 DrugDDI.d561.s15.e1 false
interaction DrugDDI.d561.s15.e0 DrugDDI.d561.s15.e2 false
interaction DrugDDI.d561.s15.e1 DrugDDI.d561.s15.e2 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s0
No drugs are known to interfere with the conversion of fosphenytoin to phenytoin .

DrugDDI.d466.s0.e0 2 6
drug
drugs
DrugDDI.d466.s0.e1 45 56
drug
fosphenytoin
DrugDDI.d466.s0.e2 59 67
drug
phenytoin

interaction DrugDDI.d466.s0.e0 DrugDDI.d466.s0.e1 false
interaction DrugDDI.d466.s0.e0 DrugDDI.d466.s0.e2 false
interaction DrugDDI.d466.s0.e1 DrugDDI.d466.s0.e2 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s1
Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of fosphenytoin to phenytoin .

DrugDDI.d466.s1.e0 111 122
drug
phosphatases
DrugDDI.d466.s1.e1 148 152
drug
drugs
DrugDDI.d466.s1.e2 202 213
drug
fosphenytoin
DrugDDI.d466.s1.e3 216 224
drug
phenytoin

interaction DrugDDI.d466.s1.e0 DrugDDI.d466.s1.e1 false
interaction DrugDDI.d466.s1.e0 DrugDDI.d466.s1.e2 false
interaction DrugDDI.d466.s1.e0 DrugDDI.d466.s1.e3 false
interaction DrugDDI.d466.s1.e1 DrugDDI.d466.s1.e2 false
interaction DrugDDI.d466.s1.e1 DrugDDI.d466.s1.e3 false
interaction DrugDDI.d466.s1.e2 DrugDDI.d466.s1.e3 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s2
Drugs highly bound to albumin could increase the unbound fraction of fosphenytoin .

DrugDDI.d466.s2.e0 0 4
drug
Drugs
DrugDDI.d466.s2.e1 18 24
drug
albumin
DrugDDI.d466.s2.e2 58 69
drug
fosphenytoin

interaction DrugDDI.d466.s2.e0 DrugDDI.d466.s2.e1 false
interaction DrugDDI.d466.s2.e0 DrugDDI.d466.s2.e2 true
interaction DrugDDI.d466.s2.e1 DrugDDI.d466.s2.e2 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s3
Although, it is unknown whether this could result in clinically significant effects, caution is advised when administering Cerebyx with other drugs that significantly bind to serum albumin .

DrugDDI.d466.s3.e0 106 112
drug
Cerebyx
DrugDDI.d466.s3.e1 122 126
drug
drugs
DrugDDI.d466.s3.e2 150 161
drug
serum albumin

interaction DrugDDI.d466.s3.e0 DrugDDI.d466.s3.e1 true
interaction DrugDDI.d466.s3.e0 DrugDDI.d466.s3.e2 false
interaction DrugDDI.d466.s3.e1 DrugDDI.d466.s3.e2 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s4
The pharmacokinetics and protein binding of fosphenytoin , phenytoin , and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.

DrugDDI.d466.s4.e0 38 49
drug
fosphenytoin
DrugDDI.d466.s4.e1 51 59
drug
phenytoin
DrugDDI.d466.s4.e2 64 71
drug
diazepam
DrugDDI.d466.s4.e3 90 97
drug
diazepam
DrugDDI.d466.s4.e4 101 107
drug
Cerebyx

interaction DrugDDI.d466.s4.e0 DrugDDI.d466.s4.e1 false
interaction DrugDDI.d466.s4.e0 DrugDDI.d466.s4.e2 false
interaction DrugDDI.d466.s4.e0 DrugDDI.d466.s4.e3 false
interaction DrugDDI.d466.s4.e0 DrugDDI.d466.s4.e4 false
interaction DrugDDI.d466.s4.e1 DrugDDI.d466.s4.e2 false
interaction DrugDDI.d466.s4.e1 DrugDDI.d466.s4.e3 false
interaction DrugDDI.d466.s4.e1 DrugDDI.d466.s4.e4 false
interaction DrugDDI.d466.s4.e2 DrugDDI.d466.s4.e3 false
interaction DrugDDI.d466.s4.e2 DrugDDI.d466.s4.e4 false
interaction DrugDDI.d466.s4.e3 DrugDDI.d466.s4.e4 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s5
The most significant drug interactions following administration of Cerebyx are expected to occur with drugs that interact with phenytoin .

DrugDDI.d466.s5.e0 59 65
drug
Cerebyx
DrugDDI.d466.s5.e1 88 92
drug
drugs
DrugDDI.d466.s5.e2 109 117
drug
phenytoin

interaction DrugDDI.d466.s5.e0 DrugDDI.d466.s5.e1 true
interaction DrugDDI.d466.s5.e0 DrugDDI.d466.s5.e2 false
interaction DrugDDI.d466.s5.e1 DrugDDI.d466.s5.e2 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s6
Phenytoin is extensively bound to serum plasma proteins and is prone to competitive displacement.

DrugDDI.d466.s6.e0 0 8
drug
Phenytoin
DrugDDI.d466.s6.e1 40 47
drug
proteins

interaction DrugDDI.d466.s6.e0 DrugDDI.d466.s6.e1 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s7
Phenytoin is metabolized by hepatic cytochrome P450 enzyme s and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism.

DrugDDI.d466.s7.e0 0 8
drug
Phenytoin
DrugDDI.d466.s7.e1 24 50
drug
hepatic cytochrome P450 enzyme

interaction DrugDDI.d466.s7.e0 DrugDDI.d466.s7.e1 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s8
Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity.

DrugDDI.d466.s8.e0 65 73
drug
phenytoin
DrugDDI.d466.s8.new.DISO.e1 107 118
DISO
drug toxicity



Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s9
Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes.

DrugDDI.d466.s9.e0 0 8
drug
Phenytoin



Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s10
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone , chboramphenicol, chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , H2-antagonists, halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone .

DrugDDI.d466.s10.e0 56 60
drug
Drugs
DrugDDI.d466.s10.e1 82 90
drug
phenytoin
DrugDDI.d466.s10.e2 132 141
drug
amiodarone
DrugDDI.d466.s10.e3 159 174
drug
chlordiazepoxide
DrugDDI.d466.s10.e4 176 185
drug
cimetidine
DrugDDI.d466.s10.e5 187 194
drug
diazepam
DrugDDI.d466.s10.e6 196 204
drug
dicumarol
DrugDDI.d466.s10.e7 206 215
drug
disulfiram
DrugDDI.d466.s10.e8 217 225
drug
estrogens
DrugDDI.d466.s10.e9 227 238
drug
ethosuximide
DrugDDI.d466.s10.e10 240 249
drug
fluoxetine
DrugDDI.d466.s10.e11 266 274
drug
halothane
DrugDDI.d466.s10.e12 276 284
drug
isoniazid
DrugDDI.d466.s10.e13 286 300
drug
methylphenidate
DrugDDI.d466.s10.e14 302 315
drug
phenothiazines
DrugDDI.d466.s10.e15 317 330
drug
phenylbutazone
DrugDDI.d466.s10.e16 332 342
drug
salicylates
DrugDDI.d466.s10.e17 344 355
drug
succinimides
DrugDDI.d466.s10.e18 357 368
drug
sulfonamides
DrugDDI.d466.s10.e19 370 380
drug
tolbutamide
DrugDDI.d466.s10.e20 382 390
drug
trazodone

interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e1 true
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e2 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e3 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e4 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e5 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e6 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e7 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e8 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e9 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e10 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e11 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e0 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e2 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e3 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e4 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e5 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e6 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e7 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e8 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e9 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e10 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e11 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e1 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e3 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e4 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e5 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e6 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e7 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e8 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e9 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e10 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e11 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e2 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e4 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e5 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e6 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e7 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e8 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e9 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e10 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e11 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e3 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e5 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e6 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e7 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e8 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e9 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e10 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e11 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e4 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e6 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e7 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e8 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e9 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e10 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e11 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e5 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e7 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e8 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e9 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e10 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e11 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e6 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e8 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e9 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e10 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e11 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e7 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e9 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e10 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e11 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e8 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e9 DrugDDI.d466.s10.e10 false
interaction DrugDDI.d466.s10.e9 DrugDDI.d466.s10.e11 false
interaction DrugDDI.d466.s10.e9 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e9 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e9 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e9 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e9 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e9 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e9 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e9 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e9 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e10 DrugDDI.d466.s10.e11 false
interaction DrugDDI.d466.s10.e10 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e10 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e10 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e10 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e10 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e10 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e10 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e10 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e10 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e11 DrugDDI.d466.s10.e12 false
interaction DrugDDI.d466.s10.e11 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e11 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e11 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e11 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e11 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e11 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e11 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e11 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e12 DrugDDI.d466.s10.e13 false
interaction DrugDDI.d466.s10.e12 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e12 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e12 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e12 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e12 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e12 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e12 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e13 DrugDDI.d466.s10.e14 false
interaction DrugDDI.d466.s10.e13 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e13 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e13 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e13 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e13 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e13 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e14 DrugDDI.d466.s10.e15 false
interaction DrugDDI.d466.s10.e14 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e14 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e14 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e14 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e14 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e15 DrugDDI.d466.s10.e16 false
interaction DrugDDI.d466.s10.e15 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e15 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e15 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e15 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e16 DrugDDI.d466.s10.e17 false
interaction DrugDDI.d466.s10.e16 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e16 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e16 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e17 DrugDDI.d466.s10.e18 false
interaction DrugDDI.d466.s10.e17 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e17 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e18 DrugDDI.d466.s10.e19 false
interaction DrugDDI.d466.s10.e18 DrugDDI.d466.s10.e20 false
interaction DrugDDI.d466.s10.e19 DrugDDI.d466.s10.e20 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s12
- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine , chronic alcohol abuse, reserpine .

DrugDDI.d466.s12.e0 1 5
drug
Drugs
DrugDDI.d466.s12.e1 27 35
drug
phenytoin
DrugDDI.d466.s12.e2 58 70
drug
carbamazepine
DrugDDI.d466.s12.new.DISO.e4 72 90
DISO
chronic alcohol abuse
DrugDDI.d466.s12.e3 92 100
drug
reserpine

interaction DrugDDI.d466.s12.e0 DrugDDI.d466.s12.e1 true
interaction DrugDDI.d466.s12.e0 DrugDDI.d466.s12.e2 false
interaction DrugDDI.d466.s12.e0 DrugDDI.d466.s12.e3 false
interaction DrugDDI.d466.s12.e1 DrugDDI.d466.s12.e2 false
interaction DrugDDI.d466.s12.e1 DrugDDI.d466.s12.e3 false
interaction DrugDDI.d466.s12.e2 DrugDDI.d466.s12.e3 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s14
- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital , vaiproic acid, and sodium valproate .

DrugDDI.d466.s14.e0 1 5
drug
Drugs
DrugDDI.d466.s14.e1 43 51
drug
phenytoin
DrugDDI.d466.s14.e2 74 86
drug
phenobarbital
DrugDDI.d466.s14.e3 104 118
drug
sodium valproate

interaction DrugDDI.d466.s14.e0 DrugDDI.d466.s14.e1 true
interaction DrugDDI.d466.s14.e0 DrugDDI.d466.s14.e2 false
interaction DrugDDI.d466.s14.e0 DrugDDI.d466.s14.e3 false
interaction DrugDDI.d466.s14.e1 DrugDDI.d466.s14.e2 false
interaction DrugDDI.d466.s14.e1 DrugDDI.d466.s14.e3 false
interaction DrugDDI.d466.s14.e2 DrugDDI.d466.s14.e3 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s15
Similarly, the effects of phenytoin on phenobarbital , valproic acid and sodium plasma valproate concentrations are unpredictable .

DrugDDI.d466.s15.e0 22 30
drug
phenytoin
DrugDDI.d466.s15.e1 33 45
drug
phenobarbital
DrugDDI.d466.s15.e2 47 58
drug
valproic acid
DrugDDI.d466.s15.e3 74 82
drug
valproate

interaction DrugDDI.d466.s15.e0 DrugDDI.d466.s15.e1 false
interaction DrugDDI.d466.s15.e0 DrugDDI.d466.s15.e2 false
interaction DrugDDI.d466.s15.e0 DrugDDI.d466.s15.e3 false
interaction DrugDDI.d466.s15.e1 DrugDDI.d466.s15.e2 false
interaction DrugDDI.d466.s15.e1 DrugDDI.d466.s15.e3 false
interaction DrugDDI.d466.s15.e2 DrugDDI.d466.s15.e3 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s17
- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted .

DrugDDI.d466.s17.e0 33 56
drug
tricyclic antidepressants
DrugDDI.d466.s17.e1 103 109
drug
Cerebyx

interaction DrugDDI.d466.s17.e0 DrugDDI.d466.s17.e1 true

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s19
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants , corticosteroids , coumarin , digitoxin , doxycycline , estrogens , furosemide , oral contraceptives , rifampin , quinidine , theophylline , vitamin D .

DrugDDI.d466.s19.e0 1 5
drug
Drugs
DrugDDI.d466.s19.e1 31 39
drug
phenytoin
DrugDDI.d466.s19.e2 48 61
drug
anticoagulants
DrugDDI.d466.s19.e3 63 77
drug
corticosteroids
DrugDDI.d466.s19.e4 79 86
drug
coumarin
DrugDDI.d466.s19.e5 88 96
drug
digitoxin
DrugDDI.d466.s19.e6 98 108
drug
doxycycline
DrugDDI.d466.s19.e7 110 118
drug
estrogens
DrugDDI.d466.s19.e8 120 129
drug
furosemide
DrugDDI.d466.s19.e9 131 148
drug
oral contraceptives
DrugDDI.d466.s19.e10 150 157
drug
rifampin
DrugDDI.d466.s19.e11 159 167
drug
quinidine
DrugDDI.d466.s19.e12 169 180
drug
theophylline
DrugDDI.d466.s19.e13 182 189
drug
vitamin D

interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e1 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e2 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e3 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e4 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e5 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e6 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e7 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e8 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e9 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e10 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e11 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e0 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e2 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e3 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e4 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e5 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e6 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e7 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e8 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e9 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e10 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e11 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e1 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e2 DrugDDI.d466.s19.e3 false
interaction DrugDDI.d466.s19.e2 DrugDDI.d466.s19.e4 false
interaction DrugDDI.d466.s19.e2 DrugDDI.d466.s19.e5 false
interaction DrugDDI.d466.s19.e2 DrugDDI.d466.s19.e6 false
interaction DrugDDI.d466.s19.e2 DrugDDI.d466.s19.e7 false
interaction DrugDDI.d466.s19.e2 DrugDDI.d466.s19.e8 false
interaction DrugDDI.d466.s19.e2 DrugDDI.d466.s19.e9 false
interaction DrugDDI.d466.s19.e2 DrugDDI.d466.s19.e10 false
interaction DrugDDI.d466.s19.e2 DrugDDI.d466.s19.e11 false
interaction DrugDDI.d466.s19.e2 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e2 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e3 DrugDDI.d466.s19.e4 false
interaction DrugDDI.d466.s19.e3 DrugDDI.d466.s19.e5 false
interaction DrugDDI.d466.s19.e3 DrugDDI.d466.s19.e6 false
interaction DrugDDI.d466.s19.e3 DrugDDI.d466.s19.e7 false
interaction DrugDDI.d466.s19.e3 DrugDDI.d466.s19.e8 false
interaction DrugDDI.d466.s19.e3 DrugDDI.d466.s19.e9 false
interaction DrugDDI.d466.s19.e3 DrugDDI.d466.s19.e10 false
interaction DrugDDI.d466.s19.e3 DrugDDI.d466.s19.e11 false
interaction DrugDDI.d466.s19.e3 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e3 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e4 DrugDDI.d466.s19.e5 false
interaction DrugDDI.d466.s19.e4 DrugDDI.d466.s19.e6 false
interaction DrugDDI.d466.s19.e4 DrugDDI.d466.s19.e7 false
interaction DrugDDI.d466.s19.e4 DrugDDI.d466.s19.e8 false
interaction DrugDDI.d466.s19.e4 DrugDDI.d466.s19.e9 false
interaction DrugDDI.d466.s19.e4 DrugDDI.d466.s19.e10 false
interaction DrugDDI.d466.s19.e4 DrugDDI.d466.s19.e11 false
interaction DrugDDI.d466.s19.e4 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e4 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e5 DrugDDI.d466.s19.e6 false
interaction DrugDDI.d466.s19.e5 DrugDDI.d466.s19.e7 false
interaction DrugDDI.d466.s19.e5 DrugDDI.d466.s19.e8 false
interaction DrugDDI.d466.s19.e5 DrugDDI.d466.s19.e9 false
interaction DrugDDI.d466.s19.e5 DrugDDI.d466.s19.e10 false
interaction DrugDDI.d466.s19.e5 DrugDDI.d466.s19.e11 false
interaction DrugDDI.d466.s19.e5 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e5 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e6 DrugDDI.d466.s19.e7 false
interaction DrugDDI.d466.s19.e6 DrugDDI.d466.s19.e8 false
interaction DrugDDI.d466.s19.e6 DrugDDI.d466.s19.e9 false
interaction DrugDDI.d466.s19.e6 DrugDDI.d466.s19.e10 false
interaction DrugDDI.d466.s19.e6 DrugDDI.d466.s19.e11 false
interaction DrugDDI.d466.s19.e6 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e6 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e7 DrugDDI.d466.s19.e8 false
interaction DrugDDI.d466.s19.e7 DrugDDI.d466.s19.e9 false
interaction DrugDDI.d466.s19.e7 DrugDDI.d466.s19.e10 false
interaction DrugDDI.d466.s19.e7 DrugDDI.d466.s19.e11 false
interaction DrugDDI.d466.s19.e7 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e7 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e8 DrugDDI.d466.s19.e9 false
interaction DrugDDI.d466.s19.e8 DrugDDI.d466.s19.e10 false
interaction DrugDDI.d466.s19.e8 DrugDDI.d466.s19.e11 false
interaction DrugDDI.d466.s19.e8 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e8 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e9 DrugDDI.d466.s19.e10 false
interaction DrugDDI.d466.s19.e9 DrugDDI.d466.s19.e11 false
interaction DrugDDI.d466.s19.e9 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e9 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e10 DrugDDI.d466.s19.e11 false
interaction DrugDDI.d466.s19.e10 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e10 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e11 DrugDDI.d466.s19.e12 false
interaction DrugDDI.d466.s19.e11 DrugDDI.d466.s19.e13 false
interaction DrugDDI.d466.s19.e12 DrugDDI.d466.s19.e13 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s20
Monitoring of plasma phenytoin concentrations may be helpful when possible drug interactions are suspected.

DrugDDI.d466.s20.e0 18 26
drug
phenytoin



Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s21
Drug /Laboratory Test Interactions Phenytoin may decrease serum concentrations of 14.

DrugDDI.d466.s21.e0 0 3
drug
Drug
DrugDDI.d466.s21.e1 31 39
drug
Phenytoin

interaction DrugDDI.d466.s21.e0 DrugDDI.d466.s21.e1 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s22
It may also produce artifactually low results in dexamethasone or metyrapone tests.

DrugDDI.d466.s22.e0 41 53
drug
dexamethasone



Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s23
Phenytoin may also cause increased serum concentrations of glucose , alkaline phosphatase , and gamma glutamyl transpeptidase (GGT).

DrugDDI.d466.s23.e0 0 8
drug
Phenytoin
DrugDDI.d466.s23.e1 51 57
drug
glucose
DrugDDI.d466.s23.e2 59 77
drug
alkaline phosphatase
DrugDDI.d466.s23.e3 82 108
drug
gamma glutamyl transpeptidase

interaction DrugDDI.d466.s23.e0 DrugDDI.d466.s23.e1 true
interaction DrugDDI.d466.s23.e0 DrugDDI.d466.s23.e2 false
interaction DrugDDI.d466.s23.e0 DrugDDI.d466.s23.e3 false
interaction DrugDDI.d466.s23.e1 DrugDDI.d466.s23.e2 false
interaction DrugDDI.d466.s23.e1 DrugDDI.d466.s23.e3 false
interaction DrugDDI.d466.s23.e2 DrugDDI.d466.s23.e3 false

Abstract Id: DrugDDI.d466
Sentence Id: DrugDDI.d466.s24
Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations following Cerebyx administration.

DrugDDI.d466.s24.e0 64 72
drug
phenytoin
DrugDDI.d466.s24.e1 96 102
drug
Cerebyx

interaction DrugDDI.d466.s24.e0 DrugDDI.d466.s24.e1 false

Abstract Id: DrugDDI.d281
Sentence Id: DrugDDI.d281.s0
No drug interactions have been observed with the Vitrasert Implant.

DrugDDI.d281.s0.e0 41 49
drug
Vitrasert



Abstract Id: DrugDDI.d281
Sentence Id: DrugDDI.d281.s1
There is limited experience with use of retinal tamponades in conjunction with the Vitrasert Implant.

DrugDDI.d281.s1.e0 70 78
drug
Vitrasert



Abstract Id: DrugDDI.d178
Sentence Id: DrugDDI.d178.s0
Substances that are inducers of CYP3A4 activity increase the metabolism of gefitinib and decrease its plasma concentrations.

DrugDDI.d178.s0.e0 27 32
drug
CYP3A4
DrugDDI.d178.s0.e1 64 72
drug
gefitinib

interaction DrugDDI.d178.s0.e0 DrugDDI.d178.s0.e1 false

Abstract Id: DrugDDI.d178
Sentence Id: DrugDDI.d178.s1
In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin , a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).

DrugDDI.d178.s1.e0 26 31
drug
CYP3A4
DrugDDI.d178.s1.e1 45 54
drug
rifampicin
DrugDDI.d178.s1.e2 57 65
drug
phenytoin
DrugDDI.d178.s1.new.DISO.e3 130 148
DISO
adverse drug reaction

interaction DrugDDI.d178.s1.e0 DrugDDI.d178.s1.e1 false
interaction DrugDDI.d178.s1.e0 DrugDDI.d178.s1.e2 false
interaction DrugDDI.d178.s1.e1 DrugDDI.d178.s1.e2 false

Abstract Id: DrugDDI.d178
Sentence Id: DrugDDI.d178.s2
International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.

DrugDDI.d178.s2.e0 99 106
drug
warfarin
DrugDDI.d178.s2.e1 114 119
drug
IRESSA

interaction DrugDDI.d178.s2.e0 DrugDDI.d178.s2.e1 true

Abstract Id: DrugDDI.d178
Sentence Id: DrugDDI.d178.s3
Patients taking warfarin should be monitored regularly for changes in prothrombin time or INR.

DrugDDI.d178.s3.e0 14 21
drug
warfarin



Abstract Id: DrugDDI.d178
Sentence Id: DrugDDI.d178.s4
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole ) decrease gefitinib metabolism and increase gefitinib plasma concentrations.

DrugDDI.d178.s4.e0 35 40
drug
CYP3A4
DrugDDI.d178.s4.e1 53 64
drug
ketoconazole
DrugDDI.d178.s4.e2 68 79
drug
itraconazole
DrugDDI.d178.s4.e3 89 97
drug
gefitinib
DrugDDI.d178.s4.e4 119 127
drug
gefitinib

interaction DrugDDI.d178.s4.e0 DrugDDI.d178.s4.e1 false
interaction DrugDDI.d178.s4.e0 DrugDDI.d178.s4.e2 false
interaction DrugDDI.d178.s4.e0 DrugDDI.d178.s4.e3 false
interaction DrugDDI.d178.s4.e0 DrugDDI.d178.s4.e4 false
interaction DrugDDI.d178.s4.e1 DrugDDI.d178.s4.e2 false
interaction DrugDDI.d178.s4.e1 DrugDDI.d178.s4.e3 true
interaction DrugDDI.d178.s4.e1 DrugDDI.d178.s4.e4 false
interaction DrugDDI.d178.s4.e2 DrugDDI.d178.s4.e3 true
interaction DrugDDI.d178.s4.e2 DrugDDI.d178.s4.e4 false
interaction DrugDDI.d178.s4.e3 DrugDDI.d178.s4.e4 false

Abstract Id: DrugDDI.d178
Sentence Id: DrugDDI.d178.s6
therefore, caution should be used when administering CYP3A4 inhibitors with IRESSA .

DrugDDI.d178.s6.e0 46 51
drug
CYP3A4
DrugDDI.d178.s6.e1 66 71
drug
IRESSA

interaction DrugDDI.d178.s6.e0 DrugDDI.d178.s6.e1 false

Abstract Id: DrugDDI.d178
Sentence Id: DrugDDI.d178.s7
Drugs that cause significant sustained elevation in gastric pH ( histamine H2-receptor antagonists such as ranitidine or cimetidine ) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.

DrugDDI.d178.s7.e0 0 4
drug
Drugs
DrugDDI.d178.s7.e1 55 85
drug
histamine H2-receptor antagonists
DrugDDI.d178.s7.e2 92 101
drug
ranitidine
DrugDDI.d178.s7.e3 104 113
drug
cimetidine
DrugDDI.d178.s7.e4 146 151
drug
IRESSA

interaction DrugDDI.d178.s7.e0 DrugDDI.d178.s7.e1 false
interaction DrugDDI.d178.s7.e0 DrugDDI.d178.s7.e2 false
interaction DrugDDI.d178.s7.e0 DrugDDI.d178.s7.e3 false
interaction DrugDDI.d178.s7.e0 DrugDDI.d178.s7.e4 true
interaction DrugDDI.d178.s7.e1 DrugDDI.d178.s7.e2 false
interaction DrugDDI.d178.s7.e1 DrugDDI.d178.s7.e3 false
interaction DrugDDI.d178.s7.e1 DrugDDI.d178.s7.e4 false
interaction DrugDDI.d178.s7.e2 DrugDDI.d178.s7.e3 false
interaction DrugDDI.d178.s7.e2 DrugDDI.d178.s7.e4 true
interaction DrugDDI.d178.s7.e3 DrugDDI.d178.s7.e4 false

Abstract Id: DrugDDI.d178
Sentence Id: DrugDDI.d178.s8
Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine .

DrugDDI.d178.s8.e0 30 35
drug
IRESSA
DrugDDI.d178.s8.e1 39 49
drug
vinorelbine
DrugDDI.d178.s8.e2 88 93
drug
IRESSA
DrugDDI.d178.s8.e3 129 139
drug
vinorelbine

interaction DrugDDI.d178.s8.e0 DrugDDI.d178.s8.e1 false
interaction DrugDDI.d178.s8.e0 DrugDDI.d178.s8.e2 false
interaction DrugDDI.d178.s8.e0 DrugDDI.d178.s8.e3 false
interaction DrugDDI.d178.s8.e1 DrugDDI.d178.s8.e2 false
interaction DrugDDI.d178.s8.e1 DrugDDI.d178.s8.e3 false
interaction DrugDDI.d178.s8.e2 DrugDDI.d178.s8.e3 true

Abstract Id: DrugDDI.d147
Sentence Id: DrugDDI.d147.s1
For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.

DrugDDI.d147.s1.e0 37 42
drug
Gemzar
DrugDDI.d147.s1.e1 46 54
drug
cisplatin

interaction DrugDDI.d147.s1.e0 DrugDDI.d147.s1.e1 false

Abstract Id: DrugDDI.d57
Sentence Id: DrugDDI.d57.s4
increased creatine .

DrugDDI.d57.s4.e0 9 16
drug
creatine



Abstract Id: DrugDDI.d57
Sentence Id: DrugDDI.d57.s7
phosphokinase .

DrugDDI.d57.s7.e0 0 12
drug
phosphokinase



Abstract Id: DrugDDI.d57
Sentence Id: DrugDDI.d57.s8
antibody .

DrugDDI.d57.s8.e0 0 7
drug
antibody



Abstract Id: DrugDDI.d57
Sentence Id: DrugDDI.d57.s10
increased bilirubin .

DrugDDI.d57.s10.e0 9 17
drug
bilirubin



Abstract Id: DrugDDI.d57
Sentence Id: DrugDDI.d57.s13
increased liver .

DrugDDI.d57.s13.e0 9 13
drug
liver



Abstract Id: DrugDDI.d57
Sentence Id: DrugDDI.d57.s16
transaminases ( AST .

DrugDDI.d57.s16.e0 0 12
drug
transaminases
DrugDDI.d57.s16.e1 14 16
drug
AST

interaction DrugDDI.d57.s16.e0 DrugDDI.d57.s16.e1 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s0
Many other medicines may increase or decrease the effects of glimepiride or affect your condition.

DrugDDI.d465.s0.e0 9 17
drug
medicines
DrugDDI.d465.s0.e1 51 61
drug
glimepiride

interaction DrugDDI.d465.s0.e0 DrugDDI.d465.s0.e1 true

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s1
Before taking glimepiride , tell your doctor if you are taking any of the following medicines : - aspirin or another salicylate such as magnesium / choline salicylate ( Trilisate ), salsalate ( Disalcid , others), choline salicylate ( Arthropan ), magnesium salicylate ( Magan ), or bismuth subsalicylate ( Pepto-Bismol ); .

DrugDDI.d465.s1.e0 12 22
drug
glimepiride
DrugDDI.d465.s1.e1 69 77
drug
medicines
DrugDDI.d465.s1.e2 80 86
drug
aspirin
DrugDDI.d465.s1.e3 96 105
drug
salicylate
DrugDDI.d465.s1.e4 112 120
drug
magnesium
DrugDDI.d465.s1.e5 122 138
drug
choline salicylate
DrugDDI.d465.s1.e6 140 148
drug
Trilisate
DrugDDI.d465.s1.e7 151 159
drug
salsalate
DrugDDI.d465.s1.e8 161 168
drug
Disalcid
DrugDDI.d465.s1.e9 178 194
drug
choline salicylate
DrugDDI.d465.s1.e10 196 204
drug
Arthropan
DrugDDI.d465.s1.e11 207 225
drug
magnesium salicylate
DrugDDI.d465.s1.e12 227 231
drug
Magan
DrugDDI.d465.s1.e13 236 255
drug
bismuth subsalicylate
DrugDDI.d465.s1.e14 257 268
drug
Pepto-Bismol

interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e1 true
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e2 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e3 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e4 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e5 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e6 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e7 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e8 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e9 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e10 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e11 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e0 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e2 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e3 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e4 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e5 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e6 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e7 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e8 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e9 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e10 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e11 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e1 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e3 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e4 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e5 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e6 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e7 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e8 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e9 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e10 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e11 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e2 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e3 DrugDDI.d465.s1.e4 false
interaction DrugDDI.d465.s1.e3 DrugDDI.d465.s1.e5 false
interaction DrugDDI.d465.s1.e3 DrugDDI.d465.s1.e6 false
interaction DrugDDI.d465.s1.e3 DrugDDI.d465.s1.e7 false
interaction DrugDDI.d465.s1.e3 DrugDDI.d465.s1.e8 false
interaction DrugDDI.d465.s1.e3 DrugDDI.d465.s1.e9 false
interaction DrugDDI.d465.s1.e3 DrugDDI.d465.s1.e10 false
interaction DrugDDI.d465.s1.e3 DrugDDI.d465.s1.e11 false
interaction DrugDDI.d465.s1.e3 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e3 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e3 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e4 DrugDDI.d465.s1.e5 false
interaction DrugDDI.d465.s1.e4 DrugDDI.d465.s1.e6 false
interaction DrugDDI.d465.s1.e4 DrugDDI.d465.s1.e7 false
interaction DrugDDI.d465.s1.e4 DrugDDI.d465.s1.e8 false
interaction DrugDDI.d465.s1.e4 DrugDDI.d465.s1.e9 false
interaction DrugDDI.d465.s1.e4 DrugDDI.d465.s1.e10 false
interaction DrugDDI.d465.s1.e4 DrugDDI.d465.s1.e11 false
interaction DrugDDI.d465.s1.e4 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e4 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e4 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e5 DrugDDI.d465.s1.e6 false
interaction DrugDDI.d465.s1.e5 DrugDDI.d465.s1.e7 false
interaction DrugDDI.d465.s1.e5 DrugDDI.d465.s1.e8 false
interaction DrugDDI.d465.s1.e5 DrugDDI.d465.s1.e9 false
interaction DrugDDI.d465.s1.e5 DrugDDI.d465.s1.e10 false
interaction DrugDDI.d465.s1.e5 DrugDDI.d465.s1.e11 false
interaction DrugDDI.d465.s1.e5 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e5 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e5 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e6 DrugDDI.d465.s1.e7 false
interaction DrugDDI.d465.s1.e6 DrugDDI.d465.s1.e8 false
interaction DrugDDI.d465.s1.e6 DrugDDI.d465.s1.e9 false
interaction DrugDDI.d465.s1.e6 DrugDDI.d465.s1.e10 false
interaction DrugDDI.d465.s1.e6 DrugDDI.d465.s1.e11 false
interaction DrugDDI.d465.s1.e6 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e6 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e6 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e7 DrugDDI.d465.s1.e8 false
interaction DrugDDI.d465.s1.e7 DrugDDI.d465.s1.e9 false
interaction DrugDDI.d465.s1.e7 DrugDDI.d465.s1.e10 false
interaction DrugDDI.d465.s1.e7 DrugDDI.d465.s1.e11 false
interaction DrugDDI.d465.s1.e7 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e7 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e7 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e8 DrugDDI.d465.s1.e9 false
interaction DrugDDI.d465.s1.e8 DrugDDI.d465.s1.e10 false
interaction DrugDDI.d465.s1.e8 DrugDDI.d465.s1.e11 false
interaction DrugDDI.d465.s1.e8 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e8 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e8 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e9 DrugDDI.d465.s1.e10 false
interaction DrugDDI.d465.s1.e9 DrugDDI.d465.s1.e11 false
interaction DrugDDI.d465.s1.e9 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e9 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e9 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e10 DrugDDI.d465.s1.e11 false
interaction DrugDDI.d465.s1.e10 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e10 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e10 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e11 DrugDDI.d465.s1.e12 false
interaction DrugDDI.d465.s1.e11 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e11 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e12 DrugDDI.d465.s1.e13 false
interaction DrugDDI.d465.s1.e12 DrugDDI.d465.s1.e14 false
interaction DrugDDI.d465.s1.e13 DrugDDI.d465.s1.e14 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s2
- a nonsteroidal anti-inflammatory drug ( NSAID ) such as ibuprofen ( Motrin , Advil , Nuprin , others), ketoprofen ( Orudis , Orudis KT , Oruvail ), diclofenac ( Voltaren , Cataflam ), etodolac ( Lodine ), indomethacin ( Indocin ), nabumetone ( Relafen ), oxaprozin ( Daypro ), and naproxen ( Anaprox , Naprosyn , Aleve ); .

DrugDDI.d465.s2.e0 2 34
drug
nonsteroidal anti-inflammatory drug
DrugDDI.d465.s2.e1 36 40
drug
NSAID
DrugDDI.d465.s2.e2 48 56
drug
ibuprofen
DrugDDI.d465.s2.e3 58 63
drug
Motrin
DrugDDI.d465.s2.e4 65 69
drug
Advil
DrugDDI.d465.s2.e5 71 76
drug
Nuprin
DrugDDI.d465.s2.e6 86 95
drug
ketoprofen
DrugDDI.d465.s2.e7 97 102
drug
Orudis
DrugDDI.d465.s2.e8 104 111
drug
Orudis KT
DrugDDI.d465.s2.e9 113 119
drug
Oruvail
DrugDDI.d465.s2.e10 122 131
drug
diclofenac
DrugDDI.d465.s2.e11 133 140
drug
Voltaren
DrugDDI.d465.s2.e12 142 149
drug
Cataflam
DrugDDI.d465.s2.e13 152 159
drug
etodolac
DrugDDI.d465.s2.e14 161 166
drug
Lodine
DrugDDI.d465.s2.e15 169 180
drug
indomethacin
DrugDDI.d465.s2.e16 182 188
drug
Indocin
DrugDDI.d465.s2.e17 191 200
drug
nabumetone
DrugDDI.d465.s2.e18 202 208
drug
Relafen
DrugDDI.d465.s2.e19 211 219
drug
oxaprozin
DrugDDI.d465.s2.e20 221 226
drug
Daypro
DrugDDI.d465.s2.e21 232 239
drug
naproxen
DrugDDI.d465.s2.e22 241 247
drug
Anaprox
DrugDDI.d465.s2.e23 249 256
drug
Naprosyn
DrugDDI.d465.s2.e24 258 262
drug
Aleve

interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e1 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e2 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e3 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e4 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e5 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e6 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e7 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e8 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e9 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e10 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e11 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e0 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e2 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e3 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e4 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e5 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e6 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e7 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e8 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e9 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e10 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e11 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e1 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e3 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e4 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e5 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e6 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e7 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e8 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e9 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e10 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e11 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e2 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e4 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e5 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e6 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e7 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e8 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e9 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e10 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e11 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e3 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e5 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e6 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e7 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e8 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e9 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e10 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e11 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e4 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e6 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e7 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e8 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e9 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e10 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e11 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e5 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e7 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e8 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e9 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e10 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e11 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e6 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e8 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e9 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e10 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e11 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e7 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e9 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e10 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e11 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e8 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e10 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e11 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e9 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e11 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e10 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e12 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e11 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e13 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e12 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e13 DrugDDI.d465.s2.e14 false
interaction DrugDDI.d465.s2.e13 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e13 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e13 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e13 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e13 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e13 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e13 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e13 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e13 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e13 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e14 DrugDDI.d465.s2.e15 false
interaction DrugDDI.d465.s2.e14 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e14 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e14 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e14 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e14 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e14 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e14 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e14 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e14 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e15 DrugDDI.d465.s2.e16 false
interaction DrugDDI.d465.s2.e15 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e15 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e15 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e15 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e15 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e15 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e15 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e15 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e16 DrugDDI.d465.s2.e17 false
interaction DrugDDI.d465.s2.e16 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e16 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e16 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e16 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e16 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e16 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e16 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e17 DrugDDI.d465.s2.e18 false
interaction DrugDDI.d465.s2.e17 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e17 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e17 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e17 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e17 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e17 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e18 DrugDDI.d465.s2.e19 false
interaction DrugDDI.d465.s2.e18 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e18 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e18 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e18 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e18 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e19 DrugDDI.d465.s2.e20 false
interaction DrugDDI.d465.s2.e19 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e19 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e19 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e19 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e20 DrugDDI.d465.s2.e21 false
interaction DrugDDI.d465.s2.e20 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e20 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e20 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e21 DrugDDI.d465.s2.e22 false
interaction DrugDDI.d465.s2.e21 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e21 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e22 DrugDDI.d465.s2.e23 false
interaction DrugDDI.d465.s2.e22 DrugDDI.d465.s2.e24 false
interaction DrugDDI.d465.s2.e23 DrugDDI.d465.s2.e24 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s3
- a sulfa-based drug such as sulfamethoxazole-trimethoprim ( Bactrim , Septra ), sulfisoxazole ( Gantrisin ), or sulfasalazine ( Azulfidine ); .

DrugDDI.d465.s3.e0 2 16
drug
sulfa-based drug
DrugDDI.d465.s3.e1 23 51
drug
sulfamethoxazole-trimethoprim
DrugDDI.d465.s3.e2 53 59
drug
Bactrim
DrugDDI.d465.s3.e3 61 66
drug
Septra
DrugDDI.d465.s3.e4 69 81
drug
sulfisoxazole
DrugDDI.d465.s3.e5 83 91
drug
Gantrisin
DrugDDI.d465.s3.e6 96 108
drug
sulfasalazine
DrugDDI.d465.s3.e7 110 119
drug
Azulfidine

interaction DrugDDI.d465.s3.e0 DrugDDI.d465.s3.e1 false
interaction DrugDDI.d465.s3.e0 DrugDDI.d465.s3.e2 false
interaction DrugDDI.d465.s3.e0 DrugDDI.d465.s3.e3 false
interaction DrugDDI.d465.s3.e0 DrugDDI.d465.s3.e4 false
interaction DrugDDI.d465.s3.e0 DrugDDI.d465.s3.e5 false
interaction DrugDDI.d465.s3.e0 DrugDDI.d465.s3.e6 false
interaction DrugDDI.d465.s3.e0 DrugDDI.d465.s3.e7 false
interaction DrugDDI.d465.s3.e1 DrugDDI.d465.s3.e2 false
interaction DrugDDI.d465.s3.e1 DrugDDI.d465.s3.e3 false
interaction DrugDDI.d465.s3.e1 DrugDDI.d465.s3.e4 false
interaction DrugDDI.d465.s3.e1 DrugDDI.d465.s3.e5 false
interaction DrugDDI.d465.s3.e1 DrugDDI.d465.s3.e6 false
interaction DrugDDI.d465.s3.e1 DrugDDI.d465.s3.e7 false
interaction DrugDDI.d465.s3.e2 DrugDDI.d465.s3.e3 false
interaction DrugDDI.d465.s3.e2 DrugDDI.d465.s3.e4 false
interaction DrugDDI.d465.s3.e2 DrugDDI.d465.s3.e5 false
interaction DrugDDI.d465.s3.e2 DrugDDI.d465.s3.e6 false
interaction DrugDDI.d465.s3.e2 DrugDDI.d465.s3.e7 false
interaction DrugDDI.d465.s3.e3 DrugDDI.d465.s3.e4 false
interaction DrugDDI.d465.s3.e3 DrugDDI.d465.s3.e5 false
interaction DrugDDI.d465.s3.e3 DrugDDI.d465.s3.e6 false
interaction DrugDDI.d465.s3.e3 DrugDDI.d465.s3.e7 false
interaction DrugDDI.d465.s3.e4 DrugDDI.d465.s3.e5 false
interaction DrugDDI.d465.s3.e4 DrugDDI.d465.s3.e6 false
interaction DrugDDI.d465.s3.e4 DrugDDI.d465.s3.e7 false
interaction DrugDDI.d465.s3.e5 DrugDDI.d465.s3.e6 false
interaction DrugDDI.d465.s3.e5 DrugDDI.d465.s3.e7 false
interaction DrugDDI.d465.s3.e6 DrugDDI.d465.s3.e7 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s4
- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid ( Marplan ), tranylcypromine ( Parnate ), or phenelzine ( Nardil ); .

DrugDDI.d465.s4.e0 2 26
drug
monoamine oxidase inhibitor
DrugDDI.d465.s4.e1 39 51
drug
isocarboxazid
DrugDDI.d465.s4.e2 53 59
drug
Marplan
DrugDDI.d465.s4.e3 62 76
drug
tranylcypromine
DrugDDI.d465.s4.e4 78 84
drug
Parnate
DrugDDI.d465.s4.e5 89 98
drug
phenelzine
DrugDDI.d465.s4.e6 100 105
drug
Nardil

interaction DrugDDI.d465.s4.e0 DrugDDI.d465.s4.e1 false
interaction DrugDDI.d465.s4.e0 DrugDDI.d465.s4.e2 false
interaction DrugDDI.d465.s4.e0 DrugDDI.d465.s4.e3 false
interaction DrugDDI.d465.s4.e0 DrugDDI.d465.s4.e4 false
interaction DrugDDI.d465.s4.e0 DrugDDI.d465.s4.e5 false
interaction DrugDDI.d465.s4.e0 DrugDDI.d465.s4.e6 false
interaction DrugDDI.d465.s4.e1 DrugDDI.d465.s4.e2 false
interaction DrugDDI.d465.s4.e1 DrugDDI.d465.s4.e3 false
interaction DrugDDI.d465.s4.e1 DrugDDI.d465.s4.e4 false
interaction DrugDDI.d465.s4.e1 DrugDDI.d465.s4.e5 false
interaction DrugDDI.d465.s4.e1 DrugDDI.d465.s4.e6 false
interaction DrugDDI.d465.s4.e2 DrugDDI.d465.s4.e3 false
interaction DrugDDI.d465.s4.e2 DrugDDI.d465.s4.e4 false
interaction DrugDDI.d465.s4.e2 DrugDDI.d465.s4.e5 false
interaction DrugDDI.d465.s4.e2 DrugDDI.d465.s4.e6 false
interaction DrugDDI.d465.s4.e3 DrugDDI.d465.s4.e4 false
interaction DrugDDI.d465.s4.e3 DrugDDI.d465.s4.e5 false
interaction DrugDDI.d465.s4.e3 DrugDDI.d465.s4.e6 false
interaction DrugDDI.d465.s4.e4 DrugDDI.d465.s4.e5 false
interaction DrugDDI.d465.s4.e4 DrugDDI.d465.s4.e6 false
interaction DrugDDI.d465.s4.e5 DrugDDI.d465.s4.e6 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s5
- a beta-blocker such as propranolol ( Inderal ), atenolol ( Tenormin ), acebutolol ( Sectral ), metoprolol ( Lopressor ), and others; .

DrugDDI.d465.s5.e0 2 13
drug
beta-blocker
DrugDDI.d465.s5.e1 20 30
drug
propranolol
DrugDDI.d465.s5.e2 32 38
drug
Inderal
DrugDDI.d465.s5.e3 41 48
drug
atenolol
DrugDDI.d465.s5.e4 50 57
drug
Tenormin
DrugDDI.d465.s5.e5 60 69
drug
acebutolol
DrugDDI.d465.s5.e6 71 77
drug
Sectral
DrugDDI.d465.s5.e7 80 89
drug
metoprolol
DrugDDI.d465.s5.e8 91 99
drug
Lopressor

interaction DrugDDI.d465.s5.e0 DrugDDI.d465.s5.e1 false
interaction DrugDDI.d465.s5.e0 DrugDDI.d465.s5.e2 false
interaction DrugDDI.d465.s5.e0 DrugDDI.d465.s5.e3 false
interaction DrugDDI.d465.s5.e0 DrugDDI.d465.s5.e4 false
interaction DrugDDI.d465.s5.e0 DrugDDI.d465.s5.e5 false
interaction DrugDDI.d465.s5.e0 DrugDDI.d465.s5.e6 false
interaction DrugDDI.d465.s5.e0 DrugDDI.d465.s5.e7 false
interaction DrugDDI.d465.s5.e0 DrugDDI.d465.s5.e8 false
interaction DrugDDI.d465.s5.e1 DrugDDI.d465.s5.e2 false
interaction DrugDDI.d465.s5.e1 DrugDDI.d465.s5.e3 false
interaction DrugDDI.d465.s5.e1 DrugDDI.d465.s5.e4 false
interaction DrugDDI.d465.s5.e1 DrugDDI.d465.s5.e5 false
interaction DrugDDI.d465.s5.e1 DrugDDI.d465.s5.e6 false
interaction DrugDDI.d465.s5.e1 DrugDDI.d465.s5.e7 false
interaction DrugDDI.d465.s5.e1 DrugDDI.d465.s5.e8 false
interaction DrugDDI.d465.s5.e2 DrugDDI.d465.s5.e3 false
interaction DrugDDI.d465.s5.e2 DrugDDI.d465.s5.e4 false
interaction DrugDDI.d465.s5.e2 DrugDDI.d465.s5.e5 false
interaction DrugDDI.d465.s5.e2 DrugDDI.d465.s5.e6 false
interaction DrugDDI.d465.s5.e2 DrugDDI.d465.s5.e7 false
interaction DrugDDI.d465.s5.e2 DrugDDI.d465.s5.e8 false
interaction DrugDDI.d465.s5.e3 DrugDDI.d465.s5.e4 false
interaction DrugDDI.d465.s5.e3 DrugDDI.d465.s5.e5 false
interaction DrugDDI.d465.s5.e3 DrugDDI.d465.s5.e6 false
interaction DrugDDI.d465.s5.e3 DrugDDI.d465.s5.e7 false
interaction DrugDDI.d465.s5.e3 DrugDDI.d465.s5.e8 false
interaction DrugDDI.d465.s5.e4 DrugDDI.d465.s5.e5 false
interaction DrugDDI.d465.s5.e4 DrugDDI.d465.s5.e6 false
interaction DrugDDI.d465.s5.e4 DrugDDI.d465.s5.e7 false
interaction DrugDDI.d465.s5.e4 DrugDDI.d465.s5.e8 false
interaction DrugDDI.d465.s5.e5 DrugDDI.d465.s5.e6 false
interaction DrugDDI.d465.s5.e5 DrugDDI.d465.s5.e7 false
interaction DrugDDI.d465.s5.e5 DrugDDI.d465.s5.e8 false
interaction DrugDDI.d465.s5.e6 DrugDDI.d465.s5.e7 false
interaction DrugDDI.d465.s5.e6 DrugDDI.d465.s5.e8 false
interaction DrugDDI.d465.s5.e7 DrugDDI.d465.s5.e8 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s6
- a diuretic ( water pill) such as hydrochlorothiazide ( HCTZ , Hydrodiuril ), chlorothiazide ( Diuril ), and others; .

DrugDDI.d465.s6.e0 2 9
drug
diuretic
DrugDDI.d465.s6.e1 11 15
drug
water
DrugDDI.d465.s6.e2 27 45
drug
hydrochlorothiazide
DrugDDI.d465.s6.e3 47 50
drug
HCTZ
DrugDDI.d465.s6.e4 52 62
drug
Hydrodiuril
DrugDDI.d465.s6.e5 65 78
drug
chlorothiazide
DrugDDI.d465.s6.e6 80 85
drug
Diuril

interaction DrugDDI.d465.s6.e0 DrugDDI.d465.s6.e1 false
interaction DrugDDI.d465.s6.e0 DrugDDI.d465.s6.e2 false
interaction DrugDDI.d465.s6.e0 DrugDDI.d465.s6.e3 false
interaction DrugDDI.d465.s6.e0 DrugDDI.d465.s6.e4 false
interaction DrugDDI.d465.s6.e0 DrugDDI.d465.s6.e5 false
interaction DrugDDI.d465.s6.e0 DrugDDI.d465.s6.e6 false
interaction DrugDDI.d465.s6.e1 DrugDDI.d465.s6.e2 false
interaction DrugDDI.d465.s6.e1 DrugDDI.d465.s6.e3 false
interaction DrugDDI.d465.s6.e1 DrugDDI.d465.s6.e4 false
interaction DrugDDI.d465.s6.e1 DrugDDI.d465.s6.e5 false
interaction DrugDDI.d465.s6.e1 DrugDDI.d465.s6.e6 false
interaction DrugDDI.d465.s6.e2 DrugDDI.d465.s6.e3 false
interaction DrugDDI.d465.s6.e2 DrugDDI.d465.s6.e4 false
interaction DrugDDI.d465.s6.e2 DrugDDI.d465.s6.e5 false
interaction DrugDDI.d465.s6.e2 DrugDDI.d465.s6.e6 false
interaction DrugDDI.d465.s6.e3 DrugDDI.d465.s6.e4 false
interaction DrugDDI.d465.s6.e3 DrugDDI.d465.s6.e5 false
interaction DrugDDI.d465.s6.e3 DrugDDI.d465.s6.e6 false
interaction DrugDDI.d465.s6.e4 DrugDDI.d465.s6.e5 false
interaction DrugDDI.d465.s6.e4 DrugDDI.d465.s6.e6 false
interaction DrugDDI.d465.s6.e5 DrugDDI.d465.s6.e6 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s7
- a steroid medicine such as prednisone ( Deltasone , Orasone , others), methylprednisolone ( Medrol , others), prednisolone ( Prelone , Pediapred , others), and others; .

DrugDDI.d465.s7.e0 2 16
drug
steroid medicine
DrugDDI.d465.s7.e1 23 32
drug
prednisone
DrugDDI.d465.s7.e2 34 42
drug
Deltasone
DrugDDI.d465.s7.e3 44 50
drug
Orasone
DrugDDI.d465.s7.e4 60 77
drug
methylprednisolone
DrugDDI.d465.s7.e5 79 84
drug
Medrol
DrugDDI.d465.s7.e6 94 105
drug
prednisolone
DrugDDI.d465.s7.e7 107 113
drug
Prelone
DrugDDI.d465.s7.e8 115 123
drug
Pediapred

interaction DrugDDI.d465.s7.e0 DrugDDI.d465.s7.e1 false
interaction DrugDDI.d465.s7.e0 DrugDDI.d465.s7.e2 false
interaction DrugDDI.d465.s7.e0 DrugDDI.d465.s7.e3 false
interaction DrugDDI.d465.s7.e0 DrugDDI.d465.s7.e4 false
interaction DrugDDI.d465.s7.e0 DrugDDI.d465.s7.e5 false
interaction DrugDDI.d465.s7.e0 DrugDDI.d465.s7.e6 false
interaction DrugDDI.d465.s7.e0 DrugDDI.d465.s7.e7 false
interaction DrugDDI.d465.s7.e0 DrugDDI.d465.s7.e8 false
interaction DrugDDI.d465.s7.e1 DrugDDI.d465.s7.e2 false
interaction DrugDDI.d465.s7.e1 DrugDDI.d465.s7.e3 false
interaction DrugDDI.d465.s7.e1 DrugDDI.d465.s7.e4 false
interaction DrugDDI.d465.s7.e1 DrugDDI.d465.s7.e5 false
interaction DrugDDI.d465.s7.e1 DrugDDI.d465.s7.e6 false
interaction DrugDDI.d465.s7.e1 DrugDDI.d465.s7.e7 false
interaction DrugDDI.d465.s7.e1 DrugDDI.d465.s7.e8 false
interaction DrugDDI.d465.s7.e2 DrugDDI.d465.s7.e3 false
interaction DrugDDI.d465.s7.e2 DrugDDI.d465.s7.e4 false
interaction DrugDDI.d465.s7.e2 DrugDDI.d465.s7.e5 false
interaction DrugDDI.d465.s7.e2 DrugDDI.d465.s7.e6 false
interaction DrugDDI.d465.s7.e2 DrugDDI.d465.s7.e7 false
interaction DrugDDI.d465.s7.e2 DrugDDI.d465.s7.e8 false
interaction DrugDDI.d465.s7.e3 DrugDDI.d465.s7.e4 false
interaction DrugDDI.d465.s7.e3 DrugDDI.d465.s7.e5 false
interaction DrugDDI.d465.s7.e3 DrugDDI.d465.s7.e6 false
interaction DrugDDI.d465.s7.e3 DrugDDI.d465.s7.e7 false
interaction DrugDDI.d465.s7.e3 DrugDDI.d465.s7.e8 false
interaction DrugDDI.d465.s7.e4 DrugDDI.d465.s7.e5 false
interaction DrugDDI.d465.s7.e4 DrugDDI.d465.s7.e6 false
interaction DrugDDI.d465.s7.e4 DrugDDI.d465.s7.e7 false
interaction DrugDDI.d465.s7.e4 DrugDDI.d465.s7.e8 false
interaction DrugDDI.d465.s7.e5 DrugDDI.d465.s7.e6 false
interaction DrugDDI.d465.s7.e5 DrugDDI.d465.s7.e7 false
interaction DrugDDI.d465.s7.e5 DrugDDI.d465.s7.e8 false
interaction DrugDDI.d465.s7.e6 DrugDDI.d465.s7.e7 false
interaction DrugDDI.d465.s7.e6 DrugDDI.d465.s7.e8 false
interaction DrugDDI.d465.s7.e7 DrugDDI.d465.s7.e8 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s8
- a phenothiazine such as chlorpromazine ( Thorazine ), fluphenazine ( Prolixin , Permitil ), prochlorperazine ( Compazine ), promethazine ( Phenergan ), and others; .

DrugDDI.d465.s8.e0 2 14
drug
phenothiazine
DrugDDI.d465.s8.e1 21 34
drug
chlorpromazine
DrugDDI.d465.s8.e2 36 44
drug
Thorazine
DrugDDI.d465.s8.e3 47 58
drug
fluphenazine
DrugDDI.d465.s8.e4 60 67
drug
Prolixin
DrugDDI.d465.s8.e5 69 76
drug
Permitil
DrugDDI.d465.s8.e6 79 94
drug
prochlorperazine
DrugDDI.d465.s8.e7 96 104
drug
Compazine
DrugDDI.d465.s8.e8 107 118
drug
promethazine
DrugDDI.d465.s8.e9 120 128
drug
Phenergan

interaction DrugDDI.d465.s8.e0 DrugDDI.d465.s8.e1 false
interaction DrugDDI.d465.s8.e0 DrugDDI.d465.s8.e2 false
interaction DrugDDI.d465.s8.e0 DrugDDI.d465.s8.e3 false
interaction DrugDDI.d465.s8.e0 DrugDDI.d465.s8.e4 false
interaction DrugDDI.d465.s8.e0 DrugDDI.d465.s8.e5 false
interaction DrugDDI.d465.s8.e0 DrugDDI.d465.s8.e6 false
interaction DrugDDI.d465.s8.e0 DrugDDI.d465.s8.e7 false
interaction DrugDDI.d465.s8.e0 DrugDDI.d465.s8.e8 false
interaction DrugDDI.d465.s8.e0 DrugDDI.d465.s8.e9 false
interaction DrugDDI.d465.s8.e1 DrugDDI.d465.s8.e2 false
interaction DrugDDI.d465.s8.e1 DrugDDI.d465.s8.e3 false
interaction DrugDDI.d465.s8.e1 DrugDDI.d465.s8.e4 false
interaction DrugDDI.d465.s8.e1 DrugDDI.d465.s8.e5 false
interaction DrugDDI.d465.s8.e1 DrugDDI.d465.s8.e6 false
interaction DrugDDI.d465.s8.e1 DrugDDI.d465.s8.e7 false
interaction DrugDDI.d465.s8.e1 DrugDDI.d465.s8.e8 false
interaction DrugDDI.d465.s8.e1 DrugDDI.d465.s8.e9 false
interaction DrugDDI.d465.s8.e2 DrugDDI.d465.s8.e3 false
interaction DrugDDI.d465.s8.e2 DrugDDI.d465.s8.e4 false
interaction DrugDDI.d465.s8.e2 DrugDDI.d465.s8.e5 false
interaction DrugDDI.d465.s8.e2 DrugDDI.d465.s8.e6 false
interaction DrugDDI.d465.s8.e2 DrugDDI.d465.s8.e7 false
interaction DrugDDI.d465.s8.e2 DrugDDI.d465.s8.e8 false
interaction DrugDDI.d465.s8.e2 DrugDDI.d465.s8.e9 false
interaction DrugDDI.d465.s8.e3 DrugDDI.d465.s8.e4 false
interaction DrugDDI.d465.s8.e3 DrugDDI.d465.s8.e5 false
interaction DrugDDI.d465.s8.e3 DrugDDI.d465.s8.e6 false
interaction DrugDDI.d465.s8.e3 DrugDDI.d465.s8.e7 false
interaction DrugDDI.d465.s8.e3 DrugDDI.d465.s8.e8 false
interaction DrugDDI.d465.s8.e3 DrugDDI.d465.s8.e9 false
interaction DrugDDI.d465.s8.e4 DrugDDI.d465.s8.e5 false
interaction DrugDDI.d465.s8.e4 DrugDDI.d465.s8.e6 false
interaction DrugDDI.d465.s8.e4 DrugDDI.d465.s8.e7 false
interaction DrugDDI.d465.s8.e4 DrugDDI.d465.s8.e8 false
interaction DrugDDI.d465.s8.e4 DrugDDI.d465.s8.e9 false
interaction DrugDDI.d465.s8.e5 DrugDDI.d465.s8.e6 false
interaction DrugDDI.d465.s8.e5 DrugDDI.d465.s8.e7 false
interaction DrugDDI.d465.s8.e5 DrugDDI.d465.s8.e8 false
interaction DrugDDI.d465.s8.e5 DrugDDI.d465.s8.e9 false
interaction DrugDDI.d465.s8.e6 DrugDDI.d465.s8.e7 false
interaction DrugDDI.d465.s8.e6 DrugDDI.d465.s8.e8 false
interaction DrugDDI.d465.s8.e6 DrugDDI.d465.s8.e9 false
interaction DrugDDI.d465.s8.e7 DrugDDI.d465.s8.e8 false
interaction DrugDDI.d465.s8.e7 DrugDDI.d465.s8.e9 false
interaction DrugDDI.d465.s8.e8 DrugDDI.d465.s8.e9 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s9
- phenytoin ( Dilantin ); .

DrugDDI.d465.s9.e0 1 9
drug
phenytoin
DrugDDI.d465.s9.e1 11 18
drug
Dilantin

interaction DrugDDI.d465.s9.e0 DrugDDI.d465.s9.e1 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s10
- isoniazid ( Nydrazid ); .

DrugDDI.d465.s10.e0 1 9
drug
isoniazid
DrugDDI.d465.s10.e1 11 18
drug
Nydrazid

interaction DrugDDI.d465.s10.e0 DrugDDI.d465.s10.e1 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s11
- rifampin ( Rifadin , Rifamate ); .

DrugDDI.d465.s11.e0 1 8
drug
rifampin
DrugDDI.d465.s11.e1 10 16
drug
Rifadin
DrugDDI.d465.s11.e2 18 25
drug
Rifamate

interaction DrugDDI.d465.s11.e0 DrugDDI.d465.s11.e1 false
interaction DrugDDI.d465.s11.e0 DrugDDI.d465.s11.e2 false
interaction DrugDDI.d465.s11.e1 DrugDDI.d465.s11.e2 false

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s12
or - over-the-counter cough, cold, allergy, or weight loss medications .

DrugDDI.d465.s12.e0 50 60
drug
medications



Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s13
You may require a dosage adjustment or special monitoring if you are taking any of the medicines listed above.

DrugDDI.d465.s13.e0 71 79
drug
medicines



Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s14
Drugs other than those listed here may also interact with glimepiride or affect your condition.

DrugDDI.d465.s14.e0 0 4
drug
Drugs
DrugDDI.d465.s14.e1 48 58
drug
glimepiride

interaction DrugDDI.d465.s14.e0 DrugDDI.d465.s14.e1 true

Abstract Id: DrugDDI.d465
Sentence Id: DrugDDI.d465.s15
Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines , including herbal products.

DrugDDI.d465.s15.e0 58 82
drug
over-the-counter medicines



Abstract Id: DrugDDI.d244
Sentence Id: DrugDDI.d244.s0
The use of codeine may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , psychotropics or other drugs that produce CNS depression.

DrugDDI.d244.s0.e0 8 14
drug
codeine
DrugDDI.d244.s0.e1 34 46
drug
CNS depressant
DrugDDI.d244.s0.e2 76 82
drug
alcohol
DrugDDI.d244.s0.e3 84 97
drug
antihistamines
DrugDDI.d244.s0.e4 119 123
drug
drugs

interaction DrugDDI.d244.s0.e0 DrugDDI.d244.s0.e1 false
interaction DrugDDI.d244.s0.e0 DrugDDI.d244.s0.e2 true
interaction DrugDDI.d244.s0.e0 DrugDDI.d244.s0.e3 false
interaction DrugDDI.d244.s0.e0 DrugDDI.d244.s0.e4 true
interaction DrugDDI.d244.s0.e1 DrugDDI.d244.s0.e2 false
interaction DrugDDI.d244.s0.e1 DrugDDI.d244.s0.e3 false
interaction DrugDDI.d244.s0.e1 DrugDDI.d244.s0.e4 false
interaction DrugDDI.d244.s0.e2 DrugDDI.d244.s0.e3 false
interaction DrugDDI.d244.s0.e2 DrugDDI.d244.s0.e4 false
interaction DrugDDI.d244.s0.e3 DrugDDI.d244.s0.e4 false

Abstract Id: DrugDDI.d244
Sentence Id: DrugDDI.d244.s1
Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).

DrugDDI.d244.s1.e0 26 41
drug
dextromethorphan
DrugDDI.d244.s1.e1 62 87
drug
monoamine oxidase inhibitors

interaction DrugDDI.d244.s1.e0 DrugDDI.d244.s1.e1 true

Abstract Id: DrugDDI.d244
Sentence Id: DrugDDI.d244.s2
The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol , antihistamines , psychotropics or other drugs that produce CNS depression.

DrugDDI.d244.s2.e0 8 35
drug
dextromethorphan hydrobromide
DrugDDI.d244.s2.e1 55 67
drug
CNS depressant
DrugDDI.d244.s2.e2 97 103
drug
alcohol
DrugDDI.d244.s2.e3 105 118
drug
antihistamines
DrugDDI.d244.s2.e4 140 144
drug
drugs

interaction DrugDDI.d244.s2.e0 DrugDDI.d244.s2.e1 false
interaction DrugDDI.d244.s2.e0 DrugDDI.d244.s2.e2 true
interaction DrugDDI.d244.s2.e0 DrugDDI.d244.s2.e3 false
interaction DrugDDI.d244.s2.e0 DrugDDI.d244.s2.e4 true
interaction DrugDDI.d244.s2.e1 DrugDDI.d244.s2.e2 false
interaction DrugDDI.d244.s2.e1 DrugDDI.d244.s2.e3 false
interaction DrugDDI.d244.s2.e1 DrugDDI.d244.s2.e4 false
interaction DrugDDI.d244.s2.e2 DrugDDI.d244.s2.e3 false
interaction DrugDDI.d244.s2.e2 DrugDDI.d244.s2.e4 false
interaction DrugDDI.d244.s2.e3 DrugDDI.d244.s2.e4 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s0
Calcium Supplements/ Antacids .

DrugDDI.d184.s0.e0 0 6
drug
Calcium
DrugDDI.d184.s0.e1 19 26
drug
Antacids

interaction DrugDDI.d184.s0.e0 DrugDDI.d184.s0.e1 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s1
Products containing calcium and other multivalent cations (such as aluminum, magnesium , iron ) are likely to interfere with absorption of Ibandronate .

DrugDDI.d184.s1.e0 18 24
drug
calcium
DrugDDI.d184.s1.e1 44 50
drug
cations
DrugDDI.d184.s1.e2 67 75
drug
magnesium
DrugDDI.d184.s1.e3 77 80
drug
iron
DrugDDI.d184.s1.e4 118 128
drug
Ibandronate

interaction DrugDDI.d184.s1.e0 DrugDDI.d184.s1.e1 false
interaction DrugDDI.d184.s1.e0 DrugDDI.d184.s1.e2 false
interaction DrugDDI.d184.s1.e0 DrugDDI.d184.s1.e3 false
interaction DrugDDI.d184.s1.e0 DrugDDI.d184.s1.e4 false
interaction DrugDDI.d184.s1.e1 DrugDDI.d184.s1.e2 false
interaction DrugDDI.d184.s1.e1 DrugDDI.d184.s1.e3 false
interaction DrugDDI.d184.s1.e1 DrugDDI.d184.s1.e4 false
interaction DrugDDI.d184.s1.e2 DrugDDI.d184.s1.e3 false
interaction DrugDDI.d184.s1.e2 DrugDDI.d184.s1.e4 true
interaction DrugDDI.d184.s1.e3 DrugDDI.d184.s1.e4 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s2
Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids , supplements or vitamins ).

DrugDDI.d184.s2.e0 0 10
drug
Ibandronate
DrugDDI.d184.s2.e1 85 91
drug
cations
DrugDDI.d184.s2.e2 102 109
drug
antacids
DrugDDI.d184.s2.e3 124 131
drug
vitamins

interaction DrugDDI.d184.s2.e0 DrugDDI.d184.s2.e1 false
interaction DrugDDI.d184.s2.e0 DrugDDI.d184.s2.e2 true
interaction DrugDDI.d184.s2.e0 DrugDDI.d184.s2.e3 false
interaction DrugDDI.d184.s2.e1 DrugDDI.d184.s2.e2 false
interaction DrugDDI.d184.s2.e1 DrugDDI.d184.s2.e3 false
interaction DrugDDI.d184.s2.e2 DrugDDI.d184.s2.e3 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s3
H2 Blockers and Proton Pump Inhibitors (PPIs) .

DrugDDI.d184.s3.e0 0 9
drug
H2 Blockers
DrugDDI.d184.s3.e1 13 32
drug
Proton Pump Inhibitors

interaction DrugDDI.d184.s3.e0 DrugDDI.d184.s3.e1 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s4
Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and PPIs).

DrugDDI.d184.s4.e0 31 41
drug
Ibandronate
DrugDDI.d184.s4.e1 91 107
drug
anti-peptic agents
DrugDDI.d184.s4.e2 118 127
drug
H2 blockers

interaction DrugDDI.d184.s4.e0 DrugDDI.d184.s4.e1 false
interaction DrugDDI.d184.s4.e0 DrugDDI.d184.s4.e2 false
interaction DrugDDI.d184.s4.e1 DrugDDI.d184.s4.e2 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s5
Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate was similar to that in placebo-treated patients.

DrugDDI.d184.s5.e0 96 106
drug
Ibandronate



Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s6
Similarly, of over 1600 patients enrolled in a study comparing once-monthly with daily dosing regimens of ibandronate , 14% of patients used anti-peptic agents .

DrugDDI.d184.s6.e0 90 100
drug
ibandronate
DrugDDI.d184.s6.e1 119 135
drug
anti-peptic agents

interaction DrugDDI.d184.s6.e0 DrugDDI.d184.s6.e1 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s7
Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate 150 mg once monthly was similar to that in patients treated with Ibandronate 2.5 mg once daily.

DrugDDI.d184.s7.e0 96 111
drug
Ibandronate 150 mg
DrugDDI.d184.s7.e1 160 175
drug
Ibandronate 2.5 mg

interaction DrugDDI.d184.s7.e0 DrugDDI.d184.s7.e1 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s8
Aspirin / Nonsteroidal Antiinflammatory Drug s ( NSAIDs ) .

DrugDDI.d184.s8.e0 0 6
drug
Aspirin
DrugDDI.d184.s8.e1 8 39
drug
Nonsteroidal Antiinflammatory Drug
DrugDDI.d184.s8.e2 42 47
drug
NSAIDs

interaction DrugDDI.d184.s8.e0 DrugDDI.d184.s8.e1 false
interaction DrugDDI.d184.s8.e0 DrugDDI.d184.s8.e2 false
interaction DrugDDI.d184.s8.e1 DrugDDI.d184.s8.e2 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s9
In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 62% of the 2946 patients.

DrugDDI.d184.s9.e0 56 62
drug
aspirin
DrugDDI.d184.s9.e1 66 99
drug
nonsteroidal anti-inflammatory drugs

interaction DrugDDI.d184.s9.e0 DrugDDI.d184.s9.e1 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s10
Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).

DrugDDI.d184.s10.e0 5 11
drug
aspirin
DrugDDI.d184.s10.e1 14 18
drug
NSAID
DrugDDI.d184.s10.e2 94 109
drug
ibandronate 2.5 mg

interaction DrugDDI.d184.s10.e0 DrugDDI.d184.s10.e1 false
interaction DrugDDI.d184.s10.e0 DrugDDI.d184.s10.e2 false
interaction DrugDDI.d184.s10.e1 DrugDDI.d184.s10.e2 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s11
Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 39% of the 1602 patients.

DrugDDI.d184.s11.e0 44 50
drug
aspirin
DrugDDI.d184.s11.e1 54 87
drug
nonsteroidal anti-inflammatory drugs

interaction DrugDDI.d184.s11.e0 DrugDDI.d184.s11.e1 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s12
The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).

DrugDDI.d184.s12.e0 70 76
drug
aspirin
DrugDDI.d184.s12.e1 79 84
drug
NSAIDs
DrugDDI.d184.s12.e2 111 126
drug
ibandronate 2.5 mg

interaction DrugDDI.d184.s12.e0 DrugDDI.d184.s12.e1 false
interaction DrugDDI.d184.s12.e0 DrugDDI.d184.s12.e2 false
interaction DrugDDI.d184.s12.e1 DrugDDI.d184.s12.e2 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s13
However, since aspirin , NSAIDs , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate .

DrugDDI.d184.s13.e0 13 19
drug
aspirin
DrugDDI.d184.s13.e1 21 26
drug
NSAIDs
DrugDDI.d184.s13.e2 31 45
drug
bisphosphonates
DrugDDI.d184.s13.e3 138 144
drug
aspirin
DrugDDI.d184.s13.e4 147 152
drug
NSAIDs
DrugDDI.d184.s13.e5 157 167
drug
Ibandronate

interaction DrugDDI.d184.s13.e0 DrugDDI.d184.s13.e1 false
interaction DrugDDI.d184.s13.e0 DrugDDI.d184.s13.e2 false
interaction DrugDDI.d184.s13.e0 DrugDDI.d184.s13.e3 false
interaction DrugDDI.d184.s13.e0 DrugDDI.d184.s13.e4 false
interaction DrugDDI.d184.s13.e0 DrugDDI.d184.s13.e5 false
interaction DrugDDI.d184.s13.e1 DrugDDI.d184.s13.e2 false
interaction DrugDDI.d184.s13.e1 DrugDDI.d184.s13.e3 false
interaction DrugDDI.d184.s13.e1 DrugDDI.d184.s13.e4 false
interaction DrugDDI.d184.s13.e1 DrugDDI.d184.s13.e5 false
interaction DrugDDI.d184.s13.e2 DrugDDI.d184.s13.e3 false
interaction DrugDDI.d184.s13.e2 DrugDDI.d184.s13.e4 false
interaction DrugDDI.d184.s13.e2 DrugDDI.d184.s13.e5 false
interaction DrugDDI.d184.s13.e3 DrugDDI.d184.s13.e4 false
interaction DrugDDI.d184.s13.e3 DrugDDI.d184.s13.e5 true
interaction DrugDDI.d184.s13.e4 DrugDDI.d184.s13.e5 false

Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s14
Drug /Laboratory Test Interactions .

DrugDDI.d184.s14.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s15
Bisphosphonates are known to interfere with the use of bone-imaging agents.

DrugDDI.d184.s15.e0 0 14
drug
Bisphosphonates



Abstract Id: DrugDDI.d184
Sentence Id: DrugDDI.d184.s16
Specific studies with ibandronate have not been performed.

DrugDDI.d184.s16.e0 19 29
drug
ibandronate



Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s1
No evaluation of EXTRANEAL s effects on the cytochrome P450 system was conducted.

DrugDDI.d246.s1.e0 14 22
drug
EXTRANEAL
DrugDDI.d246.s1.e1 36 49
drug
cytochrome P450

interaction DrugDDI.d246.s1.e0 DrugDDI.d246.s1.e1 false

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s2
As with other dialysis solutions , blood concentrations of dialyzable drugs may be reduced by dialysis.

DrugDDI.d246.s2.e0 11 27
drug
dialysis solutions
DrugDDI.d246.s2.e1 60 64
drug
drugs

interaction DrugDDI.d246.s2.e0 DrugDDI.d246.s2.e1 false

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s3
Dosage adjustment of concomitant medications may be necessary.

DrugDDI.d246.s3.e0 29 39
drug
medications



Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s4
In patients using cardiac glycosides ( digoxin and others), plasma levels of calcium , potassium and magnesium must be carefully monitored.

DrugDDI.d246.s4.e0 15 31
drug
cardiac glycosides
DrugDDI.d246.s4.e1 33 39
drug
digoxin
DrugDDI.d246.s4.e2 65 71
drug
calcium
DrugDDI.d246.s4.e3 73 81
drug
potassium
DrugDDI.d246.s4.e4 85 93
drug
magnesium

interaction DrugDDI.d246.s4.e0 DrugDDI.d246.s4.e1 false
interaction DrugDDI.d246.s4.e0 DrugDDI.d246.s4.e2 false
interaction DrugDDI.d246.s4.e0 DrugDDI.d246.s4.e3 false
interaction DrugDDI.d246.s4.e0 DrugDDI.d246.s4.e4 false
interaction DrugDDI.d246.s4.e1 DrugDDI.d246.s4.e2 false
interaction DrugDDI.d246.s4.e1 DrugDDI.d246.s4.e3 false
interaction DrugDDI.d246.s4.e1 DrugDDI.d246.s4.e4 false
interaction DrugDDI.d246.s4.e2 DrugDDI.d246.s4.e3 false
interaction DrugDDI.d246.s4.e2 DrugDDI.d246.s4.e4 false
interaction DrugDDI.d246.s4.e3 DrugDDI.d246.s4.e4 false

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s5
Insulin : A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulin s ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL .

DrugDDI.d246.s5.e0 0 6
drug
Insulin
DrugDDI.d246.s5.e1 80 88
drug
EXTRANEAL
DrugDDI.d246.s5.e2 91 97
drug
insulin
DrugDDI.d246.s5.e3 135 141
drug
insulin
DrugDDI.d246.s5.e4 175 181
drug
insulin
DrugDDI.d246.s5.e5 218 226
drug
EXTRANEAL

interaction DrugDDI.d246.s5.e0 DrugDDI.d246.s5.e1 false
interaction DrugDDI.d246.s5.e0 DrugDDI.d246.s5.e2 false
interaction DrugDDI.d246.s5.e0 DrugDDI.d246.s5.e3 false
interaction DrugDDI.d246.s5.e0 DrugDDI.d246.s5.e4 false
interaction DrugDDI.d246.s5.e0 DrugDDI.d246.s5.e5 false
interaction DrugDDI.d246.s5.e1 DrugDDI.d246.s5.e2 false
interaction DrugDDI.d246.s5.e1 DrugDDI.d246.s5.e3 false
interaction DrugDDI.d246.s5.e1 DrugDDI.d246.s5.e4 false
interaction DrugDDI.d246.s5.e1 DrugDDI.d246.s5.e5 false
interaction DrugDDI.d246.s5.e2 DrugDDI.d246.s5.e3 false
interaction DrugDDI.d246.s5.e2 DrugDDI.d246.s5.e4 false
interaction DrugDDI.d246.s5.e2 DrugDDI.d246.s5.e5 false
interaction DrugDDI.d246.s5.e3 DrugDDI.d246.s5.e4 false
interaction DrugDDI.d246.s5.e3 DrugDDI.d246.s5.e5 false
interaction DrugDDI.d246.s5.e4 DrugDDI.d246.s5.e5 false

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s6
However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.

DrugDDI.d246.s6.e0 74 82
drug
EXTRANEAL
DrugDDI.d246.s6.e1 104 110
drug
insulin

interaction DrugDDI.d246.s6.e0 DrugDDI.d246.s6.e1 true

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s7
Heparin : No human drug interaction studies with heparin were conducted.

DrugDDI.d246.s7.e0 0 6
drug
Heparin
DrugDDI.d246.s7.e1 41 47
drug
heparin

interaction DrugDDI.d246.s7.e0 DrugDDI.d246.s7.e1 false

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s8
In vitro studies demonstrated no evidence of incompatibility of heparin with EXTRANEAL .

DrugDDI.d246.s8.e0 55 61
drug
heparin
DrugDDI.d246.s8.e1 66 74
drug
EXTRANEAL

interaction DrugDDI.d246.s8.e0 DrugDDI.d246.s8.e1 false

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s9
Antibiotics : No human drug interaction studies with antibiotics were conducted.

DrugDDI.d246.s9.e0 0 10
drug
Antibiotics
DrugDDI.d246.s9.e1 45 55
drug
antibiotics

interaction DrugDDI.d246.s9.e0 DrugDDI.d246.s9.e1 false

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s10
In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin , cefazolin , ampicillin , ampicillin /flucoxacillin, ceftazidime , gentamicin , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL .

DrugDDI.d246.s10.e0 64 73
drug
vancomycin
DrugDDI.d246.s10.e1 75 83
drug
cefazolin
DrugDDI.d246.s10.e2 85 94
drug
ampicillin
DrugDDI.d246.s10.e3 96 105
drug
ampicillin
DrugDDI.d246.s10.e4 121 131
drug
ceftazidime
DrugDDI.d246.s10.e5 133 142
drug
gentamicin
DrugDDI.d246.s10.e6 147 158
drug
amphotericin
DrugDDI.d246.s10.e7 205 215
drug
antibiotics
DrugDDI.d246.s10.e8 220 228
drug
EXTRANEAL

interaction DrugDDI.d246.s10.e0 DrugDDI.d246.s10.e1 false
interaction DrugDDI.d246.s10.e0 DrugDDI.d246.s10.e2 false
interaction DrugDDI.d246.s10.e0 DrugDDI.d246.s10.e3 false
interaction DrugDDI.d246.s10.e0 DrugDDI.d246.s10.e4 false
interaction DrugDDI.d246.s10.e0 DrugDDI.d246.s10.e5 false
interaction DrugDDI.d246.s10.e0 DrugDDI.d246.s10.e6 false
interaction DrugDDI.d246.s10.e0 DrugDDI.d246.s10.e7 false
interaction DrugDDI.d246.s10.e0 DrugDDI.d246.s10.e8 false
interaction DrugDDI.d246.s10.e1 DrugDDI.d246.s10.e2 false
interaction DrugDDI.d246.s10.e1 DrugDDI.d246.s10.e3 false
interaction DrugDDI.d246.s10.e1 DrugDDI.d246.s10.e4 false
interaction DrugDDI.d246.s10.e1 DrugDDI.d246.s10.e5 false
interaction DrugDDI.d246.s10.e1 DrugDDI.d246.s10.e6 false
interaction DrugDDI.d246.s10.e1 DrugDDI.d246.s10.e7 false
interaction DrugDDI.d246.s10.e1 DrugDDI.d246.s10.e8 false
interaction DrugDDI.d246.s10.e2 DrugDDI.d246.s10.e3 false
interaction DrugDDI.d246.s10.e2 DrugDDI.d246.s10.e4 false
interaction DrugDDI.d246.s10.e2 DrugDDI.d246.s10.e5 false
interaction DrugDDI.d246.s10.e2 DrugDDI.d246.s10.e6 false
interaction DrugDDI.d246.s10.e2 DrugDDI.d246.s10.e7 false
interaction DrugDDI.d246.s10.e2 DrugDDI.d246.s10.e8 false
interaction DrugDDI.d246.s10.e3 DrugDDI.d246.s10.e4 false
interaction DrugDDI.d246.s10.e3 DrugDDI.d246.s10.e5 false
interaction DrugDDI.d246.s10.e3 DrugDDI.d246.s10.e6 false
interaction DrugDDI.d246.s10.e3 DrugDDI.d246.s10.e7 false
interaction DrugDDI.d246.s10.e3 DrugDDI.d246.s10.e8 false
interaction DrugDDI.d246.s10.e4 DrugDDI.d246.s10.e5 false
interaction DrugDDI.d246.s10.e4 DrugDDI.d246.s10.e6 false
interaction DrugDDI.d246.s10.e4 DrugDDI.d246.s10.e7 false
interaction DrugDDI.d246.s10.e4 DrugDDI.d246.s10.e8 false
interaction DrugDDI.d246.s10.e5 DrugDDI.d246.s10.e6 false
interaction DrugDDI.d246.s10.e5 DrugDDI.d246.s10.e7 false
interaction DrugDDI.d246.s10.e5 DrugDDI.d246.s10.e8 false
interaction DrugDDI.d246.s10.e6 DrugDDI.d246.s10.e7 false
interaction DrugDDI.d246.s10.e6 DrugDDI.d246.s10.e8 false
interaction DrugDDI.d246.s10.e7 DrugDDI.d246.s10.e8 false

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s11
Drug /Laboratory Test Interactions Blood Glucose Blood glucose measurement must be done with a glucose -specific method to prevent maltose interference with test results.

DrugDDI.d246.s11.e0 0 3
drug
Drug
DrugDDI.d246.s11.e1 81 87
drug
glucose
DrugDDI.d246.s11.e2 105 111
drug
prevent
DrugDDI.d246.s11.e3 112 118
drug
maltose

interaction DrugDDI.d246.s11.e0 DrugDDI.d246.s11.e1 false
interaction DrugDDI.d246.s11.e0 DrugDDI.d246.s11.e2 false
interaction DrugDDI.d246.s11.e0 DrugDDI.d246.s11.e3 false
interaction DrugDDI.d246.s11.e1 DrugDDI.d246.s11.e2 false
interaction DrugDDI.d246.s11.e1 DrugDDI.d246.s11.e3 false
interaction DrugDDI.d246.s11.e2 DrugDDI.d246.s11.e3 false

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s12
Since falsely elevated glucose levels have been observed with blood glucose monitoring devices and test strips that use glucose dehydrogenase pyrroloquinolinequinone ( GDH PQQ)-based methods, GDH PQQ-based methods should not be used to measure glucose levels in patients administered EXTRANEAL ..

DrugDDI.d246.s12.e0 102 121
drug
glucose dehydrogenase
DrugDDI.d246.s12.e1 146 148
drug
GDH
DrugDDI.d246.s12.e2 167 169
drug
GDH
DrugDDI.d246.s12.e3 245 253
drug
EXTRANEAL

interaction DrugDDI.d246.s12.e0 DrugDDI.d246.s12.e1 false
interaction DrugDDI.d246.s12.e0 DrugDDI.d246.s12.e2 false
interaction DrugDDI.d246.s12.e0 DrugDDI.d246.s12.e3 false
interaction DrugDDI.d246.s12.e1 DrugDDI.d246.s12.e2 false
interaction DrugDDI.d246.s12.e1 DrugDDI.d246.s12.e3 false
interaction DrugDDI.d246.s12.e2 DrugDDI.d246.s12.e3 false

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s13
Serum Amylase : An apparent decrease in serum amylase activity has been observed in patients administered EXTRANEAL .

DrugDDI.d246.s13.e0 90 98
drug
EXTRANEAL



Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s14
Preliminary investigations indicate that icodextrin and its metabolites interfere with enzymatic-based amylase assays, resulting in inaccurately low values.

DrugDDI.d246.s14.e0 37 46
drug
icodextrin
DrugDDI.d246.s14.e1 53 63
drug
metabolites
DrugDDI.d246.s14.e2 92 98
drug
amylase

interaction DrugDDI.d246.s14.e0 DrugDDI.d246.s14.e1 false
interaction DrugDDI.d246.s14.e0 DrugDDI.d246.s14.e2 true
interaction DrugDDI.d246.s14.e1 DrugDDI.d246.s14.e2 true

Abstract Id: DrugDDI.d246
Sentence Id: DrugDDI.d246.s15
This should be taken into account when evaluating serum amylase levels for diagnosis or monitoring of pancreatitis in patients using EXTRANEAL .

DrugDDI.d246.s15.new.DISO.e1 86 97
DISO
pancreatitis
DrugDDI.d246.s15.e0 113 121
drug
EXTRANEAL



Abstract Id: DrugDDI.d470
Sentence Id: DrugDDI.d470.s0
The physician should be alert for possible combined drug actions, desirable or undesirable, involving ifosfamide even though ifosfamide has been used successfully concurrently with other drugs , including other cytotoxic drugs .

DrugDDI.d470.s0.e0 88 97
drug
ifosfamide
DrugDDI.d470.s0.e1 108 117
drug
ifosfamide
DrugDDI.d470.s0.e2 162 166
drug
drugs
DrugDDI.d470.s0.e3 177 195
drug
other cytotoxic drugs

interaction DrugDDI.d470.s0.e0 DrugDDI.d470.s0.e1 false
interaction DrugDDI.d470.s0.e0 DrugDDI.d470.s0.e2 false
interaction DrugDDI.d470.s0.e0 DrugDDI.d470.s0.e3 false
interaction DrugDDI.d470.s0.e1 DrugDDI.d470.s0.e2 false
interaction DrugDDI.d470.s0.e1 DrugDDI.d470.s0.e3 false
interaction DrugDDI.d470.s0.e2 DrugDDI.d470.s0.e3 false

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s0
In occasional susceptible patients or in those receiving anticholinergic drugs (including antiparkinsonism agents) in addition, the atropine -like effects may become more pronounced (e.g., paralytic ileus).

DrugDDI.d188.s0.e0 49 68
drug
anticholinergic drugs
DrugDDI.d188.s0.e1 116 123
drug
atropine

interaction DrugDDI.d188.s0.e0 DrugDDI.d188.s0.e1 true

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s1
Close supervision and careful adjustment of dosage is required when this drug is administered concomitantly with anticholinergic drugs .

DrugDDI.d188.s1.e0 62 65
drug
drug
DrugDDI.d188.s1.e1 97 116
drug
anticholinergic drugs

interaction DrugDDI.d188.s1.e0 DrugDDI.d188.s1.e1 true

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s2
Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine , norepinephrine ), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.

DrugDDI.d188.s2.e0 31 43
drug
decongestants
DrugDDI.d188.s2.e1 47 62
drug
local anesthetics
DrugDDI.d188.s2.e2 78 97
drug
sympathomimetic amine
DrugDDI.d188.s2.e3 104 114
drug
epinephrine
DrugDDI.d188.s2.e4 116 129
drug
norepinephrine
DrugDDI.d188.s2.e5 158 181
drug
tricyclic antidepressants

interaction DrugDDI.d188.s2.e0 DrugDDI.d188.s2.e1 false
interaction DrugDDI.d188.s2.e0 DrugDDI.d188.s2.e2 false
interaction DrugDDI.d188.s2.e0 DrugDDI.d188.s2.e3 false
interaction DrugDDI.d188.s2.e0 DrugDDI.d188.s2.e4 false
interaction DrugDDI.d188.s2.e0 DrugDDI.d188.s2.e5 true
interaction DrugDDI.d188.s2.e1 DrugDDI.d188.s2.e2 false
interaction DrugDDI.d188.s2.e1 DrugDDI.d188.s2.e3 false
interaction DrugDDI.d188.s2.e1 DrugDDI.d188.s2.e4 false
interaction DrugDDI.d188.s2.e1 DrugDDI.d188.s2.e5 false
interaction DrugDDI.d188.s2.e2 DrugDDI.d188.s2.e3 false
interaction DrugDDI.d188.s2.e2 DrugDDI.d188.s2.e4 false
interaction DrugDDI.d188.s2.e2 DrugDDI.d188.s2.e5 true
interaction DrugDDI.d188.s2.e3 DrugDDI.d188.s2.e4 false
interaction DrugDDI.d188.s2.e3 DrugDDI.d188.s2.e5 false
interaction DrugDDI.d188.s2.e4 DrugDDI.d188.s2.e5 true

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s3
Caution should be exercised when imipramine hydrochloride is used with agents that lower blood pressure.

DrugDDI.d188.s3.e0 28 50
drug
imipramine hydrochloride



Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s4
Imipramine hydrochloride may potentiate the effects of CNS depressant drugs .

DrugDDI.d188.s4.e0 0 22
drug
Imipramine hydrochloride
DrugDDI.d188.s4.e1 48 65
drug
CNS depressant drugs

interaction DrugDDI.d188.s4.e0 DrugDDI.d188.s4.e1 true

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s5
The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates , phenytoin ), and adjustment of the dosage of imipramine may therefore be necessary.

DrugDDI.d188.s5.e0 24 33
drug
imipramine
DrugDDI.d188.s5.e1 52 55
drug
drug
DrugDDI.d188.s5.e2 87 102
drug
enzyme inhibitors
DrugDDI.d188.s5.e3 109 118
drug
cimetidine
DrugDDI.d188.s5.e4 120 129
drug
fluoxetine
DrugDDI.d188.s5.e5 198 209
drug
barbiturates
DrugDDI.d188.s5.e6 211 219
drug
phenytoin
DrugDDI.d188.s5.e7 248 257
drug
imipramine

interaction DrugDDI.d188.s5.e0 DrugDDI.d188.s5.e1 false
interaction DrugDDI.d188.s5.e0 DrugDDI.d188.s5.e2 true
interaction DrugDDI.d188.s5.e0 DrugDDI.d188.s5.e3 false
interaction DrugDDI.d188.s5.e0 DrugDDI.d188.s5.e4 true
interaction DrugDDI.d188.s5.e0 DrugDDI.d188.s5.e5 false
interaction DrugDDI.d188.s5.e0 DrugDDI.d188.s5.e6 true
interaction DrugDDI.d188.s5.e0 DrugDDI.d188.s5.e7 false
interaction DrugDDI.d188.s5.e1 DrugDDI.d188.s5.e2 false
interaction DrugDDI.d188.s5.e1 DrugDDI.d188.s5.e3 false
interaction DrugDDI.d188.s5.e1 DrugDDI.d188.s5.e4 false
interaction DrugDDI.d188.s5.e1 DrugDDI.d188.s5.e5 false
interaction DrugDDI.d188.s5.e1 DrugDDI.d188.s5.e6 false
interaction DrugDDI.d188.s5.e1 DrugDDI.d188.s5.e7 false
interaction DrugDDI.d188.s5.e2 DrugDDI.d188.s5.e3 false
interaction DrugDDI.d188.s5.e2 DrugDDI.d188.s5.e4 false
interaction DrugDDI.d188.s5.e2 DrugDDI.d188.s5.e5 false
interaction DrugDDI.d188.s5.e2 DrugDDI.d188.s5.e6 false
interaction DrugDDI.d188.s5.e2 DrugDDI.d188.s5.e7 false
interaction DrugDDI.d188.s5.e3 DrugDDI.d188.s5.e4 false
interaction DrugDDI.d188.s5.e3 DrugDDI.d188.s5.e5 false
interaction DrugDDI.d188.s5.e3 DrugDDI.d188.s5.e6 false
interaction DrugDDI.d188.s5.e3 DrugDDI.d188.s5.e7 false
interaction DrugDDI.d188.s5.e4 DrugDDI.d188.s5.e5 false
interaction DrugDDI.d188.s5.e4 DrugDDI.d188.s5.e6 false
interaction DrugDDI.d188.s5.e4 DrugDDI.d188.s5.e7 false
interaction DrugDDI.d188.s5.e5 DrugDDI.d188.s5.e6 false
interaction DrugDDI.d188.s5.e5 DrugDDI.d188.s5.e7 false
interaction DrugDDI.d188.s5.e6 DrugDDI.d188.s5.e7 false

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s6
Drugs Metabolized by P450 2D6 : The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 ( debrisoquin hydroxylase ) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); .

DrugDDI.d188.s6.e0 0 4
drug
Drugs
DrugDDI.d188.s6.e1 18 24
drug
P450 2D6
DrugDDI.d188.s6.e2 53 56
drug
drug
DrugDDI.d188.s6.e3 94 115
drug
debrisoquin hydroxylase

interaction DrugDDI.d188.s6.e0 DrugDDI.d188.s6.e1 false
interaction DrugDDI.d188.s6.e0 DrugDDI.d188.s6.e2 false
interaction DrugDDI.d188.s6.e0 DrugDDI.d188.s6.e3 false
interaction DrugDDI.d188.s6.e1 DrugDDI.d188.s6.e2 false
interaction DrugDDI.d188.s6.e1 DrugDDI.d188.s6.e3 false
interaction DrugDDI.d188.s6.e2 DrugDDI.d188.s6.e3 false

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s7
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.

DrugDDI.d188.s7.e0 41 54
drug
P450 2D6 isozyme



Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s8
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.

DrugDDI.d188.s8.e0 60 83
drug
tricyclic antidepressants



Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s9
Depending on the fraction of drug metabolized by P450 2D6 , the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).

DrugDDI.d188.s9.e0 24 27
drug
drug
DrugDDI.d188.s9.e1 41 47
drug
P450 2D6

interaction DrugDDI.d188.s9.e0 DrugDDI.d188.s9.e1 false

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s10
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o.

DrugDDI.d188.s10.e0 18 22
drug
drugs
DrugDDI.d188.s10.e1 47 53
drug
isozyme

interaction DrugDDI.d188.s10.e0 DrugDDI.d188.s10.e1 false

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s12
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.

DrugDDI.d188.s12.e0 91 95
drug
drugs



Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s13
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme ( quinidine ; .

DrugDDI.d188.s13.e0 3 7
drug
drugs
DrugDDI.d188.s13.e1 19 35
drug
cytochrome P450 2D6
DrugDDI.d188.s13.e2 80 88
drug
quinidine

interaction DrugDDI.d188.s13.e0 DrugDDI.d188.s13.e1 false
interaction DrugDDI.d188.s13.e0 DrugDDI.d188.s13.e2 false
interaction DrugDDI.d188.s13.e1 DrugDDI.d188.s13.e2 false

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s14
cimetidine ) and many that are substrates for P450 2D6 (many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics propafenone and flecainide ).

DrugDDI.d188.s14.e0 0 9
drug
cimetidine
DrugDDI.d188.s14.e1 38 44
drug
P450 2D6
DrugDDI.d188.s14.e2 55 69
drug
antidepressants
DrugDDI.d188.s14.e3 71 84
drug
phenothiazines
DrugDDI.d188.s14.e4 113 123
drug
propafenone
DrugDDI.d188.s14.e5 127 136
drug
flecainide

interaction DrugDDI.d188.s14.e0 DrugDDI.d188.s14.e1 false
interaction DrugDDI.d188.s14.e0 DrugDDI.d188.s14.e2 false
interaction DrugDDI.d188.s14.e0 DrugDDI.d188.s14.e3 false
interaction DrugDDI.d188.s14.e0 DrugDDI.d188.s14.e4 false
interaction DrugDDI.d188.s14.e0 DrugDDI.d188.s14.e5 false
interaction DrugDDI.d188.s14.e1 DrugDDI.d188.s14.e2 false
interaction DrugDDI.d188.s14.e1 DrugDDI.d188.s14.e3 false
interaction DrugDDI.d188.s14.e1 DrugDDI.d188.s14.e4 false
interaction DrugDDI.d188.s14.e1 DrugDDI.d188.s14.e5 false
interaction DrugDDI.d188.s14.e2 DrugDDI.d188.s14.e3 false
interaction DrugDDI.d188.s14.e2 DrugDDI.d188.s14.e4 false
interaction DrugDDI.d188.s14.e2 DrugDDI.d188.s14.e5 false
interaction DrugDDI.d188.s14.e3 DrugDDI.d188.s14.e4 false
interaction DrugDDI.d188.s14.e3 DrugDDI.d188.s14.e5 false
interaction DrugDDI.d188.s14.e4 DrugDDI.d188.s14.e5 false

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s15
While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition.

DrugDDI.d188.s15.e0 20 46
drug
serotonin reuptake inhibitors
DrugDDI.d188.s15.e1 60 69
drug
fluoxetine
DrugDDI.d188.s15.e2 71 80
drug
sertraline
DrugDDI.d188.s15.e3 85 94
drug
paroxetine
DrugDDI.d188.s15.e4 103 109
drug
P450 2D6

interaction DrugDDI.d188.s15.e0 DrugDDI.d188.s15.e1 false
interaction DrugDDI.d188.s15.e0 DrugDDI.d188.s15.e2 false
interaction DrugDDI.d188.s15.e0 DrugDDI.d188.s15.e3 false
interaction DrugDDI.d188.s15.e0 DrugDDI.d188.s15.e4 false
interaction DrugDDI.d188.s15.e1 DrugDDI.d188.s15.e2 false
interaction DrugDDI.d188.s15.e1 DrugDDI.d188.s15.e3 false
interaction DrugDDI.d188.s15.e1 DrugDDI.d188.s15.e4 false
interaction DrugDDI.d188.s15.e2 DrugDDI.d188.s15.e3 false
interaction DrugDDI.d188.s15.e2 DrugDDI.d188.s15.e4 false
interaction DrugDDI.d188.s15.e3 DrugDDI.d188.s15.e4 false

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s18
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine , given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).

DrugDDI.d188.s18.e0 103 112
drug
fluoxetine
DrugDDI.d188.s18.e1 149 164
drug
active metabolite

interaction DrugDDI.d188.s18.e0 DrugDDI.d188.s18.e1 false

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s19
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug .

DrugDDI.d188.s19.e0 16 39
drug
tricyclic antidepressants
DrugDDI.d188.s19.e1 44 48
drug
drugs
DrugDDI.d188.s19.e2 63 79
drug
cytochrome P450 2D6
DrugDDI.d188.s19.e3 133 155
drug
tricyclic antidepressant
DrugDDI.d188.s19.e4 166 169
drug
drug

interaction DrugDDI.d188.s19.e0 DrugDDI.d188.s19.e1 false
interaction DrugDDI.d188.s19.e0 DrugDDI.d188.s19.e2 false
interaction DrugDDI.d188.s19.e0 DrugDDI.d188.s19.e3 false
interaction DrugDDI.d188.s19.e0 DrugDDI.d188.s19.e4 false
interaction DrugDDI.d188.s19.e1 DrugDDI.d188.s19.e2 false
interaction DrugDDI.d188.s19.e1 DrugDDI.d188.s19.e3 false
interaction DrugDDI.d188.s19.e1 DrugDDI.d188.s19.e4 false
interaction DrugDDI.d188.s19.e2 DrugDDI.d188.s19.e3 false
interaction DrugDDI.d188.s19.e2 DrugDDI.d188.s19.e4 false
interaction DrugDDI.d188.s19.e3 DrugDDI.d188.s19.e4 false

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s20
Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of tricyclic antidepressant may be required.

DrugDDI.d188.s20.e0 35 39
drug
drugs
DrugDDI.d188.s20.e1 82 104
drug
tricyclic antidepressant

interaction DrugDDI.d188.s20.e0 DrugDDI.d188.s20.e1 false

Abstract Id: DrugDDI.d188
Sentence Id: DrugDDI.d188.s21
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6 .

DrugDDI.d188.s21.e0 86 89
drug
drug
DrugDDI.d188.s21.e1 112 118
drug
P450 2D6

interaction DrugDDI.d188.s21.e0 DrugDDI.d188.s21.e1 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s0
In normal volunteers receiving indomethacin , the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin .

DrugDDI.d83.s0.e0 27 38
drug
indomethacin
DrugDDI.d83.s0.e1 59 68
drug
diflunisal
DrugDDI.d83.s0.e2 137 148
drug
indomethacin

interaction DrugDDI.d83.s0.e0 DrugDDI.d83.s0.e1 false
interaction DrugDDI.d83.s0.e0 DrugDDI.d83.s0.e2 false
interaction DrugDDI.d83.s0.e1 DrugDDI.d83.s0.e2 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s1
In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.

DrugDDI.d83.s1.e0 28 34
drug
INDOCIN
DrugDDI.d83.s1.e1 38 47
drug
diflunisal
DrugDDI.d83.s1.new.DISO.e2 74 99
DISO
gastrointestinal hemorrhage

interaction DrugDDI.d83.s1.e0 DrugDDI.d83.s1.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s2
Therefore, diflunisal and INDOCIN should not be used concomitantly.

DrugDDI.d83.s2.e0 10 19
drug
diflunisal
DrugDDI.d83.s2.e1 23 29
drug
INDOCIN

interaction DrugDDI.d83.s2.e0 DrugDDI.d83.s2.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s3
In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.

DrugDDI.d83.s3.e0 80 86
drug
aspirin
DrugDDI.d83.s3.e1 102 113
drug
indomethacin

interaction DrugDDI.d83.s3.e0 DrugDDI.d83.s3.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s4
The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.

DrugDDI.d83.s4.e0 19 25
drug
INDOCIN
DrugDDI.d83.s4.e1 35 40
drug
NSAIDs

interaction DrugDDI.d83.s4.e0 DrugDDI.d83.s4.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s5
Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants .

DrugDDI.d83.s5.e0 28 34
drug
INDOCIN
DrugDDI.d83.s5.new.DISO.e2 54 72
DISO
hypoprothrombinemia
DrugDDI.d83.s5.e1 83 96
drug
anticoagulants

interaction DrugDDI.d83.s5.e0 DrugDDI.d83.s5.e1 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s6
However, when any additional drug , including INDOCIN , is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.

DrugDDI.d83.s6.e0 25 28
drug
drug
DrugDDI.d83.s6.e1 39 45
drug
INDOCIN

interaction DrugDDI.d83.s6.e0 DrugDDI.d83.s6.e1 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s7
In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN .

DrugDDI.d83.s7.e0 86 99
drug
anticoagulants
DrugDDI.d83.s7.e1 103 109
drug
INDOCIN

interaction DrugDDI.d83.s7.e0 DrugDDI.d83.s7.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s8
Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.

DrugDDI.d83.s8.e0 28 34
drug
INDOCIN
DrugDDI.d83.s8.e1 38 51
drug
anticoagulants

interaction DrugDDI.d83.s8.e0 DrugDDI.d83.s8.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s9
When INDOCIN is given to patients receiving probenecid , the plasma levels of indomethacin are likely to be increased.

DrugDDI.d83.s9.e0 4 10
drug
INDOCIN
DrugDDI.d83.s9.e1 37 46
drug
probenecid
DrugDDI.d83.s9.e2 65 76
drug
indomethacin

interaction DrugDDI.d83.s9.e0 DrugDDI.d83.s9.e1 true
interaction DrugDDI.d83.s9.e0 DrugDDI.d83.s9.e2 false
interaction DrugDDI.d83.s9.e1 DrugDDI.d83.s9.e2 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s10
Therefore, a lower total daily dosage of INDOCIN may produce a satisfactory therapeutic effect.

DrugDDI.d83.s10.e0 34 40
drug
INDOCIN



Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s11
When increases in the dose of INDOCIN are made, they should be made carefully and in small increments.

DrugDDI.d83.s11.e0 24 30
drug
INDOCIN



Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s12
Caution should be used if INDOCIN is administered simultaneously with methotrexate .

DrugDDI.d83.s12.e0 21 27
drug
INDOCIN
DrugDDI.d83.s12.e1 60 71
drug
methotrexate

interaction DrugDDI.d83.s12.e0 DrugDDI.d83.s12.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s13
INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.

DrugDDI.d83.s13.e0 0 6
drug
INDOCIN
DrugDDI.d83.s13.e1 53 64
drug
methotrexate

interaction DrugDDI.d83.s13.e0 DrugDDI.d83.s13.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s14
Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin .

DrugDDI.d83.s14.e0 16 50
drug
non-steroidal anti-inflammatory drugs
DrugDDI.d83.s14.e1 68 79
drug
cyclosporine
DrugDDI.d83.s14.e2 180 191
drug
prostacyclin

interaction DrugDDI.d83.s14.e0 DrugDDI.d83.s14.e1 true
interaction DrugDDI.d83.s14.e0 DrugDDI.d83.s14.e2 false
interaction DrugDDI.d83.s14.e1 DrugDDI.d83.s14.e2 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s15
NSAIDs should be used with caution in patients taking cyclosporine , and renal function should be carefully monitored.

DrugDDI.d83.s15.e0 0 5
drug
NSAIDs
DrugDDI.d83.s15.e1 45 56
drug
cyclosporine

interaction DrugDDI.d83.s15.e0 DrugDDI.d83.s15.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s16
Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.

DrugDDI.d83.s16.e0 69 75
drug
lithium
DrugDDI.d83.s16.e1 95 101
drug
lithium
DrugDDI.d83.s16.e2 170 176
drug
lithium

interaction DrugDDI.d83.s16.e0 DrugDDI.d83.s16.e1 false
interaction DrugDDI.d83.s16.e0 DrugDDI.d83.s16.e2 false
interaction DrugDDI.d83.s16.e1 DrugDDI.d83.s16.e2 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s17
This effect has been attributed to inhibition of prostaglandin synthesis.

DrugDDI.d83.s17.e0 41 53
drug
prostaglandin



Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s18
As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.

DrugDDI.d83.s18.e0 19 25
drug
INDOCIN
DrugDDI.d83.s18.e1 29 35
drug
lithium
DrugDDI.d83.s18.new.DISO.e2 103 117
DISO
lithium toxicity

interaction DrugDDI.d83.s18.e0 DrugDDI.d83.s18.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s19
(Read circulars for lithium preparation s before use of such concomitant therapy.) .

DrugDDI.d83.s19.e0 17 34
drug
lithium preparation



Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s20
In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment.

DrugDDI.d83.s20.e0 40 46
drug
lithium
DrugDDI.d83.s20.e1 105 108
drug
drug

interaction DrugDDI.d83.s20.e0 DrugDDI.d83.s20.e1 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s21
INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin .

DrugDDI.d83.s21.e0 0 6
drug
INDOCIN
DrugDDI.d83.s21.e1 29 35
drug
digoxin
DrugDDI.d83.s21.e2 106 112
drug
digoxin

interaction DrugDDI.d83.s21.e0 DrugDDI.d83.s21.e1 true
interaction DrugDDI.d83.s21.e0 DrugDDI.d83.s21.e2 false
interaction DrugDDI.d83.s21.e1 DrugDDI.d83.s21.e2 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s22
Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.

DrugDDI.d83.s22.e0 14 20
drug
INDOCIN
DrugDDI.d83.s22.e1 24 30
drug
digoxin

interaction DrugDDI.d83.s22.e0 DrugDDI.d83.s22.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s23
In some patients, the administration of INDOCIN can reduce the diuretic , natriuretic, and antihypertensive effects of loop, potassium -sparing, and thiazide diuretics .

DrugDDI.d83.s23.e0 34 40
drug
INDOCIN
DrugDDI.d83.s23.e1 53 60
drug
diuretic
DrugDDI.d83.s23.e2 77 92
drug
antihypertensive
DrugDDI.d83.s23.e3 107 115
drug
potassium
DrugDDI.d83.s23.e4 128 144
drug
thiazide diuretics

interaction DrugDDI.d83.s23.e0 DrugDDI.d83.s23.e1 false
interaction DrugDDI.d83.s23.e0 DrugDDI.d83.s23.e2 false
interaction DrugDDI.d83.s23.e0 DrugDDI.d83.s23.e3 false
interaction DrugDDI.d83.s23.e0 DrugDDI.d83.s23.e4 true
interaction DrugDDI.d83.s23.e1 DrugDDI.d83.s23.e2 false
interaction DrugDDI.d83.s23.e1 DrugDDI.d83.s23.e3 false
interaction DrugDDI.d83.s23.e1 DrugDDI.d83.s23.e4 false
interaction DrugDDI.d83.s23.e2 DrugDDI.d83.s23.e3 false
interaction DrugDDI.d83.s23.e2 DrugDDI.d83.s23.e4 false
interaction DrugDDI.d83.s23.e3 DrugDDI.d83.s23.e4 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s24
Therefore, when INDOCIN and INDOCIN .

DrugDDI.d83.s24.e0 14 20
drug
INDOCIN
DrugDDI.d83.s24.e1 24 30
drug
INDOCIN

interaction DrugDDI.d83.s24.e0 DrugDDI.d83.s24.e1 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s25
( Indomethacin ) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

DrugDDI.d83.s25.e0 1 12
drug
Indomethacin
DrugDDI.d83.s25.e1 14 22
drug
diuretics
DrugDDI.d83.s25.e2 111 118
drug
diuretic

interaction DrugDDI.d83.s25.e0 DrugDDI.d83.s25.e1 false
interaction DrugDDI.d83.s25.e0 DrugDDI.d83.s25.e2 false
interaction DrugDDI.d83.s25.e1 DrugDDI.d83.s25.e2 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s26
INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion.

DrugDDI.d83.s26.e0 0 6
drug
INDOCIN
DrugDDI.d83.s26.e1 81 90
drug
furosemide
DrugDDI.d83.s26.e2 108 111
drug
salt

interaction DrugDDI.d83.s26.e0 DrugDDI.d83.s26.e1 false
interaction DrugDDI.d83.s26.e0 DrugDDI.d83.s26.e2 false
interaction DrugDDI.d83.s26.e1 DrugDDI.d83.s26.e2 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s28
It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.

DrugDDI.d83.s28.e0 34 44
drug
triamterene
DrugDDI.d83.s28.e1 69 75
drug
INDOCIN
DrugDDI.d83.s28.new.DISO.e2 96 112
DISO
acute renal failure

interaction DrugDDI.d83.s28.e0 DrugDDI.d83.s28.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s29
INDOCIN and triamterene should not be administered together.

DrugDDI.d83.s29.e0 0 6
drug
INDOCIN
DrugDDI.d83.s29.e1 10 20
drug
triamterene

interaction DrugDDI.d83.s29.e0 DrugDDI.d83.s29.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s30
INDOCIN and potassium-sparing diuretics each may be associated with increased serum potassium levels.

DrugDDI.d83.s30.e0 0 6
drug
INDOCIN
DrugDDI.d83.s30.e1 10 35
drug
potassium-sparing diuretics

interaction DrugDDI.d83.s30.e0 DrugDDI.d83.s30.e1 true

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s31
The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.

DrugDDI.d83.s31.e0 21 27
drug
INDOCIN
DrugDDI.d83.s31.e1 31 56
drug
potassium-sparing diuretics
DrugDDI.d83.s31.e2 59 67
drug
potassium

interaction DrugDDI.d83.s31.e0 DrugDDI.d83.s31.e1 true
interaction DrugDDI.d83.s31.e0 DrugDDI.d83.s31.e2 false
interaction DrugDDI.d83.s31.e1 DrugDDI.d83.s31.e2 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s32
Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN .

DrugDDI.d83.s32.e0 31 39
drug
diuretics
DrugDDI.d83.s32.e1 106 118
drug
prostaglandin
DrugDDI.d83.s32.e2 130 136
drug
INDOCIN

interaction DrugDDI.d83.s32.e0 DrugDDI.d83.s32.e1 false
interaction DrugDDI.d83.s32.e0 DrugDDI.d83.s32.e2 false
interaction DrugDDI.d83.s32.e1 DrugDDI.d83.s32.e2 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s33
Blunting of the antihypertensive effect of beta-adrenoceptor blocking agent s by non-steroidal antiinflammatory drugs including INDOCIN has been reported.

DrugDDI.d83.s33.e0 13 28
drug
antihypertensive
DrugDDI.d83.s33.e1 37 66
drug
beta-adrenoceptor blocking agent
DrugDDI.d83.s33.e2 70 103
drug
non-steroidal antiinflammatory drugs
DrugDDI.d83.s33.e3 113 119
drug
INDOCIN

interaction DrugDDI.d83.s33.e0 DrugDDI.d83.s33.e1 false
interaction DrugDDI.d83.s33.e0 DrugDDI.d83.s33.e2 false
interaction DrugDDI.d83.s33.e0 DrugDDI.d83.s33.e3 false
interaction DrugDDI.d83.s33.e1 DrugDDI.d83.s33.e2 true
interaction DrugDDI.d83.s33.e1 DrugDDI.d83.s33.e3 false
interaction DrugDDI.d83.s33.e2 DrugDDI.d83.s33.e3 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s35
INDOCIN can reduce the antihypertensive effects of captopril and losartan .

DrugDDI.d83.s35.e0 0 6
drug
INDOCIN
DrugDDI.d83.s35.e1 19 34
drug
antihypertensive
DrugDDI.d83.s35.e2 44 52
drug
captopril
DrugDDI.d83.s35.e3 56 63
drug
losartan

interaction DrugDDI.d83.s35.e0 DrugDDI.d83.s35.e1 false
interaction DrugDDI.d83.s35.e0 DrugDDI.d83.s35.e2 true
interaction DrugDDI.d83.s35.e0 DrugDDI.d83.s35.e3 false
interaction DrugDDI.d83.s35.e1 DrugDDI.d83.s35.e2 false
interaction DrugDDI.d83.s35.e1 DrugDDI.d83.s35.e3 false
interaction DrugDDI.d83.s35.e2 DrugDDI.d83.s35.e3 false

Abstract Id: DrugDDI.d83
Sentence Id: DrugDDI.d83.s36
False-negative results in the dexamethasone suppression test (DST) in patients being treated with INDOCIN have been reported.

DrugDDI.d83.s36.e0 85 91
drug
INDOCIN



Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s0
A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.

DrugDDI.d395.s0.e0 55 61
drug
insulin



Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s1
@@ @ The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors , disopyramide , fibrates , fluoxetine , monoamine oxidase (MAO) inhibitors, propoxyphene , salicylates , somatostatin analog (e.g., octreotide ), sulfonamide antibiotics.

DrugDDI.d395.s1.new.DISO.e11 103 114
DISO
hypoglycemia
DrugDDI.d395.s1.e0 120 131
drug
antidiabetic
DrugDDI.d395.s1.e1 141 153
drug
ACE inhibitors
DrugDDI.d395.s1.e2 155 166
drug
disopyramide
DrugDDI.d395.s1.e3 168 175
drug
fibrates
DrugDDI.d395.s1.e4 177 186
drug
fluoxetine
DrugDDI.d395.s1.e5 188 203
drug
monoamine oxidase
DrugDDI.d395.s1.e6 220 231
drug
propoxyphene
DrugDDI.d395.s1.e7 233 243
drug
salicylates
DrugDDI.d395.s1.e8 245 262
drug
somatostatin analog
DrugDDI.d395.s1.e9 269 278
drug
octreotide
DrugDDI.d395.s1.e10 281 291
drug
sulfonamide

interaction DrugDDI.d395.s1.e0 DrugDDI.d395.s1.e1 false
interaction DrugDDI.d395.s1.e0 DrugDDI.d395.s1.e2 false
interaction DrugDDI.d395.s1.e0 DrugDDI.d395.s1.e3 false
interaction DrugDDI.d395.s1.e0 DrugDDI.d395.s1.e4 false
interaction DrugDDI.d395.s1.e0 DrugDDI.d395.s1.e5 false
interaction DrugDDI.d395.s1.e0 DrugDDI.d395.s1.e6 false
interaction DrugDDI.d395.s1.e0 DrugDDI.d395.s1.e7 false
interaction DrugDDI.d395.s1.e0 DrugDDI.d395.s1.e8 false
interaction DrugDDI.d395.s1.e0 DrugDDI.d395.s1.e9 false
interaction DrugDDI.d395.s1.e0 DrugDDI.d395.s1.e10 false
interaction DrugDDI.d395.s1.e1 DrugDDI.d395.s1.e2 false
interaction DrugDDI.d395.s1.e1 DrugDDI.d395.s1.e3 false
interaction DrugDDI.d395.s1.e1 DrugDDI.d395.s1.e4 false
interaction DrugDDI.d395.s1.e1 DrugDDI.d395.s1.e5 false
interaction DrugDDI.d395.s1.e1 DrugDDI.d395.s1.e6 false
interaction DrugDDI.d395.s1.e1 DrugDDI.d395.s1.e7 false
interaction DrugDDI.d395.s1.e1 DrugDDI.d395.s1.e8 false
interaction DrugDDI.d395.s1.e1 DrugDDI.d395.s1.e9 false
interaction DrugDDI.d395.s1.e1 DrugDDI.d395.s1.e10 false
interaction DrugDDI.d395.s1.e2 DrugDDI.d395.s1.e3 false
interaction DrugDDI.d395.s1.e2 DrugDDI.d395.s1.e4 false
interaction DrugDDI.d395.s1.e2 DrugDDI.d395.s1.e5 false
interaction DrugDDI.d395.s1.e2 DrugDDI.d395.s1.e6 false
interaction DrugDDI.d395.s1.e2 DrugDDI.d395.s1.e7 false
interaction DrugDDI.d395.s1.e2 DrugDDI.d395.s1.e8 false
interaction DrugDDI.d395.s1.e2 DrugDDI.d395.s1.e9 false
interaction DrugDDI.d395.s1.e2 DrugDDI.d395.s1.e10 false
interaction DrugDDI.d395.s1.e3 DrugDDI.d395.s1.e4 false
interaction DrugDDI.d395.s1.e3 DrugDDI.d395.s1.e5 false
interaction DrugDDI.d395.s1.e3 DrugDDI.d395.s1.e6 false
interaction DrugDDI.d395.s1.e3 DrugDDI.d395.s1.e7 false
interaction DrugDDI.d395.s1.e3 DrugDDI.d395.s1.e8 false
interaction DrugDDI.d395.s1.e3 DrugDDI.d395.s1.e9 false
interaction DrugDDI.d395.s1.e3 DrugDDI.d395.s1.e10 false
interaction DrugDDI.d395.s1.e4 DrugDDI.d395.s1.e5 false
interaction DrugDDI.d395.s1.e4 DrugDDI.d395.s1.e6 false
interaction DrugDDI.d395.s1.e4 DrugDDI.d395.s1.e7 false
interaction DrugDDI.d395.s1.e4 DrugDDI.d395.s1.e8 false
interaction DrugDDI.d395.s1.e4 DrugDDI.d395.s1.e9 false
interaction DrugDDI.d395.s1.e4 DrugDDI.d395.s1.e10 false
interaction DrugDDI.d395.s1.e5 DrugDDI.d395.s1.e6 false
interaction DrugDDI.d395.s1.e5 DrugDDI.d395.s1.e7 false
interaction DrugDDI.d395.s1.e5 DrugDDI.d395.s1.e8 false
interaction DrugDDI.d395.s1.e5 DrugDDI.d395.s1.e9 false
interaction DrugDDI.d395.s1.e5 DrugDDI.d395.s1.e10 false
interaction DrugDDI.d395.s1.e6 DrugDDI.d395.s1.e7 false
interaction DrugDDI.d395.s1.e6 DrugDDI.d395.s1.e8 false
interaction DrugDDI.d395.s1.e6 DrugDDI.d395.s1.e9 false
interaction DrugDDI.d395.s1.e6 DrugDDI.d395.s1.e10 false
interaction DrugDDI.d395.s1.e7 DrugDDI.d395.s1.e8 false
interaction DrugDDI.d395.s1.e7 DrugDDI.d395.s1.e9 false
interaction DrugDDI.d395.s1.e7 DrugDDI.d395.s1.e10 false
interaction DrugDDI.d395.s1.e8 DrugDDI.d395.s1.e9 false
interaction DrugDDI.d395.s1.e8 DrugDDI.d395.s1.e10 false
interaction DrugDDI.d395.s1.e9 DrugDDI.d395.s1.e10 false

Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s2
@@ @ The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids , niacin , danazol , diuretics , sympathomimetic agents (e.g., epinephrine , salbutamol , terbutaline ), isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens (e.g., in oral contraceptives ).

DrugDDI.d395.s2.e0 83 97
drug
corticosteroids
DrugDDI.d395.s2.e1 99 104
drug
niacin
DrugDDI.d395.s2.e2 106 112
drug
danazol
DrugDDI.d395.s2.e3 114 122
drug
diuretics
DrugDDI.d395.s2.e4 124 144
drug
sympathomimetic agents
DrugDDI.d395.s2.e5 151 161
drug
epinephrine
DrugDDI.d395.s2.e6 163 172
drug
salbutamol
DrugDDI.d395.s2.e7 174 184
drug
terbutaline
DrugDDI.d395.s2.e8 187 195
drug
isoniazid
DrugDDI.d395.s2.e9 197 220
drug
phenothiazine derivatives
DrugDDI.d395.s2.e10 222 231
drug
somatropin
DrugDDI.d395.s2.e11 233 247
drug
thyroid hormones
DrugDDI.d395.s2.e12 249 257
drug
estrogens
DrugDDI.d395.s2.e13 259 270
drug
progestogens
DrugDDI.d395.s2.e14 279 296
drug
oral contraceptives

interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e1 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e2 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e3 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e4 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e5 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e6 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e7 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e8 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e9 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e10 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e11 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e0 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e2 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e3 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e4 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e5 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e6 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e7 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e8 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e9 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e10 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e11 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e1 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e3 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e4 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e5 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e6 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e7 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e8 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e9 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e10 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e11 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e2 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e3 DrugDDI.d395.s2.e4 false
interaction DrugDDI.d395.s2.e3 DrugDDI.d395.s2.e5 false
interaction DrugDDI.d395.s2.e3 DrugDDI.d395.s2.e6 false
interaction DrugDDI.d395.s2.e3 DrugDDI.d395.s2.e7 false
interaction DrugDDI.d395.s2.e3 DrugDDI.d395.s2.e8 false
interaction DrugDDI.d395.s2.e3 DrugDDI.d395.s2.e9 false
interaction DrugDDI.d395.s2.e3 DrugDDI.d395.s2.e10 false
interaction DrugDDI.d395.s2.e3 DrugDDI.d395.s2.e11 false
interaction DrugDDI.d395.s2.e3 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e3 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e3 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e4 DrugDDI.d395.s2.e5 false
interaction DrugDDI.d395.s2.e4 DrugDDI.d395.s2.e6 false
interaction DrugDDI.d395.s2.e4 DrugDDI.d395.s2.e7 false
interaction DrugDDI.d395.s2.e4 DrugDDI.d395.s2.e8 false
interaction DrugDDI.d395.s2.e4 DrugDDI.d395.s2.e9 false
interaction DrugDDI.d395.s2.e4 DrugDDI.d395.s2.e10 false
interaction DrugDDI.d395.s2.e4 DrugDDI.d395.s2.e11 false
interaction DrugDDI.d395.s2.e4 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e4 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e4 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e5 DrugDDI.d395.s2.e6 false
interaction DrugDDI.d395.s2.e5 DrugDDI.d395.s2.e7 false
interaction DrugDDI.d395.s2.e5 DrugDDI.d395.s2.e8 false
interaction DrugDDI.d395.s2.e5 DrugDDI.d395.s2.e9 false
interaction DrugDDI.d395.s2.e5 DrugDDI.d395.s2.e10 false
interaction DrugDDI.d395.s2.e5 DrugDDI.d395.s2.e11 false
interaction DrugDDI.d395.s2.e5 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e5 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e5 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e6 DrugDDI.d395.s2.e7 false
interaction DrugDDI.d395.s2.e6 DrugDDI.d395.s2.e8 false
interaction DrugDDI.d395.s2.e6 DrugDDI.d395.s2.e9 false
interaction DrugDDI.d395.s2.e6 DrugDDI.d395.s2.e10 false
interaction DrugDDI.d395.s2.e6 DrugDDI.d395.s2.e11 false
interaction DrugDDI.d395.s2.e6 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e6 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e6 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e7 DrugDDI.d395.s2.e8 false
interaction DrugDDI.d395.s2.e7 DrugDDI.d395.s2.e9 false
interaction DrugDDI.d395.s2.e7 DrugDDI.d395.s2.e10 false
interaction DrugDDI.d395.s2.e7 DrugDDI.d395.s2.e11 false
interaction DrugDDI.d395.s2.e7 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e7 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e7 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e8 DrugDDI.d395.s2.e9 false
interaction DrugDDI.d395.s2.e8 DrugDDI.d395.s2.e10 false
interaction DrugDDI.d395.s2.e8 DrugDDI.d395.s2.e11 false
interaction DrugDDI.d395.s2.e8 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e8 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e8 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e9 DrugDDI.d395.s2.e10 false
interaction DrugDDI.d395.s2.e9 DrugDDI.d395.s2.e11 false
interaction DrugDDI.d395.s2.e9 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e9 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e9 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e10 DrugDDI.d395.s2.e11 false
interaction DrugDDI.d395.s2.e10 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e10 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e10 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e11 DrugDDI.d395.s2.e12 false
interaction DrugDDI.d395.s2.e11 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e11 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e12 DrugDDI.d395.s2.e13 false
interaction DrugDDI.d395.s2.e12 DrugDDI.d395.s2.e14 false
interaction DrugDDI.d395.s2.e13 DrugDDI.d395.s2.e14 false

Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s3
@@ @ Beta-blockers , clonidine , lithium salt s, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin .

DrugDDI.d395.s3.e0 2 15
drug
@ Beta-blockers
DrugDDI.d395.s3.e1 17 25
drug
clonidine
DrugDDI.d395.s3.e2 27 37
drug
lithium salt
DrugDDI.d395.s3.e3 43 49
drug
alcohol
DrugDDI.d395.s3.e4 110 116
drug
insulin

interaction DrugDDI.d395.s3.e0 DrugDDI.d395.s3.e1 false
interaction DrugDDI.d395.s3.e0 DrugDDI.d395.s3.e2 false
interaction DrugDDI.d395.s3.e0 DrugDDI.d395.s3.e3 false
interaction DrugDDI.d395.s3.e0 DrugDDI.d395.s3.e4 false
interaction DrugDDI.d395.s3.e1 DrugDDI.d395.s3.e2 false
interaction DrugDDI.d395.s3.e1 DrugDDI.d395.s3.e3 false
interaction DrugDDI.d395.s3.e1 DrugDDI.d395.s3.e4 false
interaction DrugDDI.d395.s3.e2 DrugDDI.d395.s3.e3 false
interaction DrugDDI.d395.s3.e2 DrugDDI.d395.s3.e4 false
interaction DrugDDI.d395.s3.e3 DrugDDI.d395.s3.e4 false

Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s4
Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.

DrugDDI.d395.s4.e0 0 10
drug
Pentamidine
DrugDDI.d395.s4.new.DISO.e1 19 30
DISO
hypoglycemia
DrugDDI.d395.s4.new.DISO.e2 61 73
DISO
hyperglycemia



Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s5
@@ @ : In addition, under the influence of sympatholytic medicinal products such as beta-blockers , clonidine , guanethidine , and reserpine , the signs of hypoglycemia may be reduced or absent.

DrugDDI.d395.s5.e0 34 46
drug
sympatholytic
DrugDDI.d395.s5.e1 70 82
drug
beta-blockers
DrugDDI.d395.s5.e2 84 92
drug
clonidine
DrugDDI.d395.s5.e3 94 105
drug
guanethidine
DrugDDI.d395.s5.e4 110 118
drug
reserpine
DrugDDI.d395.s5.new.DISO.e5 130 141
DISO
hypoglycemia

interaction DrugDDI.d395.s5.e0 DrugDDI.d395.s5.e1 false
interaction DrugDDI.d395.s5.e0 DrugDDI.d395.s5.e2 false
interaction DrugDDI.d395.s5.e0 DrugDDI.d395.s5.e3 false
interaction DrugDDI.d395.s5.e0 DrugDDI.d395.s5.e4 false
interaction DrugDDI.d395.s5.e1 DrugDDI.d395.s5.e2 false
interaction DrugDDI.d395.s5.e1 DrugDDI.d395.s5.e3 false
interaction DrugDDI.d395.s5.e1 DrugDDI.d395.s5.e4 false
interaction DrugDDI.d395.s5.e2 DrugDDI.d395.s5.e3 false
interaction DrugDDI.d395.s5.e2 DrugDDI.d395.s5.e4 false
interaction DrugDDI.d395.s5.e3 DrugDDI.d395.s5.e4 false

Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s6
Mixing of Insulins .

DrugDDI.d395.s6.e0 8 15
drug
Insulins



Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s7
@@ @ : A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog , but that the time to peak and the total bioavailability of NovoLog were not significantly affected.

DrugDDI.d395.s7.e0 69 75
drug
NovoLog
DrugDDI.d395.s7.new.DISO.e4 80 82
DISO
NPH
DrugDDI.d395.s7.e1 83 94
drug
human insulin
DrugDDI.d395.s7.e2 168 174
drug
NovoLog
DrugDDI.d395.s7.e3 224 230
drug
NovoLog

interaction DrugDDI.d395.s7.e0 DrugDDI.d395.s7.e1 false
interaction DrugDDI.d395.s7.e0 DrugDDI.d395.s7.e2 false
interaction DrugDDI.d395.s7.e0 DrugDDI.d395.s7.e3 false
interaction DrugDDI.d395.s7.e1 DrugDDI.d395.s7.e2 false
interaction DrugDDI.d395.s7.e1 DrugDDI.d395.s7.e3 false
interaction DrugDDI.d395.s7.e2 DrugDDI.d395.s7.e3 false

Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s8
If NovoLog is mixed with NPH human insulin , NovoLog should be drawn into the syringe first.

DrugDDI.d395.s8.e0 2 8
drug
NovoLog
DrugDDI.d395.s8.new.DISO.e3 20 22
DISO
NPH
DrugDDI.d395.s8.e1 23 34
drug
human insulin
DrugDDI.d395.s8.e2 36 42
drug
NovoLog

interaction DrugDDI.d395.s8.e0 DrugDDI.d395.s8.e1 false
interaction DrugDDI.d395.s8.e0 DrugDDI.d395.s8.e2 false
interaction DrugDDI.d395.s8.e1 DrugDDI.d395.s8.e2 false

Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s10
Because there are no data on the compatibility of NovoLog and crystalline zinc insulin preparation s, NovoLog should not be mixed with these preparations.

DrugDDI.d395.s10.e0 41 47
drug
NovoLog
DrugDDI.d395.s10.e1 51 83
drug
crystalline zinc insulin preparation
DrugDDI.d395.s10.e2 86 92
drug
NovoLog

interaction DrugDDI.d395.s10.e0 DrugDDI.d395.s10.e1 true
interaction DrugDDI.d395.s10.e0 DrugDDI.d395.s10.e2 false
interaction DrugDDI.d395.s10.e1 DrugDDI.d395.s10.e2 false

Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s11
@@ @ : The effects of mixing NovoLog with insulins of animal source or insulin preparations produced by other manufacturers have not been studied .

DrugDDI.d395.s11.e0 22 28
drug
NovoLog
DrugDDI.d395.s11.e1 33 40
drug
insulins
DrugDDI.d395.s11.e2 57 75
drug
insulin preparations

interaction DrugDDI.d395.s11.e0 DrugDDI.d395.s11.e1 false
interaction DrugDDI.d395.s11.e0 DrugDDI.d395.s11.e2 false
interaction DrugDDI.d395.s11.e1 DrugDDI.d395.s11.e2 false

Abstract Id: DrugDDI.d395
Sentence Id: DrugDDI.d395.s13
@@ @ : When used in external subcutaneous infusion pumps for insulin , NovoLog should not be mixed with any other insulins or diluent.

DrugDDI.d395.s13.e0 50 56
drug
insulin
DrugDDI.d395.s13.e1 58 64
drug
NovoLog
DrugDDI.d395.s13.e2 93 100
drug
insulins

interaction DrugDDI.d395.s13.e0 DrugDDI.d395.s13.e1 false
interaction DrugDDI.d395.s13.e0 DrugDDI.d395.s13.e2 false
interaction DrugDDI.d395.s13.e1 DrugDDI.d395.s13.e2 true

Abstract Id: DrugDDI.d396
Sentence Id: DrugDDI.d396.s0
No significant drug -drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide , digoxin , warfarin , and nifedipine .

DrugDDI.d396.s0.e0 13 16
drug
drug
DrugDDI.d396.s0.e1 105 123
drug
hydrochlorothiazide
DrugDDI.d396.s0.e2 125 131
drug
digoxin
DrugDDI.d396.s0.e3 133 140
drug
warfarin
DrugDDI.d396.s0.e4 145 154
drug
nifedipine

interaction DrugDDI.d396.s0.e0 DrugDDI.d396.s0.e1 false
interaction DrugDDI.d396.s0.e0 DrugDDI.d396.s0.e2 false
interaction DrugDDI.d396.s0.e0 DrugDDI.d396.s0.e3 false
interaction DrugDDI.d396.s0.e0 DrugDDI.d396.s0.e4 false
interaction DrugDDI.d396.s0.e1 DrugDDI.d396.s0.e2 false
interaction DrugDDI.d396.s0.e1 DrugDDI.d396.s0.e3 false
interaction DrugDDI.d396.s0.e1 DrugDDI.d396.s0.e4 false
interaction DrugDDI.d396.s0.e2 DrugDDI.d396.s0.e3 false
interaction DrugDDI.d396.s0.e2 DrugDDI.d396.s0.e4 false
interaction DrugDDI.d396.s0.e3 DrugDDI.d396.s0.e4 false

Abstract Id: DrugDDI.d396
Sentence Id: DrugDDI.d396.s1
In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine .

DrugDDI.d396.s1.e0 63 72
drug
irbesartan
DrugDDI.d396.s1.e1 106 111
drug
CYP 2C9
DrugDDI.d396.s1.e2 146 156
drug
tolbutamide
DrugDDI.d396.s1.e3 160 169
drug
nifedipine

interaction DrugDDI.d396.s1.e0 DrugDDI.d396.s1.e1 false
interaction DrugDDI.d396.s1.e0 DrugDDI.d396.s1.e2 true
interaction DrugDDI.d396.s1.e0 DrugDDI.d396.s1.e3 false
interaction DrugDDI.d396.s1.e1 DrugDDI.d396.s1.e2 false
interaction DrugDDI.d396.s1.e1 DrugDDI.d396.s1.e3 false
interaction DrugDDI.d396.s1.e2 DrugDDI.d396.s1.e3 false

Abstract Id: DrugDDI.d396
Sentence Id: DrugDDI.d396.s2
However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.

DrugDDI.d396.s2.e0 53 62
drug
irbesartan
DrugDDI.d396.s2.e1 86 93
drug
warfarin

interaction DrugDDI.d396.s2.e0 DrugDDI.d396.s2.e1 false

Abstract Id: DrugDDI.d396
Sentence Id: DrugDDI.d396.s3
Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isozymes 1A1 , 1A2,2A6,2B6,2D6,2E1,or 3A4.

DrugDDI.d396.s3.e0 51 55
drug
drugs
DrugDDI.d396.s3.e1 86 110
drug
cytochrome P450 isozymes 1A1

interaction DrugDDI.d396.s3.e0 DrugDDI.d396.s3.e1 false

Abstract Id: DrugDDI.d396
Sentence Id: DrugDDI.d396.s4
In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin .

DrugDDI.d396.s4.e0 54 61
drug
warfarin
DrugDDI.d396.s4.e1 63 81
drug
hydrochlorothiazide
DrugDDI.d396.s4.e2 85 91
drug
digoxin
DrugDDI.d396.s4.e3 93 102
drug
irbesartan
DrugDDI.d396.s4.e4 159 166
drug
warfarin
DrugDDI.d396.s4.e5 204 210
drug
digoxin

interaction DrugDDI.d396.s4.e0 DrugDDI.d396.s4.e1 false
interaction DrugDDI.d396.s4.e0 DrugDDI.d396.s4.e2 false
interaction DrugDDI.d396.s4.e0 DrugDDI.d396.s4.e3 false
interaction DrugDDI.d396.s4.e0 DrugDDI.d396.s4.e4 false
interaction DrugDDI.d396.s4.e0 DrugDDI.d396.s4.e5 false
interaction DrugDDI.d396.s4.e1 DrugDDI.d396.s4.e2 false
interaction DrugDDI.d396.s4.e1 DrugDDI.d396.s4.e3 false
interaction DrugDDI.d396.s4.e1 DrugDDI.d396.s4.e4 false
interaction DrugDDI.d396.s4.e1 DrugDDI.d396.s4.e5 false
interaction DrugDDI.d396.s4.e2 DrugDDI.d396.s4.e3 false
interaction DrugDDI.d396.s4.e2 DrugDDI.d396.s4.e4 false
interaction DrugDDI.d396.s4.e2 DrugDDI.d396.s4.e5 false
interaction DrugDDI.d396.s4.e3 DrugDDI.d396.s4.e4 false
interaction DrugDDI.d396.s4.e3 DrugDDI.d396.s4.e5 false
interaction DrugDDI.d396.s4.e4 DrugDDI.d396.s4.e5 false

Abstract Id: DrugDDI.d396
Sentence Id: DrugDDI.d396.s5
The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide .

DrugDDI.d396.s5.e0 21 30
drug
irbesartan
DrugDDI.d396.s5.e1 66 75
drug
nifedipine
DrugDDI.d396.s5.e2 78 96
drug
hydrochlorothiazide

interaction DrugDDI.d396.s5.e0 DrugDDI.d396.s5.e1 false
interaction DrugDDI.d396.s5.e0 DrugDDI.d396.s5.e2 false
interaction DrugDDI.d396.s5.e1 DrugDDI.d396.s5.e2 false

Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s0
The adverse effects of CAMPTOSAR , such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.

DrugDDI.d177.s0.e0 19 27
drug
CAMPTOSAR
DrugDDI.d177.s0.e1 95 119
drug
other antineoplastic agents

interaction DrugDDI.d177.s0.e0 DrugDDI.d177.s0.e1 true

Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s1
Patients who have previously received pelvic/ abdominal irradiation are at increased risk of severe myelosuppression following the administration of CAMPTOSAR .

DrugDDI.d177.s1.new.DISO.e1 86 101
DISO
myelosuppression
DrugDDI.d177.s1.e0 130 138
drug
CAMPTOSAR



Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s2
The concurrent administration of CAMPTOSAR with irradiation has not been adequately studied and is not recommended.

DrugDDI.d177.s2.e0 29 37
drug
CAMPTOSAR



Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s3
Lymphocytopenia has been reported in patients receiving CAMPTOSAR , and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.

DrugDDI.d177.s3.new.DISO.e3 0 14
DISO
Lymphocytopenia
DrugDDI.d177.s3.e0 49 57
drug
CAMPTOSAR
DrugDDI.d177.s3.e1 97 109
drug
dexamethasone
DrugDDI.d177.s3.e2 112 121
drug
antiemetic

interaction DrugDDI.d177.s3.e0 DrugDDI.d177.s3.e1 false
interaction DrugDDI.d177.s3.e0 DrugDDI.d177.s3.e2 false
interaction DrugDDI.d177.s3.e1 DrugDDI.d177.s3.e2 false

Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s5
Hyperglycemia has also been reported in patients receiving CAMPTOSAR .

DrugDDI.d177.s5.new.DISO.e1 0 12
DISO
Hyperglycemia
DrugDDI.d177.s5.e0 51 59
drug
CAMPTOSAR



Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s6
Usually, this has been observed in patients with a history of diabetes mellitus or evidence of glucose intolerance prior to administration of CAMPTOSAR .

DrugDDI.d177.s6.new.DISO.e1 51 66
DISO
diabetes mellitus
DrugDDI.d177.s6.e0 120 128
drug
CAMPTOSAR



Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s7
It is probable that dexamethasone , given as antiemetic prophylaxis, contributed to hyperglycemia in some patients.

DrugDDI.d177.s7.e0 16 28
drug
dexamethasone
DrugDDI.d177.s7.e1 37 46
drug
antiemetic
DrugDDI.d177.s7.new.DISO.e2 72 84
DISO
hyperglycemia

interaction DrugDDI.d177.s7.e0 DrugDDI.d177.s7.e1 false

Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s8
The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).

DrugDDI.d177.s8.e0 97 112
drug
prochlorperazine
DrugDDI.d177.s8.e1 142 150
drug
CAMPTOSAR
DrugDDI.d177.s8.e2 164 168
drug
drugs

interaction DrugDDI.d177.s8.e0 DrugDDI.d177.s8.e1 true
interaction DrugDDI.d177.s8.e0 DrugDDI.d177.s8.e2 false
interaction DrugDDI.d177.s8.e1 DrugDDI.d177.s8.e2 false

Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s9
The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.

DrugDDI.d177.s9.e0 68 83
drug
prochlorperazine



Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s10
It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.

DrugDDI.d177.s10.e0 21 28
drug
laxative
DrugDDI.d177.s10.e1 49 57
drug
CAMPTOSAR

interaction DrugDDI.d177.s10.e0 DrugDDI.d177.s10.e1 false

Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s11
In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR , the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.

DrugDDI.d177.s11.e0 79 87
drug
CAMPTOSAR
DrugDDI.d177.s11.e1 118 126
drug
diuretics
DrugDDI.d177.s11.e2 143 151
drug
CAMPTOSAR

interaction DrugDDI.d177.s11.e0 DrugDDI.d177.s11.e1 false
interaction DrugDDI.d177.s11.e0 DrugDDI.d177.s11.e2 false
interaction DrugDDI.d177.s11.e1 DrugDDI.d177.s11.e2 true

Abstract Id: DrugDDI.d177
Sentence Id: DrugDDI.d177.s12
Drug-Laboratory Test Interactions : There are no known interactions between CAMPTOSAR and laboratory tests.

DrugDDI.d177.s12.e0 66 74
drug
CAMPTOSAR



Abstract Id: DrugDDI.d171
Sentence Id: DrugDDI.d171.s0
Isoflurane potentiates the muscle relaxant effect of all muscle relaxants , most notably nondepolarizing muscle relaxants , and MAC (minimum alveolar concentration) is reduced by concomitant administration of N span class= c13 2O.

DrugDDI.d171.s0.e0 0 9
drug
Isoflurane
DrugDDI.d171.s0.e1 24 37
drug
muscle relaxant
DrugDDI.d171.s0.e2 49 63
drug
muscle relaxants
DrugDDI.d171.s0.e3 91 105
drug
muscle relaxants

interaction DrugDDI.d171.s0.e0 DrugDDI.d171.s0.e1 false
interaction DrugDDI.d171.s0.e0 DrugDDI.d171.s0.e2 true
interaction DrugDDI.d171.s0.e0 DrugDDI.d171.s0.e3 false
interaction DrugDDI.d171.s0.e1 DrugDDI.d171.s0.e2 false
interaction DrugDDI.d171.s0.e1 DrugDDI.d171.s0.e3 false
interaction DrugDDI.d171.s0.e2 DrugDDI.d171.s0.e3 false

Abstract Id: DrugDDI.d250
Sentence Id: DrugDDI.d250.s0
The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators .

DrugDDI.d250.s0.e0 24 42
drug
isosorbide dinitrate
DrugDDI.d250.s0.e1 72 83
drug
vasodilators

interaction DrugDDI.d250.s0.e0 DrugDDI.d250.s0.e1 false

Abstract Id: DrugDDI.d250
Sentence Id: DrugDDI.d250.s1
Alcohol , in particular, has been found to exhibit additive effects of this variety.

DrugDDI.d250.s1.e0 0 6
drug
Alcohol



Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s0
The following drug interactions were studied with ketoprofen doses of 200 mg/day.

DrugDDI.d347.s0.e0 43 52
drug
ketoprofen



Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s1
The possibility of increased interaction should be kept in mind when Orudis doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs.

DrugDDI.d347.s1.e0 58 63
drug
Orudis
DrugDDI.d347.s1.e1 106 115
drug
ketoprofen

interaction DrugDDI.d347.s1.e0 DrugDDI.d347.s1.e1 false

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s3
Antacids : Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis .

DrugDDI.d347.s3.e0 0 7
drug
Antacids
DrugDDI.d347.s3.e1 36 53
drug
magnesium hydroxide
DrugDDI.d347.s3.e2 57 73
drug
aluminum hydroxide
DrugDDI.d347.s3.e3 126 135
drug
ketoprofen
DrugDDI.d347.s3.e4 150 155
drug
Orudis

interaction DrugDDI.d347.s3.e0 DrugDDI.d347.s3.e1 false
interaction DrugDDI.d347.s3.e0 DrugDDI.d347.s3.e2 false
interaction DrugDDI.d347.s3.e0 DrugDDI.d347.s3.e3 false
interaction DrugDDI.d347.s3.e0 DrugDDI.d347.s3.e4 false
interaction DrugDDI.d347.s3.e1 DrugDDI.d347.s3.e2 false
interaction DrugDDI.d347.s3.e1 DrugDDI.d347.s3.e3 false
interaction DrugDDI.d347.s3.e1 DrugDDI.d347.s3.e4 false
interaction DrugDDI.d347.s3.e2 DrugDDI.d347.s3.e3 false
interaction DrugDDI.d347.s3.e2 DrugDDI.d347.s3.e4 false
interaction DrugDDI.d347.s3.e3 DrugDDI.d347.s3.e4 false

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s5
Aspirin : Ketoprofen does not alter aspirin absorption; .

DrugDDI.d347.s5.e0 0 6
drug
Aspirin
DrugDDI.d347.s5.e1 8 17
drug
Ketoprofen
DrugDDI.d347.s5.e2 30 36
drug
aspirin

interaction DrugDDI.d347.s5.e0 DrugDDI.d347.s5.e1 false
interaction DrugDDI.d347.s5.e0 DrugDDI.d347.s5.e2 false
interaction DrugDDI.d347.s5.e1 DrugDDI.d347.s5.e2 false

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s6
however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin .

DrugDDI.d347.s6.e0 61 67
drug
aspirin
DrugDDI.d347.s6.e1 77 86
drug
ketoprofen
DrugDDI.d347.s6.e2 113 122
drug
ketoprofen
DrugDDI.d347.s6.e3 159 165
drug
aspirin
DrugDDI.d347.s6.e4 182 188
drug
aspirin

interaction DrugDDI.d347.s6.e0 DrugDDI.d347.s6.e1 true
interaction DrugDDI.d347.s6.e0 DrugDDI.d347.s6.e2 false
interaction DrugDDI.d347.s6.e0 DrugDDI.d347.s6.e3 false
interaction DrugDDI.d347.s6.e0 DrugDDI.d347.s6.e4 false
interaction DrugDDI.d347.s6.e1 DrugDDI.d347.s6.e2 false
interaction DrugDDI.d347.s6.e1 DrugDDI.d347.s6.e3 false
interaction DrugDDI.d347.s6.e1 DrugDDI.d347.s6.e4 false
interaction DrugDDI.d347.s6.e2 DrugDDI.d347.s6.e3 false
interaction DrugDDI.d347.s6.e2 DrugDDI.d347.s6.e4 false
interaction DrugDDI.d347.s6.e3 DrugDDI.d347.s6.e4 false

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s8
Therefore, concurrent use of aspirin and ketoprofen is not recommended.

DrugDDI.d347.s8.e0 25 31
drug
aspirin
DrugDDI.d347.s8.e1 35 44
drug
ketoprofen

interaction DrugDDI.d347.s8.e0 DrugDDI.d347.s8.e1 true

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s10
Diuretic : Hydrochlorothiazide , given concomitantly with ketoprofen , produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.

DrugDDI.d347.s10.e0 0 7
drug
Diuretic
DrugDDI.d347.s10.e1 9 27
drug
Hydrochlorothiazide
DrugDDI.d347.s10.e2 51 60
drug
ketoprofen
DrugDDI.d347.s10.e3 128 146
drug
hydrochlorothiazide

interaction DrugDDI.d347.s10.e0 DrugDDI.d347.s10.e1 false
interaction DrugDDI.d347.s10.e0 DrugDDI.d347.s10.e2 false
interaction DrugDDI.d347.s10.e0 DrugDDI.d347.s10.e3 false
interaction DrugDDI.d347.s10.e1 DrugDDI.d347.s10.e2 true
interaction DrugDDI.d347.s10.e1 DrugDDI.d347.s10.e3 false
interaction DrugDDI.d347.s10.e2 DrugDDI.d347.s10.e3 false

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s11
Patients taking diuretics are at a greater risk of developing renal failure secondary to a decrease in renal blood flow caused by prostaglandin inhibition.

DrugDDI.d347.s11.e0 14 22
drug
diuretics



Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s13
Digoxin : In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin .

DrugDDI.d347.s13.e0 0 6
drug
Digoxin
DrugDDI.d347.s13.new.DISO.e5 32 53
DISO
congestive heart failure
DrugDDI.d347.s13.e1 59 68
drug
ketoprofen
DrugDDI.d347.s13.e2 72 78
drug
digoxin
DrugDDI.d347.s13.e3 109 118
drug
ketoprofen
DrugDDI.d347.s13.e4 146 152
drug
digoxin

interaction DrugDDI.d347.s13.e0 DrugDDI.d347.s13.e1 false
interaction DrugDDI.d347.s13.e0 DrugDDI.d347.s13.e2 false
interaction DrugDDI.d347.s13.e0 DrugDDI.d347.s13.e3 false
interaction DrugDDI.d347.s13.e0 DrugDDI.d347.s13.e4 false
interaction DrugDDI.d347.s13.e1 DrugDDI.d347.s13.e2 false
interaction DrugDDI.d347.s13.e1 DrugDDI.d347.s13.e3 false
interaction DrugDDI.d347.s13.e1 DrugDDI.d347.s13.e4 false
interaction DrugDDI.d347.s13.e2 DrugDDI.d347.s13.e3 false
interaction DrugDDI.d347.s13.e2 DrugDDI.d347.s13.e4 false
interaction DrugDDI.d347.s13.e3 DrugDDI.d347.s13.e4 false

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s15
Warfarin : In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time.

DrugDDI.d347.s15.e0 0 7
drug
Warfarin
DrugDDI.d347.s15.e1 58 67
drug
ketoprofen
DrugDDI.d347.s15.e2 111 118
drug
warfarin

interaction DrugDDI.d347.s15.e0 DrugDDI.d347.s15.e1 false
interaction DrugDDI.d347.s15.e0 DrugDDI.d347.s15.e2 false
interaction DrugDDI.d347.s15.e1 DrugDDI.d347.s15.e2 false

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s16
Bleeding from a number of sites may be a complication of warfarin treatment and GI bleeding a complication of ketoprofen treatment.

DrugDDI.d347.s16.e0 91 100
drug
ketoprofen



Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s17
Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs .

DrugDDI.d347.s17.e0 55 64
drug
ketoprofen
DrugDDI.d347.s17.e1 121 130
drug
ketoprofen
DrugDDI.d347.s17.e2 134 141
drug
warfarin
DrugDDI.d347.s17.e3 181 185
drug
drugs

interaction DrugDDI.d347.s17.e0 DrugDDI.d347.s17.e1 false
interaction DrugDDI.d347.s17.e0 DrugDDI.d347.s17.e2 false
interaction DrugDDI.d347.s17.e0 DrugDDI.d347.s17.e3 false
interaction DrugDDI.d347.s17.e1 DrugDDI.d347.s17.e2 true
interaction DrugDDI.d347.s17.e1 DrugDDI.d347.s17.e3 false
interaction DrugDDI.d347.s17.e2 DrugDDI.d347.s17.e3 false

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s19
Probenecid : Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.

DrugDDI.d347.s19.e0 0 9
drug
Probenecid
DrugDDI.d347.s19.e1 11 20
drug
Probenecid
DrugDDI.d347.s19.e2 46 55
drug
ketoprofen
DrugDDI.d347.s19.e3 86 95
drug
ketoprofen

interaction DrugDDI.d347.s19.e0 DrugDDI.d347.s19.e1 false
interaction DrugDDI.d347.s19.e0 DrugDDI.d347.s19.e2 false
interaction DrugDDI.d347.s19.e0 DrugDDI.d347.s19.e3 false
interaction DrugDDI.d347.s19.e1 DrugDDI.d347.s19.e2 true
interaction DrugDDI.d347.s19.e1 DrugDDI.d347.s19.e3 false
interaction DrugDDI.d347.s19.e2 DrugDDI.d347.s19.e3 false

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s20
Therefore, the combination of ketoprofen and probenecid is not recommended.

DrugDDI.d347.s20.e0 26 35
drug
ketoprofen
DrugDDI.d347.s20.e1 39 48
drug
probenecid

interaction DrugDDI.d347.s20.e0 DrugDDI.d347.s20.e1 true

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s22
Methotrexate : Ketoprofen , like other NSAIDs , may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.

DrugDDI.d347.s22.e0 0 11
drug
Methotrexate
DrugDDI.d347.s22.e1 13 22
drug
Ketoprofen
DrugDDI.d347.s22.e2 33 38
drug
NSAIDs
DrugDDI.d347.s22.e3 73 84
drug
methotrexate
DrugDDI.d347.s22.e4 118 121
drug
drug

interaction DrugDDI.d347.s22.e0 DrugDDI.d347.s22.e1 false
interaction DrugDDI.d347.s22.e0 DrugDDI.d347.s22.e2 false
interaction DrugDDI.d347.s22.e0 DrugDDI.d347.s22.e3 false
interaction DrugDDI.d347.s22.e0 DrugDDI.d347.s22.e4 false
interaction DrugDDI.d347.s22.e1 DrugDDI.d347.s22.e2 false
interaction DrugDDI.d347.s22.e1 DrugDDI.d347.s22.e3 true
interaction DrugDDI.d347.s22.e1 DrugDDI.d347.s22.e4 false
interaction DrugDDI.d347.s22.e2 DrugDDI.d347.s22.e3 false
interaction DrugDDI.d347.s22.e2 DrugDDI.d347.s22.e4 false
interaction DrugDDI.d347.s22.e3 DrugDDI.d347.s22.e4 false

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s24
Lithium : Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.

DrugDDI.d347.s24.e0 0 6
drug
Lithium
DrugDDI.d347.s24.e1 8 42
drug
Nonsteroidal anti-inflammatory agents

interaction DrugDDI.d347.s24.e0 DrugDDI.d347.s24.e1 false

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s25
It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium .

DrugDDI.d347.s25.e0 53 62
drug
ketoprofen
DrugDDI.d347.s25.e1 83 89
drug
lithium

interaction DrugDDI.d347.s25.e0 DrugDDI.d347.s25.e1 true

Abstract Id: DrugDDI.d347
Sentence Id: DrugDDI.d347.s26
DRUG /LABORATORY TEST INTERACTIONS: EFFECT ON BLOOD COAGULATION Ketoprofen decreases platelet adhesion and aggregation.

DrugDDI.d347.s26.e0 0 3
drug
DRUG
DrugDDI.d347.s26.e1 56 65
drug
Ketoprofen

interaction DrugDDI.d347.s26.e0 DrugDDI.d347.s26.e1 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s0
Ketorolac is highly bound to human plasma protein (mean 99.2%).

DrugDDI.d334.s0.e0 0 8
drug
Ketorolac
DrugDDI.d334.s0.e1 29 41
drug
plasma protein

interaction DrugDDI.d334.s0.e0 DrugDDI.d334.s0.e1 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s1
Warfarin , Digoxin , Salicylate , and Heparin : The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.

DrugDDI.d334.s1.e0 0 7
drug
Warfarin
DrugDDI.d334.s1.e1 9 15
drug
Digoxin
DrugDDI.d334.s1.e2 17 26
drug
Salicylate
DrugDDI.d334.s1.e3 58 65
drug
warfarin
DrugDDI.d334.s1.e4 68 81
drug
plasma proteins
DrugDDI.d334.s1.e5 105 125
drug
ketorolac tromethamine
DrugDDI.d334.s1.e6 151 159
drug
ketorolac
DrugDDI.d334.s1.e7 185 189
drug
5 to10

interaction DrugDDI.d334.s1.e0 DrugDDI.d334.s1.e1 false
interaction DrugDDI.d334.s1.e0 DrugDDI.d334.s1.e2 false
interaction DrugDDI.d334.s1.e0 DrugDDI.d334.s1.e3 false
interaction DrugDDI.d334.s1.e0 DrugDDI.d334.s1.e4 false
interaction DrugDDI.d334.s1.e0 DrugDDI.d334.s1.e5 false
interaction DrugDDI.d334.s1.e0 DrugDDI.d334.s1.e6 false
interaction DrugDDI.d334.s1.e0 DrugDDI.d334.s1.e7 false
interaction DrugDDI.d334.s1.e1 DrugDDI.d334.s1.e2 false
interaction DrugDDI.d334.s1.e1 DrugDDI.d334.s1.e3 false
interaction DrugDDI.d334.s1.e1 DrugDDI.d334.s1.e4 false
interaction DrugDDI.d334.s1.e1 DrugDDI.d334.s1.e5 false
interaction DrugDDI.d334.s1.e1 DrugDDI.d334.s1.e6 false
interaction DrugDDI.d334.s1.e1 DrugDDI.d334.s1.e7 false
interaction DrugDDI.d334.s1.e2 DrugDDI.d334.s1.e3 false
interaction DrugDDI.d334.s1.e2 DrugDDI.d334.s1.e4 false
interaction DrugDDI.d334.s1.e2 DrugDDI.d334.s1.e5 false
interaction DrugDDI.d334.s1.e2 DrugDDI.d334.s1.e6 false
interaction DrugDDI.d334.s1.e2 DrugDDI.d334.s1.e7 false
interaction DrugDDI.d334.s1.e3 DrugDDI.d334.s1.e4 false
interaction DrugDDI.d334.s1.e3 DrugDDI.d334.s1.e5 true
interaction DrugDDI.d334.s1.e3 DrugDDI.d334.s1.e6 false
interaction DrugDDI.d334.s1.e3 DrugDDI.d334.s1.e7 false
interaction DrugDDI.d334.s1.e4 DrugDDI.d334.s1.e5 false
interaction DrugDDI.d334.s1.e4 DrugDDI.d334.s1.e6 false
interaction DrugDDI.d334.s1.e4 DrugDDI.d334.s1.e7 false
interaction DrugDDI.d334.s1.e5 DrugDDI.d334.s1.e6 false
interaction DrugDDI.d334.s1.e5 DrugDDI.d334.s1.e7 false
interaction DrugDDI.d334.s1.e6 DrugDDI.d334.s1.e7 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s2
Ketorolac does not alter digoxin protein binding.

DrugDDI.d334.s2.e0 0 8
drug
Ketorolac
DrugDDI.d334.s2.e1 21 27
drug
digoxin

interaction DrugDDI.d334.s2.e0 DrugDDI.d334.s2.e1 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s3
In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.

DrugDDI.d334.s3.e0 56 65
drug
salicylate
DrugDDI.d334.s3.e1 89 97
drug
ketorolac
DrugDDI.d334.s3.e2 184 192
drug
ketorolac

interaction DrugDDI.d334.s3.e0 DrugDDI.d334.s3.e1 true
interaction DrugDDI.d334.s3.e0 DrugDDI.d334.s3.e2 false
interaction DrugDDI.d334.s3.e1 DrugDDI.d334.s3.e2 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s4
Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.

DrugDDI.d334.s4.e0 27 33
drug
digoxin
DrugDDI.d334.s4.e1 35 42
drug
warfarin
DrugDDI.d334.s4.e2 44 52
drug
ibuprofen
DrugDDI.d334.s4.e3 54 61
drug
naproxen
DrugDDI.d334.s4.e4 63 71
drug
piroxicam
DrugDDI.d334.s4.e5 73 85
drug
acetaminophen
DrugDDI.d334.s4.e6 87 95
drug
phenytoin
DrugDDI.d334.s4.e7 121 141
drug
ketorolac tromethamine

interaction DrugDDI.d334.s4.e0 DrugDDI.d334.s4.e1 false
interaction DrugDDI.d334.s4.e0 DrugDDI.d334.s4.e2 false
interaction DrugDDI.d334.s4.e0 DrugDDI.d334.s4.e3 false
interaction DrugDDI.d334.s4.e0 DrugDDI.d334.s4.e4 false
interaction DrugDDI.d334.s4.e0 DrugDDI.d334.s4.e5 false
interaction DrugDDI.d334.s4.e0 DrugDDI.d334.s4.e6 false
interaction DrugDDI.d334.s4.e0 DrugDDI.d334.s4.e7 false
interaction DrugDDI.d334.s4.e1 DrugDDI.d334.s4.e2 false
interaction DrugDDI.d334.s4.e1 DrugDDI.d334.s4.e3 false
interaction DrugDDI.d334.s4.e1 DrugDDI.d334.s4.e4 false
interaction DrugDDI.d334.s4.e1 DrugDDI.d334.s4.e5 false
interaction DrugDDI.d334.s4.e1 DrugDDI.d334.s4.e6 false
interaction DrugDDI.d334.s4.e1 DrugDDI.d334.s4.e7 false
interaction DrugDDI.d334.s4.e2 DrugDDI.d334.s4.e3 false
interaction DrugDDI.d334.s4.e2 DrugDDI.d334.s4.e4 false
interaction DrugDDI.d334.s4.e2 DrugDDI.d334.s4.e5 false
interaction DrugDDI.d334.s4.e2 DrugDDI.d334.s4.e6 false
interaction DrugDDI.d334.s4.e2 DrugDDI.d334.s4.e7 false
interaction DrugDDI.d334.s4.e3 DrugDDI.d334.s4.e4 false
interaction DrugDDI.d334.s4.e3 DrugDDI.d334.s4.e5 false
interaction DrugDDI.d334.s4.e3 DrugDDI.d334.s4.e6 false
interaction DrugDDI.d334.s4.e3 DrugDDI.d334.s4.e7 false
interaction DrugDDI.d334.s4.e4 DrugDDI.d334.s4.e5 false
interaction DrugDDI.d334.s4.e4 DrugDDI.d334.s4.e6 false
interaction DrugDDI.d334.s4.e4 DrugDDI.d334.s4.e7 false
interaction DrugDDI.d334.s4.e5 DrugDDI.d334.s4.e6 false
interaction DrugDDI.d334.s4.e5 DrugDDI.d334.s4.e7 false
interaction DrugDDI.d334.s4.e6 DrugDDI.d334.s4.e7 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s5
In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg warfarin , causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin .

DrugDDI.d334.s5.e0 84 91
drug
warfarin
DrugDDI.d334.s5.e1 158 165
drug
warfarin

interaction DrugDDI.d334.s5.e0 DrugDDI.d334.s5.e1 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s6
In another study, TORADOLIV/IM was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo.

DrugDDI.d334.s6.e0 56 62
drug
heparin
DrugDDI.d334.s6.e1 190 196
drug
heparin

interaction DrugDDI.d334.s6.e0 DrugDDI.d334.s6.e1 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s7
Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin , the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.

DrugDDI.d334.s7.e0 63 69
drug
TORADOL
DrugDDI.d334.s7.e1 73 80
drug
warfarin
DrugDDI.d334.s7.e2 83 89
drug
heparin
DrugDDI.d334.s7.e3 110 116
drug
TORADOL
DrugDDI.d334.s7.e4 133 146
drug
anticoagulants

interaction DrugDDI.d334.s7.e0 DrugDDI.d334.s7.e1 false
interaction DrugDDI.d334.s7.e0 DrugDDI.d334.s7.e2 false
interaction DrugDDI.d334.s7.e0 DrugDDI.d334.s7.e3 false
interaction DrugDDI.d334.s7.e0 DrugDDI.d334.s7.e4 false
interaction DrugDDI.d334.s7.e1 DrugDDI.d334.s7.e2 false
interaction DrugDDI.d334.s7.e1 DrugDDI.d334.s7.e3 false
interaction DrugDDI.d334.s7.e1 DrugDDI.d334.s7.e4 false
interaction DrugDDI.d334.s7.e2 DrugDDI.d334.s7.e3 false
interaction DrugDDI.d334.s7.e2 DrugDDI.d334.s7.e4 false
interaction DrugDDI.d334.s7.e3 DrugDDI.d334.s7.e4 true

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s8
Furosemide TORADOLIV /IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).

DrugDDI.d334.s8.e0 0 18
drug
Furosemide TORADOLIV
DrugDDI.d334.s8.e1 32 39
drug
diuretic
DrugDDI.d334.s8.e2 50 59
drug
furosemide
DrugDDI.d334.s8.e3 112 117
drug
sodium

interaction DrugDDI.d334.s8.e0 DrugDDI.d334.s8.e1 false
interaction DrugDDI.d334.s8.e0 DrugDDI.d334.s8.e2 true
interaction DrugDDI.d334.s8.e0 DrugDDI.d334.s8.e3 false
interaction DrugDDI.d334.s8.e1 DrugDDI.d334.s8.e2 false
interaction DrugDDI.d334.s8.e1 DrugDDI.d334.s8.e3 false
interaction DrugDDI.d334.s8.e2 DrugDDI.d334.s8.e3 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s9
Probenecid Concomitant administration of TORADOLORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.

DrugDDI.d334.s9.e0 0 9
drug
Probenecid
DrugDDI.d334.s9.e1 51 60
drug
probenecid
DrugDDI.d334.s9.e2 91 99
drug
ketorolac
DrugDDI.d334.s9.e3 125 133
drug
ketorolac

interaction DrugDDI.d334.s9.e0 DrugDDI.d334.s9.e1 true
interaction DrugDDI.d334.s9.e0 DrugDDI.d334.s9.e2 false
interaction DrugDDI.d334.s9.e0 DrugDDI.d334.s9.e3 false
interaction DrugDDI.d334.s9.e1 DrugDDI.d334.s9.e2 false
interaction DrugDDI.d334.s9.e1 DrugDDI.d334.s9.e3 false
interaction DrugDDI.d334.s9.e2 DrugDDI.d334.s9.e3 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s10
Therefore, concomitant use of TORADOL and probenecid is contraindicated.

DrugDDI.d334.s10.e0 26 32
drug
TORADOL
DrugDDI.d334.s10.e1 36 45
drug
probenecid

interaction DrugDDI.d334.s10.e0 DrugDDI.d334.s10.e1 true

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s11
Lithium Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs .

DrugDDI.d334.s11.e0 0 6
drug
Lithium
DrugDDI.d334.s11.e1 24 30
drug
lithium
DrugDDI.d334.s11.e2 68 74
drug
lithium
DrugDDI.d334.s11.e3 112 124
drug
prostaglandin
DrugDDI.d334.s11.e4 145 149
drug
drugs

interaction DrugDDI.d334.s11.e0 DrugDDI.d334.s11.e1 false
interaction DrugDDI.d334.s11.e0 DrugDDI.d334.s11.e2 false
interaction DrugDDI.d334.s11.e0 DrugDDI.d334.s11.e3 true
interaction DrugDDI.d334.s11.e0 DrugDDI.d334.s11.e4 false
interaction DrugDDI.d334.s11.e1 DrugDDI.d334.s11.e2 false
interaction DrugDDI.d334.s11.e1 DrugDDI.d334.s11.e3 false
interaction DrugDDI.d334.s11.e1 DrugDDI.d334.s11.e4 false
interaction DrugDDI.d334.s11.e2 DrugDDI.d334.s11.e3 false
interaction DrugDDI.d334.s11.e2 DrugDDI.d334.s11.e4 false
interaction DrugDDI.d334.s11.e3 DrugDDI.d334.s11.e4 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s12
The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.

DrugDDI.d334.s12.e0 11 17
drug
TORADOL
DrugDDI.d334.s12.e1 26 32
drug
lithium
DrugDDI.d334.s12.e2 95 101
drug
TORADOL

interaction DrugDDI.d334.s12.e0 DrugDDI.d334.s12.e1 false
interaction DrugDDI.d334.s12.e0 DrugDDI.d334.s12.e2 false
interaction DrugDDI.d334.s12.e1 DrugDDI.d334.s12.e2 true

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s13
Methotrexate Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate , enhancing the toxicity of methotrexate .

DrugDDI.d334.s13.e0 0 11
drug
Methotrexate
DrugDDI.d334.s13.e1 39 50
drug
methotrexate
DrugDDI.d334.s13.e2 58 63
drug
NSAIDs
DrugDDI.d334.s13.e3 101 112
drug
methotrexate
DrugDDI.d334.s13.e4 136 147
drug
methotrexate

interaction DrugDDI.d334.s13.e0 DrugDDI.d334.s13.e1 false
interaction DrugDDI.d334.s13.e0 DrugDDI.d334.s13.e2 false
interaction DrugDDI.d334.s13.e0 DrugDDI.d334.s13.e3 false
interaction DrugDDI.d334.s13.e0 DrugDDI.d334.s13.e4 false
interaction DrugDDI.d334.s13.e1 DrugDDI.d334.s13.e2 true
interaction DrugDDI.d334.s13.e1 DrugDDI.d334.s13.e3 false
interaction DrugDDI.d334.s13.e1 DrugDDI.d334.s13.e4 false
interaction DrugDDI.d334.s13.e2 DrugDDI.d334.s13.e3 false
interaction DrugDDI.d334.s13.e2 DrugDDI.d334.s13.e4 false
interaction DrugDDI.d334.s13.e3 DrugDDI.d334.s13.e4 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s14
The effect of TORADOL on methotrexate clearance has not been studied.

DrugDDI.d334.s14.e0 11 17
drug
TORADOL
DrugDDI.d334.s14.e1 20 31
drug
methotrexate

interaction DrugDDI.d334.s14.e0 DrugDDI.d334.s14.e1 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s15
Nondepolarizing Muscle Relaxants : In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and nondepolarizing muscle relaxants that resulted in apnea.

DrugDDI.d334.s15.e0 15 29
drug
Muscle Relaxants
DrugDDI.d334.s15.e1 135 149
drug
muscle relaxants

interaction DrugDDI.d334.s15.e0 DrugDDI.d334.s15.e1 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s16
The concurrent use of TORADOL with muscle relaxants has not been formally studied.

DrugDDI.d334.s16.e0 18 24
drug
TORADOL
DrugDDI.d334.s16.e1 29 43
drug
muscle relaxants

interaction DrugDDI.d334.s16.e0 DrugDDI.d334.s16.e1 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s17
ACE Inhibitors Concomitant use of ACE inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients.

DrugDDI.d334.s17.e0 0 12
drug
ACE Inhibitors
DrugDDI.d334.s17.e1 29 41
drug
ACE inhibitors

interaction DrugDDI.d334.s17.e0 DrugDDI.d334.s17.e1 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s18
Antiepileptic Drugs Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs ( phenytoin , carbamazepine ).

DrugDDI.d334.s18.e0 0 17
drug
Antiepileptic Drugs
DrugDDI.d334.s18.e1 79 85
drug
TORADOL
DrugDDI.d334.s18.e2 89 106
drug
antiepileptic drugs
DrugDDI.d334.s18.e3 108 116
drug
phenytoin
DrugDDI.d334.s18.e4 118 130
drug
carbamazepine

interaction DrugDDI.d334.s18.e0 DrugDDI.d334.s18.e1 false
interaction DrugDDI.d334.s18.e0 DrugDDI.d334.s18.e2 false
interaction DrugDDI.d334.s18.e0 DrugDDI.d334.s18.e3 false
interaction DrugDDI.d334.s18.e0 DrugDDI.d334.s18.e4 false
interaction DrugDDI.d334.s18.e1 DrugDDI.d334.s18.e2 true
interaction DrugDDI.d334.s18.e1 DrugDDI.d334.s18.e3 false
interaction DrugDDI.d334.s18.e1 DrugDDI.d334.s18.e4 true
interaction DrugDDI.d334.s18.e2 DrugDDI.d334.s18.e3 false
interaction DrugDDI.d334.s18.e2 DrugDDI.d334.s18.e4 false
interaction DrugDDI.d334.s18.e3 DrugDDI.d334.s18.e4 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s19
Psychoactive Drugs Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs ( fluoxetine , thiothixene , alprazolam ).

DrugDDI.d334.s19.e0 0 16
drug
Psychoactive Drugs
DrugDDI.d334.s19.e1 51 57
drug
TORADOL
DrugDDI.d334.s19.e2 81 97
drug
psychoactive drugs
DrugDDI.d334.s19.e3 99 108
drug
fluoxetine
DrugDDI.d334.s19.e4 110 120
drug
thiothixene
DrugDDI.d334.s19.e5 122 131
drug
alprazolam

interaction DrugDDI.d334.s19.e0 DrugDDI.d334.s19.e1 false
interaction DrugDDI.d334.s19.e0 DrugDDI.d334.s19.e2 false
interaction DrugDDI.d334.s19.e0 DrugDDI.d334.s19.e3 false
interaction DrugDDI.d334.s19.e0 DrugDDI.d334.s19.e4 false
interaction DrugDDI.d334.s19.e0 DrugDDI.d334.s19.e5 false
interaction DrugDDI.d334.s19.e1 DrugDDI.d334.s19.e2 true
interaction DrugDDI.d334.s19.e1 DrugDDI.d334.s19.e3 false
interaction DrugDDI.d334.s19.e1 DrugDDI.d334.s19.e4 true
interaction DrugDDI.d334.s19.e1 DrugDDI.d334.s19.e5 false
interaction DrugDDI.d334.s19.e2 DrugDDI.d334.s19.e3 false
interaction DrugDDI.d334.s19.e2 DrugDDI.d334.s19.e4 false
interaction DrugDDI.d334.s19.e2 DrugDDI.d334.s19.e5 false
interaction DrugDDI.d334.s19.e3 DrugDDI.d334.s19.e4 false
interaction DrugDDI.d334.s19.e3 DrugDDI.d334.s19.e5 false
interaction DrugDDI.d334.s19.e4 DrugDDI.d334.s19.e5 false

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s20
Morphine TORADOLIV/IM has been administered concurrently with morphine in several clinical trials of postoperative pain without evidence of adverse interactions.

DrugDDI.d334.s20.e0 0 7
drug
Morphine
DrugDDI.d334.s20.e1 55 62
drug
morphine

interaction DrugDDI.d334.s20.e0 DrugDDI.d334.s20.e1 true

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s21
Do not mix TORADOL and morphine in the same syringe.

DrugDDI.d334.s21.e0 8 14
drug
TORADOL
DrugDDI.d334.s21.e1 18 25
drug
morphine

interaction DrugDDI.d334.s21.e0 DrugDDI.d334.s21.e1 true

Abstract Id: DrugDDI.d334
Sentence Id: DrugDDI.d334.s22
There is no evidence in animal or human studies that TORADOL induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs .

DrugDDI.d334.s22.e0 43 49
drug
TORADOL
DrugDDI.d334.s22.e1 115 119
drug
drugs

interaction DrugDDI.d334.s22.e0 DrugDDI.d334.s22.e1 false

Abstract Id: DrugDDI.d415
Sentence Id: DrugDDI.d415.s0
Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.

DrugDDI.d415.s0.e0 0 25
drug
Medroxyprogesterone Acetate
DrugDDI.d415.s0.e1 86 111
drug
medroxyprogesterone acetate
DrugDDI.d415.s0.new.DISO.e2 138 149
DISO
breast cancer

interaction DrugDDI.d415.s0.e0 DrugDDI.d415.s0.e1 true

Abstract Id: DrugDDI.d415
Sentence Id: DrugDDI.d415.s1
H1 and H2 Blockers - Although not reported, L-histidine , via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers .

DrugDDI.d415.s1.e0 5 14
drug
H2 Blockers
DrugDDI.d415.s1.e1 36 46
drug
L-histidine
DrugDDI.d415.s1.e2 107 116
drug
H2 blockers

interaction DrugDDI.d415.s1.e0 DrugDDI.d415.s1.e1 false
interaction DrugDDI.d415.s1.e0 DrugDDI.d415.s1.e2 false
interaction DrugDDI.d415.s1.e1 DrugDDI.d415.s1.e2 true

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s0
Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.

DrugDDI.d201.s0.e0 9 17
drug
Lapatinib
DrugDDI.d201.s0.e1 20 23
drug
Drug
DrugDDI.d201.s0.e2 66 74
drug
Lapatinib
DrugDDI.d201.s0.e3 83 88
drug
CYP3A4
DrugDDI.d201.s0.e4 92 97
drug
CYP2C8

interaction DrugDDI.d201.s0.e0 DrugDDI.d201.s0.e1 true
interaction DrugDDI.d201.s0.e0 DrugDDI.d201.s0.e2 false
interaction DrugDDI.d201.s0.e0 DrugDDI.d201.s0.e3 false
interaction DrugDDI.d201.s0.e0 DrugDDI.d201.s0.e4 false
interaction DrugDDI.d201.s0.e1 DrugDDI.d201.s0.e2 false
interaction DrugDDI.d201.s0.e1 DrugDDI.d201.s0.e3 false
interaction DrugDDI.d201.s0.e1 DrugDDI.d201.s0.e4 false
interaction DrugDDI.d201.s0.e2 DrugDDI.d201.s0.e3 false
interaction DrugDDI.d201.s0.e2 DrugDDI.d201.s0.e4 false
interaction DrugDDI.d201.s0.e3 DrugDDI.d201.s0.e4 false

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s1
Caution should be exercised and dose reduction of the concomitant substrate drug should be considered when dosing lapatinib concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4 or CYP2C8 .

DrugDDI.d201.s1.e0 65 68
drug
drug
DrugDDI.d201.s1.e1 97 105
drug
lapatinib
DrugDDI.d201.s1.e2 122 132
drug
medications
DrugDDI.d201.s1.e3 180 185
drug
CYP3A4
DrugDDI.d201.s1.e4 188 193
drug
CYP2C8

interaction DrugDDI.d201.s1.e0 DrugDDI.d201.s1.e1 false
interaction DrugDDI.d201.s1.e0 DrugDDI.d201.s1.e2 false
interaction DrugDDI.d201.s1.e0 DrugDDI.d201.s1.e3 false
interaction DrugDDI.d201.s1.e0 DrugDDI.d201.s1.e4 false
interaction DrugDDI.d201.s1.e1 DrugDDI.d201.s1.e2 true
interaction DrugDDI.d201.s1.e1 DrugDDI.d201.s1.e3 false
interaction DrugDDI.d201.s1.e1 DrugDDI.d201.s1.e4 false
interaction DrugDDI.d201.s1.e2 DrugDDI.d201.s1.e3 false
interaction DrugDDI.d201.s1.e2 DrugDDI.d201.s1.e4 false
interaction DrugDDI.d201.s1.e3 DrugDDI.d201.s1.e4 false

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s2
Lapatinib did not significantly inhibit the following enzymes in human liver microsomes: CYP1A2 , CYP2C9 , CYP2C19 , and CYP2D6 or UGT enzymes in vitro, however, the clinical significance is unknown.

DrugDDI.d201.s2.e0 0 8
drug
Lapatinib
DrugDDI.d201.s2.e1 77 82
drug
CYP1A2
DrugDDI.d201.s2.e2 84 89
drug
CYP2C9
DrugDDI.d201.s2.e3 91 97
drug
CYP2C19
DrugDDI.d201.s2.e4 102 107
drug
CYP2D6

interaction DrugDDI.d201.s2.e0 DrugDDI.d201.s2.e1 false
interaction DrugDDI.d201.s2.e0 DrugDDI.d201.s2.e2 false
interaction DrugDDI.d201.s2.e0 DrugDDI.d201.s2.e3 false
interaction DrugDDI.d201.s2.e0 DrugDDI.d201.s2.e4 false
interaction DrugDDI.d201.s2.e1 DrugDDI.d201.s2.e2 false
interaction DrugDDI.d201.s2.e1 DrugDDI.d201.s2.e3 false
interaction DrugDDI.d201.s2.e1 DrugDDI.d201.s2.e4 false
interaction DrugDDI.d201.s2.e2 DrugDDI.d201.s2.e3 false
interaction DrugDDI.d201.s2.e2 DrugDDI.d201.s2.e4 false
interaction DrugDDI.d201.s2.e3 DrugDDI.d201.s2.e4 false

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s3
Lapatinib inhibits human P- glycoprotein .

DrugDDI.d201.s3.e0 0 8
drug
Lapatinib
DrugDDI.d201.s3.e1 24 35
drug
glycoprotein

interaction DrugDDI.d201.s3.e0 DrugDDI.d201.s3.e1 true

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s4
If TYKERB is administered with drugs that are substrates of Pgp, increased concentrations of the substrate drug are likely, and caution should be exercised.

DrugDDI.d201.s4.e0 26 30
drug
drugs
DrugDDI.d201.s4.e1 91 94
drug
drug

interaction DrugDDI.d201.s4.e0 DrugDDI.d201.s4.e1 false

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s5
Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4 , and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.

DrugDDI.d201.s5.e0 0 4
drug
Drugs
DrugDDI.d201.s5.e1 24 40
drug
Cytochrome P450 3A4
DrugDDI.d201.s5.e2 87 92
drug
CYP3A4
DrugDDI.d201.s5.e3 152 157
drug
CYP3A4
DrugDDI.d201.s5.e4 163 171
drug
lapatinib

interaction DrugDDI.d201.s5.e0 DrugDDI.d201.s5.e1 false
interaction DrugDDI.d201.s5.e0 DrugDDI.d201.s5.e2 false
interaction DrugDDI.d201.s5.e0 DrugDDI.d201.s5.e3 false
interaction DrugDDI.d201.s5.e0 DrugDDI.d201.s5.e4 false
interaction DrugDDI.d201.s5.e1 DrugDDI.d201.s5.e2 false
interaction DrugDDI.d201.s5.e1 DrugDDI.d201.s5.e3 false
interaction DrugDDI.d201.s5.e1 DrugDDI.d201.s5.e4 false
interaction DrugDDI.d201.s5.e2 DrugDDI.d201.s5.e3 false
interaction DrugDDI.d201.s5.e2 DrugDDI.d201.s5.e4 false
interaction DrugDDI.d201.s5.e3 DrugDDI.d201.s5.e4 true

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s6
Dose adjustment of lapatinib should be considered for patients who must receive concomitant strong inhibitors or concomitant strong inducers of CYP3A4 enzymes.

DrugDDI.d201.s6.e0 16 24
drug
lapatinib
DrugDDI.d201.s6.e1 124 129
drug
CYP3A4

interaction DrugDDI.d201.s6.e0 DrugDDI.d201.s6.e1 true

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s7
Ketoconazole : In healthy subjects receiving ketoconazole , a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.

DrugDDI.d201.s7.e0 0 11
drug
Ketoconazole
DrugDDI.d201.s7.e1 39 50
drug
ketoconazole
DrugDDI.d201.s7.e2 53 58
drug
CYP3A4
DrugDDI.d201.s7.e3 118 126
drug
lapatinib

interaction DrugDDI.d201.s7.e0 DrugDDI.d201.s7.e1 false
interaction DrugDDI.d201.s7.e0 DrugDDI.d201.s7.e2 false
interaction DrugDDI.d201.s7.e0 DrugDDI.d201.s7.e3 false
interaction DrugDDI.d201.s7.e1 DrugDDI.d201.s7.e2 false
interaction DrugDDI.d201.s7.e1 DrugDDI.d201.s7.e3 true
interaction DrugDDI.d201.s7.e2 DrugDDI.d201.s7.e3 false

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s8
Carbamazepine : In healthy subjects receiving the CYP3A4 inducer, carbamazepine , at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.

DrugDDI.d201.s8.e0 0 12
drug
Carbamazepine
DrugDDI.d201.s8.e1 43 48
drug
CYP3A4
DrugDDI.d201.s8.e2 57 69
drug
carbamazepine
DrugDDI.d201.s8.e3 147 155
drug
lapatinib

interaction DrugDDI.d201.s8.e0 DrugDDI.d201.s8.e1 false
interaction DrugDDI.d201.s8.e0 DrugDDI.d201.s8.e2 false
interaction DrugDDI.d201.s8.e0 DrugDDI.d201.s8.e3 false
interaction DrugDDI.d201.s8.e1 DrugDDI.d201.s8.e2 false
interaction DrugDDI.d201.s8.e1 DrugDDI.d201.s8.e3 false
interaction DrugDDI.d201.s8.e2 DrugDDI.d201.s8.e3 true

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s9
Drugs that Inhibit Drug Transport Systems Lapatinib is a substrate of the efflux transporter P-glycoprotein (Pgp, ABCB1 ).

DrugDDI.d201.s9.e0 0 4
drug
Drugs
DrugDDI.d201.s9.e1 36 44
drug
Lapatinib
DrugDDI.d201.s9.e2 68 78
drug
transporter
DrugDDI.d201.s9.e3 98 102
drug
ABCB1

interaction DrugDDI.d201.s9.e0 DrugDDI.d201.s9.e1 false
interaction DrugDDI.d201.s9.e0 DrugDDI.d201.s9.e2 false
interaction DrugDDI.d201.s9.e0 DrugDDI.d201.s9.e3 false
interaction DrugDDI.d201.s9.e1 DrugDDI.d201.s9.e2 false
interaction DrugDDI.d201.s9.e1 DrugDDI.d201.s9.e3 false
interaction DrugDDI.d201.s9.e2 DrugDDI.d201.s9.e3 false

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s10
If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.

DrugDDI.d201.s10.e0 26 30
drug
drugs
DrugDDI.d201.s10.e1 71 79
drug
lapatinib

interaction DrugDDI.d201.s10.e0 DrugDDI.d201.s10.e1 false

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s11
Other Chemotherapy Agents : In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine ).

DrugDDI.d201.s11.e0 68 76
drug
lapatinib
DrugDDI.d201.s11.e1 81 92
drug
capecitabine
DrugDDI.d201.s11.e2 154 164
drug
metabolites
DrugDDI.d201.s11.e3 167 178
drug
capecitabine

interaction DrugDDI.d201.s11.e0 DrugDDI.d201.s11.e1 false
interaction DrugDDI.d201.s11.e0 DrugDDI.d201.s11.e2 false
interaction DrugDDI.d201.s11.e0 DrugDDI.d201.s11.e3 false
interaction DrugDDI.d201.s11.e1 DrugDDI.d201.s11.e2 false
interaction DrugDDI.d201.s11.e1 DrugDDI.d201.s11.e3 false
interaction DrugDDI.d201.s11.e2 DrugDDI.d201.s11.e3 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s0
Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .

DrugDDI.d581.s0.e0 0 13
drug
Cholestyramine
DrugDDI.d581.s0.e1 17 24
drug
Charcoal
DrugDDI.d581.s0.e2 41 54
drug
cholestyramine
DrugDDI.d581.s0.e3 57 73
drug
activated charcoal
DrugDDI.d581.s0.e4 161 176
drug
active metabolite
DrugDDI.d581.s0.e5 179 189
drug
leflunomide

interaction DrugDDI.d581.s0.e0 DrugDDI.d581.s0.e1 false
interaction DrugDDI.d581.s0.e0 DrugDDI.d581.s0.e2 true
interaction DrugDDI.d581.s0.e0 DrugDDI.d581.s0.e3 false
interaction DrugDDI.d581.s0.e0 DrugDDI.d581.s0.e4 false
interaction DrugDDI.d581.s0.e0 DrugDDI.d581.s0.e5 false
interaction DrugDDI.d581.s0.e1 DrugDDI.d581.s0.e2 false
interaction DrugDDI.d581.s0.e1 DrugDDI.d581.s0.e3 false
interaction DrugDDI.d581.s0.e1 DrugDDI.d581.s0.e4 false
interaction DrugDDI.d581.s0.e1 DrugDDI.d581.s0.e5 false
interaction DrugDDI.d581.s0.e2 DrugDDI.d581.s0.e3 false
interaction DrugDDI.d581.s0.e2 DrugDDI.d581.s0.e4 false
interaction DrugDDI.d581.s0.e2 DrugDDI.d581.s0.e5 false
interaction DrugDDI.d581.s0.e3 DrugDDI.d581.s0.e4 false
interaction DrugDDI.d581.s0.e3 DrugDDI.d581.s0.e5 false
interaction DrugDDI.d581.s0.e4 DrugDDI.d581.s0.e5 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s1
Hepatotoxic Drugs Increased side effects may occur when leflunomide is given concomitantly with hepatotoxic substances.

DrugDDI.d581.s1.e0 11 15
drug
Drugs
DrugDDI.d581.s1.e1 48 58
drug
leflunomide

interaction DrugDDI.d581.s1.e0 DrugDDI.d581.s1.e1 true

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s2
This is also to be considered when leflunomide treatment is followed by such drugs without a drug elimination procedure.

DrugDDI.d581.s2.e0 28 38
drug
leflunomide
DrugDDI.d581.s2.e1 64 68
drug
drugs

interaction DrugDDI.d581.s2.e0 DrugDDI.d581.s2.e1 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s3
In a small (n=30) combination study of ARAVA with methotrexate , a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.

DrugDDI.d581.s3.e0 32 36
drug
ARAVA
DrugDDI.d581.s3.e1 41 52
drug
methotrexate
DrugDDI.d581.s3.e2 76 87
drug
liver enzymes

interaction DrugDDI.d581.s3.e0 DrugDDI.d581.s3.e1 true
interaction DrugDDI.d581.s3.e0 DrugDDI.d581.s3.e2 false
interaction DrugDDI.d581.s3.e1 DrugDDI.d581.s3.e2 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s4
All elevations resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide .

DrugDDI.d581.s4.e0 45 49
drug
drugs
DrugDDI.d581.s4.e1 76 86
drug
leflunomide

interaction DrugDDI.d581.s4.e0 DrugDDI.d581.s4.e1 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s6
All of these also resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide .

DrugDDI.d581.s6.e0 46 50
drug
drugs
DrugDDI.d581.s6.e1 77 87
drug
leflunomide

interaction DrugDDI.d581.s6.e0 DrugDDI.d581.s6.e1 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s7
Three patients met ACR criteria for liver biopsy (1: Roegnik Grade I, 2: Roegnik Grade IIIa).

DrugDDI.d581.s7.e0 13 15
drug
met



Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s9
NSAIDs : In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.

DrugDDI.d581.s9.e0 0 5
drug
NSAIDs
DrugDDI.d581.s9.e1 86 95
drug
diclofenac
DrugDDI.d581.s9.e2 99 107
drug
ibuprofen

interaction DrugDDI.d581.s9.e0 DrugDDI.d581.s9.e1 false
interaction DrugDDI.d581.s9.e0 DrugDDI.d581.s9.e2 false
interaction DrugDDI.d581.s9.e1 DrugDDI.d581.s9.e2 true

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s11
however, there was extensive concomitant use of NSAIDs in clinical studies and no differential effect was observed.

DrugDDI.d581.s11.e0 41 46
drug
NSAIDs



Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s12
Tolbutamide : In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range.

DrugDDI.d581.s12.e0 0 10
drug
Tolbutamide
DrugDDI.d581.s12.e1 91 101
drug
tolbutamide

interaction DrugDDI.d581.s12.e0 DrugDDI.d581.s12.e1 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s14
Rifampin Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin , M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.

DrugDDI.d581.s14.e0 0 7
drug
Rifampin
DrugDDI.d581.s14.e1 57 61
drug
ARAVA
DrugDDI.d581.s14.e2 96 103
drug
rifampin
DrugDDI.d581.s14.e3 153 157
drug
ARAVA

interaction DrugDDI.d581.s14.e0 DrugDDI.d581.s14.e1 false
interaction DrugDDI.d581.s14.e0 DrugDDI.d581.s14.e2 false
interaction DrugDDI.d581.s14.e0 DrugDDI.d581.s14.e3 false
interaction DrugDDI.d581.s14.e1 DrugDDI.d581.s14.e2 true
interaction DrugDDI.d581.s14.e1 DrugDDI.d581.s14.e3 false
interaction DrugDDI.d581.s14.e2 DrugDDI.d581.s14.e3 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s15
Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin .

DrugDDI.d581.s15.e0 24 28
drug
ARAVA
DrugDDI.d581.s15.e1 123 127
drug
ARAVA
DrugDDI.d581.s15.e2 131 138
drug
rifampin

interaction DrugDDI.d581.s15.e0 DrugDDI.d581.s15.e1 false
interaction DrugDDI.d581.s15.e0 DrugDDI.d581.s15.e2 false
interaction DrugDDI.d581.s15.e1 DrugDDI.d581.s15.e2 true

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s16
Warfarin Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.

DrugDDI.d581.s16.e0 0 7
drug
Warfarin
DrugDDI.d581.s16.e1 54 58
drug
ARAVA
DrugDDI.d581.s16.e2 62 69
drug
warfarin

interaction DrugDDI.d581.s16.e0 DrugDDI.d581.s16.e1 false
interaction DrugDDI.d581.s16.e0 DrugDDI.d581.s16.e2 false
interaction DrugDDI.d581.s16.e1 DrugDDI.d581.s16.e2 true

Abstract Id: DrugDDI.d379
Sentence Id: DrugDDI.d379.s0
Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.

DrugDDI.d379.s0.e0 30 39
drug
cimetidine
DrugDDI.d379.s0.e1 43 50
drug
warfarin
DrugDDI.d379.s0.e2 85 90
drug
Femara
DrugDDI.d379.s0.e3 100 104
drug
drugs

interaction DrugDDI.d379.s0.e0 DrugDDI.d379.s0.e1 false
interaction DrugDDI.d379.s0.e0 DrugDDI.d379.s0.e2 false
interaction DrugDDI.d379.s0.e0 DrugDDI.d379.s0.e3 false
interaction DrugDDI.d379.s0.e1 DrugDDI.d379.s0.e2 false
interaction DrugDDI.d379.s0.e1 DrugDDI.d379.s0.e3 false
interaction DrugDDI.d379.s0.e2 DrugDDI.d379.s0.e3 false

Abstract Id: DrugDDI.d379
Sentence Id: DrugDDI.d379.s1
(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.

DrugDDI.d379.s1.e0 43 48
drug
Femara
DrugDDI.d379.s1.e1 52 64
drug
tamoxifen 20 mg
DrugDDI.d379.s1.e2 92 100
drug
letrozole

interaction DrugDDI.d379.s1.e0 DrugDDI.d379.s1.e1 true
interaction DrugDDI.d379.s1.e0 DrugDDI.d379.s1.e2 false
interaction DrugDDI.d379.s1.e1 DrugDDI.d379.s1.e2 false

Abstract Id: DrugDDI.d379
Sentence Id: DrugDDI.d379.s2
There is no clinical experience to date on the use of Femara in combination with other anticancer agents.

DrugDDI.d379.s2.e0 43 48
drug
Femara



Abstract Id: DrugDDI.d379
Sentence Id: DrugDDI.d379.s3
Drug /Laboratory Test-Interactions None observed.

DrugDDI.d379.s3.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d341
Sentence Id: DrugDDI.d341.s0
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital , phenytoin and primidone , and increase the frequency of seizures in susceptible pediatric patients.

DrugDDI.d341.s0.e0 0 8
drug
Folic acid
DrugDDI.d341.s0.e1 39 51
drug
antiepileptic
DrugDDI.d341.s0.e2 60 72
drug
phenobarbital
DrugDDI.d341.s0.e3 74 82
drug
phenytoin
DrugDDI.d341.s0.e4 86 94
drug
primidone
DrugDDI.d341.s0.e5 142 150
drug
pediatric

interaction DrugDDI.d341.s0.e0 DrugDDI.d341.s0.e1 false
interaction DrugDDI.d341.s0.e0 DrugDDI.d341.s0.e2 true
interaction DrugDDI.d341.s0.e0 DrugDDI.d341.s0.e3 false
interaction DrugDDI.d341.s0.e0 DrugDDI.d341.s0.e4 true
interaction DrugDDI.d341.s0.e0 DrugDDI.d341.s0.e5 false
interaction DrugDDI.d341.s0.e1 DrugDDI.d341.s0.e2 false
interaction DrugDDI.d341.s0.e1 DrugDDI.d341.s0.e3 false
interaction DrugDDI.d341.s0.e1 DrugDDI.d341.s0.e4 false
interaction DrugDDI.d341.s0.e1 DrugDDI.d341.s0.e5 false
interaction DrugDDI.d341.s0.e2 DrugDDI.d341.s0.e3 false
interaction DrugDDI.d341.s0.e2 DrugDDI.d341.s0.e4 false
interaction DrugDDI.d341.s0.e2 DrugDDI.d341.s0.e5 false
interaction DrugDDI.d341.s0.e3 DrugDDI.d341.s0.e4 false
interaction DrugDDI.d341.s0.e3 DrugDDI.d341.s0.e5 false
interaction DrugDDI.d341.s0.e4 DrugDDI.d341.s0.e5 false

Abstract Id: DrugDDI.d341
Sentence Id: DrugDDI.d341.s1
Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.

DrugDDI.d341.s1.e0 86 95
drug
leucovorin
DrugDDI.d341.s1.e1 200 211
drug
methotrexate

interaction DrugDDI.d341.s1.e0 DrugDDI.d341.s1.e1 false

Abstract Id: DrugDDI.d341
Sentence Id: DrugDDI.d341.s2
However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate .

DrugDDI.d341.s2.e0 19 28
drug
leucovorin
DrugDDI.d341.s2.e1 76 87
drug
methotrexate

interaction DrugDDI.d341.s2.e0 DrugDDI.d341.s2.e1 true

Abstract Id: DrugDDI.d341
Sentence Id: DrugDDI.d341.s3
Leucovorin may enhance the toxicity of 5- fluorouracil .

DrugDDI.d341.s3.e0 0 9
drug
Leucovorin
DrugDDI.d341.s3.e1 35 46
drug
fluorouracil

interaction DrugDDI.d341.s3.e0 DrugDDI.d341.s3.e1 true

Abstract Id: DrugDDI.d484
Sentence Id: DrugDDI.d484.s0
Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.

DrugDDI.d484.s0.e0 8 14
drug
BETAGAN
DrugDDI.d484.s0.e1 99 105
drug
BETAGAN
DrugDDI.d484.s0.e2 109 119
drug
epinephrine

interaction DrugDDI.d484.s0.e0 DrugDDI.d484.s0.e1 false
interaction DrugDDI.d484.s0.e0 DrugDDI.d484.s0.e2 false
interaction DrugDDI.d484.s0.e1 DrugDDI.d484.s0.e2 false

Abstract Id: DrugDDI.d484
Sentence Id: DrugDDI.d484.s1
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine , because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.

DrugDDI.d484.s1.e0 46 57
drug
beta-blocker
DrugDDI.d484.s1.e1 114 118
drug
drugs
DrugDDI.d484.s1.e2 125 133
drug
reserpine

interaction DrugDDI.d484.s1.e0 DrugDDI.d484.s1.e1 true
interaction DrugDDI.d484.s1.e0 DrugDDI.d484.s1.e2 false
interaction DrugDDI.d484.s1.e1 DrugDDI.d484.s1.e2 false

Abstract Id: DrugDDI.d484
Sentence Id: DrugDDI.d484.s2
Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonist s should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.

DrugDDI.d484.s2.e0 17 45
drug
beta-adrenergic blocking agents
DrugDDI.d484.s2.e1 78 94
drug
calcium antagonist
DrugDDI.d484.s2.new.DISO.e2 124 161
DISO
atrioventricular conduction disturbances
DrugDDI.d484.s2.new.DISO.e3 167 184
DISO
ventricular failure

interaction DrugDDI.d484.s2.e0 DrugDDI.d484.s2.e1 true

Abstract Id: DrugDDI.d484
Sentence Id: DrugDDI.d484.s4
The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonist s may have additive effects on prolonging atrioventricular conduction time.

DrugDDI.d484.s4.e0 19 47
drug
beta-adrenergic blocking agents
DrugDDI.d484.s4.e1 52 60
drug
digitalis
DrugDDI.d484.s4.e2 64 80
drug
calcium antagonist

interaction DrugDDI.d484.s4.e0 DrugDDI.d484.s4.e1 true
interaction DrugDDI.d484.s4.e0 DrugDDI.d484.s4.e2 false
interaction DrugDDI.d484.s4.e1 DrugDDI.d484.s4.e2 false

Abstract Id: DrugDDI.d484
Sentence Id: DrugDDI.d484.s5
Phenothiazine -related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other@s metabolism.

DrugDDI.d484.s5.e0 0 12
drug
Phenothiazine
DrugDDI.d484.s5.e1 33 61
drug
beta-adrenergic blocking agents

interaction DrugDDI.d484.s5.e0 DrugDDI.d484.s5.e1 true

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s0
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide , digoxin , warfarin , cimetidine and phenobarbital .

DrugDDI.d112.s0.e0 86 104
drug
hydrochlorothiazide
DrugDDI.d112.s0.e1 106 112
drug
digoxin
DrugDDI.d112.s0.e2 114 121
drug
warfarin
DrugDDI.d112.s0.e3 123 132
drug
cimetidine
DrugDDI.d112.s0.e4 136 148
drug
phenobarbital

interaction DrugDDI.d112.s0.e0 DrugDDI.d112.s0.e1 false
interaction DrugDDI.d112.s0.e0 DrugDDI.d112.s0.e2 false
interaction DrugDDI.d112.s0.e0 DrugDDI.d112.s0.e3 false
interaction DrugDDI.d112.s0.e0 DrugDDI.d112.s0.e4 false
interaction DrugDDI.d112.s0.e1 DrugDDI.d112.s0.e2 false
interaction DrugDDI.d112.s0.e1 DrugDDI.d112.s0.e3 false
interaction DrugDDI.d112.s0.e1 DrugDDI.d112.s0.e4 false
interaction DrugDDI.d112.s0.e2 DrugDDI.d112.s0.e3 false
interaction DrugDDI.d112.s0.e2 DrugDDI.d112.s0.e4 false
interaction DrugDDI.d112.s0.e3 DrugDDI.d112.s0.e4 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s1
Rifampin , an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite .

DrugDDI.d112.s1.e0 0 7
drug
Rifampin
DrugDDI.d112.s1.e1 63 70
drug
losartan
DrugDDI.d112.s1.e2 77 92
drug
active metabolite

interaction DrugDDI.d112.s1.e0 DrugDDI.d112.s1.e1 true
interaction DrugDDI.d112.s1.e0 DrugDDI.d112.s1.e2 false
interaction DrugDDI.d112.s1.e1 DrugDDI.d112.s1.e2 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s2
In humans, two inhibitors of P450 3A4 have been studied.

DrugDDI.d112.s2.e0 24 30
drug
P450 3A4



Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s3
Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan , and erythromycin had no clinically significant effect after oral administration.

DrugDDI.d112.s3.e0 0 11
drug
Ketoconazole
DrugDDI.d112.s3.e1 39 46
drug
losartan
DrugDDI.d112.s3.e2 52 67
drug
active metabolite
DrugDDI.d112.s3.e3 100 107
drug
losartan
DrugDDI.d112.s3.e4 112 123
drug
erythromycin

interaction DrugDDI.d112.s3.e0 DrugDDI.d112.s3.e1 false
interaction DrugDDI.d112.s3.e0 DrugDDI.d112.s3.e2 false
interaction DrugDDI.d112.s3.e0 DrugDDI.d112.s3.e3 false
interaction DrugDDI.d112.s3.e0 DrugDDI.d112.s3.e4 false
interaction DrugDDI.d112.s3.e1 DrugDDI.d112.s3.e2 false
interaction DrugDDI.d112.s3.e1 DrugDDI.d112.s3.e3 false
interaction DrugDDI.d112.s3.e1 DrugDDI.d112.s3.e4 false
interaction DrugDDI.d112.s3.e2 DrugDDI.d112.s3.e3 false
interaction DrugDDI.d112.s3.e2 DrugDDI.d112.s3.e4 false
interaction DrugDDI.d112.s3.e3 DrugDDI.d112.s3.e4 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s4
Fluconazole , an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.

DrugDDI.d112.s4.e0 0 10
drug
Fluconazole
DrugDDI.d112.s4.e1 25 28
drug
P450
DrugDDI.d112.s4.e2 42 57
drug
active metabolite
DrugDDI.d112.s4.e3 83 90
drug
losartan

interaction DrugDDI.d112.s4.e0 DrugDDI.d112.s4.e1 false
interaction DrugDDI.d112.s4.e0 DrugDDI.d112.s4.e2 true
interaction DrugDDI.d112.s4.e0 DrugDDI.d112.s4.e3 false
interaction DrugDDI.d112.s4.e1 DrugDDI.d112.s4.e2 false
interaction DrugDDI.d112.s4.e1 DrugDDI.d112.s4.e3 false
interaction DrugDDI.d112.s4.e2 DrugDDI.d112.s4.e3 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s5
The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined.

DrugDDI.d112.s5.e0 48 55
drug
losartan
DrugDDI.d112.s5.e1 71 74
drug
P450

interaction DrugDDI.d112.s5.e0 DrugDDI.d112.s5.e1 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s6
Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9 .

DrugDDI.d112.s6.e0 26 33
drug
losartan
DrugDDI.d112.s6.e1 36 51
drug
active metabolite
DrugDDI.d112.s6.e2 93 109
drug
cytochrome P450 2C9

interaction DrugDDI.d112.s6.e0 DrugDDI.d112.s6.e1 false
interaction DrugDDI.d112.s6.e0 DrugDDI.d112.s6.e2 false
interaction DrugDDI.d112.s6.e1 DrugDDI.d112.s6.e2 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s7
These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4 .

DrugDDI.d112.s7.e0 35 42
drug
losartan
DrugDDI.d112.s7.e1 48 63
drug
active metabolite
DrugDDI.d112.s7.e2 85 88
drug
P450
DrugDDI.d112.s7.e3 98 104
drug
P450 3A4

interaction DrugDDI.d112.s7.e0 DrugDDI.d112.s7.e1 false
interaction DrugDDI.d112.s7.e0 DrugDDI.d112.s7.e2 true
interaction DrugDDI.d112.s7.e0 DrugDDI.d112.s7.e3 false
interaction DrugDDI.d112.s7.e1 DrugDDI.d112.s7.e2 false
interaction DrugDDI.d112.s7.e1 DrugDDI.d112.s7.e3 false
interaction DrugDDI.d112.s7.e2 DrugDDI.d112.s7.e3 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s8
As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone , triamterene , amiloride ), potassium supplement s, or salt substitutes containing potassium may lead to increases in serum potassium.

DrugDDI.d112.s8.e0 11 15
drug
drugs
DrugDDI.d112.s8.e1 25 37
drug
angiotensin II
DrugDDI.d112.s8.e2 67 92
drug
potassium-sparing diuretics
DrugDDI.d112.s8.e3 99 112
drug
spironolactone
DrugDDI.d112.s8.e4 114 124
drug
triamterene
DrugDDI.d112.s8.e5 126 134
drug
amiloride
DrugDDI.d112.s8.e6 137 155
drug
potassium supplement
DrugDDI.d112.s8.e7 160 163
drug
salt
DrugDDI.d112.s8.e8 185 193
drug
potassium

interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e1 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e2 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e3 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e4 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e5 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e6 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e7 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e2 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e3 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e4 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e5 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e6 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e7 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e3 false
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e4 false
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e5 false
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e6 true
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e7 false
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e3 DrugDDI.d112.s8.e4 false
interaction DrugDDI.d112.s8.e3 DrugDDI.d112.s8.e5 false
interaction DrugDDI.d112.s8.e3 DrugDDI.d112.s8.e6 false
interaction DrugDDI.d112.s8.e3 DrugDDI.d112.s8.e7 true
interaction DrugDDI.d112.s8.e3 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e4 DrugDDI.d112.s8.e5 false
interaction DrugDDI.d112.s8.e4 DrugDDI.d112.s8.e6 true
interaction DrugDDI.d112.s8.e4 DrugDDI.d112.s8.e7 false
interaction DrugDDI.d112.s8.e4 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e5 DrugDDI.d112.s8.e6 false
interaction DrugDDI.d112.s8.e5 DrugDDI.d112.s8.e7 true
interaction DrugDDI.d112.s8.e5 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e6 DrugDDI.d112.s8.e7 false
interaction DrugDDI.d112.s8.e6 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e7 DrugDDI.d112.s8.e8 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s9
As with other antihypertensive agents , the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin .

DrugDDI.d112.s9.e0 11 32
drug
antihypertensive agents
DrugDDI.d112.s9.e1 37 52
drug
antihypertensive
DrugDDI.d112.s9.e2 61 68
drug
losartan
DrugDDI.d112.s9.e3 86 119
drug
non-steroidal anti-inflammatory drug

interaction DrugDDI.d112.s9.e0 DrugDDI.d112.s9.e1 false
interaction DrugDDI.d112.s9.e0 DrugDDI.d112.s9.e2 false
interaction DrugDDI.d112.s9.e0 DrugDDI.d112.s9.e3 false
interaction DrugDDI.d112.s9.e1 DrugDDI.d112.s9.e2 false
interaction DrugDDI.d112.s9.e1 DrugDDI.d112.s9.e3 false
interaction DrugDDI.d112.s9.e2 DrugDDI.d112.s9.e3 true

Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s0
When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents : Anesthetics , general: exaggeration of the hypotension induced by general anesthetics .

DrugDDI.d464.s0.e0 41 45
drug
drugs
DrugDDI.d464.s0.e1 61 97
drug
beta-adrenergic receptor blocking agents
DrugDDI.d464.s0.e2 99 109
drug
Anesthetics
DrugDDI.d464.s0.e3 156 173
drug
general anesthetics

interaction DrugDDI.d464.s0.e0 DrugDDI.d464.s0.e1 true
interaction DrugDDI.d464.s0.e0 DrugDDI.d464.s0.e2 false
interaction DrugDDI.d464.s0.e0 DrugDDI.d464.s0.e3 false
interaction DrugDDI.d464.s0.e1 DrugDDI.d464.s0.e2 true
interaction DrugDDI.d464.s0.e1 DrugDDI.d464.s0.e3 false
interaction DrugDDI.d464.s0.e2 DrugDDI.d464.s0.e3 false

Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s1
Antidiabetic drugs (oral agents and insulin ): hypoglycemia or hyperglycemia; .

DrugDDI.d464.s1.e0 0 16
drug
Antidiabetic drugs
DrugDDI.d464.s1.e1 31 37
drug
insulin
DrugDDI.d464.s1.new.DISO.e2 40 51
DISO
hypoglycemia
DrugDDI.d464.s1.new.DISO.e3 54 66
DISO
hyperglycemia

interaction DrugDDI.d464.s1.e0 DrugDDI.d464.s1.e1 false

Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s2
adjust dosage of antidiabetic drug accordingly.

DrugDDI.d464.s2.e0 14 29
drug
antidiabetic drug



Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s3
Catecholamine-depleting drugs (e.g., reserpine ): additive effect; .

DrugDDI.d464.s3.e0 23 27
drug
drugs
DrugDDI.d464.s3.e1 34 42
drug
reserpine

interaction DrugDDI.d464.s3.e0 DrugDDI.d464.s3.e1 false

Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s5
Response to Treatment for Anaphylactic Reaction: While taking beta-blockers , patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.

DrugDDI.d464.s5.e0 54 66
drug
beta-blockers



Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s6
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

DrugDDI.d464.s6.e0 46 56
drug
epinephrine



Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s0
Elevated plasma levels of theophylline have been reported with concomitant quinolone use.

DrugDDI.d485.s0.e0 22 33
drug
theophylline
DrugDDI.d485.s0.e1 65 73
drug
quinolone

interaction DrugDDI.d485.s0.e0 DrugDDI.d485.s0.e1 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s1
There have been reports of theophylline -related side effects in patients on concomitant therapy with quinolones and theophylline .

DrugDDI.d485.s1.e0 22 33
drug
theophylline
DrugDDI.d485.s1.e1 87 96
drug
quinolones
DrugDDI.d485.s1.e2 100 111
drug
theophylline

interaction DrugDDI.d485.s1.e0 DrugDDI.d485.s1.e1 false
interaction DrugDDI.d485.s1.e0 DrugDDI.d485.s1.e2 false
interaction DrugDDI.d485.s1.e1 DrugDDI.d485.s1.e2 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s2
Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted, as required.

DrugDDI.d485.s2.e0 22 33
drug
theophylline



Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s3
Quinolones have been shown to interfere with the metabolism of caffeine .

DrugDDI.d485.s3.e0 0 9
drug
Quinolones
DrugDDI.d485.s3.e1 53 60
drug
caffeine

interaction DrugDDI.d485.s3.e0 DrugDDI.d485.s3.e1 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s4
This may lead to reduced clearance of caffeine and the prolongation of its plasma half-life.

DrugDDI.d485.s4.e0 31 38
drug
caffeine



Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s5
Quinolones , including nalidixic acid , may enhance the effects of the oral anticoagulant warfarin or its derivatives .

DrugDDI.d485.s5.e0 0 9
drug
Quinolones
DrugDDI.d485.s5.e1 20 32
drug
nalidixic acid
DrugDDI.d485.s5.e2 59 83
drug
oral anticoagulant warfarin
DrugDDI.d485.s5.e3 89 99
drug
derivatives

interaction DrugDDI.d485.s5.e0 DrugDDI.d485.s5.e1 false
interaction DrugDDI.d485.s5.e0 DrugDDI.d485.s5.e2 true
interaction DrugDDI.d485.s5.e0 DrugDDI.d485.s5.e3 false
interaction DrugDDI.d485.s5.e1 DrugDDI.d485.s5.e2 false
interaction DrugDDI.d485.s5.e1 DrugDDI.d485.s5.e3 true
interaction DrugDDI.d485.s5.e2 DrugDDI.d485.s5.e3 false

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s7
Nitrofurantoin interferes with the therapeutic action of nalidixic acid .

DrugDDI.d485.s7.e0 0 13
drug
Nitrofurantoin
DrugDDI.d485.s7.e1 50 62
drug
nalidixic acid

interaction DrugDDI.d485.s7.e0 DrugDDI.d485.s7.e1 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s8
Antacids containing magnesium , aluminum, or calcium ; .

DrugDDI.d485.s8.e0 0 7
drug
Antacids
DrugDDI.d485.s8.e1 18 26
drug
magnesium
DrugDDI.d485.s8.e2 39 45
drug
calcium

interaction DrugDDI.d485.s8.e0 DrugDDI.d485.s8.e1 false
interaction DrugDDI.d485.s8.e0 DrugDDI.d485.s8.e2 false
interaction DrugDDI.d485.s8.e1 DrugDDI.d485.s8.e2 false

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s9
sucralfate or divalent or trivalent cations such as iron ; .

DrugDDI.d485.s9.e0 0 9
drug
sucralfate
DrugDDI.d485.s9.e1 31 37
drug
cations
DrugDDI.d485.s9.e2 44 47
drug
iron

interaction DrugDDI.d485.s9.e0 DrugDDI.d485.s9.e1 false
interaction DrugDDI.d485.s9.e0 DrugDDI.d485.s9.e2 false
interaction DrugDDI.d485.s9.e1 DrugDDI.d485.s9.e2 false

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s10
multivitamins containing zinc ; .

DrugDDI.d485.s10.e0 0 12
drug
multivitamins
DrugDDI.d485.s10.e1 23 26
drug
zinc

interaction DrugDDI.d485.s10.e0 DrugDDI.d485.s10.e1 false

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s11
and Videx@, ( Didanosine ), chewable/ buffer ed tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones , resulting in systemic levels considerably lower than desired.

DrugDDI.d485.s11.e0 11 20
drug
Didanosine
DrugDDI.d485.s11.e1 32 37
drug
buffer
DrugDDI.d485.s11.e2 52 60
drug
pediatric
DrugDDI.d485.s11.e3 126 135
drug
quinolones

interaction DrugDDI.d485.s11.e0 DrugDDI.d485.s11.e1 false
interaction DrugDDI.d485.s11.e0 DrugDDI.d485.s11.e2 false
interaction DrugDDI.d485.s11.e0 DrugDDI.d485.s11.e3 true
interaction DrugDDI.d485.s11.e1 DrugDDI.d485.s11.e2 false
interaction DrugDDI.d485.s11.e1 DrugDDI.d485.s11.e3 true
interaction DrugDDI.d485.s11.e2 DrugDDI.d485.s11.e3 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s12
These agents should not be taken within the two hour period before or within the two-hour period after nalidixic acid administration.

DrugDDI.d485.s12.e0 85 97
drug
nalidixic acid



Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s13
Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine .

DrugDDI.d485.s13.e0 21 32
drug
cyclosporine
DrugDDI.d485.s13.e1 76 85
drug
quinolones
DrugDDI.d485.s13.e2 89 100
drug
cyclosporine

interaction DrugDDI.d485.s13.e0 DrugDDI.d485.s13.e1 false
interaction DrugDDI.d485.s13.e0 DrugDDI.d485.s13.e2 false
interaction DrugDDI.d485.s13.e1 DrugDDI.d485.s13.e2 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s14
Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.

DrugDDI.d485.s14.e0 10 21
drug
cyclosporine
DrugDDI.d485.s14.e1 64 75
drug
cyclosporine
DrugDDI.d485.s14.e2 106 110
drug
drugs

interaction DrugDDI.d485.s14.e0 DrugDDI.d485.s14.e1 false
interaction DrugDDI.d485.s14.e0 DrugDDI.d485.s14.e2 false
interaction DrugDDI.d485.s14.e1 DrugDDI.d485.s14.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s0
In vitro drug metabolism studies indicate that Starlix is predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%).

DrugDDI.d249.s0.e0 40 46
drug
Starlix
DrugDDI.d249.s0.e1 78 91
drug
cytochrome P450
DrugDDI.d249.s0.e2 128 133
drug
CYP3A4

interaction DrugDDI.d249.s0.e0 DrugDDI.d249.s0.e1 true
interaction DrugDDI.d249.s0.e0 DrugDDI.d249.s0.e2 false
interaction DrugDDI.d249.s0.e1 DrugDDI.d249.s0.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s1
Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide .

DrugDDI.d249.s1.e0 0 6
drug
Starlix
DrugDDI.d249.s1.e1 33 47
drug
CYP2C9 isoenzyme
DrugDDI.d249.s1.e2 108 118
drug
tolbutamide

interaction DrugDDI.d249.s1.e0 DrugDDI.d249.s1.e1 true
interaction DrugDDI.d249.s1.e0 DrugDDI.d249.s1.e2 false
interaction DrugDDI.d249.s1.e1 DrugDDI.d249.s1.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s2
Inhibition of CYP3A4 metabolic reactions was not detected in in vitro experiments.

DrugDDI.d249.s2.e0 12 17
drug
CYP3A4



Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s3
Glyburide : In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily.

DrugDDI.d249.s3.e0 0 8
drug
Glyburide
DrugDDI.d249.s3.e1 98 104
drug
Starlix
DrugDDI.d249.s3.e2 154 162
drug
glyburide

interaction DrugDDI.d249.s3.e0 DrugDDI.d249.s3.e1 false
interaction DrugDDI.d249.s3.e0 DrugDDI.d249.s3.e2 false
interaction DrugDDI.d249.s3.e1 DrugDDI.d249.s3.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s5
Metformin : When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.

DrugDDI.d249.s5.e0 0 8
drug
Metformin
DrugDDI.d249.s5.e1 14 20
drug
Starlix
DrugDDI.d249.s5.e2 84 97
drug
metformin 500 mg
DrugDDI.d249.s5.new.DISO.e3 127 139
DISO
Type 2 diabetes

interaction DrugDDI.d249.s5.e0 DrugDDI.d249.s5.e1 false
interaction DrugDDI.d249.s5.e0 DrugDDI.d249.s5.e2 false
interaction DrugDDI.d249.s5.e1 DrugDDI.d249.s5.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s6
Digoxin : When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.

DrugDDI.d249.s6.e0 0 6
drug
Digoxin
DrugDDI.d249.s6.e1 12 18
drug
Starlix
DrugDDI.d249.s6.e2 84 90
drug
digoxin

interaction DrugDDI.d249.s6.e0 DrugDDI.d249.s6.e1 false
interaction DrugDDI.d249.s6.e0 DrugDDI.d249.s6.e2 false
interaction DrugDDI.d249.s6.e1 DrugDDI.d249.s6.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s7
Warfarin : When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.

DrugDDI.d249.s7.e0 0 7
drug
Warfarin
DrugDDI.d249.s7.e1 44 50
drug
Starlix
DrugDDI.d249.s7.e2 123 130
drug
warfarin

interaction DrugDDI.d249.s7.e0 DrugDDI.d249.s7.e1 false
interaction DrugDDI.d249.s7.e0 DrugDDI.d249.s7.e2 false
interaction DrugDDI.d249.s7.e1 DrugDDI.d249.s7.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s9
Diclofenac : Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.

DrugDDI.d249.s9.e0 0 9
drug
Diclofenac
DrugDDI.d249.s9.e1 49 55
drug
Starlix
DrugDDI.d249.s9.e2 96 105
drug
diclofenac

interaction DrugDDI.d249.s9.e0 DrugDDI.d249.s9.e1 false
interaction DrugDDI.d249.s9.e0 DrugDDI.d249.s9.e2 false
interaction DrugDDI.d249.s9.e1 DrugDDI.d249.s9.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s10
Nateglinide is highly bound to plasma proteins (98%), mainly albumin .

DrugDDI.d249.s10.e0 0 10
drug
Nateglinide
DrugDDI.d249.s10.e1 26 39
drug
plasma proteins
DrugDDI.d249.s10.e2 52 58
drug
albumin

interaction DrugDDI.d249.s10.e0 DrugDDI.d249.s10.e1 false
interaction DrugDDI.d249.s10.e0 DrugDDI.d249.s10.e2 false
interaction DrugDDI.d249.s10.e1 DrugDDI.d249.s10.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s11
In vitro displacement studies with highly protein -bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding.

DrugDDI.d249.s11.e0 36 42
drug
protein
DrugDDI.d249.s11.e1 60 69
drug
furosemide
DrugDDI.d249.s11.e2 71 81
drug
propranolol
DrugDDI.d249.s11.e3 83 91
drug
captopril
DrugDDI.d249.s11.e4 93 103
drug
nicardipine
DrugDDI.d249.s11.e5 105 115
drug
pravastatin
DrugDDI.d249.s11.e6 117 125
drug
glyburide
DrugDDI.d249.s11.e7 127 134
drug
warfarin
DrugDDI.d249.s11.e8 136 144
drug
phenytoin
DrugDDI.d249.s11.e9 146 164
drug
acetylsalicylic acid
DrugDDI.d249.s11.e10 166 176
drug
tolbutamide
DrugDDI.d249.s11.e11 181 189
drug
metformin
DrugDDI.d249.s11.e12 220 230
drug
nateglinide

interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e1 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e2 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e3 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e4 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e5 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e2 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e3 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e4 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e5 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e3 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e4 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e5 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e4 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e5 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e5 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e7 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e7 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e7 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e7 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e7 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e8 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e8 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e8 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e8 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e9 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e9 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e9 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e10 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e10 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e11 DrugDDI.d249.s11.e12 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s12
Similarly, nateglinide had no influence on the serum protein binding of propranolol , glyburide , nicardipine , warfarin , phenytoin , acetylsalicylic acid , and tolbutamide in vitro .

DrugDDI.d249.s12.e0 10 20
drug
nateglinide
DrugDDI.d249.s12.e1 45 58
drug
protein binding
DrugDDI.d249.s12.e2 61 71
drug
propranolol
DrugDDI.d249.s12.e3 73 81
drug
glyburide
DrugDDI.d249.s12.e4 83 93
drug
nicardipine
DrugDDI.d249.s12.e5 95 102
drug
warfarin
DrugDDI.d249.s12.e6 104 112
drug
phenytoin
DrugDDI.d249.s12.e7 114 132
drug
acetylsalicylic acid
DrugDDI.d249.s12.e8 137 147
drug
tolbutamide

interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e1 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e2 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e3 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e4 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e5 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e2 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e3 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e4 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e5 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e3 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e4 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e5 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e3 DrugDDI.d249.s12.e4 false
interaction DrugDDI.d249.s12.e3 DrugDDI.d249.s12.e5 false
interaction DrugDDI.d249.s12.e3 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e3 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e3 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e4 DrugDDI.d249.s12.e5 false
interaction DrugDDI.d249.s12.e4 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e4 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e4 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e5 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e5 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e5 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e6 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e6 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e7 DrugDDI.d249.s12.e8 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s14
Certain drugs , including nonsteroidal anti-inflammatory agents ( NSAIDs ), salicylates , monoamine oxidase inhibitors , and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs .

DrugDDI.d249.s14.e0 7 11
drug
drugs
DrugDDI.d249.s14.e1 22 56
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d249.s14.e2 58 63
drug
NSAIDs
DrugDDI.d249.s14.e3 66 76
drug
salicylates
DrugDDI.d249.s14.e4 78 103
drug
monoamine oxidase inhibitors
DrugDDI.d249.s14.e5 108 150
drug
non-selective beta-adrenergic-blocking agents
DrugDDI.d249.s14.e6 167 184
drug
hypoglycemic action
DrugDDI.d249.s14.e7 187 193
drug
Starlix
DrugDDI.d249.s14.e8 206 222
drug
antidiabetic drugs

interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e1 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e2 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e3 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e4 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e5 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e2 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e3 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e4 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e5 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e3 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e4 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e5 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e3 DrugDDI.d249.s14.e4 false
interaction DrugDDI.d249.s14.e3 DrugDDI.d249.s14.e5 false
interaction DrugDDI.d249.s14.e3 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e3 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e3 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e4 DrugDDI.d249.s14.e5 false
interaction DrugDDI.d249.s14.e4 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e4 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e4 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e5 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e5 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e5 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e6 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e6 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e7 DrugDDI.d249.s14.e8 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s15
Certain drugs including thiazides , corticosteroids , thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs .

DrugDDI.d249.s15.e0 7 11
drug
drugs
DrugDDI.d249.s15.e1 21 29
drug
thiazides
DrugDDI.d249.s15.e2 31 45
drug
corticosteroids
DrugDDI.d249.s15.e3 47 53
drug
thyroid
DrugDDI.d249.s15.e4 66 81
drug
sympathomimetics
DrugDDI.d249.s15.e5 94 111
drug
hypoglycemic action
DrugDDI.d249.s15.e6 114 120
drug
Starlix
DrugDDI.d249.s15.e7 133 149
drug
antidiabetic drugs

interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e1 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e2 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e3 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e4 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e5 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e2 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e3 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e4 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e5 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e2 DrugDDI.d249.s15.e3 false
interaction DrugDDI.d249.s15.e2 DrugDDI.d249.s15.e4 false
interaction DrugDDI.d249.s15.e2 DrugDDI.d249.s15.e5 false
interaction DrugDDI.d249.s15.e2 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e2 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e3 DrugDDI.d249.s15.e4 false
interaction DrugDDI.d249.s15.e3 DrugDDI.d249.s15.e5 false
interaction DrugDDI.d249.s15.e3 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e3 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e4 DrugDDI.d249.s15.e5 false
interaction DrugDDI.d249.s15.e4 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e4 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e5 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e5 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e6 DrugDDI.d249.s15.e7 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s16
When these drugs are administered to or withdrawn from patients receiving Starlix , the patient should be observed closely for changes in glycemic control.

DrugDDI.d249.s16.e0 9 13
drug
drugs
DrugDDI.d249.s16.e1 63 69
drug
Starlix

interaction DrugDDI.d249.s16.e0 DrugDDI.d249.s16.e1 false

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s0
In clinical studies, Tilade has been co-administered with other anti-asthma medications , including inhaled and oral bronchodilators , and inhaled corticosteroids , with no evidence of increased frequency of adverse events or laboratory abnormalities.

DrugDDI.d312.s0.e0 18 23
drug
Tilade
DrugDDI.d312.s0.e1 55 76
drug
anti-asthma medications
DrugDDI.d312.s0.e2 101 115
drug
bronchodilators
DrugDDI.d312.s0.e3 127 141
drug
corticosteroids

interaction DrugDDI.d312.s0.e0 DrugDDI.d312.s0.e1 false
interaction DrugDDI.d312.s0.e0 DrugDDI.d312.s0.e2 false
interaction DrugDDI.d312.s0.e0 DrugDDI.d312.s0.e3 false
interaction DrugDDI.d312.s0.e1 DrugDDI.d312.s0.e2 false
interaction DrugDDI.d312.s0.e1 DrugDDI.d312.s0.e3 false
interaction DrugDDI.d312.s0.e2 DrugDDI.d312.s0.e3 false

Abstract Id: DrugDDI.d336
Sentence Id: DrugDDI.d336.s0
Caution should be taken in concurrent or serial use of other neurotoxic and/ or nephrotoxic drugs because of possible enhancement of the nephrotoxicity and/or ototoxicity of neomycin .

DrugDDI.d336.s0.e0 77 81
drug
drugs
DrugDDI.d336.s0.new.DISO.e2 115 128
DISO
nephrotoxicity
DrugDDI.d336.s0.e1 148 155
drug
neomycin

interaction DrugDDI.d336.s0.e0 DrugDDI.d336.s0.e1 true

Abstract Id: DrugDDI.d336
Sentence Id: DrugDDI.d336.s1
Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin@s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate@s neuromuscular blocking effects.

DrugDDI.d336.s1.e0 54 68
drug
aminoglycosides
DrugDDI.d336.s1.e1 72 81
drug
polymyxins
DrugDDI.d336.s1.new.DISO.e3 113 126
DISO
nephrotoxicity
DrugDDI.d336.s1.e2 157 164
drug
neomycin

interaction DrugDDI.d336.s1.e0 DrugDDI.d336.s1.e1 true
interaction DrugDDI.d336.s1.e0 DrugDDI.d336.s1.e2 false
interaction DrugDDI.d336.s1.e1 DrugDDI.d336.s1.e2 false

Abstract Id: DrugDDI.d336
Sentence Id: DrugDDI.d336.s2
Oral neomycin inhibits the gastrointestinal absorption of penicillin V , oral vitamin B-12 , methotrexate and 5-fluorouracil .

DrugDDI.d336.s2.e0 0 11
drug
Oral neomycin
DrugDDI.d336.s2.e1 51 61
drug
penicillin V
DrugDDI.d336.s2.e2 63 77
drug
oral vitamin B-12
DrugDDI.d336.s2.e3 79 90
drug
methotrexate
DrugDDI.d336.s2.e4 94 107
drug
5-fluorouracil

interaction DrugDDI.d336.s2.e0 DrugDDI.d336.s2.e1 true
interaction DrugDDI.d336.s2.e0 DrugDDI.d336.s2.e2 false
interaction DrugDDI.d336.s2.e0 DrugDDI.d336.s2.e3 true
interaction DrugDDI.d336.s2.e0 DrugDDI.d336.s2.e4 false
interaction DrugDDI.d336.s2.e1 DrugDDI.d336.s2.e2 false
interaction DrugDDI.d336.s2.e1 DrugDDI.d336.s2.e3 false
interaction DrugDDI.d336.s2.e1 DrugDDI.d336.s2.e4 false
interaction DrugDDI.d336.s2.e2 DrugDDI.d336.s2.e3 false
interaction DrugDDI.d336.s2.e2 DrugDDI.d336.s2.e4 false
interaction DrugDDI.d336.s2.e3 DrugDDI.d336.s2.e4 false

Abstract Id: DrugDDI.d336
Sentence Id: DrugDDI.d336.s3
The gastrointestinal absorption of digoxin also appears to be inhibited.

DrugDDI.d336.s3.e0 31 37
drug
digoxin



Abstract Id: DrugDDI.d336
Sentence Id: DrugDDI.d336.s5
Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.

DrugDDI.d336.s5.e0 0 11
drug
Oral neomycin
DrugDDI.d336.s5.e1 40 47
drug
coumarin
DrugDDI.d336.s5.e2 50 63
drug
anticoagulants

interaction DrugDDI.d336.s5.e0 DrugDDI.d336.s5.e1 true
interaction DrugDDI.d336.s5.e0 DrugDDI.d336.s5.e2 false
interaction DrugDDI.d336.s5.e1 DrugDDI.d336.s5.e2 false

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s0
Beta-adrenergic Blocking Agents : Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agent s is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.

DrugDDI.d266.s0.e0 0 28
drug
Beta-adrenergic Blocking Agents
DrugDDI.d266.s0.e1 128 137
drug
nifedipine
DrugDDI.d266.s0.e2 141 158
drug
beta-blocking agent
DrugDDI.d266.s0.new.DISO.e3 280 301
DISO
congestive heart failure

interaction DrugDDI.d266.s0.e0 DrugDDI.d266.s0.e1 false
interaction DrugDDI.d266.s0.e0 DrugDDI.d266.s0.e2 false
interaction DrugDDI.d266.s0.e1 DrugDDI.d266.s0.e2 true

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s1
Long Acting Nitrates : Nifedipine may be safely co-administered with nitrates , but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.

DrugDDI.d266.s1.e0 10 17
drug
Nitrates
DrugDDI.d266.s1.e1 19 28
drug
Nifedipine
DrugDDI.d266.s1.e2 59 66
drug
nitrates

interaction DrugDDI.d266.s1.e0 DrugDDI.d266.s1.e1 false
interaction DrugDDI.d266.s1.e0 DrugDDI.d266.s1.e2 false
interaction DrugDDI.d266.s1.e1 DrugDDI.d266.s1.e2 false

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s2
Digitalis : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.

DrugDDI.d266.s2.e0 0 8
drug
Digitalis
DrugDDI.d266.s2.e1 141 147
drug
digoxin
DrugDDI.d266.s2.e2 151 160
drug
nifedipine
DrugDDI.d266.s2.e3 246 255
drug
nifedipine

interaction DrugDDI.d266.s2.e0 DrugDDI.d266.s2.e1 false
interaction DrugDDI.d266.s2.e0 DrugDDI.d266.s2.e2 false
interaction DrugDDI.d266.s2.e0 DrugDDI.d266.s2.e3 false
interaction DrugDDI.d266.s2.e1 DrugDDI.d266.s2.e2 true
interaction DrugDDI.d266.s2.e1 DrugDDI.d266.s2.e3 false
interaction DrugDDI.d266.s2.e2 DrugDDI.d266.s2.e3 false

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s3
Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.

DrugDDI.d266.s3.e0 39 48
drug
nifedipine
DrugDDI.d266.s3.e1 53 59
drug
digoxin

interaction DrugDDI.d266.s3.e0 DrugDDI.d266.s3.e1 true

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s7
Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.

DrugDDI.d266.s7.e0 153 162
drug
nifedipine



Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s8
Quinidine : Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine ).

DrugDDI.d266.s8.e0 0 8
drug
Quinidine
DrugDDI.d266.s8.e1 81 89
drug
quinidine
DrugDDI.d266.s8.e2 93 102
drug
nifedipine
DrugDDI.d266.s8.e3 131 139
drug
quinidine

interaction DrugDDI.d266.s8.e0 DrugDDI.d266.s8.e1 false
interaction DrugDDI.d266.s8.e0 DrugDDI.d266.s8.e2 false
interaction DrugDDI.d266.s8.e0 DrugDDI.d266.s8.e3 false
interaction DrugDDI.d266.s8.e1 DrugDDI.d266.s8.e2 true
interaction DrugDDI.d266.s8.e1 DrugDDI.d266.s8.e3 false
interaction DrugDDI.d266.s8.e2 DrugDDI.d266.s8.e3 false

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s9
Coumarin Anticoagulant s: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulant s to whom nifedipine was administered.

DrugDDI.d266.s9.e0 0 20
drug
Coumarin Anticoagulant
DrugDDI.d266.s9.e1 89 109
drug
coumarin anticoagulant
DrugDDI.d266.s9.e2 117 126
drug
nifedipine

interaction DrugDDI.d266.s9.e0 DrugDDI.d266.s9.e1 false
interaction DrugDDI.d266.s9.e0 DrugDDI.d266.s9.e2 false
interaction DrugDDI.d266.s9.e1 DrugDDI.d266.s9.e2 true

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s10
However, the relationship to nifedipine therapy is uncertain.

DrugDDI.d266.s10.e0 25 34
drug
nifedipine



Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s11
Cimetidine : A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.

DrugDDI.d266.s11.e0 0 9
drug
Cimetidine
DrugDDI.d266.s11.e1 71 80
drug
nifedipine
DrugDDI.d266.s11.e2 145 154
drug
cimetidine
DrugDDI.d266.s11.e3 172 181
drug
nifedipine

interaction DrugDDI.d266.s11.e0 DrugDDI.d266.s11.e1 false
interaction DrugDDI.d266.s11.e0 DrugDDI.d266.s11.e2 false
interaction DrugDDI.d266.s11.e0 DrugDDI.d266.s11.e3 false
interaction DrugDDI.d266.s11.e1 DrugDDI.d266.s11.e2 false
interaction DrugDDI.d266.s11.e1 DrugDDI.d266.s11.e3 false
interaction DrugDDI.d266.s11.e2 DrugDDI.d266.s11.e3 true

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s12
Ranitidine produced smaller, non-significant increases.

DrugDDI.d266.s12.e0 0 9
drug
Ranitidine



Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s13
The effect may be mediated by the known inhibition of cimetidine on hepatic cytochrome P-450 , the enzyme system probably responsible for the first-pass metabolism of nifedipine .

DrugDDI.d266.s13.e0 44 53
drug
cimetidine
DrugDDI.d266.s13.e1 63 77
drug
cytochrome P-450
DrugDDI.d266.s13.e2 141 150
drug
nifedipine

interaction DrugDDI.d266.s13.e0 DrugDDI.d266.s13.e1 false
interaction DrugDDI.d266.s13.e0 DrugDDI.d266.s13.e2 true
interaction DrugDDI.d266.s13.e1 DrugDDI.d266.s13.e2 false

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s14
If nifedipine therapy is initiated in a patient currently receiving cimetidine , cautious titration is advised.

DrugDDI.d266.s14.e0 2 11
drug
nifedipine
DrugDDI.d266.s14.e1 58 67
drug
cimetidine

interaction DrugDDI.d266.s14.e0 DrugDDI.d266.s14.e1 true

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s0
A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.

DrugDDI.d234.s0.e0 30 40
drug
nisoldipine
DrugDDI.d234.s0.e1 83 97
drug
cimetidine 400 mg

interaction DrugDDI.d234.s0.e0 DrugDDI.d234.s0.e1 true

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s1
Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %).

DrugDDI.d234.s1.e0 0 14
drug
Ranitidine 150 mg
DrugDDI.d234.s1.e1 56 66
drug
nisoldipine

interaction DrugDDI.d234.s1.e0 DrugDDI.d234.s1.e1 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s2
No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.

DrugDDI.d234.s2.e0 32 60
drug
histamine H2 receptor antagonist



Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s3
Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.

DrugDDI.d234.s3.e0 18 26
drug
phenytoin
DrugDDI.d234.s3.e1 35 39
drug
SULAR
DrugDDI.d234.s3.e2 76 86
drug
nisoldipine

interaction DrugDDI.d234.s3.e0 DrugDDI.d234.s3.e1 true
interaction DrugDDI.d234.s3.e0 DrugDDI.d234.s3.e2 false
interaction DrugDDI.d234.s3.e1 DrugDDI.d234.s3.e2 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s4
Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.

DrugDDI.d234.s4.e0 18 22
drug
SULAR
DrugDDI.d234.s4.e1 27 35
drug
phenytoin
DrugDDI.d234.s4.e2 46 51
drug
CYP3A4
DrugDDI.d234.s4.e3 88 103
drug
antihypertensive

interaction DrugDDI.d234.s4.e0 DrugDDI.d234.s4.e1 true
interaction DrugDDI.d234.s4.e0 DrugDDI.d234.s4.e2 false
interaction DrugDDI.d234.s4.e0 DrugDDI.d234.s4.e3 false
interaction DrugDDI.d234.s4.e1 DrugDDI.d234.s4.e2 false
interaction DrugDDI.d234.s4.e1 DrugDDI.d234.s4.e3 false
interaction DrugDDI.d234.s4.e2 DrugDDI.d234.s4.e3 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s5
Pharmacokinetic interactions between nisoldipine and beta-blockers ( atenolol , propranolol ) were variable and not significant.

DrugDDI.d234.s5.e0 34 44
drug
nisoldipine
DrugDDI.d234.s5.e1 48 60
drug
beta-blockers
DrugDDI.d234.s5.e2 62 69
drug
atenolol
DrugDDI.d234.s5.e3 71 81
drug
propranolol

interaction DrugDDI.d234.s5.e0 DrugDDI.d234.s5.e1 true
interaction DrugDDI.d234.s5.e0 DrugDDI.d234.s5.e2 false
interaction DrugDDI.d234.s5.e0 DrugDDI.d234.s5.e3 true
interaction DrugDDI.d234.s5.e1 DrugDDI.d234.s5.e2 false
interaction DrugDDI.d234.s5.e1 DrugDDI.d234.s5.e3 false
interaction DrugDDI.d234.s5.e2 DrugDDI.d234.s5.e3 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s6
Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine .

DrugDDI.d234.s6.e0 0 10
drug
Propranolol
DrugDDI.d234.s6.e1 82 92
drug
nisoldipine

interaction DrugDDI.d234.s6.e0 DrugDDI.d234.s6.e1 true

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s7
The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.

DrugDDI.d234.s7.e0 24 28
drug
SULAR
DrugDDI.d234.s7.e1 58 65
drug
atenolol
DrugDDI.d234.s7.e2 89 104
drug
antihypertensive

interaction DrugDDI.d234.s7.e0 DrugDDI.d234.s7.e1 true
interaction DrugDDI.d234.s7.e0 DrugDDI.d234.s7.e2 false
interaction DrugDDI.d234.s7.e1 DrugDDI.d234.s7.e2 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s8
Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.

DrugDDI.d234.s8.e0 0 8
drug
Quinidine
DrugDDI.d234.s8.e1 16 18
drug
bid
DrugDDI.d234.s8.e2 53 63
drug
nisoldipine

interaction DrugDDI.d234.s8.e0 DrugDDI.d234.s8.e1 false
interaction DrugDDI.d234.s8.e0 DrugDDI.d234.s8.e2 true
interaction DrugDDI.d234.s8.e1 DrugDDI.d234.s8.e2 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s9
The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.

DrugDDI.d234.s9.e0 51 61
drug
nisoldipine



Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s11
No significant interactions were found between nisoldipine and warfarin or digoxin .

DrugDDI.d234.s11.e0 41 51
drug
nisoldipine
DrugDDI.d234.s11.e1 55 62
drug
warfarin
DrugDDI.d234.s11.e2 65 71
drug
digoxin

interaction DrugDDI.d234.s11.e0 DrugDDI.d234.s11.e1 false
interaction DrugDDI.d234.s11.e0 DrugDDI.d234.s11.e2 false
interaction DrugDDI.d234.s11.e1 DrugDDI.d234.s11.e2 false

Abstract Id: DrugDDI.d306
Sentence Id: DrugDDI.d306.s0
Tizoxanide is highly bound to plasma protein ( 99.9%).

DrugDDI.d306.s0.e0 0 9
drug
Tizoxanide
DrugDDI.d306.s0.e1 25 37
drug
plasma protein

interaction DrugDDI.d306.s0.e0 DrugDDI.d306.s0.e1 true

Abstract Id: DrugDDI.d306
Sentence Id: DrugDDI.d306.s1
Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin ).

DrugDDI.d306.s1.e0 46 57
drug
nitazoxanide
DrugDDI.d306.s1.e1 180 187
drug
warfarin

interaction DrugDDI.d306.s1.e0 DrugDDI.d306.s1.e1 true

Abstract Id: DrugDDI.d306
Sentence Id: DrugDDI.d306.s2
In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes.

DrugDDI.d306.s2.e0 44 53
drug
tizoxanide
DrugDDI.d306.s2.e1 88 101
drug
cytochrome P450

interaction DrugDDI.d306.s2.e0 DrugDDI.d306.s2.e1 false

Abstract Id: DrugDDI.d306
Sentence Id: DrugDDI.d306.s3
Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.

DrugDDI.d306.s3.e0 115 126
drug
nitazoxanide
DrugDDI.d306.s3.e1 148 152
drug
drugs
DrugDDI.d306.s3.e2 188 201
drug
cytochrome P450

interaction DrugDDI.d306.s3.e0 DrugDDI.d306.s3.e1 false
interaction DrugDDI.d306.s3.e0 DrugDDI.d306.s3.e2 false
interaction DrugDDI.d306.s3.e1 DrugDDI.d306.s3.e2 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s0
Oxcarbazepine can inhibit CYP2C19 and induce CYP3A4 /5 with potentially important effects on plasma concentrations of other drugs .

DrugDDI.d20.s0.e0 0 12
drug
Oxcarbazepine
DrugDDI.d20.s0.e1 23 29
drug
CYP2C19
DrugDDI.d20.s0.e2 39 44
drug
CYP3A4
DrugDDI.d20.s0.e3 107 111
drug
drugs

interaction DrugDDI.d20.s0.e0 DrugDDI.d20.s0.e1 false
interaction DrugDDI.d20.s0.e0 DrugDDI.d20.s0.e2 false
interaction DrugDDI.d20.s0.e0 DrugDDI.d20.s0.e3 true
interaction DrugDDI.d20.s0.e1 DrugDDI.d20.s0.e2 false
interaction DrugDDI.d20.s0.e1 DrugDDI.d20.s0.e3 false
interaction DrugDDI.d20.s0.e2 DrugDDI.d20.s0.e3 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s1
In addition, several AED@s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.

DrugDDI.d20.s1.e0 30 43
drug
cytochrome P450
DrugDDI.d20.s1.e1 85 97
drug
oxcarbazepine

interaction DrugDDI.d20.s1.e0 DrugDDI.d20.s1.e1 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s2
Oxcarbazepine was evaluated in human liver microsomes to determine its capacity to inhibit the major cytochrome P450 enzymes responsible for the metabolism of other drugs .

DrugDDI.d20.s2.e0 0 12
drug
Oxcarbazepine
DrugDDI.d20.s2.e1 86 99
drug
cytochrome P450
DrugDDI.d20.s2.e2 141 145
drug
drugs

interaction DrugDDI.d20.s2.e0 DrugDDI.d20.s2.e1 false
interaction DrugDDI.d20.s2.e0 DrugDDI.d20.s2.e2 false
interaction DrugDDI.d20.s2.e1 DrugDDI.d20.s2.e2 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s3
Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite (MHD) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated ( CYP1A2 , CYP2A6 , CYP2C9 , CYP2D6 , CYP2E1 , CYP4A9 and CYP4A11 ) with the exception of CYP2C19 and CYP3A4 /5.

DrugDDI.d20.s3.e0 22 34
drug
oxcarbazepine
DrugDDI.d20.s3.e1 58 87
drug
active 10-monohydroxy metabolite
DrugDDI.d20.s3.e2 154 167
drug
cytochrome P450
DrugDDI.d20.s3.e3 185 190
drug
CYP1A2
DrugDDI.d20.s3.e4 192 197
drug
CYP2A6
DrugDDI.d20.s3.e5 199 204
drug
CYP2C9
DrugDDI.d20.s3.e6 206 211
drug
CYP2D6
DrugDDI.d20.s3.e7 213 218
drug
CYP2E1
DrugDDI.d20.s3.e8 229 235
drug
CYP4A11
DrugDDI.d20.s3.e9 255 261
drug
CYP2C19
DrugDDI.d20.s3.e10 265 270
drug
CYP3A4

interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e1 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e2 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e3 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e4 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e5 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e2 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e3 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e4 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e5 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e3 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e4 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e5 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e4 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e5 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e5 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e5 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e5 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e5 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e5 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e5 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e6 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e6 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e6 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e6 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e7 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e7 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e7 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e8 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e8 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e9 DrugDDI.d20.s3.e10 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s4
Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance.

DrugDDI.d20.s4.e0 20 22
drug
CYP



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s5
The inhibition of CYP-2C19 by OXC and MHD, however, is clinically relevant.

DrugDDI.d20.s5.e0 15 22
drug
CYP-2C19



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s6
In vitro, the UDP-glucuronyl transferase level was increased, indicating induction of this enzyme.

DrugDDI.d20.s6.e0 11 35
drug
UDP-glucuronyl transferase



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s7
Increases of 22% with MHD and 47% with oxcarbazepine were observed.

DrugDDI.d20.s7.e0 31 43
drug
oxcarbazepine



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s8
As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase , it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid , lamotrigine ).

DrugDDI.d20.s8.e0 56 80
drug
UDP-glucuronyl transferase
DrugDDI.d20.s8.e1 110 114
drug
drugs
DrugDDI.d20.s8.e2 158 182
drug
UDP-glucuronyl transferase
DrugDDI.d20.s8.e3 189 200
drug
valproic acid
DrugDDI.d20.s8.e4 202 212
drug
lamotrigine

interaction DrugDDI.d20.s8.e0 DrugDDI.d20.s8.e1 false
interaction DrugDDI.d20.s8.e0 DrugDDI.d20.s8.e2 false
interaction DrugDDI.d20.s8.e0 DrugDDI.d20.s8.e3 false
interaction DrugDDI.d20.s8.e0 DrugDDI.d20.s8.e4 false
interaction DrugDDI.d20.s8.e1 DrugDDI.d20.s8.e2 false
interaction DrugDDI.d20.s8.e1 DrugDDI.d20.s8.e3 false
interaction DrugDDI.d20.s8.e1 DrugDDI.d20.s8.e4 false
interaction DrugDDI.d20.s8.e2 DrugDDI.d20.s8.e3 false
interaction DrugDDI.d20.s8.e2 DrugDDI.d20.s8.e4 false
interaction DrugDDI.d20.s8.e3 DrugDDI.d20.s8.e4 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s9
In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family ( CYP3A4 and CYP3A5 ) responsible for the metabolism of dihydropyridine calcium antagonist s and oral contraceptives , resulting in a lower plasma concentration of these drugs .

DrugDDI.d20.s9.e0 11 23
drug
oxcarbazepine
DrugDDI.d20.s9.e1 50 65
drug
cytochrome P450 3A
DrugDDI.d20.s9.e2 73 78
drug
CYP3A4
DrugDDI.d20.s9.e3 82 87
drug
CYP3A5
DrugDDI.d20.s9.e4 133 149
drug
calcium antagonist
DrugDDI.d20.s9.e5 154 171
drug
oral contraceptives
DrugDDI.d20.s9.e6 216 220
drug
drugs

interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e1 false
interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e2 false
interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e3 false
interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e4 true
interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e5 true
interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e6 false
interaction DrugDDI.d20.s9.e1 DrugDDI.d20.s9.e2 false
interaction DrugDDI.d20.s9.e1 DrugDDI.d20.s9.e3 false
interaction DrugDDI.d20.s9.e1 DrugDDI.d20.s9.e4 false
interaction DrugDDI.d20.s9.e1 DrugDDI.d20.s9.e5 false
interaction DrugDDI.d20.s9.e1 DrugDDI.d20.s9.e6 false
interaction DrugDDI.d20.s9.e2 DrugDDI.d20.s9.e3 false
interaction DrugDDI.d20.s9.e2 DrugDDI.d20.s9.e4 false
interaction DrugDDI.d20.s9.e2 DrugDDI.d20.s9.e5 false
interaction DrugDDI.d20.s9.e2 DrugDDI.d20.s9.e6 false
interaction DrugDDI.d20.s9.e3 DrugDDI.d20.s9.e4 false
interaction DrugDDI.d20.s9.e3 DrugDDI.d20.s9.e5 false
interaction DrugDDI.d20.s9.e3 DrugDDI.d20.s9.e6 false
interaction DrugDDI.d20.s9.e4 DrugDDI.d20.s9.e5 false
interaction DrugDDI.d20.s9.e4 DrugDDI.d20.s9.e6 false
interaction DrugDDI.d20.s9.e5 DrugDDI.d20.s9.e6 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s10
As binding of MHD to plasma proteins is low (40%), clinically significant interactions with other drugs through competition for protein binding sites are unlikely.

DrugDDI.d20.s10.e0 16 29
drug
plasma proteins
DrugDDI.d20.s10.e1 83 87
drug
drugs
DrugDDI.d20.s10.e2 109 115
drug
protein

interaction DrugDDI.d20.s10.e0 DrugDDI.d20.s10.e1 false
interaction DrugDDI.d20.s10.e0 DrugDDI.d20.s10.e2 false
interaction DrugDDI.d20.s10.e1 DrugDDI.d20.s10.e2 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s11
Antiepileptic drugs Potential interactions between Trileptal and other AEDs were assessed in clinical studies.

DrugDDI.d20.s11.e0 0 17
drug
Antiepileptic drugs
DrugDDI.d20.s11.e1 46 54
drug
Trileptal

interaction DrugDDI.d20.s11.e0 DrugDDI.d20.s11.e1 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s12
The effect of these interactions on mean AUCs and Cmin are summarized in Table 2: Table 2: Summary of AED interactions with Trileptal .

DrugDDI.d20.s12.e0 102 110
drug
Trileptal



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s15
Trileptal dose (mg/day) .

DrugDDI.d20.s15.e0 0 8
drug
Trileptal



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s16
Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval) .

DrugDDI.d20.s16.e0 11 19
drug
Trileptal



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s18
Carbamazepine .

DrugDDI.d20.s18.e0 0 12
drug
Carbamazepine



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s22
Phenobarbital .

DrugDDI.d20.s22.e0 0 12
drug
Phenobarbital



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s26
Phenytoin .

DrugDDI.d20.s26.e0 0 8
drug
Phenytoin



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s31
Valproic acid .

DrugDDI.d20.s31.e0 0 11
drug
Valproic acid



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s35
1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.

DrugDDI.d20.s35.e0 75 83
drug
Trileptal
DrugDDI.d20.s35.e1 113 121
drug
phenytoin
DrugDDI.d20.s35.e2 145 153
drug
Trileptal

interaction DrugDDI.d20.s35.e0 DrugDDI.d20.s35.e1 false
interaction DrugDDI.d20.s35.e0 DrugDDI.d20.s35.e2 false
interaction DrugDDI.d20.s35.e1 DrugDDI.d20.s35.e2 true

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s36
Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.

DrugDDI.d20.s36.e0 26 34
drug
Trileptal
DrugDDI.d20.s36.e1 100 108
drug
phenytoin

interaction DrugDDI.d20.s36.e0 DrugDDI.d20.s36.e1 true

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s37
The increase of phenobarbital level, however, is small (15%) when given with Trileptal .

DrugDDI.d20.s37.e0 65 73
drug
Trileptal



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s38
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine , phenytoin and phenobarbital ) have been shown to decrease the plasma levels of MHD (29-40%).

DrugDDI.d20.s38.e0 16 29
drug
cytochrome P450
DrugDDI.d20.s38.e1 42 54
drug
carbamazepine
DrugDDI.d20.s38.e2 56 64
drug
phenytoin
DrugDDI.d20.s38.e3 68 80
drug
phenobarbital

interaction DrugDDI.d20.s38.e0 DrugDDI.d20.s38.e1 false
interaction DrugDDI.d20.s38.e0 DrugDDI.d20.s38.e2 false
interaction DrugDDI.d20.s38.e0 DrugDDI.d20.s38.e3 false
interaction DrugDDI.d20.s38.e1 DrugDDI.d20.s38.e2 false
interaction DrugDDI.d20.s38.e1 DrugDDI.d20.s38.e3 false
interaction DrugDDI.d20.s38.e2 DrugDDI.d20.s38.e3 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s39
No autoinduction has been observed with Trileptal .

DrugDDI.d20.s39.e0 34 42
drug
Trileptal



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s40
Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).

DrugDDI.d20.s40.e0 41 49
drug
Trileptal
DrugDDI.d20.s40.e1 56 72
drug
oral contraceptive
DrugDDI.d20.s40.e2 146 161
drug
ethinylestradiol
DrugDDI.d20.s40.e3 169 182
drug
levonorgestrel

interaction DrugDDI.d20.s40.e0 DrugDDI.d20.s40.e1 true
interaction DrugDDI.d20.s40.e0 DrugDDI.d20.s40.e2 false
interaction DrugDDI.d20.s40.e0 DrugDDI.d20.s40.e3 false
interaction DrugDDI.d20.s40.e1 DrugDDI.d20.s40.e2 false
interaction DrugDDI.d20.s40.e1 DrugDDI.d20.s40.e3 false
interaction DrugDDI.d20.s40.e2 DrugDDI.d20.s40.e3 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s43
Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.

DrugDDI.d20.s43.e0 25 33
drug
Trileptal
DrugDDI.d20.s43.e1 46 59
drug
contraceptives
DrugDDI.d20.s43.e2 74 87
drug
contraceptives

interaction DrugDDI.d20.s43.e0 DrugDDI.d20.s43.e1 true
interaction DrugDDI.d20.s43.e0 DrugDDI.d20.s43.e2 false
interaction DrugDDI.d20.s43.e1 DrugDDI.d20.s43.e2 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s44
Studies with other oral or implant contraceptives have not been conducted.

DrugDDI.d20.s44.e0 29 42
drug
contraceptives



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s45
Calcium Antagonist s After repeated co-administration of Trileptal , the AUC of felodipine was lowered by 28% [90% CI: 20-33].

DrugDDI.d20.s45.e0 0 16
drug
Calcium Antagonist
DrugDDI.d20.s45.e1 50 58
drug
Trileptal
DrugDDI.d20.s45.e2 68 77
drug
felodipine

interaction DrugDDI.d20.s45.e0 DrugDDI.d20.s45.e1 false
interaction DrugDDI.d20.s45.e0 DrugDDI.d20.s45.e2 false
interaction DrugDDI.d20.s45.e1 DrugDDI.d20.s45.e2 true

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s46
Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD.

DrugDDI.d20.s46.e0 0 8
drug
Verapamil



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s47
Other drug interactions Cimetidine , erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.

DrugDDI.d20.s47.e0 21 30
drug
Cimetidine
DrugDDI.d20.s47.e1 32 43
drug
erythromycin
DrugDDI.d20.s47.e2 47 64
drug
dextropropoxyphene

interaction DrugDDI.d20.s47.e0 DrugDDI.d20.s47.e1 false
interaction DrugDDI.d20.s47.e0 DrugDDI.d20.s47.e2 false
interaction DrugDDI.d20.s47.e1 DrugDDI.d20.s47.e2 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s48
Results with warfarin wshow no evidence of interaction with either single or repeated doses of Trileptal .

DrugDDI.d20.s48.e0 11 18
drug
warfarin
DrugDDI.d20.s48.e1 80 88
drug
Trileptal

interaction DrugDDI.d20.s48.e0 DrugDDI.d20.s48.e1 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s0
In a Phase : I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin ).

DrugDDI.d480.s0.e0 37 41
drug
TAXOL
DrugDDI.d480.s0.e1 59 67
drug
cisplatin
DrugDDI.d480.s0.e2 143 147
drug
TAXOL
DrugDDI.d480.s0.e3 161 169
drug
cisplatin
DrugDDI.d480.s0.e4 202 206
drug
TAXOL
DrugDDI.d480.s0.e5 213 221
drug
cisplatin

interaction DrugDDI.d480.s0.e0 DrugDDI.d480.s0.e1 false
interaction DrugDDI.d480.s0.e0 DrugDDI.d480.s0.e2 false
interaction DrugDDI.d480.s0.e0 DrugDDI.d480.s0.e3 false
interaction DrugDDI.d480.s0.e0 DrugDDI.d480.s0.e4 false
interaction DrugDDI.d480.s0.e0 DrugDDI.d480.s0.e5 false
interaction DrugDDI.d480.s0.e1 DrugDDI.d480.s0.e2 false
interaction DrugDDI.d480.s0.e1 DrugDDI.d480.s0.e3 false
interaction DrugDDI.d480.s0.e1 DrugDDI.d480.s0.e4 false
interaction DrugDDI.d480.s0.e1 DrugDDI.d480.s0.e5 false
interaction DrugDDI.d480.s0.e2 DrugDDI.d480.s0.e3 false
interaction DrugDDI.d480.s0.e2 DrugDDI.d480.s0.e4 false
interaction DrugDDI.d480.s0.e2 DrugDDI.d480.s0.e5 false
interaction DrugDDI.d480.s0.e3 DrugDDI.d480.s0.e4 false
interaction DrugDDI.d480.s0.e3 DrugDDI.d480.s0.e5 false
interaction DrugDDI.d480.s0.e4 DrugDDI.d480.s0.e5 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s1
Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin .

DrugDDI.d480.s1.e0 59 68
drug
paclitaxel
DrugDDI.d480.s1.e1 100 104
drug
TAXOL
DrugDDI.d480.s1.e2 129 137
drug
cisplatin

interaction DrugDDI.d480.s1.e0 DrugDDI.d480.s1.e1 false
interaction DrugDDI.d480.s1.e0 DrugDDI.d480.s1.e2 false
interaction DrugDDI.d480.s1.e1 DrugDDI.d480.s1.e2 true

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s2
The metabolism of TAXOL is catalyzed by cytochrome P450 isoen-zymes CYP2C8 and CYP3A4 .

DrugDDI.d480.s2.e0 15 19
drug
TAXOL
DrugDDI.d480.s2.e1 33 46
drug
cytochrome P450
DrugDDI.d480.s2.e2 67 72
drug
CYP3A4

interaction DrugDDI.d480.s2.e0 DrugDDI.d480.s2.e1 true
interaction DrugDDI.d480.s2.e0 DrugDDI.d480.s2.e2 true
interaction DrugDDI.d480.s2.e1 DrugDDI.d480.s2.e2 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s3
In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4 .

DrugDDI.d480.s3.e0 92 96
drug
TAXOL
DrugDDI.d480.s3.e1 146 159
drug
cytochrome P450
DrugDDI.d480.s3.e2 179 184
drug
CYP3A4

interaction DrugDDI.d480.s3.e0 DrugDDI.d480.s3.e1 true
interaction DrugDDI.d480.s3.e0 DrugDDI.d480.s3.e2 true
interaction DrugDDI.d480.s3.e1 DrugDDI.d480.s3.e2 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s4
Potential interactions between TAXOL , a substrate of CYP3A4 , and protease inhibitors ( ritonavir , saquinavir , indinavir , and nelfinavir ), which are substrates and/or inhibitors of CYP3A4 , have not been evaluated in clinical trials.

DrugDDI.d480.s4.e0 28 32
drug
TAXOL
DrugDDI.d480.s4.e1 46 51
drug
CYP3A4
DrugDDI.d480.s4.e2 56 73
drug
protease inhibitors
DrugDDI.d480.s4.e3 75 83
drug
ritonavir
DrugDDI.d480.s4.e4 85 94
drug
saquinavir
DrugDDI.d480.s4.e5 96 104
drug
indinavir
DrugDDI.d480.s4.e6 109 118
drug
nelfinavir
DrugDDI.d480.s4.e7 157 162
drug
CYP3A4

interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e1 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e2 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e3 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e4 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e5 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e2 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e3 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e4 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e5 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e2 DrugDDI.d480.s4.e3 false
interaction DrugDDI.d480.s4.e2 DrugDDI.d480.s4.e4 false
interaction DrugDDI.d480.s4.e2 DrugDDI.d480.s4.e5 false
interaction DrugDDI.d480.s4.e2 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e2 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e3 DrugDDI.d480.s4.e4 false
interaction DrugDDI.d480.s4.e3 DrugDDI.d480.s4.e5 false
interaction DrugDDI.d480.s4.e3 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e3 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e4 DrugDDI.d480.s4.e5 false
interaction DrugDDI.d480.s4.e4 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e4 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e5 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e5 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e6 DrugDDI.d480.s4.e7 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s5
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.

DrugDDI.d480.s5.e0 47 57
drug
doxorubicin
DrugDDI.d480.s5.e1 65 80
drug
active metabolite
DrugDDI.d480.s5.e2 113 122
drug
paclitaxel
DrugDDI.d480.s5.e3 126 136
drug
doxorubicin

interaction DrugDDI.d480.s5.e0 DrugDDI.d480.s5.e1 false
interaction DrugDDI.d480.s5.e0 DrugDDI.d480.s5.e2 false
interaction DrugDDI.d480.s5.e0 DrugDDI.d480.s5.e3 false
interaction DrugDDI.d480.s5.e1 DrugDDI.d480.s5.e2 false
interaction DrugDDI.d480.s5.e1 DrugDDI.d480.s5.e3 false
interaction DrugDDI.d480.s5.e2 DrugDDI.d480.s5.e3 true

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s6
Hematology: TAXOL therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3.

DrugDDI.d480.s6.e0 11 15
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s7
In order to monitor the occurrence of myelotoxicity, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL .

DrugDDI.d480.s7.e0 130 134
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s8
Patients should not be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level 1500 cells/mm3 and platelets recover to a level 100,000 cells/mm3.

DrugDDI.d480.s8.e0 51 55
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s9
In the case of severe neutropenia ( 500 cells/mm3 for seven days or more) during a course of TAXOL therapy, a 20% reduction in dose for subsequent courses of therapy is recommended.

DrugDDI.d480.s9.new.DISO.e1 17 27
DISO
neutropenia
DrugDDI.d480.s9.e0 75 79
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s10
For patients with advanced HIV disease and poor-risk AIDS-related Kaposi@s sarcoma, TAXOL , at the recommended dose for this disease, can be initiated and repeated if the neutrophil count is at least 1000 cells/mm3.

DrugDDI.d480.s10.e0 23 25
drug
HIV
DrugDDI.d480.s10.new.DISO.e2 65 71
DISO
sarcoma
DrugDDI.d480.s10.e1 73 77
drug
TAXOL

interaction DrugDDI.d480.s10.e0 DrugDDI.d480.s10.e1 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s11
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor@ EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL .

DrugDDI.d480.s11.e0 115 125
drug
cyclosporin
DrugDDI.d480.s11.e1 152 161
drug
teniposide
DrugDDI.d480.s11.e2 208 212
drug
TAXOL

interaction DrugDDI.d480.s11.e0 DrugDDI.d480.s11.e1 false
interaction DrugDDI.d480.s11.e0 DrugDDI.d480.s11.e2 true
interaction DrugDDI.d480.s11.e1 DrugDDI.d480.s11.e2 true

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s12
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone ), diphen -hydramine and H2 antagonists (such as cimetidine or ranitidine ).

DrugDDI.d480.s12.e0 83 87
drug
TAXOL
DrugDDI.d480.s12.e1 112 126
drug
corticosteroids
DrugDDI.d480.s12.e2 134 146
drug
dexamethasone
DrugDDI.d480.s12.e3 149 154
drug
diphen
DrugDDI.d480.s12.e4 188 197
drug
cimetidine
DrugDDI.d480.s12.e5 200 209
drug
ranitidine

interaction DrugDDI.d480.s12.e0 DrugDDI.d480.s12.e1 false
interaction DrugDDI.d480.s12.e0 DrugDDI.d480.s12.e2 false
interaction DrugDDI.d480.s12.e0 DrugDDI.d480.s12.e3 false
interaction DrugDDI.d480.s12.e0 DrugDDI.d480.s12.e4 false
interaction DrugDDI.d480.s12.e0 DrugDDI.d480.s12.e5 false
interaction DrugDDI.d480.s12.e1 DrugDDI.d480.s12.e2 false
interaction DrugDDI.d480.s12.e1 DrugDDI.d480.s12.e3 false
interaction DrugDDI.d480.s12.e1 DrugDDI.d480.s12.e4 false
interaction DrugDDI.d480.s12.e1 DrugDDI.d480.s12.e5 false
interaction DrugDDI.d480.s12.e2 DrugDDI.d480.s12.e3 false
interaction DrugDDI.d480.s12.e2 DrugDDI.d480.s12.e4 false
interaction DrugDDI.d480.s12.e2 DrugDDI.d480.s12.e5 false
interaction DrugDDI.d480.s12.e3 DrugDDI.d480.s12.e4 false
interaction DrugDDI.d480.s12.e3 DrugDDI.d480.s12.e5 false
interaction DrugDDI.d480.s12.e4 DrugDDI.d480.s12.e5 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s14
However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators , angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy.

DrugDDI.d480.s14.e0 76 90
drug
bronchodilators
DrugDDI.d480.s14.e1 158 162
drug
TAXOL

interaction DrugDDI.d480.s14.e0 DrugDDI.d480.s14.e1 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s15
Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOL .

DrugDDI.d480.s15.e0 82 86
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s16
Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL , but generally do not require treatment.

DrugDDI.d480.s16.e0 92 96
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s17
Occasionally TAXOL infusions must be interrupted or discontinued because of initial or recurrent hypertension.

DrugDDI.d480.s17.e0 12 16
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s18
Frequent vital sign monitoring, particularly during the first hour of TAXOL infusion, is recommended.

DrugDDI.d480.s18.e0 60 64
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s20
Nervous System: Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and requires a dose reduction of 20% for all subsequentcourses of TAXOL .

DrugDDI.d480.s20.new.DISO.e1 37 56
DISO
peripheral neuropathy
DrugDDI.d480.s20.e0 168 172
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s21
TAXOL contains dehydrated alcohol USP , 396 mg/mL; .

DrugDDI.d480.s21.e0 0 4
drug
TAXOL
DrugDDI.d480.s21.e1 13 32
drug
dehydrated alcohol USP

interaction DrugDDI.d480.s21.e0 DrugDDI.d480.s21.e1 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s22
consideration should be given to possible CNS and other effects of alcohol .

DrugDDI.d480.s22.e0 56 62
drug
alcohol



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s23
Hepatic: There is limited evidence that the myelotoxicity of TAXOL may be exacerbated in patients with serum total bilirubin 2 times ULN.

DrugDDI.d480.s23.e0 52 56
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s24
Extreme caution should be exercised when administering TAXOL to such patients, with dose reduction as recommended in DOSAGE AND ADMINISTRATION, Table 17.

DrugDDI.d480.s24.e0 48 52
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s27
Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, ie, recall, has been reported rarely.

DrugDDI.d480.s27.e0 80 84
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s28
Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of TAXOL safety.

DrugDDI.d480.s28.new.DISO.e1 35 43
DISO
phlebitis
DrugDDI.d480.s28.new.DISO.e2 45 54
DISO
cellulitis
DrugDDI.d480.s28.new.DISO.e3 83 90
DISO
necrosis
DrugDDI.d480.s28.new.DISO.e4 95 102
DISO
fibrosis
DrugDDI.d480.s28.e0 154 158
drug
TAXOL



Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s0
Aminoglycosides : The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside .

DrugDDI.d235.s0.e0 0 14
drug
Aminoglycosides
DrugDDI.d235.s0.e1 27 38
drug
piperacillin
DrugDDI.d235.s0.e2 45 58
drug
aminoglycoside
DrugDDI.d235.s0.e3 105 118
drug
aminoglycoside

interaction DrugDDI.d235.s0.e0 DrugDDI.d235.s0.e1 false
interaction DrugDDI.d235.s0.e0 DrugDDI.d235.s0.e2 false
interaction DrugDDI.d235.s0.e0 DrugDDI.d235.s0.e3 false
interaction DrugDDI.d235.s0.e1 DrugDDI.d235.s0.e2 true
interaction DrugDDI.d235.s0.e1 DrugDDI.d235.s0.e3 false
interaction DrugDDI.d235.s0.e2 DrugDDI.d235.s0.e3 false

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s1
Vecuronium : When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium .

DrugDDI.d235.s1.e0 0 9
drug
Vecuronium
DrugDDI.d235.s1.e1 44 55
drug
piperacillin
DrugDDI.d235.s1.e2 118 127
drug
vecuronium

interaction DrugDDI.d235.s1.e0 DrugDDI.d235.s1.e1 false
interaction DrugDDI.d235.s1.e0 DrugDDI.d235.s1.e2 false
interaction DrugDDI.d235.s1.e1 DrugDDI.d235.s1.e2 true

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s2
Caution is indicated when piperacillin is used perioperatively.

DrugDDI.d235.s2.e0 22 33
drug
piperacillin



Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s3
In one controlled clinical study, the ureidopenicillins, including piperacillin , were reported to prolong the action of vecuronium .

DrugDDI.d235.s3.e0 59 70
drug
piperacillin
DrugDDI.d235.s3.e1 104 113
drug
vecuronium

interaction DrugDDI.d235.s3.e0 DrugDDI.d235.s3.e1 true

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s4
Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin .

DrugDDI.d235.s4.e0 93 123
drug
non-depolarizing muscle relaxants
DrugDDI.d235.s4.e1 155 166
drug
piperacillin

interaction DrugDDI.d235.s4.e0 DrugDDI.d235.s4.e1 true

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s5
Probenecid : The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.

DrugDDI.d235.s5.e0 0 9
drug
Probenecid
DrugDDI.d235.s5.e1 31 40
drug
probenecid
DrugDDI.d235.s5.e2 71 78
drug
PIPRACIL
DrugDDI.d235.s5.e3 99 110
drug
piperacillin

interaction DrugDDI.d235.s5.e0 DrugDDI.d235.s5.e1 false
interaction DrugDDI.d235.s5.e0 DrugDDI.d235.s5.e2 false
interaction DrugDDI.d235.s5.e0 DrugDDI.d235.s5.e3 false
interaction DrugDDI.d235.s5.e1 DrugDDI.d235.s5.e2 true
interaction DrugDDI.d235.s5.e1 DrugDDI.d235.s5.e3 false
interaction DrugDDI.d235.s5.e2 DrugDDI.d235.s5.e3 false

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s6
Anticoagulants Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin , oral anticoagulants , or other drugs that may affect the blood coagulation system or the thrombocyte function.

DrugDDI.d235.s6.e0 0 13
drug
Anticoagulants
DrugDDI.d235.s6.e1 129 135
drug
heparin
DrugDDI.d235.s6.e2 137 154
drug
oral anticoagulants
DrugDDI.d235.s6.e3 163 167
drug
drugs

interaction DrugDDI.d235.s6.e0 DrugDDI.d235.s6.e1 false
interaction DrugDDI.d235.s6.e0 DrugDDI.d235.s6.e2 false
interaction DrugDDI.d235.s6.e0 DrugDDI.d235.s6.e3 false
interaction DrugDDI.d235.s6.e1 DrugDDI.d235.s6.e2 false
interaction DrugDDI.d235.s6.e1 DrugDDI.d235.s6.e3 false
interaction DrugDDI.d235.s6.e2 DrugDDI.d235.s6.e3 false

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s7
Methotrexate Piperacillin sodium may reduce the excretion of methotrexate .

DrugDDI.d235.s7.e0 0 23
drug
Methotrexate Piperacillin
DrugDDI.d235.s7.e1 53 64
drug
methotrexate

interaction DrugDDI.d235.s7.e0 DrugDDI.d235.s7.e1 true

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s8
Therefore, serum levels of methotrexate should be monitored in patients to avoid drug toxicity.

DrugDDI.d235.s8.e0 23 34
drug
methotrexate
DrugDDI.d235.s8.new.DISO.e1 69 80
DISO
drug toxicity



Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s9
Drug /Laboratory Test Interactions : As with other penicillins , the administration of PIPRACIL may result in a false-positive reaction for glucose in the urine using a copper -reduction method.

DrugDDI.d235.s9.e0 0 3
drug
Drug
DrugDDI.d235.s9.e1 38 53
drug
other penicillins
DrugDDI.d235.s9.e2 74 81
drug
PIPRACIL
DrugDDI.d235.s9.e3 119 125
drug
glucose
DrugDDI.d235.s9.e4 142 147
drug
copper

interaction DrugDDI.d235.s9.e0 DrugDDI.d235.s9.e1 false
interaction DrugDDI.d235.s9.e0 DrugDDI.d235.s9.e2 false
interaction DrugDDI.d235.s9.e0 DrugDDI.d235.s9.e3 false
interaction DrugDDI.d235.s9.e0 DrugDDI.d235.s9.e4 false
interaction DrugDDI.d235.s9.e1 DrugDDI.d235.s9.e2 false
interaction DrugDDI.d235.s9.e1 DrugDDI.d235.s9.e3 false
interaction DrugDDI.d235.s9.e1 DrugDDI.d235.s9.e4 false
interaction DrugDDI.d235.s9.e2 DrugDDI.d235.s9.e3 false
interaction DrugDDI.d235.s9.e2 DrugDDI.d235.s9.e4 false
interaction DrugDDI.d235.s9.e3 DrugDDI.d235.s9.e4 false

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s10
It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.

DrugDDI.d235.s10.e0 47 60
drug
glucose oxidase



Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s11
There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin / tazobactam injection who were subsequently found to be free of Aspergillus infection.

DrugDDI.d235.s11.e0 113 124
drug
piperacillin
DrugDDI.d235.s11.e1 126 135
drug
tazobactam
DrugDDI.d235.s11.new.DISO.e2 179 198
DISO
Aspergillus infection

interaction DrugDDI.d235.s11.e0 DrugDDI.d235.s11.e1 false

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s12
Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported.

DrugDDI.d235.s12.e0 34 48
drug
polysaccharides



Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s13
Therefore, positive test results in patients receiving piperacillin should be interpreted cautiously and confirmed by other diagnostic methods.

DrugDDI.d235.s13.e0 48 59
drug
piperacillin



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s0
Effect of other drugs on Vardenafil .

DrugDDI.d253.s0.e0 13 17
drug
drugs
DrugDDI.d253.s0.e1 20 29
drug
Vardenafil

interaction DrugDDI.d253.s0.e0 DrugDDI.d253.s0.e1 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s1
In vitro studies: Studies in human liver microsomes showed that vardenafil is metabolized primarily by cytochrome P450 ( CYP ) isoforms 3A4/5, and to a lesser degree by CYP2C9 .

DrugDDI.d253.s1.e0 54 63
drug
vardenafil
DrugDDI.d253.s1.e1 88 101
drug
cytochrome P450
DrugDDI.d253.s1.e2 103 105
drug
CYP
DrugDDI.d253.s1.e3 107 114
drug
isoforms
DrugDDI.d253.s1.e4 141 146
drug
CYP2C9

interaction DrugDDI.d253.s1.e0 DrugDDI.d253.s1.e1 false
interaction DrugDDI.d253.s1.e0 DrugDDI.d253.s1.e2 false
interaction DrugDDI.d253.s1.e0 DrugDDI.d253.s1.e3 false
interaction DrugDDI.d253.s1.e0 DrugDDI.d253.s1.e4 false
interaction DrugDDI.d253.s1.e1 DrugDDI.d253.s1.e2 false
interaction DrugDDI.d253.s1.e1 DrugDDI.d253.s1.e3 false
interaction DrugDDI.d253.s1.e1 DrugDDI.d253.s1.e4 false
interaction DrugDDI.d253.s1.e2 DrugDDI.d253.s1.e3 false
interaction DrugDDI.d253.s1.e2 DrugDDI.d253.s1.e4 false
interaction DrugDDI.d253.s1.e3 DrugDDI.d253.s1.e4 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s2
Therefore, inhibitors of these enzymes are expected to reduce vardenafil clearance.

DrugDDI.d253.s2.e0 53 62
drug
vardenafil



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s3
In vivo studies: Cytochrome P450 Inhibitors .

DrugDDI.d253.s3.e0 14 27
drug
Cytochrome P450



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s4
Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.

DrugDDI.d253.s4.e0 0 9
drug
Cimetidine
DrugDDI.d253.s4.e1 36 45
drug
vardenafil
DrugDDI.d253.s4.e2 97 106
drug
vardenafil
DrugDDI.d253.s4.e3 134 143
drug
Vardenafil

interaction DrugDDI.d253.s4.e0 DrugDDI.d253.s4.e1 false
interaction DrugDDI.d253.s4.e0 DrugDDI.d253.s4.e2 false
interaction DrugDDI.d253.s4.e0 DrugDDI.d253.s4.e3 false
interaction DrugDDI.d253.s4.e1 DrugDDI.d253.s4.e2 false
interaction DrugDDI.d253.s4.e1 DrugDDI.d253.s4.e3 false
interaction DrugDDI.d253.s4.e2 DrugDDI.d253.s4.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s5
Erythromycin ( 500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.

DrugDDI.d253.s5.e0 0 11
drug
Erythromycin
DrugDDI.d253.s5.e1 13 15
drug
500
DrugDDI.d253.s5.e2 49 58
drug
vardenafil
DrugDDI.d253.s5.e3 109 121
drug
Vardenafil 5 mg

interaction DrugDDI.d253.s5.e0 DrugDDI.d253.s5.e1 false
interaction DrugDDI.d253.s5.e0 DrugDDI.d253.s5.e2 true
interaction DrugDDI.d253.s5.e0 DrugDDI.d253.s5.e3 false
interaction DrugDDI.d253.s5.e1 DrugDDI.d253.s5.e2 false
interaction DrugDDI.d253.s5.e1 DrugDDI.d253.s5.e3 false
interaction DrugDDI.d253.s5.e2 DrugDDI.d253.s5.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s6
It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin .

DrugDDI.d253.s6.e0 42 51
drug
Vardenafil
DrugDDI.d253.s6.e1 93 104
drug
erythromycin

interaction DrugDDI.d253.s6.e0 DrugDDI.d253.s6.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s7
Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.

DrugDDI.d253.s7.e0 0 11
drug
Ketoconazole
DrugDDI.d253.s7.e1 54 63
drug
vardenafil
DrugDDI.d253.s7.e2 114 123
drug
Vardenafil

interaction DrugDDI.d253.s7.e0 DrugDDI.d253.s7.e1 true
interaction DrugDDI.d253.s7.e0 DrugDDI.d253.s7.e2 false
interaction DrugDDI.d253.s7.e1 DrugDDI.d253.s7.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s8
A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole .

DrugDDI.d253.s8.e0 5 14
drug
Vardenafil
DrugDDI.d253.s8.e1 77 88
drug
ketoconazole

interaction DrugDDI.d253.s8.e0 DrugDDI.d253.s8.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s9
Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.

DrugDDI.d253.s9.e0 18 29
drug
ketoconazole
DrugDDI.d253.s9.e1 99 108
drug
Vardenafil
DrugDDI.d253.s9.e2 169 185
drug
ketoconazole 400 mg

interaction DrugDDI.d253.s9.e0 DrugDDI.d253.s9.e1 true
interaction DrugDDI.d253.s9.e0 DrugDDI.d253.s9.e2 false
interaction DrugDDI.d253.s9.e1 DrugDDI.d253.s9.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s10
HIV Protease Inhibitors : Indinavir ( 800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.

DrugDDI.d253.s10.e0 0 20
drug
HIV Protease Inhibitors
DrugDDI.d253.s10.e1 22 30
drug
Indinavir
DrugDDI.d253.s10.e2 32 34
drug
800
DrugDDI.d253.s10.e3 63 76
drug
Vardenafil 10 mg
DrugDDI.d253.s10.e4 105 114
drug
vardenafil
DrugDDI.d253.s10.e5 136 145
drug
vardenafil
DrugDDI.d253.s10.e6 170 179
drug
vardenafil

interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e1 false
interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e2 false
interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e3 false
interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e4 false
interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e5 false
interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e6 false
interaction DrugDDI.d253.s10.e1 DrugDDI.d253.s10.e2 false
interaction DrugDDI.d253.s10.e1 DrugDDI.d253.s10.e3 true
interaction DrugDDI.d253.s10.e1 DrugDDI.d253.s10.e4 false
interaction DrugDDI.d253.s10.e1 DrugDDI.d253.s10.e5 false
interaction DrugDDI.d253.s10.e1 DrugDDI.d253.s10.e6 false
interaction DrugDDI.d253.s10.e2 DrugDDI.d253.s10.e3 false
interaction DrugDDI.d253.s10.e2 DrugDDI.d253.s10.e4 false
interaction DrugDDI.d253.s10.e2 DrugDDI.d253.s10.e5 false
interaction DrugDDI.d253.s10.e2 DrugDDI.d253.s10.e6 false
interaction DrugDDI.d253.s10.e3 DrugDDI.d253.s10.e4 false
interaction DrugDDI.d253.s10.e3 DrugDDI.d253.s10.e5 false
interaction DrugDDI.d253.s10.e3 DrugDDI.d253.s10.e6 false
interaction DrugDDI.d253.s10.e4 DrugDDI.d253.s10.e5 false
interaction DrugDDI.d253.s10.e4 DrugDDI.d253.s10.e6 false
interaction DrugDDI.d253.s10.e5 DrugDDI.d253.s10.e6 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s11
It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir .

DrugDDI.d253.s11.e0 93 101
drug
indinavir



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s12
Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.

DrugDDI.d253.s12.e0 0 8
drug
Ritonavir
DrugDDI.d253.s12.e1 41 53
drug
Vardenafil 5 mg
DrugDDI.d253.s12.e2 82 91
drug
vardenafil
DrugDDI.d253.s12.e3 116 125
drug
vardenafil

interaction DrugDDI.d253.s12.e0 DrugDDI.d253.s12.e1 true
interaction DrugDDI.d253.s12.e0 DrugDDI.d253.s12.e2 false
interaction DrugDDI.d253.s12.e0 DrugDDI.d253.s12.e3 false
interaction DrugDDI.d253.s12.e1 DrugDDI.d253.s12.e2 false
interaction DrugDDI.d253.s12.e1 DrugDDI.d253.s12.e3 false
interaction DrugDDI.d253.s12.e2 DrugDDI.d253.s12.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s13
The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir , a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9 .

DrugDDI.d253.s13.e0 57 66
drug
vardenafil
DrugDDI.d253.s13.e1 69 77
drug
ritonavir
DrugDDI.d253.s13.e2 92 97
drug
CYP3A4
DrugDDI.d253.s13.e3 125 130
drug
CYP2C9

interaction DrugDDI.d253.s13.e0 DrugDDI.d253.s13.e1 true
interaction DrugDDI.d253.s13.e0 DrugDDI.d253.s13.e2 false
interaction DrugDDI.d253.s13.e0 DrugDDI.d253.s13.e3 false
interaction DrugDDI.d253.s13.e1 DrugDDI.d253.s13.e2 false
interaction DrugDDI.d253.s13.e1 DrugDDI.d253.s13.e3 false
interaction DrugDDI.d253.s13.e2 DrugDDI.d253.s13.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s14
Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.

DrugDDI.d253.s14.e0 0 8
drug
Ritonavir
DrugDDI.d253.s14.e1 45 54
drug
vardenafil

interaction DrugDDI.d253.s14.e0 DrugDDI.d253.s14.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s15
Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir .

DrugDDI.d253.s15.e0 106 114
drug
ritonavir



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s16
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs : glyburide , warfarin , digoxin , Maalox , and ranitidine .

DrugDDI.d253.s16.e0 70 79
drug
vardenafil
DrugDDI.d253.s16.e1 95 99
drug
drugs
DrugDDI.d253.s16.e2 101 109
drug
glyburide
DrugDDI.d253.s16.e3 111 118
drug
warfarin
DrugDDI.d253.s16.e4 120 126
drug
digoxin
DrugDDI.d253.s16.e5 128 133
drug
Maalox
DrugDDI.d253.s16.e6 138 147
drug
ranitidine

interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e1 false
interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e2 false
interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e3 false
interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e4 false
interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e5 false
interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e6 false
interaction DrugDDI.d253.s16.e1 DrugDDI.d253.s16.e2 false
interaction DrugDDI.d253.s16.e1 DrugDDI.d253.s16.e3 false
interaction DrugDDI.d253.s16.e1 DrugDDI.d253.s16.e4 false
interaction DrugDDI.d253.s16.e1 DrugDDI.d253.s16.e5 false
interaction DrugDDI.d253.s16.e1 DrugDDI.d253.s16.e6 false
interaction DrugDDI.d253.s16.e2 DrugDDI.d253.s16.e3 false
interaction DrugDDI.d253.s16.e2 DrugDDI.d253.s16.e4 false
interaction DrugDDI.d253.s16.e2 DrugDDI.d253.s16.e5 false
interaction DrugDDI.d253.s16.e2 DrugDDI.d253.s16.e6 false
interaction DrugDDI.d253.s16.e3 DrugDDI.d253.s16.e4 false
interaction DrugDDI.d253.s16.e3 DrugDDI.d253.s16.e5 false
interaction DrugDDI.d253.s16.e3 DrugDDI.d253.s16.e6 false
interaction DrugDDI.d253.s16.e4 DrugDDI.d253.s16.e5 false
interaction DrugDDI.d253.s16.e4 DrugDDI.d253.s16.e6 false
interaction DrugDDI.d253.s16.e5 DrugDDI.d253.s16.e6 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s17
In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.

DrugDDI.d253.s17.e0 5 12
drug
warfarin
DrugDDI.d253.s17.e1 19 28
drug
vardenafil

interaction DrugDDI.d253.s17.e0 DrugDDI.d253.s17.e1 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s18
Effects of Vardenafil on other drugs .

DrugDDI.d253.s18.e0 9 18
drug
Vardenafil
DrugDDI.d253.s18.e1 26 30
drug
drugs

interaction DrugDDI.d253.s18.e0 DrugDDI.d253.s18.e1 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s19
In vitro studies: Vardenafil and its metabolites had no effect on CYP1A2 , 2A6, and 2E1 ( Ki 100uM ).

DrugDDI.d253.s19.e0 15 24
drug
Vardenafil
DrugDDI.d253.s19.e1 31 41
drug
metabolites
DrugDDI.d253.s19.e2 55 60
drug
CYP1A2
DrugDDI.d253.s19.e3 73 79
drug
Ki   100uM

interaction DrugDDI.d253.s19.e0 DrugDDI.d253.s19.e1 false
interaction DrugDDI.d253.s19.e0 DrugDDI.d253.s19.e2 false
interaction DrugDDI.d253.s19.e0 DrugDDI.d253.s19.e3 false
interaction DrugDDI.d253.s19.e1 DrugDDI.d253.s19.e2 false
interaction DrugDDI.d253.s19.e1 DrugDDI.d253.s19.e3 false
interaction DrugDDI.d253.s19.e2 DrugDDI.d253.s19.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s20
Weak inhibitory effects toward other isoforms ( CYP2C8 , 2C9, 2C19, 2D6, 3A4) were found, but Ki values were in excess of plasma concentrations achieved following dosing.

DrugDDI.d253.s20.e0 32 39
drug
isoforms
DrugDDI.d253.s20.e1 41 46
drug
CYP2C8

interaction DrugDDI.d253.s20.e0 DrugDDI.d253.s20.e1 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s21
The most potent inhibitory activity was observed for vardenafil metabolite M1, which had a Ki of 1.4 uM toward CYP3A4 , which is about 20 times higher than the M1 Cmax values after an 80 mg Vardenafil dose.

DrugDDI.d253.s21.e0 45 54
drug
vardenafil
DrugDDI.d253.s21.e1 92 97
drug
CYP3A4
DrugDDI.d253.s21.e2 154 163
drug
Vardenafil

interaction DrugDDI.d253.s21.e0 DrugDDI.d253.s21.e1 false
interaction DrugDDI.d253.s21.e0 DrugDDI.d253.s21.e2 false
interaction DrugDDI.d253.s21.e1 DrugDDI.d253.s21.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s22
In vivo studies: Nitrates : The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.

DrugDDI.d253.s22.e0 14 21
drug
Nitrates
DrugDDI.d253.s22.e1 66 73
drug
nitrates
DrugDDI.d253.s22.e2 101 110
drug
vardenafil
DrugDDI.d253.s22.e3 185 194
drug
Vardenafil

interaction DrugDDI.d253.s22.e0 DrugDDI.d253.s22.e1 false
interaction DrugDDI.d253.s22.e0 DrugDDI.d253.s22.e2 false
interaction DrugDDI.d253.s22.e0 DrugDDI.d253.s22.e3 false
interaction DrugDDI.d253.s22.e1 DrugDDI.d253.s22.e2 false
interaction DrugDDI.d253.s22.e1 DrugDDI.d253.s22.e3 false
interaction DrugDDI.d253.s22.e2 DrugDDI.d253.s22.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s23
These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.

DrugDDI.d253.s23.e0 31 44
drug
Vardenafil 20 mg



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s24
Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.

DrugDDI.d253.s24.e0 37 44
drug
nitrates
DrugDDI.d253.s24.new.DISO.e3 60 79
DISO
ischemic heart disease
DrugDDI.d253.s24.e1 119 128
drug
Vardenafil
DrugDDI.d253.s24.e2 132 139
drug
nitrates

interaction DrugDDI.d253.s24.e0 DrugDDI.d253.s24.e1 false
interaction DrugDDI.d253.s24.e0 DrugDDI.d253.s24.e2 false
interaction DrugDDI.d253.s24.e1 DrugDDI.d253.s24.e2 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s25
Nifedipine : Vardenafil 20 mg , when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine , a drug that is metabolized via CYP3A4 .

DrugDDI.d253.s25.e0 0 9
drug
Nifedipine
DrugDDI.d253.s25.e1 11 24
drug
Vardenafil 20 mg
DrugDDI.d253.s25.e2 61 74
drug
nifedipine 30 mg
DrugDDI.d253.s25.e3 164 173
drug
nifedipine
DrugDDI.d253.s25.e4 176 179
drug
drug
DrugDDI.d253.s25.e5 200 205
drug
CYP3A4

interaction DrugDDI.d253.s25.e0 DrugDDI.d253.s25.e1 false
interaction DrugDDI.d253.s25.e0 DrugDDI.d253.s25.e2 false
interaction DrugDDI.d253.s25.e0 DrugDDI.d253.s25.e3 false
interaction DrugDDI.d253.s25.e0 DrugDDI.d253.s25.e4 false
interaction DrugDDI.d253.s25.e0 DrugDDI.d253.s25.e5 false
interaction DrugDDI.d253.s25.e1 DrugDDI.d253.s25.e2 false
interaction DrugDDI.d253.s25.e1 DrugDDI.d253.s25.e3 false
interaction DrugDDI.d253.s25.e1 DrugDDI.d253.s25.e4 false
interaction DrugDDI.d253.s25.e1 DrugDDI.d253.s25.e5 false
interaction DrugDDI.d253.s25.e2 DrugDDI.d253.s25.e3 false
interaction DrugDDI.d253.s25.e2 DrugDDI.d253.s25.e4 false
interaction DrugDDI.d253.s25.e2 DrugDDI.d253.s25.e5 false
interaction DrugDDI.d253.s25.e3 DrugDDI.d253.s25.e4 false
interaction DrugDDI.d253.s25.e3 DrugDDI.d253.s25.e5 false
interaction DrugDDI.d253.s25.e4 DrugDDI.d253.s25.e5 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s26
Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.

DrugDDI.d253.s26.e0 0 9
drug
Nifedipine
DrugDDI.d253.s26.e1 38 47
drug
Vardenafil

interaction DrugDDI.d253.s26.e0 DrugDDI.d253.s26.e1 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s27
In these patients whose hypertension was controlled with nifedipine , Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.

DrugDDI.d253.s27.e0 49 58
drug
nifedipine
DrugDDI.d253.s27.e1 60 73
drug
Vardenafil 20 mg

interaction DrugDDI.d253.s27.e0 DrugDDI.d253.s27.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s28
Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin , significant hypotension developed in a substantial number of subjects.

DrugDDI.d253.s28.e0 19 28
drug
Vardenafil
DrugDDI.d253.s28.e1 108 116
drug
terazosin

interaction DrugDDI.d253.s28.e0 DrugDDI.d253.s28.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s29
With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.

DrugDDI.d253.s29.e0 24 37
drug
Vardenafil 10 mg
DrugDDI.d253.s29.e1 41 51
drug
terazosin 10

interaction DrugDDI.d253.s29.e0 DrugDDI.d253.s29.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s30
With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.

DrugDDI.d253.s30.e0 24 37
drug
Vardenafil 20 mg
DrugDDI.d253.s30.e1 41 51
drug
terazosin 10

interaction DrugDDI.d253.s30.e0 DrugDDI.d253.s30.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s31
When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.

DrugDDI.d253.s31.e0 4 13
drug
Vardenafil
DrugDDI.d253.s31.e1 36 46
drug
terazosin 10
DrugDDI.d253.s31.e2 88 97
drug
Vardenafil

interaction DrugDDI.d253.s31.e0 DrugDDI.d253.s31.e1 false
interaction DrugDDI.d253.s31.e0 DrugDDI.d253.s31.e2 false
interaction DrugDDI.d253.s31.e1 DrugDDI.d253.s31.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s32
In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.

DrugDDI.d253.s32.e0 19 28
drug
tamsulosin
DrugDDI.d253.s32.e1 71 84
drug
Vardenafil 20 mg
DrugDDI.d253.s32.e2 88 102
drug
tamsulosin 0.4 mg

interaction DrugDDI.d253.s32.e0 DrugDDI.d253.s32.e1 false
interaction DrugDDI.d253.s32.e0 DrugDDI.d253.s32.e2 false
interaction DrugDDI.d253.s32.e1 DrugDDI.d253.s32.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s33
Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.

DrugDDI.d253.s33.e0 38 51
drug
Vardenafil 10 mg
DrugDDI.d253.s33.e1 55 69
drug
tamsulosin 0.4 mg

interaction DrugDDI.d253.s33.e0 DrugDDI.d253.s33.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s34
The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.

DrugDDI.d253.s34.e0 31 40
drug
Vardenafil



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s35
Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.

DrugDDI.d253.s35.e0 17 26
drug
Vardenafil
DrugDDI.d253.s35.e1 54 66
drug
alpha-blocker

interaction DrugDDI.d253.s35.e0 DrugDDI.d253.s35.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s36
Ritonavir and indinavir : Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir , the Cmax and AUC of ritonavir were reduced by approximately 20%.

DrugDDI.d253.s36.e0 0 8
drug
Ritonavir
DrugDDI.d253.s36.e1 12 20
drug
indinavir
DrugDDI.d253.s36.e2 58 67
drug
Vardenafil
DrugDDI.d253.s36.e3 80 88
drug
ritonavir
DrugDDI.d253.s36.e4 105 113
drug
ritonavir

interaction DrugDDI.d253.s36.e0 DrugDDI.d253.s36.e1 false
interaction DrugDDI.d253.s36.e0 DrugDDI.d253.s36.e2 false
interaction DrugDDI.d253.s36.e0 DrugDDI.d253.s36.e3 false
interaction DrugDDI.d253.s36.e0 DrugDDI.d253.s36.e4 false
interaction DrugDDI.d253.s36.e1 DrugDDI.d253.s36.e2 false
interaction DrugDDI.d253.s36.e1 DrugDDI.d253.s36.e3 false
interaction DrugDDI.d253.s36.e1 DrugDDI.d253.s36.e4 false
interaction DrugDDI.d253.s36.e2 DrugDDI.d253.s36.e3 true
interaction DrugDDI.d253.s36.e2 DrugDDI.d253.s36.e4 false
interaction DrugDDI.d253.s36.e3 DrugDDI.d253.s36.e4 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s37
Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir , the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.

DrugDDI.d253.s37.e0 26 35
drug
Vardenafil
DrugDDI.d253.s37.e1 48 56
drug
indinavir
DrugDDI.d253.s37.e2 73 81
drug
indinavir

interaction DrugDDI.d253.s37.e0 DrugDDI.d253.s37.e1 true
interaction DrugDDI.d253.s37.e0 DrugDDI.d253.s37.e2 false
interaction DrugDDI.d253.s37.e1 DrugDDI.d253.s37.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s38
Alcohol : Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.

DrugDDI.d253.s38.e0 0 6
drug
Alcohol
DrugDDI.d253.s38.e1 8 14
drug
Alcohol
DrugDDI.d253.s38.e2 85 94
drug
vardenafil

interaction DrugDDI.d253.s38.e0 DrugDDI.d253.s38.e1 false
interaction DrugDDI.d253.s38.e0 DrugDDI.d253.s38.e2 false
interaction DrugDDI.d253.s38.e1 DrugDDI.d253.s38.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s39
Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).

DrugDDI.d253.s39.e0 0 9
drug
Vardenafil
DrugDDI.d253.s39.e1 55 61
drug
alcohol
DrugDDI.d253.s39.e2 133 139
drug
alcohol

interaction DrugDDI.d253.s39.e0 DrugDDI.d253.s39.e1 false
interaction DrugDDI.d253.s39.e0 DrugDDI.d253.s39.e2 false
interaction DrugDDI.d253.s39.e1 DrugDDI.d253.s39.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s40
Aspirin : Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).

DrugDDI.d253.s40.e0 0 6
drug
Aspirin
DrugDDI.d253.s40.e1 8 17
drug
Vardenafil
DrugDDI.d253.s40.e2 80 86
drug
aspirin

interaction DrugDDI.d253.s40.e0 DrugDDI.d253.s40.e1 false
interaction DrugDDI.d253.s40.e0 DrugDDI.d253.s40.e2 false
interaction DrugDDI.d253.s40.e1 DrugDDI.d253.s40.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s41
Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide ( glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).

DrugDDI.d253.s41.e0 18 27
drug
Vardenafil
DrugDDI.d253.s41.e1 62 70
drug
glyburide
DrugDDI.d253.s41.e2 72 78
drug
glucose
DrugDDI.d253.s41.e3 82 88
drug
insulin
DrugDDI.d253.s41.e4 107 114
drug
warfarin

interaction DrugDDI.d253.s41.e0 DrugDDI.d253.s41.e1 false
interaction DrugDDI.d253.s41.e0 DrugDDI.d253.s41.e2 false
interaction DrugDDI.d253.s41.e0 DrugDDI.d253.s41.e3 false
interaction DrugDDI.d253.s41.e0 DrugDDI.d253.s41.e4 false
interaction DrugDDI.d253.s41.e1 DrugDDI.d253.s41.e2 false
interaction DrugDDI.d253.s41.e1 DrugDDI.d253.s41.e3 false
interaction DrugDDI.d253.s41.e1 DrugDDI.d253.s41.e4 false
interaction DrugDDI.d253.s41.e2 DrugDDI.d253.s41.e3 false
interaction DrugDDI.d253.s41.e2 DrugDDI.d253.s41.e4 false
interaction DrugDDI.d253.s41.e3 DrugDDI.d253.s41.e4 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s0
Zidovudine : There is no significant pharmacokinetic interaction between ZDV and zalcitabine which has been confirmed clinically.

DrugDDI.d528.s0.e0 0 9
drug
Zidovudine
DrugDDI.d528.s0.e1 64 66
drug
ZDV
DrugDDI.d528.s0.e2 70 80
drug
zalcitabine

interaction DrugDDI.d528.s0.e0 DrugDDI.d528.s0.e1 false
interaction DrugDDI.d528.s0.e0 DrugDDI.d528.s0.e2 false
interaction DrugDDI.d528.s0.e1 DrugDDI.d528.s0.e2 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s1
Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV , as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).

DrugDDI.d528.s1.e0 0 10
drug
Zalcitabine
DrugDDI.d528.s1.e1 72 74
drug
ZDV

interaction DrugDDI.d528.s1.e0 DrugDDI.d528.s1.e1 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s2
In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.

DrugDDI.d528.s2.e0 28 37
drug
didanosine
DrugDDI.d528.s2.e1 41 49
drug
stavudine
DrugDDI.d528.s2.e2 107 117
drug
zalcitabine

interaction DrugDDI.d528.s2.e0 DrugDDI.d528.s2.e1 false
interaction DrugDDI.d528.s2.e0 DrugDDI.d528.s2.e2 false
interaction DrugDDI.d528.s2.e1 DrugDDI.d528.s2.e2 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s3
Lamivudine : In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.

DrugDDI.d528.s3.e0 0 9
drug
Lamivudine
DrugDDI.d528.s3.e1 89 98
drug
lamivudine
DrugDDI.d528.s3.e2 121 131
drug
zalcitabine

interaction DrugDDI.d528.s3.e0 DrugDDI.d528.s3.e1 false
interaction DrugDDI.d528.s3.e0 DrugDDI.d528.s3.e2 false
interaction DrugDDI.d528.s3.e1 DrugDDI.d528.s3.e2 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s4
Effects were already seen with doses corresponding to relevant plasma levels in humans, and the intracellular phosphorylation of zalcitabine to its three metabolites (including the active zalcitabine triphosphate metabolite) was significantly inhibited.

DrugDDI.d528.s4.e0 111 121
drug
zalcitabine
DrugDDI.d528.s4.e1 132 142
drug
metabolites
DrugDDI.d528.s4.e2 162 172
drug
zalcitabine

interaction DrugDDI.d528.s4.e0 DrugDDI.d528.s4.e1 false
interaction DrugDDI.d528.s4.e0 DrugDDI.d528.s4.e2 false
interaction DrugDDI.d528.s4.e1 DrugDDI.d528.s4.e2 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s5
Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100); .

DrugDDI.d528.s5.e0 0 10
drug
Zalcitabine
DrugDDI.d528.s5.e1 20 29
drug
lamivudine

interaction DrugDDI.d528.s5.e0 DrugDDI.d528.s5.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s6
however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine .

DrugDDI.d528.s6.e0 66 75
drug
lamivudine
DrugDDI.d528.s6.e1 116 125
drug
lamivudine
DrugDDI.d528.s6.e2 154 172
drug
deoxycytidine kinase
DrugDDI.d528.s6.e3 177 187
drug
zalcitabine

interaction DrugDDI.d528.s6.e0 DrugDDI.d528.s6.e1 false
interaction DrugDDI.d528.s6.e0 DrugDDI.d528.s6.e2 false
interaction DrugDDI.d528.s6.e0 DrugDDI.d528.s6.e3 false
interaction DrugDDI.d528.s6.e1 DrugDDI.d528.s6.e2 false
interaction DrugDDI.d528.s6.e1 DrugDDI.d528.s6.e3 false
interaction DrugDDI.d528.s6.e2 DrugDDI.d528.s6.e3 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s7
These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine .

DrugDDI.d528.s7.e0 57 67
drug
zalcitabine
DrugDDI.d528.s7.e1 71 80
drug
lamivudine
DrugDDI.d528.s7.e2 151 161
drug
zalcitabine
DrugDDI.d528.s7.e3 209 219
drug
zalcitabine

interaction DrugDDI.d528.s7.e0 DrugDDI.d528.s7.e1 true
interaction DrugDDI.d528.s7.e0 DrugDDI.d528.s7.e2 false
interaction DrugDDI.d528.s7.e0 DrugDDI.d528.s7.e3 false
interaction DrugDDI.d528.s7.e1 DrugDDI.d528.s7.e2 false
interaction DrugDDI.d528.s7.e1 DrugDDI.d528.s7.e3 false
interaction DrugDDI.d528.s7.e2 DrugDDI.d528.s7.e3 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s9
Concomitant use of zalcitabine and lamivudine is not recommended.

DrugDDI.d528.s9.e0 16 26
drug
zalcitabine
DrugDDI.d528.s9.e1 30 39
drug
lamivudine

interaction DrugDDI.d528.s9.e0 DrugDDI.d528.s9.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s10
Saquinavir : The combination of HIVID , saquinavir , and ZDV has been studied (as triple combination) in adults.

DrugDDI.d528.s10.e0 0 9
drug
Saquinavir
DrugDDI.d528.s10.e1 27 31
drug
HIVID
DrugDDI.d528.s10.e2 33 42
drug
saquinavir
DrugDDI.d528.s10.e3 47 49
drug
ZDV

interaction DrugDDI.d528.s10.e0 DrugDDI.d528.s10.e1 false
interaction DrugDDI.d528.s10.e0 DrugDDI.d528.s10.e2 false
interaction DrugDDI.d528.s10.e0 DrugDDI.d528.s10.e3 false
interaction DrugDDI.d528.s10.e1 DrugDDI.d528.s10.e2 false
interaction DrugDDI.d528.s10.e1 DrugDDI.d528.s10.e3 false
interaction DrugDDI.d528.s10.e2 DrugDDI.d528.s10.e3 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s11
Pharmacokinetic data suggest that absorption, metabolism, and elimination of each of these drugs are unchanged when they are used together.

DrugDDI.d528.s11.e0 79 83
drug
drugs



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s12
Drugs Associated With Peripheral Neuropathy: The concomitant use of HIVID with drugs that have the potential to cause peripheral neuropathy should be avoided where possible.

DrugDDI.d528.s12.e0 0 4
drug
Drugs
DrugDDI.d528.s12.new.DISO.e3 19 38
DISO
Peripheral Neuropathy
DrugDDI.d528.s12.e1 59 63
drug
HIVID
DrugDDI.d528.s12.e2 68 72
drug
drugs
DrugDDI.d528.s12.new.DISO.e4 110 119
DISO
neuropathy

interaction DrugDDI.d528.s12.e0 DrugDDI.d528.s12.e1 false
interaction DrugDDI.d528.s12.e0 DrugDDI.d528.s12.e2 false
interaction DrugDDI.d528.s12.e1 DrugDDI.d528.s12.e2 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s13
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .

DrugDDI.d528.s13.e0 0 4
drug
Drugs
DrugDDI.d528.s13.new.DISO.e17 31 50
DISO
peripheral neuropathy
DrugDDI.d528.s13.e1 58 90
drug
antiretroviral nucleoside analogues
DrugDDI.d528.s13.e2 92 106
drug
chloramphenicol
DrugDDI.d528.s13.e3 108 116
drug
cisplatin
DrugDDI.d528.s13.e4 118 124
drug
dapsone
DrugDDI.d528.s13.e5 126 135
drug
disulfiram
DrugDDI.d528.s13.e6 137 147
drug
ethionamide
DrugDDI.d528.s13.e7 149 160
drug
glutethimide
DrugDDI.d528.s13.e8 162 165
drug
gold
DrugDDI.d528.s13.e9 167 177
drug
hydralazine
DrugDDI.d528.s13.e10 179 188
drug
iodoquinol
DrugDDI.d528.s13.e11 190 198
drug
isoniazid
DrugDDI.d528.s13.e12 200 212
drug
metronidazole
DrugDDI.d528.s13.e13 214 227
drug
nitrofurantoin
DrugDDI.d528.s13.e14 229 237
drug
phenytoin
DrugDDI.d528.s13.e15 239 247
drug
ribavirin
DrugDDI.d528.s13.e16 252 262
drug
vincristine

interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e1 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e2 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e3 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e4 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e5 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e2 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e3 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e4 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e5 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e3 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e4 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e5 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e4 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e5 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e5 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e11 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e11 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e11 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e11 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e11 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e12 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e12 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e12 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e12 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e13 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e13 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e13 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e14 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e14 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e15 DrugDDI.d528.s13.e16 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s14
Concomitant use of HIVID with didanosine is not recommended.

DrugDDI.d528.s14.e0 16 20
drug
HIVID
DrugDDI.d528.s14.e1 25 34
drug
didanosine

interaction DrugDDI.d528.s14.e0 DrugDDI.d528.s14.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s15
Intravenous Pentamidin e: Treatment with HIVID should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.

DrugDDI.d528.s15.e0 11 20
drug
Pentamidin
DrugDDI.d528.s15.e1 36 40
drug
HIVID
DrugDDI.d528.s15.e2 73 76
drug
drug
DrugDDI.d528.s15.new.DISO.e3 103 114
DISO
pancreatitis

interaction DrugDDI.d528.s15.e0 DrugDDI.d528.s15.e1 false
interaction DrugDDI.d528.s15.e0 DrugDDI.d528.s15.e2 false
interaction DrugDDI.d528.s15.e1 DrugDDI.d528.s15.e2 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s16
Death due to fulminant pancreatitis possibly related to intravenous pentamidin e and HIVID has been reported.

DrugDDI.d528.s16.new.DISO.e2 19 30
DISO
pancreatitis
DrugDDI.d528.s16.e0 59 68
drug
pentamidin
DrugDDI.d528.s16.e1 73 77
drug
HIVID

interaction DrugDDI.d528.s16.e0 DrugDDI.d528.s16.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s17
If intravenous pentamidin e is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.

DrugDDI.d528.s17.e0 13 22
drug
pentamidin
DrugDDI.d528.s17.new.DISO.e2 41 68
DISO
Pneumocystis carinii pneumonia
DrugDDI.d528.s17.e1 83 87
drug
HIVID

interaction DrugDDI.d528.s17.e0 DrugDDI.d528.s17.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s18
Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).

DrugDDI.d528.s18.e0 0 11
drug
Amphotericin
DrugDDI.d528.s18.e1 13 21
drug
Foscarnet
DrugDDI.d528.s18.e2 26 40
drug
Aminoglycosides
DrugDDI.d528.s18.e3 42 46
drug
Drugs
DrugDDI.d528.s18.e4 53 64
drug
amphotericin
DrugDDI.d528.s18.e5 66 74
drug
foscarnet
DrugDDI.d528.s18.e6 79 93
drug
aminoglycosides
DrugDDI.d528.s18.new.DISO.e9 124 143
DISO
peripheral neuropathy
DrugDDI.d528.s18.e7 151 155
drug
HIVID
DrugDDI.d528.s18.e8 216 226
drug
zalcitabine

interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e1 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e2 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e3 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e4 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e5 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e8 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e2 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e3 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e4 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e5 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e8 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e3 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e4 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e5 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e8 false
interaction DrugDDI.d528.s18.e3 DrugDDI.d528.s18.e4 false
interaction DrugDDI.d528.s18.e3 DrugDDI.d528.s18.e5 false
interaction DrugDDI.d528.s18.e3 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e3 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e3 DrugDDI.d528.s18.e8 true
interaction DrugDDI.d528.s18.e4 DrugDDI.d528.s18.e5 false
interaction DrugDDI.d528.s18.e4 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e4 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e4 DrugDDI.d528.s18.e8 true
interaction DrugDDI.d528.s18.e5 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e5 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e5 DrugDDI.d528.s18.e8 true
interaction DrugDDI.d528.s18.e6 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e6 DrugDDI.d528.s18.e8 true
interaction DrugDDI.d528.s18.e7 DrugDDI.d528.s18.e8 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s19
Patients who require the use of one of these drugs with HIVID should have frequent clinical and laboratory monitoring with dosage adjustment for any significant change in renal function.

DrugDDI.d528.s19.e0 36 40
drug
drugs
DrugDDI.d528.s19.e1 45 49
drug
HIVID

interaction DrugDDI.d528.s19.e0 DrugDDI.d528.s19.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s20
Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine .

DrugDDI.d528.s20.e0 0 9
drug
Probenecid
DrugDDI.d528.s20.e1 12 21
drug
Cimetidine
DrugDDI.d528.s20.e2 50 59
drug
probenecid
DrugDDI.d528.s20.e3 62 71
drug
cimetidine
DrugDDI.d528.s20.e4 97 107
drug
zalcitabine
DrugDDI.d528.s20.e5 156 166
drug
zalcitabine

interaction DrugDDI.d528.s20.e0 DrugDDI.d528.s20.e1 false
interaction DrugDDI.d528.s20.e0 DrugDDI.d528.s20.e2 false
interaction DrugDDI.d528.s20.e0 DrugDDI.d528.s20.e3 false
interaction DrugDDI.d528.s20.e0 DrugDDI.d528.s20.e4 false
interaction DrugDDI.d528.s20.e0 DrugDDI.d528.s20.e5 false
interaction DrugDDI.d528.s20.e1 DrugDDI.d528.s20.e2 false
interaction DrugDDI.d528.s20.e1 DrugDDI.d528.s20.e3 false
interaction DrugDDI.d528.s20.e1 DrugDDI.d528.s20.e4 false
interaction DrugDDI.d528.s20.e1 DrugDDI.d528.s20.e5 false
interaction DrugDDI.d528.s20.e2 DrugDDI.d528.s20.e3 false
interaction DrugDDI.d528.s20.e2 DrugDDI.d528.s20.e4 true
interaction DrugDDI.d528.s20.e2 DrugDDI.d528.s20.e5 false
interaction DrugDDI.d528.s20.e3 DrugDDI.d528.s20.e4 true
interaction DrugDDI.d528.s20.e3 DrugDDI.d528.s20.e5 false
interaction DrugDDI.d528.s20.e4 DrugDDI.d528.s20.e5 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s21
Patients receiving these drugs in combination with zalcitabine should be monitored for signs of toxicity and the dose of zalcitabine reduced if warranted.

DrugDDI.d528.s21.e0 22 26
drug
drugs
DrugDDI.d528.s21.e1 44 54
drug
zalcitabine
DrugDDI.d528.s21.e2 102 112
drug
zalcitabine

interaction DrugDDI.d528.s21.e0 DrugDDI.d528.s21.e1 true
interaction DrugDDI.d528.s21.e0 DrugDDI.d528.s21.e2 false
interaction DrugDDI.d528.s21.e1 DrugDDI.d528.s21.e2 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s22
Magnesium /Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium /aluminum-containing antacid products.

DrugDDI.d528.s22.e0 0 8
drug
Magnesium
DrugDDI.d528.s22.e1 9 35
drug
/Aluminum-containing Antacid
DrugDDI.d528.s22.e2 57 67
drug
zalcitabine
DrugDDI.d528.s22.e3 127 135
drug
magnesium
DrugDDI.d528.s22.e4 136 162
drug
/aluminum-containing antacid

interaction DrugDDI.d528.s22.e0 DrugDDI.d528.s22.e1 false
interaction DrugDDI.d528.s22.e0 DrugDDI.d528.s22.e2 false
interaction DrugDDI.d528.s22.e0 DrugDDI.d528.s22.e3 false
interaction DrugDDI.d528.s22.e0 DrugDDI.d528.s22.e4 false
interaction DrugDDI.d528.s22.e1 DrugDDI.d528.s22.e2 false
interaction DrugDDI.d528.s22.e1 DrugDDI.d528.s22.e3 false
interaction DrugDDI.d528.s22.e1 DrugDDI.d528.s22.e4 false
interaction DrugDDI.d528.s22.e2 DrugDDI.d528.s22.e3 true
interaction DrugDDI.d528.s22.e2 DrugDDI.d528.s22.e4 true
interaction DrugDDI.d528.s22.e3 DrugDDI.d528.s22.e4 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s23
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium / aluminum-containing antacids .

DrugDDI.d528.s23.e0 54 64
drug
zalcitabine
DrugDDI.d528.s23.e1 111 119
drug
magnesium
DrugDDI.d528.s23.e2 121 147
drug
aluminum-containing antacids

interaction DrugDDI.d528.s23.e0 DrugDDI.d528.s23.e1 true
interaction DrugDDI.d528.s23.e0 DrugDDI.d528.s23.e2 true
interaction DrugDDI.d528.s23.e1 DrugDDI.d528.s23.e2 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s24
Metoclopramide : Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.

DrugDDI.d528.s24.e0 0 13
drug
Metoclopramide
DrugDDI.d528.s24.e1 67 77
drug
zalcitabine
DrugDDI.d528.s24.e2 81 94
drug
metoclopramide

interaction DrugDDI.d528.s24.e0 DrugDDI.d528.s24.e1 false
interaction DrugDDI.d528.s24.e0 DrugDDI.d528.s24.e2 false
interaction DrugDDI.d528.s24.e1 DrugDDI.d528.s24.e2 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s25
Doxorubicin : Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.

DrugDDI.d528.s25.e0 0 10
drug
Doxorubicin
DrugDDI.d528.s25.e1 12 22
drug
Doxorubicin
DrugDDI.d528.s25.e2 40 50
drug
zalcitabine

interaction DrugDDI.d528.s25.e0 DrugDDI.d528.s25.e1 false
interaction DrugDDI.d528.s25.e0 DrugDDI.d528.s25.e2 false
interaction DrugDDI.d528.s25.e1 DrugDDI.d528.s25.e2 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s26
Although there may be decreased zalcitabine activity because of lessened active metabolite formation, the clinical relevance of these in vitro results are not known.

DrugDDI.d528.s26.e0 27 37
drug
zalcitabine
DrugDDI.d528.s26.e1 63 78
drug
active metabolite

interaction DrugDDI.d528.s26.e0 DrugDDI.d528.s26.e1 false

